<SEC-DOCUMENT>0001564590-21-015214.txt : 20210325
<SEC-HEADER>0001564590-21-015214.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210324202230
ACCESSION NUMBER:		0001564590-21-015214
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			89bio, Inc.
		CENTRAL INDEX KEY:			0001785173
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831114349
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39122
		FILM NUMBER:		21769751

	BUSINESS ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
		BUSINESS PHONE:		4155004614

	MAIL ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>etnb-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39122 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-4946844</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">142 Sansome Street, Second Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California 94104</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">94104</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (415)&#160;500-4614 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading<br />Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value $0.001 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETNB</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO<font style="font-size:8.5pt;">&#160;</font><font style="font-size:8.5pt;font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act<font style="font-size:8.5pt;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr style="height:4.95pt;">
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an <font style="font-size:8pt;">emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</font><font style="font-size:8pt;font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="font-size:8pt;">aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2020, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $72,707,052, based on the closing price on The Nasdaq Global Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 1, 2021, there were 19,946,426 shares of the Registrant&#8217;s common stock outstanding.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders, to be held on or about June 2, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">SIGNATURES</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Annual Report on Form 10-K, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to acquisitions, business trends and other information referred to in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this Annual Report on Form 10-K. Such risks, uncertainties and other important factors include, among others, the risks, uncertainties and factors set forth in &#8220;Risk Factors,&#8221; and the following risks, uncertainties and factors:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans to develop and commercialize BIO89-100 or any future product candidates;&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ongoing and planned clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing of and our ability to obtain regulatory approvals for BIO89-100 or any future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the effect of the ongoing COVID-19 pandemic on our business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the rate and degree of market acceptance and clinical utility of BIO89-100 or any future product candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant competition in our industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our intellectual property position;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">loss of key members of management;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our failure to maintain effective internal controls.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of these risks and uncertainties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this Annual Report on Form 10-K apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Annual Report on Form 10-K. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In this Annual Report on Form 10-K, unless context otherwise requires or where otherwise indicated, the terms &#8220;89bio&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;the company,&#8221; and &#8220;our business&#8221; refer to 89bio, Inc. and its consolidated subsidiaries.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate,&#160;BIO89-100,&#160;a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (&#8220;FGF21&#8221;), is currently being developed for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) and for the treatment of severe hypertriglyceridemia (&#8220;SHTG&#8221;). NASH is a severe form of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (&#8220;HCC&#8221;) and death. There are currently no approved products for the treatment of NASH. </font>In September 2020, we announced positive topline data from the Phase 1b/2a trial of BIO89-100 in NASH. We plan to initiate a Phase 2b trial in NASH patients in the first half of 2021. In December 2020, we initiated a paired-biopsy open-label cohort as part of the Phase 1b/2a trial in NASH patients assessing histology endpoints with topline data anticipated by the end of 2021. SHTG is<font style="Background-color:#FFFFFF;"> a condition identified by severely elevated levels of triglycerides (greater than or equal to 500 mg/dL), which is associated with an increased risk of NASH, cardiovascular events and acute pancreatitis. We initiated our Phase&#160;2 trial (ENTRIGUE) in SHTG patients in the third quarter of 2020 and expect to report topline data in the second half of 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a promising class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH. <font style="Background-color:#FFFFFF;">FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis, improve the histological features of NASH and address cardio-metabolic dysregulation.&#160;</font>It is thought to exert effects on liver fibrosis by improving metabolic regulation, which reduces ongoing liver injury thus giving the liver time to heal. FGF21 also generates an&#160;on-target&#160;effect to increase adiponectin, a hormone released from adipose tissue that, among other functions, can suppress development and progression of hepatic fibrosis. However, FGF21 in its native form suffers from a short half-life and a tendency to aggregate in solution, both of which impact its suitability as a viable drug. To address these challenges, we have specifically engineered&#160;BIO89-100&#160;to extend the half-life of the molecule while maintaining potency and thereby the clinical benefits of FGF21.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100&#160;may be a differentiated FGF21 therapy based on its robust and durable biological effects, a favorable tolerability profile and its potential for every two-week dosing. <font style="Background-color:#FFFFFF;">Combining these characteristics with the ability to address the key liver pathologies in NASH, as well as the underlying metabolic dysregulation in NASH patients,&#160;BIO89-100&#160;has the potential to become a backbone of treatment in NASH. </font>BIO89-100 also has a long half-life which allows convenient weekly or every-two-week dosing that will support adoption and compliance amongst patients living with this chronic, progressive and generally asymptomatic liver disease. It is currently the only FGF21 analog being tested for every-two-week dosing. BIO89-100 is also being developed as a liquid formulation, which will be convenient for patients to administer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100&#160;has been evaluated in multiple animal studies of NASH, diabetes and obesity, including studies in mice and&#160;non-human&#160;primates and has completed a Phase 1a first-in-human single ascending dose (&#8220;SAD&#8221;) clinical trial in 58 healthy volunteers. In these preclinical studies and in the SAD trial, consistent beneficial effects across a range of relevant endpoints were observed. In the SAD trial,&#160;BIO89-100&#160;demonstrated a favorable tolerability profile and a half-life of 55 to 100 hours. At doses of 9.1 mg and higher, significant improvements in key lipid parameters were observed at Day 8 and Day 15 after dosing on Day 1. BIO89-100 was well tolerated across the dose range in this trial. There were no deaths, serious adverse events or discontinuations due to adverse events. The most commonly observed treatment-related adverse events, occurring in at least two subjects in the pooled BIO89-100 group, were injection site reactions and headache, all of which were reported as mild. In April 2020, we announced data from a preclinical study with&#160;BIO89-100&#160;demonstrating low nanomolar potency against FGF receptors&#160;1c, 2c and 3c similar to recombinant human FGF21 (&#8220;rhFGF21&#8221;). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> September</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2020, we</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">announced</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">positive</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">topline </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data from a </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1b/2a </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">study in NASH patients</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which has informed the advancement of our clinical strategy in</font><font style="color:#000000;"> NASH. </font><font style="Background-color:#FFFFFF;">Th</font><font style="Background-color:#FFFFFF;">is</font><font style="Background-color:#FFFFFF;"> 13-week phase 1b/2a multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose-ranging trial enrolled a total of 81 patients</font><font style="Background-color:#FFFFFF;"> with </font><font style="Background-color:#FFFFFF;">biopsy-confirmed NASH and phenotypic NASH (</font><font style="Background-color:#FFFFFF;">&#8220;</font><font style="Background-color:#FFFFFF;">PNASH</font><font style="Background-color:#FFFFFF;">&#8221;</font><font style="Background-color:#FFFFFF;">)</font><font style="Background-color:#FFFFFF;">. </font><font style="Background-color:#FFFFFF;">All dose groups in the trial demonstrated statistically significant reductions in liver fat at week 13, with relative reduction of up to 60% versus baseline, and up to 70% versus placebo, as measured by magnetic resonance imaging&#8212;proton density fat factor (</font><font style="Background-color:#FFFFFF;">&#8220;</font><font style="Background-color:#FFFFFF;">MRI-PDFF</font><font style="Background-color:#FFFFFF;">&#8221;</font><font style="Background-color:#FFFFFF;">).</font><font style="Background-color:#FFFFFF;"> </font><font style="Background-color:#FFFFFF;">A majority of</font><font style="Background-color:#FFFFFF;"> patients achieved a &#8805; 30% (up to 88%) or a &#8805; 50% (up to 71%) reduction in liver fat</font><font style="Background-color:#FFFFFF;"> from baseline</font><font style="Background-color:#FFFFFF;">. ALT</font><font style="Background-color:#FFFFFF;">, a liver enzyme,</font><font style="Background-color:#FFFFFF;"> was significantly reduced (up to 44%) in these patients and key lipid markers like triglycerides, LDL, and non-HDL were also significantly improved. </font><font style="Background-color:#FFFFFF;">B</font><font style="Background-color:#FFFFFF;">aseline characteristics</font><font style="Background-color:#FFFFFF;"> were </font><font style="Background-color:#FFFFFF;">similar</font><font style="Background-color:#FFFFFF;"> across the sub-populations of biopsy-confirmed NASH and PNASH patients enrolled in the trial and </font><font style="Background-color:#FFFFFF;">r</font><font style="Background-color:#FFFFFF;">esults</font><font style="Background-color:#FFFFFF;"> were </font><font style="Background-color:#FFFFFF;">also </font><font style="Background-color:#FFFFFF;">consistent</font><font style="Background-color:#FFFFFF;"> across </font><font style="Background-color:#FFFFFF;">the two</font><font style="Background-color:#FFFFFF;"> sub-</font><font style="Background-color:#FFFFFF;">groups</font><font style="Background-color:#FFFFFF;">. </font><font style="Background-color:#FFFFFF;">In this study, </font><font style="Background-color:#FFFFFF;">BIO89-100 </font><font style="Background-color:#FFFFFF;">presented</font><font style="Background-color:#FFFFFF;"> </font><font style="Background-color:#FFFFFF;">a favorable safety and tolerability profile with rates of gastrointestinal side effects such as nausea, diarrhea and vomiting </font><font style="Background-color:#FFFFFF;">similar to</font><font style="Background-color:#FFFFFF;"> placebo.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No adverse effects on blood pressure or heart rate were observed and no hypersensitivity adverse events were reported.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In March 2021, we presented a new analysis of data from this study that showed that BIO89-100 treatment resulted in significant reductions in liver volume of up to 15% and liver fat volume of up to 65% in treated patients at 13 weeks compared to baseline, as measured by MRI-PDFF.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we initiated a paired-biopsy, open-label cohort as part of the Phase 1b/2a trial assessing histology endpoints, with data anticipated by the end of 2021. This cohort is expected to enroll approximately 20 patients with biopsy-confirmed NASH who will be treated for 20 weeks with 27 mg of BIO89-100 once weekly. The cohort will build on the&#160;<font style="text-decoration:none;color:#auto;">recent data</font><font style="color:#000000;">&#160;from </font>89bio&#8217;s Phase 1b/2a trial and will provide an early opportunity to demonstrate BIO89-100&#8217;s benefits on histology endpoints.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the potential of FGF21 to meaningfully reduce triglycerides and provide other metabolic benefits, and the established regulatory path for approval, we are developing BIO89-100 for the treatment of SHTG. We initiated our Phase 2 trial (ENTRIGUE) in SHTG patients in the third quarter of 2020 and expect to enroll approximately 90 patients, who could be on stable background medications. ENTRIGUE is a Phase 2 multi-center, randomized, double-blind, placebo-controlled study designed to evaluate safety, efficacy and tolerability in patients who will receive BIO89-100 administered weekly (9 mg, 18 mg or 27 mg) or every two weeks (36 mg) or placebo. The primary endpoint is the reduction in fasting triglycerides from baseline. Key secondary endpoints include other lipid and metabolic markers and change in liver fat measured by MRI-PDFF. Topline data from ENTRIGUE are expected in the second half of 2021. We have recently expanded ENTRIGUE with an additional cohort of patients on fibrates to assess the benefit of 27 mg weekly BIO89-100 when added to background fibrates. In this cohort, a total of 36 patients will be randomized to either receive BIO89-100 or placebo. The primary endpoint and key secondary endpoint are the same as in ENTRIGUE. We also expect to initiate registrational trials in SHTG in 2022, pending positive data from ENTRIGUE. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk64485949"></a>Impact of&#160;COVID-19&#160;Pandemic</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has disrupted and may continue to disrupt our business and delay our preclinical and clinical programs and timelines. The extent to which the COVID-19 pandemic may impact our future operating results and financial condition is uncertain.<font style="color:#000000;"> We initiated our Phase 2 trial (ENTRIGUE) in SHTG patients in the third quarter of 2020 as well as a new paired-biopsy open-label histology cohort as part of the Phase 1b/2a trial in the fourth quarter of 2020. The COVID-19 surge observed late in the fourth quarter of 2020 and the first quarter of 2021 has impacted enrollment in these studies. We plan to initiate a Phase 2b trial in NASH patients in the first half of 2021. We do not yet know the full extent of potential delays, which could prevent or delay us from obtaining approval for&#160;BIO89-100.&#160;For more information regarding risks related to the ongoing&#160;COVID-19&#160;pandemic, please see the risk factor entitled &#8220;The ongoing COVID-19 pandemic has resulted and may in the future result in significant disruptions to our clinical trials or other business operations, which could have a material adverse effect on our business,&#8221; in Part I. Item 1A of this Annual Report on Form 10-K. To the extent the ongoing&#160;COVID-19&#160;pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks set forth under &#8220;Risk Factors&#8221; in this Annual Report on Form&#160;10-K.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Strategy</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to become a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The key components of our strategy are to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Rapidly advance&#160;BIO89-100&#160;through clinical development for the treatment of NASH</font><font style="color:#000000;">. We believe&#160;BIO89-100&#160;may be a differentiated FGF21 therapy based on its robust and durable biological effects, a favorable tolerability profile and its potential for every two-week dosing. Following positive results in September 2020 from our Phase 1b/2a trial&#160;in NASH patients we plan to initiate a Phase 2b trial in NASH patients with F2 and F3 fibrosis in the first half of 2021. Additionally, we recently initiated a paired-biopsy, open-label histology cohort in NASH patients and are also evaluating the opportunity to test BIO89-100 in NASH patients with cirrhosis while we analyze and await data in cirrhotic patients from other FGF21 analogs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Pursue SHTG as a second indication with BIO89-100 given its unique profile and its potential for a quicker path to market. </font><font style="color:#000000;">While we are focused on becoming a leader in the treatment of NASH, BIO89-100&#8217;s mechanism of action supports its potential to become the treatment leader in other cardio-metabolic and liver diseases. In the third quarter of 2020, we initiated our Phase&#160;2 trial (</font><font style="color:#000000;">ENTRIGUE) </font><font style="color:#000000;">in SHTG. Based on U.S. Food and Drug Administration (&#8220;FDA&#8221;) guidance for the development of SHTG treatments, as well as the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for&#160;BIO89-100.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Scale-up&#160;and optimize the manufacturing of&#160;BIO89-100</font><font style="color:#000000;">. We currently use an external contract manufacturing organization (&#8220;CMO&#8221;) to manufacture&#160;BIO89-100&#160;for our ongoing and planned clinical trials. While these trials are ongoing, we plan to work with our CMO to optimize and&#160;scale-up&#160;the manufacturing process for&#160;BIO89-100&#160;to support the increased production that will be needed for later-stage clinical trials and commercialization, if&#160;BIO89-100&#160;is approved.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Establish a commercial infrastructure in key geographies</font><font style="color:#000000;">. We have worldwide rights to&#160;BIO89-100&#160;and intend to develop the sales infrastructure required for commercialization in the United States. We also plan to evaluate options, including strategic collaborations, for commercializing&#160;BIO89-100,&#160;if approved, in other key markets, such as Europe and China.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Build a diversified multi-asset pipeline of novel therapies</font><font style="color:#000000;">. We intend to employ a value-driven strategy to identify, acquire, develop and commercialize product candidates for liver and cardio-metabolic diseases. We intend to focus on product candidates that we believe have attractive profiles and address a clear unmet medical need and can advance quickly and efficiently into late-stage development.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our Focus on Liver and Cardio-Metabolic Disease</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on developing and commercializing therapeutic interventions that have a clinically meaningful impact on patients with liver and cardio-metabolic diseases. These diseases, including NASH and SHTG, represent leading global causes of morbidity and mortality. Despite a wave of public health campaigns to promote better diet and exercise habits and a range of treatment options available for many of these diseases, there is a significant unmet medical need for more effective therapies to improve patient outcomes and reduce the burden on global healthcare systems.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently developing our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, for the treatment of NASH and SHTG. We believe BIO89-100 is an ideal candidate for the treatment of NASH based on its ability to address the key liver pathologies in NASH, its ability to address the underlying metabolic dysregulation in NASH patients, its favorable tolerability profile, and its potential for a longer dosing interval. Multiple epidemiological studies have linked NAFLD to increased cardiovascular disease, concluding that the majority of deaths among NAFLD patients are attributable to cardiovascular disease. As a result, we believe it is important that new therapeutics options for NASH address the underlying cardiovascular and metabolic dysregulations in these patients.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the potential of BIO89-100 to meaningfully reduce triglycerides, we are also developing</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 for the treatment of SHTG. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 may </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> competitive differentiation </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from approved therapies and other molecules in development</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based on its impact on</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> improving</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> liver fat and other metabolic markers</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in addition to triglyceride reduction</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is regulatory precedence for the approval of therap</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the treatment of SHTG in the United States </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the reduction in triglycerides from baseline as the primary endpoint for full approval. Based </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Disease Overview - NASH</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASH, a severe form of NAFLD, is characterized histologically by the additional presence of inflammation and hepatocellular injury such as visible ballooning and has a significantly worse prognosis, with the potential to progress to liver fibrosis, cirrhosis or HCC. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASH represents a large and rapidly growing problem in the United States and worldwide. Diagnoses have been on the rise and are expected to increase dramatically in the next decade. The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 20% to 25% of NAFLD patients, is driven primarily by the worldwide obesity epidemic. <font style="color:#000000;">As a result, the prevalence of NASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin resistance and Type 2 diabetes. The prevalence of these conditions is expected to increase further in view of the unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary behavior that characterize modern lifestyle. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of NASH cases in the United States is projected to expand from 16.5&#160;million in 2015 to 27&#160;million in 2030, with similar prevalence growth expected in Europe, yet there are no approved treatments. <font style="color:#000000;">Approximately 20% of the 16.5 million NASH cases in 2015 had F3 or F4 fibrosis, a number that is expected to increase to 7.9 million by 2030, which will be approximately 30% of the total NASH population. Similar growth trends for NASH cases are expected in Europe (12.6 million in 2016 to 18.3 million in 2030 within France, Germany, Italy, Spain and the United Kingdom) as well as China (32.6 million in 2016 to 48.3 million in 2030). </font>Figure 1 below shows the increase in prevalence and liver-related mortality rates by fibrosis stage.<font style="color:#000000;"> The expected lifetime economic burden of all patients with NASH in the United States in 2017 was estimated at $223 billion. </font>Diet and exercise are currently the standard of care for NAFLD and NASH, but adherence to this treatment regimen is poor and there remains a high unmet need in the treatment of NASH.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 1: Prevalence and Liver-Related Mortality Rate by Fibrosis Stage</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000001.jpg" title="" alt="" style="width:624px;height:318px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to handle lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. NASH patients have an excessive accumulation of fat in the liver resulting primarily from a caloric intake above and beyond energy needs. A healthy liver contains less than 5% fat, but a liver in someone with NASH can contain more than 20% fat. This abnormal liver fat contributes to the progression to NASH, a liver necro-inflammatory state, that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure&#8212;<font style="color:#000000;">cirrhosis develops in approximately 20% and 45% of patients. In some cases, cirrhosis progresses to decompensated cirrhosis, which results in permanent liver damage that can lead to liver failure. In addition, it is estimated that 8% of patients with advanced fibrosis will develop HCC. </font>NASH is a complex, multifaceted disease that doesn&#8217;t just affect the liver. Patients with NASH frequently have other significant metabolic&#160;co-morbidities&#160;such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Disease Overview - SHTG</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing BIO89-100 for the treatment of SHTG. Hypertriglyceridemia (&#8220;HTG&#8221;) is characterized by elevated fasting plasma triglyceride levels higher than 200 mg/dL and SHTG is typically defined as triglyceride levels of greater than or equal to 500 mg/dL. SHTG is associated with an increased risk of NAFLD, NASH and cardiovascular diseases, as well as acute pancreatitis, accounting for up to 10% of all acute pancreatitis episodes. A recent third-party study utilizing an omega-3 fatty acid (&#8220;omega-3 FA&#8221;) demonstrated the linkage between a reduction in triglycerides and favorable cardiovascular clinical outcomes. <font style="color:#000000;">Additionally, SHTG increases the risk of developing NAFLD, NASH and cardiovascular disease. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is estimated that there are 4 million patients in the United States with triglyceride levels of greater than or equal to 500 mg/dL. Of these patients, it is estimated that 56% have hepatic fat and up to 72% have other dyslipidemias or Type 2 diabetes. This patient population is expected to increase due to the triple epidemic of obesity, metabolic syndrome and Type 2 diabetes. In addition, the addressable market has the potential to expand as a result of increasing awareness of the importance of treating elevated triglyceride levels, similar to the focus today of physicians on managing LDL levels, as well as due to third party commercial efforts expected to promote triglyceride reduction. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The treatment regimen for SHTG includes dietary restrictions and lipid-lowering drug treatment such as fibrates, omega-3 fish oils and niacin. Some statins are indicated in HTG but do not have an indication for use in SHT</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G.</font><font style="color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite multiple agents approved for the treatment of SHTG, these agents have limitations that may not make them ideal for all patients. For example, fibrates have demonstrated reductions in triglycerides of up to approximately 55% at 12 weeks of treatment. However, they have also shown increases in LDL-C (up to 45%), a detrimental effect in this patient population, risk of drug-drug interactions and increases in transaminases, as well as tolerability issues including myopathy. Omega 3 fish oils have shown more modest benefits in reduction of triglycerides from baseline of approximately 25% to 45%. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> fish oils have also showed major increases in LDL-C (up to 45%). Fish oils also have a significant pill burden given the high daily doses required. In addition, these agents fail to meaningfully address the related co-morbidities of SHTG, including glycemic control, which, when left untreated, may further exacerbate the condition. In third-party studies, up to 50% of treated SHTG patients were unable to reduce their triglyceride levels to &lt; 500 mg/dL despite using approved drugs and are considered refractory patients. These refractory patients have substantial unmet medical need and represent a significant market opportunity</font><font style="color:#000000;">. </font><font style="color:#000000;">D</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">espite these limitations, the existing drugs have achieved commercial success with two third parties each generating peak sales of approximately $1 billion or greater. Given the continuing unmet need in SHTG and limitations of current treatments, there are several agents in development for the treatment of SHTG, including a fibrate, and novel drugs targeting </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aspects of HTG and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHTG, including ANGPTL3 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ApoC</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> III inhibitors. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Etiology of NASH</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Understanding of the pathophysiologic mechanisms that lead to NASH has evolved in recent years. Excessive caloric overload, metabolic dysregulation, cardio-metabolic co-morbidities and genetic risk factors increase the likelihood of developing NASH, with a multitude of potential mechanistic contributors to pathophysiology. In NASH, the liver&#8217;s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed. This occurs when there is an excess of free fatty acids deposited in the liver or their disposal from the liver is impaired. The accumulation of surplus free fatty acids leads to the formation of toxic lipid species. These toxic lipids then induce endoplasmic reticulum stress, oxidative stress and an inflammatory response, which can result in hepatocellular injury and death. This may lead to fibrosis and genomic instability, which may worsen over time to cirrhosis and HCC, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical pathophysiologic mechanisms underlying development and progression of NASH include (1) reduced ability to handle lipids, (2) increased insulin resistance, (3) injury to hepatocytes and (4) development and progression of liver fibrosis in response to hepatocyte injury.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:normal;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reduced Ability to Handle Lipids</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excess consumption of calories, poor diet and a sedentary lifestyle, each often associated with obesity, can burden the body with a surplus of carbohydrates and lipids. This burden can be progressively more difficult for the liver to handle thereby resulting in steatosis in the liver. The problem is compounded further as insulin resistance develops.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Free fatty acids (&#8220;FFA&#8221;) accumulate in the liver primarily from three sources, namely, through (1) the transfer from peripheral adipose tissues where triglycerides are mobilized, (2) de-novo lipogenesis (&#8220;DNL&#8221;), and (3) direct dietary intake. The FFA that lead to NASH are believed to arise primarily from the peripheral tissue pool and secondarily through DNL. The increase in the influx of FFA to the liver from the peripheral tissues is driven by excessive caloric intake greater than the body&#8217;s demand and increased insulin resistance resulting in deposition of fat to the liver for processing. DNL is a distinct process in the liver by which hepatocytes convert excess carbohydrates, especially fructose, to fatty acids.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three main fates of fatty acids in the liver are (1) mitochondrial beta-oxidation (to release ATP, or energy), (2) re-esterification to form triglyceride, which can then be exported into the blood as very low density lipoproteins, or (3) stored in lipid droplets, resulting in liver steatosis and ultimately NASH. Adiponectin, a hormone derived from adipose tissue, appears to have a pivotal role in improving fatty acid oxidation and decreasing fatty acid synthesis, components of lipid handling.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An increase in cholesterol accumulation in the liver can also contribute to NASH, though its role is not as clearly defined as in the case of triglycerides. The dysregulation of the cholesterol pathway can result in an increase in the cholesterol levels in the liver. The increased cholesterol can accumulate in the liver cell membranes and activate Kupffer cells (activated stellate macrophages), thereby triggering inflammatory pathways and resulting in the progression of NASH.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:normal;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Increased Insulin Resistance</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insulin resistance, which typically develops in obese individuals, is considered to be a fundamental underlying mechanism in the majority of NASH patients. Fatty acids are primarily delivered to the liver from blood following lipolysis of triglycerides in adipose tissue, a process that is regulated by the actions of insulin on adipocytes. Insulin resistance in adipose tissue manifests as dysregulated lipolysis resulting in excessive delivery of FFA to the liver. The liver tries to cope with the large influx of FFA; however, the build-up of metabolic intermediates interferes with signaling, resulting in hepatic insulin resistance and the inability of the liver to process this excess FFA influx. The state of hepatic insulin resistance further exacerbates the problem by triggering DNL and the build-up of excess fat in the liver.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:normal;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Injury to Hepatocytes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the disposal of fatty acids through beta-oxidation or the formation of triglycerides is chronically overwhelmed, fatty acids can form lipotoxic species that lead to stress on the endoplasmic reticulum, oxidative stress and inflammation, all of which are pivotal processes in the development of NASH. Liver inflammation may be an important link between the initial metabolic stress and subsequent hepatocyte death and stimulation of fibrogenesis in NASH by promotion of the expression of pro-inflammatory cytokines and of apoptosis (cell death). These processes are core to the steatohepatitis that gives NASH its name. For example, hepatocyte apoptosis results in the ballooning of cells, a classic pathological feature of NASH. While hepatocytes are the primary and major target of toxic lipids, other cells such as Kupffer cells and hepatic stellate cells are also affected by lipotoxicity and contribute to the development of NASH pathology.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional factors, including dysregulation of cytokines and adipokines, energy depletion, anti-oxidant deficiencies, products of the gut microbiome and iron load may modulate hepatocyte vulnerability to the development of lipotoxic stress, injury and inflammation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:normal;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development and Progression of Liver Fibrosis in Response to Hepatocyte Injury</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signaling from stressed or injured hepatocytes and Kupffer cells leads to activation of quiescent hepatic stellate cells. Upon activation, hepatic stellate cells release collagen and other factors. When the production of collagen and matrix proteins is faster than their degradation, accumulation of these proteins in the extracellular matrix can lead to progressive fibrosis. As the lipotoxicity and inflammation continue to damage the liver, the hepatic stellate cells continue to be activated resulting in greater collagen deposition that ultimately leads to fibrosis and cirrhosis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Co-morbidities Associated with NASH</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with NASH frequently have other significant co-morbidities&#8212;hypertriglyceridemia, obesity, hyperlipidemia/dyslipidemia, hyperglycemia (including Type 2 diabetes) and systemic hypertension, a constellation of which is commonly referred to as metabolic syndrome&#8212;which also increase the risk of developing cardiovascular disease. Figure 2 below shows certain co-morbidities associated with NASH.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 2: NASH Co-morbidities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr style="height:23.5pt;">
<td valign="middle"  BGCOLOR="#3297D3" style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selected Co-morbidities</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prevalence in NASH Population</p></td>
</tr>
<tr style="height:17pt;">
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hypertriglyceridemia</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
</tr>
<tr style="height:17pt;">
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obesity</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82%</p></td>
</tr>
<tr style="height:17pt;">
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hyperlipidemia / Dyslipidemia</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72%</p></td>
</tr>
<tr style="height:17pt;">
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Metabolic syndrome</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71%</p></td>
</tr>
<tr style="height:17pt;">
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type 2 diabetes</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, NASH was found to independently increase the risk of non-liver-related adverse outcomes, including cardiovascular risk and malignancy. Multiple epidemiological studies have linked NASH to increased cardiovascular morbidity, concluding that the majority of deaths among NASH patients are attributable to cardiovascular disease (cardiovascular death is four times higher than death related to liver disease).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In considering therapeutic options to treat NASH, we believe it is important to address the underlying metabolic co-morbidities in addition to the liver pathology.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Diagnosis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most people with NASH are asymptomatic and their disease is often discovered incidentally following a liver imaging procedure, such as an ultrasound, prescribed for other reasons or as part of an investigation for elevated liver enzymes. Once suspected clinically, a liver biopsy is required to definitively diagnose NASH, which necessitates the joint presence of steatosis, ballooning and lobular inflammation. Once pathologically confirmed, the severity of NAFLD and NASH is determined using the histologically validated NAS, which grades disease activity on a scale of 0 to 8. The NAS is the sum of the individual scores for steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) but does not include a score for fibrosis. Fibrosis staging (F0-F4) relies on the Kleiner classification (F0 = no fibrosis; F1 = perisinusoidal or periportal fibrosis (not both); F2 = both perisinusoidal and periportal fibrosis; F3 = bridging fibrosis; F4 = cirrhosis).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Histological diagnosis remains the gold standard for assessment of NASH and fibrosis. However, given that liver biopsy is associated with risks of pain, bleeding and other morbidity, as well as significant cost, the procedure is not practical for general patient screening. Several non-invasive tools such as clinical risk scores and imaging techniques are increasingly used to assess NASH patients. Clinical risk scores such as the NAFLD fibrosis score, Fibrosis-4 index, the Enhanced Liver Fibrosis score and vibration-controlled transient elastography (&#8220;VCTE&#8221;), have been validated and are increasingly used. These tools have an excellent negative predictive value and an acceptable positive predictive value for detection of advanced (&#8805; F3) fibrosis and are increasingly used in clinical settings. Additionally, evidence is emerging that shows a correlation between reduction in steatosis as measured by MRI-PDFF and improvement in histological changes in the liver. Extensive efforts are also under way to develop non-invasive means to identify patients with NAS &#8805; 4 or fibrosis &#8805; F2 patients without a need for a liver biopsy. In draft guidance, the FDA encouraged sponsors to identify biochemical or noninvasive imaging biomarkers that, once characterized and agreed by the FDA, could replace liver biopsies for patient selection and efficacy assessment in clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the validation and subsequent adoption of these new tools will result in an increase in the diagnosis and treatment rates for NASH in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FGF21 Overview</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibroblast growth factors (&#8220;FGFs&#8221;), including FGF21 and FGF19, are a large family of cell-signaling proteins involved in the regulation of many processes within the body. FGF21 is an endogenous metabolic hormone that regulates energy homeostasis, glucose-lipid-protein metabolism and insulin sensitivity, and modulates the pathways that mitigate against intracellular stress. FGF21 is secreted primarily by the liver but is also secreted by the white adipose tissue (&#8220;WAT&#8221;), skeletal muscle and the pancreas. FGF21 exerts its biological benefits through the activation of three fibroblast growth factor receptors (&#8220;FGFRs&#8221;), FGFR1c, FGFR2c and FGFR3c, and requires co-activation of the transmembrane protein cofactor beta Klotho (&#8220;&#223;-Klotho&#8221;). FGF21 is not believed to activate FGFR4, which has been associated with adverse effects. FGF21 can act directly or indirectly on target organs by mediating downstream regulators, such as adiponectin, and upstream regulators that induce FGF21, such as nutritional stress or transcription factors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biological Effects of FGF21: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reducing Liver Steatosis by Improving Lipid Handling and Insulin Sensitivity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> <font style="font-weight:normal;font-style:normal;">FGF21 has been clinically shown to reduce liver steatosis. FGF21 reduces liver steatosis by (1) increasing fatty acid oxidation in the liver, (2) reducing the deposition of free fatty acids from peripheral tissue to the liver and (3) reducing DNL in the liver. FGF21 exerts its systemic effects by reducing the serum levels of lipids (e.g., triglycerides, LDL cholesterol) and increasing insulin sensitivity. Increasing insulin sensitivity reduces lipolysis and can also reduce serum levels of lipids. In particular, FGF21 has been demonstrated to reduce liver fat in patients with NASH in multiple clinical trials.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Improving Liver Inflammation and Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> <font style="font-weight:normal;font-style:normal;">FGF21 is also believed to reduce liver fibrosis, the pathological change mostly clearly linked to liver-related morbidity in NASH patients via two potential pathways. One pathway is through the metabolic benefits of FGF21 described above. Long-term improvements in metabolic regulation reduce the ongoing liver injury that drives fibrosis and thus allows the liver time to heal. The other pathway is a direct anti-fibrotic effect mediated via adiponectin, an adipokine that is upregulated by FGF21. Increased adiponectin downregulates the hepatic stellate cells that are activated upon hepatic injury and responsible for collagen deposition and subsequent fibrosis. FGF21 demonstrated an improvement in liver fibrosis in patients in NASH in a clinical trial.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FGF21 Signaling</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, FGF21 exerts its biological benefits through the co-activation of FGFRs and &#223;-Klotho. FGFRs are expressed widely throughout the body whereas &#223;-Klotho is primarily expressed in metabolic tissues such as adipose tissue, liver, and pancreas, thereby providing organ specificity to FGF21.The binding of FGF21 is a two-step process. The C-terminus of FGF21 initially binds to &#223;-Klotho enabling the N-terminus to form an expanded complex with one of the FGFRs. Once the co-receptor complex has formed with &#223;<font style="font-style:italic;">-</font>Klotho and one of the FGFRs, a series of intracellular signaling cascades is initiated. These signaling cascades enable FGF21 to exert its biological functions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FGF21 activates three specific FGFRs (FGFR1c, FGFR2c and FGFR3c), which based on nonclinical studies and clinical trials, appear to be responsible for mediating the desired therapeutic actions of FGF21 in NASH. FGF21 is not believed to activate FGFR4. Activation of FGFR4 results in an increase in LDL cholesterol and has been implicated in the etiology or progression of HCC. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">BIO89-100</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, for the treatment of NASH and SHTG. BIO89-100 has been specifically engineered to retain the activity of native FGF21 while extending its half-life. Specifically, it has been engineered to: (1) protect against proteolysis and reduce renal clearance, (2) have an extended half-life, (3) minimize susceptibility to aggregate in solution and (4) optimize its potency, enabling the potential use of lower dosage/doses. Additionally, we believe that BIO89-100 may enhance binding affinity for &#223;-Klotho, by altering the conformation of the C-terminus which could have a positive impact on efficacy.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Primary Structure and Protein Engineering of BIO89-100</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. The mutations were incorporated into the FGF21 sequence after existing proline to create a consensus sequence for glycosylation. Subsequently, the glycosyl linker and a single 20 kDa glycoPEG moiety were enzymatically introduced at the O-linked glycosylation consensus site (position 173) via the proprietary glycoPEGylation technology. Our glycoPEG moiety is an activated form of the PEG molecule with the use of Sialic Acid, CMP-SA-PEG. The proximity of the mutations ensures consistent and efficient attachment of the glycoPEG moiety.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 has two modified natural amino acid residues:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">S173T: Serine modified to Threonine at position 173; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">R176A: Arginine modified to Alanine at position 176.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a Methionine residue was introduced at the N-terminus which acts as the translation initiation signal. Figure 3 below shows the structure of BIO89-100.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 3: Structure of BIO89-100</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000002.jpg" title="" alt="" style="width:624px;height:255px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in the size of the molecule from 19.4 kDa to 40 kDa together with the site-specific mutations adjacent to the primary cleavage site of FGF21 (by the FAP enzyme between positions 171 and 172 on the native amino acid chain, which would be represented by positions 172 and 173 in our molecule starting with Methionine in position 1) are designed to prolong the half-life of the molecule. Additionally, we believe that the use of glycoPEGylation technology produces a comparatively stronger and more flexible structure, which aids in the development of a stable formulation. PEGylation technology has been used successfully in many pharmaceutical products including products that have been marketed for more than 10 years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 uses a proprietary glycoPEGylation technology that has been previously validated by a third party, as this technology is incorporated in another pharmaceutical product (Lonquex&#174; by Teva) that has received regulatory approval and is currently commercialized in the European Union.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Development and Selection of BIO89-100</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discovery program that led to the selection of BIO89-100 was directed towards achieving an optimal pharmacokinetic (&#8220;PK&#8221;) and efficacy profile. It has been shown that the in vivo half-life of FGF21 can be extended by covalently linking a single glycoPEG moiety to the molecule. We performed extensive screening of FGF21 analogs with mutations at different positions including close to the N-terminus, as well as different glycoPEGylations to select an optimized molecule based on its potency, PK and in-vivo efficacy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Stage I&#8212;Optimizing Selection of Mutation Sites&#8212;In Vitro Potency Testing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutations were inserted at different sites for both non-PEGylated FGF21 analogs and corresponding glycoPEGylated analogs and screened in a cell-based potency assay to select analogs that did not lose potency relative to the native hormone. Amongst the multiple glycoPEGylated analogs tested, only mutations at sites towards either N-terminus or C-terminus showed potency comparable to that of native FGF21 hormone and were selected for further development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Stage II&#8212;Optimizing for glycoPEG (20 kDa vs 30 kDa)&#8212;In Vitro Potency Testing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analogs selected in Stage I were prepared with either a 20 kDa or a 30 kDa glycoPEG moiety and tested for potency in mouse adipocytes (3T3-L1) and human embryonic kidney (HEK-293) cell lines. Minimal differences in potencies were observed between the 20 kDa and 30 kDa glycoPEGylated analogs. However, only the glycoPEGylated analogs that had mutations and a glycoPEG attachment at the C-terminus, as distinct from those with mutations at the N-terminus, maintained their potency in both mouse and human cell lines. These analogs were selected for future development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Stage III&#8212;Optimizing for PK Properties and Efficacy&#8212;In Vivo Testing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selected analogs from Stage II with either a 20 kDa or a 30 kDa glycoPEG moiety, were chosen for in vivo testing in a diabetic mouse model. In addition to PK, changes from baseline in glucose, triglycerides and insulin were measured. The data showed that the circulating half-life of the glycoPEGylated analogs for both glycoPEG sizes was extended (range 15 to 30 hours) as compared to native FGF21 (2 hours). As expected, all analogs were observed to cause a reduction in blood glucose levels. However, the 20 kDa glycoPEGylated analogs were observed to outperform the 30 kDa analogs by improving triglycerides at lower doses and across broader dose ranges. BIO89-100 resulted in the greatest reduction of insulin and was selected as the candidate for clinical development.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, the mutations made to the native FGF21 molecule and the addition of the 20 kDA glycoPEG moiety via the use of the glycoPEGylation technology were observed to significantly improve the PK properties of the molecule while retaining the therapeutic benefits. We believe that BIO89-100 is a well-balanced molecule with a unique profile, which has the potential to have therapeutic benefits in NASH and cardio-metabolic diseases. Figure 4 below sets forth what we believe are the key features and potential benefits of BIO89-100:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure </font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">4</font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">: Summary of BIO89-100 Attributes and Benefits</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#3297D3" style="width:20%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:28.3pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Features</p></td>
<td valign="top"  BGCOLOR="#3297D3" style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0.4pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top"  BGCOLOR="#3297D3" style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:34.25pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential Benefit</p></td>
</tr>
<tr>
<td rowspan="3" valign="top"  style="width:20%; border-top:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.5pt;;margin-right:4.7%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of PEG (via glycoPEGylation)</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:6.62%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Increases protein size and hydrodynamic volume that reduces renal filtration</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;margin-right:6.62%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Prevents degradation by endocytosis and proteolytic enzymes</font></p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Prolongs half-life</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;margin-right:2.78%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Protects antigenic sites present on the protein surface (i.e. antigenic epitopes)</font></p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Reduces immunogenicity</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:1.71%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Steric repulsion between the PEGylated surfaces increases water solubility and reduces aggregates</font></p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:6.41%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Results in more stable formulation</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.5pt;;margin-right:8.97%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Site-Specific Mutations</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:7.26%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Mutation at position 173 is immediately adjacent to the primary cleavage (FAP enzyme) site of FGF21</font></p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Prolongs half-life</font></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"  style="width:20%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.5pt;;margin-right:4.91%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GlycoPEGylation Technology</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:1.5%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Allows site specific linkage (glycoPEG moiety to position 173)</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:20pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Proximity of the glycoPEG moiety to the</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:20pt;;margin-right:1.71%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-terminus induces conformational changes to the molecule</p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:1.07%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Retains potency against receptor to improve efficacy</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;margin-right:2.14%;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Provides a strong and flexible glycosyl bond that helps the glycoPEG moiety remain intact, further reducing degradation</font></p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:20pt;;text-indent:-15pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9642;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color:#000000;">Further enhances half-life</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Therapeutic Potential of BIO89-100 Supported by Preclinical Animal Models of NASH, Diabetes and Obesity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 was evaluated in multiple distinct animal models of NASH, diabetes and obesity, including non-human primate studies. In each of these studies, consistent and significant beneficial effects were observed across a range of endpoints, specifically, robust improvements in lipid handling, glycemic control and insulin resistance as well as significant improvements in hepatic steatosis, injury and fibrosis. We believe these results demonstrate the potential of BIO89-100 to simultaneously address the multiple drivers of NASH pathogenesis. The histological endpoints, NAS and fibrosis score, mirror the endpoints we expect to assess in our clinical development. In addition, treatment with BIO89-100 in animal models was observed to result in consistent reductions in body weight.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 has been evaluated in three animal models of direct relevance to NASH. These included: (1) Stelic Animal Model (&#8220;STAM&#8221;), (2) Diet-induced NASH (&#8220;DIN&#8221;) model and (3) spontaneous diabetic obese cynomolgus monkey model. Additional studies done in diabetes mouse model and diet induced obesity mouse model showed benefits in key markers of relevance in NASH.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A wide range of doses were tested in these studies as well as weekly and once every two-week dosing regimen was tested in a cynomolgus monkey study. The key outcomes of these studies are summarized in Figure 5 below.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure </font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">5</font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">: Summary of NASH Pharmacology Studies</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.46%;">
<tr style="height:37.75pt;">
<td valign="middle"  BGCOLOR="#3297D3" style="width:31.02%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66893449"></a>Preclinical pharmacology study with</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:11.5%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Improved</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Insulin</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sensitivity</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:14.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Improved Triglycerides and Cholesterol</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:13.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reduced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hepatocyte</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Injury</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:17.26%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reduced Liver Steatosis, Inflammation &amp; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fibrosis</p></td>
<td valign="middle"  BGCOLOR="#3297D3" style="width:12.46%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Body</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weight</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reduction</p></td>
</tr>
<tr style="height:18.35pt;">
<td valign="middle"  style="width:31.02%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DIN mouse model I (10 weeks)</p></td>
<td valign="middle"  style="width:11.5%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:14.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:13.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:17.26%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:12.46%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
</tr>
<tr style="height:18.35pt;">
<td valign="middle"  style="width:31.02%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DIN mouse model II (19 weeks)</p></td>
<td valign="middle"  style="width:11.5%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:14.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:13.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:17.26%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:12.46%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
</tr>
<tr style="height:28.8pt;">
<td valign="middle"  style="width:31.02%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diabetic obese cynomolgus monkey study 1 (8 weeks; weekly dosing)</p></td>
<td valign="middle"  style="width:11.5%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:14.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:13.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:17.26%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not evaluated</p></td>
<td valign="middle"  style="width:12.46%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
</tr>
<tr style="height:28.8pt;">
<td valign="middle"  style="width:31.02%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diabetic obese cynomolgus monkey study 2 (4 weeks; QW or Q2W dosing)</p></td>
<td valign="middle"  style="width:11.5%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:14.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:13.4%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
<td valign="middle"  style="width:17.26%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not evaluated</p></td>
<td valign="middle"  style="width:12.46%; border-top:solid 0.75pt #231F20; border-bottom:solid 0.75pt #231F20; border-left:solid 0.75pt #231F20; border-right:solid 0.75pt #231F20;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#10003;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legend:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#10003;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Statistically significant benefit observed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Improvement observed, but did not achieve statistical significance.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BIO89-100 Clinical Development in NASH</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1a Clinical Trial of Single Dose of BIO89-100 in Healthy Volunteers</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted a Phase 1a clinical trial to evaluate the safety, tolerability and PK of BIO89-100 in 58 healthy volunteers. In this randomized, double-blind, placebo-controlled, Phase 1a, first-in-human, SAD clinical trial the PK profile of BIO89-100 was generally dose-proportional or slightly more than dose-proportional with a half-life of approximately 55 to 100 hours. The observed median time of maximum serum concentration ranged from 36 to 60 hours. At single doses of 9.1 mg and higher, significant improvements were observed in key lipid parameters measured at Day 8 and Day 15 after dosing on Day 1. The mean changes versus baseline include significant reductions in triglycerides (up to 51%) and LDL-C (up to 37%) and increase in HDL-C (up to 36%) despite the baseline values being in the normal range. BIO89-100 demonstrated rapid (starting from Day 2), sustained and durable improvements on lipid parameters for two weeks or more after single dose administration. The effect on lipid parameters was generally dose-dependent. BIO89-100 was well tolerated across the dose range and there were no deaths, serious adverse events or discontinuations due to adverse events. The most commonly observed treatment-related adverse events, occurring in at least two subjects in the pooled BIO89-100 group, were injection site reactions and headache, all of which were reported as mild. No clinically meaningful trends were observed in gastrointestinal events, laboratories or vital signs including blood pressure or heart rate changes. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1b/2a Proof of Concept Clinical Trial in NASH Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we presented positive topline results from our Phase 1b/2a trial in NASH patients which has informed the advancement of our clinical strategy in <font style="color:#000000;">NASH. </font>We plan to initiate a Phase 2b trial in NASH patients in the first half of 2021.<font style="Background-color:#FFFFFF;">The 13-week phase 1b/2a multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose-ranging trial enrolled a total of 81 patients</font><font style="Background-color:#FFFFFF;">&#160;to receive weekly (3mg/9mg/18mg/27mg) or every two-week (18mg/36mg) dosing of BIO89-100 or placebo for up to 12 weeks. Key endpoints assessed were safety, tolerability, and PK of BIO89-100 as well as change in liver fat measured by MRI-PDFF and other metabolic markers. The trial design is shown in Figure 6 below. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure</font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"> 6</font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">: </font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1b/2a Trial Design</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000003.jpg" title="" alt="" style="width:433px;height:324px;"><font style="Background-color:#FFFFFF;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As shown in Figure 7 below, all dose groups demonstrated significant reductions in liver fat at week 13, with relative reductions up to 60% versus baseline and up to 70% versus placebo, as measured by MRI-PDFF. </font><font style="Background-color:#FFFFFF;">43% of the patients at the highest dose achieved normal liver fat content of &lt; 5%. </font><font style="Background-color:#FFFFFF;">A significant proportion of patients responded to therapy with up to 88% and 71% of patients achieving a&#160;&#179;30% or a&#160;&#179;50% reduction in liver fat versus baseline, respectively.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 7: Relative Reduction in Liver Fat vs. Placebo at Week 13</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000004.jpg" title="" alt="" style="width:472px;height:308px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000005.jpg" title="" alt="" style="width:679px;height:24px;"><font style="Background-color:#FFFFFF;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As shown in Figure 8 below, treatment with BIO89-100 also resulted in significant improvements in liver transaminases, with up to a 44% reduction in ALT and a 35 U/L decrease in ALT in patients with elevated baseline levels. Treatment with BIO89-100 resulted in significant reductions in triglycerides (up to 28%; p &lt;0.05), non-HDL (up to 16%; p&lt;0.01) and LDL-C (up to 16%; p&lt;0.05). Triglycerides were reduced to a greater extent in patients with elevated triglycerides at baseline (TG &#8805;200 mg/dL), and 53% of the BIO89-100 patients in this group normalized triglyceride levels versus 0% in the placebo group. BIO89-100 also demonstrated significant increases in the insulin-sensitizing hormone adiponectin (up to 61%; p&lt;0.001). Improvements were also noted across the spectrum of metabolic marker data vs. placebo for the 27mg QW dose group including HOMA-IR, glucose, HbA1c, weight (p&lt;0.05) and adiponectin (p&lt;0.001). </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 8: Clinically Meaningful ALT Reduction; Greater Reduction in Patients with High ALT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000006.jpg" title="" alt="" style="width:624px;height:322px;"><font style="Background-color:#FFFFFF;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Baseline characteristics were similar across the sub-populations of biopsy-confirmed NASH and PNASH patients enrolled in the trial and results were also consistent across the two sub-groups. Specifically, the reductions in liver fat, percentage of responders on MRI-PDFF, and BIO89-100&#8217;s effect on reducing ALT and triglycerides were also similar across these sub-populations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As shown in Figures 9 and 10 below, BIO89-100 was well-tolerated across all doses with no deaths or serious adverse events related to treatment and a low incidence of treatment-related adverse events (&#8220;TRAEs&#8221;) that occurred in &#8805; 10% of patients. The only treatment-related adverse event that occurred in&#160;&#8805;10% of all BIO89-100-treated subjects was mild, increased appetite (15.9%) consistent with other investigational FGF21 analogs. Low frequency of gastrointestinal (&#8220;GI&#8221;) related adverse events was observed with a profile for BIO89-100 that was similar to placebo. Low rates of diarrhea (9.5% vs. 11.1% for placebo) and nausea (4.8% vs. 11.1% for placebo) and importantly, no vomiting were reported in BIO89-100 treated patients. No adverse effects on heart rate or blood pressure were observed.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure </font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">9</font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">: </font><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Safety Overview</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000007.jpg" title="" alt="" style="width:624px;height:170px;"><font style="Background-color:#FFFFFF;"></font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Figure 10: Treatment-Related Emergent AEs in &#8805; 10% of Pooled BIO89-100 Group</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqb5bzr5wcdj000008.jpg" title="" alt="" style="width:624px;height:73px;"><font style="Background-color:#FFFFFF;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paired-biopsy, Open-label Histology Cohort</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we initiated a paired-biopsy, open-label cohort as part of the Phase 1b/2a trial assessing histology endpoints, with data anticipated by the end of 2021. This cohort is expected to enroll approximately 20 patients with biopsy-confirmed NASH who will be treated for 20 weeks with 27 mg of BIO89-100 once weekly. The cohort will build on the&#160;<font style="text-decoration:none;color:#auto;">recent data</font><font style="color:#000000;">&#160;from </font>89bio&#8217;s Phase 1b/2a trial and will provide an early opportunity to demonstrate BIO89-100&#8217;s benefits on histology endpoints.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BIO89-100 Clinical Development in SHTG</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 has demonstrated significant reduction in triglyceride levels across all our preclinical and clinical studies. In diabetic obese cynomolgus monkeys with elevated triglyceride levels, BIO89-100 showed significant effects on triglycerides with a maximal reduction of 78% and 76% at doses of 1 mg/kg. In monkeys treated with baseline levels of triglycerides greater than 500mg/dL (n=4), the three monkeys treated with BIO89-100 1 mg/kg weekly had triglyceride reductions &gt;90% at study end. In our Phase 1a clinical study, in patients with baseline triglyceride values in the normal range (mean baseline 94 mg/dL), BIO89-100 demonstrated reductions of triglycerides from baseline up to 51% at Day 8 after a single dose in healthy volunteers. In our Phase 1b/2a trial, treatment with BIO89-100 <font style="Background-color:#FFFFFF;color:#000000;">resulted in significant reductions in triglycerides (up to 28%; p &lt;0.05). Triglycerides were reduced to a greater extent in patients with elevated triglycerides at baseline (TG &#179;200 mg/mL), and 53% of the BIO89-100 patients in this group normalized triglyceride levels versus 0% in the placebo group. </font>While currently approved SHTG therapies decrease triglyceride levels, they generally do not have broader metabolic benefits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated our Phase&#160;2 trial (ENTRIGUE) in SHTG patients in the third quarter of 2020 and expect to enroll approximately 90 patients who could be on stable background medications. In this Phase&#160;2 multi-center, randomized, double-blind, placebo-controlled study designed to evaluate safety, efficacy and tolerability, <font style="color:#000000;">patients will receive </font>BIO89-100 administered weekly <font style="color:#000000;">(9 mg, 18 mg or 27 mg) </font>or every two weeks<font style="color:#000000;"> (36 mg) or placebo</font>. The primary endpoint is the reduction in fasting triglycerides from baseline. Key secondary endpoints include other lipids and metabolic markers and change in liver fat measured by MRI-PDFF.&#160;Topline data from ENTRIGUE are expected in the second half of 2021. <font style="color:#000000;">We have expanded </font>ENTRIGUE<font style="color:#000000;"> with an additional cohort of patients on fibrates to assess the benefit of 27 mg weekly BIO89-100 when added to background fibrates. In this cohort, a total of 36 patients will be randomized to either BIO89-100 or placebo. The primary endpoint and key secondary endpoint are the same as in </font>ENTRIGUE<font style="color:#000000;">. </font>We also expect to initiate registrational trials in SHTG in 2022, pending positive data from ENTRIGUE. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is regulatory precedence for the approval of therap</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the treatment of SHTG in the United States </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the reduction in triglycerides from baseline as the primary endpoint for full approval. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA surrogate endpoint table for drug approval lists a reduction in triglycerides from baseline as the endpoint for full approval of a therapy in SHTG. A clinical outcome study was not required for certain third-party approvals in SHTG or as a post-marketing commitment. The SHTG Phase 3 trial for some of these products consisted of a single study of a 12-week duration with 75 to 100 patients per treatment group. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with Teva</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements Relating to FGF21 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into an Asset Transfer and License Agreement (the &#8220;FGF21 Agreement&#8221;) with Teva Pharmaceutical Industries Ltd (&#8220;Teva&#8221;), under which we acquired certain patents, intellectual property and other assets relating to Teva&#8217;s glycoPEGylated FGF21 program. Under this agreement, Teva also granted a perpetual, non-exclusive (but exclusive as to BIO89-100), non-transferable, worldwide license to patents and know-how related to glycoPEGylation technology for use in the research, development, manufacture and commercialization of the compound BIO89-100 and products containing BIO89-100. In addition, we entered into a Sublicense Agreement with ratiopharm (the &#8220;ratiopharm Sublicense&#8221;), under which we were granted a perpetual, exclusive, worldwide sublicense to patents and know-how related to glycoPEGylation technology used in the development, manufacture and commercialization of BIO89-100 and products containing BIO89-100.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FGF21 Agreement, we are obligated to use commercially reasonable efforts to develop and commercialize BIO89-100 in each of the United States and five major European countries. We have the right to sublicense all rights licensed to us by Teva under the FGF21 Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the FGF21 Agreement and the FASN Agreement (as defined and described below), we paid Teva a nonrefundable upfront payment of $6.0 million. In addition, under the FGF21 Agreement, we are required to make certain payments to Teva totaling $2.5 million for the achievement of certain clinical development milestones, and additional payments totaling up to $65.0 million upon achievement of certain commercial milestones. We are also obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales of products containing BIO89-100. Our royalty obligations will terminate, on a product-by-product and country-by-country basis, at the later of: (1) the date of expiration of the last to expire valid claim in the assigned patents that covers BIO89-100 in such country, (2) the expiration of data or regulatory exclusivity for BIO89-100 in such country and (3) 10 years from the first commercial sale of BIO89-100 in such country. We are not required to make any payments to ratiopharm pursuant to the ratiopharm Sublicense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the FGF21 Agreement will continue, on a product-by-product and country-by-country basis, until the royalty term with respect to BIO89-100 in such country expires. The ratiopharm Sublicense will continue until terminated in accordance with its terms. We may terminate the FGF21 Agreement and the ratiopharm Sublicense for any reason. Either party may terminate the FGF21 Agreement for cause for the other party&#8217;s uncured material breach. ratiopharm may terminate the ratiopharm Sublicense for certain material breaches by us. Either party may terminate the FGF21 Agreement or the ratiopharm Sublicense in the event of bankruptcy of the other party. Teva may terminate the FGF21 Agreement if we challenge the validity of any patent licensed to us under the FGF21 Agreement. Termination of the FGF21 Agreement or the ratiopharm Sublicense will impact our rights under the intellectual property licensed to us by Teva and ratiopharm, respectively, but will not affect our rights under the assets assigned to us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we also entered into a Reagent Supply and Technology Transfer Agreement, under which Teva will supply us with certain reagents required for the glycoPEGylation process that are necessary for our development and commercialization of BIO89-100, and transfer to us certain know-how required for the production of such reagents. The term of this agreement was recently extended by mutual agreement until December 31, 2022.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FASN Agreements</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into an Asset Transfer and License Agreement with Teva under which we acquired from Teva patents, intellectual property and other assets relating to Teva&#8217;s development program of small molecule inhibitors of FASN (the &#8220;FASN Agreement&#8221;). Under the FASN Agreement we are obligated to use commercially reasonable efforts to develop and commercialize FASN in the United States and five major European countries. We have the right to sublicense all rights licensed to us by Teva under the FASN Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the FASN Agreement and the FGF21 Agreement (as described above), we paid Teva a nonrefundable upfront payment of $6.0 million. In addition, under the FASN Agreement, we are required to make certain payments to Teva totaling $2.5 million for the achievement of certain clinical development milestones, and additional payments totaling up to $65.0 million upon achievement of certain commercial milestones. We are also obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales of products arising from the FASN program. Our royalty obligations will terminate, on a product-by-product and country-by-country basis, at the later of: (1) the date of expiration of the last to expire valid claim in the assigned patents that covers FASN in such country, (2) the expiration of data or regulatory exclusivity for such product arising from the FASN program in such country and (3) 10 years from the first commercial sale of a product arising from the FASN program in such country.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the FASN Agreement will continue, on a product-by-product and country-by-country basis, until the royalty term with respect to the product arising from the FASN program in such country expires. We may terminate the FASN Agreement for any reason. Either party may terminate the agreement for cause for the other party&#8217;s uncured material breach, or in the event of bankruptcy of the other party.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Government Regulation and Product Approval</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics, such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before biologic product candidates may be marketed in the United States is expensive and time-consuming. Generally, this process involves completing pre-clinical laboratory studies before the FDA will allow human clinical trials to commence. We are then required to complete human clinical trials to demonstrate that a product candidate is safe and effective. Following the completion of these clinical trials, we are required to prepare and submit a biologics license (&#8220;BLA&#8221;) application, which presents the FDA with detailed clinical and safety data, as well as manufacturing data. As part of the review of a BLA, the FDA may inspect manufacturing facilities to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and may also inspect selected clinical investigation sites to assess compliance with current Good Clinical Practices (&#8220;cGCP&#8221;). This process takes many years from inception through filing of a BLA application and the likelihood of success is highly uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and Clinical Development</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to beginning the first clinical trial with a product candidate, we must submit an investigational new drug (&#8220;IND&#8221;) application to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is the general investigational plan and the protocol(s) for clinical studies. Submission of an IND may or may not result in FDA authorization to begin a clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cGCPs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Furthermore, an independent </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review board (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRB</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">site,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase 1</font><font style="color:#000000;">&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase 2</font><font style="color:#000000;">&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Phase 3</font><font style="color:#000000;">&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies must finalize a process for manufacturing the product in commercial quantities in accordance with current<font style="letter-spacing:0.05pt;"> </font>good manufacturing<font style="letter-spacing:0.1pt;"> </font>practices<font style="letter-spacing:0.1pt;"> </font>(&#8220;cGMP&#8221;) requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BLA Submission and Review</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is may be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates a BLA and conducts</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> necessary</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> inspections, the FDA may </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe deficiencies that the FDA has identified in the BLA. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require, or companies may voluntarily pursue, one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expedited Programs for Serious Conditions</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs and biologics to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval. These programs can significantly reduce the time it takes for the FDA to review a BLA, but they do not guarantee that a product will receive FDA approval. Even if a product qualifies initially, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review will not be shortened.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon companies and third-party manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program, among other potential consequences. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among other things, adverse publicity, warning letters, corrective </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advertising</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and potential civil and criminal penalties. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biosimilars and Reference Product Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended (collectively, the &#8220;Affordable Care Act&#8221;) includes a provision called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other U.S. Healthcare Laws and Compliance Requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;), the federal False Claims Act, HIPAA and similar foreign, federal and state fraud, abuse and transparency laws.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal AKS prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving any remuneration, to induce or in return for either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal false claims laws, including the False Claims Act (&#8220;FCA&#8221;), which imposes significant penalties and can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of federal government funds, including federal healthcare programs, such as Medicare and Medicaid. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim for purposes of the FCA.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The FCA imposes mandatory treble damages and per-violation civil penalties up to approximately $23,000.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs and biologics covered by Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such reporting obligations will be expanded to include payments and other transfers of value provided in 2021 to certain other healthcare professionals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is a difficult and costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Data Privacy and Security</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous state, federal and foreign laws, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. Entities that are found to be in violation of HIPAA or other laws may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations. Further, entities that knowingly obtain, use, or disclose certain individually identifiable health information in an improper fashion may be subject to criminal penalties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, private health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
<p style="margin-top:6pt;margin-bottom:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. The Affordable Care Act and its implementing regulations, among other things, revised the methodology for calculating rebates for covered outpatient drugs and certain biologics owed by manufacturers to the state and federal government under the Medicaid Drug Rebate Program, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and expanded programs designed to test innovative payment models, service delivery models, or value-based arrangements, and fund comparative effectiveness research.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There remain legal and political challenges to certain aspects of the Affordable Care Act. In December 2018, a United States District Court judge in Texas ruled that the Affordable Care Act is unconstitutional in its entirety </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because the &#8220;individual mandate&#8221; was repealed by Congress </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2017. The decision </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been appealed to the United States </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supreme Court</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> decision is expected by spring 2021.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> It is unclear how such litigation and other efforts to repeal</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> replace</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or otherwise modify</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Affordable Care Act will impact </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement of pharmaceutical and biological products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. In October 2020, the FDA issued guidance describing procedures for manufacturers to facilitate the importation of FDA-approved biologics manufactured abroad and originally intended for sale in a foreign country into the United States. Previously, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the Biden administration has stayed the effective dates of some last-minute drug price regulations issued by the Trump administration, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Regulation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, local, state and federal laws, including in the United States and Israel, regarding such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous or biohazardous substances, we could be liable for damages, environmental remediation, and/or governmental fines. We believe that we are in material compliance with applicable environmental laws and occupational health and safety laws that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. We may incur significant costs to comply with such laws and regulations now or in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of BIO89-100 and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Given the high incidence of NASH, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as NASH, will increase.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64489519"></a>If BIO89-100 is approved for the treatment of NASH, future competition could also arise from products currently in development, including: GS-0976, an ACC inhibitor, and GS-9674, an FXR agonist, from Gilead Sciences, Inc.; PF-05221304, an ACC inhibitor, and PF-06835919, a KHK inhibitor, from Pfizer Inc.; Ocaliva, an FXR agonist from Intercept Pharmaceuticals, Inc.; Resmetirom, a beta-thyroid hormone receptor agonist from Madrigal Pharmaceuticals, Inc.; VK2809, a beta-thyroid hormone receptor agonist from Viking Therapeutics, Inc.; Aldafermin, an FGF19 analog from NGM Biopharmaceuticals, Inc.; MK-3655, an FGFR1c/KLB agonist antibody from Merck &amp; Co., Inc.; Pegbelfermin, a PEGylated FGF21 analog from Bristol-Myers Squibb Company; Efruxifermin, a FGF21 fusion protein from Akero Therapeutics, Inc.; Elobixibat, an IBAT-inhibitor from Albireo Pharma, Inc.; a Galectin-3 inhibitor from Galectin Therapeutics Inc.; a synthetic conjugate of cholic acid and arachidic acid from Galmed Pharmaceuticals Ltd.; MET409/MET642, FXR agonists from Metacrine, Inc, Novartis AG and Terns Pharmaceuticals; Semaglutide, a GLP-1 receptor agonist from Novo Nordisk A/S; ALT-801, a dual GLP-1/glucagon agonist from Altimmune; Tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly and Company; and Lanifibranor, a PPAR alpha/delta/gamma agonist from Iventiva; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If BIO89-100 is approved for the treatment of SHTG, we would face competition from currently approved and marketed products, including statins, fibrates, Vascepa, and Lovaza, as well as generic products. Further competition could arise from products currently in development, including: AKCEA-APOCIII-LRx, an ApoC III inhibitor from Ionis; Vupanorsen/AKCEA-ANGPTL3, an anti-ANGPTL3 from Pfizer; Evinacumab, an Anti-ANGPTL3 from Regeneron Pharmaceuticals, Inc.; Pemafibrate, a PPAR alpha agonist from Kowa Research Institute, Inc.; and ARO-APOC3, an ApoC III inhibitor and ARO-ANG3, an anti-ANGPTL3 from Arrowhead Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. As a result, our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop and succeed in obtaining approval for drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing and Supply</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities for the production of BIO89-100, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely, and expect to continue to rely, on third parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing if BIO89-100 or any future product candidate receives marketing approval.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 drug substance is manufactured by fermentation of a recombinant strain of the bacterium E. coli. Product accumulates as insoluble particles (inclusion bodies) within the cells and is recovered by cell disruption, followed by solubilization of the inclusion bodies, protein refolding and purification with two chromatographic separation columns. Purified material is glycoPEGylated in a 2-step enzymatic reaction where a 20kDa linear glycoPEG moiety is attached to the protein through GalNAc and Sialic Acid linkers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GlycoPEGylated</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> protein is purified with two chromatographic columns to yield product with target quality attributes. Purified </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">glycoPEGylated</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> protein is concentrated and then formulated to a target concentration with formulation buffer as drug product.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Northway Biotechpharma (&#8220;BTPH&#8221;) is our sole source supplier for BIO89-100. Any reduction or halt in supply of drug product from BTPH could limit our ability to develop BIO89-100 until a replacement contract manufacturer is found and qualified. We currently have material available to support our ongoing clinical trials for the treatment of NASH and SHTG.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are working with BTPH on process optimization to support large-scale production for future trials and commercialization. In parallel, we have entered into a contract with a formulation development company to explore the potential for a new refrigerated liquid formulation and/or a freeze-dried, or lyophilized product.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BTPH Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, we entered into a master services agreement with BTPH, under which BTPH agreed to provide us certain services, including development, manufacturing, and storing of BIO89-100, under statements of work for such services to be agreed by the parties from time to time. The master services agreement will continue for the duration of time that BTPH is providing services to us, unless earlier terminated by either party upon its terms. We may terminate the agreement at any time after a specified notice period and subject to the payment of certain agreed upon fees where such termination results in cancellation of manufacturing scheduled within a certain period. In addition, either party may terminate the agreement for cause for the other party&#8217;s uncured material breach, in the event of bankruptcy of the other party, in the event of the commission of fraud by the other party or in the event of a force majeure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sales and Marketing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the geographic market for a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we develop on our own is limited or that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to establish direct sales capability until shortly before the products are approved for commercial sale.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek third-party support from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part upon our ability to protect our core technology and intellectual property. To protect our intellectual property rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment agreements. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, novel biological discoveries, new targets and applications, and other inventions that are important to our business. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, methods of making and methods of use. As we continue the development of our product candidates, we plan to identify additional means of obtaining patent protection that would potentially enhance commercial success, including pursuit of claims directed to new therapeutic indications.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FGF21 Patents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FGF21 patent portfolio includes four families:</p>
<p style="margin-top:6pt;margin-bottom:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first family is entitled &#8220;Remodeling and GlycoPEGylation of Fibroblast Growth Factor (FGF)&#8221;. This patent family provides granted patent protection in 39 countries around the globe, including the United States (U.S. Patent Number 9,200,049, expiry date: June 25, 2028; and U.S. Patent No. 10,874,714, expiry date: October 10, 2028), Canada, Europe (broadly), and Japan (latter three expire October 31, 2025) for FGF21 conjugates comprising a variety of modifying groups that can be attached at several different amino acid positions. GlycoPEGylated FGF21 is specifically claimed. The granted claims broadly protect our lead drug candidate BIO89-100 and pharmaceutical compositions thereof, as well as methods for making and using BIO89-100 to treat FGF21 deficiency in a patient in need thereof. One U.S. application is pending in this family.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second family is entitled &#8220;Mutant FGF-21 Peptide Conjugate and Uses Thereof&#8221; and is specifically directed to BIO89-100. The PCT Application for this family was filed on September 4, 2018 (PCT/IB2018/00112). A U.S. Prioritized Examination Continuation Patent Application (Application Serial No. 16/225,640) was filed on December 19, 2018 as a continuation of PCT/IB2018/0112 and from which U.S. Patent Number 10,407,479 was issued on September 10, 2019. The term of the U.S. Patent Number 10,407,479 is September 4, 2038. The issued claims are directed to BIO89-100 and a defined genus specifically encompassing BIO89-100 and compositions thereof (including site-specific mutations at positions 173 and 176), as well as methods for making and using BIO89-100 for a variety of therapeutic indications. Such indications include methods for treating NASH or metabolic syndrome. Subjects where there is a need to reduce blood glucose or to reduce HbA1C include those afflicted with diabetes Type 2, NASH and metabolic syndrome. The claims encompass different therapeutic regimens for administering BIO89-100 (e.g., once a week or once every two weeks), which regimens are based on BIO89-100&#8217;s surprisingly long half-life in vivo. One U.S. application is pending in this family. National phase entry of this PCT Application has been initiated in Australia (granted), Korea (allowed), Europe, China,&#160;Hong Kong, Japan (allowed), Canada and Israel to pursue global protection of specific mutant FGF21 peptide conjugates, and particularly BIO89-100, in these jurisdictions. Australian patent No. 2018322943 was granted on September 17, 2020 (expiry date: September 4, 2038). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third family is entitled &#8220;Methods </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Treatment Using Mutant FGF-21 Peptide Conjugates&#8221;. A U.S. patent application was filed </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 28, 2020 (US Serial Number 16/885,353). This patent application is not published. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fourth family is entitled &#8220;Methods for promoting weight loss&#8221;. A PCT application was filed January 29, 2021 (PCT/IB2021/000044) with claims directed towards method to reduce total body weight, body fat content and/or BMI. National phase entry of this application is due by July 31, 2022. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to file patent applications to cover various formulations of FGF21. We have filed a provisional application on March 11, 2021 on stable liquid formulation of FGF21.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FASN Patents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FASN patent portfolio currently consists of three patent families, including patents and/or patent applications in the United States, the European Patent Convention, Canada, Mexico, Israel, China and Japan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first patent family, directed to TEV-48317, which we acquired from Teva under the FASN Agreement, and other 1,4-substituted piperidine-based FASN inhibitors, is currently protected by three granted U.S. patents that cover these compounds, pharmaceutical compositions comprising these compounds, and/or methods of treating FASN-mediated disorders using these compounds. The non-extended term for these patents would expire on June 17, 2036. A pending U.S. application has also been filed. The first patent family also includes two foreign patents and four patent applications. The second patent family is directed to other 1,4-substituted piperidine-based FASN inhibitors, pharmaceutical compositions, and methods of treating FASN-mediated disorders. The second patent family includes one granted U.S. patent, three foreign patents, and two foreign patent applications. The third patent family is directed to spiropiperidine FASN inhibitors, pharmaceutical compositions containing these compounds, and methods of treating FASN-mediated disorders using these compounds. The third patent family includes one U.S. patent application and five foreign patent applications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk64489766"></a>Employees</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 26 full-time employees and 27 total employees. 19 employees are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in January 2018 in Israel under the name 89Bio Ltd. 89bio, Inc., the registrant whose name appears on the cover page of this Annual Report on Form 10-K, was incorporated in June 2019 for the purpose of an internal reorganization transaction. In September 2019, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. Following this exchange, 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located at 142 Sansome Street, San Francisco, California 94104 and our telephone number is (415) 500-4614. Our website is <font style="font-style:italic;">www.89bio.com</font>. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the SEC our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We make available on our website at <font style="font-style:italic;">www.89bio.com</font>, under &#8220;Investors,&#8221; free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company (&#8220;emerging growth company&#8221;), as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including relief from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, less extensive disclosure obligations regarding executive compensation in our registration statements, periodic reports and proxy statements, exemptions from the requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder approval of any golden parachute payments not previously approved. We may also elect to take advantage of other reduced reporting requirements in future filings. As a result, our stockholders may not have access to certain information that they may deem important and the information that we provide to our stockholders may be different than, and not comparable to, information presented by other public reporting companies. We could remain an emerging growth company until the earlier of (1) the last day of the year following the fifth anniversary of the completion of our initial public offering (&#8220;IPO&#8221;), (2) the last day of the year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act also provides that an emerging growth company may take advantage of the extended transition period provided in the Securities Act for complying with new or revised accounting standards. An emerging growth company may therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as are required of other public companies that are not emerging growth companies, which may make comparison of our consolidated financial information to those of other public companies more difficult.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company (&#8220;smaller reporting company&#8221;), as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">An<font style="letter-spacing:-0.05pt;">&#160;</font>investment<font style="letter-spacing:0.05pt;">&#160;</font>in our common<font style="letter-spacing:-0.05pt;">&#160;</font>stock<font style="letter-spacing:0.05pt;">&#160;</font>involves<font style="letter-spacing:0.05pt;">&#160;</font>a high degree of risk.<font style="letter-spacing:0.05pt;">&#160;</font>You<font style="letter-spacing:-0.05pt;">&#160;</font>should carefully<font style="letter-spacing:0.1pt;">&#160;</font>consider<font style="letter-spacing:0.05pt;">&#160;</font>the risks<font style="letter-spacing:0.05pt;">&#160;</font>and uncertainties<font style="letter-spacing:0.1pt;">&#160;</font>described<font style="letter-spacing:0.05pt;">&#160;</font>below before<font style="letter-spacing:0.05pt;">&#160;</font>deciding<font style="letter-spacing:0.05pt;">&#160;</font>whether to make an investment decision with respect to shares of our common<font style="letter-spacing:-0.05pt;">&#160;</font>stock.<font style="letter-spacing:0.05pt;">&#160;</font>You should also refer<font style="letter-spacing:0.05pt;">&#160;</font>to the other information<font style="letter-spacing:0.05pt;">&#160;</font>contained<font style="letter-spacing:0.05pt;">&#160;</font>in this<font style="letter-spacing:0.05pt;">&#160;</font>Annual Report on Form 10-K,<font style="letter-spacing:0.05pt;">&#160;</font>including<font style="letter-spacing:0.05pt;">&#160;</font>&#8220;Management&#8217;s<font style="letter-spacing:0.05pt;">&#160;</font>Discussion<font style="letter-spacing:0.05pt;">&#160;</font>and Analysis<font style="letter-spacing:0.05pt;">&#160;</font>of Financial<font style="letter-spacing:0.05pt;">&#160;</font>Condition and Results<font style="letter-spacing:0.05pt;">&#160;</font>of Operations&#8221; and our audited<font style="letter-spacing:0.05pt;">&#160;</font>consolidated financial<font style="letter-spacing:0.05pt;">&#160;</font>statements<font style="letter-spacing:0.05pt;">&#160;</font>and related<font style="letter-spacing:0.05pt;">&#160;</font>notes. Our<font style="letter-spacing:-0.05pt;">&#160;</font>business,<font style="letter-spacing:0.05pt;">&#160;</font>financial<font style="letter-spacing:0.05pt;">&#160;</font>condition,<font style="letter-spacing:0.05pt;">&#160;</font>results<font style="letter-spacing:0.05pt;">&#160;</font>of operations<font style="letter-spacing:0.05pt;">&#160;</font>and prospects<font style="letter-spacing:0.05pt;">&#160;</font>could be materially<font style="letter-spacing:0.05pt;">&#160;</font>and adversely<font style="letter-spacing:0.05pt;">&#160;</font>affected<font style="letter-spacing:0.05pt;">&#160;</font>by any of these<font style="letter-spacing:0.05pt;">&#160;</font>risks<font style="letter-spacing:0.05pt;">&#160;</font>or uncertainties.<font style="letter-spacing:0.1pt;">&#160;</font>In any such case, the trading<font style="letter-spacing:0.05pt;">&#160;</font>price<font style="letter-spacing:0.05pt;">&#160;</font>of our common<font style="letter-spacing:-0.05pt;">&#160;</font>stock<font style="letter-spacing:0.05pt;">&#160;</font>could decline,<font style="letter-spacing:0.05pt;">&#160;</font>and you could lose all or part of your investment. We caution you that the risks, uncertainties and other factors referred to below and elsewhere in this Annual Report on Form 10-K may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for us to predict all risks.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Risk Factor Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves significant risks. You should carefully consider the risks described below before making a decision to invest in our common stock. If we are unable to successfully address these risks and challenges, our business, financial condition, results of operations, or prospects could be materially adversely affected. In such case, the trading price of our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we expect to incur significant and increasing operating losses and we may never be profitable. Our stock is a highly speculative investment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The ongoing COVID-19 pandemic has resulted and may in the future result in significant disruptions to our clinical trials or other business operations, which could have a material adverse effect on our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our business depends on the success of BIO89-100, our only product candidate under clinical development, which has not completed a pivotal trial. If we are unable to obtain regulatory approval for and successfully commercialize BIO89-100 or other future product candidates, or we experience significant delays in doing so, our business will be materially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we experience delays in clinical testing, our commercial prospects will be adversely affected, our costs may increase and our business may be harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">BIO89-100 and any future product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are developing BIO89-100 for the treatment of NASH, an indication for which there are no approved products. This makes it difficult to predict the timing and costs of the clinical development of BIO89-100 for the treatment of NASH.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates, which could adversely affect our stock price, our ability to attract additional capital and our development program.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We have relied on, and expect to continue to rely on, third-party manufacturers to produce BIO89-100 or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">The manufacture of biologic products is </font><font style="color:#000000;">complex</font><font style="color:#000000;"> and we are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our products</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of BIO89-100 or develop new product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than us.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our Loan and Security Agreement with Silicon Valley Bank contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">BIO89-100 has not received regulatory approval. If we are unable to obtain regulatory approvals to market BIO89-100 or any future product candidates, our business will be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our success depends upon our ability to obtain and maintain intellectual property protection for our products and technologies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We rely on a license from Teva and a sublicense from ratiopharm to patents and know-how related to glycoPEGylation technology that are used in the development, manufacture and commercialization of BIO89-100. Any termination or loss of significant rights, including the right to glycoPEGylation technology, or breach, under these agreements or any future license agreement related to our product candidates, would materially and adversely affect our ability to continue the development and commercialization of the related product candidates.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Our Business and<font style="letter-spacing:-0.05pt;"> </font>Industry</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical<font style="letter-spacing:0.1pt;"> </font>company with a limited<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>history<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>no<font style="letter-spacing:-0.05pt;"> </font>products approved<font style="letter-spacing:1.05pt;"> </font>for commercial<font style="letter-spacing:0.1pt;"> </font>sale. We have incurred net losses<font style="letter-spacing:0.05pt;"> </font>since our inception,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>expect<font style="letter-spacing:0.05pt;"> </font>to incur significant<font style="letter-spacing:0.1pt;"> </font>and increasing<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>losses<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may never be profitable.<font style="letter-spacing:0.1pt;"> </font>Our<font style="letter-spacing:-0.05pt;"> </font>stock is a highly speculative<font style="letter-spacing:0.1pt;"> </font>investment.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage<font style="letter-spacing:0.05pt;"> </font>biopharmaceutical<font style="letter-spacing:0.15pt;"> </font>company with a limited<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>history<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may make it<font style="letter-spacing:1.1pt;"> </font>difficult<font style="letter-spacing:0.1pt;"> </font>to evaluate<font style="letter-spacing:0.05pt;"> </font>the success<font style="letter-spacing:0.05pt;"> </font>of our business<font style="letter-spacing:0.05pt;"> </font>to date and to assess<font style="letter-spacing:0.05pt;"> </font>our future<font style="letter-spacing:0.05pt;"> </font>viability.<font style="letter-spacing:0.1pt;"> </font>We commenced operations<font style="letter-spacing:0.05pt;"> </font>in 2018, and to date, our operations<font style="letter-spacing:0.05pt;"> </font>have been focused on organizing<font style="letter-spacing:0.05pt;"> </font>and staffing<font style="letter-spacing:0.1pt;"> </font>our company, raising<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.05pt;"> </font>acquiring<font style="letter-spacing:0.05pt;"> </font>our initial<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100 and licensing<font style="letter-spacing:0.05pt;"> </font>certain related<font style="letter-spacing:0.05pt;"> </font>technology, conducting<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>and providing<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>support<font style="letter-spacing:0.05pt;"> </font>for these<font style="letter-spacing:0.05pt;"> </font>operations.<font style="letter-spacing:0.05pt;"> </font>Investment<font style="letter-spacing:0.1pt;"> </font>in biopharmaceutical<font style="letter-spacing:0.15pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>is highly speculative<font style="letter-spacing:0.1pt;"> </font>because<font style="letter-spacing:0.05pt;"> </font>it entails<font style="letter-spacing:0.05pt;"> </font>substantial<font style="letter-spacing:0.1pt;"> </font>upfront<font style="letter-spacing:0.05pt;"> </font>capital expenditures<font style="letter-spacing:0.1pt;"> </font>and significant<font style="letter-spacing:0.1pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>any potential<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>will fail<font style="letter-spacing:0.05pt;"> </font>to demonstrate<font style="letter-spacing:0.1pt;"> </font>adequate<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>and/or an acceptable<font style="letter-spacing:0.1pt;"> </font>safety<font style="letter-spacing:0.05pt;"> </font>profile,<font style="letter-spacing:0.05pt;"> </font>gain regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>and become<font style="letter-spacing:0.05pt;"> </font>commercially<font style="letter-spacing:0.15pt;"> </font>viable.<font style="letter-spacing:0.05pt;"> </font>We have no products approved for commercial<font style="letter-spacing:0.1pt;"> </font>sale,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have not generated<font style="letter-spacing:0.05pt;"> </font>any revenue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>sales<font style="letter-spacing:0.05pt;"> </font>to date and we<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:0.05pt;"> </font>to incur<font style="letter-spacing:0.05pt;"> </font>significant<font style="letter-spacing:0.1pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to our ongoing operations.<font style="letter-spacing:0.05pt;"> </font>We have limited<font style="letter-spacing:0.1pt;"> </font>experience<font style="letter-spacing:0.05pt;"> </font>as a company conducting<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and no experience<font style="letter-spacing:0.05pt;"> </font>as a company commercializing any products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 is in development and, to date, we have not generated any revenue from the licensing or commercialization of BIO89-100. We will not be able to generate product revenue unless and until BIO89-100 or any future product candidate, alone or with future partners, successfully completes clinical trials, receives regulatory approval and is successfully commercialized. As BIO89-100 is in development, we do not expect to receive revenue from it for a number of years, if ever. Although we may seek to obtain revenue from collaboration or licensing agreements with third parties, we currently have no such agreements that could provide us with material, ongoing future revenue and we may never enter into any such agreements.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not profitable</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and have incurred</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net losses</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">since</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inception.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predictions</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">about our future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">success</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or viability</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be as accurate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as they would be if we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had a longer</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">history</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or a history</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of successfully</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and commercializing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have spent, and expect</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to continue</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to spend, significant</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resources to fund research</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and development</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of, and seek regulatory</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for, BIO89-100 and any future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to incur</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and increasing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over the next several</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as our research,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and manufacturing </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In addition, because of the numerous risks and uncertainties associated with pharmaceutical product development, including that our product candidates may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or if or when we will achieve or maintain profitability. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The size</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net losses</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will depend, in part,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the rate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">growth of our expenses</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our ability</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to generate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net losses</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incur</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may fluctuate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter-to-quarter</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such that a period-to-period</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comparison</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be a good indication</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our future performance.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eventually</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may never be profitable</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, if we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do achieve profitability,</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be able to sustain</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or increase</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profitability</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a quarterly</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or annual basis.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has resulted and may in the future result in significant disruptions to our clinical trials or other business operations, which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and its operations, including but not limited to our research and development activities, could be adversely affected by health epidemics in regions where we have business operations, and such health epidemics could cause significant disruption in the operations of third parties upon whom we rely. In response to public health directives and orders related to COVID-19 and based on guidance from public health officials, we have implemented and continue to implement work-from-home policies for our employees on an office-by-office basis. The effects of executive and similar government orders, shelter-in-place orders and our work-from-home policies may negatively impact our growth, including our ability to recruit and onboard new employees, and productivity, disrupt our business and delay our preclinical and clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, while we initiated the Phase 2 trial (ENTRIGUE) of BIO89-100 for the treatment of SHTG and a paired-biopsy histology cohort as part of the Phase 1b/2a trial of BIO89-100 in NASH in 2020, our successful completion of these trials will depend on the external environment with respect to COVID-19 remaining conducive to executing the trial safely and effectively. Similarly, while we expect to initiate a Phase 2b trial of BIO89-100 in NASH patients in the first half of 2021, we may be delayed in the initiation of such trial due to COVID-19 or the related government restrictions.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, have impacted and may continue to impact personnel at third-party manufacturing facilities in the United States, Europe and other countries, or the availability or cost of materials we use or require to conduct our business, including product development, which would disrupt our supply chain. Furthermore, some of our manufacturers and suppliers are in Europe and may be impacted by port closures and other restrictions resulting from the COVID-19 pandemic, which may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products. In particular, BTPH, our sole source supplier for BIO89-100, has missed certain project deadlines for our manufacturing scale-up due to quarantine orders and has forecasted other delays due to COVID-19-related impacts on their suppliers; however, we do not expect delays to the overall timeline for the delivery of clinical supplies.<font style="color:#1F497D;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If COVID-19 continues to spread in the United States and elsewhere, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials, including: delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials; delays or difficulties in enrolling patients in our clinical trials; delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials; changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and result in unexpected costs, or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discontinuing our clinical trials altogether; a diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; interruption of key clinical trial activities, such as clinical trial site monitoring and data entry and verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the completeness and integrity of clinical trial data and, as a result, determine the outcomes of the trial; the risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; the risk that participants enrolled in our clinical trials will not be able to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from COVID-19 or comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services; interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities; limitations in employee resources that would otherwise be focused on the conduct of our clinical trials; the refusal of the FDA to accept data from clinical trials in affected geographies; and interruption or delays to our clinical activities.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. However, any one or a combination of these events could have an adverse effect on the operation of and results from our clinical trials and on our other business operations, including preventing or delaying approval for BIO89-100.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377806"></a>Our<font style="letter-spacing:-0.05pt;"> </font>business depends on<font style="letter-spacing:-0.05pt;"> </font>the success<font style="letter-spacing:0.05pt;"> </font>of BIO89-100,<font style="letter-spacing:-0.05pt;"> </font>our only product candidate<font style="letter-spacing:0.05pt;"> </font>under clinical<font style="letter-spacing:0.05pt;"> </font>development, which<font style="letter-spacing:-0.05pt;"> </font>has not completed<font style="letter-spacing:0.05pt;"> </font>a pivotal<font style="letter-spacing:0.05pt;"> </font>trial.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>are unable to obtain regulatory<font style="letter-spacing:0.05pt;"> </font>approval for and<font style="letter-spacing:-0.05pt;"> </font>successfully<font style="letter-spacing:0.1pt;"> </font>commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or other future product candidates, or we<font style="letter-spacing:-0.05pt;"> </font>experience<font style="letter-spacing:0.05pt;"> </font>significant<font style="letter-spacing:0.1pt;"> </font>delays<font style="letter-spacing:0.05pt;"> </font>in doing so, our business will be materially<font style="letter-spacing:0.1pt;"> </font>harmed.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:-0.05pt;"> </font>date, the primary<font style="letter-spacing:0.05pt;"> </font>focus of our product<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>has been BIO89-100 for the treatment<font style="letter-spacing:0.1pt;"> </font>of patients with NASH.<font style="letter-spacing:-0.1pt;"> </font>Currently,<font style="letter-spacing:0.05pt;"> </font>BIO89-100 is our only product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>under clinical<font style="letter-spacing:0.1pt;"> </font>development.<font style="letter-spacing:0.05pt;"> </font>This may make an investment<font style="letter-spacing:0.1pt;"> </font>in our company riskier<font style="letter-spacing:0.1pt;"> </font>than similar<font style="letter-spacing:0.1pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have multiple<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>in active development<font style="letter-spacing:0.05pt;"> </font>and that<font style="letter-spacing:0.05pt;"> </font>therefore<font style="letter-spacing:0.1pt;"> </font>may be able to better<font style="letter-spacing:0.05pt;"> </font>sustain<font style="letter-spacing:0.05pt;"> </font>a failure<font style="letter-spacing:0.1pt;"> </font>of a lead candidate.<font style="letter-spacing:0.05pt;"> </font>Successful<font style="letter-spacing:0.05pt;"> </font>continued development<font style="letter-spacing:0.05pt;"> </font>and ultimate<font style="letter-spacing:0.1pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 for the treatment<font style="letter-spacing:0.1pt;"> </font>of NASH<font style="letter-spacing:-0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>indications, including<font style="letter-spacing:0.05pt;"> </font>SHTG,<font style="letter-spacing:-0.1pt;"> </font>is critical<font style="letter-spacing:0.1pt;"> </font>to the future<font style="letter-spacing:0.05pt;"> </font>success<font style="letter-spacing:0.05pt;"> </font>of our business.<font style="letter-spacing:0.05pt;"> </font>We have invested,<font style="letter-spacing:0.05pt;"> </font>and will continue<font style="letter-spacing:0.05pt;"> </font>to invest,<font style="letter-spacing:0.05pt;"> </font>a significant<font style="letter-spacing:0.1pt;"> </font>portion<font style="letter-spacing:0.05pt;"> </font>of our time<font style="letter-spacing:0.05pt;"> </font>and financial<font style="letter-spacing:0.1pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>in the clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100. If we<font style="letter-spacing:-0.05pt;"> </font>cannot successfully<font style="letter-spacing:0.1pt;"> </font>develop, obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for and commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100, we<font style="letter-spacing:-0.05pt;"> </font>may not be able to continue<font style="letter-spacing:0.05pt;"> </font>our operations.<font style="letter-spacing:0.05pt;"> </font>The future<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>and commercial<font style="letter-spacing:0.1pt;"> </font>success<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 is subject<font style="letter-spacing:0.05pt;"> </font>to a number<font style="letter-spacing:0.05pt;"> </font>of risks,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>that if approved for NASH or SHTG, BIO89-100 will likely compete with products that may reach approval for the treatment of NASH prior to BIO89-100, products that are currently approved for the treatment of SHTG and the off-label use of currently marketed products for NASH and SHTG. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377814"></a>Clinical<font style="letter-spacing:0.05pt;"> </font>drug development<font style="letter-spacing:0.05pt;"> </font>involves<font style="letter-spacing:0.05pt;"> </font>a lengthy and<font style="letter-spacing:-0.05pt;"> </font>expensive<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>with uncertain timelines<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>uncertain outcomes,<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>the results<font style="letter-spacing:0.05pt;"> </font>of prior preclinical<font style="letter-spacing:0.1pt;"> </font>or clinical<font style="letter-spacing:0.05pt;"> </font>trials<font style="letter-spacing:0.05pt;"> </font>are not necessarily<font style="letter-spacing:0.1pt;"> </font>predictive<font style="letter-spacing:0.1pt;"> </font>of our future results.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>will be subject<font style="letter-spacing:0.05pt;"> </font>to rigorous<font style="letter-spacing:0.05pt;"> </font>and extensive<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and extensive<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>processes<font style="letter-spacing:0.05pt;"> </font>implemented<font style="letter-spacing:0.1pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>and comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities before<font style="letter-spacing:0.05pt;"> </font>obtaining<font style="letter-spacing:0.05pt;"> </font>marketing<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities.<font style="letter-spacing:0.1pt;"> </font>The drug development<font style="letter-spacing:0.05pt;"> </font>and approval process<font style="letter-spacing:0.05pt;"> </font>is lengthy<font style="letter-spacing:0.05pt;"> </font>and expensive,<font style="letter-spacing:0.05pt;"> </font>and approval<font style="letter-spacing:0.05pt;"> </font>is never certain.<font style="letter-spacing:0.05pt;"> </font>Investigational<font style="letter-spacing:0.15pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>drugs, such as BIO89-100, may not prove to be safe<font style="letter-spacing:0.05pt;"> </font>and effective<font style="letter-spacing:0.1pt;"> </font>in clinical<font style="letter-spacing:0.1pt;"> </font>trials.<font style="letter-spacing:0.1pt;"> </font>We have no direct<font style="letter-spacing:0.05pt;"> </font>experience<font style="letter-spacing:0.05pt;"> </font>as a company in conducting<font style="letter-spacing:0.05pt;"> </font>later<font style="letter-spacing:0.05pt;"> </font>stage<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval.<font style="letter-spacing:0.05pt;"> </font>We may be unable to conduct clinical trials<font style="letter-spacing:0.1pt;"> </font>at preferred<font style="letter-spacing:0.1pt;"> </font>sites,<font style="letter-spacing:0.05pt;"> </font>enlist<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>investigators,<font style="letter-spacing:0.1pt;"> </font>enroll<font style="letter-spacing:0.05pt;"> </font>sufficient<font style="letter-spacing:0.1pt;"> </font>numbers<font style="letter-spacing:0.05pt;"> </font>of participants<font style="letter-spacing:0.1pt;"> </font>or begin or successfully<font style="letter-spacing:0.1pt;"> </font>complete<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>in a timely<font style="letter-spacing:0.05pt;"> </font>fashion,<font style="letter-spacing:0.05pt;"> </font>if at all.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>the design of a clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>can determine<font style="letter-spacing:0.1pt;"> </font>whether its<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>will support<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of a product,<font style="letter-spacing:0.05pt;"> </font>and flaws in the design of a clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>may not become<font style="letter-spacing:0.05pt;"> </font>apparent<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>the clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>is well advanced. We<font style="letter-spacing:-0.05pt;"> </font>may be unable to design and execute<font style="letter-spacing:0.05pt;"> </font>a clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>to support<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval. Even if a current<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>is successful,<font style="letter-spacing:0.1pt;"> </font>it may be insufficient<font style="letter-spacing:0.15pt;"> </font>to demonstrate<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>BIO89-100 is safe<font style="letter-spacing:0.05pt;"> </font>or effective<font style="letter-spacing:0.1pt;"> </font>for registration<font style="letter-spacing:0.15pt;"> </font>purposes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a high failure</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for drugs and biologic</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can occur at any time</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of preclinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and early</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100 or any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be predictive</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of later-stage</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in one set of patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or line</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be predictive</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of those obtained</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in another.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In fact,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">many companies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the pharmaceutical</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and biotechnology</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industries</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have suffered significant</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">setbacks</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">late</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even after</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">achieving</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promising</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in preclinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and earlier</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data obtained</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preclinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is subject</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to varying interpretations,</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which may delay, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or prevent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is impossible</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to predict</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or if BIO89-100 or any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will prove effective</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or safe</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in humans or will receive</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approval.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Owing</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in part</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the complexity</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of biological</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pathways, BIO89-100 or any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate may not demonstrate</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the biochemical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and pharmacological</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">properties</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anticipate</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based on laboratory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or earlier</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and they may interact</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with human biological</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">systems</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other drugs in unforeseen,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ineffective</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or harmful</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ways. The number</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exposed to product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the average</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exposure</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be inadequate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to detect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rare</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">events</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or findings</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may only be detected</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">once a product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is administered</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and for greater periods</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of time.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date, our Phase 1a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Phase 1b/2a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ha</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> involved</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">small</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">population</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, because</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the small</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sample</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">size</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such trial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of th</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ese</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be subject</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to substantial variability</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may not be indicative</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of either</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interim</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> future trials of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with liver</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or cardio-metabolic</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diseases.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are unable to successfully</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demonstrate</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the safety</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and efficacy</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100 or other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and receive</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the necessary</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be materially harmed.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377824"></a>If we<font style="letter-spacing:-0.05pt;"> </font>experience<font style="letter-spacing:0.05pt;"> </font>delays<font style="letter-spacing:0.05pt;"> </font>in clinical<font style="letter-spacing:0.05pt;"> </font>testing,<font style="letter-spacing:0.05pt;"> </font>our commercial<font style="letter-spacing:0.1pt;"> </font>prospects<font style="letter-spacing:0.05pt;"> </font>will be adversely<font style="letter-spacing:0.05pt;"> </font>affected,<font style="letter-spacing:0.05pt;"> </font>our costs<font style="letter-spacing:0.05pt;"> </font>may increase<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will be able to initiate<font style="letter-spacing:0.1pt;"> </font>and complete<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials and successfully<font style="letter-spacing:0.1pt;"> </font>accomplish<font style="letter-spacing:0.1pt;"> all </font>required<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to gain approval and commercialize BIO89-100 or any future product candidates.<font style="letter-spacing:0.1pt;"> </font>We currently<font style="letter-spacing:-0.05pt;"> </font>have two active<font style="letter-spacing:0.05pt;"> </font>investigational new drug (&#8220;IND&#8221;) applications<font style="letter-spacing:-0.05pt;"> </font>with the FDA<font style="letter-spacing:-0.05pt;"> </font>in the United States<font style="letter-spacing:0.05pt;"> </font>for BIO89-100. In the future,<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may file<font style="letter-spacing:0.05pt;"> </font>an additional<font style="letter-spacing:0.1pt;"> </font>IND<font style="letter-spacing:-0.05pt;"> </font>with another<font style="letter-spacing:0.05pt;"> </font>division<font style="letter-spacing:0.05pt;"> </font>for any future<font style="letter-spacing:0.05pt;"> </font>indications or future product candidates.<font style="letter-spacing:-0.1pt;"> </font>If any such future<font style="letter-spacing:0.05pt;"> </font>IND<font style="letter-spacing:-0.05pt;"> </font>is not approved by the FDA,<font style="letter-spacing:-0.05pt;"> </font>our clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>timeline<font style="letter-spacing:0.1pt;"> </font>may be negatively<font style="letter-spacing:0.05pt;"> </font>impacted<font style="letter-spacing:0.05pt;"> </font>and any future<font style="letter-spacing:0.05pt;"> </font>clinical programs<font style="letter-spacing:0.05pt;"> </font>may be delayed<font style="letter-spacing:0.05pt;"> </font>or terminated. As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may be unable to obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>or successfully<font style="letter-spacing:0.1pt;"> </font>commercialize<font style="letter-spacing:0.15pt;"> </font>our products.<font style="letter-spacing:0.05pt;"> </font>We do not know<font style="letter-spacing:-0.05pt;"> </font>whether any other<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>will begin as planned, will need to be restructured<font style="letter-spacing:0.1pt;"> </font>or will be completed<font style="letter-spacing:0.05pt;"> </font>on schedule,<font style="letter-spacing:0.05pt;"> </font>or at all.<font style="letter-spacing:0.05pt;"> </font>Our product<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>will increase<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>experience<font style="letter-spacing:0.05pt;"> </font>delays<font style="letter-spacing:0.05pt;"> </font>in clinical<font style="letter-spacing:0.1pt;"> </font>testing.<font style="letter-spacing:0.05pt;"> </font>Significant<font style="letter-spacing:0.1pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>delays<font style="letter-spacing:0.05pt;"> </font>also could shorten<font style="letter-spacing:0.05pt;"> </font>any periods during which we<font style="letter-spacing:-0.05pt;"> </font>may have the exclusive<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or allow our competitors<font style="letter-spacing:0.1pt;"> </font>to bring products<font style="letter-spacing:0.05pt;"> </font>to market<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>do, which would impair<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to successfully commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and may harm<font style="letter-spacing:0.05pt;"> </font>our business,<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>of operations<font style="letter-spacing:0.05pt;"> </font>and prospects.<font style="letter-spacing:0.05pt;"> </font>Our or our future<font style="letter-spacing:0.05pt;"> </font>collaborators&#8217;<font style="letter-spacing:0.15pt;"> </font>inability<font style="letter-spacing:0.1pt;"> </font>to timely<font style="letter-spacing:0.05pt;"> </font>complete<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>could result<font style="letter-spacing:0.05pt;"> </font>in additional<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>to us as well as impair<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to generate<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>revenue,<font style="letter-spacing:0.05pt;"> </font>continue<font style="letter-spacing:0.05pt;"> </font>development, commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>reach<font style="letter-spacing:0.05pt;"> </font>sales<font style="letter-spacing:0.05pt;"> </font>milestone<font style="letter-spacing:0.1pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>and receive royalties<font style="letter-spacing:0.1pt;"> </font>on product<font style="letter-spacing:0.05pt;"> </font>sales.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>make changes to a product<font style="letter-spacing:0.05pt;"> </font>candidate including, for example, a new formulation,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may need to conduct additional<font style="letter-spacing:0.1pt;"> </font>nonclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>or <font style="letter-spacing:0.05pt;">clinical</font><font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>to bridge<font style="letter-spacing:0.05pt;"> </font>or demonstrate<font style="letter-spacing:0.1pt;"> </font>the comparability<font style="letter-spacing:0.15pt;"> </font>of our modified<font style="letter-spacing:0.05pt;"> </font>product candidate<font style="letter-spacing:0.05pt;"> </font>to earlier<font style="letter-spacing:0.1pt;"> </font>versions,<font style="letter-spacing:0.05pt;"> </font>which could delay our clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>plan or marketing<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for our current<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377831"></a>If we<font style="letter-spacing:-0.05pt;"> </font>encounter difficulties<font style="letter-spacing:0.15pt;"> </font>in enrolling<font style="letter-spacing:0.05pt;"> </font>patients<font style="letter-spacing:0.05pt;"> </font>in our clinical<font style="letter-spacing:0.05pt;"> </font>trials,<font style="letter-spacing:0.05pt;"> </font>our clinical<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>could be delayed<font style="letter-spacing:0.05pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>adversely<font style="letter-spacing:0.05pt;"> </font>affected.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely<font style="letter-spacing:0.05pt;"> </font>completion<font style="letter-spacing:0.1pt;"> </font>of clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>largely<font style="letter-spacing:0.05pt;"> </font>depends on patient<font style="letter-spacing:0.05pt;"> </font>enrollment.<font style="letter-spacing:0.1pt;"> </font>We may encounter<font style="letter-spacing:0.05pt;"> </font>delays in enrolling,<font style="letter-spacing:0.05pt;"> </font>or be unable to enroll,<font style="letter-spacing:0.05pt;"> </font>a sufficient<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of patients<font style="letter-spacing:0.05pt;"> </font>to complete<font style="letter-spacing:0.05pt;"> </font>any of our future clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>and even once enrolled,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may be unable to retain<font style="letter-spacing:0.05pt;"> </font>a sufficient<font style="letter-spacing:0.1pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of patients<font style="letter-spacing:0.05pt;"> </font>to complete<font style="letter-spacing:0.05pt;"> </font>any of our trials. Furthermore,<font style="letter-spacing:0.1pt;"> </font>as a result<font style="letter-spacing:0.05pt;"> </font>of the inherent<font style="letter-spacing:0.05pt;"> </font>difficulties<font style="letter-spacing:0.15pt;"> </font>in diagnosing<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">NASH,</font> which can currently<font style="letter-spacing:0.1pt;"> </font>only be definitively<font style="letter-spacing:1.15pt;"> </font>diagnosed<font style="letter-spacing:0.05pt;"> </font>through a liver<font style="letter-spacing:0.05pt;"> </font>biopsy, and identifying SHTG patients, and the significant<font style="letter-spacing:0.1pt;"> </font>competition<font style="letter-spacing:0.1pt;"> </font>for recruiting<font style="letter-spacing:0.1pt;"> </font>NASH<font style="letter-spacing:-0.1pt;"> and SHTG </font>patients<font style="letter-spacing:0.05pt;"> </font>in clinical<font style="letter-spacing:0.1pt;"> </font>trials, we<font style="letter-spacing:-0.05pt;"> </font>or our future<font style="letter-spacing:0.05pt;"> </font>collaborators<font style="letter-spacing:0.1pt;"> </font>may be unable to enroll<font style="letter-spacing:0.05pt;"> </font>the patients<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>need to complete<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>on a timely basis,<font style="letter-spacing:0.05pt;"> </font>or at all. In addition,<font style="letter-spacing:0.05pt;"> </font>our competitors,<font style="letter-spacing:0.1pt;"> </font>some of whom have significantly<font style="letter-spacing:0.15pt;"> </font>greater<font style="letter-spacing:0.05pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>do, are conducting<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>for the <font style="letter-spacing:0.05pt;">same </font>indications<font style="letter-spacing:0.1pt;"> </font>and seek to enroll<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in their</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may otherwise be eligible</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trials.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ince</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of qualified</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigators</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is limited,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to conduct some of our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the same</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sites</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some of our competitors</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use, which could further</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduce</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are available</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in these</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sites.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enroll</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a sufficient</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would result</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in significant delays</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or may require</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us to abandon one or more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">altogether.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are able to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enroll</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a sufficient</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patients</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trials,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in patient</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enrollment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may result</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in increased costs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or may affect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or outcome</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which could prevent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completion</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials and adversely</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to advance the development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100 and any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</font><font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377921"></a>BIO89-100<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>any future product candidates<font style="letter-spacing:0.05pt;"> </font>may cause undesirable<font style="letter-spacing:0.05pt;"> </font>side effects<font style="letter-spacing:0.1pt;"> </font>or have other properties<font style="letter-spacing:0.05pt;"> </font>that could delay or prevent<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>approval or limit<font style="letter-spacing:0.1pt;"> </font>the commercial<font style="letter-spacing:0.1pt;"> </font>profile<font style="letter-spacing:0.05pt;"> </font>of an<font style="letter-spacing:-0.05pt;"> </font>approved label.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable<font style="letter-spacing:0.05pt;"> </font>side effects<font style="letter-spacing:0.1pt;"> </font>caused by BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>could cause us or regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>to interrupt,<font style="letter-spacing:0.1pt;"> </font>delay or halt<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and could result<font style="letter-spacing:0.05pt;"> </font>in a more<font style="letter-spacing:0.05pt;"> </font>restrictive<font style="letter-spacing:0.15pt;"> </font>label<font style="letter-spacing:0.05pt;"> </font>or the delay or denial<font style="letter-spacing:0.05pt;"> </font>of regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities.<font style="letter-spacing:0.1pt;"> </font>Additional clinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>may be required<font style="letter-spacing:0.05pt;"> </font>to evaluate<font style="letter-spacing:0.05pt;"> </font>the safety<font style="letter-spacing:0.05pt;"> </font>profile<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates. As with other drugs, we have seen evidence of adverse effects in animal and human studies and it is possible that other adverse effects will become apparent in ongoing or future animal or human safety studies. It may be difficult<font style="letter-spacing:0.1pt;"> </font>to discern<font style="letter-spacing:0.05pt;"> </font>whether certain<font style="letter-spacing:0.05pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>or symptoms<font style="letter-spacing:0.05pt;"> </font>observed<font style="letter-spacing:0.05pt;"> </font>during our clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>or by patients<font style="letter-spacing:0.05pt;"> </font>using our approved products<font style="letter-spacing:0.05pt;"> </font>are related<font style="letter-spacing:0.05pt;"> </font>to BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or approved products<font style="letter-spacing:0.05pt;"> </font>or some other<font style="letter-spacing:0.05pt;"> </font>factor.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>and our development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>may be negatively<font style="letter-spacing:0.05pt;"> </font>affected<font style="letter-spacing:0.1pt;"> </font>even if such events<font style="letter-spacing:0.05pt;"> </font>or symptoms<font style="letter-spacing:0.05pt;"> </font>are ultimately<font style="letter-spacing:0.1pt;"> </font>determined<font style="letter-spacing:0.1pt;"> </font>to be unlikely<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product candidates<font style="letter-spacing:0.05pt;"> </font>or approved products.<font style="letter-spacing:0.05pt;"> </font>Further,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>expect<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>BIO89-100 will require<font style="letter-spacing:0.05pt;"> </font>multiple<font style="letter-spacing:0.1pt;"> </font>administrations<font style="letter-spacing:0.15pt;"> </font>via subcutaneous injection<font style="letter-spacing:0.1pt;"> </font>in the course<font style="letter-spacing:0.05pt;"> </font>of a clinical<font style="letter-spacing:0.1pt;"> </font>trial. This<font style="letter-spacing:0.05pt;"> </font>chronic<font style="letter-spacing:0.05pt;"> </font>administration<font style="letter-spacing:0.15pt;"> </font>increases<font style="letter-spacing:0.1pt;"> </font>the risk<font style="letter-spacing:0.05pt;"> that </font>rare<font style="letter-spacing:0.05pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>or chance findings<font style="letter-spacing:0.05pt;"> are discovered in the commercial setting, where BIO89-100 would be a</font>dministered<font style="letter-spacing:0.1pt;"> </font>to more patients<font style="letter-spacing:0.05pt;"> </font>or for greater<font style="letter-spacing:0.05pt;"> </font>periods<font style="letter-spacing:0.05pt;"> </font>of time, <font style="letter-spacing:0.05pt;">that were not uncovered by </font>our clinical<font style="letter-spacing:0.1pt;"> </font>drug development<font style="letter-spacing:0.05pt;"> </font>programs.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66377927"></a>We are developing<font style="letter-spacing:0.05pt;"> </font>BIO89-100<font style="letter-spacing:-0.05pt;"> </font>for the treatment<font style="letter-spacing:0.1pt;"> </font>of NASH, an indication for which there are no approved products. This makes it difficult<font style="letter-spacing:0.1pt;"> </font>to predict<font style="letter-spacing:0.05pt;"> </font>the timing<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>of the clinical<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100<font style="letter-spacing:-0.05pt;"> </font>for the treatment<font style="letter-spacing:0.1pt;"> </font>of NASH.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing<font style="letter-spacing:0.05pt;"> </font>BIO89-100 for the treatment<font style="letter-spacing:0.1pt;"> </font>of NASH,<font style="letter-spacing:-0.1pt;"> </font>an indication for which there are no approved products. Because there is no established regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> for NASH, </font>the development of a novel<font style="letter-spacing:1.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>such as BIO89-100 may be more<font style="letter-spacing:0.05pt;"> </font>expensive<font style="letter-spacing:0.05pt;"> </font>and take longer<font style="letter-spacing:0.05pt;"> </font>than for other,<font style="letter-spacing:0.05pt;"> </font>better<font style="letter-spacing:0.05pt;"> </font>known<font style="letter-spacing:-0.05pt;"> </font>or extensively<font style="letter-spacing:0.1pt;"> </font>studied<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>are in later<font style="letter-spacing:0.05pt;"> </font>stages<font style="letter-spacing:0.05pt;"> </font>of clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>for their<font style="letter-spacing:0.05pt;"> </font>potential NASH<font style="letter-spacing:-0.1pt;"> </font>therapies,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>expect<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the path for regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for NASH<font style="letter-spacing:-0.1pt;"> </font>therapies<font style="letter-spacing:0.1pt;"> </font>may continue<font style="letter-spacing:0.05pt;"> </font>to evolve in the near term<font style="letter-spacing:0.05pt;"> </font>as these<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>refine<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>strategies<font style="letter-spacing:0.1pt;"> </font>and interact<font style="letter-spacing:0.1pt;"> </font>with regulatory authorities.<font style="letter-spacing:0.1pt;"> </font>Such evolution<font style="letter-spacing:0.05pt;"> </font>may impact<font style="letter-spacing:0.05pt;"> </font>our future<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>designs,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>size<font style="letter-spacing:0.05pt;"> </font>and endpoints,<font style="letter-spacing:0.05pt;"> </font>in ways that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>cannot predict<font style="letter-spacing:0.05pt;"> </font>today. Certain of our competitors have recently experienced regulatory setbacks for NASH therapies following communications from the FDA. We currently do not know the impact, if any, that these setbacks could have on the path for regulatory approval for NASH therapies generally or for BIO89-100. Our anticipated<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>would likely<font style="letter-spacing:0.05pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>if development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>is delayed<font style="letter-spacing:0.05pt;"> </font>because<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are required<font style="letter-spacing:0.05pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>to perform<font style="letter-spacing:0.05pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>or trials<font style="letter-spacing:0.1pt;"> </font>in addition<font style="letter-spacing:0.05pt;"> </font>to, or different<font style="letter-spacing:0.1pt;"> </font>from,<font style="letter-spacing:0.05pt;"> </font>those that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>anticipate.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing BIO89-100 for the treatment of SHTG. Clinical trials for the treatment of SHTG may be relatively costly and time consuming. The requirements for approval by the FDA and comparable foreign regulatory authorities may change over time and this may require changes to ongoing or future clinical trial designs that could impact timelines and cost.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates, which could adversely affect our stock price, our ability to attract additional capital and our development program.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of efficacy,<font style="letter-spacing:0.1pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>or undesirable<font style="letter-spacing:0.1pt;"> </font>side effects<font style="letter-spacing:0.1pt;"> </font>may emerge<font style="letter-spacing:0.05pt;"> </font>in clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>conducted<font style="letter-spacing:0.05pt;"> </font>by third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>developing<font style="letter-spacing:0.05pt;"> </font>FGF<font style="letter-spacing:-0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>like<font style="letter-spacing:0.05pt;"> </font>ours. For example,<font style="letter-spacing:0.05pt;"> </font>Bristol-Myers<font style="letter-spacing:0.1pt;"> </font>Squibb Company and Akero </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc. are also developing</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FGF21</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of NASH.</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no control</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over their</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and lack of efficacy,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">events</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or undesirable</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">side effects</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experienced</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by subjects</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in their</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could adversely</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our stock price,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to attract additional</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:0.05pt;">plans for </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIO89-100 or even the viability</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100 as a product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate, including</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by creating</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a negative</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perception</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of FGF</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutics</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by healthcare</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or patients.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378101"></a>We have relied on, and expect to continue to rely on, third-party manufacturers to produce BIO89-100 or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own<font style="letter-spacing:-0.05pt;"> </font>or operate<font style="letter-spacing:0.05pt;"> </font>manufacturing facilities<font style="letter-spacing:0.15pt;"> </font>for the production<font style="letter-spacing:0.05pt;"> </font>of clinical<font style="letter-spacing:0.1pt;"> </font>or commercial<font style="letter-spacing:0.1pt;"> </font>quantities<font style="letter-spacing:0.1pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>lack the resources<font style="letter-spacing:0.05pt;"> </font>and the capabilities<font style="letter-spacing:0.15pt;"> </font>to do so. As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>rely,<font style="letter-spacing:0.05pt;"> </font>and expect<font style="letter-spacing:0.05pt;"> </font>to rely<font style="letter-spacing:0.05pt;"> </font>for the foreseeable<font style="letter-spacing:0.1pt;"> </font>future, on third-party<font style="letter-spacing:0.1pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>to supply us with BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates. We currently<font style="letter-spacing:0.1pt;"> </font>have a sole source<font style="letter-spacing:0.05pt;"> </font>relationship<font style="letter-spacing:0.1pt;"> </font>with BTPH pursuant<font style="letter-spacing:0.05pt;"> </font>to which they supply us with BIO89-100. If there<font style="letter-spacing:0.05pt;"> </font>should be any disruption<font style="letter-spacing:0.05pt;"> </font>in our supply arrangement<font style="letter-spacing:0.1pt;"> </font>with BTPH, including<font style="letter-spacing:0.05pt;"> </font>any adverse<font style="letter-spacing:0.05pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>affecting<font style="letter-spacing:0.1pt;"> </font>BTPH,<font style="letter-spacing:-0.1pt;"> </font>it could have a negative<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on the clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 and other<font style="letter-spacing:0.05pt;"> </font>operations<font style="letter-spacing:0.05pt;"> </font>while we<font style="letter-spacing:-0.05pt;"> </font>work to identify<font style="letter-spacing:0.05pt;"> </font>and qualify<font style="letter-spacing:0.05pt;"> </font>an alternate<font style="letter-spacing:0.1pt;"> </font>supply source. In addition, <font style="letter-spacing:0.1pt;">we will require large quantities of BIO89-100 for large clinical trials and to commercialize BIO89-100. Our current manufacturer </font>may not be able to scale<font style="letter-spacing:0.05pt;"> </font>production<font style="letter-spacing:0.05pt;"> </font>to the larger quantities<font style="letter-spacing:0.1pt;"> and we may not be able to find another manufacturer who has the capacity to manufacture a commercial-scale quantity of BIO89-100</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a long-term<font style="letter-spacing:0.1pt;"> </font>supply agreement<font style="letter-spacing:0.1pt;"> </font>with any third-party<font style="letter-spacing:0.1pt;"> </font>manufacturer.<font style="letter-spacing:0.1pt;"> </font>Reliance<font style="letter-spacing:0.05pt;"> </font>on third-party<font style="letter-spacing:0.05pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>entails<font style="letter-spacing:0.05pt;"> </font>risks<font style="letter-spacing:0.05pt;"> </font>to which we<font style="letter-spacing:-0.05pt;"> </font>would not be subject<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>manufacture<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or products<font style="letter-spacing:0.05pt;"> </font>ourselves.<font style="letter-spacing:0.05pt;"> </font>For example,<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>do not maintain<font style="letter-spacing:0.1pt;"> </font>our key manufacturing<font style="letter-spacing:0.1pt;"> </font>relationships,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may fail<font style="letter-spacing:0.05pt;"> </font>to find replacement<font style="letter-spacing:0.1pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>or develop our own<font style="letter-spacing:-0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>capabilities<font style="letter-spacing:0.15pt;"> </font>in a timely<font style="letter-spacing:0.05pt;"> </font>manner<font style="letter-spacing:0.05pt;"> </font>or at all,<font style="letter-spacing:0.05pt;"> </font>which could delay or impair<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for our products<font style="letter-spacing:0.05pt;"> </font>and substantially<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>our costs<font style="letter-spacing:0.05pt;"> </font>or deplete<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.05pt;"> </font>margins,<font style="letter-spacing:0.05pt;"> </font>if any. If we<font style="letter-spacing:-0.05pt;"> </font>do find replacement<font style="letter-spacing:0.1pt;"> </font>manufacturers,<font style="letter-spacing:0.15pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not be able to enter<font style="letter-spacing:0.05pt;"> </font>into agreements<font style="letter-spacing:0.1pt;"> </font>with them<font style="letter-spacing:0.05pt;"> </font>on terms<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>favorable<font style="letter-spacing:0.05pt;"> </font>to us, and there<font style="letter-spacing:0.05pt;"> </font>could be a substantial<font style="letter-spacing:0.1pt;"> </font>delay before<font style="letter-spacing:0.05pt;"> </font>new facilities<font style="letter-spacing:0.15pt;"> </font>could be qualified<font style="letter-spacing:0.1pt;"> </font>and registered<font style="letter-spacing:0.1pt;"> </font>with the FDA<font style="letter-spacing:-0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have begun producing certain of the reagents required for the glycoPEGylation at BTPH using the know-how transferred to us from Teva Pharmaceutical Industries Ltd (&#8220;Teva&#8221;) under our Reagent Supply and Technology Transfer<font style="letter-spacing:0.05pt;"> </font>Agreement<font style="letter-spacing:0.05pt;">. We have not completed the manufacturing process for these reagents and cannot guarantee that we will be able to produce them successfully, or scale up our production for the quantities needed commercialization.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Teva continues to supply us with certain reagents and will continue to do so </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">until</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31, 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We expect the manufacturing of such reagents </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be transferred</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to a new</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplier</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the end of 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Any</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complications arising</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under our agreement</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with Teva or any difficulties securing</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a new</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplier</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could considerably</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay the manufacture</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100. Any</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay in the acquisition</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or decrease</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the availability</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raw materials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Teva or any new</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplier</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could considerably</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay the manufacture</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100, which could adversely</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any planned trials or the regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals</font><font style="font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of BIO89-100.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA<font style="letter-spacing:-0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>require<font style="letter-spacing:0.05pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>to register manufacturing<font style="letter-spacing:0.1pt;"> </font>facilities.<font style="letter-spacing:0.15pt;"> </font>The FDA<font style="letter-spacing:-0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>also inspect<font style="letter-spacing:0.05pt;"> </font>these facilities<font style="letter-spacing:0.15pt;"> </font>to confirm<font style="letter-spacing:0.05pt;"> </font>compliance<font style="letter-spacing:0.1pt;"> </font>with cGMP.<font style="letter-spacing:0.05pt;"> </font>We have little<font style="letter-spacing:0.1pt;"> </font>to no control<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.05pt;"> </font>the occurrence<font style="letter-spacing:0.05pt;"> </font>of third-party<font style="letter-spacing:0.1pt;"> </font>manufacturer<font style="letter-spacing:0.1pt;"> </font>incidents.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>failure<font style="letter-spacing:0.1pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with cGMP<font style="letter-spacing:-0.05pt;"> </font>requirements<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>FDA<font style="letter-spacing:-0.05pt;"> </font>or comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.1pt;"> </font>could adversely affect<font style="letter-spacing:0.05pt;"> </font>our clinical<font style="letter-spacing:0.1pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>and our ability<font style="letter-spacing:0.05pt;"> </font>to develop BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and market<font style="letter-spacing:0.05pt;"> </font>our products<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>approval.<font style="letter-spacing:0.05pt;"> </font>Our sole source<font style="letter-spacing:0.05pt;"> </font>supplier,<font style="letter-spacing:0.05pt;"> </font>BTPH,<font style="letter-spacing:-0.1pt;"> </font>has not yet manufactured<font style="letter-spacing:0.1pt;"> </font>a commercial product,<font style="letter-spacing:0.05pt;"> </font>and as a result,<font style="letter-spacing:0.05pt;"> </font>has not been subject<font style="letter-spacing:0.05pt;"> </font>to inspection<font style="letter-spacing:0.05pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory authorities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current<font style="letter-spacing:0.05pt;"> </font>and anticipated<font style="letter-spacing:0.1pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>dependence<font style="letter-spacing:0.05pt;"> </font>upon others<font style="letter-spacing:0.05pt;"> </font>for the manufacture<font style="letter-spacing:0.1pt;"> </font>of our product candidates<font style="letter-spacing:0.05pt;"> </font>may adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our future<font style="letter-spacing:0.05pt;"> </font>profit<font style="letter-spacing:0.05pt;"> </font>margins<font style="letter-spacing:0.05pt;"> </font>and our ability<font style="letter-spacing:0.05pt;"> </font>to develop our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>any products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>receive<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>on a timely<font style="letter-spacing:0.05pt;"> </font>basis. If we<font style="letter-spacing:-0.05pt;"> </font>are required<font style="letter-spacing:0.05pt;"> </font>to change manufacturers<font style="letter-spacing:0.15pt;"> </font>for any reason,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will be required<font style="letter-spacing:0.05pt;"> </font>to verify<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the new<font style="letter-spacing:-0.05pt;"> </font>manufacturer<font style="letter-spacing:0.1pt;"> </font>maintains<font style="letter-spacing:0.1pt;"> </font>facilities<font style="letter-spacing:0.15pt;"> </font>and procedures<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>comply<font style="letter-spacing:0.05pt;"> </font>with quality standards<font style="letter-spacing:0.05pt;"> </font>and with all<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>and guidelines.<font style="letter-spacing:0.05pt;"> </font>For example,<font style="letter-spacing:0.05pt;"> </font>in the event that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>need to switch our third-party<font style="letter-spacing:0.1pt;"> </font>manufacturer<font style="letter-spacing:0.1pt;"> </font>of BIO89-100 from<font style="letter-spacing:0.05pt;"> </font>BTPH,<font style="letter-spacing:-0.1pt;"> </font>which is our sole manufacturing<font style="letter-spacing:0.1pt;"> </font>source<font style="letter-spacing:0.05pt;"> </font>for BIO89-100, we anticipate<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the complexity<font style="letter-spacing:0.1pt;"> </font>of the glycoPEGylation<font style="letter-spacing:0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>may materially<font style="letter-spacing:0.15pt;"> </font>impact<font style="letter-spacing:0.05pt;"> </font>the amount of time<font style="letter-spacing:0.05pt;"> </font>it may take to secure<font style="letter-spacing:0.05pt;"> </font>a replacement<font style="letter-spacing:0.1pt;"> </font>manufacturer.<font style="letter-spacing:0.1pt;"> </font>The delays<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with the verification<font style="letter-spacing:0.15pt;"> </font>of a new manufacturer, if we<font style="letter-spacing:-0.05pt;"> </font>are able to identify<font style="letter-spacing:0.05pt;"> </font>an alternative<font style="letter-spacing:0.1pt;"> </font>source,<font style="letter-spacing:0.05pt;"> </font>could negatively<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to develop<font style="letter-spacing:1.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>in a timely<font style="letter-spacing:0.05pt;"> </font>manner<font style="letter-spacing:0.05pt;"> </font>or within budget.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378092"></a>The<font style="letter-spacing:-0.05pt;"> </font>manufacture<font style="letter-spacing:0.05pt;"> </font>of biologic<font style="letter-spacing:0.05pt;"> </font>products is complex<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are subject<font style="letter-spacing:0.05pt;"> </font>to many manufacturing<font style="letter-spacing:0.05pt;"> </font>risks,<font style="letter-spacing:0.05pt;"> </font>any of which<font style="letter-spacing:-0.05pt;"> </font>could substantially<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>our costs<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>limit<font style="letter-spacing:0.1pt;"> </font>supply of our products.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:-0.05pt;"> </font>date, BIO89-100 has been manufactured<font style="letter-spacing:0.1pt;"> </font>by a single<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>manufacturer,<font style="letter-spacing:0.1pt;"> </font>BTPH,<font style="letter-spacing:-0.1pt;"> </font>solely<font style="letter-spacing:0.05pt;"> </font>for preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials.<font style="letter-spacing:0.1pt;"> </font>The process<font style="letter-spacing:0.05pt;"> </font>of manufacturing BIO89-100, and in particular,<font style="letter-spacing:0.1pt;"> </font>the glycoPEGylation<font style="letter-spacing:0.05pt;"> </font>process, is complex,<font style="letter-spacing:0.05pt;"> </font>highly regulated, subject<font style="letter-spacing:0.05pt;"> </font>to several<font style="letter-spacing:0.05pt;"> </font>risks and requires<font style="letter-spacing:0.05pt;"> </font>significant<font style="letter-spacing:0.1pt;"> </font>expertise<font style="letter-spacing:0.1pt;"> </font>and capital<font style="letter-spacing:0.05pt;"> </font>investment,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>of advanced manufacturing techniques<font style="letter-spacing:0.05pt;"> </font>and process<font style="letter-spacing:0.05pt;"> </font>controls.<font style="letter-spacing:0.05pt;"> </font>Manufacturers<font style="letter-spacing:0.1pt;"> </font>of biologic<font style="letter-spacing:0.05pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>often<font style="letter-spacing:0.05pt;"> </font>encounter<font style="letter-spacing:0.05pt;"> </font>difficulties<font style="letter-spacing:0.15pt;"> </font>in production, including difficulties<font style="letter-spacing:0.15pt;"> </font>with production<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and yields,<font style="letter-spacing:0.05pt;"> </font>quality<font style="letter-spacing:0.05pt;"> </font>control,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>stability<font style="letter-spacing:0.1pt;"> </font>of the product, quality<font style="letter-spacing:0.05pt;"> </font>assurance<font style="letter-spacing:0.05pt;"> </font>testing,<font style="letter-spacing:0.05pt;"> </font>operator<font style="letter-spacing:0.05pt;"> </font>error<font style="letter-spacing:0.05pt;"> </font>and shortages<font style="letter-spacing:0.05pt;"> </font>of qualified<font style="letter-spacing:0.1pt;"> </font>personnel,<font style="letter-spacing:0.05pt;"> </font>as well as compliance<font style="letter-spacing:0.1pt;"> </font>with strictly enforced<font style="letter-spacing:0.05pt;"> </font>federal,<font style="letter-spacing:0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>and foreign<font style="letter-spacing:0.05pt;"> </font>regulations.<font style="letter-spacing:0.1pt;"> </font>We cannot assure<font style="letter-spacing:0.05pt;"> </font>you that<font style="letter-spacing:0.05pt;"> </font>any stability<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>issues<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to the manufacture<font style="letter-spacing:0.1pt;"> </font>of BIO89-100 will not occur in the future. We have limited<font style="letter-spacing:0.1pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>capabilities<font style="letter-spacing:0.15pt;"> </font>and have access<font style="letter-spacing:0.05pt;"> </font>only to external<font style="letter-spacing:0.05pt;"> </font>manufacturing capabilities.<font style="letter-spacing:0.15pt;"> </font>We do not have and we<font style="letter-spacing:-0.05pt;"> </font>do not currently<font style="letter-spacing:0.1pt;"> </font>plan to acquire<font style="letter-spacing:0.05pt;"> </font>or develop the facilities<font style="letter-spacing:0.15pt;"> </font>or capabilities<font style="letter-spacing:0.15pt;"> </font>to manufacture<font style="letter-spacing:0.1pt;"> </font>bulk drug substance<font style="letter-spacing:0.05pt;"> </font>or filled<font style="letter-spacing:0.05pt;"> </font>drug product<font style="letter-spacing:0.05pt;"> </font>for use in human clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>or commercialization. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378264"></a>We<font style="letter-spacing:-0.05pt;"> </font>will require<font style="letter-spacing:0.05pt;"> </font>substantial<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>to finance our operations, which<font style="letter-spacing:-0.05pt;"> </font>may not be available<font style="letter-spacing:0.05pt;"> </font>to us on<font style="letter-spacing:-0.05pt;"> </font>acceptable<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>or at all. As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not complete<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>commercialization<font style="letter-spacing:0.15pt;"> </font>of BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or develop<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:-0.05pt;"> </font>a clinical-stage<font style="letter-spacing:0.05pt;"> </font>biopharmaceutical<font style="letter-spacing:0.15pt;"> </font>company, our operations<font style="letter-spacing:0.05pt;"> </font>have consumed<font style="letter-spacing:0.05pt;"> </font>significant<font style="letter-spacing:0.1pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:1.1pt;"> </font>cash since<font style="letter-spacing:0.05pt;"> </font>our <font style="letter-spacing:-0.1pt;">inception</font>.<font style="letter-spacing:0.05pt;"> </font>We expect<font style="letter-spacing:0.05pt;"> </font>our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>to increase<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with our ongoing activities,<font style="letter-spacing:0.1pt;"> </font>particularly<font style="letter-spacing:0.15pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>conduct <font style="letter-spacing:0.05pt;">clinical trials </font>of and seek regulatory<font style="letter-spacing:0.1pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>for BIO89-100. <font style="letter-spacing:-0.05pt;">We</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">believe</font><font style="letter-spacing:-0.2pt;"> </font>that<font style="letter-spacing:-0.2pt;"> our existing cash, cash equivalents and short-term investments, together with the proceeds available from our line of credit pursuant to our Loan Agreement (as defined above),</font><font style="letter-spacing:-0.1pt;"> will</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">fund</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">projected</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">operating</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">requirements</font><font style="letter-spacing:-0.2pt;"> </font><font style="color:#231F20;letter-spacing:0.1pt;">into the second quarter of 2023</font><font style="letter-spacing:-0.1pt;">.</font><font style="letter-spacing:-0.2pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>to discover,<font style="letter-spacing:0.05pt;"> </font>develop, obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for and commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates. We do not have any committed<font style="letter-spacing:0.1pt;"> </font>external<font style="letter-spacing:0.05pt;"> </font>source<font style="letter-spacing:0.05pt;"> </font>of funds other than the unused portion of the line of credit available to us pursuant to the Loan Agreement.<font style="letter-spacing:0.05pt;"> </font>We expect<font style="letter-spacing:0.05pt;"> </font>to finance<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>cash needs through public<font style="letter-spacing:0.05pt;"> </font>or private<font style="letter-spacing:0.05pt;"> </font>equity<font style="letter-spacing:0.05pt;"> </font>or debt offerings<font style="letter-spacing:0.1pt;"> </font>or product collaborations.<font style="letter-spacing:0.1pt;"> </font>Additional<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>may not be available<font style="letter-spacing:0.1pt;"> </font>in sufficient<font style="letter-spacing:0.1pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>or on reasonable<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>if at all.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>do not raise<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>capital,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be able to expand our operations</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or otherwise</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capitalize</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our business</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunities,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and financial</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be negatively</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impacted</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may need to: </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly delay, scale back or discontinue research and discovery efforts and the development or commercialization of any product candidates or cease operations altogether;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek strategic alliances for research and development programs when we otherwise would not, or at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; or</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relinquish, or license on unfavorable terms, our rights to technologies or any product candidates that we otherwise would seek to develop or commercialize ourselves. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In addition, if BIO89-100 receives approval and is commercialized, we will be required to make milestone and royalty payments to Teva, from whom we acquired certain patents and intellectual property relating to BIO89-100, and from whom we licensed patents and know-how related to glycoPEGylation technology that is used in the manufacture of BIO89-100. For additional information regarding this license agreement, please see Note 5 to of our accompanying audited consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378273"></a>We face substantial<font style="letter-spacing:0.05pt;"> </font>competition,<font style="letter-spacing:0.1pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>may result<font style="letter-spacing:0.05pt;"> </font>in others discovering,<font style="letter-spacing:0.05pt;"> </font>developing<font style="letter-spacing:0.05pt;"> </font>or commercializing competing<font style="letter-spacing:0.05pt;"> </font>products before<font style="letter-spacing:0.05pt;"> </font>or more successfully<font style="letter-spacing:0.1pt;"> </font>than us.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical<font style="letter-spacing:0.15pt;"> </font>industry<font style="letter-spacing:0.05pt;"> </font>is intensely<font style="letter-spacing:0.05pt;"> </font>competitive<font style="letter-spacing:0.1pt;"> </font>and subject<font style="letter-spacing:0.05pt;"> </font>to rapid<font style="letter-spacing:0.05pt;"> </font>innovation<font style="letter-spacing:0.05pt;"> </font>and significant technological<font style="letter-spacing:0.1pt;"> </font>advancements.<font style="letter-spacing:0.1pt;"> </font>Our competitors include<font style="letter-spacing:0.05pt;"> </font>multinational<font style="letter-spacing:0.15pt;"> </font>pharmaceutical<font style="letter-spacing:0.15pt;"> </font>companies,<font style="letter-spacing:0.05pt;"> </font>specialized<font style="letter-spacing:0.1pt;"> </font>biotechnology<font style="letter-spacing:0.05pt;"> </font>companies,<font style="letter-spacing:0.05pt;"> </font>universities<font style="letter-spacing:0.1pt;"> </font>and other research<font style="letter-spacing:0.05pt;"> </font>institutions.<font style="letter-spacing:0.1pt;"> </font>A<font style="letter-spacing:-0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of biotechnology<font style="letter-spacing:0.05pt;"> </font>and pharmaceutical<font style="letter-spacing:0.15pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>are pursuing<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>or marketing<font style="letter-spacing:0.1pt;"> </font>of pharmaceuticals<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>target<font style="letter-spacing:0.05pt;"> </font>the same<font style="letter-spacing:0.05pt;"> </font>diseases<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are targeting.<font style="letter-spacing:0.1pt;"> Certain of these companies have recently published positive data regarding their clinical trials, which may further increase the competition we face. </font>Smaller<font style="letter-spacing:0.05pt;"> </font>or earlier-stage companies<font style="letter-spacing:0.05pt;"> </font>may also prove to be significant<font style="letter-spacing:0.1pt;"> </font>competitors,<font style="letter-spacing:0.1pt;"> </font>particularly<font style="letter-spacing:0.15pt;"> </font>through collaborative<font style="letter-spacing:0.1pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>with large,<font style="letter-spacing:0.05pt;"> </font>established<font style="letter-spacing:0.1pt;"> </font>companies.<font style="letter-spacing:0.05pt;"> </font>Given the high incidence<font style="letter-spacing:0.05pt;"> </font>of NASH<font style="letter-spacing:-0.1pt;"> </font>and <font style="letter-spacing:-0.05pt;">SHTG,</font> it is likely<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the number<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:1.15pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>seeking<font style="letter-spacing:0.05pt;"> </font>to develop products<font style="letter-spacing:0.05pt;"> </font>and therapies<font style="letter-spacing:0.1pt;"> </font>for the treatment<font style="letter-spacing:0.1pt;"> </font>of liver<font style="letter-spacing:0.05pt;"> </font>and cardio-metabolic<font style="letter-spacing:0.15pt;"> </font>diseases, such as NASH<font style="letter-spacing:-0.1pt;"> </font>and <font style="letter-spacing:-0.05pt;">SHTG,</font> will increase.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<font style="letter-spacing:0.05pt;"> </font>are numerous<font style="letter-spacing:1.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>approved therapies<font style="letter-spacing:0.1pt;"> </font>for treating<font style="letter-spacing:0.1pt;"> </font>diseases<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than NASH<font style="letter-spacing:-0.1pt;"> </font>and some of these<font style="letter-spacing:0.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>approved therapies<font style="letter-spacing:0.1pt;"> </font>may exert<font style="letter-spacing:0.05pt;"> </font>effects<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>could be similar<font style="letter-spacing:0.1pt;"> </font>to BIO89-100 in NASH. Many of these<font style="letter-spacing:0.05pt;"> </font>approved drugs are well-established<font style="letter-spacing:0.1pt;"> </font>therapies<font style="letter-spacing:0.1pt;"> </font>or products<font style="letter-spacing:0.05pt;"> </font>and are widely accepted<font style="letter-spacing:0.05pt;"> </font>by physicians,<font style="letter-spacing:0.05pt;"> </font>patients<font style="letter-spacing:0.05pt;"> </font>and third-party<font style="letter-spacing:0.1pt;"> </font>payors. Some of these<font style="letter-spacing:0.05pt;"> </font>drugs are branded and subject<font style="letter-spacing:0.05pt;"> </font>to patent<font style="letter-spacing:0.05pt;"> </font>protection,<font style="letter-spacing:0.1pt;"> </font>and others<font style="letter-spacing:0.05pt;"> </font>are available<font style="letter-spacing:0.1pt;"> </font>on a generic<font style="letter-spacing:0.05pt;"> </font>basis.<font style="letter-spacing:0.05pt;"> </font>This may make it difficult<font style="letter-spacing:0.1pt;"> </font>for us to differentiate<font style="letter-spacing:0.15pt;"> </font>our products<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>approved therapies,<font style="letter-spacing:0.1pt;"> </font>which may adversely<font style="letter-spacing:0.05pt;"> </font>impact<font style="letter-spacing:0.05pt;"> </font>our business<font style="letter-spacing:0.05pt;"> </font>strategy. We expect that<font style="letter-spacing:0.05pt;"> </font>if BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>are approved, they will be priced<font style="letter-spacing:0.05pt;"> </font>at a significant<font style="letter-spacing:0.1pt;"> </font>premium over competitive<font style="letter-spacing:0.1pt;"> </font>generic<font style="letter-spacing:0.05pt;"> </font>products,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>branded generic<font style="letter-spacing:0.05pt;"> </font>products.<font style="letter-spacing:0.05pt;"> </font>Insurers<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>payors may also encourage<font style="letter-spacing:0.05pt;"> </font>the use of generic<font style="letter-spacing:0.05pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>or specific<font style="letter-spacing:0.1pt;"> </font>branded products prior to utilization of BIO89-100.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>many companies<font style="letter-spacing:0.05pt;"> </font>are developing<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>therapeutics,<font style="letter-spacing:0.1pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>cannot predict<font style="letter-spacing:0.05pt;"> </font>what the standard<font style="letter-spacing:0.05pt;"> </font>of care will be as BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>progress<font style="letter-spacing:0.05pt;"> </font>through clinical<font style="letter-spacing:0.1pt;"> </font>development.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>are approved for liver or cardio-metabolic<font style="letter-spacing:0.15pt;"> </font>indications,<font style="letter-spacing:0.1pt;"> </font>such as SHTG, the commercial<font style="letter-spacing:0.1pt;"> </font>success<font style="letter-spacing:0.05pt;"> </font>of our products<font style="letter-spacing:0.05pt;"> </font>will also depend on our ability<font style="letter-spacing:0.05pt;"> </font>to demonstrate<font style="letter-spacing:0.1pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>over the then-prevailing<font style="letter-spacing:0.1pt;"> </font>standard<font style="letter-spacing:0.05pt;"> </font>of care,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>diet,<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.05pt;"> </font>and lifestyle<font style="letter-spacing:0.1pt;"> </font>modifications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<font style="letter-spacing:0.05pt;"> </font>if BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>are approved for the treatment<font style="letter-spacing:0.1pt;"> </font>of SHTG,<font style="letter-spacing:-0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will compete<font style="letter-spacing:0.05pt;"> </font>with currently<font style="letter-spacing:0.1pt;"> </font>approved therapies<font style="letter-spacing:0.1pt;"> </font>and therapies<font style="letter-spacing:0.1pt;"> </font>further<font style="letter-spacing:0.05pt;"> </font>along in development.<font style="letter-spacing:0.05pt;"> </font>Our competitors<font style="letter-spacing:0.1pt;"> </font>both in the United States<font style="letter-spacing:0.05pt;"> </font>and abroad include<font style="letter-spacing:0.05pt;"> </font>large,<font style="letter-spacing:0.05pt;"> </font>well-established<font style="letter-spacing:0.15pt;"> </font>pharmaceutical<font style="letter-spacing:0.15pt;"> </font>and generic<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>with significantly<font style="letter-spacing:0.15pt;"> </font>greater<font style="letter-spacing:0.05pt;"> </font>name recognition.<font style="letter-spacing:0.1pt;"> </font>Our competitors<font style="letter-spacing:0.1pt;"> </font>may be able to charge<font style="letter-spacing:0.05pt;"> </font>lower prices<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>can, which may adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our market<font style="letter-spacing:0.05pt;"> </font>acceptance.<font style="letter-spacing:0.05pt;"> </font>Many of these<font style="letter-spacing:0.05pt;"> </font>competitors<font style="letter-spacing:0.1pt;"> </font>have greater<font style="letter-spacing:0.05pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>do, including<font style="letter-spacing:0.05pt;"> </font>financial,<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>marketing,<font style="letter-spacing:0.1pt;"> </font>personnel<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>resources.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our competitors<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are more<font style="letter-spacing:0.05pt;"> </font>effective,<font style="letter-spacing:0.1pt;"> </font>safer<font style="letter-spacing:0.05pt;"> </font>or cheaper<font style="letter-spacing:0.05pt;"> </font>than our products<font style="letter-spacing:0.05pt;"> </font>or that reach<font style="letter-spacing:0.05pt;"> </font>the market<font style="letter-spacing:0.05pt;"> </font>sooner than our products,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not achieve<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>success.<font style="letter-spacing:0.05pt;"> </font>Many of our competitors<font style="letter-spacing:0.1pt;"> </font>have substantially<font style="letter-spacing:0.1pt;"> </font>greater<font style="letter-spacing:0.05pt;"> </font>financial,<font style="letter-spacing:0.1pt;"> </font>technical,<font style="letter-spacing:0.1pt;"> </font>human and other<font style="letter-spacing:0.05pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>do and may be better<font style="letter-spacing:0.05pt;"> </font>equipped to develop, manufacture<font style="letter-spacing:0.1pt;"> </font>and market<font style="letter-spacing:0.05pt;"> </font>technologically<font style="letter-spacing:0.1pt;"> </font>superior<font style="letter-spacing:0.05pt;"> </font>products.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>our competitors<font style="letter-spacing:0.1pt;"> </font>may obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>rapidly<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>do or may obtain<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>limit<font style="letter-spacing:0.1pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to develop or commercialize<font style="letter-spacing:0.15pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>Our competitors<font style="letter-spacing:0.1pt;"> </font>may also develop and succeed<font style="letter-spacing:0.05pt;"> </font>in obtaining<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for drugs that<font style="letter-spacing:0.05pt;"> </font>are more<font style="letter-spacing:0.05pt;"> </font>effective,<font style="letter-spacing:0.1pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convenient,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">widely used and less costly</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or have a better</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profile</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than our products</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and these</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may also be more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successful</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are in manufacturing</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and marketing</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</font><font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378281"></a>Unstable market<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>economic<font style="letter-spacing:0.05pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>may have serious<font style="letter-spacing:0.05pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>consequences on<font style="letter-spacing:-0.05pt;"> </font>our business and financial<font style="letter-spacing:0.05pt;"> </font>condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global credit<font style="letter-spacing:0.05pt;"> </font>and financial<font style="letter-spacing:0.1pt;"> </font>markets<font style="letter-spacing:0.05pt;"> </font>have experienced<font style="letter-spacing:0.05pt;"> </font>extreme<font style="letter-spacing:0.05pt;"> </font>disruptions<font style="letter-spacing:0.1pt;"> </font>at various<font style="letter-spacing:0.05pt;"> </font>points<font style="letter-spacing:0.05pt;"> </font>over the last few decades.<font style="letter-spacing:0.1pt;"> </font>If another<font style="letter-spacing:0.05pt;"> </font>such disruption<font style="letter-spacing:0.05pt;"> </font>in credit<font style="letter-spacing:0.05pt;"> </font>and financial<font style="letter-spacing:0.1pt;"> </font>markets<font style="letter-spacing:0.05pt;"> </font>and deterioration<font style="letter-spacing:0.15pt;"> </font>of confidence<font style="letter-spacing:0.05pt;"> </font>in economic<font style="letter-spacing:0.05pt;"> </font>conditions occurs,<font style="letter-spacing:0.05pt;"> </font>it may make any necessary<font style="letter-spacing:0.05pt;"> </font>debt or equity<font style="letter-spacing:0.05pt;"> </font>financing<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>difficult<font style="letter-spacing:0.1pt;"> </font>to complete,<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>costly,<font style="letter-spacing:0.05pt;"> </font>and more<font style="letter-spacing:0.05pt;"> </font>dilutive.<font style="letter-spacing:0.05pt;"> </font>Failure<font style="letter-spacing:0.05pt;"> </font>to secure<font style="letter-spacing:0.05pt;"> </font>any necessary<font style="letter-spacing:0.05pt;"> </font>financing<font style="letter-spacing:0.05pt;"> </font>in a timely<font style="letter-spacing:0.05pt;"> </font>manner<font style="letter-spacing:0.05pt;"> </font>and on favorable<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>could have a material<font style="letter-spacing:0.1pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on our growth strategy,<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>and share<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>and could require<font style="letter-spacing:0.05pt;"> </font>us to delay or abandon development<font style="letter-spacing:0.05pt;"> </font>or commercialization<font style="letter-spacing:0.2pt;"> </font>plans. In addition,<font style="letter-spacing:0.05pt;"> </font>there<font style="letter-spacing:0.05pt;"> </font>is a risk<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>one or more<font style="letter-spacing:0.05pt;"> </font>of our service<font style="letter-spacing:0.05pt;"> </font>providers,<font style="letter-spacing:0.05pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>partners<font style="letter-spacing:0.05pt;"> </font>would not survive<font style="letter-spacing:0.05pt;"> </font>or be able to meet<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>commitments<font style="letter-spacing:0.15pt;"> </font>to us under such circumstances,<font style="letter-spacing:0.15pt;"> </font>which could directly<font style="letter-spacing:0.1pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to attain<font style="letter-spacing:0.05pt;"> </font>our operating<font style="letter-spacing:0.05pt;"> </font>goals on schedule<font style="letter-spacing:0.05pt;"> </font>and on budget.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378287"></a>Our Loan and Security Agreement with Silicon Valley Bank (the &#8220;Loan Agreement&#8221;) contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Loan Agreement, we have pledged substantially all of our assets, other than our intellectual property rights, and have agreed that we may not sell or assign rights to our patents and other intellectual property without the prior consent of Silicon Valley Bank (&#8220;SVB&#8221;). Additionally, the Loan Agreement contains certain affirmative and negative covenants that could prevent us from taking certain actions without the consent of our lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders. The Loan Agreement also includes customary events of default, including, among other things, a change of control. Upon the occurrence and continuation of an event of default, all amounts due under the Loan Agreement become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of SVB), immediately due and payable. If an event of default under the Loan Agreement should occur, we could be required to immediately repay any outstanding indebtedness. If we are unable to repay such debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Loan Agreement. Even if we are able to repay any indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties<font style="letter-spacing:0.15pt;"> </font>in managing our growth, which<font style="letter-spacing:-0.05pt;"> </font>could adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the early<font style="letter-spacing:0.05pt;"> </font>stages<font style="letter-spacing:0.05pt;"> </font>of building<font style="letter-spacing:0.05pt;"> </font>the full<font style="letter-spacing:0.05pt;"> </font>team<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>anticipate we<font style="letter-spacing:-0.05pt;"> </font>will need to complete<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>BIO89-100 and other<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>As we<font style="letter-spacing:-0.05pt;"> </font>advance our preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>for product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>seek regulatory<font style="letter-spacing:0.1pt;"> </font>approval in the United States<font style="letter-spacing:0.05pt;"> </font>and elsewhere<font style="letter-spacing:0.05pt;"> </font>and increase<font style="letter-spacing:0.05pt;"> </font>the number<font style="letter-spacing:0.05pt;"> </font>of ongoing product<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>programs,<font style="letter-spacing:0.05pt;"> </font>we anticipate<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will need to increase<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>scientific<font style="letter-spacing:0.1pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>headcount.<font style="letter-spacing:0.05pt;"> </font>We will also need to establish<font style="letter-spacing:0.1pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>capabilities<font style="letter-spacing:0.15pt;"> </font>in order<font style="letter-spacing:0.05pt;"> </font>to commercialize<font style="letter-spacing:0.15pt;"> </font>any product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may be approved. Such an evolution<font style="letter-spacing:0.05pt;"> </font>may impact<font style="letter-spacing:0.05pt;"> </font>our strategic<font style="letter-spacing:0.1pt;"> </font>focus and our deployment<font style="letter-spacing:0.05pt;"> </font>and allocation<font style="letter-spacing:0.1pt;"> </font>of resources.<font style="letter-spacing:0.05pt;"> </font>Our ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and operational, financial and management controls. We may not be able to implement administrative and operational improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. In addition, in order to continue to meet our obligations as a public company and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management,<font style="letter-spacing:0.1pt;"> </font>personnel<font style="letter-spacing:0.05pt;"> </font>and systems<font style="letter-spacing:0.05pt;"> </font>may experience<font style="letter-spacing:0.05pt;"> </font>difficulty<font style="letter-spacing:0.1pt;"> </font>in adjusting<font style="letter-spacing:0.05pt;"> </font>to our growth and strategic<font style="letter-spacing:0.1pt;"> </font>focus.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We must attract</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">retain</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">highly skilled</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">employees</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in order to</font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> succeed. If we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are not able to retain</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our current senior management</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">team</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our scientific</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">advisors</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or continue to attract</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">retain</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">qualified scientific,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">technical</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">business personnel, our business will suffer.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to attract<font style="letter-spacing:0.1pt;"> </font>or retain<font style="letter-spacing:0.05pt;"> </font>qualified<font style="letter-spacing:0.1pt;"> </font>personnel<font style="letter-spacing:0.05pt;"> </font>and consultants<font style="letter-spacing:0.1pt;"> </font>due to the intense competition<font style="letter-spacing:0.1pt;"> </font>for such individuals in the biotechnology<font style="letter-spacing:0.05pt;"> </font>and pharmaceutical<font style="letter-spacing:0.15pt;"> </font>industries.<font style="letter-spacing:0.1pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>are not able to attract<font style="letter-spacing:0.1pt;"> </font>and retain<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>personnel<font style="letter-spacing:0.05pt;"> </font>and consultants<font style="letter-spacing:0.1pt;"> </font>to accomplish<font style="letter-spacing:0.1pt;"> </font>our business<font style="letter-spacing:0.05pt;"> </font>objectives,<font style="letter-spacing:0.1pt;"> </font>it may significantly<font style="letter-spacing:0.15pt;"> </font>impede<font style="letter-spacing:0.05pt;"> </font>the achievement<font style="letter-spacing:0.1pt;"> </font>of our development<font style="letter-spacing:0.05pt;"> </font>and commercial<font style="letter-spacing:0.1pt;"> </font>objectives<font style="letter-spacing:0.1pt;"> </font>and our ability<font style="letter-spacing:0.05pt;"> </font>to implement<font style="letter-spacing:0.1pt;"> </font>our business<font style="letter-spacing:0.05pt;"> </font>strategy. In addition, we are highly dependent<font style="letter-spacing:0.05pt;"> </font>on the development,<font style="letter-spacing:0.05pt;"> </font>regulatory,<font style="letter-spacing:0.1pt;"> manufacturing, </font>commercialization<font style="letter-spacing:0.2pt;"> </font>and financial<font style="letter-spacing:0.05pt;"> </font>expertise<font style="letter-spacing:0.1pt;"> </font>of the members<font style="letter-spacing:0.05pt;"> </font>of our executive<font style="letter-spacing:0.05pt;"> </font>team,<font style="letter-spacing:0.05pt;"> </font>as well as other<font style="letter-spacing:0.05pt;"> </font>key employees<font style="letter-spacing:0.05pt;"> </font>and consultants.<font style="letter-spacing:0.1pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>lose one or more<font style="letter-spacing:0.05pt;"> </font>of our executive<font style="letter-spacing:0.05pt;"> </font>officers<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>key employees<font style="letter-spacing:0.05pt;"> </font>or consultants,<font style="letter-spacing:0.1pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to implement<font style="letter-spacing:0.1pt;"> </font>our business<font style="letter-spacing:0.05pt;"> </font>strategy successfully<font style="letter-spacing:0.1pt;"> </font>could be seriously<font style="letter-spacing:0.05pt;"> </font>harmed.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are developing<font style="letter-spacing:0.05pt;"> </font>a new<font style="letter-spacing:-0.05pt;"> </font>drug product formulation<font style="letter-spacing:0.05pt;"> </font>for BIO89-100<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may be unsuccessful.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>changes in methods<font style="letter-spacing:0.05pt;"> </font>of product candidate<font style="letter-spacing:0.05pt;"> </font>manufacturing<font style="letter-spacing:0.05pt;"> </font>or formulation<font style="letter-spacing:0.05pt;"> </font>may result<font style="letter-spacing:0.05pt;"> </font>in the need to perform<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>clinical trials or obtain new drug product,<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>would<font style="letter-spacing:-0.05pt;"> </font>require<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>cause delay.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a new drug product<font style="letter-spacing:0.05pt;"> </font>formulation<font style="letter-spacing:0.1pt;"> </font>of BIO89-100 for late<font style="letter-spacing:0.05pt;"> </font>stage<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and commercialization.<font style="letter-spacing:0.2pt;"> </font>Our current<font style="letter-spacing:0.05pt;"> </font>drug product<font style="letter-spacing:0.05pt;"> </font>is stored<font style="letter-spacing:0.05pt;"> </font>as a frozen<font style="letter-spacing:0.05pt;"> </font>liquid<font style="letter-spacing:0.05pt;"> </font>and is therefore<font style="letter-spacing:0.1pt;"> </font>not well-suited<font style="letter-spacing:0.1pt;"> </font>to larger clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>or commercialization.<font style="letter-spacing:0.2pt;"> </font>We have developed a new refrigerated<font style="letter-spacing:0.15pt;"> </font>liquid<font style="letter-spacing:0.05pt;"> </font>formulation<font style="letter-spacing:0.1pt;"> and have </font>engaged a formulation<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>company to also explore<font style="letter-spacing:0.05pt;"> </font>a freeze-dried,<font style="letter-spacing:0.15pt;"> </font>or lyophilized,<font style="letter-spacing:0.1pt;"> </font>formulation. We have commenced development of a pre-filled syringe for the new drug product<font style="letter-spacing:0.05pt;"> </font>formulation and we also plan to begin development of a pen-type<font style="letter-spacing:0.05pt;"> </font>autoinjector.<font style="letter-spacing:0.1pt;"> </font>There is no assurance<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we will be successful in developing<font style="letter-spacing:0.05pt;"> </font>a new drug product<font style="letter-spacing:0.05pt;"> </font>formulation, a pre-filled syringe<font style="letter-spacing:0.1pt;"> </font>or an autoinjector<font style="letter-spacing:0.1pt;"> </font>on a timely<font style="letter-spacing:0.05pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>or at all,<font style="letter-spacing:0.05pt;"> </font>which could impede our development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>strategy<font style="letter-spacing:0.05pt;"> </font>for BIO89-100. The FDA or other<font style="letter-spacing:0.05pt;"> </font>comparable<font style="letter-spacing:0.1pt;"> </font>foreign regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>could require<font style="letter-spacing:0.05pt;"> </font>nonclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>or clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>to support<font style="letter-spacing:0.05pt;"> </font>introduction<font style="letter-spacing:0.1pt;"> </font>of any new formulation, pre-filled syringe<font style="letter-spacing:0.1pt;"> </font>and autoinjector, which could delay completion<font style="letter-spacing:0.1pt;"> </font>of clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>require<font style="letter-spacing:0.05pt;"> </font>the conduct of bridging clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>or the repetition<font style="letter-spacing:0.1pt;"> </font>of one or more<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>our clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>costs,<font style="letter-spacing:0.05pt;"> </font>delay approval<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 and jeopardize<font style="letter-spacing:0.1pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to commence<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>sales<font style="letter-spacing:0.05pt;"> </font>and generate<font style="letter-spacing:0.05pt;"> </font>revenue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>BIO89-100, if approved. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties for certain aspects of our product candidate development process and we may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to depend on collaborators, partners, licensees, clinical investigators, CROs, manufacturers and other third parties to support our discovery efforts, to formulate product candidates, to conduct clinical trials for some or all of our product candidates, to manufacture clinical and commercial scale quantities of our drug substance and drug product and to market, sell and distribute any products we successfully develop. Any<font style="letter-spacing:-0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>may terminate<font style="letter-spacing:0.1pt;"> </font>their engagements<font style="letter-spacing:0.05pt;"> </font>with us at any time.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>need to enter<font style="letter-spacing:0.05pt;"> </font>into alternative<font style="letter-spacing:0.1pt;"> </font>arrangements,<font style="letter-spacing:0.1pt;"> </font>it would delay our product development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>and such alternative<font style="letter-spacing:0.1pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>may not be available<font style="letter-spacing:0.1pt;"> </font>on terms<font style="letter-spacing:0.05pt;"> </font>acceptable<font style="letter-spacing:0.1pt;"> </font>to us. We also expect<font style="letter-spacing:0.05pt;"> </font>to rely<font style="letter-spacing:0.05pt;"> </font>on other<font style="letter-spacing:0.05pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>to store<font style="letter-spacing:0.05pt;"> </font>and distribute<font style="letter-spacing:0.1pt;"> </font>drug supplies<font style="letter-spacing:0.05pt;"> </font>for our clinical<font style="letter-spacing:0.1pt;"> </font>trials. Any<font style="letter-spacing:-0.05pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>failure<font style="letter-spacing:0.1pt;"> </font>on the part<font style="letter-spacing:0.05pt;"> </font>of our distributors<font style="letter-spacing:0.1pt;"> </font>could delay clinical<font style="letter-spacing:0.1pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>marketing<font style="letter-spacing:0.1pt;"> </font>approval and/or<font style="letter-spacing:0.05pt;"> </font>commercialization<font style="letter-spacing:0.2pt;"> </font>of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>producing<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>losses<font style="letter-spacing:0.05pt;"> </font>and depriving<font style="letter-spacing:0.05pt;"> </font>us of potential<font style="letter-spacing:0.1pt;"> </font>revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to develop and commercialize additional product candidates, we may be unable to grow our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of BIO89-100 is currently<font style="letter-spacing:0.1pt;"> </font>our primary<font style="letter-spacing:0.05pt;"> </font>focus, as part of our longer-term<font style="letter-spacing:0.1pt;"> </font>growth strategy,<font style="letter-spacing:0.05pt;"> </font>we plan to evaluate<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of other therapies<font style="letter-spacing:0.1pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to NASH<font style="letter-spacing:-0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>liver<font style="letter-spacing:0.05pt;"> </font>and cardio-metabolic<font style="letter-spacing:0.15pt;"> </font>diseases.<font style="letter-spacing:0.05pt;"> </font>The success<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>strategy<font style="letter-spacing:0.05pt;"> </font>depends primarily<font style="letter-spacing:0.1pt;"> </font>upon our ability<font style="letter-spacing:0.05pt;"> </font>to identify<font style="letter-spacing:0.05pt;"> </font>and validate<font style="letter-spacing:0.05pt;"> </font>new therapeutic<font style="letter-spacing:0.1pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>and to identify,<font style="letter-spacing:0.05pt;"> </font>develop and commercialize<font style="letter-spacing:0.15pt;"> </font>new drugs and biologics.<font style="letter-spacing:0.05pt;"> </font>Our research<font style="letter-spacing:0.05pt;"> </font>efforts<font style="letter-spacing:0.1pt;"> </font>may initially<font style="letter-spacing:0.1pt;"> </font>show promise<font style="letter-spacing:0.05pt;"> </font>in discovering<font style="letter-spacing:0.05pt;"> </font>potential new drugs and biologics,<font style="letter-spacing:0.05pt;"> </font>yet fail<font style="letter-spacing:0.05pt;"> </font>to yield<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>for clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>for a number<font style="letter-spacing:0.05pt;"> </font>of reasons.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may use our limited</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">financial</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">human</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">resources</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to pursue a particular</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">research</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">program or product candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that is ultimately</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">unsuccessful</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or less</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">successful</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">than other programs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or product candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that we may have forgone or delayed.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited<font style="letter-spacing:0.1pt;"> </font>personnel<font style="letter-spacing:0.05pt;"> </font>and financial<font style="letter-spacing:0.1pt;"> </font>resources,<font style="letter-spacing:0.05pt;"> </font>we may forego<font style="letter-spacing:0.05pt;"> </font>or delay the development<font style="letter-spacing:0.05pt;"> </font>of certain<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>or product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>later<font style="letter-spacing:0.05pt;"> </font>prove to have greater<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>potential<font style="letter-spacing:0.1pt;"> </font>than the programs<font style="letter-spacing:0.05pt;"> </font>or product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we do pursue. Our resource<font style="letter-spacing:0.05pt;"> </font>allocation<font style="letter-spacing:0.1pt;"> </font>decisions<font style="letter-spacing:0.05pt;"> </font>may cause us to fail<font style="letter-spacing:0.05pt;"> </font>to capitalize<font style="letter-spacing:0.1pt;"> </font>on viable<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>or profitable<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>opportunities.<font style="letter-spacing:0.1pt;"> </font>Our spending on current<font style="letter-spacing:0.05pt;"> </font>and future<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>for product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>may not yield<font style="letter-spacing:0.05pt;"> </font>any commercially<font style="letter-spacing:0.15pt;"> </font>viable<font style="letter-spacing:0.05pt;"> </font>products.<font style="letter-spacing:0.05pt;"> </font>Similarly,<font style="letter-spacing:0.1pt;"> </font>our decisions<font style="letter-spacing:0.05pt;"> </font>to delay or terminate<font style="letter-spacing:0.1pt;"> </font>drug development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>may also be incorrect<font style="letter-spacing:0.1pt;"> </font>and could cause us to miss valuable<font style="letter-spacing:0.05pt;"> </font>opportunities.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek to establish commercial collaborations for our product candidates, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates. Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify, in-license or acquire, discover, develop or commercialize additional product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to identify, in-license or acquire, discover, develop and commercialize additional product candidates. We cannot assure you that our effort to in-license or acquire additional product candidates will be successful. Even if we are successful in in-licensing or acquiring additional product candidates, their requisite development activities may require substantial resources, and we cannot assure you that these development activities will result in regulatory approvals.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<font style="letter-spacing:-0.05pt;"> </font>international<font style="letter-spacing:0.05pt;"> </font>operations<font style="letter-spacing:0.05pt;"> </font>may expose us to business, regulatory,<font style="letter-spacing:0.05pt;"> </font>political,<font style="letter-spacing:0.1pt;"> </font>operational,<font style="letter-spacing:0.05pt;"> </font>financial,<font style="letter-spacing:0.05pt;"> </font>pricing and<font style="letter-spacing:-0.05pt;"> </font>reimbursement<font style="letter-spacing:0.1pt;"> </font>risks<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.05pt;"> </font>with doing business outside<font style="letter-spacing:0.05pt;"> </font>of the United States.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our use of our international<font style="letter-spacing:0.15pt;"> </font>facilities<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>us to U.S.<font style="letter-spacing:-0.05pt;"> </font>and foreign<font style="letter-spacing:0.05pt;"> </font>governmental<font style="letter-spacing:0.1pt;"> </font>trade,<font style="letter-spacing:0.05pt;"> </font>import<font style="letter-spacing:0.05pt;"> </font>and export,<font style="letter-spacing:0.05pt;"> </font>and customs<font style="letter-spacing:0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>and laws. Compliance<font style="letter-spacing:0.05pt;"> </font>with these<font style="letter-spacing:0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>and laws is costly<font style="letter-spacing:0.05pt;"> </font>and exposes us to penalties<font style="letter-spacing:0.1pt;"> </font>for non-compliance.<font style="letter-spacing:0.1pt;"> </font>Doing business<font style="letter-spacing:0.05pt;"> </font>internationally<font style="letter-spacing:0.15pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>involves<font style="letter-spacing:0.05pt;"> </font>a number<font style="letter-spacing:0.05pt;"> </font>of risks,<font style="letter-spacing:0.05pt;"> any of which could </font>harm<font style="letter-spacing:0.05pt;"> </font>our ongoing international<font style="letter-spacing:0.15pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>operations<font style="letter-spacing:0.05pt;"> </font>and supply chain, as well as any future<font style="letter-spacing:0.05pt;"> </font>international<font style="letter-spacing:0.15pt;"> </font>expansion<font style="letter-spacing:0.05pt;"> </font>and operations<font style="letter-spacing:0.05pt;"> </font>and, consequently,<font style="letter-spacing:0.05pt;"> </font>our business,<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>condition, prospects<font style="letter-spacing:0.05pt;"> </font>and results<font style="letter-spacing:0.05pt;"> </font>of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face<font style="letter-spacing:0.05pt;"> </font>an inherent<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>of product<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.1pt;"> </font>exposure<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to the testing<font style="letter-spacing:0.05pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>in human clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and will face<font style="letter-spacing:0.05pt;"> </font>an even greater<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>commercialize<font style="letter-spacing:0.15pt;"> </font>any resulting<font style="letter-spacing:0.1pt;"> </font>products.<font style="letter-spacing:0.05pt;"> </font>Product liability<font style="letter-spacing:0.1pt;"> </font>claims<font style="letter-spacing:0.05pt;"> </font>may be brought against<font style="letter-spacing:0.05pt;"> </font>us by subjects<font style="letter-spacing:0.05pt;"> </font>enrolled<font style="letter-spacing:0.05pt;"> </font>in our clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>patients,<font style="letter-spacing:0.05pt;"> </font>or others<font style="letter-spacing:0.05pt;"> </font>using our products.<font style="letter-spacing:0.05pt;"> </font>Our clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.1pt;"> </font>insurance<font style="letter-spacing:0.05pt;"> </font>coverage<font style="letter-spacing:0.05pt;"> </font>may not adequately<font style="letter-spacing:0.05pt;"> </font>cover all<font style="letter-spacing:0.05pt;"> </font>liabilities<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may incur. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">employees,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">contractors,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">vendors, principal</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">investigators,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consultants</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">future partners</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may engage in misconduct</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or other improper</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">activities,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">including noncompliance</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with regulatory</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">standards and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">requirements and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">insider</font><font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trading.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk<font style="letter-spacing:0.05pt;"> </font>of fraud<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>misconduct<font style="letter-spacing:0.05pt;"> </font>by our employees,<font style="letter-spacing:0.05pt;"> </font>contractors,<font style="letter-spacing:0.1pt;"> </font>vendors, principal<font style="letter-spacing:0.1pt;"> </font>investigators,<font style="letter-spacing:0.1pt;"> </font>consultants<font style="letter-spacing:0.1pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>partners.<font style="letter-spacing:0.05pt;"> </font>Misconduct<font style="letter-spacing:0.05pt;"> </font>by these<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>could include<font style="letter-spacing:0.05pt;"> </font>failures<font style="letter-spacing:0.1pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with FDA<font style="letter-spacing:-0.05pt;"> </font>regulations,<font style="letter-spacing:0.1pt;"> </font>to provide<font style="letter-spacing:0.05pt;"> </font>accurate<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>to the FDA,<font style="letter-spacing:-0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with federal<font style="letter-spacing:0.05pt;"> </font>and state healthcare<font style="letter-spacing:0.1pt;"> </font>fraud<font style="letter-spacing:0.05pt;"> </font>and abuse laws and regulations,<font style="letter-spacing:0.1pt;"> </font>to report<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>or data timely,<font style="letter-spacing:0.05pt;"> </font>completely<font style="letter-spacing:0.1pt;"> </font>or accurately,<font style="letter-spacing:0.1pt;"> </font>or to disclose<font style="letter-spacing:0.05pt;"> </font>unauthorized<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>to us. Most states<font style="letter-spacing:0.05pt;"> </font>also have statutes<font style="letter-spacing:0.1pt;"> </font>or regulations<font style="letter-spacing:0.1pt;"> </font>similar<font style="letter-spacing:0.1pt;"> </font>to these<font style="letter-spacing:0.05pt;"> </font>federal<font style="letter-spacing:0.05pt;"> </font>laws, which may apply to items such as pharmaceutical<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>and services<font style="letter-spacing:0.05pt;"> </font>reimbursed<font style="letter-spacing:0.1pt;"> </font>by private<font style="letter-spacing:0.05pt;"> </font>insurers.<font style="letter-spacing:0.05pt;"> </font>We and/or<font style="letter-spacing:0.05pt;"> </font>our future<font style="letter-spacing:0.05pt;"> </font>partners<font style="letter-spacing:0.05pt;"> </font>may be subject<font style="letter-spacing:0.05pt;"> </font>to administrative,<font style="letter-spacing:0.15pt;"> </font>civil<font style="letter-spacing:0.05pt;"> </font>and criminal<font style="letter-spacing:0.1pt;"> </font>sanctions<font style="letter-spacing:0.05pt;"> </font>for violations<font style="letter-spacing:0.1pt;"> </font>of any of these<font style="letter-spacing:0.05pt;"> </font>laws.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend on<font style="letter-spacing:-0.05pt;"> </font>our information<font style="letter-spacing:0.05pt;"> </font>technology<font style="letter-spacing:0.05pt;"> </font>systems<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>those of our third-party<font style="letter-spacing:0.1pt;"> </font>collaborators,<font style="letter-spacing:0.1pt;"> </font>service providers,<font style="letter-spacing:0.05pt;"> </font>contractors<font style="letter-spacing:0.05pt;"> </font>or consultants.<font style="letter-spacing:0.05pt;"> </font>Our<font style="letter-spacing:-0.05pt;"> </font>internal<font style="letter-spacing:0.05pt;"> </font>computer<font style="letter-spacing:0.05pt;"> </font>systems,<font style="letter-spacing:0.05pt;"> </font>or those of our third-party<font style="letter-spacing:0.1pt;"> </font>collaborators, service<font style="letter-spacing:0.05pt;"> </font>providers,<font style="letter-spacing:0.05pt;"> </font>contractors<font style="letter-spacing:0.05pt;"> </font>or consultants,<font style="letter-spacing:0.05pt;"> </font>may fail<font style="letter-spacing:0.05pt;"> </font>or suffer<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>breaches, disruptions,<font style="letter-spacing:0.05pt;"> </font>or incidents, which<font style="letter-spacing:-0.05pt;"> </font>could result<font style="letter-spacing:0.05pt;"> </font>in a material<font style="letter-spacing:0.1pt;"> </font>disruption<font style="letter-spacing:0.05pt;"> </font>of our development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>or loss of data or compromise<font style="letter-spacing:0.1pt;"> </font>the privacy,<font style="letter-spacing:0.05pt;"> </font>security,<font style="letter-spacing:0.05pt;"> </font>integrity<font style="letter-spacing:0.1pt;"> </font>or confidentiality<font style="letter-spacing:0.15pt;"> </font>of sensitive<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to our business and<font style="letter-spacing:-0.05pt;"> </font>have a material<font style="letter-spacing:0.1pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>our reputation,<font style="letter-spacing:0.05pt;"> </font>business, financial<font style="letter-spacing:0.05pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>or results<font style="letter-spacing:0.05pt;"> </font>of operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary<font style="letter-spacing:0.05pt;"> </font>course<font style="letter-spacing:0.05pt;"> </font>of our business,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>collect,<font style="letter-spacing:0.05pt;"> </font>store<font style="letter-spacing:0.05pt;"> </font>and transmit<font style="letter-spacing:0.1pt;"> </font>large<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of confidential information,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property,<font style="letter-spacing:0.05pt;"> </font>proprietary<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>and personal<font style="letter-spacing:0.05pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>Our internal<font style="letter-spacing:0.1pt;"> </font>technology<font style="letter-spacing:0.05pt;"> </font>systems<font style="letter-spacing:0.05pt;"> </font>and infrastructure,<font style="letter-spacing:0.15pt;"> </font>and those of our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>collaborators, service<font style="letter-spacing:0.05pt;"> </font>providers,<font style="letter-spacing:0.05pt;"> </font>contractors<font style="letter-spacing:0.1pt;"> </font>and consultants<font style="letter-spacing:0.1pt;"> </font>are vulnerable<font style="letter-spacing:0.05pt;"> </font>to damage<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>computer<font style="letter-spacing:0.05pt;"> </font>viruses,<font style="letter-spacing:0.05pt;"> </font>unauthorized access<font style="letter-spacing:0.05pt;"> </font>or use resulting<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>malware,<font style="letter-spacing:0.05pt;"> </font>natural<font style="letter-spacing:0.05pt;"> </font>disasters,<font style="letter-spacing:0.1pt;"> </font>terrorism,<font style="letter-spacing:0.1pt;"> </font>war and telecommunication<font style="letter-spacing:0.15pt;"> </font>and electrical failures,<font style="letter-spacing:0.1pt;"> </font>denial-of-service<font style="letter-spacing:0.2pt;"> </font>attacks,<font style="letter-spacing:0.05pt;"> </font>cyber-attacks<font style="letter-spacing:0.1pt;"> </font>or cyber-intrusions<font style="letter-spacing:0.15pt;"> </font>over the Internet,<font style="letter-spacing:0.1pt;"> </font>hacking, phishing<font style="letter-spacing:0.05pt;"> </font>and other social<font style="letter-spacing:0.05pt;"> </font>engineering<font style="letter-spacing:0.05pt;"> </font>attacks,<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>inside<font style="letter-spacing:0.05pt;"> </font>our organizations<font style="letter-spacing:0.1pt;"> </font>(including<font style="letter-spacing:0.05pt;"> </font>employees<font style="letter-spacing:0.05pt;"> </font>or contractors),<font style="letter-spacing:0.1pt;"> </font>loss or theft,<font style="letter-spacing:0.05pt;"> </font>or persons<font style="letter-spacing:0.05pt;"> </font>with access<font style="letter-spacing:0.05pt;"> </font>to systems<font style="letter-spacing:0.05pt;"> </font>inside<font style="letter-spacing:0.05pt;"> </font>our organization.<font style="letter-spacing:0.1pt;"> </font>While<font style="letter-spacing:0.05pt;"> </font>to our knowledge we<font style="letter-spacing:-0.05pt;"> </font>have not experienced<font style="letter-spacing:0.05pt;"> </font>any material<font style="letter-spacing:0.1pt;"> </font>system<font style="letter-spacing:0.05pt;"> </font>failure,<font style="letter-spacing:0.1pt;"> </font>accident<font style="letter-spacing:0.05pt;"> </font>or security<font style="letter-spacing:0.05pt;"> </font>breach<font style="letter-spacing:0.05pt;"> </font>to date we have been subject to periodic phishing attempts. If a material system<font style="letter-spacing:0.05pt;"> </font>failure,<font style="letter-spacing:0.1pt;"> </font>accident<font style="letter-spacing:0.05pt;"> </font>or security<font style="letter-spacing:0.05pt;"> </font>breach were to occur and cause interruptions<font style="letter-spacing:0.1pt;"> </font>in our operations<font style="letter-spacing:0.05pt;"> </font>or the operations<font style="letter-spacing:0.05pt;"> </font>of third-party<font style="letter-spacing:0.1pt;"> </font>collaborators,<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers, contractors<font style="letter-spacing:0.1pt;"> </font>and consultants,<font style="letter-spacing:0.1pt;"> </font>it could result<font style="letter-spacing:0.05pt;"> </font>in a material<font style="letter-spacing:0.1pt;"> </font>disruption<font style="letter-spacing:0.05pt;"> </font>of our development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>and significant reputational,<font style="letter-spacing:0.1pt;"> </font>financial,<font style="letter-spacing:0.1pt;"> </font>legal,<font style="letter-spacing:0.05pt;"> </font>regulatory,<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>or operational<font style="letter-spacing:0.1pt;"> </font>harm.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:-0.05pt;"> </font>the extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>any real<font style="letter-spacing:0.05pt;"> </font>or perceived<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>breach<font style="letter-spacing:0.05pt;"> </font>affects<font style="letter-spacing:0.1pt;"> </font>our systems<font style="letter-spacing:0.05pt;"> </font>(or those of our third-party<font style="letter-spacing:0.1pt;"> </font>collaborators,<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers,<font style="letter-spacing:0.05pt;"> </font>contractors<font style="letter-spacing:0.1pt;"> </font>or consultants),<font style="letter-spacing:0.1pt;"> </font>or results<font style="letter-spacing:0.05pt;"> </font>in the loss of or accidental,<font style="letter-spacing:0.1pt;"> </font>unlawful<font style="letter-spacing:0.05pt;"> </font>or unauthorized<font style="letter-spacing:0.05pt;"> </font>access<font style="letter-spacing:0.05pt;"> </font>to, use of, release<font style="letter-spacing:0.05pt;"> </font>of, or other<font style="letter-spacing:0.05pt;"> </font>processing<font style="letter-spacing:0.05pt;"> </font>of personally<font style="letter-spacing:0.05pt;"> </font>identifiable information<font style="letter-spacing:0.1pt;"> </font>or damage<font style="letter-spacing:0.05pt;"> </font>to our data or applications<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>data or applications<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to our technology<font style="letter-spacing:0.05pt;"> </font>or product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>or inappropriate<font style="letter-spacing:0.1pt;"> </font>disclosure<font style="letter-spacing:0.1pt;"> </font>of confidential<font style="letter-spacing:0.1pt;"> </font>or proprietary<font style="letter-spacing:0.1pt;"> </font>information,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>could incur liabilities<font style="letter-spacing:0.15pt;"> </font>and the further<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>could be delayed.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>failure<font style="letter-spacing:0.1pt;"> </font>or perceived<font style="letter-spacing:0.05pt;"> </font>failure<font style="letter-spacing:0.1pt;"> </font>by us or any third-party<font style="letter-spacing:0.1pt;"> </font>collaborators,<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers,<font style="letter-spacing:0.05pt;"> </font>contractors<font style="letter-spacing:0.1pt;"> </font>or consultants<font style="letter-spacing:0.1pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with our privacy,<font style="letter-spacing:0.05pt;"> </font>confidentiality,<font style="letter-spacing:0.15pt;"> </font>data security<font style="letter-spacing:0.05pt;"> </font>or similar<font style="letter-spacing:0.1pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>or any data security incidents<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>breaches<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.05pt;"> </font>in the accidental,<font style="letter-spacing:0.1pt;"> </font>unlawful<font style="letter-spacing:0.05pt;"> </font>or unauthorized<font style="letter-spacing:0.05pt;"> </font>access<font style="letter-spacing:0.05pt;"> </font>to, use of, release<font style="letter-spacing:0.05pt;"> </font>of, processing<font style="letter-spacing:0.05pt;"> </font>of, or transfer<font style="letter-spacing:0.1pt;"> </font>of sensitive<font style="letter-spacing:0.1pt;"> </font>information,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>personally<font style="letter-spacing:0.05pt;"> </font>identifiable<font style="letter-spacing:0.15pt;"> </font>information,<font style="letter-spacing:0.1pt;"> </font>may result<font style="letter-spacing:0.05pt;"> </font>in negative<font style="letter-spacing:0.05pt;"> </font>publicity,<font style="letter-spacing:0.05pt;"> </font>harm<font style="letter-spacing:0.05pt;"> </font>to our reputation,<font style="letter-spacing:0.1pt;"> </font>governmental<font style="letter-spacing:0.1pt;"> </font>investigations,<font style="letter-spacing:0.1pt;"> </font>enforcement<font style="letter-spacing:0.1pt;"> </font>actions,<font style="letter-spacing:0.05pt;"> </font>regulatory fines,<font style="letter-spacing:0.05pt;"> </font>litigation<font style="letter-spacing:0.1pt;"> </font>or public<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>us, could cause third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>to lose trust<font style="letter-spacing:0.05pt;"> </font>in us or could result<font style="letter-spacing:0.05pt;"> </font>in claims<font style="letter-spacing:0.05pt;"> </font>by third<font style="letter-spacing:0.05pt;"> </font>parties,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>those that<font style="letter-spacing:0.05pt;"> </font>assert<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have breached<font style="letter-spacing:0.05pt;"> </font>our privacy,<font style="letter-spacing:0.05pt;"> </font>confidentiality,<font style="letter-spacing:0.15pt;"> </font>data security<font style="letter-spacing:0.05pt;"> </font>or similar<font style="letter-spacing:0.1pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>any of which could have a material<font style="letter-spacing:0.1pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on our reputation,<font style="letter-spacing:0.1pt;"> </font>business, financial<font style="letter-spacing:0.1pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>or results<font style="letter-spacing:0.05pt;"> </font>of operations.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approvals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378352"></a>BIO89-100<font style="letter-spacing:-0.05pt;"> </font>has not received<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>approval. If we<font style="letter-spacing:-0.05pt;"> </font>are unable to obtain regulatory<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>to market BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or any future product candidates,<font style="letter-spacing:0.05pt;"> </font>our business will be adversely<font style="letter-spacing:0.05pt;"> </font>affected.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect<font style="letter-spacing:0.05pt;"> </font>BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>to be commercially<font style="letter-spacing:0.15pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for several years,<font style="letter-spacing:0.05pt;"> </font>if at all.<font style="letter-spacing:0.05pt;"> </font>BIO89-100 is and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>will be subject<font style="letter-spacing:0.05pt;"> </font>to strict<font style="letter-spacing:0.1pt;"> </font>regulation<font style="letter-spacing:0.1pt;"> </font>by regulatory authorities<font style="letter-spacing:0.1pt;"> </font>in the United States<font style="letter-spacing:0.05pt;"> </font>and in other<font style="letter-spacing:0.05pt;"> </font>countries.<font style="letter-spacing:0.05pt;"> </font>We cannot market<font style="letter-spacing:0.05pt;"> </font>any product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have completed<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and have obtained<font style="letter-spacing:0.05pt;"> </font>the necessary<font style="letter-spacing:0.05pt;"> </font>regulatory approvals.<font style="letter-spacing:0.05pt;"> </font>We do not know<font style="letter-spacing:-0.05pt;"> </font>whether regulatory<font style="letter-spacing:0.1pt;"> </font>agencies<font style="letter-spacing:0.05pt;"> </font>will grant<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product candidate.<font style="letter-spacing:0.05pt;"> </font>Even if we<font style="letter-spacing:-0.05pt;"> </font>complete<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>successfully,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not be able to obtain regulatory<font style="letter-spacing:0.1pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>or we<font style="letter-spacing:-0.05pt;"> </font>may not receive<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>to make claims<font style="letter-spacing:0.05pt;"> </font>about our products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>believe<font style="letter-spacing:0.05pt;"> </font>to be necessary<font style="letter-spacing:0.05pt;"> </font>to effectively<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>our products.<font style="letter-spacing:0.05pt;"> </font>Data obtained<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>is subject to varying<font style="letter-spacing:0.05pt;"> </font>interpretations<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>could </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or prevent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and failure</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to comply</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or inadequate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">processes</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are examples</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">problems</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could prevent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the United States</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the EU</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have not approved any products</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of NASH,</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and while there</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are recent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidelines</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the FDA</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of drugs for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of NASH</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and a FDA</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surrogate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">table</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for drug approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includes</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">SHTG,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> it is unclear</font><font style="letter-spacing:1.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether the requirements</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will change in the future.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such changes may require</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us to conduct new</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could delay our timeframe</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and increase</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our programs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to BIO89-100 or any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of NASH</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="letter-spacing:-0.05pt;">SHTG.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> While</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has approved reduction</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:1.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">triglycerides</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">levels</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a surrogate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the full</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of drugs for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of SHTG,</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is unclear whether this</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will apply to any product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop. If such endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is not deemed</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to apply to our product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it would delay our development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timeline</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and increase</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the costs</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our programs for the treatment</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="letter-spacing:-0.05pt;">SHTG.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We have not had any discussions with the FDA</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a surrogate</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="letter-spacing:1.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accelerated</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our SHTG</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be subject</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to smaller</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may expect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a relatively</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quick</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> overall</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timeline</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for this</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indication. These expectations</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are based on a published</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surrogate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endpoint</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">table</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for drug approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includes </font><font style="letter-spacing:-0.05pt;">SHTG,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as the development</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">path followed</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developed</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an SHTG</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapy.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even<font style="letter-spacing:-0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>are able to obtain regulatory<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>for BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or any future product candidate,<font style="letter-spacing:0.05pt;"> </font>if they exhibit<font style="letter-spacing:0.05pt;"> </font>harmful<font style="letter-spacing:0.05pt;"> </font>side effects<font style="letter-spacing:0.1pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>approval, our regulatory<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>could be revoked or otherwise<font style="letter-spacing:0.05pt;"> </font>negatively impacted,<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>could be subject<font style="letter-spacing:0.05pt;"> </font>to costly<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>damaging product liability<font style="letter-spacing:0.1pt;"> </font>claims.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<font style="letter-spacing:-0.05pt;"> if we </font><font style="letter-spacing:-0.1pt;">receive</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">regulatory</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approval</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">BIO89-100</font><font style="letter-spacing:-0.05pt;"> or </font><font style="letter-spacing:-0.1pt;">any future</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">candidates, </font><font style="letter-spacing:-0.05pt;">we </font><font style="letter-spacing:-0.1pt;">will</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">have</font><font style="letter-spacing:2.2pt;"> </font><font style="letter-spacing:-0.1pt;">tested</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">them</font><font style="letter-spacing:-0.05pt;"> in </font><font style="letter-spacing:-0.1pt;">only</font><font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">small</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">number</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">patients</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">during</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">clinical</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">trials.</font><font style="letter-spacing:-0.05pt;"> If </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">applications</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">marketing</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">are</font><font style="letter-spacing:2.8pt;"> </font><font style="letter-spacing:-0.1pt;">approved</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">more</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">patients</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">begin</font><font style="letter-spacing:-0.05pt;"> to </font><font style="letter-spacing:-0.1pt;">use</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">new risks</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">side</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">effects</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">associated</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">with</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">products</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">may</font><font style="letter-spacing:3.4pt;"> </font><font style="letter-spacing:-0.05pt;">be </font><font style="letter-spacing:-0.1pt;">discovered.</font><font style="letter-spacing:-0.05pt;"> As </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">result,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">regulatory</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">authorities</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">may</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">revoke</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">their</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approvals.</font><font style="letter-spacing:-0.05pt;"> We </font><font style="letter-spacing:-0.1pt;">have</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">not</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">had</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">any</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">discussions</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">with</font><font style="letter-spacing:2.6pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">FDA regarding</font><font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">surrogate</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">endpoint</font><font style="letter-spacing:-0.05pt;"> or </font><font style="letter-spacing:-0.1pt;">accelerated</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approval</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">regulations.</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">However,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">based</font><font style="letter-spacing:-0.05pt;"> on </font><font style="letter-spacing:-0.1pt;">recent</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">guidelines</font><font style="letter-spacing:2pt;"> </font><font style="letter-spacing:-0.1pt;">issued</font><font style="letter-spacing:-0.05pt;"> by </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">FDA for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">development</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">drugs</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">treatment</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">NASH,</font><font style="letter-spacing:-0.05pt;"> if </font><font style="letter-spacing:-0.1pt;">BIO89-100</font><font style="letter-spacing:-0.05pt;"> is </font><font style="letter-spacing:-0.1pt;">approved</font><font style="letter-spacing:-0.05pt;"> by </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">FDA</font><font style="letter-spacing:2.7pt;"> </font><font style="letter-spacing:-0.1pt;">based</font><font style="letter-spacing:-0.05pt;"> on </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">surrogate</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">endpoint</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">pursuant</font><font style="letter-spacing:-0.05pt;"> to </font><font style="letter-spacing:-0.1pt;">section</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">506(c)</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Federal</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Food,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Drug,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Cosmetic</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Act</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:2.6pt;"> </font><font style="letter-spacing:-0.1pt;">accelerated</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approval</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">regulations</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">(21</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">C.F.R.</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">part</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">314,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">subpart</font><font style="letter-spacing:-0.05pt;"> H; 21 </font><font style="letter-spacing:-0.1pt;">C.F.R.</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">part</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">601,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">subpart</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">E),</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">consistent</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">with</font><font style="letter-spacing:2.7pt;"> </font><font style="letter-spacing:-0.1pt;">FDA guidance,</font><font style="letter-spacing:-0.05pt;"> we </font><font style="letter-spacing:-0.1pt;">will</font><font style="letter-spacing:-0.05pt;"> be </font><font style="letter-spacing:-0.1pt;">required</font><font style="letter-spacing:-0.05pt;"> to </font><font style="letter-spacing:-0.1pt;">conduct</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">additional</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">clinical</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">trials</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">establishing</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">clinical</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">benefit</font><font style="letter-spacing:-0.05pt;"> on </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">ultimate</font><font style="letter-spacing:2.4pt;"> </font><font style="letter-spacing:-0.1pt;">outcome</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">NASH.</font><font style="letter-spacing:-0.05pt;"> If </font><font style="letter-spacing:-0.1pt;">BIO89-100</font><font style="letter-spacing:-0.05pt;"> is </font><font style="letter-spacing:-0.1pt;">approved</font><font style="letter-spacing:-0.05pt;"> by </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">FDA for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">treatment</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">SHTG based</font><font style="letter-spacing:-0.05pt;"> on an </font><font style="letter-spacing:-0.1pt;">endpoint</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:2.4pt;"> </font><font style="letter-spacing:-0.1pt;">reduction</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">triglycerides,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">FDA may</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">still</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">require</font><font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">cardiovascular</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">outcomes</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">study</font><font style="letter-spacing:-0.05pt;"> as </font><font style="letter-spacing:-0.1pt;">part</font><font style="letter-spacing:-0.05pt;"> of </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">post-marketing</font><font style="letter-spacing:2.1pt;"> </font><font style="letter-spacing:-0.1pt;">authorization</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">commitment.</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Such</font><font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">study</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">would</font><font style="letter-spacing:-0.05pt;"> be </font><font style="letter-spacing:-0.1pt;">time</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">consuming</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">costly</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">cannot</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">guarantee</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">that</font><font style="letter-spacing:-0.05pt;"> we </font><font style="letter-spacing:-0.1pt;">will</font><font style="letter-spacing:2.6pt;"> </font><font style="letter-spacing:-0.1pt;">see</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">positive</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">results, which could result</font><font style="letter-spacing:-0.05pt;"> in</font><font style="letter-spacing:-0.1pt;"> the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">revocation </font><font style="letter-spacing:-0.05pt;">of </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approval. Additionally, we</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">may </font><font style="letter-spacing:-0.05pt;">be </font><font style="letter-spacing:-0.1pt;">required </font><font style="letter-spacing:-0.05pt;">to</font><font style="letter-spacing:2.7pt;"> </font><font style="letter-spacing:-0.1pt;">conduct</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">additional</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">clinical</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">trials, make</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">changes</font><font style="letter-spacing:-0.05pt;"> in </font><font style="letter-spacing:-0.1pt;">labeling </font><font style="letter-spacing:-0.05pt;">of </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product, reformulate</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:-0.05pt;"> or </font><font style="letter-spacing:-0.1pt;">make</font><font style="letter-spacing:2.4pt;"> </font><font style="letter-spacing:-0.1pt;">changes</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">obtain</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">new approvals</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">suppliers&#8217;</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">manufacturing</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">facilities</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">BIO89-100</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">any</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">future</font><font style="letter-spacing:3.2pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">candidates. </font><font style="letter-spacing:-0.05pt;">We </font><font style="letter-spacing:-0.1pt;">might</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">have</font><font style="letter-spacing:-0.05pt;"> to</font><font style="letter-spacing:-0.1pt;"> withdraw </font><font style="letter-spacing:-0.05pt;">or </font><font style="letter-spacing:-0.1pt;">recall</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">products</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">from</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">marketplace. </font><font style="letter-spacing:-0.05pt;">We </font><font style="letter-spacing:-0.1pt;">may also</font><font style="letter-spacing:2.4pt;"> </font><font style="letter-spacing:-0.1pt;">experience</font><font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">significant</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">drop</font><font style="letter-spacing:-0.05pt;"> in </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">potential</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">sales</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:-0.05pt;"> if </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">when</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">regulatory</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approvals</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">for</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">such</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:2.8pt;"> </font><font style="letter-spacing:-0.1pt;">are</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">revoked.</font><font style="letter-spacing:-0.05pt;"> As </font>a<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">result,</font><font style="letter-spacing:-0.05pt;"> we </font><font style="letter-spacing:-0.1pt;">may</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">experience</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">harm</font><font style="letter-spacing:-0.05pt;"> to </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">reputation</font><font style="letter-spacing:-0.05pt;"> in </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">marketplace</font><font style="letter-spacing:-0.05pt;"> or </font><font style="letter-spacing:-0.1pt;">become</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">subject</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">to</font> <font style="letter-spacing:-0.1pt;">lawsuits,</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">including</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">class</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">actions.</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Any</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">these</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">results</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">could</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">decrease</font><font style="letter-spacing:-0.05pt;"> or </font><font style="letter-spacing:-0.1pt;">prevent</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">any</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">sales</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">approved</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product</font><font style="letter-spacing:2.7pt;"> </font><font style="letter-spacing:-0.05pt;">or </font><font style="letter-spacing:-0.1pt;">substantially</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">increase</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">costs</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">expenses</font><font style="letter-spacing:-0.05pt;"> of </font><font style="letter-spacing:-0.1pt;">commercializing</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">marketing</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">our</font><font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">product.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>approval processes<font style="letter-spacing:0.05pt;"> </font>of the FDA<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>comparable<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>authorities<font style="letter-spacing:0.05pt;"> </font>are lengthy, time-consuming<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>inherently<font style="letter-spacing:0.05pt;"> </font>unpredictable.<font style="letter-spacing:0.05pt;"> </font>Our<font style="letter-spacing:-0.05pt;"> </font>inability<font style="letter-spacing:0.1pt;"> </font>to obtain regulatory<font style="letter-spacing:0.05pt;"> </font>approval for BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or any future product candidates<font style="letter-spacing:0.05pt;"> </font>would<font style="letter-spacing:-0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>harm our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>do not have any product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have received<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval.<font style="letter-spacing:0.05pt;"> </font>The time required<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the FDA<font style="letter-spacing:-0.05pt;"> </font>and comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>is unpredictable<font style="letter-spacing:0.1pt;"> </font>but typically<font style="letter-spacing:0.1pt;"> </font>takes<font style="letter-spacing:0.05pt;"> </font>many years<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>the commencement<font style="letter-spacing:0.1pt;"> </font>of preclinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and depends upon numerous<font style="letter-spacing:0.05pt;"> </font>factors,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the substantial<font style="letter-spacing:0.1pt;"> </font>discretion<font style="letter-spacing:0.1pt;"> </font>of the regulatory<font style="letter-spacing:0.1pt;"> </font>authorities.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>approval policies,<font style="letter-spacing:0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>or the type and amount<font style="letter-spacing:0.05pt;"> </font>of clinical<font style="letter-spacing:0.1pt;"> </font>data necessary<font style="letter-spacing:0.05pt;"> </font>to gain approval<font style="letter-spacing:0.05pt;"> </font>may change during the course<font style="letter-spacing:0.05pt;"> </font>of a product<font style="letter-spacing:0.05pt;"> </font>candidate&#8217;s<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>and may vary among jurisdictions.<font style="letter-spacing:0.15pt;"> </font>It is possible<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>none of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>will ever obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval. BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>could fail<font style="letter-spacing:0.05pt;"> </font>to receive<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the FDA<font style="letter-spacing:-0.05pt;"> </font>or comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>for many reasons<font style="letter-spacing:0.05pt;">, including those referenced in Part I, Item 1. &#8220;Business&#8212;</font>Government Regulation and Product Approval<font style="letter-spacing:0.05pt;">&#8221;</font>. If we<font style="letter-spacing:-0.05pt;"> </font>were to obtain<font style="letter-spacing:0.05pt;"> </font>approval,<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>may approve any of our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>for fewer or more<font style="letter-spacing:0.05pt;"> </font>limited indications<font style="letter-spacing:0.1pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">request,</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may grant</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contingent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the performance</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of costly</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">post-marketing</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or may approve a product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a label</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does not include</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the labeling</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessary</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or desirable</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the successful</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of th</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even<font style="letter-spacing:-0.05pt;"> </font>if BIO89-100<font style="letter-spacing:-0.05pt;"> </font>or any future product candidate<font style="letter-spacing:0.05pt;"> </font>receives<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>approval, it may still<font style="letter-spacing:0.05pt;"> </font>face future development<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>regulatory<font style="letter-spacing:0.05pt;"> </font>difficulties.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we<font style="letter-spacing:-0.05pt;"> </font>obtained<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for a product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>it would be subject<font style="letter-spacing:0.05pt;"> </font>to ongoing requirements<font style="letter-spacing:0.1pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>and comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>governing<font style="letter-spacing:0.05pt;"> </font>the manufacture,<font style="letter-spacing:0.1pt;"> </font>quality control,<font style="letter-spacing:0.05pt;"> </font>further<font style="letter-spacing:0.05pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>labeling,<font style="letter-spacing:0.05pt;"> </font>packaging,<font style="letter-spacing:0.05pt;"> </font>storage,<font style="letter-spacing:0.05pt;"> </font>distribution,<font style="letter-spacing:0.1pt;"> </font>safety<font style="letter-spacing:0.05pt;"> </font>surveillance,<font style="letter-spacing:0.1pt;"> </font>import,<font style="letter-spacing:0.05pt;"> </font>export, advertising,<font style="letter-spacing:0.1pt;"> </font>promotion,<font style="letter-spacing:0.05pt;"> </font>recordkeeping<font style="letter-spacing:0.1pt;"> </font>and reporting<font style="letter-spacing:0.05pt;"> </font>of safety<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>post-market<font style="letter-spacing:0.1pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>manufacturers<font style="letter-spacing:0.15pt;"> </font>of drug products<font style="letter-spacing:0.05pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>facilities<font style="letter-spacing:0.15pt;"> </font>are subject<font style="letter-spacing:0.05pt;"> </font>to continual<font style="letter-spacing:0.05pt;"> </font>review and periodic<font style="letter-spacing:0.05pt;"> </font>inspections<font style="letter-spacing:0.1pt;"> </font>by the FDA<font style="letter-spacing:-0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>authorities<font style="letter-spacing:0.1pt;"> </font>for compliance<font style="letter-spacing:0.1pt;"> </font>with cGMP,<font style="letter-spacing:-0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>and standards.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>or a regulatory<font style="letter-spacing:0.1pt;"> </font>agency discover<font style="letter-spacing:0.05pt;"> </font>previously<font style="letter-spacing:0.05pt;"> </font>unknown<font style="letter-spacing:-0.05pt;"> </font>problems<font style="letter-spacing:0.05pt;"> </font>with a product,<font style="letter-spacing:0.05pt;"> </font>such as adverse events<font style="letter-spacing:0.05pt;"> </font>of unanticipated<font style="letter-spacing:0.1pt;"> </font>severity<font style="letter-spacing:0.05pt;"> </font>or frequency,<font style="letter-spacing:0.05pt;"> </font>or problems<font style="letter-spacing:0.05pt;"> </font>with the facility<font style="letter-spacing:0.1pt;"> </font>where the product<font style="letter-spacing:0.05pt;"> </font>is manufactured,<font style="letter-spacing:0.1pt;"> </font>a regulatory<font style="letter-spacing:0.1pt;"> </font>agency may impose<font style="letter-spacing:0.05pt;"> </font>restrictions<font style="letter-spacing:0.15pt;"> </font>on that<font style="letter-spacing:0.05pt;"> </font>product,<font style="letter-spacing:0.05pt;"> </font>the manufacturing<font style="letter-spacing:0.1pt;"> </font>facility<font style="letter-spacing:0.1pt;"> </font>or us, including<font style="letter-spacing:0.05pt;"> </font>requiring recall<font style="letter-spacing:0.05pt;"> </font>or withdrawal<font style="letter-spacing:0.05pt;"> </font>of the product<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the market<font style="letter-spacing:0.05pt;"> </font>or suspension<font style="letter-spacing:0.05pt;"> </font>of manufacturing.<font style="letter-spacing:0.1pt;"> </font>If we,<font style="letter-spacing:-0.05pt;"> </font>our product candidates<font style="letter-spacing:0.05pt;"> </font>or the manufacturing<font style="letter-spacing:0.1pt;"> </font>facilities<font style="letter-spacing:0.15pt;"> </font>for our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>fail<font style="letter-spacing:0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with applicable<font style="letter-spacing:0.1pt;"> </font>regulatory requirements,<font style="letter-spacing:0.1pt;"> </font>or undesirable<font style="letter-spacing:0.1pt;"> </font>side effects<font style="letter-spacing:0.1pt;"> </font>caused by such products<font style="letter-spacing:0.05pt;"> </font>are identified,<font style="letter-spacing:0.1pt;"> </font>a regulatory<font style="letter-spacing:0.1pt;"> </font>agency may: issue<font style="letter-spacing:0.05pt;"> </font>safety<font style="letter-spacing:0.05pt;"> </font>alerts,<font style="letter-spacing:0.05pt;"> </font>Dear Healthcare<font style="letter-spacing:0.05pt;"> </font>Provider<font style="letter-spacing:0.05pt;"> </font>letters,<font style="letter-spacing:0.1pt;"> </font>press<font style="letter-spacing:0.05pt;"> </font>releases<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>communications containing<font style="letter-spacing:0.05pt;"> </font>warnings about such product; mandate<font style="letter-spacing:0.05pt;"> </font>modifications<font style="letter-spacing:0.15pt;"> </font>to promotional<font style="letter-spacing:0.1pt;"> </font>materials<font style="letter-spacing:0.1pt;"> </font>or require<font style="letter-spacing:0.05pt;"> </font>us to provide<font style="letter-spacing:0.05pt;"> </font>corrective<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>to healthcare<font style="letter-spacing:0.1pt;"> </font>practitioners; require<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>conduct post-marketing<font style="letter-spacing:0.15pt;"> </font>studies; require<font style="letter-spacing:0.05pt;"> </font>us to enter<font style="letter-spacing:0.05pt;"> </font>into a consent<font style="letter-spacing:0.05pt;"> </font>decree,<font style="letter-spacing:0.05pt;"> </font>which can include<font style="letter-spacing:0.05pt;"> </font>imposition<font style="letter-spacing:0.1pt;"> </font>of various<font style="letter-spacing:0.05pt;"> </font>fines, reimbursements<font style="letter-spacing:0.15pt;"> </font>for inspection<font style="letter-spacing:0.05pt;"> </font>costs,<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>due dates<font style="letter-spacing:0.05pt;"> </font>for specific<font style="letter-spacing:0.1pt;"> </font>actions<font style="letter-spacing:0.05pt;"> </font>and penalties<font style="letter-spacing:0.1pt;"> </font>for noncompliance; seek an injunction<font style="letter-spacing:0.05pt;"> </font>or impose<font style="letter-spacing:0.05pt;"> </font>civil<font style="letter-spacing:0.05pt;"> </font>or criminal<font style="letter-spacing:0.1pt;"> </font>penalties<font style="letter-spacing:0.1pt;"> </font>or monetary<font style="letter-spacing:0.05pt;"> </font>fines; suspend marketing<font style="letter-spacing:0.1pt;"> </font>of, withdraw regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of or recall<font style="letter-spacing:0.05pt;"> </font>such product; suspend any ongoing clinical<font style="letter-spacing:0.1pt;"> </font>studies; refuse<font style="letter-spacing:0.05pt;"> </font>to approve pending applications<font style="letter-spacing:0.1pt;"> </font>or supplements<font style="letter-spacing:0.1pt;"> </font>to applications<font style="letter-spacing:0.1pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>by us; suspend or impose<font style="letter-spacing:0.05pt;"> </font>restrictions<font style="letter-spacing:0.15pt;"> </font>on operations,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>costly<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>requirements;<font style="letter-spacing:0.15pt;"> </font>or seize<font style="letter-spacing:0.05pt;"> </font>or detain<font style="letter-spacing:0.05pt;"> </font>products,<font style="letter-spacing:0.05pt;"> </font>refuse<font style="letter-spacing:0.05pt;"> </font>to permit<font style="letter-spacing:0.05pt;"> </font>the import<font style="letter-spacing:0.05pt;"> </font>or export<font style="letter-spacing:0.05pt;"> </font>of products<font style="letter-spacing:0.05pt;"> </font>or require<font style="letter-spacing:0.05pt;"> </font>us to initiate<font style="letter-spacing:0.1pt;"> </font>a product<font style="letter-spacing:0.05pt;"> </font>recall. The occurrence<font style="letter-spacing:0.05pt;"> </font>of any event or penalty<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>above may inhibit<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to commercialize<font style="letter-spacing:0.15pt;"> </font>our products<font style="letter-spacing:0.05pt;"> </font>and generate<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#auto;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Risks Relating to Intellectual<font style="letter-spacing:0.1pt;"> </font>Property</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk66378343"></a>Our<font style="letter-spacing:-0.05pt;"> </font>success<font style="letter-spacing:0.05pt;"> </font>depends upon<font style="letter-spacing:-0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to obtain and<font style="letter-spacing:-0.05pt;"> </font>maintain<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.1pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.05pt;"> </font>for our products and<font style="letter-spacing:-0.05pt;"> </font>technologies.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success<font style="letter-spacing:0.05pt;"> </font>will depend in significant<font style="letter-spacing:0.1pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>on our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors&#8217;,<font style="letter-spacing:0.1pt;"> </font>licensees&#8217;<font style="letter-spacing:0.1pt;"> </font>or collaborators&#8217;<font style="letter-spacing:0.15pt;"> </font>ability<font style="letter-spacing:0.05pt;"> </font>to establish<font style="letter-spacing:0.1pt;"> </font>and maintain<font style="letter-spacing:0.1pt;"> </font>adequate<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.1pt;"> </font>of our owned<font style="letter-spacing:-0.05pt;"> </font>and licensed<font style="letter-spacing:0.05pt;"> </font>intellectual property<font style="letter-spacing:0.05pt;"> </font>covering<font style="letter-spacing:0.05pt;"> </font>the product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>plan to develop, and the ability<font style="letter-spacing:0.05pt;"> </font>to develop these<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates and commercialize<font style="letter-spacing:0.15pt;"> </font>the products<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>therefrom,<font style="letter-spacing:0.1pt;"> </font>without infringing<font style="letter-spacing:0.1pt;"> </font>the intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of others. In addition<font style="letter-spacing:0.05pt;"> </font>to taking<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>steps<font style="letter-spacing:0.05pt;"> </font>to protect<font style="letter-spacing:0.05pt;"> </font>our intellectual<font style="letter-spacing:0.15pt;"> </font>property,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>hold issued<font style="letter-spacing:0.05pt;"> </font>patents,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have applied<font style="letter-spacing:0.05pt;"> </font>for patents,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>intend<font style="letter-spacing:0.05pt;"> </font>to continue<font style="letter-spacing:0.05pt;"> </font>to apply for, patents<font style="letter-spacing:0.05pt;"> </font>with claims<font style="letter-spacing:0.05pt;"> </font>covering<font style="letter-spacing:0.05pt;"> </font>our technologies,<font style="letter-spacing:0.1pt;"> </font>processes<font style="letter-spacing:0.05pt;"> </font>and product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>and where we<font style="letter-spacing:-0.05pt;"> </font>deem it appropriate<font style="letter-spacing:0.1pt;"> </font>to do so. We have filed<font style="letter-spacing:0.05pt;"> </font>numerous<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications both in the United States<font style="letter-spacing:0.05pt;"> </font>and in certain<font style="letter-spacing:0.05pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>jurisdictions<font style="letter-spacing:0.15pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>to inventions<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have discovered,<font style="letter-spacing:0.05pt;"> </font>with claims<font style="letter-spacing:0.05pt;"> </font>directed<font style="letter-spacing:0.05pt;"> </font>to compositions<font style="letter-spacing:0.1pt;"> </font>of matter,<font style="letter-spacing:0.1pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>of use and other<font style="letter-spacing:0.05pt;"> </font>technologies<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to our programs.<font style="letter-spacing:0.05pt;"> </font>There can be no assurance<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>any of these<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>will issue<font style="letter-spacing:0.05pt;"> </font>as patents<font style="letter-spacing:0.05pt;"> </font>or, for those applications<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>do mature<font style="letter-spacing:0.05pt;"> </font>into patents,<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the claims<font style="letter-spacing:0.05pt;"> </font>of the patents<font style="letter-spacing:0.05pt;"> </font>will exclude<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>making,<font style="letter-spacing:0.05pt;"> </font>using or selling<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>compete<font style="letter-spacing:0.05pt;"> </font>with or are similar<font style="letter-spacing:0.1pt;"> </font>to our product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>In countries where we<font style="letter-spacing:-0.05pt;"> </font>have not sought and do not seek patent<font style="letter-spacing:0.05pt;"> </font>protection,<font style="letter-spacing:0.1pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>may be able to manufacture<font style="letter-spacing:0.1pt;"> </font>and sell<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>without our permission,<font style="letter-spacing:0.1pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>may not be able to stop them<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>doing so.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With<font style="letter-spacing:0.05pt;"> </font>respect<font style="letter-spacing:0.05pt;"> </font>to patent<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>do not know<font style="letter-spacing:-0.05pt;"> </font>whether any of the pending patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>for any of our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>will result<font style="letter-spacing:0.05pt;"> </font>in the issuance<font style="letter-spacing:0.05pt;"> </font>of patents<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>effectively<font style="letter-spacing:0.1pt;"> </font>protect<font style="letter-spacing:0.05pt;"> </font>our technologies,<font style="letter-spacing:0.1pt;"> </font>processes and product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>or if any of our issued<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>or our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors&#8217;,<font style="letter-spacing:0.1pt;"> </font>licensees&#8217;<font style="letter-spacing:0.1pt;"> </font>or collaborators&#8217;<font style="letter-spacing:0.15pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>will effectively<font style="letter-spacing:0.1pt;"> </font>prevent<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>commercializing<font style="letter-spacing:0.15pt;"> </font>competitive<font style="letter-spacing:0.1pt;"> </font>technologies, processes<font style="letter-spacing:0.05pt;"> </font>and products.<font style="letter-spacing:0.05pt;"> </font>We cannot be certain that we or our current or future licensors, licensees or collaborators were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our current or future licensors, licensees or collaborators were the first to file for patent protection of such inventions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make to our BIO89-100 or any future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to cause them</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to have what we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">view as more</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advantageous</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">properties</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be covered</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by our existing</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and patent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications, and we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be required</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to file</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forms</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of protection</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for any such altered product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">landscape</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surrounding</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the technology</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">underlying</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is crowded, and there</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can be no assurance</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be able to secure</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would adequately cover an alternative</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to BIO89-100 or any future</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.05pt;"> </font>and our current<font style="letter-spacing:0.05pt;"> </font>or future licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>may not be able to prepare,<font style="letter-spacing:0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>and prosecute<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>or desirable patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>at a reasonable<font style="letter-spacing:0.05pt;"> </font>cost or in a timely<font style="letter-spacing:0.05pt;"> </font>manner.<font style="letter-spacing:0.05pt;"> </font>It is also possible<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>or our current<font style="letter-spacing:0.05pt;"> </font>or future licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>will fail<font style="letter-spacing:0.05pt;"> </font>to identify<font style="letter-spacing:0.05pt;"> </font>patentable<font style="letter-spacing:0.1pt;"> </font>aspects<font style="letter-spacing:0.05pt;"> </font>of inventions<font style="letter-spacing:0.05pt;"> </font>made in the course<font style="letter-spacing:0.05pt;"> </font>of development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>it is too late<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.1pt;"> </font>for them.<font style="letter-spacing:0.05pt;"> </font>Moreover, in some circumstances,<font style="letter-spacing:0.15pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may not have the right<font style="letter-spacing:0.05pt;"> </font>to control<font style="letter-spacing:0.05pt;"> </font>the preparation,<font style="letter-spacing:0.1pt;"> </font>filing<font style="letter-spacing:0.05pt;"> </font>and prosecution<font style="letter-spacing:0.05pt;"> </font>of patent applications,<font style="letter-spacing:0.1pt;"> </font>or to maintain<font style="letter-spacing:0.1pt;"> </font>or enforce<font style="letter-spacing:0.05pt;"> </font>the patents,<font style="letter-spacing:0.05pt;"> </font>covering<font style="letter-spacing:0.05pt;"> </font>technology<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>license<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>or license<font style="letter-spacing:0.05pt;"> </font>to third parties<font style="letter-spacing:0.05pt;"> </font>and may be reliant<font style="letter-spacing:0.1pt;"> </font>on our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>to perform<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>activities, which means<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>may not be prosecuted,<font style="letter-spacing:0.05pt;"> </font>and these<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>enforced,<font style="letter-spacing:0.05pt;"> </font>in a manner consistent<font style="letter-spacing:0.1pt;"> </font>with the best interests<font style="letter-spacing:0.1pt;"> </font>of our business.<font style="letter-spacing:0.05pt;"> </font>If our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>fail to establish,<font style="letter-spacing:0.1pt;"> </font>maintain,<font style="letter-spacing:0.1pt;"> </font>protect<font style="letter-spacing:0.05pt;"> </font>or enforce<font style="letter-spacing:0.05pt;"> </font>such patents<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>such rights<font style="letter-spacing:0.05pt;"> </font>may be reduced<font style="letter-spacing:0.05pt;"> </font>or eliminated.<font style="letter-spacing:0.1pt;"> </font>If our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>are not fully<font style="letter-spacing:0.05pt;"> </font>cooperative<font style="letter-spacing:0.1pt;"> </font>or disagree<font style="letter-spacing:0.05pt;"> </font>with us as to the prosecution,<font style="letter-spacing:0.05pt;"> </font>maintenance<font style="letter-spacing:0.1pt;"> </font>or enforcement<font style="letter-spacing:0.1pt;"> </font>of any patent<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>such patent<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>could be compromised.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar<font style="letter-spacing:0.1pt;"> </font>to the patent<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of other<font style="letter-spacing:0.05pt;"> </font>biotechnology<font style="letter-spacing:0.05pt;"> </font>companies,<font style="letter-spacing:0.05pt;"> </font>the scope, validity<font style="letter-spacing:0.05pt;"> </font>and enforceability<font style="letter-spacing:0.15pt;"> </font>of our owned and licensed<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.05pt;"> </font>are highly uncertain<font style="letter-spacing:0.05pt;"> </font>and involve<font style="letter-spacing:0.05pt;"> </font>complex<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>and factual questions.<font style="letter-spacing:0.05pt;"> </font>The issuance<font style="letter-spacing:0.05pt;"> </font>of a patent<font style="letter-spacing:0.05pt;"> </font>is not conclusive<font style="letter-spacing:0.05pt;"> </font>as to its<font style="letter-spacing:0.05pt;"> </font>inventorship,<font style="letter-spacing:0.1pt;"> </font>scope, validity<font style="letter-spacing:0.05pt;"> </font>or enforceability,<font style="letter-spacing:0.15pt;"> </font>and our patents<font style="letter-spacing:0.05pt;"> </font>may be challenged<font style="letter-spacing:0.05pt;"> </font>in the courts<font style="letter-spacing:0.05pt;"> </font>or patent<font style="letter-spacing:0.05pt;"> </font>offices<font style="letter-spacing:0.05pt;"> </font>in the United States<font style="letter-spacing:0.05pt;"> </font>and abroad. In recent<font style="letter-spacing:0.05pt;"> </font>years, these<font style="letter-spacing:0.05pt;"> </font>areas<font style="letter-spacing:0.05pt;"> </font>have been the subject<font style="letter-spacing:0.05pt;"> </font>of much litigation<font style="letter-spacing:0.1pt;"> </font>in the industry.<font style="letter-spacing:0.05pt;"> </font>As a result,<font style="letter-spacing:0.05pt;"> </font>the issuance,<font style="letter-spacing:0.05pt;"> </font>scope, validity, enforceability<font style="letter-spacing:0.15pt;"> </font>and commercial<font style="letter-spacing:0.1pt;"> </font>value of our and our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors&#8217;,<font style="letter-spacing:0.1pt;"> </font>licensees&#8217;<font style="letter-spacing:0.1pt;"> </font>or collaborators&#8217; patent<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>are highly uncertain.<font style="letter-spacing:0.05pt;"> </font>Our and our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors&#8217;,<font style="letter-spacing:0.1pt;"> </font>licensees&#8217;<font style="letter-spacing:0.1pt;"> </font>or collaborators&#8217;<font style="letter-spacing:0.15pt;"> </font>pending and future<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>may not result<font style="letter-spacing:0.05pt;"> </font>in patents<font style="letter-spacing:0.05pt;"> </font>being issued<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>protect<font style="letter-spacing:0.05pt;"> </font>our technology<font style="letter-spacing:0.05pt;"> </font>or product candidates,<font style="letter-spacing:0.05pt;"> </font>or products<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>therefrom,<font style="letter-spacing:0.1pt;"> </font>in whole or in part,<font style="letter-spacing:0.05pt;"> </font>or that<font style="letter-spacing:0.05pt;"> </font>effectively<font style="letter-spacing:0.1pt;"> </font>prevent<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.05pt;"> </font>from commercializing<font style="letter-spacing:0.15pt;"> </font>competitive<font style="letter-spacing:0.1pt;"> </font>technologies<font style="letter-spacing:0.1pt;"> </font>and products.<font style="letter-spacing:0.05pt;"> </font>The patent<font style="letter-spacing:0.05pt;"> </font>examination<font style="letter-spacing:0.1pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>may require<font style="letter-spacing:0.05pt;"> </font>us or our current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>licensors,<font style="letter-spacing:0.1pt;"> </font>licensees<font style="letter-spacing:0.1pt;"> </font>or collaborators<font style="letter-spacing:0.1pt;"> </font>to narrow the scope of the claims<font style="letter-spacing:0.05pt;"> </font>of pending and future patent<font style="letter-spacing:0.05pt;"> </font>applications,<font style="letter-spacing:0.1pt;"> </font>which would limit<font style="letter-spacing:0.1pt;"> </font>the scope of patent<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is obtained,<font style="letter-spacing:0.05pt;"> </font>if any. Our and our current or future<font style="letter-spacing:0.05pt;"> </font>licensors&#8217;,<font style="letter-spacing:0.1pt;"> </font>licensees&#8217;<font style="letter-spacing:0.1pt;"> </font>or collaborators&#8217;<font style="letter-spacing:0.15pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>cannot be enforced<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties practicing<font style="letter-spacing:0.1pt;"> </font>the technology<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is currently<font style="letter-spacing:0.1pt;"> </font>claimed<font style="letter-spacing:0.05pt;"> </font>in such applications<font style="letter-spacing:0.1pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>and until<font style="letter-spacing:0.05pt;"> </font>a patent<font style="letter-spacing:0.05pt;"> </font>issues<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>such applications,<font style="letter-spacing:0.1pt;"> </font>and then only to the extent<font style="letter-spacing:0.05pt;"> </font>the claims<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>are broad enough to cover the technology<font style="letter-spacing:0.05pt;"> </font>being practiced<font style="letter-spacing:0.1pt;"> </font>by those third<font style="letter-spacing:0.05pt;"> </font>parties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<font style="letter-spacing:0.1pt;"> </font>given the amount<font style="letter-spacing:0.05pt;"> </font>of time<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>for the development,<font style="letter-spacing:0.05pt;"> </font>testing<font style="letter-spacing:0.05pt;"> </font>and regulatory<font style="letter-spacing:0.1pt;"> </font>review of new product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>protecting<font style="letter-spacing:0.1pt;"> </font>such candidates<font style="letter-spacing:0.05pt;"> </font>might<font style="letter-spacing:0.05pt;"> </font>expire<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>or shortly<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>the resulting products<font style="letter-spacing:0.05pt;"> </font>are commercialized.<font style="letter-spacing:0.15pt;"> </font>As a result,<font style="letter-spacing:0.05pt;"> </font>our owned and in-licensed<font style="letter-spacing:0.1pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>may not provide<font style="letter-spacing:0.05pt;"> </font>us with sufficient rights<font style="letter-spacing:0.05pt;"> </font>to exclude<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>commercializing<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>similar<font style="letter-spacing:0.1pt;"> </font>or identical<font style="letter-spacing:0.1pt;"> </font>to ours. We expect<font style="letter-spacing:0.05pt;"> </font>to seek extensions of patent<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>for our issued<font style="letter-spacing:0.05pt;"> </font>patents,<font style="letter-spacing:0.05pt;"> </font>where available.<font style="letter-spacing:0.1pt;"> </font>The applicable<font style="letter-spacing:0.1pt;"> </font>authorities,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the FDA in the United States,<font style="letter-spacing:0.05pt;"> </font>and any comparable<font style="letter-spacing:0.1pt;"> </font>foreign<font style="letter-spacing:0.05pt;"> </font>regulatory authorities,<font style="letter-spacing:0.1pt;"> </font>may not agree<font style="letter-spacing:0.05pt;"> </font>with our assessment<font style="letter-spacing:0.1pt;"> </font>of whether such extensions<font style="letter-spacing:0.05pt;"> </font>are available,<font style="letter-spacing:0.1pt;"> </font>and may refuse<font style="letter-spacing:0.05pt;"> </font>to grant extensions<font style="letter-spacing:0.05pt;"> </font>to our patents,<font style="letter-spacing:0.05pt;"> </font>or may grant<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>limited<font style="letter-spacing:0.1pt;"> </font>extensions<font style="letter-spacing:0.05pt;"> </font>than we request.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>we may not be granted<font style="letter-spacing:0.05pt;"> </font>an extension<font style="letter-spacing:0.05pt;"> </font>because<font style="letter-spacing:0.05pt;"> </font>of, for example,<font style="letter-spacing:0.05pt;"> </font>failing<font style="letter-spacing:0.05pt;"> </font>to apply within applicable<font style="letter-spacing:0.1pt;"> </font>deadlines,<font style="letter-spacing:0.05pt;"> </font>failing<font style="letter-spacing:0.05pt;"> </font>to apply prior to the expiration<font style="letter-spacing:0.1pt;"> </font>of relevant<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>failing<font style="letter-spacing:0.05pt;"> </font>to satisfy<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>requirements.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect<font style="letter-spacing:0.05pt;"> </font>our intellectual<font style="letter-spacing:0.1pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal<font style="letter-spacing:0.05pt;"> </font>protection<font style="letter-spacing:0.1pt;"> </font>afforded<font style="letter-spacing:0.05pt;"> </font>to inventors<font style="letter-spacing:0.05pt;"> </font>and owners of intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>in countries<font style="letter-spacing:0.05pt;"> </font>outside<font style="letter-spacing:0.05pt;"> </font>of the United States<font style="letter-spacing:0.05pt;"> </font>may not be as protective or effective as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and certain state laws in the United States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be able to prevent</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practicing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inventions</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in all</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outside the United States,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or from</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">selling</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or importing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made using our inventions</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in and into the United States or other</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdictions.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may use technologies</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in jurisdictions</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have not obtained</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent protection</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to develop their</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, further,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may export</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to territories where we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have patent</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but enforcement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is not as strong</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as that</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the United States.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These products may compete</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with BIO89-100 or any future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our patents</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property rights</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not be effective</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or sufficient</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to prevent</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on a license from Teva and a sublicense from ratiopharm to patents and know-how related to glycoPEGylation technology that are used in the development, manufacture and commercialization of BIO89-100. Any termination or loss of significant rights, including the right to glycoPEGylation technology, or breach, under these agreements or any future license agreement related to our product candidates, would materially and adversely affect our ability to continue the development and commercialization of the related product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="letter-spacing:-0.05pt;">April</font> 2018, we<font style="letter-spacing:-0.05pt;"> </font>entered<font style="letter-spacing:0.05pt;"> </font>into an Asset Transfer<font style="letter-spacing:0.05pt;"> </font>and License<font style="letter-spacing:0.05pt;"> </font>Agreement<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>&#8220;FGF21<font style="letter-spacing:-0.05pt;"> </font>Agreement&#8221;) with Teva under which we<font style="letter-spacing:-0.05pt;"> </font>acquired<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>patents,<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to Teva&#8217;s glycoPEGylated<font style="letter-spacing:0.05pt;"> </font>FGF21<font style="letter-spacing:-0.05pt;"> </font>program,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Under this<font style="letter-spacing:0.05pt;"> </font>agreement, we<font style="letter-spacing:-0.05pt;"> </font>were granted<font style="letter-spacing:0.05pt;"> </font>a perpetual,<font style="letter-spacing:1.1pt;"> </font>non-exclusive<font style="letter-spacing:0.1pt;"> </font>(but exclusive<font style="letter-spacing:0.05pt;"> </font>as to BIO89-100), non-transferable,<font style="letter-spacing:0.15pt;"> </font>worldwide license<font style="letter-spacing:0.05pt;"> </font>to patents<font style="letter-spacing:0.05pt;"> </font>and know-how related<font style="letter-spacing:0.05pt;"> </font>to glycoPEGylation<font style="letter-spacing:0.05pt;"> </font>technology<font style="letter-spacing:0.05pt;"> </font>used in the development,<font style="letter-spacing:0.05pt;"> </font>manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of BIO89-100 and products<font style="letter-spacing:0.05pt;"> </font>containing<font style="letter-spacing:0.05pt;"> </font>BIO89-100. The FGF21<font style="letter-spacing:-0.05pt;"> </font>Agreement<font style="letter-spacing:0.05pt;"> </font>also contains<font style="letter-spacing:0.05pt;"> </font>numerous<font style="letter-spacing:0.05pt;"> </font>covenants<font style="letter-spacing:0.05pt;"> </font>with which we<font style="letter-spacing:-0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>comply,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the utilization<font style="letter-spacing:0.1pt;"> </font>of commercially<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>efforts<font style="letter-spacing:0.1pt;"> </font>to develop and ultimately commercialize<font style="letter-spacing:0.15pt;"> </font>BIO89-100, as well as certain<font style="letter-spacing:0.05pt;"> </font>reporting<font style="letter-spacing:0.05pt;"> </font>covenants<font style="letter-spacing:0.05pt;"> </font>and the obligation<font style="letter-spacing:0.05pt;"> </font>to make royalty<font style="letter-spacing:0.05pt;"> </font>payments,<font style="letter-spacing:0.05pt;"> </font>if and when<font style="letter-spacing:-0.05pt;"> </font>BIO89-100 is approved for commercialization.<font style="letter-spacing:0.2pt;"> </font>Our failure<font style="letter-spacing:0.1pt;"> </font>to satisfy<font style="letter-spacing:0.05pt;"> </font>any of these<font style="letter-spacing:0.05pt;"> </font>covenants<font style="letter-spacing:0.05pt;"> </font>could result<font style="letter-spacing:0.05pt;"> </font>in the termination<font style="letter-spacing:0.1pt;"> </font>of the FGF21<font style="letter-spacing:-0.05pt;"> </font>Agreement.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>entered<font style="letter-spacing:0.05pt;"> </font>into a Sublicense<font style="letter-spacing:0.05pt;"> </font>Agreement<font style="letter-spacing:0.05pt;"> </font>with ratiopharm<font style="letter-spacing:0.1pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>&#8220;ratiopharm<font style="letter-spacing:0.1pt;"> </font>Sublicense&#8221;),<font style="letter-spacing:0.1pt;"> </font>under which we<font style="letter-spacing:-0.05pt;"> </font>were granted<font style="letter-spacing:0.05pt;"> </font>a perpetual,<font style="letter-spacing:0.05pt;"> </font>exclusive,<font style="letter-spacing:0.05pt;"> </font>worldwide sublicense<font style="letter-spacing:0.05pt;"> </font>to patents<font style="letter-spacing:0.05pt;"> </font>and know-how<font style="letter-spacing:-0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to glycoPEGylation<font style="letter-spacing:0.05pt;"> </font>technology<font style="letter-spacing:0.05pt;"> </font>used in the development, manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of BIO89-100 and products<font style="letter-spacing:0.05pt;"> </font>containing<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Termination<font style="letter-spacing:0.1pt;"> </font>of the FGF21<font style="letter-spacing:-0.05pt;"> </font>Agreement<font style="letter-spacing:0.05pt;"> </font>or the ratiopharm<font style="letter-spacing:0.1pt;"> </font>Sublicense<font style="letter-spacing:0.05pt;"> </font>will impact<font style="letter-spacing:0.05pt;"> </font>our rights<font style="letter-spacing:0.05pt;"> </font>under the intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>licensed<font style="letter-spacing:0.05pt;"> </font>to us by Teva and ratiopharm,<font style="letter-spacing:0.1pt;"> </font>respectively, including<font style="letter-spacing:0.05pt;"> </font>our license<font style="letter-spacing:0.05pt;"> </font>to glycoPEGylation<font style="letter-spacing:0.05pt;"> </font>technology,<font style="letter-spacing:0.05pt;"> </font>but will not affect<font style="letter-spacing:1.1pt;"> </font>our rights<font style="letter-spacing:0.05pt;"> </font>under the assets<font style="letter-spacing:0.05pt;"> </font>assigned<font style="letter-spacing:0.05pt;"> </font>to us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond this<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>our commercial<font style="letter-spacing:0.1pt;"> </font>success<font style="letter-spacing:0.05pt;"> </font>will also depend upon our ability,<font style="letter-spacing:0.05pt;"> </font>and the ability<font style="letter-spacing:0.05pt;"> </font>of our licensors,<font style="letter-spacing:0.1pt;"> </font>to develop, manufacture,<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>and sell<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and use our proprietary<font style="letter-spacing:0.1pt;"> </font>technologies without infringing<font style="letter-spacing:0.1pt;"> </font>the proprietary<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of third<font style="letter-spacing:0.05pt;"> </font>parties.<font style="letter-spacing:0.05pt;"> </font>A third<font style="letter-spacing:0.05pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>may hold intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights, including<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are important<font style="letter-spacing:0.1pt;"> </font>or necessary<font style="letter-spacing:0.05pt;"> </font>to the development<font style="letter-spacing:0.05pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>As a result, we may enter<font style="letter-spacing:0.05pt;"> </font>into additional<font style="letter-spacing:0.1pt;"> </font>license<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>in the future.<font style="letter-spacing:0.05pt;"> </font>If we fail<font style="letter-spacing:0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with the obligations<font style="letter-spacing:0.1pt;"> </font>under these<font style="letter-spacing:0.05pt;"> </font>agreements,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>and diligence<font style="letter-spacing:0.05pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>our licensors<font style="letter-spacing:0.1pt;"> </font>may have the right<font style="letter-spacing:0.05pt;"> </font>to terminate these<font style="letter-spacing:0.05pt;"> </font>agreements,<font style="letter-spacing:0.1pt;"> </font>in which event we may not be able to develop, manufacture,<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>or sell<font style="letter-spacing:0.05pt;"> </font>any product<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is covered<font style="letter-spacing:0.05pt;"> </font>by these<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>or to engage in any other<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to our business<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>require<font style="letter-spacing:0.05pt;"> </font>the freedom<font style="letter-spacing:0.05pt;"> </font>to operate<font style="letter-spacing:0.05pt;"> </font>afforded<font style="letter-spacing:0.05pt;"> </font>by the agreements,<font style="letter-spacing:0.1pt;"> </font>or we may face<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>penalties<font style="letter-spacing:0.1pt;"> </font>under the agreements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain intellectual<font style="letter-spacing:0.1pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or technology<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to develop<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>commercialize BIO89-100<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>any future product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent<font style="letter-spacing:0.05pt;"> </font>landscape<font style="letter-spacing:0.05pt;"> </font>around our programs<font style="letter-spacing:0.05pt;"> </font>is complex,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>are aware of several<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>patents and patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>containing<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>matter<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>might<font style="letter-spacing:0.05pt;"> </font>be relevant<font style="letter-spacing:0.05pt;"> </font>to BIO89-100. Depending on what claims<font style="letter-spacing:0.05pt;"> </font>ultimately<font style="letter-spacing:0.1pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>applications,<font style="letter-spacing:0.1pt;"> </font>and how<font style="letter-spacing:-0.05pt;"> </font>courts<font style="letter-spacing:0.05pt;"> </font>construe<font style="letter-spacing:0.05pt;"> </font>the issued<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>claims,<font style="letter-spacing:0.05pt;"> </font>as well as depending on the ultimate<font style="letter-spacing:0.1pt;"> </font>formulation<font style="letter-spacing:0.1pt;"> </font>and method<font style="letter-spacing:0.05pt;"> </font>of use of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>we may need to obtain<font style="letter-spacing:0.05pt;"> </font>a license<font style="letter-spacing:0.05pt;"> </font>to practice<font style="letter-spacing:0.1pt;"> </font>the technology<font style="letter-spacing:0.05pt;"> </font>claimed<font style="letter-spacing:0.05pt;"> </font>in such patents.<font style="letter-spacing:0.05pt;"> </font>There can be no assurance<font style="letter-spacing:0.05pt;"> </font>that such licenses<font style="letter-spacing:0.05pt;"> </font>will be available<font style="letter-spacing:0.1pt;"> </font>on commercially<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>or at all.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become<font style="letter-spacing:0.05pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in lawsuits<font style="letter-spacing:0.05pt;"> </font>or other proceedings<font style="letter-spacing:0.05pt;"> </font>to protect<font style="letter-spacing:0.05pt;"> </font>or enforce<font style="letter-spacing:0.05pt;"> </font>our intellectual<font style="letter-spacing:0.1pt;"> </font>property, which<font style="letter-spacing:-0.05pt;"> </font>could be expensive,<font style="letter-spacing:0.05pt;"> </font>time-consuming<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>unsuccessful<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>have a material<font style="letter-spacing:0.1pt;"> </font>adverse<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>the success of our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties<font style="letter-spacing:0.05pt;"> </font>may infringe<font style="letter-spacing:0.05pt;"> </font>our patents<font style="letter-spacing:0.05pt;"> </font>or misappropriate<font style="letter-spacing:0.15pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>violate<font style="letter-spacing:0.05pt;"> </font>our intellectual<font style="letter-spacing:0.15pt;"> </font>property rights.<font style="letter-spacing:0.05pt;"> </font>In the future,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may initiate<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>to enforce<font style="letter-spacing:0.05pt;"> </font>or defend our intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>to protect<font style="letter-spacing:0.05pt;"> </font>our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trade</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">secrets</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to determine</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the validity</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or scope of intellectual</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or control. Also, third</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may initiate</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceedings</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us to challenge</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the validity</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or scope of intellectual property</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own,</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to which we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have rights.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in any litigation</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could put one or more</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our patents</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at risk</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of being invalidated,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">narrowed, held unenforceable</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or interpreted</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such a manner</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would not preclude</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entering</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the market</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with competing</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party<font style="letter-spacing:0.1pt;"> </font>pre-issuance<font style="letter-spacing:0.1pt;"> </font>submission<font style="letter-spacing:0.05pt;"> </font>of prior<font style="letter-spacing:0.05pt;"> </font>art<font style="letter-spacing:0.05pt;"> </font>to the USPTO,<font style="letter-spacing:-0.1pt;"> </font>or opposition,<font style="letter-spacing:0.05pt;"> </font>derivation,<font style="letter-spacing:0.1pt;"> </font>revocation, reexamination,<font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;">inter</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">partes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font>review or interference<font style="letter-spacing:0.15pt;"> </font>proceedings,<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>pre-issuance<font style="letter-spacing:0.1pt;"> </font>or post-grant<font style="letter-spacing:0.1pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>or litigation<font style="letter-spacing:0.1pt;"> </font>in the United States<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>jurisdictions<font style="letter-spacing:0.15pt;"> </font>provoked by third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>or brought by us, may be necessary<font style="letter-spacing:0.05pt;"> </font>to determine<font style="letter-spacing:0.1pt;"> </font>the inventorship,<font style="letter-spacing:0.1pt;"> </font>priority,<font style="letter-spacing:0.1pt;"> </font>patentability<font style="letter-spacing:0.15pt;"> </font>or validity<font style="letter-spacing:0.05pt;"> </font>of inventions with respect<font style="letter-spacing:0.05pt;"> </font>to our patents<font style="letter-spacing:0.05pt;"> </font>or patent<font style="letter-spacing:0.05pt;"> </font>applications.<font style="letter-spacing:0.1pt;"> </font>An<font style="letter-spacing:-0.05pt;"> </font>unfavorable<font style="letter-spacing:0.05pt;"> </font>outcome<font style="letter-spacing:0.05pt;"> </font>could leave<font style="letter-spacing:0.05pt;"> </font>our technology<font style="letter-spacing:0.05pt;"> </font>or product candidates<font style="letter-spacing:0.05pt;"> </font>without patent<font style="letter-spacing:0.05pt;"> </font>protection,<font style="letter-spacing:0.1pt;"> </font>allow third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>to commercialize<font style="letter-spacing:0.15pt;"> </font>our technology<font style="letter-spacing:0.05pt;"> </font>or product<font style="letter-spacing:0.05pt;"> </font>candidates and compete<font style="letter-spacing:0.05pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>with us, without payment<font style="letter-spacing:0.05pt;"> </font>to us, or could require<font style="letter-spacing:0.05pt;"> </font>us to obtain<font style="letter-spacing:0.05pt;"> </font>license<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the prevailing<font style="letter-spacing:0.1pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>in order<font style="letter-spacing:0.05pt;"> </font>to be able to manufacture<font style="letter-spacing:0.1pt;"> </font>or commercialize<font style="letter-spacing:0.15pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>without infringing third-party<font style="letter-spacing:0.1pt;"> </font>patent<font style="letter-spacing:0.05pt;"> </font>rights.<font style="letter-spacing:0.05pt;"> </font>Our business<font style="letter-spacing:0.05pt;"> </font>could be harmed<font style="letter-spacing:0.05pt;"> </font>if the prevailing<font style="letter-spacing:0.1pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>in such a case does not offer<font style="letter-spacing:0.05pt;"> </font>us a license<font style="letter-spacing:0.05pt;"> </font>on commercially<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>or at all.<font style="letter-spacing:0.05pt;"> </font>Even if we<font style="letter-spacing:-0.05pt;"> </font>obtain<font style="letter-spacing:0.05pt;"> </font>a license,<font style="letter-spacing:0.05pt;"> </font>it may be non-exclusive,<font style="letter-spacing:0.1pt;"> </font>thereby giving our competitors<font style="letter-spacing:0.1pt;"> </font>access<font style="letter-spacing:0.05pt;"> </font>to the same<font style="letter-spacing:0.05pt;"> </font>technologies<font style="letter-spacing:0.1pt;"> </font>licensed<font style="letter-spacing:0.05pt;"> </font>to us. In addition,<font style="letter-spacing:0.05pt;"> </font>if the breadth<font style="letter-spacing:0.05pt;"> </font>or strength<font style="letter-spacing:0.05pt;"> </font>of protection<font style="letter-spacing:0.1pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>by our patents<font style="letter-spacing:0.05pt;"> </font>and patent<font style="letter-spacing:0.05pt;"> </font>applications<font style="letter-spacing:0.1pt;"> </font>is threatened,<font style="letter-spacing:0.1pt;"> </font>it could dissuade<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>from collaborating<font style="letter-spacing:0.1pt;"> </font>with us to license,<font style="letter-spacing:0.05pt;"> </font>develop or commercialize<font style="letter-spacing:0.15pt;"> </font>current<font style="letter-spacing:0.05pt;"> </font>or future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>Even if we successfully<font style="letter-spacing:0.1pt;"> </font>defend such litigation<font style="letter-spacing:0.1pt;"> </font>or proceeding,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may incur<font style="letter-spacing:0.05pt;"> </font>substantial<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and our defense<font style="letter-spacing:0.05pt;"> </font>may distract our management<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<font style="letter-spacing:0.1pt;"> </font>because<font style="letter-spacing:0.05pt;"> </font>of the substantial<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of discovery<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with intellectual property<font style="letter-spacing:0.05pt;"> </font>litigation,<font style="letter-spacing:0.1pt;"> </font>there<font style="letter-spacing:0.05pt;"> </font>is a risk<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>some of our confidential<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>could be compromised<font style="letter-spacing:0.1pt;"> </font>by disclosure during this<font style="letter-spacing:0.05pt;"> </font>type of litigation.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>many foreign<font style="letter-spacing:0.05pt;"> </font>jurisdictions<font style="letter-spacing:0.15pt;"> </font>have rules<font style="letter-spacing:0.05pt;"> </font>of discovery<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are different than those in the United States<font style="letter-spacing:0.05pt;"> </font>and that<font style="letter-spacing:0.05pt;"> </font>may make defending<font style="letter-spacing:0.05pt;"> </font>or enforcing<font style="letter-spacing:0.05pt;"> </font>our patents<font style="letter-spacing:0.05pt;"> </font>extremely<font style="letter-spacing:0.1pt;"> </font>difficult.<font style="letter-spacing:0.1pt;"> </font>There could also be public<font style="letter-spacing:0.05pt;"> </font>announcements<font style="letter-spacing:0.05pt;"> </font>of the results<font style="letter-spacing:0.05pt;"> </font>of hearings,<font style="letter-spacing:0.05pt;"> </font>motions<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>interim<font style="letter-spacing:0.1pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>or developments.<font style="letter-spacing:0.1pt;"> </font>If securities<font style="letter-spacing:0.1pt;"> </font>analysts<font style="letter-spacing:0.05pt;"> </font>or investors<font style="letter-spacing:0.05pt;"> </font>perceive<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>to be negative,<font style="letter-spacing:0.05pt;"> </font>it could have a material adverse<font style="letter-spacing:0.05pt;"> </font>effect<font style="letter-spacing:0.05pt;"> </font>on the price<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties<font style="letter-spacing:0.05pt;"> </font>may initiate<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>against us alleging<font style="letter-spacing:0.05pt;"> </font>that we<font style="letter-spacing:-0.05pt;"> </font>infringe<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.1pt;"> </font>property rights<font style="letter-spacing:0.05pt;"> </font>or we<font style="letter-spacing:-0.05pt;"> </font>may initiate<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>against third parties<font style="letter-spacing:0.05pt;"> </font>to challenge<font style="letter-spacing:0.05pt;"> </font>the validity<font style="letter-spacing:0.1pt;"> </font>or scope of intellectual<font style="letter-spacing:0.1pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>controlled<font style="letter-spacing:0.05pt;"> </font>by third parties.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties<font style="letter-spacing:0.05pt;"> </font>may initiate<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>us alleging<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>infringe<font style="letter-spacing:0.05pt;"> </font>their intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or we<font style="letter-spacing:-0.05pt;"> </font>may initiate<font style="letter-spacing:0.1pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>to challenge<font style="letter-spacing:0.05pt;"> </font>the validity<font style="letter-spacing:0.05pt;"> </font>or scope of intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>controlled<font style="letter-spacing:0.1pt;"> </font>by third<font style="letter-spacing:0.05pt;"> </font>parties,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>in oppositions,<font style="letter-spacing:0.05pt;"> </font>interferences, revocations,<font style="letter-spacing:0.1pt;"> </font>reexaminations,<font style="letter-spacing:0.1pt;"> </font><font style="font-style:italic;">inter</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font><font style="font-style:italic;">partes</font><font style="font-style:italic;letter-spacing:0.05pt;"> </font>review or derivation<font style="letter-spacing:0.1pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>the USPTO<font style="letter-spacing:-0.1pt;"> </font>or its<font style="letter-spacing:0.05pt;"> </font>counterparts in other<font style="letter-spacing:0.05pt;"> </font>jurisdictions.<font style="letter-spacing:0.15pt;"> </font>These proceedings<font style="letter-spacing:0.05pt;"> </font>can be expensive<font style="letter-spacing:0.05pt;"> </font>and time-consuming<font style="letter-spacing:0.15pt;"> </font>and many of our adversaries<font style="letter-spacing:0.1pt;"> </font>in these<font style="letter-spacing:0.05pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>may have the ability<font style="letter-spacing:0.05pt;"> </font>to dedicate<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>greater<font style="letter-spacing:0.05pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>to prosecuting<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>legal actions<font style="letter-spacing:0.05pt;"> </font>than we<font style="letter-spacing:-0.05pt;"> </font>can. We could be found liable<font style="letter-spacing:0.05pt;"> </font>for monetary<font style="letter-spacing:0.05pt;"> </font>damages,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>treble<font style="letter-spacing:0.05pt;"> </font>damages<font style="letter-spacing:0.05pt;"> </font>and attorneys&#8217;<font style="letter-spacing:0.1pt;"> </font>fees,<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>are found to have willfully<font style="letter-spacing:0.1pt;"> </font>infringed<font style="letter-spacing:0.05pt;"> </font>a patent<font style="letter-spacing:0.05pt;"> </font>of a third<font style="letter-spacing:0.05pt;"> </font>party.<font style="letter-spacing:0.05pt;"> </font>A<font style="letter-spacing:-0.05pt;"> </font>finding<font style="letter-spacing:0.05pt;"> </font>of infringement<font style="letter-spacing:0.1pt;"> </font>could prevent<font style="letter-spacing:0.05pt;"> </font>us from commercializing<font style="letter-spacing:0.15pt;"> </font>our BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or force<font style="letter-spacing:0.05pt;"> </font>us to cease<font style="letter-spacing:0.05pt;"> </font>some of our business operations,<font style="letter-spacing:0.05pt;"> </font>which could materially<font style="letter-spacing:0.15pt;"> </font>harm<font style="letter-spacing:0.05pt;"> </font>our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we<font style="letter-spacing:-0.05pt;"> </font>have reviewed<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>and patent<font style="letter-spacing:0.05pt;"> </font>filings<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>believe<font style="letter-spacing:0.05pt;"> </font>may be relevant<font style="letter-spacing:0.05pt;"> </font>to our therapeutic<font style="letter-spacing:0.1pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or products,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have not conducted<font style="letter-spacing:0.05pt;"> </font>a freedom-to-operate<font style="letter-spacing:0.2pt;"> </font>search<font style="letter-spacing:0.05pt;"> </font>or analysis for any of our therapeutic<font style="letter-spacing:0.1pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>or products,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>may not be aware of patents<font style="letter-spacing:0.05pt;"> </font>or pending or future<font style="letter-spacing:0.05pt;"> </font>patent applications<font style="letter-spacing:0.1pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>if issued,<font style="letter-spacing:0.05pt;"> </font>would block us from<font style="letter-spacing:0.05pt;"> </font>commercializing<font style="letter-spacing:0.15pt;"> </font>our product<font style="letter-spacing:0.1pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>Thus, we<font style="letter-spacing:-0.05pt;"> </font>cannot guarantee<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>our product candidates,<font style="letter-spacing:0.05pt;"> </font>or our commercialization<font style="letter-spacing:0.2pt;"> </font>thereof,<font style="letter-spacing:0.05pt;"> </font>do not and will not infringe<font style="letter-spacing:0.05pt;"> </font>any third<font style="letter-spacing:0.05pt;"> </font>party&#8217;s<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of our common stock may be volatile,<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>you may lose all or part of your investment.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock could fluctuate<font style="letter-spacing:0.1pt;"> </font>significantly,<font style="letter-spacing:0.15pt;"> </font>and you may not be able to resell your shares<font style="letter-spacing:0.05pt;"> </font>at or above the price you paid for your shares.<font style="letter-spacing:0.05pt;"> </font>Those fluctuations<font style="letter-spacing:0.1pt;"> </font>could be based on various<font style="letter-spacing:0.05pt;"> </font>factors<font style="letter-spacing:0.05pt;"> </font>in addition<font style="letter-spacing:0.05pt;"> </font>to those otherwise<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>those described<font style="letter-spacing:0.05pt;"> </font>in these<font style="letter-spacing:0.05pt;"> </font>&#8220;Risk Factors.&#8221;<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these factors</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may result</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in large</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and sudden changes in the volume</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and trading</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">price</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our common</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock. In the past, following</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of volatility</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the market</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">price</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a company&#8217;s</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholders</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have often</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">instituted securities</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">class</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company. </font><font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of our common stock, or the perception that such sales may occur, could depress the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could depress the market price of our common stock. Certain holders of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In addition, we have filed a registration statement registering under the Securities Act the shares of our common stock reserved for issuance under our 2019 Equity Incentive Plan, including shares issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. Further, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt or equity securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>may cause dilution<font style="letter-spacing:0.05pt;"> </font>to existing stockholders,<font style="letter-spacing:0.05pt;"> </font>restrict<font style="letter-spacing:0.1pt;"> </font>our operations<font style="letter-spacing:0.05pt;"> </font>or require<font style="letter-spacing:0.05pt;"> </font>us to relinquish<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>to our technologies.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing stockholders<font style="letter-spacing:0.05pt;"> </font>could suffer<font style="letter-spacing:0.05pt;"> </font>dilution<font style="letter-spacing:0.05pt;"> </font>or be negatively<font style="letter-spacing:0.05pt;"> </font>affected<font style="letter-spacing:0.1pt;"> </font>by fixed payment<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may incur<font style="letter-spacing:0.05pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>raise<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>funds through the issuance<font style="letter-spacing:0.05pt;"> </font>of additional<font style="letter-spacing:0.1pt;"> </font>equity securities<font style="letter-spacing:0.1pt;"> </font>or debt or the Loan Agreement. Furthermore,<font style="letter-spacing:1.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>may have rights<font style="letter-spacing:0.05pt;"> </font>senior<font style="letter-spacing:0.05pt;"> </font>to those of our common<font style="letter-spacing:0.05pt;"> </font>stock and could contain<font style="letter-spacing:0.05pt;"> </font>covenants<font style="letter-spacing:0.05pt;"> </font>or protective rights<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would restrict<font style="letter-spacing:0.1pt;"> </font>our operations<font style="letter-spacing:0.05pt;"> </font>and potentially<font style="letter-spacing:0.1pt;"> </font>impair<font style="letter-spacing:0.05pt;"> </font>our competitiveness,<font style="letter-spacing:0.15pt;"> </font>such as limitations<font style="letter-spacing:0.15pt;"> </font>on our ability<font style="letter-spacing:0.05pt;"> </font>to incur<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>debt, limitations<font style="letter-spacing:0.15pt;"> </font>on our ability<font style="letter-spacing:0.05pt;"> </font>to acquire,<font style="letter-spacing:0.05pt;"> </font>sell<font style="letter-spacing:0.05pt;"> </font>or license<font style="letter-spacing:0.05pt;"> </font>intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>restrictions<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>could adversely<font style="letter-spacing:0.05pt;"> </font>impact<font style="letter-spacing:0.05pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to conduct our business.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<font style="letter-spacing:-0.05pt;"> </font>directors,<font style="letter-spacing:0.05pt;"> </font>executive<font style="letter-spacing:0.05pt;"> </font>officers<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>current holders of 5% or more of our capital<font style="letter-spacing:0.05pt;"> </font>stock have substantial<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>over our company,<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>could limit<font style="letter-spacing:0.1pt;"> </font>your ability<font style="letter-spacing:0.05pt;"> </font>to influence<font style="letter-spacing:0.05pt;"> </font>the outcome<font style="letter-spacing:0.05pt;"> </font>of matters<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to stockholder<font style="letter-spacing:0.05pt;"> </font>approval, including a change of control.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our executive officers, directors and other holders of 5% or more of our common stock beneficially owned a majority of our outstanding common stock. As<font style="letter-spacing:-0.05pt;"> </font>a result, our executive officers,<font style="letter-spacing:0.1pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>and other holders of 5% or more of our common stock, if they act, will be able to influence or control matters<font style="letter-spacing:0.1pt;"> </font>requiring approval by our stockholders,<font style="letter-spacing:0.1pt;"> </font>including the election of directors<font style="letter-spacing:0.1pt;"> </font>and the approval of mergers, acquisitions<font style="letter-spacing:0.1pt;"> </font>or other extraordinary<font style="letter-spacing:0.1pt;"> </font>transactions.<font style="letter-spacing:0.1pt;"> </font>In addition, our current directors,<font style="letter-spacing:0.1pt;"> </font>executive officers<font style="letter-spacing:0.1pt;"> </font>and other holders of 5% or more of our common stock, acting together, would have the ability to control the management<font style="letter-spacing:0.1pt;"> </font>and affairs<font style="letter-spacing:0.1pt;"> </font>of our company. They may also have interests<font style="letter-spacing:0.1pt;"> </font>that differ from yours and may vote in a way<font style="letter-spacing:-0.05pt;"> </font>with which you disagree and that may be adverse to your interests.<font style="letter-spacing:0.1pt;"> </font>This concentration<font style="letter-spacing:0.1pt;"> </font>of ownership may have the effect of delaying, preventing or deterring<font style="letter-spacing:0.1pt;"> </font>a change of control of our company, could deprive our stockholders<font style="letter-spacing:0.1pt;"> </font>of an opportunity to receive a premium for their shares of our common stock as part of a sale of our company.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We previously identified<font style="letter-spacing:0.1pt;"> </font>material<font style="letter-spacing:0.1pt;"> </font>weaknesses in our internal<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>over financial<font style="letter-spacing:0.05pt;"> </font>reporting, which have been remediated. If we identify additional material weaknesses in the future or otherwise fail to maintain<font style="letter-spacing:0.05pt;"> </font>an<font style="letter-spacing:-0.05pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>system<font style="letter-spacing:0.05pt;"> </font>of internal<font style="letter-spacing:0.05pt;"> </font>controls, we<font style="letter-spacing:-0.05pt;"> </font>may not be <font style="letter-spacing:-0.1pt;">able</font> to produce timely and accurate financial<font style="letter-spacing:0.05pt;"> </font>statements, and we or our independent registered public accounting firm may conclude that our internal control over financial reporting is not effective,<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>could adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> our </font>investors&#8217;<font style="letter-spacing:0.05pt;"> </font>confidence and our stock price.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an emerging growth company under the JOBS Act, our management is required to report upon the effectiveness of our internal control over financial reporting under Section<font style="letter-spacing:0.05pt;"> </font>404 of the Sarbanes-Oxley<font style="letter-spacing:0.05pt;"> </font>Act. Our independent registered public accounting firm is not required to formally attest to the effectiveness of our internal control over financial reporting until the date we are no longer an emerging growth company and reach accelerated filer status. Any failure<font style="letter-spacing:0.1pt;"> </font>to implement<font style="letter-spacing:0.1pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>or improved<font style="letter-spacing:0.05pt;"> </font>controls,<font style="letter-spacing:0.05pt;"> </font>or difficulties<font style="letter-spacing:0.15pt;"> </font>encountered<font style="letter-spacing:0.05pt;"> </font>in their<font style="letter-spacing:0.05pt;"> </font>implementation, could cause us to fail<font style="letter-spacing:0.05pt;"> </font>to meet<font style="letter-spacing:0.05pt;"> </font>our reporting<font style="letter-spacing:0.05pt;"> </font>obligations.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>any testing<font style="letter-spacing:0.05pt;"> </font>by us conducted<font style="letter-spacing:0.05pt;"> </font>in connection with Section<font style="letter-spacing:0.05pt;"> </font>404, or any subsequent<font style="letter-spacing:0.05pt;"> </font>testing<font style="letter-spacing:0.05pt;"> </font>by our independent<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>firm,<font style="letter-spacing:0.05pt;"> </font>may reveal<font style="letter-spacing:0.05pt;"> </font>deficiencies<font style="letter-spacing:0.1pt;"> </font>in our internal<font style="letter-spacing:0.1pt;"> </font>controls<font style="letter-spacing:0.05pt;"> </font>over financial<font style="letter-spacing:0.1pt;"> </font>reporting<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are deemed<font style="letter-spacing:0.05pt;"> </font>to be material<font style="letter-spacing:0.1pt;"> </font>weaknesses<font style="letter-spacing:0.05pt;"> </font>or that<font style="letter-spacing:0.05pt;"> </font>may require prospective<font style="letter-spacing:0.1pt;"> </font>or retroactive<font style="letter-spacing:0.1pt;"> </font>changes to our consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>or identify<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>areas<font style="letter-spacing:0.05pt;"> </font>for further attention<font style="letter-spacing:0.1pt;"> </font>or improvement.<font style="letter-spacing:0.1pt;"> As previously disclosed, </font>in connection<font style="letter-spacing:0.05pt;"> </font>with our financial<font style="letter-spacing:0.1pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>close<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for 2018, we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identified</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weaknesses in the design and operating</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effectiveness</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our internal</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over financial</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rep</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orting</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> While w</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remediated such material weaknesses, w</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot assure</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you that we have identified</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weaknesses</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will not be additional</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weaknesses</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or deficiencies that</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will identify</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could prevent a third party from acquiring us (even if an acquisition would benefit our stockholders), may limit the ability of our stockholders to replace our management and limit the price that investors might be willing to pay for shares of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation<font style="letter-spacing:0.1pt;"> </font>and our amended and restated bylaws could have the effect<font style="letter-spacing:0.05pt;"> </font>of making<font style="letter-spacing:0.05pt;"> </font>it more<font style="letter-spacing:0.05pt;"> </font>difficult<font style="letter-spacing:0.1pt;"> </font>for a third<font style="letter-spacing:0.05pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>to acquire,<font style="letter-spacing:0.05pt;"> </font>or of discouraging<font style="letter-spacing:0.05pt;"> </font>a third<font style="letter-spacing:0.05pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>attempting<font style="letter-spacing:0.1pt;"> </font>to acquire,<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>of us. These provisions<font style="letter-spacing:0.05pt;"> </font>could delay or prevent<font style="letter-spacing:0.05pt;"> </font>a change in control<font style="letter-spacing:0.05pt;"> </font>of the company and could limit<font style="letter-spacing:0.1pt;"> </font>the price<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>investors might<font style="letter-spacing:0.05pt;"> </font>be willing<font style="letter-spacing:0.05pt;"> </font>to pay in the future<font style="letter-spacing:0.05pt;"> </font>for shares<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock. In addition, as<font style="letter-spacing:-0.05pt;"> </font>a Delaware corporation,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are subject<font style="letter-spacing:0.05pt;"> </font>to the anti-takeover<font style="letter-spacing:0.1pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>of Section<font style="letter-spacing:0.05pt;"> </font>203 of the Delaware General<font style="letter-spacing:0.05pt;"> </font>Corporation<font style="letter-spacing:0.05pt;"> </font>Law,<font style="letter-spacing:-0.05pt;"> </font>which prohibits<font style="letter-spacing:0.05pt;"> </font>a Delaware corporation<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>engaging in a business combination<font style="letter-spacing:0.1pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>in the statute<font style="letter-spacing:0.05pt;"> </font>with an interested<font style="letter-spacing:0.1pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>(as defined<font style="letter-spacing:0.05pt;"> </font>in the statute)<font style="letter-spacing:0.1pt;"> </font>for a period<font style="letter-spacing:0.05pt;"> </font>of three years<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>the date of the transaction<font style="letter-spacing:0.1pt;"> </font>in which the person first<font style="letter-spacing:0.05pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>an interested<font style="letter-spacing:0.1pt;"> </font>stockholder,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>the business<font style="letter-spacing:0.05pt;"> </font>combination<font style="letter-spacing:0.1pt;"> </font>is approved in advance by a majority<font style="letter-spacing:0.1pt;"> </font>of the independent<font style="letter-spacing:0.05pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>or by the holders<font style="letter-spacing:0.05pt;"> </font>of at least<font style="letter-spacing:0.05pt;"> </font>two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>disinterested<font style="letter-spacing:0.15pt;"> </font>shares.<font style="letter-spacing:0.05pt;"> </font>The application<font style="letter-spacing:0.1pt;"> </font>of Section<font style="letter-spacing:0.05pt;"> </font>203 of the Delaware General Corporation<font style="letter-spacing:0.05pt;"> </font>Law<font style="letter-spacing:-0.05pt;"> </font>could also have the effect<font style="letter-spacing:0.05pt;"> </font>of delaying<font style="letter-spacing:0.05pt;"> </font>or preventing<font style="letter-spacing:0.05pt;"> </font>a change of control<font style="letter-spacing:0.05pt;"> </font>of us.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<font style="letter-spacing:-0.05pt;"> </font>amended and restated certificate of incorporation provides<font style="letter-spacing:0.05pt;"> </font>that the Court of Chancery of the State of Delaware and<font style="letter-spacing:-0.05pt;"> </font>the federal<font style="letter-spacing:0.05pt;"> </font>district<font style="letter-spacing:0.1pt;"> </font>courts of the United States<font style="letter-spacing:0.05pt;"> </font>will be the exclusive<font style="letter-spacing:0.05pt;"> </font>forum for substantially<font style="letter-spacing:0.1pt;"> </font>all disputes<font style="letter-spacing:0.05pt;"> </font>between us and<font style="letter-spacing:-0.05pt;"> </font>our stockholders,<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>could limit<font style="letter-spacing:0.1pt;"> </font>our stockholders&#8217;<font style="letter-spacing:0.1pt;"> </font>ability<font style="letter-spacing:0.05pt;"> </font>to obtain a favorable<font style="letter-spacing:0.05pt;"> </font>judicial<font style="letter-spacing:0.05pt;"> </font>forum for disputes<font style="letter-spacing:0.05pt;"> </font>with us or our directors,<font style="letter-spacing:0.05pt;"> </font>officers<font style="letter-spacing:0.1pt;"> </font>or employees.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the Court of Chancery of the State<font style="letter-spacing:0.05pt;"> </font>of Delaware is the exclusive<font style="letter-spacing:0.05pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>for certain actions<font style="letter-spacing:0.05pt;"> </font>or proceedings<font style="letter-spacing:0.05pt;"> </font>under Delaware statutory<font style="letter-spacing:0.1pt;"> </font>or common<font style="letter-spacing:0.05pt;"> </font>law.<font style="letter-spacing:0.05pt;"> </font>Our amended and restated certificate of incorporation<font style="letter-spacing:0.1pt;"> </font>provides further<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the federal<font style="letter-spacing:0.05pt;"> </font>district<font style="letter-spacing:0.1pt;"> </font>courts<font style="letter-spacing:0.05pt;"> </font>of the United States<font style="letter-spacing:0.05pt;"> </font>will be the exclusive<font style="letter-spacing:0.05pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>for resolving<font style="letter-spacing:0.05pt;"> </font>any complaint<font style="letter-spacing:0.1pt;"> </font>asserting<font style="letter-spacing:0.1pt;"> </font>a cause of action<font style="letter-spacing:0.05pt;"> </font>arising<font style="letter-spacing:0.05pt;"> </font>under the Securities<font style="letter-spacing:0.1pt;"> </font>Act.<font style="letter-spacing:0.05pt;"> </font>These choice<font style="letter-spacing:0.05pt;"> </font>of forum<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>may limit<font style="letter-spacing:0.1pt;"> </font>a stockholder&#8217;s ability<font style="letter-spacing:0.05pt;"> </font>to bring a claim<font style="letter-spacing:0.05pt;"> </font>in a judicial<font style="letter-spacing:0.1pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>it finds<font style="letter-spacing:0.05pt;"> </font>favorable<font style="letter-spacing:0.05pt;"> </font>for disputes<font style="letter-spacing:0.05pt;"> </font>with us or our directors,<font style="letter-spacing:0.1pt;"> </font>officers<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>employees.<font style="letter-spacing:0.05pt;"> </font>If a court<font style="letter-spacing:0.05pt;"> </font>were to find the choice<font style="letter-spacing:0.05pt;"> </font>of forum<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in our amended and restated certificate of incorporation<font style="letter-spacing:0.1pt;"> </font>to be inapplicable<font style="letter-spacing:0.1pt;"> </font>or unenforceable,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may incur<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with resolving<font style="letter-spacing:0.05pt;"> </font>such action<font style="letter-spacing:0.05pt;"> </font>in other<font style="letter-spacing:0.05pt;"> </font>jurisdictions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>space, which consists<font style="letter-spacing:0.05pt;"> </font>of approximately<font style="letter-spacing:0.1pt;"> </font>1,600 square<font style="letter-spacing:0.05pt;"> </font>feet<font style="letter-spacing:0.05pt;"> </font>located<font style="letter-spacing:0.05pt;"> </font>at 6 Hamada Street, Herzliya,<font style="letter-spacing:0.05pt;"> </font>4673340, Israel.<font style="letter-spacing:0.05pt;"> </font>This lease<font style="letter-spacing:0.05pt;"> </font>expires<font style="letter-spacing:0.05pt;"> </font>on April 30, 2021. We also lease<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>space at 142 Sansome<font style="letter-spacing:0.05pt;"> </font>Street,<font style="letter-spacing:0.05pt;"> </font>San Francisco,<font style="letter-spacing:0.05pt;"> </font>California<font style="letter-spacing:0.1pt;"> </font>94104, which consists of approximately 3,600 square feet.<font style="letter-spacing:0.05pt;"> </font>This lease<font style="letter-spacing:0.05pt;"> </font>expires<font style="letter-spacing:0.05pt;"> </font>on January 14, 2022. We believe<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>our current<font style="letter-spacing:0.05pt;"> </font>spaces are adequate<font style="letter-spacing:0.05pt;"> </font>for our needs. We also believe<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will be able to obtain<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>space, as needed, on commercially<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>terms<font style="color:#000000;">. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently not a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded on The Nasdaq Global Market under the symbol &#8220;ETNB.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 1, 2021, there were approximately 12 stockholders of record of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock and have no present intention to pay cash dividends on our common stock for the foreseeable future. Any determination to pay dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements, restrictions in the agreements governing any indebtedness we may enter into, business prospects and other factors that our board of directors deems relevant.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from our Initial Public Offering</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.85%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 13, 2019, we completed our IPO, pursuant to which we issued and sold an aggregate of 6,100,390 shares of common stock (inclusive of 795,703 shares pursuant to the underwriters&#8217; option to purchase additional shares) at the IPO price of $16.00 per share. The aggregate gross proceeds from our IPO were $97.6 million, and the net proceeds were $87.7 million after deducting underwriting discounts and commissions of $6.8 million and other offering expenses of $3.1 million. The offer and sale of the shares of common stock in the IPO were registered pursuant to registration statements on Form S-1 (File Nos. 333-234174 and 333-234617), which the SEC declared effective on November&#160;8, 2019.&#160;No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. The underwriters for our IPO were BofA Securities, Inc., SVB Leerink LLC, RBC Capital Markets, LLC, and Oppenheimer &amp; Co. Inc.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.85%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the intended use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on November 12, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You<font style="letter-spacing:-0.05pt;"> </font>should read the following<font style="letter-spacing:0.05pt;"> </font>discussion<font style="letter-spacing:0.05pt;"> </font>and analysis<font style="letter-spacing:0.05pt;"> </font>of our financial<font style="letter-spacing:0.05pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>and results<font style="letter-spacing:0.05pt;"> </font>of operations<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with our consolidated<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.05pt;"> </font>and related<font style="letter-spacing:0.05pt;"> </font>notes and other financial<font style="letter-spacing:0.05pt;"> </font>information included<font style="letter-spacing:0.05pt;"> </font>elsewhere<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> Annual Report on Form 10-K. </font><font style="Background-color:#FFFFFF;color:#000000;">Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those described in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this </font><font style="letter-spacing:0.05pt;">Annual Report on Form 10-K</font><font style="Background-color:#FFFFFF;color:#000000;">.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk56027175"></a><a name="_Hlk59121803"></a><a name="_Hlk45521090"></a><font style="Background-color:#FFFFFF;">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate,&#160;BIO89-100,&#160;a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH and for the treatment of SHTG. NASH is a severe form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. </font>In September 2020, we announced positive topline data from the Phase 1b/2a trial of BIO89-100 in NASH. We plan to initiate a Phase 2b trial in NASH patients in the first half of 2021. In December 2020, we initiated a paired-biopsy open-label cohort as part of the Phase 1b/2a trial in NASH patients assessing histology endpoints with topline data anticipated by the end of 2021. SHTG is<font style="Background-color:#FFFFFF;"> a condition identified by severely elevated levels of triglycerides (greater than or equal to 500 mg/dL), which is associated with an increased risk of NASH, cardiovascular events and acute pancreatitis. We initiated our Phase&#160;2 trial (ENTRIGUE) in SHTG patients in the third quarter of 2020 and expect to report topline data in the second half of 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced<font style="letter-spacing:0.05pt;"> </font>operations<font style="letter-spacing:0.05pt;"> </font>in 2018 and have devoted substantially<font style="letter-spacing:0.1pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of our resources<font style="letter-spacing:0.05pt;"> </font>to raising<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.05pt;"> </font>acquiring<font style="letter-spacing:0.05pt;"> </font>our initial<font style="letter-spacing:0.1pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> identifying and developing </font>BIO89-100, licensing<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>technology,<font style="letter-spacing:0.05pt;"> </font>conducting<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> (</font>including<font style="letter-spacing:0.05pt;"> </font>preclinical studies<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials)<font style="letter-spacing:0.1pt;"> </font>and providing<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>support<font style="letter-spacing:0.05pt;"> </font>for these<font style="letter-spacing:0.05pt;"> </font>operations. <font style="letter-spacing:0.05pt;">Prior to our initial public offering (&#8220;IPO&#8221;), we had funded our operations primarily from the issuance and sale of capital stock. In November 2019, we completed our IPO pursuant to which we issued </font>6,100,390 <font style="letter-spacing:0.05pt;">shares of our common stock at a price of $16.00 per share. We received net proceeds of $87.7 million from the IPO.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In July 2020, we completed an underwritten public offering of 3,047,040 shares of our common stock, including 397,440 shares sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, at a public offering price of $27.50 per share. We raised a total of $83.8 million in gross proceeds from the offering, or approximately $78.2 million in net proceeds after deducting underwriters&#8217; discounts and commissions of $5.0 million and offering costs of approximately $0.6 million.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In September 2020, we completed an underwritten public offering of 3,025,000 shares of our common stock, at a public offering price of $28.00 per share. We raised a total of $84.7 million in gross proceeds from the offering, or approximately $79.5 million in net proceeds after deducting underwriting discounts and commissions of $4.6 million and offering costs of approximately $0.6 million. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:-0.05pt;"> </font>of December 31, 2020, our cash, cash equivalents<font style="letter-spacing:0.1pt;"> and short-term investments </font>totaled<font style="letter-spacing:0.05pt;"> </font>$204.6 million.<font style="letter-spacing:0.1pt;"> </font>Based on our current<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>plan, we<font style="letter-spacing:-0.05pt;"> </font>believe<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>our cash, cash equivalents and short-term investments together with the proceeds available under our term loan facility will be sufficient<font style="letter-spacing:0.1pt;"> </font>to meet<font style="letter-spacing:0.05pt;"> </font>our anticipated cash requirements<font style="letter-spacing:0.1pt;"> through the second quarter of 2023.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred<font style="letter-spacing:0.05pt;"> </font>net losses<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>our inception.<font style="letter-spacing:0.05pt;"> </font>Our net losses for the years ended December 31, 2020 and 2019 were $49.5 million and $57.4 million, respectively. As<font style="letter-spacing:-0.05pt;"> </font>of December 31, 2020, we<font style="letter-spacing:-0.05pt;"> </font>had an accumulated<font style="letter-spacing:0.1pt;"> </font>deficit<font style="letter-spacing:0.1pt;"> </font>of<font style="color:#000000;"> </font>$123.1 million.<font style="letter-spacing:0.1pt;"> </font>We expect<font style="letter-spacing:0.05pt;"> </font>to continue<font style="letter-spacing:0.05pt;"> </font>to incur<font style="letter-spacing:0.05pt;"> </font>significant<font style="letter-spacing:0.1pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>and increasing<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>losses<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>advance BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>through clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>seek regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>for BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>expand our clinical,<font style="letter-spacing:0.1pt;"> </font>regulatory,<font style="letter-spacing:0.1pt;"> </font>quality,<font style="letter-spacing:0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>and commercialization capabilities,<font style="letter-spacing:0.15pt;"> </font>protect<font style="letter-spacing:0.05pt;"> </font>our intellectual<font style="letter-spacing:0.15pt;"> </font>property,<font style="letter-spacing:0.05pt;"> </font>prepare<font style="letter-spacing:0.05pt;"> </font>for and, if approved, proceed<font style="letter-spacing:0.05pt;"> </font>to commercialization<font style="letter-spacing:0.2pt;"> </font>of BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>expand our general<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>support<font style="letter-spacing:0.05pt;"> </font>functions, including<font style="letter-spacing:0.05pt;"> </font>hiring<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>personnel,<font style="letter-spacing:0.05pt;"> </font>and incur<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with operating<font style="letter-spacing:0.05pt;"> </font>as a public<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company. Our net losses</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may fluctuate</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter-to-quarter</font><font style="letter-spacing:0.2pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and year-to-year,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depending on the timing</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our clinical</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our expenditures</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and development</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impact of COVID-19 Pandemic</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has disrupted and may continue to disrupt our business and delay our preclinical and clinical programs and timelines. The extent to which the COVID-19 pandemic may impact our future operating results and financial condition is uncertain.<font style="color:#000000;"> We initiated our Phase 2 trial </font><font style="Background-color:#FFFFFF;color:#000000;">(ENTRIGUE) </font><font style="color:#000000;">in SHTG patients in the third quarter of 2020 as well as a new paired-biopsy open-label histology cohort as part of the Phase 1b/2a trial in the fourth quarter of 2020. The COVID-19 surge observed late in the fourth quarter of 2020 and the first quarter of 2021 has impacted enrollment in these studies. We plan to initiate a Phase 2b trial in NASH patients in the first half of 2021. We do not yet know the full extent of potential delays, which could prevent or delay us from obtaining approval for&#160;BIO89-100.&#160;For more information regarding risks related to the ongoing&#160;COVID-19&#160;pandemic, please see the risk factor entitled &#8220;The ongoing COVID-19 pandemic has resulted and may in the future result in significant disruptions to our clinical trials or other business operations, which could have a material adverse effect on our business,&#8221; in Part I. Item 1A of this Annual Report on Form 10-K. To the extent the ongoing&#160;COVID-19&#160;pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks set forth under &#8220;Risk Factors&#8221; in this Annual Report on Form&#160;10-K.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and<font style="letter-spacing:-0.05pt;"> </font>Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of costs<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>for the development<font style="letter-spacing:0.05pt;"> </font>of our lead product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of external<font style="letter-spacing:0.05pt;"> </font>costs related<font style="letter-spacing:0.05pt;"> </font>to preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to acquiring<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>and intellectual property,<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>under license<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and agreements<font style="letter-spacing:0.1pt;"> </font>with contract<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>organizations<font style="letter-spacing:0.1pt;"> </font>and consultants,<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to acquiring<font style="letter-spacing:0.05pt;"> </font>and manufacturing<font style="letter-spacing:0.1pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>materials,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>under agreements<font style="letter-spacing:0.1pt;"> </font>with contract<font style="letter-spacing:0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>organizations<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>vendors, costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to the preparation<font style="letter-spacing:0.1pt;"> </font>of regulatory submissions<font style="letter-spacing:0.1pt;"> </font>and expenses<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to laboratory<font style="letter-spacing:0.1pt;"> </font>supplies<font style="letter-spacing:0.05pt;"> </font>and services,<font style="letter-spacing:0.05pt;"> </font>as well as personnel<font style="letter-spacing:0.05pt;"> </font>costs.<font style="letter-spacing:0.05pt;"> </font>Personnel<font style="letter-spacing:0.05pt;"> </font>costs consist<font style="letter-spacing:0.05pt;"> </font>of salaries,<font style="letter-spacing:0.1pt;"> </font>employee<font style="letter-spacing:0.05pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>and share-based<font style="letter-spacing:0.1pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for individuals<font style="letter-spacing:0.1pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>in the periods<font style="letter-spacing:0.05pt;"> </font>in which they are incurred.<font style="letter-spacing:0.05pt;"> </font>We accrue for costs<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>as the services<font style="letter-spacing:0.05pt;"> </font>are being provided<font style="letter-spacing:0.05pt;"> </font>by monitoring<font style="letter-spacing:0.1pt;"> </font>the status<font style="letter-spacing:0.05pt;"> </font>of specific<font style="letter-spacing:0.1pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>and the invoices<font style="letter-spacing:0.05pt;"> </font>received<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>our external<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers.<font style="letter-spacing:0.05pt;"> </font>We adjust<font style="letter-spacing:0.05pt;"> </font>our accrued expenses<font style="letter-spacing:0.05pt;"> </font>as actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>known.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with licensing<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>licenses<font style="letter-spacing:0.05pt;"> </font>to develop, use, manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have not reached<font style="letter-spacing:0.05pt;"> </font>technological<font style="letter-spacing:0.1pt;"> </font>feasibility<font style="letter-spacing:0.15pt;"> </font>and do not have alternate<font style="letter-spacing:0.1pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>use are expensed as incurred.<font style="letter-spacing:0.05pt;"> </font>Where<font style="letter-spacing:0.05pt;"> </font>contingent<font style="letter-spacing:0.05pt;"> </font>milestone<font style="letter-spacing:0.1pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>are due to third<font style="letter-spacing:0.05pt;"> </font>parties<font style="letter-spacing:0.05pt;"> </font>under research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>or license<font style="letter-spacing:0.05pt;"> </font>agreements,<font style="letter-spacing:0.1pt;"> </font>the milestone<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>are expensed when<font style="letter-spacing:-0.05pt;"> </font>the milestone<font style="letter-spacing:0.1pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>are probable<font style="letter-spacing:0.05pt;"> </font>and estimable,<font style="letter-spacing:0.1pt;"> </font>which is generally<font style="letter-spacing:0.05pt;"> </font>upon achievement<font style="letter-spacing:0.1pt;"> </font>of milestones.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect<font style="letter-spacing:0.05pt;"> </font>our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>to increase<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>for the foreseeable<font style="letter-spacing:0.1pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:0.05pt;"> </font>the development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 and continue<font style="letter-spacing:0.05pt;"> </font>to invest<font style="letter-spacing:0.05pt;"> </font>in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities.<font style="letter-spacing:0.1pt;"> </font>The process<font style="letter-spacing:0.05pt;"> </font>of conducting<font style="letter-spacing:0.05pt;"> </font>the necessary<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>to obtain<font style="letter-spacing:0.05pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>is costly<font style="letter-spacing:0.05pt;"> </font>and time<font style="letter-spacing:0.05pt;"> </font>consuming, and the successful<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 and any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>is highly uncertain.<font style="letter-spacing:0.05pt;"> </font>To<font style="letter-spacing:-0.05pt;"> </font>the extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>BIO89-100 continues<font style="letter-spacing:0.05pt;"> </font>to advance into larger<font style="letter-spacing:0.05pt;"> </font>and later<font style="letter-spacing:0.05pt;"> </font>stage<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials,<font style="letter-spacing:0.1pt;"> </font>our expenses<font style="letter-spacing:0.05pt;"> </font>will increase substantially<font style="letter-spacing:0.1pt;"> </font>and may become<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>variable.<font style="letter-spacing:0.05pt;"> </font>The actual<font style="letter-spacing:0.05pt;"> </font>probability<font style="letter-spacing:0.1pt;"> </font>of success<font style="letter-spacing:0.05pt;"> </font>for BIO89-100 or any future product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>may be affected<font style="letter-spacing:0.1pt;"> </font>by a variety<font style="letter-spacing:0.05pt;"> </font>of factors,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the safety<font style="letter-spacing:0.05pt;"> </font>and efficacy<font style="letter-spacing:0.1pt;"> </font>of our product candidates,<font style="letter-spacing:0.05pt;"> </font>investment<font style="letter-spacing:0.1pt;"> </font>in our clinical<font style="letter-spacing:0.1pt;"> </font>programs,<font style="letter-spacing:0.05pt;"> </font>manufacturing<font style="letter-spacing:0.1pt;"> </font>capability<font style="letter-spacing:0.1pt;"> </font>and competition<font style="letter-spacing:0.1pt;"> </font>with other<font style="letter-spacing:0.05pt;"> </font>products. As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are unable to determine<font style="letter-spacing:0.1pt;"> </font>the timing<font style="letter-spacing:0.05pt;"> </font>of initiation,<font style="letter-spacing:0.1pt;"> </font>duration<font style="letter-spacing:0.05pt;"> </font>and completion<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>of our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>efforts<font style="letter-spacing:0.1pt;"> </font>or when<font style="letter-spacing:-0.05pt;"> </font>and to what extent<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will generate<font style="letter-spacing:0.05pt;"> </font>revenue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the commercialization<font style="letter-spacing:0.2pt;"> </font>and sale<font style="letter-spacing:0.05pt;"> </font>of BIO89-100 or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Administrative Expenses </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of personnel<font style="letter-spacing:0.05pt;"> </font>costs,<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>for outside professional<font style="letter-spacing:0.1pt;"> </font>services,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>legal,<font style="letter-spacing:0.05pt;"> </font>human resource,<font style="letter-spacing:0.05pt;"> </font>audit<font style="letter-spacing:0.05pt;"> </font>and accounting<font style="letter-spacing:0.05pt;"> </font>services,<font style="letter-spacing:0.05pt;"> </font>consulting<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and allocated<font style="letter-spacing:0.1pt;"> </font>facilities<font style="letter-spacing:0.15pt;"> </font>costs.<font style="letter-spacing:0.05pt;"> </font>Personnel<font style="letter-spacing:0.05pt;"> </font>and related<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>of salaries,<font style="letter-spacing:0.1pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>and share-based<font style="letter-spacing:0.1pt;"> </font>compensation for personnel<font style="letter-spacing:0.05pt;"> </font>in executive,<font style="letter-spacing:0.05pt;"> </font>finance<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>administrative<font style="letter-spacing:0.15pt;"> </font>functions.<font style="letter-spacing:0.05pt;"> </font>Facilities<font style="letter-spacing:0.1pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>of rent<font style="letter-spacing:0.05pt;"> </font>and maintenance<font style="letter-spacing:0.1pt;"> </font>of facilities.<font style="letter-spacing:0.15pt;"> </font>We expect<font style="letter-spacing:0.05pt;"> </font>our general<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>to increase<font style="letter-spacing:0.05pt;"> </font>for the foreseeable future<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>the size<font style="letter-spacing:0.05pt;"> </font>of our administrative<font style="letter-spacing:0.15pt;"> </font>function<font style="letter-spacing:0.05pt;"> </font>to support<font style="letter-spacing:0.05pt;"> </font>the growth of our business<font style="letter-spacing:0.05pt;"> </font>and support our continued<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Expenses, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk47021326"></a>Other expenses<font style="letter-spacing:-0.2pt;">,</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.15pt;">net</font><font style="letter-spacing:-0.4pt;"> primarily </font><font style="letter-spacing:-0.2pt;">consists</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">of</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.15pt;">the</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.2pt;">revaluation</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">of</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.15pt;">our</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.2pt;">convertible</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.2pt;">preferred</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.2pt;">stock</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.2pt;">liability, prior to extinguishment upon our IPO. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended<font style="letter-spacing:-0.05pt;"> </font>December 31, 2020<font style="font-weight:normal;color:#000000;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>2019</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>our results<font style="letter-spacing:0.05pt;"> </font>of operations<font style="letter-spacing:0.05pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,346</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,853</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,640</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,640</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,921</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and<font style="letter-spacing:-0.05pt;"> </font>Development<font style="letter-spacing:0.05pt;"> </font>Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>the period-over-period<font style="letter-spacing:0.15pt;"> </font>changes in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses for the periods<font style="letter-spacing:0.05pt;"> </font>indicated (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,160</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract manufacturing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,072</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel-related expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,841</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,688</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,346</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,853</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33176730"></a>Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>increased<font style="letter-spacing:0.05pt;"> </font>by $14.9 million,<font style="letter-spacing:0.1pt;"> </font>or 70%, to $36.2 million in 2020 compared to $21.3 million in 2019. The change<font style="letter-spacing:0.05pt;"> </font>was primarily<font style="letter-spacing:0.1pt;"> </font>due to an increase of $8.2 million<font style="letter-spacing:0.1pt;"> </font>in clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>costs as a result of our ongoing Phase 1b/2a study in NASH and the initiation of our Phase 2 trial <font style="Background-color:#FFFFFF;color:#000000;">(ENTRIGUE)</font> in SHTG patients in the third quarter of 2020, as well as our new paired-biopsy histology cohort as part of the Phase 1b/2a trial in the fourth quarter of 2020, an increase of $5.7 million in contract manufacturing costs as a result of the manufacture of additional supplies for our ongoing clinical trials, including our clinical trials initiated in the second half of 2020 and an increase of $3.2 million in personnel-related costs, including share-based compensation, due to higher headcount. The increases were partially offset by a decrease of $2.4 million in preclinical costs. The timing of such preclinical costs is dependent upon the status and stage of our clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">General</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Administrative</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Expenses</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33177028"></a>General<font style="letter-spacing:0.05pt;"> </font>and administrative<font style="letter-spacing:0.15pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>increased<font style="letter-spacing:0.05pt;"> </font>by $7.9 million,<font style="letter-spacing:0.1pt;"> </font>or 149%, to $13.2 million in 2020 compared to $5.3 million in 2019. The change was primarily<font style="letter-spacing:0.1pt;"> </font>due to an increase<font style="letter-spacing:0.05pt;"> </font>of $4.2 million<font style="letter-spacing:0.1pt;"> </font>in personnel-related<font style="letter-spacing:0.15pt;"> </font>costs,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>share-based compensation,<font style="letter-spacing:0.1pt;"> </font>driven<font style="letter-spacing:0.05pt;"> </font>by higher headcount, an increase<font style="letter-spacing:0.05pt;"> </font>of $2.5 million<font style="letter-spacing:0.1pt;"> </font>in professional<font style="letter-spacing:0.1pt;"> </font>services including legal and accounting consulting service fees<font style="letter-spacing:0.05pt;"> and an </font>increase<font style="letter-spacing:0.05pt;"> of $</font>1.4<font style="letter-spacing:0.05pt;"> million in insurance related costs. The increases were partially offset by a decrease of $0.3 million in travel related expenses.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Other<font style="letter-spacing:0.05pt;"> </font>Expenses, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses,<font style="letter-spacing:0.05pt;"> </font>net decreased<font style="letter-spacing:0.05pt;"> </font>by $30.4 million<font style="letter-spacing:0.1pt;"> to $</font>0.2 million <font style="letter-spacing:0.1pt;">in</font> 2020<font style="letter-spacing:0.1pt;"> </font>compared to $30.6 million<font style="letter-spacing:0.1pt;"> in 2019. In 2019, other expenses, net consisted primarily of </font>the revaluation<font style="letter-spacing:0.1pt;"> </font>of our convertible<font style="letter-spacing:0.1pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>liability which was extinguished upon our IPO in November 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and<font style="letter-spacing:-0.05pt;"> </font>Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have incurred significant net losses and negative cash flows from operations. <font style="color:#231F20;">As</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">of December 31, 2020, we</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">had available</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">cash, cash equivalents</font><font style="color:#231F20;letter-spacing:0.1pt;"> and short-term investments </font><font style="color:#231F20;">of $204.6 million</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">and an accumulated</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">deficit</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of $123.1 million. Prior to our IPO, we funded our operations from the issuance and sale of capital stock.</font><font style="color:#231F20;letter-spacing:0.1pt;"> In connection with our IPO, we issued and sold an aggregate of 6,100,390 shares of common stock at a price of $16.00 per share. We received proceeds of $87.7 million, net of underwriting discounts and commissions and estimated offering costs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, we entered into a secured term loan facility with an aggregate committed principal amount of up to $15.0 million. <font style="color:#000000;">As of December 31, 2020, we had not drawn any amount under the term loan facility.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed an underwritten public offering of 3,047,040 shares of our common stock, including 397,440 shares sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, at a public offering price of $27.50 per share. Upon completion of the offering, we received gross proceeds of $83.8 million, before deducting underwriting discounts and commissions and offering expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In September 2020, we completed an underwritten public offering of 3,025,000 shares of our common stock, at a public offering price of $28.00 per share. Upon completion of the offering, we received gross proceeds of $84.7 million, before deducting underwriting discounts and commissions and offering expenses</font><font style="color:#231F20;letter-spacing:0.1pt;">.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary<font style="letter-spacing:0.05pt;"> </font>use of cash is to fund operating<font style="letter-spacing:0.05pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>which consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenditures<font style="letter-spacing:0.1pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to our lead product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100. We plan to increase<font style="letter-spacing:0.05pt;"> </font>our research and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>for the foreseeable<font style="letter-spacing:0.1pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>continue<font style="letter-spacing:0.05pt;"> </font>the clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of our current<font style="letter-spacing:0.05pt;"> </font>and future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>At this<font style="letter-spacing:0.05pt;"> </font>time,<font style="letter-spacing:0.05pt;"> </font>due to the inherently<font style="letter-spacing:0.1pt;"> </font>unpredictable<font style="letter-spacing:0.1pt;"> </font>nature<font style="letter-spacing:0.05pt;"> </font>of clinical development,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>cannot reasonably<font style="letter-spacing:0.05pt;"> </font>estimate<font style="letter-spacing:0.1pt;"> </font>the costs<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will incur<font style="letter-spacing:0.05pt;"> </font>and the timelines<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>will be required<font style="letter-spacing:0.05pt;"> </font>to complete<font style="letter-spacing:0.05pt;"> </font>development,<font style="letter-spacing:0.05pt;"> </font>obtain<font style="letter-spacing:0.05pt;"> </font>marketing<font style="letter-spacing:0.1pt;"> </font>approval,<font style="letter-spacing:0.05pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>our current<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidate<font style="letter-spacing:0.05pt;"> </font>or any future<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates.<font style="letter-spacing:0.05pt;"> </font>For the same<font style="letter-spacing:0.05pt;"> </font>reasons,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are also unable to predict<font style="letter-spacing:0.05pt;"> </font>when,<font style="letter-spacing:-0.05pt;"> </font>if ever, we<font style="letter-spacing:-0.05pt;"> </font>will generate revenue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>sales<font style="letter-spacing:0.05pt;"> </font>or our current<font style="letter-spacing:0.05pt;"> </font>or any future<font style="letter-spacing:0.05pt;"> </font>license<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>which we<font style="letter-spacing:-0.05pt;"> </font>may enter<font style="letter-spacing:0.05pt;"> </font>into or whether, or when,<font style="letter-spacing:-0.05pt;"> </font>if ever, we<font style="letter-spacing:-0.05pt;"> </font>may achieve<font style="letter-spacing:0.05pt;"> </font>profitability.<font style="letter-spacing:0.15pt;"> </font>Clinical<font style="letter-spacing:0.05pt;"> </font>and preclinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>timelines,<font style="letter-spacing:0.1pt;"> </font>the probability<font style="letter-spacing:0.1pt;"> </font>of success,<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>can differ<font style="letter-spacing:0.05pt;"> </font>materially<font style="letter-spacing:0.15pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>expectations.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>cannot forecast<font style="letter-spacing:0.1pt;"> </font>the timing<font style="letter-spacing:0.05pt;"> </font>and amounts<font style="letter-spacing:0.05pt;"> </font>of milestone,<font style="letter-spacing:0.1pt;"> </font>royalty<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>revenue<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>licensing<font style="letter-spacing:0.05pt;"> </font>activities,<font style="letter-spacing:0.1pt;"> </font>which future<font style="letter-spacing:0.05pt;"> </font>product candidates<font style="letter-spacing:0.05pt;"> </font>may be subject<font style="letter-spacing:0.05pt;"> </font>to future<font style="letter-spacing:0.05pt;"> </font>collaborations,<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>such arrangements<font style="letter-spacing:0.1pt;"> </font>will be secured,<font style="letter-spacing:0.05pt;"> </font>if at all,<font style="letter-spacing:0.05pt;"> </font>and to what degree<font style="letter-spacing:0.05pt;"> </font>such arrangements<font style="letter-spacing:0.1pt;"> </font>would affect<font style="letter-spacing:0.05pt;"> </font>our development<font style="letter-spacing:0.05pt;"> </font>plans and capital<font style="letter-spacing:0.05pt;"> </font>requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>plans, we<font style="letter-spacing:-0.05pt;"> </font>expect<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>our existing<font style="letter-spacing:0.05pt;"> </font>cash, cash equivalents and short-term investments together with the proceeds available under our term loan facility,<font style="letter-spacing:0.1pt;"> </font>will be sufficient<font style="letter-spacing:0.1pt;"> </font>to fund our operations<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">through the second quarter of 2023</font>.<font style="letter-spacing:0.05pt;"> </font>However, our operating<font style="letter-spacing:0.05pt;"> </font>plans and other<font style="letter-spacing:0.05pt;"> </font>demands<font style="letter-spacing:0.05pt;"> </font>on our cash resources<font style="letter-spacing:0.05pt;"> </font>may change as a result<font style="letter-spacing:0.05pt;"> </font>of many factors,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>may seek additional<font style="letter-spacing:0.1pt;"> </font>funds sooner than planned. There can be no assurance<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will be successful<font style="letter-spacing:0.1pt;"> </font>in acquiring<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>funding at levels<font style="letter-spacing:0.05pt;"> </font>sufficient<font style="letter-spacing:0.1pt;"> </font>to fund our operations<font style="letter-spacing:0.05pt;"> </font>or on terms<font style="letter-spacing:0.05pt;"> </font>favorable<font style="letter-spacing:0.05pt;"> </font>to us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funding requirements</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will depend on many factors,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the following:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the progress,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">timing,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">scope, results</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and costs</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of our clinical</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">trials</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of BIO89-100 and preclinical studies</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or clinical</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">trials</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">of other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">potential</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">product</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">candidates</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">may choose to pursue in the future, including</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">the ability</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to enroll</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">patients</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">in a timely</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">manner</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">for our clinical</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the costs</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and timing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of obtaining</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">clinical</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">and commercial</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">supplies</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and validating</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">the commercial manufacturing</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">process</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">for BIO89-100 and any other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">product</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">candidates</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">may identify</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the cost, timing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and outcomes</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of regulatory</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the timing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and amount</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of any milestone,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">royalty</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">payments</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">we</font><font style="color:#231F20;letter-spacing:-0.05pt;"> </font><font style="color:#231F20;">are required</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to make pursuant</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to current</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or any future</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">collaboration</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">or license</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">agreements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">costs</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of acquiring</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">or in-licensing</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">product</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">candidates</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the terms</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and timing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">of establishing</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">and maintaining</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">collaborations,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">licenses</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and other</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">similar arrangements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the costs</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">associated</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">with attracting,</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">hiring</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and retaining</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">additional</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">qualified</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">personnel</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">as our business</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">grows;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">our efforts</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">to enhance operational</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">systems</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and hire</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">additional</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">personnel</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">to satisfy</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">our obligations</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">as a public</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">company, including</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">enhanced internal</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">controls</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">over financial</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">reporting;</font><font style="color:#231F20;letter-spacing:0.1pt;"> </font><font style="color:#231F20;">and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#231F20;">the cost of preparing,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">filing,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">prosecuting,</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">defending</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and enforcing</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">any patent</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">claims</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">and other intellectual</font><font style="color:#231F20;letter-spacing:0.15pt;"> </font><font style="color:#231F20;">property</font><font style="color:#231F20;letter-spacing:0.05pt;"> </font><font style="color:#231F20;">rights.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect<font style="letter-spacing:0.05pt;"> </font>to continue<font style="letter-spacing:0.05pt;"> </font>to generate<font style="letter-spacing:0.05pt;"> </font>substantial<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>losses<font style="letter-spacing:0.05pt;"> </font>for the foreseeable<font style="letter-spacing:0.1pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>expand our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities.<font style="letter-spacing:0.1pt;"> </font>We will continue<font style="letter-spacing:0.05pt;"> </font>to fund our operations<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>through utilization<font style="letter-spacing:0.1pt;"> </font>of our current<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>resources<font style="letter-spacing:0.05pt;"> </font>and through additional<font style="letter-spacing:0.1pt;"> </font>raises<font style="letter-spacing:0.05pt;"> </font>of capital <font style="color:#000000;">to advance our current product candidate through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future</font>.<font style="letter-spacing:0.05pt;"> </font>However, there<font style="letter-spacing:0.05pt;"> </font>is no assurance<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>such funding will be available<font style="letter-spacing:0.1pt;"> </font>to us or that<font style="letter-spacing:0.05pt;"> </font>it will be obtained<font style="letter-spacing:0.05pt;"> </font>on terms<font style="letter-spacing:0.05pt;"> </font>favorable<font style="letter-spacing:0.05pt;"> </font>to us or will provide<font style="letter-spacing:0.05pt;"> </font>us with sufficient<font style="letter-spacing:0.1pt;"> </font>funds to meet<font style="letter-spacing:0.05pt;"> </font>our objectives.<font style="letter-spacing:0.1pt;"> </font><font style="color:#000000;">Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:-0.05pt;"> </font>the extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>raise<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>through partnerships<font style="letter-spacing:0.1pt;"> </font>or licensing<font style="letter-spacing:0.05pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>with third parties,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may have to relinquish<font style="letter-spacing:0.1pt;"> </font>valuable<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>to our product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>revenue<font style="letter-spacing:0.05pt;"> </font>streams<font style="letter-spacing:0.1pt;"> </font>or research programs<font style="letter-spacing:0.05pt;"> </font>or to grant<font style="letter-spacing:0.05pt;"> </font>licenses<font style="letter-spacing:0.05pt;"> </font>on terms<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may not be favorable<font style="letter-spacing:0.05pt;"> </font>to us. If we<font style="letter-spacing:-0.05pt;"> </font>raise<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>through public<font style="letter-spacing:0.05pt;"> </font>or private<font style="letter-spacing:0.05pt;"> </font>equity<font style="letter-spacing:0.05pt;"> </font>offerings,<font style="letter-spacing:0.1pt;"> </font>the ownership interest<font style="letter-spacing:0.1pt;"> </font>of our then-existing<font style="letter-spacing:0.1pt;"> </font>stockholders<font style="letter-spacing:0.1pt;"> </font>will be diluted,<font style="letter-spacing:0.05pt;"> </font>and the terms<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>may include<font style="letter-spacing:0.05pt;"> </font>liquidation<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>preferences<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>our stockholders&#8217; rights.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>raise<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>through debt financing,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may be subject<font style="letter-spacing:0.05pt;"> </font>to covenants<font style="letter-spacing:0.05pt;"> </font>limiting<font style="letter-spacing:0.1pt;"> </font>or restricting<font style="letter-spacing:0.15pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to take specific<font style="letter-spacing:0.1pt;"> </font>actions,<font style="letter-spacing:0.05pt;"> </font>such as incurring<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>debt, making<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>expenditures<font style="letter-spacing:0.1pt;"> </font>or declaring<font style="letter-spacing:0.05pt;"> </font>dividends.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>are unable to obtain<font style="letter-spacing:0.05pt;"> </font>adequate<font style="letter-spacing:0.05pt;"> </font>financing<font style="letter-spacing:0.05pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>needed, we<font style="letter-spacing:-0.05pt;"> </font>may have to delay, reduce the scope of or suspend one or more<font style="letter-spacing:0.05pt;"> </font>of our clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>or preclinical<font style="letter-spacing:0.1pt;"> </font>studies,<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and development programs<font style="letter-spacing:0.05pt;"> </font>or commercialization<font style="letter-spacing:0.2pt;"> </font>efforts<font style="letter-spacing:0.1pt;"> </font>or grant<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>to develop and market<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>even if we would otherwise<font style="letter-spacing:0.05pt;"> </font>prefer<font style="letter-spacing:0.05pt;"> </font>to develop and market<font style="letter-spacing:0.05pt;"> </font>such product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>ourselves.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash<font style="letter-spacing:-0.05pt;"> </font>Flows</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>table<font style="letter-spacing:0.05pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>our cash flows for the periods presented<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,924</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,702</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents, and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Cash<font style="letter-spacing:-0.05pt;"> </font>Used in Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, net cash used in operating<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>was $46.2 million, which consisted<font style="letter-spacing:0.05pt;"> </font>of a net loss of $49.5 million and a net change of $1.0 million in our net operating assets and liabilities,<font style="letter-spacing:0.1pt;"> </font>partially<font style="letter-spacing:0.1pt;"> </font>offset<font style="letter-spacing:0.05pt;"> </font>by non-cash<font style="letter-spacing:0.05pt;"> </font>charges<font style="letter-spacing:0.05pt;"> </font>of $4.3 million. The change in our operating<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>was primarily<font style="letter-spacing:0.1pt;"> </font>due to a $3.6 million<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>in prepaid and other current assets<font style="letter-spacing:0.05pt;"> </font>due to the timing<font style="letter-spacing:0.05pt;"> </font>of payments as well as increased scale of operations and the initiation of clinical trials in the second half of 2020, offset in part by a $2.6 million increase in accounts payable and accrued expenses as we grew our operations.<font style="letter-spacing:0.15pt;"> </font>The non-cash<font style="letter-spacing:0.05pt;"> </font>charges<font style="letter-spacing:0.05pt;"> </font>are primarily<font style="letter-spacing:0.1pt;"> </font>comprised of $3.8 million<font style="letter-spacing:0.1pt;"> </font>in share-based compensation, $0.3 million in amortization of premium on available-for-sale securities and $0.2 million in amortization of debt issuance costs.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, net cash used in operating<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>was $25.5 million, which consisted<font style="letter-spacing:0.05pt;"> </font>of a net loss of $57.4 million,<font style="letter-spacing:0.1pt;"> </font>partially<font style="letter-spacing:0.1pt;"> </font>offset<font style="letter-spacing:0.05pt;"> </font>by non-cash<font style="letter-spacing:0.05pt;"> </font>charges<font style="letter-spacing:0.05pt;"> </font>of $31.0 million<font style="letter-spacing:0.1pt;"> </font>and a net change of $0.9 million<font style="letter-spacing:0.1pt;"> </font>in our net operating<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities.<font style="letter-spacing:0.15pt;"> </font>The non-cash<font style="letter-spacing:0.05pt;"> </font>charges<font style="letter-spacing:0.05pt;"> </font>are primarily<font style="letter-spacing:0.1pt;"> </font>comprised of the revaluation<font style="letter-spacing:0.1pt;"> </font>of our convertible<font style="letter-spacing:0.1pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.1pt;"> </font>of $30.6 million and<font style="letter-spacing:0.1pt;"> </font>$0.4 million<font style="letter-spacing:0.1pt;"> </font>in share-based compensation.<font style="letter-spacing:0.1pt;"> </font>The change in our operating<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>was primarily<font style="letter-spacing:0.1pt;"> </font>due to a $2.9 million<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>in accounts payable and accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>grew our operations,<font style="letter-spacing:0.05pt;"> offset in part </font>by a $2.0 million<font style="letter-spacing:0.1pt;"> </font>increase<font style="letter-spacing:0.05pt;"> </font>in other current assets and other assets<font style="letter-spacing:0.05pt;"> </font>due to the timing<font style="letter-spacing:0.05pt;"> </font>of payments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Cash<font style="letter-spacing:-0.05pt;"> </font>Used in Investing<font style="letter-spacing:0.05pt;"> </font>Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, net cash used in investing activities<font style="letter-spacing:0.1pt;"> was $106.8 million, which </font>consisted<font style="letter-spacing:0.05pt;"> </font>of $118.9 million in purchases<font style="letter-spacing:0.05pt;"> </font>of available-for-sale securities and $0.1 million in purchases of property and equipment, offset in part by $12.2 million in proceeds from maturities of available-for-sale securities.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year<font style="letter-spacing:0.05pt;"> </font>ended December 31, 2019, net cash used in investing activities<font style="letter-spacing:0.1pt;"> </font>consisted<font style="letter-spacing:0.05pt;"> </font>of purchases<font style="letter-spacing:0.05pt;"> </font>of property and equipment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Cash<font style="letter-spacing:-0.05pt;"> </font>Provided by Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020 net cash provided by financing<font style="letter-spacing:0.05pt;"> </font>activities was $157.9 million, which<font style="letter-spacing:0.1pt;"> </font>consisted of $157.7 million in net proceeds from the issuance of common stock from our public offerings and $0.4 million in proceeds from the issuance of common stock upon exercise of stock options and employee share purchase plan (&#8220;ESPP&#8221;) purchases, offset in part by a $0.2 million payment of debt issuance costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year<font style="letter-spacing:0.05pt;"> </font>ended December 31, 2019 net cash provided<font style="letter-spacing:0.05pt;"> </font>by financing<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>was $107.7 million, which consisted<font style="letter-spacing:0.05pt;"> </font>of $87.7 million in net proceeds<font style="letter-spacing:0.1pt;"> from our initial public offering and $20.0 million in net proceeds </font>from<font style="letter-spacing:0.05pt;"> </font>the issuance<font style="letter-spacing:0.05pt;"> </font>and sale<font style="letter-spacing:0.05pt;"> </font>of our convertible<font style="letter-spacing:0.1pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Other<font style="letter-spacing:0.05pt;"> </font>Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Off-Balance<font style="letter-spacing:0.05pt;"> </font>Sheet Arrangements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered<font style="letter-spacing:0.05pt;"> </font>into any off-balance<font style="letter-spacing:0.1pt;"> </font>sheet<font style="letter-spacing:0.05pt;"> </font>arrangements,<font style="letter-spacing:0.1pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>in the rules<font style="letter-spacing:0.05pt;"> </font>and regulations<font style="letter-spacing:0.1pt;"> </font>of the SEC,<font style="letter-spacing:-0.05pt;"> </font>and do not have any holdings<font style="letter-spacing:0.05pt;"> </font>in variable<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Critical<font style="letter-spacing:0.05pt;"> </font>Accounting Polices<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s<font style="letter-spacing:0.1pt;"> </font>discussion<font style="letter-spacing:0.05pt;"> </font>and analysis<font style="letter-spacing:0.05pt;"> </font>of our financial<font style="letter-spacing:0.1pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>and results<font style="letter-spacing:0.05pt;"> </font>of operations<font style="letter-spacing:0.05pt;"> </font>is based on our consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements,<font style="letter-spacing:0.1pt;"> </font>which have been prepared<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.05pt;"> </font>with United States<font style="letter-spacing:0.05pt;"> </font>generally accepted<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>principles (&#8220;GAAP&#8221;). The preparation<font style="letter-spacing:0.1pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>requires<font style="letter-spacing:0.05pt;"> </font>us to make<font style="letter-spacing:1.1pt;"> </font>estimates<font style="letter-spacing:0.1pt;"> </font>and assumptions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the reported<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>and the disclosure<font style="letter-spacing:0.1pt;"> </font>of contingent<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and liabilities</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of the date of the consolidated</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as well as the reported expenses</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incurred</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the reporting</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are based on our historical</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and on various</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believe</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are reasonable</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the circumstances,</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of which form</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the basis for making</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">judgments</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">about the carrying</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value of assets</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and liabilities</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are not readily</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">apparent</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other sources.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual results</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may differ</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimates</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under different</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assumptions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or conditions.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the accounting</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discussed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below are critical</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to understanding</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our historical</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and future</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance, as these</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relate</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the more</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">areas</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involving</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management&#8217;s</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">judgments</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and estimate</font><font style="color:#000000;">s.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued expenses for estimated preclinical and clinical trial and research expenses related to the services performed but not yet invoiced pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies, and clinical trials, and research services on our behalf. Payments for these services are based on the terms of individual agreements and payment timing may differ significantly from the period in which the services were performed. Our estimates are based on factors such as the work completed, including the level of patient enrollment. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. Our estimates of accrued expenses are based on the facts and circumstances known at the time. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. As actual costs become known, we adjust our accrued expenses. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure compensation expense related to share-based awards granted to employees, directors, and non-employee service providers, including stock options, based on the estimated fair value. We estimate the fair value of the awards on the date of grant, and the resulting share-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the share-based awards, which have graded vesting, is recognized as an expense using the straight-line method over the requisite service period of each award, which is generally the vesting period of the respective awards. We recognize forfeitures as they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the Black-Scholes option-pricing model to estimate the fair value of stock option awards that requires the use of subjective assumptions to determine the fair value of share-based awards. These assumptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected volatility&#8212;Since we have limited trading history for our common stock due to our short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected term&#8212;The expected term of options granted to employees and directors is determined using the &#8220;simplified&#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Risk-free interest rate&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected dividend&#8212;We have never paid dividends and have no foreseeable plans to pay dividends on our shares of common stock. Therefore, we use an expected dividend of zero.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to use judgment in evaluating the expected volatility and expected term utilized for our share-based compensation calculations on a prospective basis.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 to our consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>appearing under Part II Item 8<font style="letter-spacing:0.05pt;"> </font>for more information<font style="letter-spacing:0.1pt;"> </font>about recent<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>pronouncements,<font style="letter-spacing:0.1pt;"> </font>the timing<font style="letter-spacing:0.05pt;"> </font>of their<font style="letter-spacing:0.05pt;"> </font>adoption,<font style="letter-spacing:0.05pt;"> </font>and our assessment,<font style="letter-spacing:0.1pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have made one yet, of their<font style="letter-spacing:0.05pt;"> </font>potential<font style="letter-spacing:0.1pt;"> </font>impact<font style="letter-spacing:0.05pt;"> </font>on our financial<font style="letter-spacing:0.1pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>of results<font style="letter-spacing:0.05pt;"> </font>of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">JOBS<font style="letter-spacing:-0.05pt;"> </font>Act Accounting Election</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging<font style="letter-spacing:0.05pt;"> </font>growth company,<font style="letter-spacing:0.05pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>in the JOBS<font style="letter-spacing:-0.05pt;"> </font>Act. Under the JOBS<font style="letter-spacing:-0.05pt;"> </font>Act, emerging growth companies<font style="letter-spacing:0.05pt;"> </font>can delay adopting<font style="letter-spacing:0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>or revised<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>standards<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>subsequent<font style="letter-spacing:0.05pt;"> </font>to the enactment<font style="letter-spacing:0.1pt;"> </font>of the JOBS<font style="letter-spacing:-0.05pt;"> </font>Act until<font style="letter-spacing:0.05pt;"> </font>such time<font style="letter-spacing:0.05pt;"> </font>as those standards<font style="letter-spacing:0.05pt;"> </font>apply to private<font style="letter-spacing:0.05pt;"> </font>companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have elected<font style="letter-spacing:0.05pt;"> </font>to use this<font style="letter-spacing:0.05pt;"> </font>extended<font style="letter-spacing:0.05pt;"> </font>transition<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>to enable<font style="letter-spacing:0.05pt;"> </font>us to comply<font style="letter-spacing:0.05pt;"> </font>with new<font style="letter-spacing:-0.05pt;"> </font>or revised accounting<font style="letter-spacing:0.05pt;"> </font>standards<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have different<font style="letter-spacing:0.1pt;"> </font>effective<font style="letter-spacing:0.1pt;"> </font>dates<font style="letter-spacing:0.05pt;"> </font>for public<font style="letter-spacing:0.05pt;"> </font>and private<font style="letter-spacing:0.05pt;"> </font>companies<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>the earlier<font style="letter-spacing:0.1pt;"> </font>of the date we<font style="letter-spacing:-0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>are no longer<font style="letter-spacing:0.05pt;"> </font>an emerging<font style="letter-spacing:0.05pt;"> </font>growth company or (ii)<font style="letter-spacing:0.05pt;"> </font>affirmatively<font style="letter-spacing:0.15pt;"> </font>and irrevocably<font style="letter-spacing:0.1pt;"> </font>opt out of the extended<font style="letter-spacing:0.05pt;"> </font>transition<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>in the JOBS<font style="letter-spacing:-0.05pt;"> </font>Act. As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>our consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>and our interim<font style="letter-spacing:0.1pt;"> </font>consolidated financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>may not be comparable<font style="letter-spacing:0.1pt;"> </font>to companies<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>comply<font style="letter-spacing:0.05pt;"> </font>with new or revised<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>pronouncements.<font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89BIO, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:94.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr style="height:9.1pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Reports of Independent Registered Public Accounting Firms</font></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><font style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered<font style="letter-spacing:0.05pt;"> </font>Public Accounting Firm</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors<br />89bio, Inc.:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:italic;text-transform:none;font-variant: normal;">Opinion on the<font style="font-style:normal;"> </font>Consolidated Financial Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheet of 89bio, Inc.&#160;and subsidiaries (the Company) as of December&#160;31,&#160;2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year ended December&#160;31,&#160;2020, and the related notes (collectively, the consolidated financial statements).&#160;In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2020, and the results of its operations and its cash flows for the year ended December&#160;31,&#160;2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:italic;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California<br />March&#160;24,&#160;2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered<font style="letter-spacing:0.05pt;">&#160;</font>Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:-0.05pt;">&#160;</font>the stockholders and the Board of Directors<font style="letter-spacing:0.05pt;">&#160;</font>of 89bio, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheet of 89bio, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flow, for the year ended December 31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;DELOITTE&#160;&amp; TOUCHE LLP</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began serving as the Company&#8217;s auditor in 2019. In 2020, we became the predecessor auditor.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,966</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,074</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,553</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,065</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">989</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,609</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value, 10,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized as of December 31, 2020 and 2019, respectively, no shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value, 100,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized as of December 31, 2020 and 2019, respectively; 19,931,660</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and 13,788,982 shares issued and outstanding as of December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,046</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,526</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,596</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,074</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,553</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,346</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,640</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,640</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,509</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.08</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net loss per share,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,087,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,344,191</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a>Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible&#160;Preferred&#160;Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,073</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,176</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs of $0 and settlement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; the convertible preferred stock liability of $6,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock upon completion of initial public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,077,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in connection with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; initial public offering, net of issuance costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of $3,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,100,390</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,685</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,691</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital contribution related to extinguishment of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,788,982</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,526</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,596</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public offerings,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $1,208</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,072,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,680</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,366</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon ESPP purchase</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock warrant in connection with debt financing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.5%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.5%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,931,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,046</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,961</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">89bio, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><font style="Background-color:#FFFFFF;">Consolidated Statements<a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a> of Cash Flows</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(In thousands)</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaids and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,918</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,131</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,447</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon public offerings,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,680</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon initial public offering,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,691</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:28.05pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock and convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock liability, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon stock option exercises</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon ESPP purchases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of debt issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,924</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,702</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,257</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of cash and cash equivalents, and restricted cash:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,183</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash information:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock warrant in connection with term loan facility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock at close of initial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; public offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital contribution related to extinguishment of convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc. (&#8220;89bio&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company&#8217;s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21, is currently being developed for the treatment of nonalcoholic steatohepatitis and for the treatment of severe hypertriglyceridemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc. was formed as a Delaware corporation in June 2019, for the purpose of completing an initial public offering (&#8220;IPO&#8221;) and related transactions in order to carry on the business of 89Bio Ltd., which was incorporated in Israel in January 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company completed an internal reorganization transaction in September 2019, pursuant to which 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (the &#8220;Reorganization&#8221;). As part of the Reorganization, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. The Reorganization was considered a transaction between entities under common control.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, 89bio, Inc. completed its IPO, pursuant to which it issued and sold an aggregate of 6,100,390 shares of common stock (inclusive of 795,703 shares pursuant to the underwriters&#8217; option to purchase additional shares), at the IPO price of $16.00 per share, <font style="Background-color:#FFFFFF;color:#000000;">resulting in net proceeds of $87.7 million after deducting underwriting discounts and commissions of $6.8 million and other offering expenses of $3.1 million. Upon the closing of the IPO, the Company&#8217;s outstanding convertible preferred stock automatically converted into 7,077,366 shares of common stock of 89bio, Inc. based on a proportional adjustment to the conversion ratio of the convertible preferred stock on a 1-for-6.217 basis.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company completed an underwritten public offering of 3,047,040 shares of its common stock (inclusive of 397,440 shares pursuant to the underwriters&#8217; option to purchase additional shares), at the public offering price of $27.50 per share. The Company raised a total of $83.8 million in gross proceeds from the offering, or approximately $78.2 million in net proceeds after deducting underwriting discounts and commissions of $5.0 million and offering costs of approximately $0.6 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company completed an underwritten public offering of 3,025,000 shares of its common stock, at a public offering price of $28.00 per share. The Company raised a total of $84.7 million in gross proceeds from the offering, or approximately $79.5 million in net proceeds after deducting underwriting discounts and commissions of $4.6 million and offering costs of approximately $0.6 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk29911817"></a>Liquidity </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate substantial operating losses for the foreseeable future until it completes development of its products and seeks regulatory approvals to market such products. The Company had cash, cash equivalents and short-term investments of $204.6 million as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its cash, cash equivalents and short-term investments as of December 31, 2020, together with proceeds available from the Company&#8217;s term loan (see Note 6), will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the date these audited consolidated financial statements are filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassification</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year footnote amounts have been updated for consistency with the current year presentation. Such reclassification has no effect on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain transactions during the years ended December 31, 2020 and 2019 were denominated in currencies other than the U.S. dollar. Gains and losses from foreign currency transactions were not material for all periods presented and are reflected in the consolidated statements of operations and comprehensive loss as a component of other expenses, net. The Company&#8217;s subsidiary in Lithuania uses the Euro as its functional currency for financial reporting. The re-measurement from Euros to U.S. dollars results in translation gain and loss adjustments, which are reflected as a component of comprehensive loss as foreign currency translation adjustments.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1<font style="font-weight:normal;">&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2<font style="font-weight:normal;">&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3<font style="font-weight:normal;">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.05pt;"> </font>instruments<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>the Company to a concentration<font style="letter-spacing:0.1pt;"> </font>of credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>consist primarily<font style="letter-spacing:0.1pt;"> </font>of cash and cash equivalents.<font style="letter-spacing:0.1pt;"> </font>Bank<font style="letter-spacing:-0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>are held by accredited<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>and these deposits<font style="letter-spacing:0.05pt;"> </font>may at times<font style="letter-spacing:0.05pt;"> </font>be in excess<font style="letter-spacing:0.05pt;"> </font>of insured<font style="letter-spacing:0.05pt;"> </font>limits. The Company limits<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with cash and cash equivalents<font style="letter-spacing:0.1pt;"> </font>by placing<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>with financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>it believes<font style="letter-spacing:0.05pt;"> </font>are of high quality.<font style="letter-spacing:0.05pt;"> </font>The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any losses<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>of cash or cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Risks and Uncertainties </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company&#8217;s early stages of clinical drug development; the Company&#8217;s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company&#8217;s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company&#8217;s ability to enroll patients in its ongoing and future clinical trials; the Company&#8217;s ability to successfully manufacture and supply its product candidates for clinical trials; the Company&#8217;s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company&#8217;s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company&#8217;s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has disrupted and may continue to disrupt the Company&#8217;s business and delay its preclinical and clinical programs and timelines. <font style="color:#000000;">The Company does not yet know the full extent of potential delays to clinical trials, which could prevent or delay the Company from obtaining approval for&#160;BIO89-100.&#160;</font>The extent to which the COVID-19 pandemic may impact the Company&#8217;s future operating results and financial condition is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one operating<font style="letter-spacing:0.05pt;"> </font>segment.<font style="letter-spacing:0.05pt;"> </font>The Company&#8217;s chief<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>decision<font style="letter-spacing:0.05pt;"> </font>maker,<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>Chief Executive<font style="letter-spacing:0.05pt;"> </font>Officer,<font style="letter-spacing:0.05pt;"> </font>manages<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s operations<font style="letter-spacing:0.05pt;"> </font>on a consolidated<font style="letter-spacing:0.1pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>for the purposes<font style="letter-spacing:0.05pt;"> </font>of allocating resources<font style="letter-spacing:0.05pt;"> </font>and evaluating<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>performance.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper that are stated at fair value.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of a money market account that serves as collateral for the Company&#8217;s operating lease agreement for its facility in Israel.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Generally, investments with original maturities beyond three months at the date of purchase are classified as short-term because it is management&#8217;s intent to use the investments to fund current operations or to make them available for current operations.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss.&#160;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other expenses, net. The cost of investments sold is based on the specific-identification method. There are </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> material realized gains or losses on investments for the periods presented. Interest on available-for-sale securities is included in other expenses, net and is not material for all periods presented.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and equipment<font style="letter-spacing:0.05pt;"> </font>are stated<font style="letter-spacing:0.05pt;"> </font>at cost, less<font style="letter-spacing:0.05pt;"> </font>accumulated<font style="letter-spacing:0.1pt;"> </font>depreciation.<font style="letter-spacing:0.1pt;"> </font>Depreciation<font style="letter-spacing:0.1pt;"> </font>is calculated<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the estimated<font style="letter-spacing:0.1pt;"> </font>useful<font style="letter-spacing:0.05pt;"> </font>lives<font style="letter-spacing:0.05pt;"> </font>of the related<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.05pt;"> </font>ranging<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>to seven years.<font style="letter-spacing:0.05pt;"> </font>Leasehold<font style="letter-spacing:0.05pt;"> </font>improvements<font style="letter-spacing:0.1pt;"> </font>are amortized<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the shorter<font style="letter-spacing:0.05pt;"> </font>of the assets&#8217;<font style="letter-spacing:0.05pt;"> </font>estimated useful<font style="letter-spacing:0.05pt;"> </font>life<font style="letter-spacing:0.05pt;"> </font>or the remaining<font style="letter-spacing:0.1pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of the lease.<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gains or losses are recorded in the consolidated statements of operations and comprehensive loss. </font>Maintenance<font style="letter-spacing:0.1pt;"> </font>and repair<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment<font style="letter-spacing:0.1pt;"> </font>of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically<font style="letter-spacing:0.1pt;"> </font>evaluates<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>long-lived<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>and equipment,<font style="letter-spacing:0.05pt;"> </font>for impairment<font style="letter-spacing:0.1pt;"> </font>whenever events<font style="letter-spacing:0.05pt;"> </font>or changes in business<font style="letter-spacing:0.05pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>indicate<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets or group of assets<font style="letter-spacing:0.05pt;"> </font>may not be fully<font style="letter-spacing:0.05pt;"> </font>recoverable.<font style="letter-spacing:0.1pt;"> </font>If indicators<font style="letter-spacing:0.1pt;"> </font>of impairment<font style="letter-spacing:0.1pt;"> </font>exist<font style="letter-spacing:0.05pt;"> </font>and the undiscounted<font style="letter-spacing:0.05pt;"> </font>future cash flows that<font style="letter-spacing:0.05pt;"> </font>the assets<font style="letter-spacing:0.05pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to generate<font style="letter-spacing:0.05pt;"> </font>are less<font style="letter-spacing:0.05pt;"> </font>than the carrying<font style="letter-spacing:0.05pt;"> </font>value of the assets,<font style="letter-spacing:0.05pt;"> </font>the Company reduces<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets<font style="letter-spacing:0.05pt;"> </font>through an impairment<font style="letter-spacing:0.1pt;"> </font>charge,<font style="letter-spacing:0.05pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>estimated<font style="letter-spacing:0.1pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>values<font style="letter-spacing:0.05pt;"> </font>based on a discounted<font style="letter-spacing:0.05pt;"> </font>cash flow approach<font style="letter-spacing:0.05pt;"> </font>or, when<font style="letter-spacing:-0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>and appropriate,<font style="letter-spacing:0.1pt;"> </font>to comparable<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>values.<font style="letter-spacing:0.05pt;"> </font>There were no such indicators<font style="letter-spacing:0.1pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>study and research<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>based on the services<font style="letter-spacing:0.05pt;"> </font>performed,<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to contracts<font style="letter-spacing:0.1pt;"> </font>with research<font style="letter-spacing:0.05pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>conduct and manage<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and research<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>behalf. The Company records<font style="letter-spacing:0.05pt;"> </font>the costs<font style="letter-spacing:0.05pt;"> </font>of research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>based upon the estimated<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of services<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>but not yet invoiced<font style="letter-spacing:0.05pt;"> </font>and includes<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>in accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>in the consolidated<font style="letter-spacing:0.1pt;"> </font>balance sheets.<font style="letter-spacing:0.05pt;"> </font>These costs<font style="letter-spacing:0.05pt;"> </font>are a component<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>based on factors<font style="letter-spacing:0.05pt;"> </font>such as estimates<font style="letter-spacing:0.1pt;"> </font>of the work completed<font style="letter-spacing:0.05pt;"> </font>and in accordance<font style="letter-spacing:0.05pt;"> </font>with agreements established<font style="letter-spacing:0.1pt;"> </font>with its<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>under the service<font style="letter-spacing:0.05pt;"> </font>agreements.<font style="letter-spacing:0.1pt;"> </font>The Company makes<font style="letter-spacing:0.05pt;"> </font>judgments<font style="letter-spacing:0.05pt;"> </font>and estimates<font style="letter-spacing:0.1pt;"> </font>in determining<font style="letter-spacing:0.1pt;"> </font>the accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>balance.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>known,<font style="letter-spacing:-0.05pt;"> </font>the Company adjusts<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>accrued<font style="letter-spacing:0.05pt;"> </font>expenses. The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any material<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>between accrued<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>incurred.<font style="letter-spacing:0.05pt;"> </font>However, the status<font style="letter-spacing:0.05pt;"> </font>and timing<font style="letter-spacing:0.05pt;"> </font>of actual<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>performed<font style="letter-spacing:0.1pt;"> </font>may vary from<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s estimates,<font style="letter-spacing:0.1pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>in adjustments<font style="letter-spacing:0.1pt;"> </font>to expense in future<font style="letter-spacing:0.05pt;"> </font>periods.<font style="letter-spacing:0.05pt;"> </font>Changes in these<font style="letter-spacing:0.05pt;"> </font>estimates that<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.05pt;"> </font>in material<font style="letter-spacing:0.1pt;"> </font>changes to the Company&#8217;s accrued expenses<font style="letter-spacing:0.05pt;"> </font>could materially<font style="letter-spacing:0.15pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s results<font style="letter-spacing:0.05pt;"> </font>of operations.<font style="letter-spacing:0.05pt;"> </font>Contingent<font style="letter-spacing:0.05pt;"> </font>milestone<font style="letter-spacing:0.1pt;"> </font>payments,<font style="letter-spacing:0.05pt;"> </font>if any, are expensed when<font style="letter-spacing:-0.05pt;"> </font>the milestone<font style="letter-spacing:0.1pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>are probable and estimable, which is generally<font style="letter-spacing:0.05pt;"> </font>upon achievement<font style="letter-spacing:0.1pt;"> </font>of the milestone.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>facilities<font style="letter-spacing:0.1pt;"> </font>under non-cancelable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and recognizes related<font style="letter-spacing:0.05pt;"> </font>rent<font style="letter-spacing:0.05pt;"> </font>expense on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the term<font style="letter-spacing:0.05pt;"> </font>of the lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Liability</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The freestanding instruments related to the commitment by the Series A convertible preferred stockholders to purchase and by the Company to sell its Series A convertible preferred stock in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per stock, were considered a liability (or an asset), measured at fair value as the shares underlying the <font style="color:#231F20;">rights</font> contained liquidation preferences upon certain &#8220;deemed liquidation events&#8221; that were not solely within the Company&#8217;s control and which were considered in-substance contingent redemption features. The instruments were subject to revaluation at each balance sheet date until settlement or extinguishment, with revaluations recognized as either a component of other expenses, net in the consolidated statements of operations and comprehensive loss, or additional paid-in capital in the consolidated balance sheets. Upon the completion of the Company&#8217;s IPO, the remaining shares of convertible preferred stock that were previously issuable under subsequent closings were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders.&nbsp;&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and<font style="letter-spacing:-0.05pt;"> </font>Development<font style="letter-spacing:0.05pt;"> </font>Expenses<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of costs<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>for the development<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s lead product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of external<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to acquiring<font style="letter-spacing:0.05pt;"> </font>and licensing<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>and intellectual<font style="letter-spacing:0.15pt;"> </font>properties,<font style="letter-spacing:0.1pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical development<font style="letter-spacing:0.05pt;"> </font>and related<font style="letter-spacing:0.05pt;"> </font>supplies, and personnel<font style="letter-spacing:0.05pt;"> </font>costs.<font style="letter-spacing:0.05pt;"> </font>Personnel<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>of salaries,<font style="letter-spacing:0.1pt;"> </font>employee<font style="letter-spacing:0.05pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for individuals<font style="letter-spacing:0.1pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>efforts. Payments<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with licensing<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>licenses<font style="letter-spacing:0.05pt;"> </font>to develop, use, manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have not reached<font style="letter-spacing:0.05pt;"> </font>technological<font style="letter-spacing:0.1pt;"> </font>feasibility<font style="letter-spacing:0.15pt;"> </font>and do not have alternate<font style="letter-spacing:0.1pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>use are expensed as incurred.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards made to employees,<font style="letter-spacing:0.05pt;"> </font>directors,<font style="letter-spacing:0.1pt;"> </font>and<font style="color:#000000;"> </font>non-employee<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>based on estimated fair values and recognizes compensation over the requisite service period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates<font style="letter-spacing:0.1pt;"> </font>the fair<font style="letter-spacing:0.05pt;"> </font>value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards on the date of grant<font style="letter-spacing:0.05pt;"> </font>using a<font style="color:#000000;"> </font>Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model.<font style="letter-spacing:0.05pt;"> </font>The Company recognizes<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for the value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards, which have graded vesting,<font style="letter-spacing:0.05pt;"> </font>using the straight-line<font style="letter-spacing:0.15pt;"> </font>method<font style="letter-spacing:0.05pt;"> </font>over the requisite<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of each award. The Company accounts<font style="letter-spacing:0.05pt;"> </font>for forfeitures<font style="letter-spacing:0.15pt;"> </font>as they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model<font style="letter-spacing:0.05pt;"> </font>requires<font style="letter-spacing:0.05pt;"> </font>a number<font style="letter-spacing:0.05pt;"> </font>of assumptions,<font style="letter-spacing:0.1pt;"> </font>of which the most significant<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>volatility,<font style="letter-spacing:0.1pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>option term<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the grant<font style="letter-spacing:0.05pt;"> </font>date until<font style="letter-spacing:0.05pt;"> </font>the options<font style="letter-spacing:0.05pt;"> </font>are exercised<font style="letter-spacing:0.05pt;"> </font>or expire),<font style="letter-spacing:0.05pt;"> </font>risk-free<font style="letter-spacing:0.1pt;"> </font>rate,<font style="letter-spacing:0.05pt;"> </font>and expected<font style="letter-spacing:0.05pt;"> </font>divided<font style="letter-spacing:0.05pt;"> </font>rate. These assumptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected volatility&#8212;Since the Company has limited trading history for its common stock due to its short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected term&#8212;The expected term of options granted to employees and directors is determined using the &#8220;simplified&#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Risk-free interest rate&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected dividend&#8212;The Company has never paid dividends and has no foreseeable plans to pay dividends on its shares of common stock. Therefore, an expected dividend of zero is used.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>are accounted<font style="letter-spacing:0.05pt;"> </font>for under the asset<font style="letter-spacing:0.05pt;"> </font>and liability<font style="letter-spacing:0.1pt;"> </font>method.<font style="letter-spacing:0.05pt;"> </font>Under this<font style="letter-spacing:0.05pt;"> </font>method,<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are recognized<font style="letter-spacing:0.05pt;"> </font>for the future<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to differences<font style="letter-spacing:0.1pt;"> </font>between the consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>carrying<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of existing<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>tax bases and operating<font style="letter-spacing:0.05pt;"> </font>loss and tax credit<font style="letter-spacing:0.05pt;"> </font>carryforwards.<font style="letter-spacing:0.1pt;"> </font>Deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are measured<font style="letter-spacing:0.05pt;"> </font>using enacted<font style="letter-spacing:0.05pt;"> </font>tax rates<font style="letter-spacing:0.05pt;"> </font>applied<font style="letter-spacing:0.05pt;"> </font>to taxable<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>in the years<font style="letter-spacing:0.05pt;"> </font>in which those temporary<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>The effect<font style="letter-spacing:0.05pt;"> </font>on deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>of a change in tax rates<font style="letter-spacing:0.05pt;"> </font>is recognized<font style="letter-spacing:0.05pt;"> </font>as income<font style="letter-spacing:0.05pt;"> </font>or loss in the period that<font style="letter-spacing:0.05pt;"> </font>includes<font style="letter-spacing:0.05pt;"> </font>the enactment<font style="letter-spacing:0.1pt;"> </font>date. A<font style="letter-spacing:-0.05pt;"> </font>valuation<font style="letter-spacing:0.05pt;"> </font>allowance<font style="letter-spacing:0.05pt;"> </font>is established<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to reduce<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>to the amount<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>Interest<font style="letter-spacing:0.1pt;"> </font>and penalties<font style="letter-spacing:0.1pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to unrecognized<font style="letter-spacing:0.05pt;"> </font>tax benefits<font style="letter-spacing:0.05pt;"> </font>are included<font style="letter-spacing:0.05pt;"> </font>within the provision<font style="letter-spacing:0.05pt;"> </font>of income<font style="letter-spacing:0.05pt;"> </font>tax. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and<font style="letter-spacing:-0.05pt;"> </font>Diluted Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>during the period.<font style="letter-spacing:0.05pt;"> </font>Diluted<font style="letter-spacing:0.05pt;"> </font>loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the number<font style="letter-spacing:0.05pt;"> </font>of additional<font style="letter-spacing:0.1pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would have been outstanding<font style="letter-spacing:0.05pt;"> </font>if all<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>had been issued.<font style="letter-spacing:0.05pt;"> </font>Since the Company is in a loss position<font style="letter-spacing:0.05pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented,<font style="letter-spacing:0.05pt;"> </font>basic<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>is the same<font style="letter-spacing:0.05pt;"> </font>as diluted<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>the effects of potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>are antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive<font style="letter-spacing:0.05pt;"> </font>Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s comprehensive loss is comprised of changes in unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <font style="font-style:italic;">Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</font>, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard effective from January 1, 2020, with the removed and modified disclosures adopted on a retrospective basis and the new disclosures adopted on a prospective basis. The standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02&#8212;<font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;), requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for nonpublic entities for fiscal years beginning after December 15, 2021. As an emerging growth company, ASU 2016-02 is effective for the Company for the year ending December 31, 2022 and interim periods within the year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,669</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,890</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,884</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,592</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency discount securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,848</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,446</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and available-for-sale securities by contractual maturity as of December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,304</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through two years</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,552</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not hold any financial assets as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock liability represented a Level 3 financial liability measured at fair value on a recurring basis prior to its extinguishment in the fourth quarter of 2019. Accordingly, there was no Level 3 financial liability outstanding during the year ended and as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, changes in the fair value of the Company&#8217;s Level&#160;3 financial liability measured on a recurring basis were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; recorded in other expenses (income), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partial settlement of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liability upon third closing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital contribution related to extinguishment of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock liability resulted from the initial sale of Series A convertible preferred stock where the investors&#8217; committed to purchase additional shares of Series A convertible preferred stock in subsequent closings, contingent upon the achievement by the Company of certain development milestones and approval by the board of directors. The investors&#8217; commitment to purchase and the Company&#8217;s commitment to sell shares of Series A convertible preferred stock represented a freestanding instrument accounted for at fair value and re-measured at each reporting date. The Company estimated the fair value of this commitment using the Black Scholes option pricing model using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.99-$2.57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00-2.25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0-2.4%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Consolidated Balance Sheet Components </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for property and equipment was $60,000 and $17,000 for the years ended December 31, 2020 and 2019, respectively.<font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee and related expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and legal fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,620</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, the Company entered<font style="letter-spacing:0.05pt;"> </font>into an operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>for its<font style="letter-spacing:0.05pt;"> </font>facility<font style="letter-spacing:0.1pt;"> </font>in Israel.<font style="letter-spacing:0.05pt;"> </font>The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months. Under the lease agreement,<font style="letter-spacing:0.1pt;"> </font>monthly<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>are approximately<font style="letter-spacing:0.1pt;"> </font>$4,000. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into an operating lease for its headquarters in San Francisco. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease term is for </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24 months</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, expiring in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2022</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and monthly lease payments </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during 2020 were</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,500</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum<font style="letter-spacing:0.1pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>under the Company&#8217;s non-cancellable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>as of December<font style="letter-spacing:0.05pt;"> </font>31, 2020, are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.86%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum annual payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $273,000 and $159,000 for years ended December 31, 2020 and 2019, respectively. The Company has security deposit balances of $95,000, which are included in restricted cash and other assets in the consolidated balance sheets as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Asset Transfer and License Agreement with Teva Pharmaceutical Industries Ltd </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company concurrently entered into two Asset Transfer and License Agreements (the &#8220;Teva Agreements&#8221;) with Teva Pharmaceutical Industries Ltd (&#8220;Teva&#8221;) under which it acquired certain patents and intellectual property relating to two programs: (1)&#160;Teva&#8217;s glycoPEGylated FGF21 program, including the compound TEV-47948 (BIO89-100), a glycoPEGylated long-acting FGF21 and (2)&#160;Teva&#8217;s development program of small molecule inhibitors of Fatty Acid Synthase. Pursuant to the Teva Agreements, the Company paid Teva an initial nonrefundable upfront payment of $6.0&#160;million and the Company could be obligated to pay Teva up to $67.5&#160;million under each program, for a total of $135.0&#160;million, upon the achievement of certain clinical development and commercial milestones. In addition, the Company is obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales on all products containing the Teva compounds. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Teva Agreements can be terminated (i)&#160;by the Company without cause, after the first anniversary of the effective date, upon 120 days&#8217; written notice to Teva, (ii)&#160;by either party, if the other party materially breaches any of its obligations under the Agreements and fails to cure such breach within 60 days after receiving notice thereof, or (iii)&#160;by either party, if a bankruptcy petition is filed against the other party and is not dismissed within 60 days. In addition, Teva can also terminate the agreement related to the Company&#8217;s glycoPEGylated FGF21 program in the event the Company, or any of its affiliates or sublicensees, challenges any of the Teva patents licensed to the Company, and the challenge is not withdrawn within 30 days of written notice from Teva. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, there were no license payment expenses related to the Teva Agreements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Term Loan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loan and Security Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the lenders referred to therein (the &#8220;Lenders&#8221;), and Silicon Valley Bank, as collateral agent. The Loan Agreement provides for (i) a secured term A loan facility (the &#8220;Term A Loan Facility&#8221;) of up to $10.0 million and (ii) a secured term B loan facility (the &#8220;Term B Loan Facility&#8221;) of up to $5.0 million that is available upon the Company satisfying certain milestones. The Term A Loan Facility matures on November 1, 2022, provided, that if the Term B Loan Facility is funded, the facilities instead mature on September 1, 2023. The loans will bear interest at the greater of (i) 4.50% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 1.25%. As of December 31, 2020, the Company had not drawn any amount under the Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Loan Agreement, the Company agreed to issue the Lenders warrants to purchase shares of the Company&#8217;s common stock. In April 2020, the Company issued Silicon Valley Bank a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrant to purchase </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock with a warrant exercise price of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.06</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share that is immediately exercisable. The initial expiration date </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 7,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2030</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was changed to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2025</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in connection with the July 2020 offering. The Company determined the fair value of the warrant at the issuance date by&#160;using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75%</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> dividends, expected volatility of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92.3%</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and expected term of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0 years</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Upon issuance, the fair value allocated to the warrant of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million was recorded as a debt issuance cost and classified within other assets and met the requirements for equity classification within additional paid-in capital on the consolidated balance sheets. An additional warrant to purchase </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,333</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock will be issued in connection with the Term B Loan Facility, if funded, with the exercise price determined on the Company&#8217;s stock price at the time of issuance.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company incurred $0.2 million in closing costs that were recorded as debt issuance costs and classified within other assets on the consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deferred assets related to the debt issuance cost and warrant are recognized as interest expense over the duration of the Loan Agreement and are recorded within other expenses, net on the consolidated statements of operations and comprehensive loss. As of December 31, 2020, the remaining unamortized debt issuance costs classified within other assets on the consolidated balance sheet is $0.6 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into the Series A Share Purchase Agreement (the &#8220;Series A SPA&#8221;), pursuant to which the investors committed to invest an aggregate amount of up to $60.0 million for the issuance of shares of Series A convertible preferred stock at a price of $1.00 per share in subsequent closings. Upon the completion of the Company&#8217;s IPO on November 13, 2019, there were 16,000,000 remaining shares of convertible preferred stock that were previously issuable that were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders during 2019. Additionally, immediately prior to the completion of the Company&#8217;s IPO, all outstanding shares of convertible preferred stock automatically converted into 7,077,366 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Share-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company&#8217;s board of directors adopted the 89Bio Ltd. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). In connection with the Reorganization in September 2019, the Company&#8217;s board of directors approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;), which became effective in September 2019. From and after the effective date of the 2019 Plan, the Company will no longer be making any future awards under the 2018 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved 2,844,193 shares of common stock for issuance under the 2019 Plan. In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2020, in an amount equal to 4% of the total number of shares of the Company&#8217;s capital stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&#8217;s board of directors. As of December 31, 2020, there were 1,433,991 shares of common stock available for issuance as future option grants under the 2019 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following 36-month period. The options will expire within ten years from the date of grant. The exercise price of awards granted will not be less than the estimated fair value of the shares on the date of grant.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee S</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">tock</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Purchase Plan</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective following the date of the IPO. The Company initially reserved 225,188 shares of common stock for purchase under the ESPP. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on the first day of January for a period of up to ten years, in an amount equal to 1% <font style="color:#000000;">of the total number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&#8217;s board of directors. Purchases will be accomplished through the participation of discrete offering periods and each offering is expected to be 6 months long. For each offering period, ESPP participants will purchase shares of common stock at a price per share equal to</font> 85% <font style="color:#000000;">of the lesser of the fair market value of the Company&#8217;s common stock on (1) the first trading day of the applicable offering period or (2) the last trading day of the applicable offering period</font>.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first six-month offering period under the ESPP commenced on January 1, 2020 and ended on June 30, 2020 and the second six-month offering period commenced on July 1, 2020 and ended on December 31, 2020. A total of 7,272 shares of common stock were purchased pursuant to the ESPP for the year ended December 31, 2020.<font style="font-size:12pt;">&#160;</font>As of December 31, 2020, there were 355,806 shares of common stock available for issuance under the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded share-based compensation for the periods indicated as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of option awards granted for the periods indicated was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67407930"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0-6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9-6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.4-97.6%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.8-87.6%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2-1.5%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6-2.6%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.78</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.87</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,918</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,684</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the estimated total grant date fair value of options vested was $0.8 million. The weighted-average<font style="letter-spacing:0.1pt;"> </font>grant<font style="letter-spacing:0.05pt;"> </font>date fair<font style="letter-spacing:0.05pt;"> </font>value of options<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>for the years ended December 31, 2020 and 2019 was $21.88 and $2.90 per share, respectively.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>of December<font style="letter-spacing:0.05pt;"> </font>31, 2020, there<font style="letter-spacing:0.05pt;"> </font>was $13.5 million of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unrecognized</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share-based compensation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost related</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to stock options</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">granted</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Plan, which is expected</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be recognized</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over a weighted-average</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.5</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> years</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">9. Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Tax Rates Applicable to the Income of the Company and its Subsidiaries</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89Bio Ltd</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio Management, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UAB 89bio Lithuania</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income<font style="letter-spacing:0.05pt;"> </font>tax benefit (expense)<font style="letter-spacing:0.05pt;"> </font>is comprised<font style="letter-spacing:0.05pt;"> </font>of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.05pt;"> </font>Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>reflect<font style="letter-spacing:0.1pt;"> </font>the net tax effects<font style="letter-spacing:0.1pt;"> </font>of temporary<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>between the carrying<font style="letter-spacing:0.05pt;"> </font>amounts of assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>for financial<font style="letter-spacing:0.1pt;"> </font>reporting<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>and the amounts<font style="letter-spacing:0.05pt;"> </font>used for income<font style="letter-spacing:0.05pt;"> </font>tax purposes. Significant<font style="letter-spacing:0.1pt;"> </font>components<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,342</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,005</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,936</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. research and development expenses and accrued expenses disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification had no impact on the consolidated financial statements for the year ended December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recorded</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a valuation</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allowance</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively,</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in respect</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of deferred</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax assets</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulting</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax loss carryforwards</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporary</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">differences.</font><font style="letter-spacing:0.1pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon future earnings, if any, the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and amount of which are uncertain. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through an </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustment to income tax expense. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation allowance increased by $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in 20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which primarily relates to significant taxable losses.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The change in valuation allowance during 2020 also includes a partial release of the valuation allowance against deferred tax assets in Israel due to achievement of recent profitability and the expectation of future profitability in the jurisdiction, which decreased the valuation allowance by $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in 2020. The valuation allowance increased by $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in 2019, which primarily relates to significant taxable losses. It also includ</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a recapture of the valuation allowance against the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred tax assets in the United States due to the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eorganization that occurred in 2019, which increased the valuation allowance by $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Available<font style="letter-spacing:0.05pt;"> </font>Carryforward<font style="letter-spacing:0.05pt;"> </font>Tax <font style="letter-spacing:-0.05pt;">Losses and Credits</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company has an accumulated<font style="letter-spacing:0.1pt;"> </font>tax loss carryforward<font style="letter-spacing:0.1pt;"> </font>of approximately $54.1 million and $17.3 million for U.S. and Israeli tax purposes, respectively. As of December 31, 2019, the Company has an accumulated tax loss carryforward of approximately $9.1 million and $23.8 million for U.S. and Israeli tax purposes. Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized. Carryforward tax losses in Israel have no expiration date. <font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company has federal research and development credit carryforwards of approximately $0.6 million, which expire beginning in 2040. As of December 31, 2020 and 2019, the Company has state research and development credit carryforwards of approximately $0.7 million and $0.2 million, respectively, which will carry forward indefinitely.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss from Continuing Operations, Before Income Tax</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,760</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reconciliation of Income Tax Benefit (Expense) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation<font style="letter-spacing:0.15pt;"> </font>of income tax benefit (expense) based on the statutory<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>to the effective<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>is as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at statutory rates</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,285</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;uncertain tax position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,914</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Israel effective tax rate due to the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; reorganization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,039</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits, net of uncertain tax position disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification has no impact on the consolidated financial statements for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the U.S. federal and state net operating losses and credit carryforwards may be subject to an annual limitation provided for in Section 382 of the Internal Revenue Code and similar state codes. Any annual limitation could result in a deferral of the utilization of the net operating loss and credit carryforwards.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the amount of gross unrecognized tax benefits increased by $0.3 million and $39,000, respectively. If the total amount of unrecognized tax benefits was recognized, it would not have an impact to the effective tax rate as it would be offset by the reversal of related deferred tax assets which are subject to a full valuation allowance.&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2020 and 2019, such interest and penalties are not material.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States, California, and several foreign jurisdictions. To date, the Company has not been subject to any federal or state income tax audits. The Company is currently under examination by the Israeli taxing authorities for 2019 and 2018. As of December 31, 2020, all tax years remain open to examination.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020 and December 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act and the Consolidated Appropriation Act (&#8220;CAA&#8221;), respectively, as a result of the COVID-19 pandemic, which contain among other things, numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company has evaluated the current legislation and at this time, does not anticipate the CARES Act or the CAA to have a material impact on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares, including all outstanding stock options, have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future option grants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,332,386</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844,193</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With<a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a> Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our management, with the participation and supervision of our principal executive officer and our principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2020 to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk36643333"></a>Remediation Efforts on Previously Reported Material Weaknesses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the audit of our consolidated financial statements for the period from January 18, 2018 (inception) to December 31, 2018, material weaknesses were identified in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis by the company&#8217;s internal controls. The material weaknesses that were identified related to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We did not have an internal finance department. Consequently, we lacked sufficient personnel with an appropriate level of knowledge and requisite U.S. generally accepted accounting principles expertise to identify, evaluate and account for complex and non-routine transactions and an adequate supervisory review structure that is needed to comply with financial reporting requirements. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We did not have an adequate assessment of risks that could significantly impact internal controls over financial reporting and did not effectively design and monitor controls in response to the risks of material misstatement. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019 and 2020, we implemented controls to remedy these material weaknesses. In 2019, we hired our Chief Financial Officer, principal accounting officer and additional qualified accounting and finance personnel, formalized our hiring practices and engaged financial consultants to enable the implementation of internal controls over financial reporting. In April 2020, we added a financial expert to the audit committee of the board of directors and in June 2020, we appointed a new board member, who also serves as audit committee chair.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these remediation activities and based on testing of the new and modified controls for operating effectiveness, our management concluded that we remediated the previously reported material weakness as of December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Other than the changes in connection with the remediation of our previously disclosed material weaknesses, no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and&#160;15d-15(f)&#160;under the Exchange Act) occurred during the quarter ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As of December 31, 2020, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (&#8220;2013 Framework&#8221;). Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2020. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Attestation Report of Registered Public Accounting Firm </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As an emerging growth company, we are not required to provide and this Annual Report on Form 10-K does not include an attestation report on our internal control over financial reporting issued by the Company&#8217;s independent registered public accounting firm. Our auditors will not be required to formally opine on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 until we are no longer an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, and are no longer a non-accelerated filer.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item 10 is incorporated herein by reference to information in our proxy statement for our 2021 Annual Meeting of Stockholders (the &#8220;2021 Proxy Statement&#8221;), which we expect to be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2020, including under the heading &#8220;Directors, Executive Officers and Corporate Governance.&#8221;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on our website located at </font><font style="Background-color:#FFFFFF;">www</font><font style="Background-color:#FFFFFF;">.89bio.com</font><font style="Background-color:#FFFFFF;">, under &#8220;Corporate Governance</font><font style="Background-color:#FFFFFF;">.</font><font style="Background-color:#FFFFFF;">&#8221;</font><font style="Background-color:#FFFFFF;"> We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 is incorporated herein by reference to information in our 2021 Proxy Statement, including under headings &#8220;Executive Compensation&#8221; and &#8220;Directors, Executive Officers and Corporate Governance.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 is incorporated herein by reference to information in our 2021 Proxy Statement, including under headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Compensation-Securities Authorized for Issuance Under Equity Compensation Plans.&#8221; <font style="font-weight:bold;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 is incorporated herein by reference to information in our 2021 Proxy Statement, including under headings &#8220;Directors, Executive Officers and Corporate Governance&#8221; and &#8220;Certain Relationships and Related Party Transactions.&#8221; <font style="font-weight:bold;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 is incorporated herein by reference to information in our 2021 Proxy Statement, including under headings &#8220;Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><a name="PART_IV"></a>PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following documents are filed as a part of this report: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:15.38%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Consolidated Financial Statements at Part II Item 8 &#8220;Financial Statements and Supplementary Data.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:15.38%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statement schedules are omitted as they are either not applicable or the information required is presented in the financial statements and notes thereto under Part II Item 8 &#8220;Financial Statements and Supplementary Data.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits:</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;2.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519266760/d743471dex21.htm"><font style="text-decoration:underline;">Contribution and Exchange Agreement, dated as of September 17, 2019, by and among 89Bio Ltd., the Company and its shareholders (filed with the SEC as Exhibit 2.1 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr style="height:8.25pt;">
<td valign="top"  style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;3.1</font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519292680/d829788dex31.htm"><font style="text-decoration:underline;">Second Amended and Restated Certificate of Incorporation of the Company (filed with the SEC as Exhibit 3.1 to the Company&#8217;s Form 8-K filed on November 15, 2019)</font></a></p></td>
</tr>
<tr style="height:8.25pt;">
<td valign="top"  style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2 </p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519292680/d829788dex32.htm"><font style="text-decoration:underline;">Second Amended and Restated Bylaws of the Company (filed with the SEC as Exhibit 3.2 to the Company&#8217;s Form 8-K filed on November 15, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519275407/d743471dex41.htm"><font style="text-decoration:underline;">Specimen common stock certificate of the Company (filed with the SEC as Exhibit 4.1 to the Company&#8217;s Form S-1/A filed on October 28, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519266760/d743471dex42.htm"><font style="text-decoration:underline;">Investors&#8217; Rights Agreement, dated as of September 17, 2019, by and among the Company and certain of its shareholders (filed with the SEC as Exhibit 4.2 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3<font style="Background-color:#FFFFFF;">*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex43_8.htm"><font style="text-decoration:underline;">Description of Securities</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.4</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520104858/d912211dex41.htm"><font style="text-decoration:underline;">Form of Warrant to Purchase Common Stock for Silicon Valley Bank (filed with SEC as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex101.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement for directors and executive officers (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001785173/000119312519275407/d743471dex102.htm"><font style="text-decoration:underline;">Amended and Restated 2019 Equity Incentive Plan and form of agreements thereunder (filed with the SEC as Exhibit 10.2 to the Company&#8217;s Form S-1/A filed on October 28, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519275407/d743471dex103.htm"><font style="text-decoration:underline;">2019 Employee Stock Purchase Plan (filed with the SEC as Exhibit 10.3 to the Company&#8217;s Form S-1/A filed on October 28, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520132419/d898684dex101.htm"><font style="text-decoration:underline;">Executive Employment Offer Letter, dated April 15, 2020, by and between the Company and Rohan Palekar (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 4, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520245305/d23969dex105.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Amended and Restated Executive Employment Agreement, dated July&#160;28, 2020, by and between 89Bio Ltd. and Ram Waisbourd</font><font style="text-decoration:underline;"> (filed with the SEC as Exhibit 10.5 to the Company&#8217;s S-1 filed on September 14, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="color:#000000;">&#160;</font>10.6+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520132419/d898684dex103.htm"><font style="text-decoration:underline;">Executive Employment Offer Letter, dated April 15, 2020, by and between the Company and Hank Mansbach (filed with the SEC as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on May 4, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520132419/d898684dex104.htm"><font style="text-decoration:underline;">Executive Employment Offer Letter, dated April 15, 2020, by and between the Company and Quoc Le-Nguyen (filed with the SEC as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on May 4, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520132419/d898684dex102.htm"><font style="text-decoration:underline;">Executive Employment Offer Letter, dated April 15, 2020, by and between the Company and Ryan Martins (filed with the SEC as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 4, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex109.htm"><font style="text-decoration:underline;">Director Offer Letter, dated July 1, 2018, by and between 89Bio Ltd. and Michael Hayden (filed with the SEC as Exhibit 10.9 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000156459020053677/etnb-ex101_102.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Policy (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 13, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11</font><font style="color:#000000;">&#8224;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex1011.htm"><font style="text-decoration:underline;">Asset Transfer and License Agreement&#8212;FGF21 by and among 89Bio Ltd., ratiopharm GmbH, Teva Branded Pharmaceutical Products R&amp;D, Inc. and Teva Pharmaceutical Industries Ltd, dated as of April 16, 2018 (filed with the SEC as Exhibit 10.11 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-Right:0pt;padding-Top:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex1012.htm"><font style="text-decoration:underline;">Reagent Supply and Technology Transfer Agreement by and between 89Bio Ltd. and Teva Biotech GmbH, dated as of April 16, 2018, as amended (filed with the SEC as Exhibit 10.12 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex1013.htm"><font style="text-decoration:underline;">Sublicense Agreement by and between 89Bio Ltd. and ratiopharm GmbH, dated as of April 16, 2018 (filed with the SEC as Exhibit 10.13 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="color:#000000;">10.14+</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex1014.htm"><font style="text-decoration:underline;">Master Services Agreement by and between 89Bio Ltd. and Biotechpharma UAB, dated as of May 7, 2018, as amended (filed with the SEC as Exhibit 10.14 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="color:#000000;">10.15</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000156459020011636/etnb-ex1015_527.htm"><font style="text-decoration:underline;">Office Lease by and between 89bio, Inc. and King Family Irrevocable Trust, dated as of December 5, 2019 (filed with the SEC as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K filed on March 18, 2020)</font></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="color:#000000;">10.16</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520104858/d912211dex101.htm"><font style="text-decoration:underline;">Loan and Security Agreement, dated as of April 7, 2020, among Silicon Valley Bank, the Lenders party thereto, 89bio, Inc., 89bio Management, Inc. and 89Bio Ltd. (filed with the SEC as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<font style="color:#000000;">16.1</font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312520117165/d919569dex161.htm"><font style="text-decoration:underline;">Letter from Deloitte &amp; Touche LLP, dated April 21, 2020 (filed with the SEC as Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K filed on April 23, 2020)</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1785173/000119312519266760/d743471dex211.htm"><font style="text-decoration:underline;">List of subsidiaries (filed with the SEC as Exhibit 21.1 to the Company&#8217;s Form S-1 filed on October 11, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;23.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex231_6.htm"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;23.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex232_10.htm"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex311_12.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex312_9.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:16.35pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160; 32.1#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="etnb-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-right:84.62%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of the exhibit have been omitted for confidentiality purposes.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item&#160;16. Form 10-K Summary. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">None.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 24, 2021 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Rohan Palekar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rohan Palekar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 24, 2021 </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ryan Martins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Martins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer<font style="font-style:italic;font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32411537"></a>POWER OF ATTORNEY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Rohan Palekar, Ram Waisbourd and Ryan Martins, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Rohan Palekar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rohan Palekar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">principal executive officer</font>)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ryan Martins</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ryan Martins</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">principal financial and accounting officer</font>)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven Altschuler</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Steven Altschuler, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Derek DiRocco</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derek DiRocco, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Gregory Grunberg</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gregory Grunberg, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Hayden</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael Hayden, M.B., Ch.B., Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Anat Naschitz</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anat Naschitz</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Lota Zoth</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lota Zoth, C.P.A.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>etnb-ex43_8.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex43_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our second amended and restated certificate of incorporation (the &#8220;Amended Certificate&#8221;), our&#160;second amended and restated bylaws (the &#8220;Amended Bylaws&#8221;) and applicable provisions of Delaware corporate law. You should read our Amended Certificate and&#160;Amended Bylaws,&#160;which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 100,000,000 shares of common stock and 10,000,000 shares of preferred stock. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Amended Certificate authorizes the issuance of up to&#160;100,000,000&#160;shares of our common stock. All outstanding shares of our common stock are validly issued, fully paid and nonassessable.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. A majority vote of the shares present in person or represented by proxy and entitled to vote on the subject matter is required for the holders of our common stock to take action on all matters (except for election of directors (as discussed below)), except as otherwise required by law, our Amended Certificate or our Amended Bylaws. Our Amended Certificate does not provide for cumulative voting in the election of directors. The holders of our common stock will receive ratably any dividends declared by our board of directors out of funds legally available therefor. In the event of our liquidation, dissolution or&#160;winding-up,&#160;the holders of our common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our Amended Certificate, our board of directors has the authority, without further action by our stockholders, to issue up to&#160;10,000,000&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock are entitled to rights with respect to the registration of these securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). These rights are provided under the terms of our investors&#8217; rights agreement, effective as of September 17, 2019 (the &#8220;IRA&#8221;). The IRA includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Demand Registration Rights</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of our common stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are entitled to demand registration rights. Under the terms of the IRA, we will be required, upon the written request of at least 50% of the holders of the registrable securities, including either </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Israel Partners II, L.P. or </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OrbiMed</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Private Investments VI, LP, provided that the anticipated aggregate offering price is at least $10&#160;million, to file a registration statement on Form&#160;S-1&#160;and use commercially reasonable efforts to effect the registration of these shares for public resale. The right to have such shares registered on Form&#160;S-1&#160;is further subject to other specified conditions and limitations.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Piggyback Registration Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the IRA, if we register any of our common stock either for our own account or for the account of other security holders, the holders of registrable shares party to the IRA are entitled to include their shares in the registration, subject to certain marketing and other limitations. We may terminate or withdraw any registration initiated before the effective date of such registration in our sole discretion.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Form&#160;S-3&#160;Registration Rights</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the IRA, if we are eligible to file a registration statement on Form&#160;S-3,&#160;upon the written request of at least 10% of the holders of registrable securities to sell registrable securities at an aggregate price of at least $5&#160;million, we will be required to use commercially reasonable efforts to effect a registration of such shares. The right to have such shares registered on Form&#160;S-3&#160;is further subject to other specified conditions and limitations.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Our Amended Certificate, Amended Bylaws and Delaware Law</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Amended Certificate and our Amended Bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue&#160;non-negotiated&#160;takeover attempts.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Issuance of undesignated preferred stock:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Under our Amended Certificate, our board of directors has the authority, without further action by the stockholders, to issue up to&#160;10,000,000&#160;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to make it more difficult to attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Classified board:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Our Amended Certificate establishes a classified board of directors consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision may have the effect of delaying a change in control of our board of directors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Election and removal of directors and board vacancies:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Our Amended Bylaws provide that directors will be elected by a plurality vote. Our Amended Certificate and Amended Bylaws also provide that our board of directors has the right to increase or decrease the size of the board and to fill vacancies on the board. Directors may be removed only for cause by the affirmative vote of the holders of at least 66<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#8260;<sub style="font-size:85%; vertical-align:bottom">3</sub>% of the votes that all our stockholders would be entitled to cast in an annual election of directors. Only our board of directors is authorized to fill vacant directorships. In addition the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of the directors then in office. These provisions prevent stockholders from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">Requirements for advance notification of stockholder nominations and proposals:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Our Amended Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder&#8217;s notice. Business that may be conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to nominate directors at annual meetings of stockholders.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">No written consent of stockholders:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Our Amended Certificate provides that all stockholder actions be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our Amended Bylaws or removal of directors by our stockholders without holding a meeting of stockholders</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">No stockholder ability to call special meetings:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Our Amended Certificate and Amended Bylaws provide that only a majority of the members of our board of directors then in office may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Amendments to certificate of incorporation and bylaws:&#160;</font><font style="font-weight:normal;font-style:normal;color:#000000;">Any amendment to our Amended Certificate will be required to be approved by a majority of our board of directors as well as, if required by law or the Amended Certificate, a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of provisions to board classification, stockholder action, certificate amendments, and liability of directors must be approved by not less than 66<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#8260;<sub style="font-size:85%; vertical-align:bottom">3</sub>% of the outstanding shares entitled to vote on the amendment, voting together as a single class. Any amendment to our Amended Bylaws must be approved by either a majority of our board of directors or not less than 66<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#8260;<sub style="font-size:85%; vertical-align:bottom">3</sub>% of the outstanding shares entitled to vote on the amendment, voting together as a single class.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions are designed to enhance the likelihood of continued stability in the composition of our board of directors and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of us and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Section&#160;203 of the Delaware General Corporation Law</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Choice of Forum</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Amended Certificate requires that the Court of Chancery of the State of Delaware be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders; (3)&#160;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law, our Amended Certificate or Amended Bylaws; or (4)&#160;any action asserting a claim against us or any director or officer or other employee that is governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Our Amended Certificate provides further that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors or officers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Stock Transfer and Trust Company, LLC serves as the transfer agent and registrar for our common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Listing</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;ETNB.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>etnb-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:20pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors<br />89bio, Inc.:</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (Nos. 333-237263 and 333-235577) on Form S-8 of 89bio, Inc. of our report dated March&#160;24, 2021, with respect to the consolidated balance sheet of 89bio, Inc. as of December&#160;31, 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year ended December&#160;31, 2020, and the related notes, which report appears in the December&#160;31, 2020 annual report on Form 10-K of 89bio, Inc.</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66889358"></a>San Francisco, California<br />March 24, 2021</p>
<p style="text-align:left;margin-top:63pt;margin-bottom:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>etnb-ex232_10.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex232_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement Nos. 333-235577 and 333-237263 on Form S-8 of our report dated March 18, 2020, relating to the financial statements of 89bio, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>etnb-ex311_12.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex311_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Rohan Palekar, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of 89bio, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="color:#000000;">Rohan Palekar</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rohan Palekar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>etnb-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Ryan Martins, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of 89bio, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk67433007"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))<a name="_Hlk67433007"></a> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="color:#000000;">Ryan Martins</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Martins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>etnb-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
etnb-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of 89bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 24, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Rohan Palekar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rohan Palekar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk26284955"></a>Date: March 24, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ryan Martins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Martins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: A signed original of this written statement required by &#167;906 has been provided to 89bio, Inc. and will be retained by 89bio, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gqb5bzr5wcdj000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F KX# 2(  A$! Q$!_\0
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M\1.)'@O_ #X+98H)W,>Z9\\F7 Z8Z8J#_A7OBO\ Z \O_?Q/_BJ/^%>^*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ2_^@&M"K?P+Y_H0OC?HOU"BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M56PB>&W=)%PQFE8#/9I&(_0BK5)0GI836MQ**** $HHHH 2D-+2&@ I*6DH
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M_;%M',(!%G>'4N=R,I Q@@'OUP/UJZNGV4:;$M+=5&1M$0 YZ]N^!FGQ6MO
M%$,$4>P%5V(!@'J!CMP*- ,#5=9OQI]Q);VUS8/!\XDN($D67LJ !^"Q(Z],
M<U-J.MR>']+M)]33SF92LTD(P!)L+  >A(VCW(K;DC25=DB*ZY!PPR,@Y'ZU
M5O\ 3K?4?)%R'9(I!($#D*S Y&1WP1F@#FQX[B)N$;3IHY8B457+89PX0KD+
MUR>,9/'0=*?_ ,)D[VJW$&EO(GV5;AQYP!7<[(%'')ROY=L\5TDEC:2&0O:P
M,9<"0M&#OQTSZT+96JQM&MM"$9=I41C!&2<8],DG\31H!7TC4DU?3(KU$V"3
M(*Y)VD$@CD ]1Z"KU,CBCAC6.*-8XUX54& /PI] "4444 )2&EI#0 4E+24
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M 8 H8(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH BN!F!A]/YUY_P#$:PGO?"Q>WC+M;2K,R <E0"#^
M6<UZ(PW+@'%5?L0QR^?PI25U8NG-TYJ:Z'BOA7P#=ZQY5_JS-!9-\RPCAY!_
M0?K7K%O:Q6MND%O"D4* !41< "M06@'1\?1:#:9_Y:?I2A!05D77Q$ZTKR*&
MP^PI=G/)'X"KOV/_ *:?I1]C_P"FGZ59@4]B^]&T>@JY]C_Z:?I1]B_Z:?\
MCM RI25;^Q?]-/\ QVC[%_TT_P#':!%.DJ[]A_Z:?^.TGV'_ *:?^.T!8I&B
MKOV#_II_X[2?8/\ IK_X[0%BE15W[!_TU_\ ':/[/_Z:_P#CO_UZ+@4J2KW]
MG_\ 37_QW_Z]']G_ /37_P =_P#KT 4**O?V=_TU_P#'?_KT?V=_TU_\=_\
MKT7"Q0HJ]_9W_37_ ,=_^O1_9O\ TU_\=_\ KT7"Q0I#6A_9O_37_P =_P#K
MT?V;_P!-O_'?_KT7"QGTE:/]F?\ 3;_QW_Z])_9G_3;_ ,=_^O1<+&?25H_V
M9_TV_P#'?_KT?V7_ --O_'?_ *]%PL9U)6C_ &7_ --O_'?_ *]']E_]-O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 445Y?\ $?\ Y&&W_P"O1?\
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MZ-']F/\ F_ /[57\GX_\ ]\HKP/SYO\ GJ__ 'T://F_YZO_ -]&C^S'_-^
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MYF[_ +&6\_\ 9*[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\O\ B/\ \C#;_P#7HO\ Z&]>H5Y?
M\1_^1AM_^O1?_0WKMP'\8X,Q_@?,X^BBBO=/GPHHHH **** /<-!_P"1>TS_
M *](O_0!6A6?H/\ R+VF?]>D7_H K0KYBI\;/K*?P+T"BBBH+/+_ (C_ /(P
MV_\ UZ+_ .AO5/2+)KSPCJXAM3/<"6+9LCW.!GG&.:N?$?\ Y&&W_P"O1?\
MT-ZY2*YN+<$0SR1@]=CD9_*O?HQ<L/%+R/G:\U'$S;\_R.K@T6":PT>ROHY+
M>XN%ND3<H0K("I3=QDCZ^M7(/!VERM)$TUPTD#)!+Y1SB0KN9L;3QSC'L>:X
MA[JXD96>>5F0Y4LY)!]12I=W,32-'<2H9/OE7(W?7UINC4Z2M_PXE7I7UA?_
M (8Z'4-%TJSTZV4W+1W4P=A/*6\LA7*_=52<D?RJS:>'=(N%TFV>6<W%Z'8S
M1O\ (0I/0%<\XXS_ /6KD6D=U56=F5!A03D#Z4X3S QD2N#']P[C\OT]*ITI
M\MN;4A5J?-?D5M#MY_#MI;:=>PVZR,;AK7:LB_/&6D8$*6 X/X>]7$\*Z39>
M:_V6XN&-O.!&S;CE0/N_*/F.>,9 /2N-M[/5=2A-RDDLBRS+#EI"2[]1^ ZY
M/3-2:E!K6ESP_:KJ<2R%O+*S,3P=OZ_RK!TY-\O/K_P#H56"7-[/3_@F\G@V
MPDTZVE-S/%)*L4A<C*#>P&W[O!'KGKU%5_$.EVNF^&E2"VGB(U!EW7 &]@%(
MR#@?*<9KF7EO?*2WD>X\LG*1L3@G/4#ZT.]]=921KB;8>58LVT@?X5JJ4^9.
M4[HRE6IN+486=CTV#3=-)TV]>WAS!#'"Z>6/G:38%)]>IK"N?"MC+Y\A-P'E
M^T3"= !##L8X5N/ZUS5G9ZK?6=S=0O-]GM5WO(SD ;>0!ZD?I1IMAJNKQSQ6
MCNT0(:4/-M4L>F<G!)/2L8T7"[Y]C:5>-2R]GN=/;Z1HMNT]N+*XN+G^R_M)
MW,",D#A1C[W/!I;;PK9VUOI]VRS?:%GM2ZNP96WN 01C&/H3[UST>D:ZMO->
MIYJ>4'1OWV'*IPP SD@=Z2\T_7=/TZ&XN'F2W^4!1-GR^Z@J#\OJ*?(V[*H+
MG25W3_ ZW^SK![Y%FLQ,"+\K&JJ,%92!CCDXZ>E8-QH>FQZ VL*THB:!4CB9
MQN%QN(8=.@QFL 3W\>V<2W*[<E9 S#&[KS[_ *UH>;JFL6UCI,-JJQ@YC5$V
M^8V.68GJ<9YJE2G!WYM.OXLEUH5%;EUZ>NB.NT:&S;2M%BD%L7FAD8P/;*QN
M,'H'/0UGV7A:PETTWMU!<Q2 /.8]^ %5ON_=....3GVKE9K:]MX[-S(S&0%H
M41R63!QT['-,6XU"2,QI-=,C$Y4,Q!)Y/%"H2U<9[_YL;Q$=%.&W^2.VF\*:
M;>:O?DQ3V\<<B1+%%QU'WP-IX]/<'FJ+^$K)=!NKE)+A[B$3-N8[%(1B!@$<
M@@9ZYKGI#J\,,%X\UT%N@4C?S3EPIQCKG&:8L.H?V9<.))!;0R*LT6\C:6S@
ME?3CK0J=1)>_V_R%*K3;?[OO_F4*V/#_ (@N= O?,CR\#G$L)/##U'H?>L>B
MNN45-<LMCBA.4)*4=SVU6L/$FEPR(YDMS+%,-IP0\;K(H/T91D4_3]&M-,GN
M)X/.:6<*KO-*TA"J6*J"3PH+MCZUQGP\T_4DEDO?,,5@XP48?ZT^H],>OX5Z
M'7SN(IQIU'&+N?38:K*K34I*QP_PV_YF[_L9;S_V2NXKA_AM_P S=_V,MY_[
M)7<5B;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'X NVO@^KHL=NG/EJX)D/IQT%>CHB11K'&H5%&%51@ >E9XK&I+EIO7N:8/
M-OGJK3L9FL:BVB6EFUO8^;%)=V]JVU@BPK)(L>['?&X< ?E5;P]XB?7)[F-[
M,6XCCCGB(EW[XW:15W<#:V8CE><9'-;<L,5P@2:))%#*X5U! 92&4\]P0"#V
M(!J&UT^RL6F:TM((&G??*8HPI=O4XZFO(/:.&^'6H0QZEXJL&2Y,TOB.]=66
MUD:(#Y>L@78IX/!(/3U&?0JX?X;?\S=_V,MY_P"R5W% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 457OKZWTZSDN[N3RX(\;FVDXR0!P.>I%8_
M_";^'?\ H(?^09/_ (FKC2G)7BFS.56G!VE)+YG05SD$M_-XVN+>+4YVL;6
M23P/'%MWOG:JD(&  !)R3U%/_P"$W\._]!#_ ,@R?_$U7;Q1X2?[1NF@;[2,
M3YM'/FC&,-\OS<<<U2H5;WY7]Q+Q%%JW.OO1C#Q#K,>OW]G=:G!;VQBN76Y
MBEBMQ&RA2 IW9 )#!^^,>E=)X2N]0OM$%SJ#2-YDKFW>6-4D>'/R,RJ  2/0
M#M6:=;\#L)P4LC]H $V;$_O0.@;Y.<>]3V?BCPCIT'D6,T%K#G=Y<%HZ+GUP
M%IJA5M;E?W"]O2O?G6_<ZBBN?_X3?P[_ -!#_P @R?\ Q-:&F:WIVL^;]@N/
M.\K&_P"1EQG..H'H:F5*I%7E%KY%QK4Y.T9)OU-"BBBLS0**** "O+_B/_R,
M-O\ ]>B_^AO7J%>7_$?_ )&&W_Z]%_\ 0WKMP'\8X,Q_@?,X^BBBO=/GPHHH
MH **** /<-!_Y%[3/^O2+_T 5H5GZ#_R+VF?]>D7_H K0KYBI\;/K*?P+T"B
MBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***Q]"UJ;5S>+/9_9'@EVK&WF!RN3AB'C3&<<;=P]^* .?^&W_,W?]C+>
M?^R5W%<!\-KN/[?XNL]LWF_\)#>2[O)?R\908\S&W=_LYSCG&*[^@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **JW.I6%G(([J]MH'(W!9954D>N"?:H?[>T?_ *"MC_X$)_C5*$GLB7.*
MT;$UO5!I&E378C,LH^6&(=9)#PJ_G^F:R&U^_?P-9ZX)-/MI9($FN'N%<QH"
M,G:H.2<X &X=>M7[Z\\-:G;_ &>_NM*NH<[MDTD;@'UP3UYZUEOI?@J33X;
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M %%%% !1110 =JYKPC=ZM=+='4WO'*[/^/FU\G8YSO1/D7<@XPWS=>IKI:*
M,&Q\+Q:7+?/I^I7ULM]=R7DR+Y3 ROC<1N0D#@<9[5<_LR[_ .@[J'_?%O\
M_&JTJ* ,W^S+O_H.ZA_WQ;__ !JC^S+O_H.ZA_WQ;_\ QJM*B@#-_LR[_P"@
M[J'_ 'Q;_P#QJC^S+O\ Z#NH?]\6_P#\:K2HH S?[,N_^@[J'_?%O_\ &J/[
M,N_^@[J'_?%O_P#&JTJ* ,W^S+O_ *#NH?\ ?%O_ /&J/[,N_P#H.ZA_WQ;_
M /QJM*B@#-_LR[_Z#NH?]\6__P :H_LR[_Z#NH?]\6__ ,:K2HH S?[,N_\
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MT!E.,,#GI@]:/[-_O_A_P0_M7^Y^/_ /H&BOG^BC^S/[WX?\$7]J_P!S\?\
M@'T!17S_ $4?V9_>_#_@A_:O]S\?^ ?0%%?/]%']F?WOP_X(?VK_ '/Q_P"
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MM%4O[3@_NR?D/\:/[3@_NR?D/\:+,+HNT52_M.#^[)^0_P :/[3@_NR?D/\
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MUJW:ZM8WMU+;6T_F2QC+ *0#@X."1AL'@X)Q6&? >FM%-&]U>/YS*S,S1D\
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G^S(/[TGYC_"C^S(/[TGYC_"BBB["R#^S(/[TGYC_  J[111<9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gqb5bzr5wcdj000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Z VH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_Z=/_(G_P!:C^WLO_Y^?A+_ "#ZG7_E_(W:*PO^$D_Z=/\ R)_]:C_A)/\
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MJE;^7\C<HK#_ .$C3_GV;_OO_P"M1_PD:?\ /LW_ 'W_ /6H_MS ?\_/P?\
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MG*3D[L****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?7UC%9LTY-_++&LN0%W?,1N(W?*?3.*[6DU8$[A1112&%%%% !1110 4444
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M(Q\V. ,>M;WAM=130;==5W_:AN_UC OMR=NXC@MMQFM6BANXK!1112&%%%%
M!1110 4444 %9.N:$-=MI+6?4+R&UD4+)# (\-@YSED+9Z=#VK6HHO8#*N-"
MCO=-6TO+RZN&202Q7#;%DB<?=*[5 R/<'KSFFIX?C-XEW>7MW?3Q(R0M/Y8$
M6X88J$51DCC)!K7HIW8K&/\ \(Y9G0+71O,G^SVQC*-N&\[&##)QCJ.>*L7>
ME1SZI;ZH&?[5:Q21Q)D!#OQG/&>P[UH4478['G5K:W%MX<BMK.WUR#7T.%C#
M7 MT??D\L?),>/KD>]>B+NV+NQNQSCIFEHH;N)*P4444AA1110 4444 %%%%
M !6)+X;%Q UK<ZMJ4]DQ^:VDD3#+G.TOL\PCZMDCJ36W11<#-O\ 1+>]DM9D
MDEM+BTR()K?:&12,%<,"I!P."#TJJWA:RDM9HI9KF6:>>.XFN69?,D9&!4'"
MX & , #CWYK<HIW8K%*73(9M7MM39I!-;Q/$B@C:0Q&<\9S\H[UA>(M",>DZ
MO+8Q3W$U_-%+/&&^950KDQXP=P"Y R>?RKJJ*$V@L<G:"0Z_8'2!JXM0'^VF
M_:XV;<?* )^=V[^[VSFNLHHH;N""BBBD,**** "BBB@ HHHH **** "BBB@
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MW3T]0HHHJ1A1110 4444 %%%% !1110 4444 %%%% !7*>./^9;_ .P[:_\
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M.VO_ +-51W$]CJZ***D9XU\6O^1JM?\ KR3_ -#>N#KO/BU_R-5K_P!>2?\
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M78_#?_D8KC_KT;_T-*YL9_ EZ'5@O]XAZGJ-%%%?,GU@4444 9^O?\B[J?\
MUZ2_^@&O#:]RU[_D7=3_ .O27_T UX;7MY5\$O4\'./CCZ!1117J'CA1110
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MF>7T445[9\^%%%% !1110 4444 %:GAK_D:M'_Z_8?\ T,5EUJ>&O^1JT?\
MZ_8?_0Q4S^%ET_C1]&T445\Z?3E=/^0C-]W_ %4?3KU?K[?_ %ZL573_ )",
MWW?]5'TZ]7Z^W_UZL4 %>&Z]_P C%J?_ %]R_P#H9KW*O#=>_P"1BU/_ *^Y
M?_0S7JY5\<O0\?./@CZF?1117M'@A1110 4444 %%%% !78_#?\ Y&*X_P"O
M1O\ T-*XZNQ^&_\ R,5Q_P!>C?\ H:5S8S^!+T.K!?[Q#U/4:***^9/K HHH
MH S]>_Y%W4_^O27_ - ->&U[EKW_ "+NI_\ 7I+_ .@&O#:]O*O@EZG@YQ\<
M?0****]0\<**** "BBB@ HHHH *]1^&__(NW'_7VW_H"5Y=7J/PW_P"1=N/^
MOMO_ $!*X,Q_@?,]'*_]X^3.QHHHKY\^E"BBB@ HHHH **** "BBB@"E#8W$
M5V9WU6\FC))\ATAV#/;*H&X^OUS7-MJ"-X\BU 6FI?91I[0&0Z=.!O,@./N9
MZ=^E=C133%8YB-I=#\4ZK/<6]U)9Z@(Y8I;>W>;:Z+M96" D'H02,'\*=HR7
M&F:7JFJSV4_G7ER]TEHB[I " $4@=&.!GTSSTKI:*+A8XR]TBXAM[*YU*!K[
M[1=B75(XHC*"NQ@B! "61&*\8.<9(ZUM>%X)K?1%26-XE\V5H8I 0R1%R44@
M\C"XX[=.,5LT4-W06(KJVAO;2:UN$WPSQM'(N2-RL,$9'/0UY]X@\(Z%H%WX
M>NM,L?(F?6;:-F\UVRI).,,Q'4"O1JY3QQ_S+?\ V';7_P!FIQ;N*2T.KHHH
MJ2CQKXM?\C5:_P#7DG_H;UP==Y\6O^1JM?\ KR3_ -#>N#KWL-_"B?.XK^-(
M****V.<**** "BBB@ HHHH ZCX=?\CWIO_;7_P!%/7O->#?#K_D>]-_[:_\
MHIZ]YKR<?_%7I_F>UEW\)^O^04445PGH!1110!\O4445](?*A1110 4444 %
M%%% !1110!ZA\'O^8U_VP_\ :E>HUY=\'O\ F-?]L/\ VI7J->)C/XTOZZ'T
M&"_@1^?YA1117,=05R_Q%_Y$34O^V7_HU*ZBN7^(O_(B:E_VR_\ 1J5K1_BQ
M]495_P"%+T9X-1117OGS04444 %%%% !1110 4444 >\_#K_ )$33?\ MK_Z
M->NHKE_AU_R(FF_]M?\ T:]=17@5OXLO5GTM#^%'T04445D:A7EWQA_Y@O\
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M0C-]W_51].O5^OM_]>K% !7ANO?\C%J?_7W+_P"AFO<J\-U[_D8M3_Z^Y?\
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M *Y3QQ_S+?\ V';7_P!FKJZY3QQ_S+?_ &';7_V:JCN)['5T445(SQKXM?\
M(U6O_7DG_H;UP==Y\6O^1JM?^O)/_0WK@Z][#?PHGSN*_C2"BBBMCG"BBB@
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M.<?''T"BBBO4/'"BBB@ HHHH **** "O4?AO_P B[<?]?;?^@)7EU>H_#?\
MY%VX_P"OMO\ T!*X,Q_@?,]'*_\ >/DSL:***^?/I0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Y3QQ_P RW_V';7_V:NKKE/''_,M_]AVU_P#9JJ.X
MGL=71114C/&OBU_R-5K_ ->2?^AO7!UWGQ:_Y&JU_P"O)/\ T-ZX.O>PW\*)
M\[BOXT@HHHK8YPHHHH **** "BBB@#J/AU_R/>F_]M?_ $4]>\UX-\.O^1[T
MW_MK_P"BGKWFO)Q_\5>G^9[67?PGZ_Y!1117">@%%%% 'R]1117TA\J%%%%
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M73^-'T;1117SI].5T_Y",WW?]5'TZ]7Z^W_UZL573_D(S?=_U4?3KU?K[?\
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M^C4KJ*Y?XB_\B)J7_;+_ -&I6M'^+'U1E7_A2]&>#4445[Y\T%%%% !1110
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ML8+% S&<7C%@H[E3& /?YN/>N>\1P/9'3M6.H2ZELNT^SV<^S8Y<@9C$87+
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M](?*A1110 4444 %%%% !1110!ZA\'O^8U_VP_\ :E>HUY=\'O\ F-?]L/\
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MHHH *]1^&_\ R+MQ_P!?;?\ H"5Y=7J/PW_Y%VX_Z^V_] 2N#,?X'S/1RO\
MWCY,[&BBBOGSZ4**** "BBB@ HHHH **** "BBB@ HHHH **** "N4\<?\RW
M_P!AVU_]FKJZY3QQ_P RW_V';7_V:JCN)['5T445(SQKXM?\C5:_]>2?^AO7
M!UWGQ:_Y&JU_Z\D_]#>N#KWL-_"B?.XK^-(****V.<**** "BBB@ HHHH ZC
MX=?\CWIO_;7_ -%/7O->#?#K_D>]-_[:_P#HIZ]YKR<?_%7I_F>UEW\)^O\
MD%%%%<)Z 4444 ?+U%%%?2'RH4444 %%%% !1110 4444 >H?![_ )C7_;#_
M -J5ZC7EWP>_YC7_ &P_]J5ZC7B8S^-+^NA]!@OX$?G^84445S'4%<O\1?\
MD1-2_P"V7_HU*ZBN7^(O_(B:E_VR_P#1J5K1_BQ]495_X4O1G@U%%%>^?-!1
M110 4444 %%%% !1110![S\.O^1$TW_MK_Z->NHKE_AU_P B)IO_ &U_]&O7
M45X%;^++U9]+0_A1]$%%%%9&H5Y=\8?^8+_VW_\ :=>HUY=\8?\ F"_]M_\
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M $4]>\UX-\.O^1[TW_MK_P"BGKWFO)Q_\5>G^9[67?PGZ_Y!1117">@%%%%
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M .O27_T UX;7N6O?\B[J?_7I+_Z :\-KV\J^"7J>#G'QQ] HHHKU#QPHHHH
M**** "BBB@ KU'X;_P#(NW'_ %]M_P"@)7EU>H_#?_D7;C_K[;_T!*X,Q_@?
M,]'*_P#>/DSL:***^?/I0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
M3QQ_S+?_ &';7_V:NKKE/''_ #+?_8=M?_9JJ.XGL=71114C/&OBU_R-5K_U
MY)_Z&]<'7>?%K_D:K7_KR3_T-ZX.O>PW\*)\[BOXT@HHHK8YPHHHH **** "
MBBB@#J/AU_R/>F_]M?\ T4]>\UX-\.O^1[TW_MK_ .BGKWFO)Q_\5>G^9[67
M?PGZ_P"04445PGH!1110!\O4445](?*A1110 4444 %%%% !1110!ZA\'O\
MF-?]L/\ VI7J->7?![_F-?\ ;#_VI7J->)C/XTOZZ'T&"_@1^?YA1117,=05
MR_Q%_P"1$U+_ +9?^C4KJ*P?&>G7>K>$KZQL8O-N9?+V)N"YQ(I/)('0&M*+
M2J1;[HRK)NE)+LSY\HKJ/^%=>*O^@5_Y,1?_ !5'_"NO%7_0*_\ )B+_ .*K
MW/;4_P"9?>?/^PJ_RO[CEZ*ZC_A77BK_ *!7_DQ%_P#%4?\ "NO%7_0*_P#)
MB+_XJCVU/^9?>'L*O\K^XY>BNH_X5UXJ_P"@5_Y,1?\ Q5'_  KKQ5_T"O\
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M#RC:B]D24X206$X0^^XIC'OG%%@-:BJ%[K-C87"6\TDC7#KO$,$+S/MZ;BJ
MD#/&2,5#+X@L1IUO>VS/=K=2"*". #=(Y_A^8@ C!SN(Q@YIV87-6BLH>(++
M^QI=382I'"S1R1,H\P2 [2F <%MW P><BM*)S)"DAC>,LH)1\;E]CC(S2L ^
MN4\<?\RW_P!AVU_]FKJZY3QQ_P RW_V';7_V:JCN)['5T445(SC?%O@+_A*=
M5BOO[2^R^7 (=GD;\X9CG.X?WOTK _X4]_U'?_)3_P"SKU&BMXXFK%<J>GR.
M>>$HSES26OS/+O\ A3W_ %'?_)3_ .SH_P"%/?\ 4=_\E/\ [.O4:*KZY6_F
M_(GZE0_E_%GEW_"GO^H[_P"2G_V='_"GO^H[_P"2G_V=>HT4?7*W\WY!]2H?
MR_BSR[_A3W_4=_\ )3_[.C_A3W_4=_\ )3_[.O4:*/KE;^;\@^I4/Y?Q9Y=_
MPI[_ *CO_DI_]G1_PI[_ *CO_DI_]G7J-%'URM_-^0?4J'\OXLX/P[\-O[ U
MZVU/^UO/\C=^[^S;=VY2O7<?7TKO***QJ5)5'>3-J=*%)<L%8****@T"BBB@
M#Y>HHHKZ0^5"BBB@ HHHH **** "BBB@#U#X/?\ ,:_[8?\ M2O4:\N^#W_,
M:_[8?^U*]1KQ,9_&E_70^@P7\"/S_,****YCJ"BBB@ HHHH ***KW=_9V"HU
MY=P6PD;:AFD";CZ#/4T 6**,X&35*WUC3+RX-O:ZE9SSC.8HIU9ACKP#F@"[
M159M1L4O5LFO+=;MAE8#*OF$?[N<U)/<P6RJUQ-'$K,$4R,%!8] ,]SZ4 2T
M444 %%%% !1110 5Y=\8?^8+_P!M_P#VG7J->7?&'_F"_P#;?_VG73@_XT?Z
MZ'+C?X$OE^9Y?1117MGSX4444 %%%% !1110 5J>&O\ D:M'_P"OV'_T,5EU
MJ>&O^1JT?_K]A_\ 0Q4S^%ET_C1]&T445\Z?3E=/^0C-]W_51].O5^OM_P#7
MJQ5=/^0C-]W_ %4?3KU?K[?_ %ZL4 %>&Z]_R,6I_P#7W+_Z&:]RKPW7O^1B
MU/\ Z^Y?_0S7JY5\<O0\?./@CZF?1117M'@A1110 4444 %%%% !78_#?_D8
MKC_KT;_T-*XZNQ^&_P#R,5Q_UZ-_Z&E<V,_@2]#JP7^\0]3U&BBBOF3ZP***
M* ,_7O\ D7=3_P"O27_T UX;7N6O?\B[J?\ UZ2_^@&O#:]O*O@EZG@YQ\<?
M0****]0\<**** "BBB@ HHHH *]1^&__ "+MQ_U]M_Z E>75ZC\-_P#D7;C_
M *^V_P#0$K@S'^!\ST<K_P!X^3.QHHHKY\^E"BBB@ HHHH **** "BBB@"A'
MJ=O=7+V:1WBR?,NY[*9$X_VV4+^O/:N?_P")GX*T2S$EQ:7NG6[I#(%@:*4*
MS8# [V!()'&!GUKK7021LA+ ,""5."/H1TK'_P"$=65X/M^I7U_% X=(;@QA
M=PZ$[$4MCW)%4FA,J:(=_C'Q*SG+HUNBY'1/+R!],DUFZ5I4E_<ZNUO.+:2T
MUMY[=S'O0-L 8%<C(.X]".:Z*ZT..?4CJ%M>75C=/&(I7MRA\U1TW!U89'."
M #S3H]#MH=%DTN"2>&.0'S)5?]ZQ8Y9BQS\QYR??C'%%Q6.2L]RWEM)%B^1K
MZ3[*&;R8[FY.YI)CPV$0 A>&YR>>#79:1J0U2P^T&+RI%D>*2/=NVNC%6 /<
M9'!XX["H[S1+:ZM;2")I+3[&RM;/;[08B!MX# C&"1@@]:GT[3XM,LEMH6=P
M&9V>0Y9V8DLQ]R23QQ0VF-*Q-=2316DTEO!Y\R1LT<.\+YC <+D\#)XS7GWB
M#4]=O;OP]'J?AW^SH1K-LRS?;4FW-D_+A1GH2<^U>C5RGCC_ )EO_L.VO_LU
M$=Q2V.KHHHJ2@HHHH *:[K%&TCL%1069CT %9>I^)M&T:Y6WU'4(K>9EWA&S
MG'3/ ]C6)XEU>RU.YLM"6_AAM;R,7-U,\NP&WR,*"<<N>/IFFDV)LUO#_BBR
M\2?:C917*"V90QF0+N##(*\G@CGG'455?Q>Z.R_\(SXA.TXR+1<'_P ?K/\
M"=[I_P#PE?B.&VNK8K)-"($CD7YE6/'R@=0,=O2M+QKJ4MGH7V2T/^GZBXM+
M<9YRW!/'H,\_2JLKV%?0?:>+["\T&+5HX+M8YIO(AA:,>;*^< * <>O?L<UH
MZ9JT&J+.$BF@FMW\N:"=0'C.,C."000<Y!(K+O/#)30]*L]->-)=+FCFA\W.
MV0KG(8CD9R><&L"_,\5YJ\%W<1PM=!;C59;8EEMK=5VK&K$ EWP>PX)XZ463
MV"[1VFEZK!J\$EQ:I)Y"RM&DK !9<<%EYY7.1GCI4UY?6MA"9;J98U )YY)
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M'X;_ /(NW'_7VW_H"5P9C_ ^9Z.5_P"\?)G8T445\^?2A1110 4444 %%%%
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MBB@#U#X/?\QK_MA_[4KU&O+O@]_S&O\ MA_[4KU&O$QG\:7]=#Z#!?P(_/\
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M &?KW_(NZG_UZ2_^@&O#:]VU:"2ZT:^MX5W2RV\B(N<9)4@#FO*O^$(\1?\
M0._\CQ__ !5>OEM6$(2YFD>)FM*I.<7"+>G1'/45T/\ PA'B+_H'?^1X_P#X
MJC_A"/$7_0._\CQ__%5Z7UBC_.OO1Y?U:O\ R/[F<]170_\ "$>(O^@=_P"1
MX_\ XJC_ (0CQ%_T#O\ R/'_ /%4?6*/\Z^]!]6K_P C^YG/45T/_"$>(O\
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MF.]<#H<C!^II=+O+_P (/J&F3:'J5[$]R\]I-9P[U97.=K'/RD'U_P#UP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:0EI+/Y\G#-(>6)V@$%OXL8P#@84 =JV**+L+(****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gqb5bzr5wcdj000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (" J\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P (1XB_Z!W_ )'C_P#BJ/\ A"/$7_0._P#(\?\ \54?_"VM>_Y]--_[]O\
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M_P#Q='_"VM>_Y]--_P"_;_\ Q='ML7V7]?,/88+^:7X?Y$G_  A'B+_H'?\
MD>/_ .*I5\#>(B<&P"^YF3_XJHO^%M:]_P ^FF_]^W_^+J:'XN:LI_?Z?9/_
M +FY?YDT.MB_Y5_7S!4,%_-+^OD:=C\-[Z4@WUU% O\ =0;V_H*[?1_#NFZ(
MG^B0?O2,-,_+G\>WT%<EIOQ9TV<A-1LYK1B?OQGS%'UZ']#7=65_::E;+<V5
MQ'/"W1XVR/I['VKS\35Q,M*FB_ ]+"T<+'6EJ_Q+%%%%<1WA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %87B+_ )=O^!?TK=K"\1?\NW_ OZ5XW$'_ "+JGR_]*1TX3^,OZZ$'
MA_\ X_Y/^N1_F*Z2N;\/_P#'_)_UR/\ ,5T;NL:,[L%51EB3P!6/#7^X+U96
M-_BF-XG\26OAG2S=3CS)G.V&$'!D;^@'<UX7K>O7_B"^:ZOYBQ_@C'"1CT45
M9\6:_)XBUZ>[W-]G4[($/\*#I^)ZGZUAU]SAL.J<;O<^6Q>)=65E\(4445U'
M&%%%% !1110!LZ7I.F7-I]IU+78;!2Y18Q"TTAQCDJO0<]3Z4_6_#G]B:A:1
MS7B2V-VJR17<:$@QGJ=O7(ZXJGHVCW6N:BEG:J-Q&YW;A8T'5F/8"M/Q?JMM
M?7MK8V#;['3H1;0R'K)CJWT/]/>LFY>TLG_P#=*/L[M>GGW+-GX:\.W]Y#:6
MWBIY)YG"(HTR3DG_ (%6!J]C'IFKW5C%<BY6"0Q^:%V[B.O&3W]ZZ'PB@TK3
M=3\32@9M4,%IGO,XQG\ ?UIW@6<1S:[<S1)<;=.DD9)>5<@@X;U![U'/*+D[
MW2]-_N+Y(R45:S?KM]YQ]%>B:;XGN]3\+ZQ>ZE!:WDVFM%):>9"NV(N2O  Z
M#J,U0U/4;CQ#X .HZD4EOK:_$*3B-58H5SM.!TS5*K*]FNMMR71C:Z?2^W_!
M.*HKV&"/7=.U72AI:1VWAQ((FFW;$"@C+E]WS!N?Y>]>8:_?G4]?O;OSFF1Y
M6\MV')0'"_H!13K<[V"K1]FKMZ^A<TOPT+K3#JNI:A%ING;_ "TE="[2-Z*@
MY/U_^O4MYX7A_LJ;4]&U6+4[:WQ]H B:*2//<J>H]_\  U<\6C'ACPKY>?)^
MR-CTWY&[\<T> B5DULN,VHTR7S0>G;']:ASER^TO\OF6H0YU3MTW^5S'NM#\
MCPU8ZU'<^:EQ*\,D>S'E,.@SGG(Y[5:3PK,_@N3Q'Y^%679Y.SJN0N[=GU/3
M%6]"/]I>"M=TH@M);[;Z$=<;>'_3^==);.JZE;>$'.(Y=',++CI.P,F:4ZLH
MZ=G^ X4H2U[K\=CA=/T3[;HFIZI)<>3%9! !LW>8[' 7.1C]:R:ZK4E;2O 6
MG6##9/?7,EU*IZA5^10?Y_A7*UO3DY7?F<]2*C9=;!1115F84444 %:6BZY?
MZ!?+=6$Q1OXT/*N/1AWK-HI-)JS'&3B[H^AO"_B6U\3:8+F$>7,AVS0DY*-_
M4'L:VZ^>/"VO2>'M=@O5+>23LG0'[R'K^74>XKZ%CD26-9(V#(X#*PZ$'H:\
M7%4/92TV9[V$Q'MH:[HS=5U*6TO=-L[9$:>\GVG>"0L:C<[<=\8 ]R*U*YV[
M)/C_ $U6'R"QF*?[VY,_I6=IVD6&IZKXF^W6R7 %UM59/F"9C7E0> WN.>*C
MD7+?R_4T]H^9I=_T.SI'=8T9W8*JC)8G  KE-,>:_P#"FCS3VVJ7LIA^9[2\
M\D^F6/F)N)Q[]ZT],M4)GCETW4HHY$VL+^[^T(X/4 >:_P#(5+@E>[*C4<K6
M6_\ 78?I/B*QUN\O+>R\UA:["963".&S@KW(X/./IFDN-?CCN;F"VL;R^:U'
M[\VZIA#C.WYF7<<<X7/6J.CJ%\;^(54 *(K4  =/E:G>$F BUA7)$BZG/OW'
MGJ"/TQ52C%7:\OQ)C.323??\"Q=Z\B6NF:A:-'+I]U.L<DA!! ?A2/3#8!R*
MVZ\\*E/A-</TS*TD7./^6^5(_2O0ESM&>N*52"CMW:'2FY;]DQ:***R-@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBL3Q-KTV@6EG);V'VV:ZNTM8X?.$>68'')!'48_&A*X&W17
M*?V_XN_Z$G_RJQ?X4?V_XN_Z$G_RJQ?X57*Q7.KHKE/[?\7?]"3_ .56+_"C
M^W_%W_0D_P#E5B_PHY6%SJZ*Y3^W_%W_ $)/_E5B_P */[?\7?\ 0D_^56+_
M  HY6%SJZ*Y3^W_%W_0D_P#E5B_PH_M_Q=_T)/\ Y58O\*.5A<ZB.:*5G6.5
M':-MKA6!VGT/H:?7SQKNMZQ8>-+^^C$NF7S2#S(HY@^W@<$CAA7JG@;Q)KVN
MVP.J:24AVY6]'R+)_P !/7ZCBG*#2N)2N['9T445!05A>(O^7;_@7]*W:PO$
M7_+M_P "_I7C<0?\BZI\O_2D=.$_C+^NA!X?_P"/^3_KD?YBCQ[?MI_@V_=#
MAY5$(_X$<'],T>'_ /C_ )/^N1_F*S/BH'/A!2O072%OIAOZXI<)I/"P3_F9
MGFK:YFNQXK1117WQ\@%%%% !1110 4444 =1HOBBPTO0;C2[C13<BY?,\J79
MB:0=E.%S@>F>YK+U:^TF[2(:;HQT]E)WL;IIMX[=0,5ET5"IQ4N9?FS1U9./
M*_R1L7^N_:M T_2(+;R(+4L\A\S=YTA_B/ QWP.>M,T76?[(CU!?L_F_;+1[
M;._;LW?Q=#GZ5E44^2-K"]I*_-U-6PUG[#H>JZ;Y&_[>(AYF_'E[&STQSGZB
MG0:P%\-OHC0X66[6X-QN^[@8QMQSZ]:R**.2(*I)?D>KZKI*:CJBSIX835;=
MTC']I?VCY?F@*!N(4X'Y=J\Z\06MC9:]=VVFS^?:1OB-]V>W(SWP<C/M6;16
M=*DX=?Z^\TJUE4Z6_KT7XW.ATSQ.EOI(TG5--BU+3U<O&C2&-XV/]UQT'7\Z
MU;/Q5H+65SI#:,^FZ?=A1)-;3&28$'.6+#YE]NW/K7$T54J,&*-><?\ AC=T
MC5X?#/B.2YM?^)A9@/%ALQ^<A&.<@X['IVJ.7Q#/+XL_M_R]LGV@3",-V!X7
M/T&,UC44_9QO=[[$^TE:RVO<VO$_B ^(]46[%L+:-(A%'"'W;0,GK@=R>U8M
M%%5&*BK(F4G)\SW"BBBF2%%%% !1110 5[U\/[]K_P &V1<Y> & GV4X'Z8K
MP6O:/A0''A*;=T-V^WZ;4_KFN/').E?S._+FU5MY'0ZO87$NJ:3J%HF^2UF*
MRKN S$XPQYZX.TX]JOV^GVMK+=2PQ;7NG\R8[B=S8QGD\<#M4LL\4"JTTJ1A
MF"*78#+$X Y[DU)7DN3M8]E15VR"RL[?3[.*TM8_+@B7:BY)P/J>:EDC$L3Q
ML6"L"I*L5//H1R#[BG44KN]QV25C*MO#FG6EZUY"+L7#%2[M>S-OQTW9?# >
MAS3KK0--O+B6>6&0/,H6;RIY(Q*!_?"L W!QSGCBM.HXYXIBXBE1S&VQ]K [
M6]#Z'VI\\KWN3R0M:QDZWIDE]!I^GV\"+9"X1KC& JQI\P4#W(4<5M444G)M
M6&HI-L****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI89KRT%QO_L\W<8ESGR\Y[]LXS^%=KXDUK3=+\:S33^'[B2^AE5XY_M[)N
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M "BBB@ HHHH **** "BBB@ KE/''_,M_]AVU_P#9JZNN4\<?\RW_ -AVU_\
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M_P#DI_\ 9T?\*>_ZCO\ Y*?_ &='URC_ #?F'U*O_+^*/+Z*]0_X4]_U'?\
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M[B\R/=Z@=1^=:L'CKS()-/U#1[$Z3, 'MK-##M.<[@0>OU]!TJI0FH."5_\
MAR8SIN:FW9_\"WW#/#.=1\,:_HV-SB(7D(_VD/S8]R,5T4$R0^*;;PL[8MVT
MK[#( <#S&7>3]<\5Q-AK7]@^(&U#1T)B4LL270R2A&,-M(_0U!)K5W+K_P#;
M3%?M?GB?H=H8'(&/3M1*DY2?9_F$:T8Q2ZK\C;UR-M(\':3I#C;<3RR7DZ]Q
MSL3] :Y.M/7M=N_$6H_;;Q8EDV! D0(50/0$GU-9E;4XM1UW,*LE*7N[!111
M5F84444 %%%% %O2]1GTG4[>_MCB6!PP]_4'V(R/QKZ.L;R/4+"WO(?]7/&L
MBY]",U\S5[E\,[IKGP9 C-DP2O$/IG(_]"K@Q\$XJ9Z675&IN!=N]R^/]-+?
M<:QF5/\ >W(3^F*K:';02:OXI=X49GN?+9BO)7RQQ].:U]5TR6\O=,O;=HUG
MLY]QWYPT; JZ\=\<CW%7X[:")Y6CAC1I6W2%4 +G&,GU.*X.=*-EV_4]+V;<
MKOO?\+'*:-9MJ'@_1=VE:=J)2#'^G/C8.@V_NW]/;H*V=(T[[%+(W]C:78;E
MQNLGR6]C^[3C\ZTX8(K:%88(DBB085$4*JCV ITD:31/%*BO&X*LC#(8'J"/
M2IE4O<<:?+;NCG=)_P"1X\1?]<[7_P!!:CQC_J-(_P"PK;_^A5IPZ!HUO,DT
M&D6$4J'*NELBLI]00.*=<Z)I-Y.T]UI=E/,WWI);=&8]N215<\>=2)]G+D<?
MZ[F9XYQ_PAU^.-Q"!<COO7'ZUT*YVC/7%9&HZ*+F/3K2V2""PM[A9I8D7:"%
MR54 #&-V"?I6Q4-KE27F7%/G;?D%%%%0:!1110 4444 %%%% !1110 4444
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MV*A'FDH]SGZ*] T>XL?%.HWNC7FBZ9;*(I'BN;.#RGC*]"2#R*R9/^271?\
M85/_ *+K)5=;-:_YFKHZ73TU_ Y6BNDM?!=[=+"IO],@NIE#1VDMR!*P(RO
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MZ_6OL\+BTUR3W/G<7@Y*3G36AY[13I(Y(9&CE1D=3AE88(/N*;7H'F!1110
M4444 %=)X!_Y'?3?]]O_ $!JYNI+>XGM)UGMII(9D^[)&Q5A]"*F<>:+CW+I
MRY9J78Z34/&%YLO+.SL=.T]9F9)9+.#8\BYZ%LFG/_R2Z+_L*G_T77+$EF+,
M223DD]ZD^U7!M1:^?+]G#[Q%O.S=TSCIGWJ/9)6L7[9N_-V/1++P[9Z/K^FV
ML.B:AJ4Q,4QOO-,<2'@Y4!<$#W-$<3WFL>.+"V(-[.I,*#[S@,=P'UXK@TUC
M5([9;:/4KQ+=?NQ+.P4?09Q4'VRZ^U_:_M,WVG=O\[>=^[UW=<UG["3U;_J]
MS7V\%9)?U:QIVVE7VE7EE?:G87%M:+=(K--&4S@Y( /)X!KM/$%WJUKXHEDM
M/"MA>;I%EM[L6<DC2#@AMRMC->=W>H7NH,K7MY<7++PIFE9R/IDU+#K6JV]L
M+:'4[R. # B2=@OY XJI4I2:;(A5C%.*N=GIL6IZWHOB]/)5=1FGB+PH=OS!
MB649/L>,U3M[*YTCX=:P-3@DMS=W$26\4RE6+*<DX//3^5<C%>74$;1PW,T:
M.RLRHY 8@Y!('<'I3KS4;W4&5KV\N+ED&%,TK.0/;)H]D[VZ73^ZW^0_;1M>
MVMFOOO\ YG8>,](U'5]7M+[3;2>\LKBUB$#P1EE4 8VG'3G/6J/CUPNIZ?:/
M()+FTL(H+@@YQ(,DC/XBL&UU?4[*$PVFHW=O$3DI%.R+^0-4R2Q))))Y)-.%
M)Q:N]A3JQDG9:L2BBBMCG"BBB@ HHHH **<B/+(J1HSNQP%49)-=_P"&/AG>
M7LL=UK2M:VO7R,_O']C_ '1^OTZU%2K"FKR9K2I3JNT40?#GPJ^J:DFK74>+
M&U?*!A_K9!TQ[#J?R]:]GJ*VMH+*VCMK:)(H8UVHB#  J6O$KUG5GS,][#T%
M1ARHY[5A]D\6Z)?$8CE$MF[9Z%@&7]5(_&K.F:5/97NL32/&5O;CS8PI.0-@
M'/'7(]ZU)8(IU59HDD"L'4.H.&!R#SW!J2H<W:W]=RU37-?^MK&'I?AVVBT"
MPL-5M+.[EM8]N7C$B@D\[=P^E3R>&M%DM9;8:9;0Q2X\P6Z>26P<C)3!ZC-:
MM%#J2O>XU3A:UCG'\+)_PD%E?1SW/D01.KA[Z=G+$J1@ECQP<C.#QP:=:C[9
MX[O[E?\ 5V5HEJ3CJ['>?R&W\ZZ&HXX(H2YBB1#(V]]J@;F]3ZGWI^T;6O8G
MV23T[W)****S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KE/''_ #+?_8=M?_9JZNN4\<?\
MRW_V';7_ -FJH[B>QU=%%%2,**** "BBB@ HHHH **** "BBB@ JCJ.G?VAY
M?[WR]F?X<YSCW]JO45CB,/3Q%-TJJO%_\/T*A.4)<T=S-T_2OL,[2^=ORNW&
MS'<>_M6E114X;"TL+3]G15E\_P!1SJ2F^:6X4445T$%._P!)T_5$V7UE!< =
M/,0$CZ'J*Q9/A]X6D;<VE*#_ +,TBC\@U=-15QJ3CLVB)4X2UDDSE_\ A77A
M7_H%?^3$O_Q5'_"NO"O_ $"O_)B7_P"*KJ**KVU7^9_>3["E_*ON.7_X5UX5
M_P"@5_Y,2_\ Q5'_  KKPK_T"O\ R8E_^*KJ**/;5?YG]X>PI?RK[CE_^%=>
M%?\ H%?^3$O_ ,51_P *Z\*_] K_ ,F)?_BJZBBCVU7^9_>'L*7\J^XY?_A7
M7A7_ *!7_DQ+_P#%4?\ "NO"O_0*_P#)B7_XJNHHH]M5_F?WA["E_*ON.7_X
M5UX5_P"@5_Y,2_\ Q5'_  KKPK_T"O\ R8E_^*KJ**/;5?YG]X>PI?RK[CE_
M^%=>%?\ H%?^3$O_ ,51_P *Z\*_] K_ ,F)?_BJZBBCVU7^9_>'L*7\J^XY
M?_A77A7_ *!7_DQ+_P#%4?\ "NO"O_0*_P#)B7_XJNHHH]M5_F?WA["E_*ON
M.7_X5UX5_P"@5_Y,2_\ Q5'_  KKPK_T"O\ R8E_^*KJ**/;5?YG]X>PI?RK
M[CE_^%=>%?\ H%?^3$O_ ,51_P *Z\*_] K_ ,F)?_BJZBBCVU7^9_>'L*7\
MJ^XY?_A77A7_ *!7_DQ+_P#%4?\ "NO"O_0*_P#)B7_XJNHHH]M5_F?WA["E
M_*ON.7_X5UX5_P"@5_Y,2_\ Q5.3X?>%HVW+I2D_[4TC#\BU=-12]M4_F?WA
M["E_*ON*5AI&G:6FVQLH+?/4QQ@$_4]35VBBH;;=V:))*R"BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HK*\0?\>$?_74?R-9.C_\A6'_ (%_Z":\/%9S
M[#&QPG)>[6M^_E;]3JAAN>DZE]CJZ***]PY0K \4Z7=ZG_8OV5 _V758+F7+
M 8C7=D\]>O2H]<\9:=HS-"";F[7K%&>%/^T>WZFN(OO'VMW38ADCM4](DR?Q
M)S^F*[*."K5/>2LO,XJ^/H4GRMW?D>M45XC)XCUJ4Y;5;L?[LI7^51_V]K'_
M $%K[_P)?_&NC^RY_P R.7^V*?\ *SW*BO#?[>UC_H+7W_@2_P#C1_;VL?\
M06OO_ E_\:?]E3_F0O[8A_*SW*BO#?[>UC_H+7W_ ($O_C1_;VL?]!:^_P#
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M *ZC^1K)T?\ Y"L/_ O_ $$U\/FG_([I>L/S/4H?[K+YEKQKIYU#PS/L7=)
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MZ'4?$=W<6[;HB0JM_>V@#/Z5CUUTVW!.6YPU5&,VH[7"BBBK("BBB@ HHHH
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M]D@^VB\\O_2!'Y6_)^[G./3K4U%9)M;&S2>X4444AA3702(R-G:PP<'%.HH
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M7-ZL<OF*;V#RFW#IE-J9 SQE:H^!/^12MO\ KK-_Z-:ERI1;ZIC4VYI=&O\
M(T(?$&FSW,,"S2*\^?),L$D:2_[C,H5OP)S4B:GG79=+DBV,(!/$^[/F+G#<
M=L''YUDZJPUO7K'3+;YDT^X6[NY1TC*@[$S_ 'B3R.PI^KDQ^,?#KH#E_M$;
M8_N[ ?Y@57)'\">>6_FCHJ***Q-PHHHH **** "BBB@ HHHH **** "BBB@
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M'_UU'\C63H__ "%8?^!?^@FM;Q!_QX1_]=1_(UDZ/_R%8?\ @7_H)KX?-/\
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M)J7_ ("/_A1_PC6O?] 34O\ P$?_  K6,H15DS*49R;;1ET5J?\ "-:]_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_;_ /Q='_"VM>_Y]--_[]O_ /%T?4JH?7Z)[+17C7_"VM>_Y]--_P"_;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#5V5E_QX6__
M %R7^0KC:[*R_P"/"W_ZY+_(5\/PI_&J>B_,]3'_  H^>O$M\^I>)=1NG.=\
M[!?]T'"_H!654MRK)=S*_P!\.P;ZYJ*OUN*2BDCX.3;DVPHHHIDA1110 444
M4 %;FFZQI,%BMMJ7A^&^*,2DR3M"_)Z,1G=6'12E%25F5&3B[HV]:\1/J\EF
MD=K':6-DNVWMHR2%'!.2>I..M.OO$?VWQ>FO?9=FV:.7R/,S]S'&['?'I6%1
M4JG%="G5F]W_ $C=M/$?V7QBWB#[)NS/)-Y'F8^]GC=CMGTKH_#L,>H^%+N.
M/3EU>:2^\UK W(B,(V_?!!#'.<<?TKS^BIG236FG_ *A6<7KKO\ B==XJT>P
MT_2;6?[ -+U)Y2K60NO.S'C[YZE>>,9K"T36KK0=1%Y:;&;:4>.09613U4CT
MK.HJHPM'EEJ3*I>?-'0ZZW\5Z'97B7MIX2MTNE<,&>[=T4YYVH1@'T]*S_$U
MQI&H7(U/3KFY,]T[/<6UPO,1]F'!'H/:L&BDJ44^9#=:4H\KM]W^1TGB+Q=+
MX@TRQLVM%A,&&ED#[C,X4+NZ#' ]^M$GBZ63P:GA_P"RC<,*;GS.2@;<%QCU
M]^U<W10J4$DK;:@ZTVV[[Z!1116AD%%%% !1110 4444 %>G_"*^??J6GD_)
MA9U'H?NG_P!E_*O,*[_X2*W_  DEXP^Z+,@_7>N/Y&N?%).C(Z<&VJ\;'H'C
M5<:"ER<[;6Z@G;C/RAQG]#3[J"9_'&FW*PR&!;.96E"G:"2N 3TS6S>6L5]9
M36DZ[H9D,;CU!&#2VL M;2&W$CR") @=R"S8&,G'>O'4[1MZ_B>XZ=Y7]/P,
M/3[.Y;6/$/S7%J)IXC%.B#) C7)7<"#TQT-:$.G744RN^M7\RJ<F.1( K>QV
MQ@_D16C12<VRE!(XBTA;2_#FHZ%-I5S+<N\RQ"*V9H[@.3L8N!M'4 [B,;:G
MU*SFM]+\*Z5*WFW27< 8@]?+4EC]!BNPJG+IT,VJV^HR%S+;QM'&N1M7=C)Q
MZ\8J_:W=WZ_,S=&RLO3Y%RBBBL3<**** "BBB@ HHHH **** "BBB@ HHHH
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M&X#/3! ;\169KL@U^[_X1VU^9 R2:A*.D2 A@G^\V.G89-/\6?*NBLG#C5(
MO..N0?TS5J*NEW_I$N<K-IZ*W_!.CHHHK W"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH X:NRLO^/"W_P"N2_R%4?\
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M;6-'MFM[&]9(&.3&R+(N?4!@0/PKT_\ X5+H/_/WJ7_?Q/\ XBC_ (5+H/\
MS]ZE_P!_$_\ B*7UG#VM;3T']4Q-[WU]3R\^)-7;5AJC7KM>*I19&53M4@C
M!& .3V[U-<>+]?N]-.GSZE*]L5",I"[F'H6QN(^IKTK_ (5+H/\ S]ZE_P!_
M$_\ B*/^%2Z#_P _>I?]_$_^(H^M8?M^ OJF)[_B>6Z3XAU70_,_LZ\>!9/O
MKM#*?P8$5%JFLZCK5P)]1NGN) ,+NP H]@.!^%>K_P#"I=!_Y^]2_P"_B?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <W_ ,)!=_\ /.'_ +Y/^-=)7#5W-?+\-8ROB?:^VDY6Y;?B
M=V-IPAR\JMN5;W4K'3E5KZ]MK57.%,\JH&/MDU-!/#=0)/;RQS0N,K)&P96'
ML1UKG_$37*>(/#[6D44LWF3[4EE,:G]V?X@K$?E6?IUX;?0Y&2:X@OKW4I%>
MVMHD,B2Y.Z--YV# 7.YN",G )&/JK:'!?4[2BN,AUK5I=,\OSWAN5U<61DGC
MC9]AQ]X+\F[G^'C@>]2W6K:GID&LVPNC=36\ENEO/-&NY?.(7Y@H .T\C@>]
M'*PN=/\ ;(/MPLM_^D&+S=F#]W.,YZ=:GKCKF6ZT/7KV[FNWOS!I$DT9F15;
MAP<$H ",CT'XU<$^I:=>Z.9M1>]2_<Q2Q-$BA"4+AH]H! &TC#%N#UXHL%SI
M:CFGAMH6EGE2*->KR,% [=37'17VN/I>FZ@-6&^ZO/LQB:V0QA2S*#QAMPQG
M.X#VJ34KR\@TW7[.>X^V?9/)>*6XAC)(?!PRA0IP0<''?VHY0N=C17/W;7K^
M*+:UL]4N @'GW4)2(QI%T"_<W99O]KH&]JSKG7+U-5@FM9KR:S?4%M')BA6V
MZ[2%Y\TL#WZ$@]J7*%SKY)$BC:21U1$!9F8X  ZDFA'26-9(V5T8!E93D$'H
M0:XZPMIX;CQ;,UY/(JRO^ZDCC*/^X0@D;,G'3&<8'(/6K5C<WFI2V>GPWK62
M1:;!<.UO''N=GR  &4JJC:> .XZ8Y=@N=317(6VJZK?C2K7[8());BYMYYXX
ME/F"+(#*&R 3M]QUXK9T"ZN;BWO(KJ;SY+6[D@$I4*748() P,X.. .E)JP7
M-:BBBD,*XJ^^)^BV&H7-E+:Z@TEO*T3E(TP2I(./GZ<5VM?.7B7_ )&K6/\
MK]F_]#-=>$HQJR:D<6-KSI13B>H_\+:T'_GTU+_OVG_Q==Y7R]7U#58NA"E;
MEZBP6(G6YN?I8;)(D4;22.J(@+,S'  '4DU6M-5TZ_21[._M;E8N9&AF5PGU
MP>.E9?BC:[:/;S<VLVH1I,I'#@*Q53[;@M)JR*GBS09(U'GR>?%)@<M#LR0?
M8,$_.N.QVW-DWMHMM'<M=0BWDV[)3(-K;ONX/0YR,>M2--$DJ1-(BR29*(6
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M#*/OC!Z9X)ZUVB6MN@A"01J(5VQ84?(,8POH,>E)JP7):***0PHHHH ****
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gqb5bzr5wcdj000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G!"4# 2(  A$! Q$!_\0
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M+E HSG)!Z,1_=')I6 T:*K+J-B]\UBEY;M>(,M )5,@'J5SGN*HWNKW*:O\
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M 8X 8$9]NE+IWB"YN)M.2]L(K=-1B,EN\-P9>0H;# HN#@]L]*+,+HWZ*P]
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M\-I9AX[A0%)=Y-AY!!& P.%& <\Z=YI,]_=>(8_+=&DCMWMI&! \Q 2I!]F
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M!V]>E:_A>TFLM$6.:)H-TTLD<#8S$C.2J\<# (X[=*V:*3=P2"BBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gqb5bzr5wcdj000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000007.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (3!YX# 2(  A$! Q$!_\0
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M'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\
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MXC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\
M-'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\
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M%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\
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M_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\
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M'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\
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MXC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\
M-'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\
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M%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\
MY1Y+[@_UJXH_Z*3/_P#P\9A_\T>2^X^@O^&M/VJO^CF?V@O_  \WQ&_^:2C_
M (:T_:J_Z.9_:"_\/-\1O_FDKY]HH_U:X=_Z$&2_^&K _P#RCR7W!_K5Q1_T
M4F?_ /AXS#_YH\E]Q]!?\-:?M5?]',_M!?\ AYOB-_\ -)1_PUI^U5_T<S^T
M%_X>;XC?_-)7S[11_JUP[_T(,E_\-6!_^4>2^X/]:N*/^BDS_P#\/&8?_-'D
MON/H+_AK3]JK_HYG]H+_ ,/-\1O_ )I*/^&M/VJO^CF?V@O_  \WQ&_^:2OG
MVBC_ %:X=_Z$&2_^&K __*/)?<'^M7%'_129_P#^'C,/_FCR7W'T%_PUI^U5
M_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\
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M'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\
M6KBC_HI,_P#_  \9A_\ -'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/
MVJO^CF?V@O\ P\WQ&_\ FDKY]HH_U:X=_P"A!DO_ (:L#_\ */)?<'^M7%'_
M $4F?_\ AXS#_P":/)?<?07_  UI^U5_T<S^T%_X>;XC?_-)1_PUI^U5_P!'
M,_M!?^'F^(W_ ,TE?/M%'^K7#O\ T(,E_P##5@?_ )1Y+[@_UJXH_P"BDS__
M ,/&8?\ S1Y+[CZ"_P"&M/VJO^CF?V@O_#S?$;_YI*/^&M/VJO\ HYG]H+_P
M\WQ&_P#FDKY]HH_U:X=_Z$&2_P#AJP/_ ,H\E]P?ZU<4?]%)G_\ X>,P_P#F
MCR7W'T%_PUI^U5_T<S^T%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^
MT4?ZM<._]"#)?_#5@?\ Y1Y+[@_UJXH_Z*3/_P#P\9A_\T>2^X^@O^&M/VJO
M^CF?V@O_  \WQ&_^:2C_ (:T_:J_Z.9_:"_\/-\1O_FDKY]HH_U:X=_Z$&2_
M^&K _P#RCR7W!_K5Q1_T4F?_ /AXS#_YH\E]Q]!?\-:?M5?]',_M!?\ AYOB
M-_\ -)1_PUI^U5_T<S^T%_X>;XC?_-)7S[11_JUP[_T(,E_\-6!_^4>2^X/]
M:N*/^BDS_P#\/&8?_-'DON/H+_AK3]JK_HYG]H+_ ,/-\1O_ )I*/^&M/VJO
M^CF?V@O_  \WQ&_^:2OGVBC_ %:X=_Z$&2_^&K __*/)?<'^M7%'_129_P#^
M'C,/_FCR7W'T%_PUI^U5_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;
MXC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\
M-'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\
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M%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\
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M_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\
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M'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\
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MXC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\
M-'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\
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M%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\
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M_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\
M0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\ -'DON/H+_AK3]JK_ *.9
M_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\ FDKY]HH_U:X=_P"A!DO_
M (:L#_\ */)?<'^M7%'_ $4F?_\ AXS#_P":/)?<?07_  UI^U5_T<S^T%_X
M>;XC?_-)1_PUI^U5_P!',_M!?^'F^(W_ ,TE?/M%'^K7#O\ T(,E_P##5@?_
M )1Y+[@_UJXH_P"BDS__ ,/&8?\ S1Y+[CZ"_P"&M/VJO^CF?V@O_#S?$;_Y
MI*/^&M/VJO\ HYG]H+_P\WQ&_P#FDKY]HH_U:X=_Z$&2_P#AJP/_ ,H\E]P?
MZU<4?]%)G_\ X>,P_P#FCR7W'T%_PUI^U5_T<S^T%_X>;XC?_-)1_P -:?M5
M?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\ Y1Y+[@_UJXH_Z*3/_P#P
M\9A_\T>2^X^@O^&M/VJO^CF?V@O_  \WQ&_^:2C_ (:T_:J_Z.9_:"_\/-\1
MO_FDKY]HH_U:X=_Z$&2_^&K _P#RCR7W!_K5Q1_T4F?_ /AXS#_YH\E]Q]!?
M\-:?M5?]',_M!?\ AYOB-_\ -)1_PUI^U5_T<S^T%_X>;XC?_-)7S[11_JUP
M[_T(,E_\-6!_^4>2^X/]:N*/^BDS_P#\/&8?_-'DON/H+_AK3]JK_HYG]H+_
M ,/-\1O_ )I*/^&M/VJO^CF?V@O_  \WQ&_^:2OGVBC_ %:X=_Z$&2_^&K _
M_*/)?<'^M7%'_129_P#^'C,/_FCR7W'T%_PUI^U5_P!',_M!?^'F^(W_ ,TE
M'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\
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MXC?_ #25\^T4?ZM<._\ 0@R7_P -6!_^4>2^X/\ 6KBC_HI,_P#_  \9A_\
M-'DON/H+_AK3]JK_ *.9_:"_\/-\1O\ YI*/^&M/VJO^CF?V@O\ P\WQ&_\
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M%_X>;XC?_-)1_P -:?M5?]',_M!?^'F^(W_S25\^T4?ZM<._]"#)?_#5@?\
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M_P!',_M!?^'F^(W_ ,TE'_#6G[57_1S/[07_ (>;XC?_ #25\^T4?ZM<._\
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MBC_A.?\ BYVB_P#(@_\ "??$?_A&O]=\0O\ A5/_ "(W_"O?^01_Q.O^?_\
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M/&&DZ1=10^%M<TCQ)K_P/T#PC=>"-2TSX<Z)I4GI?P._:5_8.^!WB'^UX_\
M@H=^UG\7M"?P7?\ @NZ\!?'V\^*GQ8\)WR75UH,UGXFNI]?^!P\8MXLTBUT:
M\TNVU2+Q;#;ZK8^)O$+>*;#Q#?MHU]HWBP^D5QQQ13I5. >#L-C*E#@K@3BK
M&X*>3<2<38BOC.-<FHY[3RSGX?GA5D6&HT/K6 H9GF='$PQN*PU>OA,/B:>%
MQ-"'O5/HQ^'G"LJL/$'CG%9=3QG&7'7#658^6?<*\*86C@>#,UKY+/,*M/B"
MEBYY[BJV)^HXRK@,HJX>6%P>,HPQ]7+ZN(PTJO\ /E\,?A5X^^,B?&!_AMH!
M\2+\!/ &B_%'XL;=3T?26\*^!?$(\>G1]<":YJ&F/KQO!\,?'&-+\,KK.LP'
M1,7.G0G4]'&H>\V_[!'[8ES\.I/BFGP \=P^$X8;ZYDAO8--T_QFMMI^K7&C
M7%P/AE?ZC;?$IH&N;:2[M)E\)&/4-",'B;3VN?#ES;:K+]B?\$.[;PMX+_:0
M_P""A%G\-[!;#P3X3_9W_9)MO 6EW,<@6R\+:%X\_;6B\+6%Q$)$E"VVDVMC
M;RQ^:L@",OF*WS#$_P"".W[9O[5?[17[27PG\5?%WXU^)_%WASXR?L]^(O$?
MC;X<ZA+--X-A\>Z_HO@3Q_HWBKP;I<UW+9>![;PJNC^+?#EEX<\.V5KIM]I?
MC9VO'W^'].27V,S\:/$BOGW'&5Y#D7#674^$. .'N.\3A.),%G,LVP,,SRFE
MC\=E&-IT<URV&(QE&K5Q*NJ66RP2RFKAJM#&5\RI3P'E8#P#\*\/E7!&,SKB
M/B['RXPXWQO!&$S#(,9D4<IQM?ZO1K99FV%Y\HS.IAL%7G"5-4U7S2&+CFV#
MKQQV"H95B:F9^"_\$XOV8;G]JSXU> /$-WX-@^(_[-&BWM]<_%S6]/\ %MGI
M&DOHOB?X5?$.^^'-QINHZ3XCT7Q-K4&H>.+'PG=QS>!9K]XK9K6?66A\/7T[
M7%']NS]DWQK^R[\0M9\27_@#_A!O@=X\^,FL_#WX(WO_  E6D^)O[5=] \8>
M.=#TC[-#XC\0>+['/@KP/XDU3^T/%L%F!_9?V*[O1JU[86EW['^PSK?B?P!_
MP58O_AGX4\8>,-(\ ^(OVPOVW-)\0^$;7Q-K$'A[7]#\*0_M8ZIX*\/ZYHUO
M=0Z;K.A>!)X;*+P3IFIVMU;>&+?3-,CTE+=K*&1?%/\ @H!\1/B!XQ_:7^,W
M@OQ=XZ\8^*O!W@;XW>+]3\$^$_$GB;6]<\,^#M2M#KWARTU#PMH.IWUUI?AZ
M^MO#VNZWH-O=Z3:VEQ#HVL:KI<<BV.H7<$W)P]QQQ[QCXO\ AYF&59E@LLRC
MB[P)R'C^?#6.JYSB\EP^0YIQ#P?6SU3P6&S#"X:OQS1_M#&8'(>(94(X/"Y9
M4^K8S+L3SU7*N*. _#?@KP4\0,OS;*LRS/.N$?'KB;P]H\49?3R+"9YBN(LH
MX?XPH9"WC\3E6)Q=+@*J\OP6.SWAR-;Z]B<QIO$8/,<*XTN1G_!,#0O#_C[_
M (*,_##X9>._#?AGQM\/]6_9P_:2\::EX1\7>&]#\2:)>^)_!WB;X :-X9U:
M>SUFPO4>;2-/\<^*8K>'BU:74UO)X);RPTRXL_M[Q]^W[^RKX'^(_P 4/A__
M ,.SOV?=4_X5M\5?B?\ #+^UO^+<V7]L_P#"M_'WB+P/_;?V#_A0MW_9W]L_
MV!_:G]F_;;[^SOM?V+[??>1]KF^-/^"2G_*5/X/_ /9I'[6__J=?LIU];?'G
M]O3]G!?%_P"T3\.6_P"">/P/F\4:=\2OCY\.+OXDRW'@M=;U;Q3HOCWQGX0U
M#XEW?V;X,VVM+KNOZW97'C*^$?B@:PNJ7\X/B::_!UF3S^/*F9YE](+'9+#)
M,]XWPF'\,<5FF&X-RGBJ?"LY8O"YIP[3I9M3S.MF^382E#"O,*V J8.6-C]9
MK9W3Q<L/5C@JE?#>WP+'*LG^C1P_GSS[AS@''8OQ*CEF*XTS?@VGQ>IX;$8?
MBR<\HJY;1R3/<94JXF&68;'4L<L$_JU#(98*.*HO&4J&(_+W1? 7C'XVWG[0
M_C?X:>"%'AGX)>&)?C/\4;&RN])T[3OAU\.?$D_Q!U72'L?[1?0T\2+:6/PZ
M\8P1:)X.L=2UN"#0H#+H5FNKZ'#?^K:I^PS^UOHGPNN?C)JOP(\<67@2RMA?
M7LLUOI__  E=CIXU==&EU.]^&Z7[?$>STNTF)U+4-3N?"<5AIWAF.?QA?W%O
MX3MY]:C^Y_\ @B9K%UX=\:?M_>(+%()+W0O@;^S7K%G'=([VSW6F:K^UO>VZ
M7"120R/ TL"+*D<T3M&6"2(Q##N_^"2'[2_Q_P#BG^UQ\1?"OQ2^+WCOXCZ-
MXI^!'B[Q]J5CXPUZ\U33++Q7X1^)OPWT_3-1\*>'0\'A;P%!/:_%'Q7#J>D>
M!-"\-Z+?VW_"/:?-I_\ 9OA'PO9:1]'Q)XF<>\.9WXE\,\(9?PBL@\)N&N"\
M="OG\.(,=F,\-G6 J1PV"G4IYU"IF=>I' XVI'&5JV%GAHY="GBY9C6S;ZUE
M_P KPUX1^&_$F4>%N?\ %^9\;KB/Q?S[BW#.CD-7AO!Y9'%Y5]0QF,QD(5,B
ME'*L/0J9A2I_4Z5'&1Q7]J4GA5EU')JM+,_S0\/?L5?M5>+?A'<_'/PQ\#_&
MVO\ PWA\.7'BZRU#2;6SOO$?B7PW#I$6O6^K>!_A[;WK_$3X@6^LZ3/!=^&!
MX(\*^()O%OGPP>&(M7N94A;YT\!Z#K/Q2UKPOX=^&VF7GCS7/&VUO"&E^$H6
MU^\\31'2KG7C<:)%IOVDZC:1Z#97NO3WEKYEK;Z)97FKSS1Z=:7%S'^QO[!G
M[3_[0GQ#_P""DLP\>_&?XE>*O#'Q.G^..DZA\,]2\3S/\*- BBT:W\4>%9/"
M7@ V[Z+X8E\!:9\+=,\(^&;G0$TO4=1TS7_&.O\ CN_\:>.O%WB3Q7JOL/[
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M<:V\4^$+Z[A\8> -9M=-O(Y=0\/>/=!\-:]ID\5[8ZCIMK?Z;J%M:^[>#O\
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MAD'$%>GCI87B>O*.*P&/R]SP6&HP3=:?X34445_91_#@4444 %%%% !1110
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MF$K4OAGP=_P3=_;=\=>%?#WC+1/@!XDL=(\3Z18ZWIMGXQUSP7\._%5M9ZA
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M;<MXF\->/O!WA/3_  ]!\5=#T+Q'XGL/"[Z%^7U?I=^Q]\=?V8[O]D[XH_\
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MU:VO/'&BZ-JFHZ_\/[&."V:SO[_QQI7AZSTK7+C3_#6J3V?B+5--TN[3Q_\
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M_#OP TGQ;I5I\(+;]F.;]EP_#0-=67]E_'W3?#>G?M5^&M5TBV66#1);:X^
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M>,QM?+WBJ&-P&!6*PM.I@\?C,;EN.IT<+4]M1CAL72P^+H_9O_!5C]EOX/\
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MS#!8W,)2S6A2HYIB_;/^"NEE\$/!GCC]FW]G'X1_!;X:>$/B]X\O]$U77O\
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MCH][X3T37?$OB'Q_:>#/E[_@D[>WUA_P4/\ A&;O6+"V\+ZQ\+OCEX=@T24
M:EJWQ'FT?PUXD\*WMFXLR_V/2/ ?A7XN)J$/]IP122ZIITKZ9J,EO#>Z+XU^
MV^NJVG[9O[4FC:]<7]QK6C_&37VN3?V%Q9F+2O$]AI/CSP7;V<TB?9=2L(?
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M709O"W@;PS;^-)_$>N:S81Z-I7C/4?!_[-6E^(O$7B6QO+>[M)-=LH/"^O\
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MYHOA?38]>\$^*]:&J>$&UM]5T+4_!45]\5?B5'H>DW>A_P X=?M/_P $;_\
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M5_!FO7-SX4^&VI:+X7U9-7\1^+M$\<>(]&A^(MUHWA[7K/0K31N-_:T_;/\
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ME..4\(9-EL,5CY34_K&.GA*%+%8E\WM'*F\1&E4G6J5:U.I65*I2]D_X)O\
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MJ/@JV\ ZQ\4[=KGQMJGB5SM23Q]!X7NM/F%[K]O:>&[W7$M"WB>+\6J*G,?
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MG#8FNUQ-1QDGEV6Y?@XXG,<14Q&99/B,KS.E0EBJTH1QO)*HG'E7VO''T?\
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M:\37.H7WB?7;SX1>*/ =[XI\1Q:IJ5OJ/BJYUL/-:WT-[IEA_1Q_P4'^#/\
MP43\??M'V'B+]EG6/BO8?"5/@KX$T:YM_!7QYTOX;:$?B'8^-_BQ>^)9G\+W
MGQ$\+32:J_AS5? Z7FNC26BU"TBTVP34;EM&DMK'AXC\=<?/'>$G^JM3A?*\
MC\3<AKYY7SSC*.)>$X>@LEQ6;4:&:5<%F^78?!5H8C"/(L33K5IN.=8O#X.\
M*L73J>EPQ]'G*XY+XNXKBRCQGG.?>&/%$.'<+P_P1]4IX[B./]JY7EL\9E>'
MQV2YMB<;2K83,UQ!AJE"G&G+(\)6QJ=6C-5J?X<7O[(7[0NF_&[1_P!G&_\
M EK9_&CQ!ILNKZ)X)N/''P]BFU6RAT75/$4IL=;;Q6/#5Q=1Z%HFKZJ^G1ZR
MVHK9:;>3FUV0.1\Z:E8WVCZWXE\.:K9W>FZYX/\ %OB[P+XDTV]MIK:YTSQ3
MX$\3:MX/\4::XE1%N4T_Q#HFI6<&HV;7&EZK!!'J>CWM_I5W9WMQ[=XT\9_&
M;X0_M,>"OB/\</$7BFZ^+G[-WQ=\#>+?$6K>-M5D^(WBK3]'\!:Y;S>./"^E
M^(;S5M8>(>,/AE=^,_A_!K6C:G?6]MH?C349[2'5K"YGTW4/IO\ X*R> W\
M_MZ_$::TTZZCT7XI_#;X4_&./4WU"YFL1XAU.+Q5\*O$7A[3=)F5X-*2R3X.
MZ1XNU"73YH[75=8\>ZA?36$.J'4=1U;ZS"^(G$6!XV\,.'\YQ/".<9%XE\/<
M1ULJSSA6CCIT,=G^58;_ %EP&)RW%5LWQV&GP]B.#Z5>I*3IXBIB<QGA,5@\
MP>#K5,-2^(QGAGPQC_#[Q2XIR+#\99-G_ACQ/P]A<XR#BVOET<3E^09KBH<-
MXK#9E@Z.39;B5Q!0XMKT::]G6HK"X*CC,)C<GC7IPQ\OSLHHHK]P/P ****
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M/5]1T[3_ (::3\-+/X/? #XN>._%?CVWO=,N=1O-7TC2/B)X^DTR>T\3^$=
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M=B\1.CQ#Q%E=2>'BL75;S#/LNP.!PM'#U:-##_BM17V!\6?V/?&'PY_;7?\
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M>(P<,5B,'6P='$4<1\/T5^U?QA_8&_8:_9A^)NN/^TU^UYJ7PW^%FH:(VJ^
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MYM+,,JK9?4J0C5JX?-\LK5*-*.*CR_.%%?L-_P .3/VJO^A__9]_\*KXC?\
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MI9'@L73Q.:Y)7PE&.(R+/J.9TZ$<+*&8RPV&J82M/!XO#XG TZ^%S#\]\/\
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M&_\ !.?_ +.A\0_^LK?M+5^H/[;O_#P[_AL3]H7_ (4__P -G_\ "JO^$C\
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M3G5.K1CS+"5\MSC'X_):^%=6M.%7+)SJ3A4J3P]$HHHK]]/YU"BBB@ HHHH
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M64&G3:Y9Z[\3M0>"R\)P11R:!\CXI^'F>X'A#Q PV>XS)I<<?2&XTX0X-PV
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M?&7X2Z]_PB?Q)L/!7BKX=VGB/^R]&UWRO!WC;6?!FO\ B?1_['\2Z=K.@O\
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MK^IFPL;;3+(ZCK.L7-YJ5\UGIME9Z?;-=7,I@LK2VM8BL$$2+^5XWP3S?/\
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MVF?^S@OC-_ZL;Q)7S[7]/\-?\DYP_P#]B3*O_4"@?R1Q5_R4_$?_ &/LX_\
M5AB HHHKVSP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O[COV2_\ DU7]
MF;_LWWX,_P#JN?#=?PXU_<=^R7_R:K^S-_V;[\&?_5<^&Z_D7Z7/_).\(?\
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M_P#^9^C_ (9>_:8_Z-V^.G_AI/'_ /\ ,_7]EE%'_$VW$7_1(Y+_ .%V._\
MD0_XDNX8_P"BUS[_ ,-^7_\ R1_&G_PR]^TQ_P!&[?'3_P -)X__ /F?H_X9
M>_:8_P"C=OCI_P"&D\?_ /S/U_9911_Q-MQ%_P!$CDO_ (78[_Y$/^)+N&/^
MBUS[_P -^7__ "1_&G_PR]^TQ_T;M\=/_#2>/_\ YGZ/^&7OVF/^C=OCI_X:
M3Q__ /,_7]EE%'_$VW$7_1(Y+_X78[_Y$/\ B2[AC_HM<^_\-^7_ /R1_&G_
M ,,O?M,?]&[?'3_PTGC_ /\ F?H_X9>_:8_Z-V^.G_AI/'__ ,S]?V644?\
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MY?\ _)'\:?\ PR]^TQ_T;M\=/_#2>/\ _P"9^C_AE[]IC_HW;XZ?^&D\?_\
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M1_Q-MQ%_T2.2_P#A=CO_ )$/^)+N&/\ HM<^_P##?E__ ,D?QI_\,O?M,?\
M1NWQT_\ #2>/_P#YGZ/^&7OVF/\ HW;XZ?\ AI/'_P#\S]?V644?\3;<1?\
M1(Y+_P"%V._^1#_B2[AC_HM<^_\ #?E__P D?QI_\,O?M,?]&[?'3_PTGC__
M .9^C_AE[]IC_HW;XZ?^&D\?_P#S/U_9911_Q-MQ%_T2.2_^%V._^1#_ (DN
MX8_Z+7/O_#?E_P#\D?QI_P##+W[3'_1NWQT_\-)X_P#_ )GZ/^&7OVF/^C=O
MCI_X:3Q__P#,_7]EE%'_ !-MQ%_T2.2_^%V._P#D0_XDNX8_Z+7/O_#?E_\
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MW;XZ?^&D\?\ _P S]?V644?\3;<1?]$CDO\ X78[_P"1#_B2[AC_ *+7/O\
MPWY?_P#)'\:?_#+W[3'_ $;M\=/_  TGC_\ ^9^C_AE[]IC_ *-V^.G_ (:3
MQ_\ _,_7]EE%'_$VW$7_ $2.2_\ A=CO_D0_XDNX8_Z+7/O_  WY?_\ )'\:
M?_#+W[3'_1NWQT_\-)X__P#F?H_X9>_:8_Z-V^.G_AI/'_\ \S]?V644?\3;
M<1?]$CDO_A=CO_D0_P")+N&/^BUS[_PWY?\ _)'\:?\ PR]^TQ_T;M\=/_#2
M>/\ _P"9^C_AE[]IC_HW;XZ?^&D\?_\ S/U_9911_P 3;<1?]$CDO_A=CO\
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M&/\ HM<^_P##?E__ ,D?QI_\,O?M,?\ 1NWQT_\ #2>/_P#YGZ/^&7OVF/\
MHW;XZ?\ AI/'_P#\S]?V644?\3;<1?\ 1(Y+_P"%V._^1#_B2[AC_HM<^_\
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M'_\ \S]?V644?\3;<1?]$CDO_A=CO_D0_P")+N&/^BUS[_PWY?\ _)'\:?\
MPR]^TQ_T;M\=/_#2>/\ _P"9^C_AE[]IC_HW;XZ?^&D\?_\ S/U_9911_P 3
M;<1?]$CDO_A=CO\ Y$/^)+N&/^BUS[_PWY?_ /)'\:?_  R]^TQ_T;M\=/\
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M  TGC_\ ^9^C_AE[]IC_ *-V^.G_ (:3Q_\ _,_7]EE%'_$VW$7_ $2.2_\
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MCDO_ (78[_Y$/^)+N&/^BUS[_P -^7__ "1_&G_PR]^TQ_T;M\=/_#2>/_\
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ME_\ \D?QI_\ #+W[3'_1NWQT_P##2>/_ /YGZ/\ AE[]IC_HW;XZ?^&D\?\
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MI/'_ /\ ,_7]EE%'_$VW$7_1(Y+_ .%V._\ D0_XDNX8_P"BUS[_ ,-^7_\
MR1_&G_PR]^TQ_P!&[?'3_P -)X__ /F?H_X9>_:8_P"C=OCI_P"&D\?_ /S/
MU_9911_Q-MQ%_P!$CDO_ (78[_Y$/^)+N&/^BUS[_P -^7__ "1_&G_PR]^T
MQ_T;M\=/_#2>/_\ YGZ/^&7OVF/^C=OCI_X:3Q__ /,_7]EE%'_$VW$7_1(Y
M+_X78[_Y$/\ B2[AC_HM<^_\-^7_ /R1_&G_ ,,O?M,?]&[?'3_PTGC_ /\
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M (:3Q_\ _,_7]EE%'_$VW$7_ $2.2_\ A=CO_D0_XDNX8_Z+7/O_  WY?_\
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MY+_X78[_ .1#_B2[AC_HM<^_\-^7_P#R1_&G_P ,O?M,?]&[?'3_ ,-)X_\
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MT2.2_P#A=CO_ )$/^)+N&/\ HM<^_P##?E__ ,D?QI_\,O?M,?\ 1NWQT_\
M#2>/_P#YGZ/^&7OVF/\ HW;XZ?\ AI/'_P#\S]?V644?\3;<1?\ 1(Y+_P"%
MV._^1#_B2[AC_HM<^_\ #?E__P D?QI_\,O?M,?]&[?'3_PTGC__ .9^C_AE
M[]IC_HW;XZ?^&D\?_P#S/U_9911_Q-MQ%_T2.2_^%V._^1#_ (DNX8_Z+7/O
M_#?E_P#\D?QI_P##+W[3'_1NWQT_\-)X_P#_ )GZ/^&7OVF/^C=OCI_X:3Q_
M_P#,_7]EE%'_ !-MQ%_T2.2_^%V._P#D0_XDNX8_Z+7/O_#?E_\ \D?QI_\
M#+W[3'_1NWQT_P##2>/_ /YGZ/\ AE[]IC_HW;XZ?^&D\?\ _P S]?V644?\
M3;<1?]$CDO\ X78[_P"1#_B2[AC_ *+7/O\ PWY?_P#)'\:?_#+W[3'_ $;M
M\=/_  TGC_\ ^9^C_AE[]IC_ *-V^.G_ (:3Q_\ _,_7]EE%'_$VW$7_ $2.
M2_\ A=CO_D0_XDNX8_Z+7/O_  WY?_\ )'\:?_#+W[3'_1NWQT_\-)X__P#F
M?H_X9>_:8_Z-V^.G_AI/'_\ \S]?V644?\3;<1?]$CDO_A=CO_D0_P")+N&/
M^BUS[_PWY?\ _)'\:?\ PR]^TQ_T;M\=/_#2>/\ _P"9^C_AE[]IC_HW;XZ?
M^&D\?_\ S/U_9911_P 3;<1?]$CDO_A=CO\ Y$/^)+N&/^BUS[_PWY?_ /)'
M\:?_  R]^TQ_T;M\=/\ PTGC_P#^9^C_ (9>_:8_Z-V^.G_AI/'_ /\ ,_7]
MEE%'_$VW$7_1(Y+_ .%V._\ D0_XDNX8_P"BUS[_ ,-^7_\ R1_&G_PR]^TQ
M_P!&[?'3_P -)X__ /F?H_X9>_:8_P"C=OCI_P"&D\?_ /S/U_9911_Q-MQ%
M_P!$CDO_ (78[_Y$/^)+N&/^BUS[_P -^7__ "1_&G_PR]^TQ_T;M\=/_#2>
M/_\ YGZ/^&7OVF/^C=OCI_X:3Q__ /,_7]EE%'_$VW$7_1(Y+_X78[_Y$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Q:9_R
M#=/_ .O&T_\ 2>.O':]BTS_D&Z?_ ->-I_Z3QUG4Z?/]"X;_ "_5'E>I_P#(
M2U#_ *_KO_THDJC5[4_^0EJ'_7]=_P#I1)5&K6R]%^1 4444P"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *]BTS_D&Z?\ ]>-I_P"D\=>.U[%IG_(-T_\
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MI3<:OM$W+GARV?WW17\"L.HMJ,GB;P#X0'C+P!)X2TW3])\)?$CPNFM>%X-
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M#_\ VEZ^"/\ Z\J\$5\QPCP1_K5DG&^<?VG]0_U-R-9S]6^I?6O[2O\ 6/\
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MAZ^7?7/WU/$1J>PG3A4_;CP=\<?@K\1=9'ASX??&#X7>.O$)TB[\0C0?!WQ
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MWP!_:;^"'[4.B^-_$/P+\;?\)SH_PY\?W7PO\97G_"-^+O#/]C>.K/PEX/\
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MEB:E6<Z57%P^J8*I5<*-*C3J>[/]5****_%S]W"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^?/VMOBIXI^!?[*G[37Q
MM\#V6AZEXU^#O[/GQG^*G@_3O$]GJ.H>&]0\4_#WX<>)/%OA^R\0V&D:GHNK
M7NAW6K:1:0:M::7K.DZC<V$EQ#9:G87+Q745TZ<ZM2G2IJ\ZLXTX*Z5YSDHQ
M5W9*[:5WHNI,I1A&4Y.T81<I/72,5=O371*Y^;?[6W_!:OX/? +XOO\ L_?!
MKX9>(OVG_B]I?C;0/ /B2P\*>([/P[X-LO&>M7NL^'[CX9^'?$MAHOCK7_&O
MQAT3QE%X4\*ZMX(T+P2^C6VM^)[SPJ_C5?B5X.\3?#ZS^?M(_P"#@OPIX/\
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M%%% !1110 4444 %%%% !7Y*?M\_\%?O@)^P]XAO?AC!H=_\9?C7IFC6&O\
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M_P"QU^R=\2_B1KG_  D_Q#^(?[-'P(\<^/?$O]G:5I'_  D/C3Q;\+?"NO\
MBG7/[)T&PTK0]+_M;7-0OK_^SM&TO3=*LOM'V;3K"SLXH;>/Z7KYJ$U.$9QO
MRSC&2NK.TDFKKH[,]J4>64HW3Y9.-U>SL[75TG9]+I>@44451(4444 %%%%
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MT7QCX\?XCW6M/;Z?XC;XX/\ #OQU=>.8;W2)])\4?NA\!/\ AZ]_POWX._\
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M'H='N?$U]\''\/6LD?BOQ+H5W?2ZM%X<\02Q/I5M?VUHND3+JD]A+=Z7'?\
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M#ZR6'QATKQ+J'PP\#:4_Q)^&'AKX<^&_#?@J3P]X4\'V&A_#Z#R3X\?L@_\
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M:5X<3QM^U%\:_A_/JFJ:%9_$O_@JA^T9\+M2UW0O[,_M_0])^)W_  4&\:^
M=7UKP\VMZ9K>B)XATG3/$5WJ&@RZWH>N:-%J]M9R:MHFL:>ESIMS^CO_  5'
M_9T^%_[/?Q#_ &;XOA/IE]X9\/\ BGX+^+/ EUX06[M[_0X8O@5KG@E="\8W
M6J:A8W7CKQ3\2/%UE\8+S3/B'XX\=>,_%.K^*[/P;X+N+EHM8M=<U77L#P1_
MP3F_;*T?]J?6_B1J/P<^S^#+S_@IKXS_ &A+?6?^%A?"N;S/A!JW[=^H_&;3
M_%W]G0>.)=53[1\-9XO$G]@26*^)XMW]CS:+'KZMI8_1+_@J+^RW\=OVB_%W
M[.NJ?!OP-_PF-CX$\.?'.P\5S_\ "3>#O#W]E7?C'4_@?<>&XO*\4^(=#FOO
M[1A\'^(G\S38[R.S_L[;?O:M=V*W7ZQEW'F6T?%?P<A_KAE]/A; ^$V6X+.D
M\^PL<BP>;OAKB*EB,)F;>*6 P^9+%8?)J=2ABG#$QQ%++X."J*@C\MSKP]S+
M%^'_ -(FO+@G,,3Q)FOBEF.+X=J/AW%5<ZS'*H\1Y5B<-BLD?U26-Q6 =*OF
M-6&(P'/AZE&IBY<\J;JGVW^PY9VNG_L4_L?6%C!':V5C^RW^S]9V=M"H2&WM
M;;X3>$H;>")!PD<,2)'&HX55 '2OJ2O"_P!E[P=XD^'7[,_[.WP^\9:;_8_B
M_P "_ OX2>#?%6D?;+#4/[+\2>&/ 'A_1-<T[[?I5U?:9??8=3L;JV^V:=>W
MEA<^5YUG=7%N\<K^Z5_%EDM(I)+1)*R26R26B26UC^V,L559;EZK*HJRP6$5
M555)5555"FJBJ*?O*HI7YU+WN:]];A1110=H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?&G_!1J[CL?^">W[=]]+@16?[&G[3]
MU(6;:HCM_@CXXF?+8;:-J'+;6P.<'I7V76'XG\,>&O&_AKQ#X,\9^'=#\7>#
M_%VAZMX8\6>$_$^DV&O^&O$_AK7["XTK7?#WB'0M5M[O2]:T/6M+N[K3=6TG
M4K6YL-2L+FXL[RWFMYI(VVP]7V&(H5^7F]C6I5>7;F]G.,[7Z7M:Y%2"JTZE
M-W2J0E!M;I3BXMKSLS^7#_@VPMIE\=?MW7Y7_1;OPE^R%;PR#/S2VFK?M7RS
MKT_A2]MVZ])!TKZ0_P"#D:TGN?V3?V8)(4W)9?MN^%[NX//R0?\ #,/[5EKN
MZ'_EM=0IS@9<#.< _F/X)_9._;__ ."4W[;EK\1/@I^SU\2/C7X TO4_B#\.
MO"/B/PQX;?XVVWQP_95N==\ :_>>&?B)X@^'G@Y-?^#OQ.N;./X?7,VMZIX-
M^'RR?&SX>>(-1\!:-\7/@AH?BS1?&7K/QZ^!O_!1/_@L'^T[X*U?QM^SWXD_
M96^#_P +-._X1+PE<?%;P9?Z5I_P=T#XC6ECJWQ-\;RWWB_3?AUX\^/WC/QI
MK/PST>PC\.>"+#2?#'ANUTCX6^&-7MOAO'KOCCXQ>,/IJ="EA,XK9M+$4)Y;
M&KB,?0K0K4I5<0ZT:E6&'AAE/VJQ"K5'3E3G&*BH2YIJ:=->+*K4K9;' >RJ
M+&RH1P56DZ=10IJ*C0J5?;->R=+V7[R$U-W;5HRCRRG^S'_!#W4(M2_X)B_L
M\W,+!D3Q'^TA8Y48'F:7^U/\;=,E'WFY66T=6.1E@3M7[H_6*O&OV>?@1X!_
M9C^"'PQ^ 7PPLFM/!/PL\):;X7TNXN;'P_8ZQXAN[=&N-?\ &OBL>%=#\-:#
MJ'COQ]XBN=6\;>/]?T_0=*7Q+XU\0:_XBN+.*[U2<'V6ODDY-)R^)I.5M5S=
M;.ROKY+T/>:2;4=8IVB_[JT7X!1113$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '\JO_!R?=QIXX_82L"5$UWX3_:\N(@6()6SU
M;]E&.3"[3D WL99MPV\##;LK^[W_  3DM9K'_@GK^P?97*[+BS_8S_9?M9T_
MN36_P1\#Q2KV^ZZ,.@Z5\Z_\%=_V&]5_;3_9F#?#'POI&O\ [1WP3UH^/O@K
M'>:AX8\,7OB:WO(X=*^)7PF;QKX@T'49-*TOXA^$O^)EI&AGQ!X$\*Z[\8O!
M'P;U#X@^,M"\(>&]1U&T_&W]BC]HK_@IM^P=\$/B5^S)8?L"?&3XE:9X8\1?
M$2/X)7VH?!GXE6VA_";QSK7B/QEJ7CD:A?\ @+P=<Z=\?OA1J_Q3U*?XA:!/
MX?\ &6@7FLP:SXL'A7XS:Q\/O$WPX7X>^].A+,LORB.&G1]KE\<?A<32J5Z5
M&:6*Q4,51KI590YJ27-3DX.4N?3D>YY<:BP6+S"5:-14\:\)6I5(4JE2#GAZ
M,L/*BW3C)QJ--5(J24)0C)J?,N5_-7[6TK:+_P ' ^NW]T!'#JG[?7_!-ZWM
M&8$^9_:'P^_8GT),#*\F\9XU()&Y>C$%#_;[7\MO_!+S_@DQ\8]0^.^G_MM_
MMLZ5+HVLV'C_ %KX[^%?AQXN\-?#^;Q3\5?C5\3(K_QW>?&OXH^%;'1VT+X7
MGPEXQ\:WWC3PMX$T_P -^"?B+X;^..B:5K:Z7\+-$^&&D:#\1OZDJY,XKTZ^
M,IJC456E@\!@<MC6A_#KO!TI*I7I]7"=6I.,7M*-.,X.4)*<NC 4YT\/.56+
MA4Q&+Q6+=.7Q4H5W!4J<UTJ*%-2GJ[.:BU&49)%%%%>8=@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q$_\&W!;4_VTK?7;<*U
MC+^P/\1E\Q6+*LFH_%G]DVZMU#;5W!H[2X(;"Y\O.T9X_MVK^,O]J#_@GU^V
M!^P=^W+#^T?^Q-\"=8\2?#'0OBNWQ!_9RU'X<> ](^+6E>!;[XF>$?'(^)'P
M0\7_  2^'WAKP[X@\!_"_2=,NOB7\-]$N_#_ (>TKPEX>^"WB_X6^'_"_P <
MM&^.]U;2^'O8P"CB,NS7+HSIPQ&)GEV)P_M:D:4:KP&(G4J48SJ-056I3JOV
M:E**;B_>1Y^*O2QF!QKC.5*@L91K.$93=.&+HJG[:4(IS=.G**=1P4I1CJH2
M5S]N/^"\-I/??\$M?V@X+=-\G_";_LHW&.?]59_MB? &[G;@'A(()'/;"\D#
M)'SU_P &YVH17G[(7Q^MXV#-I7[8?BO3Y@!@K*_[/G[-FI;6^8Y/E:C$<X7@
M@;3C<WP_^V3)_P %)O\ @K/XS^$GPDT_]BSQ[^SU\*/AUJEO\0QHWQ6T76/#
M^@+\1YY[_P"'<_Q5\6?&'X@^ _ UQ/IG@;P-\0]2M="^%WPW\.W_ (QN=,U7
MXE^*Y?#_ ,6-0LO!VF_#?^B?]AW]C_P1^PY^SOX6^!/@[44\3W]IJ&M>+?B'
M\1)O#6@^%]9^)GQ&\57AO=?\5ZS8Z%#N,%E:1Z5X*\$VNNZKXI\1^&_AAX0\
M"^"M5\8^*G\,1ZW>/'6PV68/+)5(3Q"Q]?,\0J4X5(T%/"PPE"A4G!R@ZE2+
MG7:A*3C%4^;E4X.H89NOC,1C%&<:/U2GA*+G&4)59^W5>I5C&24O9P48TO>4
M>:;;CS*,K?75%%%>,>@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!_$3_P<D%M1_;/N="M0KWTG[ _PZ>*/<=SG4?BQ^UC:
M6X*[?E#2VC*K9.XDC:-N6_MVK\+_ /@M-_P3H\<_M=>&?A=\8_V=_ .D>,/V
M@_AMJ(\!>(]"_MOP+X)U/XA? [Q;>&XN;.3Q%XJTW3H?$6M?"?QF;7Q9X-T#
MQ+\1_"'A?1/!OB_X]7.C6GB+Q[XF\.Z#JOYY_ K]M'_@JK\%?V'=._9G\(?L
M/_M!'QGX-\&:=\/_ ($_'B^_9L^*%AK/PK^$VF:9H>D^$M$U7X.7WPG.B^-/
M'OPX\*VVJ>'? ?B#Q =+L56S\!W/Q6^'OQ2UOP[XYN/BC[]?#/,Z&6U\/5PZ
M='!PP.,C6Q%*C]4>'JU/95IJI*,IT:M&I[1RIQDXN,H1C.49\OETZRP=;&TJ
MT*JC5Q'UK#2A2J556]M3IQJTTZ<9*-2%:#48RM>$HMN-X\_R]^PS*VC_ /!>
MR_LKL".;6O\ @H!_P4W2V4@DNEQ:_MGZ["RY*X+6=H9.C J3@$$.O]OM?SN?
M\$=?^"0GB']D_P 16?[17[1&BZ-H/Q.\-^&O$/P[^#7P<B3P7XP@^$^C7TUM
MHNL?$S4?&6GOXEMX?B1XF\.:9=>%O"?_  @'B*U3P[\*_%_C;3O&6K^)-8^)
MFI>$OAG_ $1UPYOB*>)S'%5*,G.@G2HT9M6<X8>A2H<]NBG.G*4=7S0<9:7L
MNC 4ITL+3]K'EK5)5Z]:%[\E3$8BK6<?E&<4U=V=TVVF%%%%><=@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DI_P7-O(K'_@F
M!^T)/,0$/BO]F.VRS;0'O?VL_@991\X;GS+A-JX^8X7*YW#]:Z\:_:&^!'P_
M_:=^"/Q.^ 7Q1L#?>"/BGX3U+POJLT%EH%]J^@75PJW&@^-/"O\ PD^B^(]#
MT[QUX"\16VD^-O .OWVA:I_PC/C70-!\16UI)>:7;X[,OQ$<+C\#BIIN&&QF
M&KS25WRT:T*DK+J[1=EW,,52=?#8BC'1UJ%6DF]DZE.4$W\V?BS_ ,&XUI/;
M?LC_ +1DLJ[4OOVS?%-W;'GYX5_9P_9ALRW0=+BTG3O]SK7RA_P<J6LS_$W]
M@.^"_P"C6G@C]LV">3G"27>M_L@/ O3&66TG.,YPAP" <?.?['7@K_@II_P2
MJ_:,\9RS?L;^/_BUHWCWPII^C?%[PW\+O">N_$/X>?%+1_!>N?$C2OA-X[^'
M_P <? O@WQ5=^#-6T77[GQ7K^D>%?%^CZ?XME^&/CZXMOBO\&/#7B7Q#\-O$
MO@?OKC]A']M__@K9^UWXC^.O[4'@#Q=^RU\([RW'PVEU?5_"EGX+\;^ ?@OX
M'O[CQ%X7^$'PN\-^,=,LO&?C3QMK,GQ+\1ZU)\<?&OA;4?AW#XUUCXA:]!;?
MV5X.\&_LX1>YAZ*RK,,9FM2MAJF&IRS*O@_9UZ526-GC8XCZM0I0A+VD9+ZP
MO:NI"$8*E4<FH)U%Y=:H\9@\/E\(588AT\%AZZJ4IQCAHX548U:E2;7LY1<*
M2E3]G.;J*K3Y4Y2Y3^D;_@GE?QZI^P#^PWJ<)#0ZC^Q[^S-?Q,HPK1WGP6\$
MW"$#<V 5D! W-Q_$>M?858?ACPQX:\$^&O#W@SP9X>T/PCX/\(Z'I/ACPIX4
M\,:38:!X:\,>&M L+?2M"\/>'M"TJWM-+T70]%TNTM=-TG2=-M;:PTZPMK>S
ML[>&WACC7<KY2G'DIPA>_)",;]^5)7^=KGNS:E.4DK*4I-)ZV3;:5_)!1115
MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_$3^V
M<6U7_@OO)9V@5Y],_;X_X)KM<*&)*QVWAO\ 8NUF9F&WY2MG(S[<ME5#;ANP
MO]NU?S&_\%RO^"8?Q!^-WC"Q_:?_ &>/@^_Q*G\0_#[7O"/[4W@KP@?#MOXO
MUO2_ GAV^U+P)\3="\$V>A:9XI^+?BVZ\*PZS\*/%5KI/B?QC\5-5L=#_9[\
M'?#'X;ZKIVC^([W2?,?BM^U?_P %9/VE/V0[+]CG6_V)_C/9?$?XL:9#\&?C
M-^T%JGP3\6>'[/XE_#?Q>-4\)^(=,N/"6O\ P^T+X9_![7OB#X?U/1M#^*7Q
M.N=>C\$:!I5U\1?$7@?PM\&Y-6\(ZQ\)_HL5A/[4GEV+HU\-3H1RO 8'%SK5
MZ5.6$J8",Z52I5ISG&;A.G*-2FX*7-&+;Y6SR:-?ZC'%T*M.M*<\=BL9AU"E
M4FL1'%*DU&G.$914H3@J<XU'!QE.#7,I77R%_P &S\K:9^UAIWAZZ CO_P#A
M@7QG<21$'<O]E?$[]EBTGY)& DNI1JP*$Y(R4QAO[?:_&+_@D7_P3*NOV)_"
M_B/XO?%X:1>?M&_%WPQX>T+4-#M-/\,:C;? SP!I]S/K;_#/0?&=C;7NJ:GX
M@\4:S/I>K_&2\T'Q$?AWK6K^"_AUH7AS3=:@^&MK\2/'?[.UY>:8J&-S3,,9
M335+$XERI)II^RI4Z>'IRLTI+VD*,:MI)2CS\LHQ:<5VX&C+#8+"T)V]K3I/
MVK6J]I4J5*THKI[GM/9MIM-P<HR<6F%%%%<)TA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y*?\ !<V\BL?^"8'[0D\Q 0^*_P!F.VRS
M;0'O?VL_@991\X;GS+A-JX^8X7*YW#]:Z\:_:&^!'P__ &G?@C\3O@%\4; W
MW@CXI^$]2\+ZK-!9:!?:OH%U<*MQH/C3PK_PD^B^(]#T[QUX"\16VD^-O .O
MWVA:I_PC/C70-!\16UI)>:7;X[,OQ$<+C\#BIIN&&QF&KS25WRT:T*DK+J[1
M=EW,,52=?#8BC'1UJ%6DF]DZE.4$W\V?BS_P;C6D]M^R/^T9+*NU+[]LWQ3=
MVQY^>%?V</V8;,MT'2XM)T[_ '.M?*'_  <J6LS_ !-_8#O@O^C6G@C]LV">
M3G"27>M_L@/ O3&66TG.,YPAP" <?.?['7@K_@II_P $JOVC/&<LW[&_C_XM
M:-X]\*:?HWQ>\-_"[PGKOQ#^'GQ2T?P7KGQ(TKX3>._A_P#''P+X-\57?@S5
MM%U^Y\5Z_I'A7Q?H^G^+9?ACX^N+;XK_  8\->)?$/PV\2^!^^N/V$?VW_\
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M4IQY*<(7OR0C&_?E25_G:Y[LVI3E)*RE*32>MDVVE?R044459(4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KV+3/^0;I__7C:?^D\=>.U[%IG
M_(-T_P#Z\;3_ -)XZSJ=/G^A<-_E^J/*]3_Y"6H?]?UW_P"E$E4:O:G_ ,A+
M4/\ K^N__2B2J-6MEZ+\B HHHI@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7'_QNC^S-2_Z!U]_X"7'_P ;KV*BCG?;^OZO_2U.3S?]?T_Z6OCO]F:E_P!
MZ^_\!+C_ .-T?V9J7_0.OO\ P$N/_C=>Q44<[[?U_5_Z6IR>;_K^G_2U\=_L
MS4O^@=??^ EQ_P#&Z/[,U+_H'7W_ ("7'_QNO8J*.=]OZ_J_]+4Y/-_U_3_I
M:^._V9J7_0.OO_ 2X_\ C=']F:E_T#K[_P !+C_XW7L5%'.^W]?U?^EJ<GF_
MZ_I_TM?'?[,U+_H'7W_@)<?_ !NC^S-2_P"@=??^ EQ_\;KV*BCG?;^OZO\
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M *6OCO\ 9FI?] Z^_P# 2X_^-T?V9J7_ $#K[_P$N/\ XW7L5%'.^W]?U?\
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M[,U+_H'7W_@)<?\ QNO8J*.=]OZ_J_\ 2U.3S?\ 7]/^EKX[_9FI?] Z^_\
M 2X_^-T?V9J7_0.OO_ 2X_\ C=>Q44<[[?U_5_Z6IR>;_K^G_2U\=_LS4O\
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M EQ_\;H_LS4O^@=??^ EQ_\ &Z]BHHYWV_K^K_TM3D\W_7]/^EKX[_9FI?\
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M?U_5_P"EJ<GF_P"OZ?\ 2U\=_LS4O^@=??\ @)<?_&Z/[,U+_H'7W_@)<?\
MQNO8J*.=]OZ_J_\ 2U.3S?\ 7]/^EKX[_9FI?] Z^_\  2X_^-T?V9J7_0.O
MO_ 2X_\ C=>Q44<[[?U_5_Z6IR>;_K^G_2U\=_LS4O\ H'7W_@)<?_&Z/[,U
M+_H'7W_@)<?_ !NO8J*.=]OZ_J_]+4Y/-_U_3_I:^._V9J7_ $#K[_P$N/\
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M:E_T#K[_ ,!+C_XW7L5%'.^W]?U?^EJ<GF_Z_I_TM?'?[,U+_H'7W_@)<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !17QA^R+_P4*_8__;N'C(_LI_%W
M_A:@^'^@_#SQ/XN_XH'XH>!_[)T/XK?\)B/ -]_Q<?P5X0^W_P!O?\(!XM_T
M;3/MMYI?]D_\3JWT[[?IGVS[/JIPG3G.G4C*%2G*4)PG%QG"<&XRA.+2<91D
MG&46DTTTU="4E)1E%J49)2C).ZE&23C*+6C4DTTUHTTUH%%%%2,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$NDZEXQ\(2>&++59_'FMZH]M<:=W1XQX$S3/:\N*N(>%LZGEG!6$RS@[-?\
M4/.,/PAD>84<SQ<GE]3A>GA_K681P^!>%JX6KB,NAEE-U*^#>$J4Z$)8KSI<
M#^(N5\.U9\'<-<7Y!BLYXYPV.XTP.)\1<CS'C7B+(8Y9&GB,9@^*:V*J8'*J
M\\5.K1ER9D\TG[*CB8XBDINE3_FX_P""D=I\0-)^('_!0SP_\9M>T_Q=\=-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO7#XBK9J&)S'&XBCI\="<J<*=5=4JCIS:4DI))-I7"BBBO%/1"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^$+_ (-E-B?MZB*!
MO]&'_!/;XJ^4J.7C*)\9OV/%A8'<P?$9PKDL2K$[CN.?[O:_SY/V(OB!??\
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M444 %%%% !117D?Q0_: ^ WP0N/#]I\:?C9\(_A#=>+8=9N/"MM\4/B1X-\
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M58B4L;C\HHU*=.I1E@,+F,L/7CB*_P!85:4J<J7ZY_&G_@ME\*_!GCR7PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5^.>A:+:WVOZK=ZQ>VN@>'-$^)VG^'O"WA^VNKV:#0?"?AG2](\+>%](CL]
M\,Z/I&A:=I^G6WZGT5O1Q6*PW,L/B:]!3MS^QK5*7-;;FY)1YK7=KWMT,JM"
MC6Y?;4:57E;<?:TX5.5O1N/.G9M:.VYY%\$O@'\&/V;_  +9_#;X%?#7PE\,
M/!EH;*>72?"NE0V4NMZI8Z#HOAA?$OBS5W\W6_&GC*\T+P[H>GZSXV\7:EK?
MBW7X]+LY=<UK4;B%9J]=HHK"]VV]6VVWU;;NV^[;;;>[;NS79)+9))+HDE9)
M=DEHET04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7Q_P#M+?L"?L>_M@:EHFN_M#_ CPEX]\4^'AI5OIGCBVN?$'@CXA?V
M-HD?B]=(\(ZC\0OA[K/A3QMK?@'3[OQ[XLUJV^'FM:]J'@:/Q/JO_"6#P]_P
MDUCINK6?V!16E*M5H352C4J4:D;\M2E.5.:NK.THM25UH[/5$SA"K!PJ0C4A
M+24)Q4X26]G&2:>JOJC\]?@]_P $IO\ @GQ\!_'6F_$GX;_LS^$K7QGHALY]
M!U;Q=K_CWXH1>'=4TS7M$\3Z/XE\.:1\4/%GC'1/#WC+0M=\.Z5J'A_QMHNF
MV/BW0)(;F+1M:L;?4M2AO/T*HHHJU:M>;JUJE2M4:2=2K.52;4?A3G-N34;Z
M)NRZ"ITX4HJ%*$*<$VU"G%0BF]VHQ25WU=M0HHHK,L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOB)\-?AS\7O"&I_#[X
ML^ /!7Q0\!:W/I%SK/@CXB>%="\:^$-7N?#^MZ=XET"XU/PUXEL-3T:_GT/Q
M'H^DZ_I$MU92R:;K>EZ=JMDT-]8VT\7YGVW_  0V_P""7-K8P:=%^S-=M;V]
MK'9QR7/QX_:3O+YHHXA"KSZI=_&&?4[FZ* &2^N;N6]EES/+</.QD/ZRT5T4
ML7BJ$90H8G$483=YPI5JE.,W:UY1A)*3LVM4]--C*I0H57&56C2J2C\,JE.$
MW'6_NN2;6NNG4Y#P'\/O 7PL\*Z;X%^&/@?PA\./!&BR:E+H_@[P'X:T;PAX
M5TF76=6OM>UB73?#WA^RT[2+&35M<U34M9U)[6SB:^U;4;[4;HRWEW<32=?1
M17.:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <5\2OAWX.^+_PY\?_  F^(FD-X@^'_P 4/!7BKX=^.=!74M6T9M;\'>-M
M"O\ PUXFTA=7T&^TO7=*;4M%U.]LQJ6BZGIVK6)F^U:=?6EY%#<1_FU_PY$_
MX)?_ /1L?_F:/VA/_GL5^K5%=-'&8O#Q<,/BL30@Y<SC1KU:47*R7,XPE%.5
MDE=J]DET,:F'P]9J5:A1JR2LI5*4)M*][)RBVE=MVVNS\KK'_@B9_P $O;*_
MTZ_?]E+0M7&FZCI^IKI7BCXC?&;QAX8U*33;R"^BL/$GA#Q7\1M9\*^+- NY
M;=(-9\,>)]'U?PYX@TV2YTC7=*U'2KR[LY_U1HHK.M7KXB:J8BM5KU%%04ZU
M2=6:@G*2BI3<GRJ4I-1O9.4FE=LNG2IT8\E*G"E!R<G&G",(\S23ERQ27,U&
M*;M=I)=$%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\D?M0?L*_LK_MF7O@#4?VD_A<WQ'N_A=:^,;+P+)_PG/Q(\'+HE
MMX^E\)3^+$,/@+Q?X6@U1M4E\"^%F6768M1ETX:8R:6]DFH:FM[];T5I2K5J
M%15:%6I1JQ4E&I2G*G4BIQ<)I3@U)*4)2A*SUC)Q=TVB*E.G5@X5:<*D'9N%
M2*G!\K4HWC)-.TDI*ZT:36J1^4O_  Y$_P""7_\ T;'_ .9H_:$_^>Q7T7^S
M3_P3S_8U_9 \6>(_'O[/'P-T+P%XX\5>'8?"&K^,+G7_ !KXV\3+X4CU*+6;
MCPWH^N?$'Q+XKU+PUH6L:O::5JGB32O#=SI-CXIU#P]X4O/$D&JS^$O#,FD_
M9]%:U<;C,1#V=?%XFM"ZER5:]6I#F5[/EG-JZN[.UU=F=/#8>E+GI8>A2G9K
MFITJ<)6>ZYHQ3L^JOJ%%%%<QN%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^='Q9_X)*_\ !.WXV_$#6OBCX^_9A\)-XV\2
MF\N/$NI>"_$?Q!^%EAXEUG5/$OB3QAKGB[Q'X;^%OB_P;X8U[Q]XF\2>+-;U
M3Q9\0]6T:\\<^+))K&#Q)XAU2UT71(-.]D_9M_85_9(_9%FU6_\ V>?@=X2\
M :[K8U*#4?%[RZYXO\>2Z7K \--J?AJ#X@>.]6\3^-;'P;>77@_PYJDO@FQU
MZV\)?V[IJ^(%T5=;N;S4+CZSHKHJ8O%5:4:%7$XBK1AR\E&I6J3I1Y/@Y:<I
M.$>3[-DN7I8RC0H0J2JPHTHU97YJL:<(U)<V_--)2=[*]WKU"BBBN<U"BBB@
M HHHH **** "BBB@ HHHH **** "OY;O 7_!%;]LGP/>> /%>C_%#X"^&?B)
MX M!+X<\7>%O'OQ3L=?\):S?^%K_ ,(Z_=^$?%-K\)-+US2GU/P_K6O>'+N_
ML?[+NM2\.ZQJ>F7L*V6I7ED_]2-%??<%>)/$G 6'SK"9&LLJ87/Y9;+,\/FF
M6T,QHUGE+QLL%:G7]V/LY9AB)25FI2=.7Q4XM?G?'GAAPQXC5,DK<0_VK3Q'
M#T\=4RO$93F>(RRO0EF,<+#%/VN']]N<<'046FI02FD[3E?^=R'_ ((Z_M*_
M&#Q-+K_[3?[55E<W=BG@O1[+Q)HUUXS^-/CG5/!5IXAU?4O%_A>SUSXGQ>$K
M7P+=V>FW]XW@#59]/^)7A[3O%'BG4_$&N> ]0LM'N-!\9?3W[?/_  3/O?C=
M^SC^RA^SM^R98?"KX2^$OV<_VD[#XO2Z'XLU+Q3I6DS^%Q\%_P!HCP-KLEGJ
M6C>&O&^N>)?B%XE\>?&2Q\7^)]?\62?VGXOU"Z\8^+_%'BK4O%E](VM_L+17
M1F/BKQIFO$'#_$>-S"A/%<*XJABN'\#2P6&PV3Y94H5Z6(C&AEN&A1H6J5*-
M+V\ZBG7K4Z5*E4K2IT:,:?)D?@_P+P]D?$>1Y;EV)4.+<!B\MXBS7%YABL=G
MF9X7%X:M@YPJYGBZE:M3C3H5IQH4J"I4*<_WWL77E4J3_$OX-?L ?M;_  -_
M8?\ VC_@/X#^)WP\\-_'3XK_ +17@GXI>!?''A'XD_$SP=HWA_P;8VW[-F@^
M,K34?&>B_#Q/&.E>(+WPU\*_']K;:7HWAS4-+UV'5M%T35-<TJPUO6KO1/&_
MB[_P3N_X*8_&?X5>"?A5\2/V@/@7\3?#?PLGTG6_A_8^-_%7C*;6AXH\->"M
M>\":'J_B;XG'X$:I\1O$>KW/AWQ)K>F:_P"*?%>K>+M=UF36-0U[7/[>UY_M
M3_T,45OE7BQQ/D^+S',<+A.&JF:9CG^<<31S;&\-Y5CLSR[-\]]D\PK95CL5
M0JU\%1FZ%*5/#0G+#P<9/V;]I4Y^3,_!CA/-<KRO)*V.XLPN497D&!X8>69;
MQ3FV78#-,FRYUGA<-G.#PE:EALQE%8BO"5:K256<*LHRE:-/D_G]^)7_  0K
M^'^F?"GPA+\ /$NCV7[26EQ6FG?%+XA>,[9_"GA3X_66H^,]<\2:CJ?C+3?"
M.B^(KGP]XE^'$'B_6](^$FOPV'BKQ-=?#30_"7P6^)_B?QG9:!X&^(OPXX#Q
MC_P2M_X*$?$3X.>#_P!F[Q1^TQ\,X_@;X;TK_A!+3P?#XV^)^HZ#H?@+6?$G
MAW4+Q[KP?'\/- L?BC+\-+;0[+4_@_X.\<Z];:7X3_L/3O O@?Q/\+O#&I7>
MH6/](-%/">+O&>&R:CDM6ME>94\&\TEE>89ODV7YGF^3SSA3^NU<KS'%T:E;
M#595*E2K"I[\HN2I-RP]*C0IYYAX'\!8_-99M2P^<Y14Q& RK*\RP619]FF4
MY=G&79+3H4,OP>;83"8B$<90I87"X?"N$I1YJ5&FV_;+VI^3/_!1G_@FP_[6
MNM:!\9_A+KND^&/V@M"T3PI\-]43QSKWB*T^&WCGX3:9XNUO7%T[4TTK1_%E
MWX3\8> )_''CGQ3X.U_PWX;DC\9S:MJ'P_\ B%#-87W@CQY\(OB7Q-_P2[_X
M**^(?A1X+^#-[^T5\,]4^&/PST#5M \$_#.Y^+GQCTKP.^F7>MZ#XFTC1/%.
MG:=\*IK;Q9I/@_6?"OAZ+X9#QCIOBP?!K1K :'\*;/PMH,EQHUS_ $@4561>
M+W&/#^693E6&EDV.I</U<16X>Q6<9'EV:9AD-3$RC.;RG&XNC.MA.6I%5*;3
MDX6C33]A3I4J>W$O@QP7Q1G&:9YB_P"WLMQV?X.C@.(5D.?YEDV%X@PF'IQH
MTJ.<X7!UH4<;!4(1H2C.*4Z45SJ4TIK\%_&7_!&[6M$_8"_:%_9H^%_Q)\%>
M-OC]^T#\<OV?_B=XC^,/Q#\*1_#31$\$_ O]HSX4?$OPK\++-O"&D_$?QO;>
M$O!7P]\#>*9_#.DZ_KGC:"_^-7Q%^)7C&QG\ ^&_B/<>'?"7T!_P3/\ V#OB
M]^QGXN_:#U_XG^(_AOKUG\6/#GP1TCP['X"U?Q/JES97/PUU/XUWNNOK2>(?
M!_A:*V@NXOB1H:Z2UC-J,D\EKJHO(K!8+-[[]:**^>K\<\18K(<XX=Q>+ABL
M%GN?OB;-*U>DJF.Q.<2C&,\1+%74DJG+S3@H\LIN4M+GT%#P[X5PF=\+Y[@L
M#/!8K@[)<1D&0X?#5YT\#A<LQ-'V%2C/#OF]M-4](UJDW4YKSG*<VY/\,_@A
M_P $R_CQ\-?V_D_:JUWQ;\([OX>K^T/^U!\6CHVDZ]XRG\9_\(Y\:[/XZ6_A
M6R&G7G@*PT3^V]/?XFZ"?$%M_P )%]@M5M-7.G:EJIM[);_K_P#@HI_P3 \9
M_M6?&WPI^T-\(_B#H.C>-#\-_#?P5\>^#OB/>ZEI_@R3P1X(\0_$[QWX-\7>
M#M1\,^%?$6M6?C.U\3?$WQ+H/BK1-8M;O1?%'AW4_#VK:9K'@_4? %[I7Q,_
M9VBO8I^*O&%'BW+^-:.+PM+/,MRVCE-"<<'2>%G@*.#G@50KX67-3J\U"I+F
MF[3550K4W"K3A*/E2\(^"ZG"?$?!5;!XNMD7%&<XK/\ -*-3&UOK']J8O%83
M'2KX;$PY*E!4L5@L-6HTU>$7!PFITYSA+^;CP#_P2;_;K\)?#?\ :B^#>I?M
M):-X@^$?QD_X)Y_M=?LM_#GX7>(OVCOVD_&WPU\"?%[XS:#\,?"WP;U?3?A]
MXR\+:IX2\ ?"_P"'?AGPQXQ\/6T/@'2XYOA[H&O2:'X \"7.F:_KEM#]"?\
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MU:.&PT%3I*I5:3J3Y4N:;2N];!1117G'L!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<==>+/LUS<
M6_\ 9^_R)Y8=_P!JV[_*D9-VW[,VW=MSC<V,XR>M0?\ "9_]0W_R<_\ N6JY
M9=OR)YH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_
M ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FC
MW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\
MR.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN*
M*X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_
M .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_
M .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\
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MW_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\
M)S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[E
MHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27
M;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_
M ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FC
MW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\
MR.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN*
M*X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_
M .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_
M .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\
MY.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_
M -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M
M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF
M?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#
M?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<
M_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[
MEHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=
MOR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\
MPYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##F
MCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_
M ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XH
MKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_
M (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S
M_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;
M_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_
M '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT
M?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9
M_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-
M_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S
M_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N
M6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)
M=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S
M#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]
M_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/
M_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".X
MHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^
M$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/
M_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H
M;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3
MG_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1
M_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G
M_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4
M-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)
MS_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y
M:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDE
MV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_
MS#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW
M_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _
M\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([B
MBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_
M^$S_ .H;_P"3G_W+1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_Z
MAO\ Y.?_ '+1_P )G_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_
M^3G_ -RT?\)G_P!0W_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.
M?_<M'_"9_P#4-_\ )S_[EHY)=OR_S#FCW_/_ ".XHKA_^$S_ .H;_P"3G_W+
M1_PF?_4-_P#)S_[EHY)=OR_S#FCW_/\ R.XHKA_^$S_ZAO\ Y.?_ '+1_P )
MG_U#?_)S_P"Y:.27;\O\PYH]_P _\CN**X?_ (3/_J&_^3G_ -RT?\)G_P!0
MW_R<_P#N6CDEV_+_ ##FCW_/_([BBN'_ .$S_P"H;_Y.?_<M'_"9_P#4-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O8M,_Y!NG_]>-I_Z3QUX[7L6F?\@W3_ /KQM/\ TGCK.IT^?Z%PW^7ZH\KU
M/_D):A_U_7?_ *4251J]J?\ R$M0_P"OZ[_]*)*HU:V7HOR("BBOA^[_ ."D
MG[$-M=S6UK^T#X8\16\<.FW-MKW@G1?&7C[P=K%GJ^D:?KNGW_AKQQX)\-:_
MX.\4Z=-I^J6F_4?#>NZK8V]\+S2;FXAU;3=2LK3U\HR#/<_JU:&0Y+FV=U\/
M35:O1RC+<9F56C1<E!5:M/!T:TZ=-SE&"G-1BY-1O=I'CYSQ#D'#F'IXOB'/
M,GR'"UJOL*.)SG,\%E>'JUW&4_8TZV.KT*<ZO)"4_9QDY\L92M9-GW!17S/\
M&OVQ?V;/V@/%^L> /A-\4=.\3>--#\-P^,+SPU=:)XK\+:M<^%WU,:+=:[HE
MKXOT'0'\2Z=HFK3Z78>*;CPY_:J^$;GQ)X.C\4?V0?&GA/\ MGZ8KCQN!QN6
MXNO@,QP>*P&.PL_9XG!8W#U<+B\/4Y8S]G7P]>%.M1GRRC+EJ0C+EE%VLT=>
M79GEV<8*AF649A@LTR[%*4L-C\NQ5#'8+$1A.5*<J&*PU2K0K*%6$Z<G3J24
M9PE!VE%I%%%%<IVA117Y(?"K_@M!^R9\4KKX'VX\-_&[P);_ !]\3?#;P9X/
MU'QKX0\)RV>F>*OB_<V&C_#?1O$T?@;Q_P"-M0LY?$WBW6O#O@U+[2K'6M)T
M?6?$%EJ/B'4-(\(V>N^)M(]C+^'\ZS; YMF66Y;BL9@,BHT<1F^*H0YJ67T*
M[JJC4Q$KKEC4]A6Y;)Z4IR:2BVO$S7B3(LCQ>3X'-\TPF QG$&.CEN2X?$3<
M:N8XZ3IQCAL-%)\]5RJTHI.RYJD(WO**?ZWT445XY[84444 %%%% !1110 4
M5\5^(?\ @HE^QGX7\6>,/!.J?&_29?$7@+Q-J?@SQ9#H?A?Q[XITW2O%FAF*
M'Q#X>'B'PQX5U?P[?ZMX9U)Y_#WBFSTS5;V;PSXMTS7?!^O+IWBGP]KND:=]
M*_"[XI_#SXU^ O#WQ/\ A3XNT?QSX#\4PWDNB^(]#G::UFFTO4KW1-;TN\@F
M2&^TCQ!X;\0:9JOAKQ5X:UBUL/$'A7Q/I&K^&O$>F:9KNDZCI]MZN89%GF4X
M? 8O-,FS7+<)FM'ZQEF*S#+L9@\/F-#V=&M[? 5\11IT\91]EB*%7VF'E4A[
M.O1GS<M2#EX^ XBR#-<;F&697GF3YEF64U'2S7+\!F>"QF-RRJJDZ+I9AA,/
M7J5\%456G4I.&)ITY*I3G!KFA)+OZ**^/OVT?VK)OV1/A]X(\>Q?#^/XB)XN
M^)MC\/+C2Y/%K^#VTN&]\#^/?%ZZW#>+X7\5#4I8[CP7!I1TI[;3E:'5I=2&
MIA]-33M1,CR3-.(\UP629+A?KN:9C5='!X7VV'P_MJBISJN/ML55H8>G:%.<
MG*K5A'2U[M)WGF=Y9PWE&89[G6*6"RK*\-4QF/Q;HXBO[##TOCJ>QPM*OB*K
M5U:%&C4J2;M&#>A]@T5\Y_LG?'R;]IWX#^$?C7/X0B\"/XJUCXB:8OAB+Q$_
MBM+&'P+\3/&/P^M[HZX^@>&3<2ZS;^%8M;FM1HT"Z5-J,FDI=:HEBNJWOT97
M!B,/6PF(KX7$0=/$8:M5P]>FVFZ=:C.5.K!N+E%N$XRBW%N+M=-K4ZL!CL+F
MF!P698&JL1@<QPF&QV#KJ%2"KX7%T88C#UE"K&%6"J4:D)J-2$*D>:TXQDFD
M4445B=84444 %%%% !1110 445X%\;/VH?@9^SK>>$]/^,?C=O!]UXYMO$EY
MX70>%_&7B%-3M_",OAV'Q [3^%?#VN06#6,GBO00D6IRV<U\+UWT^.[2QU!K
M7NRW+,RSC&4<NRC+\=FN88A570P&6X3$8[&5U0HU,16='"X:G5KU%1P]*K7J
MN$)>SHTJE6=H0E)<.99IEN38*OF><9C@<IRW"J#Q.89EB\/@<%AU5JPH4G7Q
M>*J4J%)5*U2G1@ZE2//5J0IQO.<4_?:*^%_^'E/[%/\ T6C_ ,QS\6?_ )A*
M^GOA#\7_ (=_'CP!I/Q0^%/B!_%'@;7-1\4:5I>MOHVOZ ;J^\&>+-<\#^)(
M1I?B?2]&UF%=/\3^'-9TY+BXTZ*VU!+1=1TR:\TNZL[VX[LWX8XEX?A1J9]P
M[GF24\3*<,/4S?*<?EL,1.FE*I"C+&8>C&K*$91E.,')Q4DVDFCRLEXQX2XD
MK5L-P[Q3PYGV(P])5Z]#)<[RS-*U"BYJFJU:E@<57G2I.<HP52<8P<Y*-[M(
M]*HHHKPSZ,**** "BBB@ HK@_'_Q3^&/PHL=&U/XI?$;P'\-=-\1ZZGA?P]J
M'C_Q?X?\'6.O>)I-(UCQ!'X=T:[\1:AIUOJFNR:!X=\0:VFD6,D^H-I&AZQJ
M2VYLM,O9H.@\,>)_#7C;PUX>\9^#/$.A^+O!_B[0])\3^%/%?AC5K#7_  UX
MG\-:_86^JZ%XA\/:[I5Q=Z7K6AZUI=W:ZEI.K:;=7-AJ-A<V]Y9W$UO-'(UN
MG4C3A5E3FJ524X4ZCA)4ZDJ2@ZD83:Y92IJI3<U%MP52',ES1O"JTY5)T54@
MZU.%.I4I*474ITZTJL:-2<$^:,*LJ%>-.4DHU)4:JBVZ<[;E%%%06%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.^*.E:=X>T#7-&_L;PK\3/ ]YH_A_P"%?P\N;K0/B)H$2:S;6O@K7].^)?\
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M>E:_X<UGP]XU\(ZMXB\#>*?#'B76?R(_X+6?\C-^RK_V OVA?_3A\ Z^T/\
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M2W^),?\ :GQW^&GQ"UGPW)ITBZ?\2_-?^"4_[)7[/G[2O[#/PU^,'QL\ ?\
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M'5EL/ >L^&$70OB%:1_ "[>_^(FDJWC:ZA\TVGB!XO!,W*?\%O/^2V_L4_\
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M=.TZY_!67_@OWJ/BEOB?XD^#'["7Q7^(?PI^$_AS3/&7C;QOJOCM=$U'X?\
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MM\-/B5\-?A#8>(;'Q+XU\+S^%8-1UCQUX0T.&.T\3ZA;:SJ.H>%YO#VH?O\
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MYJ&F>(V^*%OHOQ6U#Q#XC\%:IX0^+.AGP;X!\7?#VYT_XA67A7X=Q2:7X?\
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M*X@>&OPU\%?\'!?ACXE_'CX6?"KP5^RIXLM?"/Q:^,GP1^$^A>+/'GQ6\/\
MA[QIH\?Q;\7>!O ^J:WXD\ >%/"7Q!\-07OA'7_%.KFVT31?BMKMGXETK1-/
MO&\1:#<Z[<:?H/33P>*JX;$XN%&3PV$I5*U>L[1A"G1ASU.5R:]I.$/>=.ES
MU.6SY-48SQ%&G5HT)U(JM7G"G2IZN4I5)<D+I)\L92]U3GRPNFN;1G]%5%%%
M<QL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 45^//[:_\ P6>_9O\ V4=<E^'7@.Q_X:5^+MI)JMOK_A_X>>,O#=GX ^'6
MJ^&?'<'@OQ/X0^*GQ)MSXFF\,?$6R;3_ !RT'P_\/^#O&?B;1]:\&+H_Q/L_
MACIWB[PCXCU;Z"_X)R?MV?\ #P'X1_$7XJ?\*L_X5+_P@/QEU3X1_P!A?\)O
M_P )Y_:W]F_#CX8_$#_A(/[4_P"$0\&?8/._X6/_ &1_97]G7GE_V-]O_M*3
M^T?L5CTUL'BL/AZ&*KT94J&)JJC0G.R=2HZ4ZZM3O[10E2ISG&I*"IS4;1FV
MTGC3Q%&K6J4*=2,ZM&#J58QNU"*J1I.\K<G-&I.,904G.+>L4DVOT$HHHKF-
M@HHHH **** "BBB@ HHHH *]BTS_ )!NG_\ 7C:?^D\=>.U[%IG_ "#=/_Z\
M;3_TGCK.IT^?Z%PW^7ZH\KU/_D):A_U_7?\ Z4251J]J?_(2U#_K^N__ $HD
MJC5K9>B_(@\6_:&^ 7PY_:?^$'BOX)?%:RU2\\%^+)O#.HW#Z'J]YH6M:5XA
M\#^+M!\?^!_$ND:C:-M34_"?CGPMX<\3V%IJ5OJ?A_4[K2(M,\3:)KWAV\U3
M1;_\D=-_X(NZG;^'M:T&_P#VH(+B#QC;> Q\0K/3?@G<:7X>\;:A\--<F\6^
M!;K6M F^,>IIJ%MX(\9W=]XL\!VFMWVMS>#-<O)M4T>_357FU&;]UZ*^VX8\
M1.,.#L)7P/#V;0P>#Q&-I9C4PU?+,HS.E''T(*G2QE&&:X#'+#8F,(QC[;#^
MRG)0I\SE[.'+\-Q9X;<&<<8G!XSB;**F.Q> P^(P>%Q6'S7.<HQ$,)BVGB,-
M.MDV8Y?4KT*K5Y4:\JM/65HKGE?\W?V5O^"9OP:_9O\ '&D_%_7-5OOB[\9/
M#VEZUI/A+Q3X@TC3])\,_#P:[<Z]9:OKWPX\')+J]QX?\:>(O!.J6'@7Q+XQ
MUCQ/XFUK^P;3Q!I?@J;P)X:^(WQ$\->)?+?VF_\ @D=\+OCM\2-;\=>"/%6C
M?"+1_B';^*[WXQ> /^%;6_C7PGX\\;>)K^TN[WQQIVFMXO\ "VG>%=1\5+<^
M*+CXL:;_ &;KFE?$KQ)JMGXXEM_#WC&X^(VM?$[]=**G!^(?&> XAQ_%6&S_
M !?]NYK2JT,RQM>GA<7''X>K"G2EAL7@L70KX#$86-.E1A1PU3"RH8>-&BJ%
M.FJ-/EC$>&/ >*X4P?!%;AO!?ZL9?5IXC Y;2J8O#O"8JE.K4CC</CL/B:69
M4L<YUZ\JF.AC%BZKKU_:UIJM4YOQB^)'_!)[X@_&G1++PA\9/VW?B?\ $7P8
MFKP7UYHWB'PUK>M75I;W-EJ'AWQ!>^$;GQ3\5O$VE>&/&=WX,U[Q1X>T+Q;+
MH&MIH3:[<3WNA^(-*?4= U3&_:/_ .".7_#0/QN_:F^,G_#1?_"(_P##2^I>
M&M0_X1S_ (5%_;W_  A7_"._ 'X:_ WR?[7_ .%GZ+_PD?VS_A7G_"4>9_9>
M@_9_[8_L39/_ &?_ &O>_MM17;4\4>.*F/>9_P!L4:6,>38WA_FPV2Y#A*"R
MG,:OML;AHX+"Y71P4)XBHE*>+CAUC;1A&.(4812\^'@_X>0RK%Y*\CQ%?+\?
MF&79IBZ>+X@XEQN(K8W*)3EEU1X_&9Q7Q\:6%E4J2IX6&)CA7*I4<Z$G.=RO
MQ)_8L_X(Y?\ #('B_P#9G\5_\-%_\+#_ .&==-N]/^P?\*B_X1+_ (3#[5\&
M_&WPE\[[5_PL_P 3?\(_Y?\ PF/_  D'E_9M;W?V=_96]?M?]I6O[;45\YE?
M$N=Y-EV>93EN-^K9?Q'A\/A,YP_U;"5OKF'PM2=6A3]KB*%6OA_9U*DY<V$J
M4)RYK3E**27U>=<*Y#Q#C,AS#.,!]<Q?#.9+-\DK?6L;A_J681BH+$>SPN(H
M4L3:*2]EBX8BAU]E?4_&7QU_P1T\#W'Q/N?&'P1^*<7P(\"077AGQ)X.^&6A
M_#EM7M?AEXYT'6;K6GU+X;Z[9^/O"P\)^$+*^MO#&J^ / ^FZ)&OPNUK3-2B
M\':]:>#)/!/@CX>\K8?\$1OAYKNL:V/BW\<_%WC+P=XNU36?$GCS0O!/AA?A
MCXH\?>)/$OC33O%OC&?Q1\0U\6>+M<&G_$>&7QII?Q'U#P];^'_B;K-UXSG\
M4^&OB?X.\4Z:NJWO[B45]77\7?$7$Y54R:MQ+7G@ZN5PR6K5^HY5'-*N50=U
M@JN>1P$<ZJT9._M5/,)2K*=2-:4U4J*7QK\%/#!YT\^?"F'^OO-XY\Z7]HYR
MLI>;Q5ECY</K,?[ =?J[Y:X2DY3E%RDV_FK]JW]F+P?^U?\ "M_ASXJU+4_#
M^H:1K4/C+P'XKTN2YE?PIXZL-&US0M.UC4-"2^L+#Q9HLFD^(]<T?6_#6K31
MQ7NEZK=7.CZCX<\5V7AWQ7H/Y.ZE_P $+M)N[S7/$&G_ +1&FZ+XZU+P/XC\
M(Z;X^L_@%HMSXGTF6YT76Y/!DDE]J'Q%NGU7PWX7\>7ND>+M4\(7;+9>)-/L
M-6T&UO?#>HZY#XJT;]]Z*Y.'_$_COA;*7D>0\05\!EGUJMC:=!83+L14PV)K
MTE1K5<%B\7@\1C,"ZE/F4HX/$4(7JUY\O/B*\JGH\2^%7A_QAG&'S_B3AS#Y
MGFN&PU+!QQ,L7F6&A7PE&N\13PV/PF#QN'P>9X>-5M^QS'#XJG*-J<HNDE!?
M ?[$W[#9_8[UCXL:N?BC_P +&/Q0TOX;::8/^$)_X1#^Q#\/;KXBW)G\W_A+
M?$_]I?VQ_P )]L\KR]/_ +/_ +)W>9>_;]MG\=_#K_@D+\1_AW\.=0^&^D_M
MJ:_I>@^*['R_B3HO@[X6Z[X.\&?$+5;OPII'@O7-5\0^#K;XY:C9ZD=;\,Z%
MI/AZ[AUZ]U^YE\.:9IF@WFH7VGZ?;1I^X%%7@O%+CG+\SSK.,-G%#^T.(<;@
MLQS:OB,DR#&1Q..RZ&*IX'%4\/C,KKX;!UL-#'8N%.>!HX9\M>:E?2W/B?"#
MP]Q629'P[4R/$0RCANCF&&R;#X;/^),%5PF'S6M3Q&8X>>.P>;T,?BZ.*KT:
M52I2QN*Q-/FI4^6,5"*7Q-^Q;^Q1X5_8]T+QHUMXJO\ Q_\ $+XBW^G_ /"8
M^-);&\\-:3<>'?">H^*)?AYX:T/P2?$'B+3M$B\-:=XLUA]8UIM1U#7O%OB/
M5]8U.^U"R\-0^#?!7@KR+]L7_@G=J_[67Q=TWXG-^T!K'@C2]%^&.B^ =$\
M7GA#4?&GAG1=7L?$WC/Q#K_C;2+.3XB>&]+TO6/&EOX@\+:+XI;3]&M=1UG3
M_ASX2BU;6M1M])T6UT3]-J*\K+N..*LIXCQ/%V!S>K3XCQ;QLJ^;5</@\7B)
M2S&$Z>,G".+PU>C1G5I5)TE.C2ISHTI.E1=.F^4]?&^'O!V8<(TN \3DM/\
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M\,<US"$.T8IT9.G'M&$I2M%>[%R=DKNY1117CG>%%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH _C1_X.1_BEK9_:D^$_@O4=+\/GPO\
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M.L+.SBAMX_I>OCW_ ()Y7\>J?L _L-ZG"0T.H_L>_LS7\3*,*T=Y\%O!-PA
MW-@%9 0-S<?Q'K7V%7RU!MT:+DVY.E3;;W;<%=OS;U?F>Y5TJU%91M4FN5*R
M5I/1)622V225@HHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#X0_;&_X)W_ 7]N7Q9\#O%7QNO\ X@H/@3<>,#H>@>#M=T70
M=&\6Z3X^UCX;:KXL\.^,KBZ\,ZMXE_LG5H_AAHNDM-X.\0^#M<M-.U+69;'6
M;;5SH^JZ/_)7\:?A3\/?@;_P6YT7X1?"GPQ9>#?AWX _;D_X)F>'_"WAVQFO
M;M+&P@\'?L3S2SWFIZI=7^LZYK6JWT]WK'B'Q)K^HZGXB\3Z_?ZGXA\1:KJF
MN:GJ&H7/]X=?P_?M@_\ *P!K'_9__P#P34_]0S]B.O:P%:K4R_/Z<ZDY4Z'"
M^;0HP<FX4HSJTJL^2.T7.I.4I-+FE=)MJ,4O.Q-.$,3ELXPC&=7.< ZLTDI5
M'%.$>:6[48QBHINRU:2;;?\ <#1117BGHA1110 4444 %%%% !1110 4444
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M"7Q$TB#PO?\ M_[:FD^%-&_9^^+/QZN/A-\'_B9\5OV;?A!\4_C%\#[SXN^
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M2=6K2C_1M7XT?LC?\%3/BS^V5!X5E^%7[&J7\AMOV>/$7Q:2/]HCP[!'\*/
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MM<\&ZO*-+U[P[K.@>*?#TT2ZCH?B3PIXLTK0O%?AN_DL;O2_$6CQ:[HNG_\
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MEUJ.K>&_A;]F^-?CGQM:7/B#0-,\':-)\-_!7AWXB_%KQ-J>D?#%<0<%4O\
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M9_:O_"+:O?'PSJNIBTTOQ+_86M_V!J%QY=IK/]C:K_9TMS_9]WY/IU?R5_\
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MA&,=D=-&E"A2IT*:Y:=*/)!;NUW)MO=RE*4I2;W;?30****Q- HHHH ****
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M)X=\0ZSX8^+7QP^'7PU\5R'2_!$OB/X"VFMW%WX@;XLK-XM\6_LE_P %N/\
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ME_$W7]=^(VG:CI36MY8^.]:U;Q?;31>(-2O-0F_.C]J+X5?M9?M%_M+?LO\
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M8?\ R119]G]P<R[K[S<HK#_X2?PW_P!##H?_ (-K#_Y(H_X2?PW_ -##H?\
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M?_@VL/\ Y(HL^S^X.9=U]YN45A_\)/X;_P"AAT/_ ,&UA_\ )%'_  D_AO\
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M3^&_^AAT/_P;6'_R119]G]P<R[K[S<HK#_X2?PW_ -##H?\ X-K#_P"2*/\
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MP_\ DBC_ (2?PW_T,.A_^#:P_P#DBBS[/[@YEW7WFY16'_PD_AO_ *&'0_\
MP;6'_P D4?\ "3^&_P#H8=#_ /!M8?\ R119]G]P<R[K[S<HK#_X2?PW_P!#
M#H?_ (-K#_Y(H_X2?PW_ -##H?\ X-K#_P"2*+/L_N#F7=?>;E%8?_"3^&_^
MAAT/_P &UA_\D4?\)/X;_P"AAT/_ ,&UA_\ )%%GV?W!S+NOO-RBL/\ X2?P
MW_T,.A_^#:P_^2*/^$G\-_\ 0PZ'_P"#:P_^2*+/L_N#F7=?>;E%8?\ PD_A
MO_H8=#_\&UA_\D4?\)/X;_Z&'0__  ;6'_R119]G]P<R[K[S<HK#_P"$G\-_
M]##H?_@VL/\ Y(H_X2?PW_T,.A_^#:P_^2*+/L_N#F7=?>;E%8?_  D_AO\
MZ&'0_P#P;6'_ ,D4?\)/X;_Z&'0__!M8?_)%%GV?W!S+NOO-RBL/_A)_#?\
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M/[@YEW7WFY16'_PD_AO_ *&'0_\ P;6'_P D4?\ "3^&_P#H8=#_ /!M8?\
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MPZ'_ .#:P_\ DBBS[/[@YEW7WFY16'_PD_AO_H8=#_\ !M8?_)%'_"3^&_\
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MBC_A)_#?_0PZ'_X-K#_Y(HL^S^X.9=U]YN45A_\ "3^&_P#H8=#_ /!M8?\
MR11_PD_AO_H8=#_\&UA_\D46?9_<',NZ^\W**P_^$G\-_P#0PZ'_ .#:P_\
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M ,)/X;_Z&'0__!M8?_)%'_"3^&_^AAT/_P &UA_\D46?9_<',NZ^\W**P_\
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M*+/L_N#F7=?>;E%8?_"3^&_^AAT/_P &UA_\D4?\)/X;_P"AAT/_ ,&UA_\
M)%%GV?W!S+NOO-RBL/\ X2?PW_T,.A_^#:P_^2*/^$G\-_\ 0PZ'_P"#:P_^
M2*+/L_N#F7=?>;E%8?\ PD_AO_H8=#_\&UA_\D4?\)/X;_Z&'0__  ;6'_R1
M19]G]P<R[K[S<HK#_P"$G\-_]##H?_@VL/\ Y(H_X2?PW_T,.A_^#:P_^2*+
M/L_N#F7=?>;E%8?_  D_AO\ Z&'0_P#P;6'_ ,D4?\)/X;_Z&'0__!M8?_)%
M%GV?W!S+NOO-RBL/_A)_#?\ T,.A_P#@VL/_ )(H_P"$G\-_]##H?_@VL/\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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M]P>SI_\ /N'_ ("O\CS'_A3'PM_Z$G1?^_4W_P >H_X4Q\+?^A)T7_OU-_\
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MMQBY7Y5*6R<N5\J;UL[;,'))J+:4I7Y4VDY6U=EN[+5VVZGTK1114C"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\:^"/&WQ!^*UO<:MX8T6VUWP;\'OASX=^,/Q[^)EMX$\$?J;^RE^T5XGU_\
MX+/_ +8/[,'C;X-?LF1^,_A7^SQX'UKQ=^T[\*O@3J'PV^.'Q;\3R?"3]AO5
M-?B\4^)M6^(_Q"U4_#ZZU7XBW=OX=\$:GK/B+4/#OA;P3\+O#U[XP\1W/@V3
M6]:_,7X:_P#!)7_@H'^QS\)_V5OVK/V+_#WB/PM^WM9>+/B+X3_:7^!>N?$;
MX9^(OA+XH\#7_CKXG>(/"WBGQA>:Q\7M!\,W_@CQ%X&\/_"SX=_$3X5>!?%-
M_-J-[JOP\^+/@*W^$/QI^&/BWXD:Y^GO[*W[*O[3.B?\%H_VQ/VWO'OP6UOX
M;_ ;X]?L]^"='\%:GXE\:?"/6/$=KXO?X3?L.:7JO@KQ!X;^'OQ&\;WECK?A
MW7_A/\2- U74K-]2\'7-_P"%)[SP_P"*=<T+6/#.L:VL3]4]EC'1E2Y)Y=AG
MAUSKZP\2LWR[ZW&O%2]ZLHO$SI*,53G@8TZT(J=.O[/+#>W2PL:L:GM(8FI[
M5N#5-47E^)6'=/2T(75.%12;JK%NI&;=*>&YO"O@Q_P4._X*V_M;?M3?MH?!
M#]E[X:_L$)X/_9/^-?Q@^&MWXF^.%M\=/"L)TSPM^T%\1?A9\-K;5M;\$?$/
MQOK6I^+_ !1X0^''B77;G^POA5%X4EU+PSK;:IK?@;^T_">B:Y]A?\$:_P#@
MJ8O_  4T^#OCW4_&&B^$_"?QL^%.J>$[_P 7^'/!%GXNMO#M_P##3XLZ9JNM
M_"+QU;0^(_[9L]$NM9G\-?$#P3JGA:R^(/CG4H-3^&MWXRU";P[H_COPQX?L
M^-_X)2_L@?M%?LU_M4?\%6/B1\:OAY_PA?@O]I/]I_Q!\1/@KK/_  EO@;Q'
M_P )IX.O?V@OVM/'%KK']G>$_$VNZKX<\WPO\3? ^J?V?XLL="U1/[;^Q26*
M:CINKVEA\D?\&Y?_  3Q_;#_ &#I/VH&_:N^$'_"JA\1/A1^QCX:\''_ (3_
M .%WCG^V-;^$\/[1R>/[+_BV_C;QA_9_]@-X]\)C[3JGV&TU7^U<Z+/J(L=2
M-G..^J2I8KV,</"5',,+##^QDKSPM3#8]XAOWI.K#V]+#3=2[]E.<:<)0I5(
MTC3"JNITW4E6DIT,5*HJB?+&K'$894$ERQ4&J,JJC%)>TBI3GSSBYKT#XM_\
M%+O^"C&O?\%5/C%_P3L_9.^&?[+.MV7@2\T5]"\5_&#P-\?[RST?09_V6OA?
M\<=5\0?%OQY\+O&>JV7@KP])XT\;S> M%\3-\.#IEQKWB3X<>"I(G\0:_%J=
M]^AWA*S_ ."PE_K?PXMO'?B+_@FMX3\-S^%/$"_%W6O"7@S]J'X@ZWI?CB/X
MA?%^;PK+\./"^L>//AE8:]X4N_A2GP#TWQ!!XF\7^'-7T[XA77Q?UK3KC5/#
M=AX,T#4OFC]GS]D#]HKP/_P7'_;D_;"\4?#S^R_V<_C#\%O#_A+X<_$3_A+?
M U[_ ,)%X@L?AI^Q'X?NM/\ ^$1T[Q-=^.M(\K5_A#\1+3[7KOAC3+)_^$>\
M^.Y>UU;0YM3^6?\ @H!^R#_P4+\8?\%/_ G[3/A3X!:)_P %!_V6/AWX'M+[
MP+^SC\5/'OP'^$/P?\*7'B[X;^-?ACX^^$T@\>7_ (VU+6]<7Q[:^%_VF]4^
M*^J?!G4[OQ#<WG@#X1)J3:9\*/#VK>&*:P]3$^SI/!T84<NP,HS<:,_;XBK@
M,OEB5?$5J>'=>&(J5U-3J15+V==1@\0E&2O5C1YIK$5)U<96BX\U2/LZ4<7B
M(T7^ZISJPI.G&F^:,?>4X.=2-"\H_6/_  3 _P""F7QQ_;'LOVU=!^*?PN^%
M_C+QU^R;KEC:^';W]D_Q&]QX0^/$-_=_%KP]9Z3\*;WXR^+-$\.:M8>)]=^#
M5]K'PO\ BKXG^(O@;P9X]\*_$;PC>:[I/PWL="U+Q!KGR7^PM_P4R_X*1?\
M!0SX$:]K7P*\:_\ !+[P_P#M/Z)XKU6P@^!?Q<\/_';PQ;^(_A5I'PU^'?B&
M[_:#\,IX-^//Q%^(VI> 8OB9\4/#'PPFMI? %IH4%Y%J]Q-\1TUR#2_"VL>M
M_P#!(G]DK]KG]F#QI_P4H^)OQ!_9H\.?!6^^/WBW2O'O[/'PAU_XP?#FX\!V
MD]MXY_:>\7Z-\*7\8_!2#XH3>!/AUX+@^(G@/P=8>(H/AA)<Z9X0>VOM!^&U
MY=:1=>#[/XX_;Q_8D_;0_;-\/_#/5/@A_P $J/ O["_[2]K^T-KWQ#US]H;P
M3^T]^S[9OIP\7KH.LV_Q-\::Y\(Y?"OC/7/'.G?&W5[[XT>*/'^F^%?&WQ7^
M')^$MKK7PBNO'_B_XV^+O#7AZJD,(Y9K&DL/3I^WK5,+5=7#U;4X8?&SCA:=
M.=557&M-T52Q.'4W1J4J<)1J>U4"*<L1RX"4_;3DXQIUJ?)5IMN6(PM/ZQ4G
M&#IQE1CSN5&OR1K4JE::G#V3J0N_\%&]0_:$TO\ X.%/V1+S]E;1/AWXA^/)
M_9$^&%AX)TKXM+JG_"N/L&M>+_V^-$\?ZQXNDT3Q+X5UN#2O"GPSU'QGXO:7
M0]2OM=\_088]"\+>-M8DL?!NO?:O[(?_  50_:!U'_@HSX\_X)K?MT^&OV;O
M#7QAL-)M['P+XC_9JE^,FJ>#M:^)UK\'?#7[1E[X#@O/'VEW>H:Q9:K\"O%&
MI^+E\6>)-.^$^G^%]=^&'B+PC';>.;[QQX0NK3L_C/\ L@?M%>+/^"[?[*O[
M9?A_X>?;_P!FWX;_ +,$'P[\:?$?_A+? UK_ &-XQ31OVX;1M'_X0^]\36WC
MW4<7'Q@^'4?]H:3X7OM+/_"1;A?%-(UUM,^2&_X)X_MAG_@XFB_;K'P@_P",
M5E^*\WB5OBE_PG_PNXT1_P#@E[#^SJM[_P (1_PFW_"QCGXQHW@_[,/"'VL8
M_P"$@, \+$:V5B*F'JX>O%_5^>CE>62H5(M>VEB5B<NI5X*3DW.2PM3$0J4$
MN6G"E*JJ<*L*E5W2A5AB%*]7EJ8RNJD6G[/V/U.K*#M9)+ZQ"FU4OS2F_9\S
M@U!?L%\)?'__  4*UC]M'XS>"OC1\"/@SX+_ &*-%\->([GX)?%?P3XQ_P"$
MM\=^,?$%MJ?PPA\'P>)Y+_QEHNM:=<:YH.I?$[5_%&@O\"=$TKPEXAT>T\(Z
M1\1?'.D:+I?Q!^*?X=_\%,OV?=<\9_\ !=G]D?XR_$O]DC]H+]HC]D7PO^SI
M\#-$^*6I_"[X'?$SXI>#[?Q!I7Q4_;+O=&A\1W/@O36L-8TGX=^*_%?PQ^(_
MQ5^'QU'4-0\4_"M-1\,77@;XBVGC2S^'/C;])OV5_P#@H[\3OVFO^"HO[8G[
M)WACPWX0UO\ 9:_9K\->)-/LOBAHGPV^*6D>+K#XO>#=?^$GP[\1>"/'OC'Q
M%XA_X0V(S?%!/VF=%\'VMOX'T&3X@:+\)[GQ%X%U7Q'X;\)Z_P"(]?\ V3KC
M=6>$Q57FIJG)X>A3E'#594U#VF!PWO1G>HXUFFI8N$KVQ<L33E"*3IQW4(UZ
M"2DYQ=><U*M!2NZ..G/E<?<YJ2G3=.C)-2]@J<E-R7._P2_X-SO@Q^T[\"_V
M"/$OA#]J#P=\3/A_K=[^T/XWU[X<^#_BDNJZ5J^E>!I_A_\ "G2?$]WHO@;7
M9H]:^'GASQ)\>-'^-'BRWT/4- \*?\)3JNO:Q\5=.TB_T?XB:;XK\2?E_P#\
M$[-4_P""A%I^WO\ \%>M._82\,_LK:S!J'[7WQSO_BSK'[5=_P#$K1_#6BWF
MD?MA?M.6OPYTGPUJ7PIU'4/%?]L>)=.U[XHZE/;O\/?$.@O%X*@BU7Q9X*O+
MG1;+QA_9;7X?_P#!*7]D#]HK]FO]JC_@JQ\2/C5\//\ A"_!?[2?[3_B#XB?
M!76?^$M\#>(_^$T\'7O[07[6GCBUUC^SO"?B;7=5\.>;X7^)O@?5/[/\66.A
M:HG]M_8I+%-1TW5[2PVI8I*AF-64,.ZM?$T*L:4HWA'FJ8BI45&C*3O""G[.
M,7SJE3FN7EJ*G4CE5H-SP--2J\E"FZ;G%M2DJ="%.#JU(I-2FXJ4W'DYYW7P
MRE%_GAX;_P"#@K]H3XH?\$]?%/[2_P +?A9\"[CXW? _XZ_!70OVB-&UK3O'
MS_#WPS^S9^TSHGC72?@/\8]+T*Y\?>%]13Q!XD^.MEX<^"5_X)\,_$[XJ:Y8
MOH^N_$?6M)\,^$/%6E'PG]/_ +3G_!:GXBV_@?\ X)LZ3^R!H/[+>K?';]O_
M $3P=?ZWH?Q1^*NL?$KP;^S[XO\ '_BGP+\&?"WPX\<67PF/ACQG<6LO[0GB
M[QU\.]:^)$EEIDVCZG^SE\7?"5M\+M:\8IJEEX ^9?\ @A[_ ,$E_P!J3X%_
M!?\ X* _ O\ ;8^&OB'X'>%OVKOV5OV<O@!9:WX1^)7P>\5>*_+T[P9^U+X+
M^*\_AB]\'>(?B;I6A^(?"%A\5O#EUHNI^*-$N]#O-2U"VFLK+Q%:Z=J]I#\0
M_P#!OA\(/B!\;OV[/!_Q!\;ZA+>>'?V!_@+XN@L;[X>^,_@WK7@C0O&WQI\7
M_&'1?"?PZG\0>"6UX?&CX:^-M5^+7[:OQ?\ #/Q#\$:]XCT:?Q%HOA>\@^)9
M\ 7/@?PKXAZJ]' QIYG7HJFX8'&9C@Z$5/G6)AF%6=+*:M.2;559?3IXO$NI
MS7JTZ>'4O:7E-94YXGGP5&;J<V)P^#Q%637+[&6#4*F80FK+DEC54I8>*MRT
MJG.THR:IU?U9^#7_  4._P""MG[6O[4?[:'P1_9<^&O[!(\)_LG_ !L^,?PU
MN_$?QRM?CIX2MFTOPM^T#\1/A;\,[;5]?\#_ !#\<ZYJ7C#Q5X2^'/B?7+S^
MPOA-%X4;4?#&LR:GK?@K^U?"FA:SQGA;_@NE\>/#_P"R1^WIXE^.?PN^"_A'
M]M']EOXR?#KX,^!_AA+=/X3^&&J^*_BWXCUSX:V?A26XC^,GQ*\0?&'XB_!;
MQ-\(?VB_BM\3?"GPTUWPYHGC'X2> =)@\%>--,@E\4_$;PW\M?\ !.7XO?ME
M?"G]OK_@KP_[*?[(FD_M9:'KG[7WQS3XI:;J7QO\!_ :X\%ZQI_[87[3@^&M
M[I_BOQI=:L^I6VL:/J'Q<_M/0-.^'VN_;+[1_#D]UXO\$16WV+QAU/PR_P""
M%_[7_P 5_P!D+]J[5_VE=9^&/_#9_P"T1^T#\#OCEX&L?'>NOX?TCP-\0_A;
M\2?C*OQ=^,OCSQ!^S[#XJ\!2Z_\ '+X<_M'_ ![M?"?PL\+>"_%'@7P3:ZIX
M+U:]OM'\6:O/H_P<Z9T<OIXRG3Q<,)2PZS7 PBJ-3FG]2<:_U[ZPJ=2=:E3Y
MU2=2591JPE*V$7L;07/"IBY4:L\/*O4K?5,>_P![!J'UE3I_4U2YX*E)I*2C
M[*\7'G]NW4N>J_&G_@ME^U9\$_V:?V8/VD++QM_P3C^/&M?%J]T2_P#BW^S+
M\+Y?B=IGQE^%^CZQH-S\1M'\/ZG<_P#"Y_'%YX2U+5O!&@:[X(^(7B_QG\/+
M>S^ _P ;-:\&^&(O!?QPTZ]N;@_0W[;_ /P56_:O\!_MY?LV?LF?L.>'/V;/
MC)X1_:8^"7[._P 4O /COQ#X6^*GQ5LM:C^-_P 3/C9X9G\;6/B;X*_$2TL&
M^"^B> ?AWH7Q*U7QWI?A?Q)9>&? MMXS\?7]YJ_AVTMX;#R'X$? C]J/X-_L
MP?"GX<_$?_@W_P#V8?VCOBY\//"&K>"_$WC6_P#BI^Q1X.U'XCZ+X1T3PII_
MPP\1>(;[Q<GQ7U'7/BIXTM'\3:;\:=8UOQ1#H]SXI\-V7Q&T.[N[7XIZCX ^
M$OV#\9_V0/VBO%G_  7;_95_;+\/_#S[?^S;\-_V8(/AWXT^(_\ PEO@:U_L
M;QBFC?MPVC:/_P (?>^)K;Q[J.+CXP?#J/\ M#2?"]]I9_X2+<+XII&NMIG%
M)X6$IR=&A[6G@)_'5PM2G4Q:QB@JD88.K/#<\(<ZC2C>G6HTH594ZM&JYU>F
M*KRI\JJ5>2>*HV<85X5(4'"G[2/-B8*LHSBKN35Z52=1*49QY:?S_P#M/_\
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M(^,/"7B?1?#*:YXX^#FD_LVR>)_ /A37?&?Q;T31=;I_%31/ /PH^/W[9?\
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M0Z)KUYX4O_$^CVOQ%\2*/#FF^%? <WQ?]3^,'P/^/?Q-^%?QX^$OP^_X(2?
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MXB\'>(]/^R2ZDEZ/[.^UFV%C=V%S=?$G@7]F3_@K+^P;^W3_ ,%"?BK^RG\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gqb5bzr5wcdj000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N D4# 2(  A$! Q$!_\0
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MAL;XR16EWYH)9P&*Y4<KG:<<GWQ6#HM]=76GZ#+8WVK7&HRRQF[60RM#Y?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK;QRSW,$NH?VE=7$VW.Y% "\ =6P>!P :ZZBBD 4444 %%%% !1110 4444
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M3?\ 0Q:O_P"!LG_Q5'_"7^)O^ABU?_P-D_\ BJQJ*+(#9_X2_P 3?]#%J_\
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MXF_Z&+5__ V3_P"*H_X2_P 3?]#%J_\ X&R?_%5C4460&S_PE_B;_H8M7_\
M V3_ .*H_P"$O\3?]#%J_P#X&R?_ !58U%%D!L_\)?XF_P"ABU?_ ,#9/_BJ
M/^$O\3?]#%J__@;)_P#%5C4460&S_P )?XF_Z&+5_P#P-D_^*H_X2[Q+G/\
MPD6K9]?MLG_Q58U%%D!?O-:U?5#&+W4[Z[*$B,33O)MSC.,DXS@?E5<&Z+E
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MXF_Z%W5__ *3_P")HN@,:BMG_A$/$W_0NZO_ . 4G_Q-'_"(>)O^A=U?_P
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MJJ<DD<=:Z>TM_LEG#;^:\HB0('D(+,!ZX[UL9DU%%%,04444 %%%% !1110
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M4C<,'HV*- ._1UDC61&#(P!4CH0:=4-I;K:64%LIRL,:Q@XQP!BIJ0!1110
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M34;9HUU:.S&HK$NQD:)G;C.,J0 2*T;?P>XU.UOKR6WN'%S<7-RAC^5FD0*
MH.>!M'6K^OZ"VHVEA%9):1BTNUN/*E3]VP"L,8'^]1H!4NM6N]-T\R0ZG;ZK
M=7$\5M;KL541W)&6VGIW_"K-I<:E;:U#:7&J65]#(K"4!5BEA<#(PH8Y!].H
MQUJ&3P_=WUD]O.+"R9)$GMY;&,@I*IR&(. 1VQ[FB/0+ZYUZRU34'L(VM"[
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MTHA$M\FQ4NT\L;F6(3(JA4W$G VD\GO1H!8TWQ=!)#)=7TTB8M[=S;"WY#R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gqb5bzr5wcdj000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000008.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G!YX# 2(  A$! Q$!_\0
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M(_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP<4__ #[#_B9SQQ_Z+?\
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MP_XF<\<?^BW_ /-:X0_^<!_01_P_7_ZM:_\ ,W__ (H:/^'Z_P#U:U_YF_\
M_%#7\^]%'_$N_@[_ -$?_P";!Q3_ //L/^)G/''_ *+?_P UKA#_ .<!_01_
MP_7_ .K6O_,W_P#XH:/^'Z__ %:U_P"9O_\ Q0U_/O11_P 2[^#O_1'_ /FP
M<4__ #[#_B9SQQ_Z+?\ \UKA#_YP']!'_#]?_JUK_P S?_\ BAH_X?K_ /5K
M7_F;_P#\4-?S[T4?\2[^#O\ T1__ )L'%/\ \^P_XF<\<?\ HM__ #6N$/\
MYP']!'_#]?\ ZM:_\S?_ /BAH_X?K_\ 5K7_ )F__P#%#7\^]%'_ !+OX._]
M$?\ ^;!Q3_\ /L/^)G/''_HM_P#S6N$/_G ?T$?\/U_^K6O_ #-__P"*&C_A
M^O\ ]6M?^9O_ /Q0U_/O11_Q+OX._P#1'_\ FP<4_P#S[#_B9SQQ_P"BW_\
M-:X0_P#G ?T$?\/U_P#JUK_S-_\ ^*&C_A^O_P!6M?\ F;__ ,4-?S[T4?\
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M>%/"[>+/!Y^)7A[Q!'_,G"7C;Q;1S[PLAQ-F_#><Y%XD<&3XGSB&#P/U#,>
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MM_#J7P]\$6VL>)?&/COPK>VWB#XB:S+K>L> -8T[XA^$=4\/>,O'OAOQ)9>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZUX!\9ZQI?AS3O$VI:-IVKM;6=_HGB"&PNM7;3_#/C72/"OB7Q/:^"_'NO\
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MM ^']QXQ\%WWA_3M7\(:$UK:ZMXN\77Z7VLZMI<_B#P?X2U_P%H7B7P)X_\
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M<33GB_?I3RJ<X8V$H1BY.<'3J2HQBI2QE.$ZN#5>E&4U[.%\#_%S&TJ-;#<
M<1U:->.73IU?J7)3<<UJ8>C@7.=2<(TO;5L5AJ,_:N#P]:O3HXGV-2:B?)M%
M?H_X+_X)3_MB^-OA9%\3[;P;HGAZXOK*PU31/ACXTUJ;PI\4]8TS4[+2K^UN
M9?#NK:;!I?A.]6'4I8K_ ,-?$+7_  ?XOT>]TG5=.UCP]87\=G;WO"_LT?\
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M,:%+">UKUL/"I]WP7X%X_BWP[\2.(X0SVGQIP3G&6Y)@N#:>7<N*QV88C/\
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MYS>'^T[#PSXQ\':IXWUN#1IM/.D:C\1;5KJQM+O6[?5]<^#OBW^WG^UO\<?
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M.M22JTI<_+4@Y%%?M-^RMX;^"'[ 7[%7PD_X*!_'7X<M\6OVD/VBM>\'Z_\
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M*IM"U>+PS=ZDYCTZU\02:?<)HUQ?R#3]6*64.HFVDNG&E:GM@61O[/O<?9I
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MS_ZKGPW7\.-?W'?LE_\ )JO[,W_9OOP9_P#5<^&Z_E_Z7/\ R3O"'_8ZQ_\
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MX-\)F_ET2>Z?2=*\6:K)X>/B_5M*LAXOO?1/V[OC9X5_:@_;&\3?M"> =/\
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M!LOB#X87DNG>#]0:Y.@Z3JGBK1?LGQ1^&^KZ5_PL.P\$>$_%6L^"M3LM<L_
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M76M+\00^E^"_V6_V0OV1OV=?AC\7?V\-'\>?%#XG_'C3[+5=$^$_A.[/AP^
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M'".'SCB;*,;G?#G"&-SNM2XHSK 82<:5&K@\)3R^OE\89E6JX>CE^)Q69X;
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MP\?^%-(\4?%'Q#I.L>&?#=GX[\>_&;Q+X9==?\.W_B/XBZE1_8$F\*_L"?\
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M_KW]I+P%X6_X*Z?#7X;_ !'_ &;/C'IFG^,/@SI>C^)-2_9C^+4VE://\/\
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MLYP>7YFLPQ&+H9AC<5.K@Z>'E4Q,J>'DG1K4,/\ M_\ \%/[%OB)_P $^/\
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M_9]MM8L?$_\ P4G^''QL\-?'KX-^/]:^'_@K5]1BO[.7Q=X,CU?XI^"?@?\
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M\-:7J6D>!]*U6"^\2OX2UGQ)HT6B:#>^)O#GYZ_\%#OV6M2^!?B70/VF=/\
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MHT)3X?4:5"5">-KY'%>V]C''XJ'W7\%/#/BS]EK_ ((]?M:R?$:/7/$WQ/\
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MR^J83"Y3/A&GG./CF&9X-3AG$,(L'6I8C$QPU7GJT?R?K]O_ /@I_8M\1/\
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MVY?@UX/T[XA^%_\ @J?I_P 3O#?[4?[,VK_&3X :=\2=+ANM+OO%^E>#[?\
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MXW,\;3PW"%+'YMA,NCCI9S@\OS-9AB,70S#&XJ=7!T\/*IB94\/).C6H8?\
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MH++PWJ,GCJXT%O"7@]])TCP?XH\0Z1X@TN;0/&WQ6F\2-XFN+?[%K%QX9O\
M2].U&^DGU+1?E,W\!>+LLS'@[A?*<HQ.)X;XKX;\*,A\4L11E0G@\3/AG,L/
M#B;%XV4I8BC/'K+I9YC,/BG06&Q.,SS$WIUZLHS/L<K^D3P3F.3<:<4YGGN#
MI<8\*\1^*F<>%T*D<12Q-/!YUE^8_P"JV78"F\/EF*PF"K8FEPS1QD*.*I8Q
MX3),-.I5>/G*GA?RXHHHK_00_P U K^X[]DO_DU7]F;_ +-]^#/_ *KGPW7\
M.-?W'?LE_P#)JO[,W_9OOP9_]5SX;K^1?I<_\D[PA_V.L?\ ^H,3^U?H5?\
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M*?UBG@L8_<="2)Z***^K/C@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ?AEN\*VNG*D>D3^$Y?[*:.33[@12>B?!*[\ 1?\$X_AYHO_  4[\/> -/\
MV6/ L/PY?]DCQW/XK^(&L_M"^*+'P[X9U&]\!V?A+P-\./#NK?$/Q#K>A_#:
MPU:R\-^*/ /BO6_B)\8/@NWCC1OB=\,M1\$6OC'X@?%_X<_X*N_'/X5_'WX)
M^$_V"_V5KV/P/^S;\*?!EYX,M==T'3)FT/7)K?X4>(/A+X,\+Z'HU]/975_\
M,OAMHGB:[U&4W<VGZCXV\::3H%WI>IZ9X9\,IJOQ!^__ (SW'[+'_!2CX2_L
M[>)+G]J_X=_LO^,/@TNO^'?&'@OX@Q:5&KCQ1X0\(2^(]!T'0_$OCWX9)>6U
MAX@T#P;?>%OB7I,OBCP\^A6WBSP?)I-KXHO=3?P5^'8CASB:ODN;<09GPEFN
M3\/^(?CK3XJPN83RO&8G/>#,AH++:%/B#"97@YTL=A<75JQQ]3"5WA^6OA<B
MRS'X"CF'U_*+_P!!83B_A*AF^6\/9-QCE/$?$OA]X+8SAS'98\XP67Y-QEGU
M6E2]EP_BLWS&&(RS'X2G'#4W5I4L75_L_%\19W@\?B,!4I9E)>-?\%:_@?I]
MS^P#\/\ X3?LYZ;X4U3_ ()QFVTGP7XGC^$FJ/XX\4:7XK\2^)_$.@:3\3/%
MWB;7-3\57/CW2;+XEZGH-SJ/BVY7QIXVL/CMK$_Q7^+/]IP:+JOC?P9[A\5K
MK]EK_@I+\!_V=/$OC#]J/X8?L[?%SX66%[I'BZP\<W/AQKNWOO$?A;PP/B%X
M=TG1O$WBWX;7E_I%[XI\.^$=8\.^.=-GN]&NM*TK4-(N-$AUVYNX_"GE/Q@^
M(7P0_8U_8$\8_LL_"OX]>$?VI/BA\9/&=[<2ZKX3GTQ/"'A;PKXC\1:/%XCU
M.^3P_P"*/&=MX:3P_P##KPVFG:1HY\2Z]K7B_P"*NIVVNMHOAWP)K.M2>"?E
M[X*_L)? _P")_P $_AYX^\7?\%#O@+\*/B%XS^&G@;6?$GP\\2:!X2>\^''Q
M&NO >@1?$'P[JT&I?M ^&]2UK3=,^)\7BRYT41P:(W_"(3Z'HR:OK\]B_CSQ
M'[G"O#63+#9I7SG$\799EN1^)T^(>"/$VEP7F]?.L^S>4?K>.GGF&KX'&8O-
MZ5">697A\/C:V7>PG+"5<EQTZD<OQ>78?YKB_BG/L3BLOPF34."\\Q^>>&4<
MCX]\+\5Q]E&&R/AW!XGZG@:<>&L10S'"4<GJXZABL;B<=A\/F*J3I3PF;8*,
M,1BL-C,7]V3?"?X%?!/_ ()'>/?@G\$?B_#^TEX9\2?M1Z1\.;;XDZ -+@\.
MW_QS_:-_;V\%: ]CI]WIFJ3Z0?"7PZ^+'Q-L-%\176E^(/%4^G67AGQ!;22:
MWK^GW?AX_%OQD_X)-?M(?!+X1?%+XR^)/%OP9UKP]\)OAWXT^)6O:/X9\2^,
M[CQ)JNC>!O#FI>)]3T[0(-;^'V@Z-/K5[9:9/;Z7#JVMZ/ILE[) E[JEA;-)
M=1:7[:7QC^"'PI_9\^$'_!/G]C[Q!'XR^%_P[\3P?$3XO_%:_;1M=7Q[XOM_
M%/B#XC0KI>J^'K;0?#^H>/=;^.&H6OQ[\7^./"N@Z7X&\-:UIGASP_\ #?2G
M.IZA!\,?AG7_ -I3]HOQ7HVH^'/%/Q]^-7B7P]K%L]GJV@Z_\4_'6LZ-JEG(
M07M=1TO4==N;&]MG*J7@N8)8F*@E3@5]IX5\*^*V*P7&?%'"^;T.%Z_$_$&)
MAALTXUX:Y\9Q%E>!P&&J9-Q+1R'#O"4\KP=;,LTSWV6"514L3A:>'EA,17P#
MPF88KX/QEXS\&J69\(<,\59)BN+_ /5?(X2KX#@?BM4\OR#,,?F5=9IPWBL]
MQ$<76S/,:6"R[*WB\9R2EAL16JQQ%*GC_KF!PGQ?^T;_ ,F]?'C_ +(S\4/_
M %"-<K^BK_@N+_R,7[$7_9._VC/_ $N_9EK\S?@M^Q]\*?VQ/AU\>? GQ-_:
MQ^'O[+)N?!Q\'Z+J?CNP\.:F=>'Q"T+Q?H^HZEI=CX@^)?PX^UCPE]DL;B]M
M+2[N?M/]K6D,]UI>Z&6X_=3]N7X5_LK?MEWWP3U(?MZ_L_?#G_A3/AOXD:%Y
M \3_  Z\8GQ+_P )]-\,Y_M(<?%CPN=(.E?\*YV"W$>JF_.LY$MF=/VWWM>.
M6=X)^(WA/4A3S2M2X&XJ_M7BBMA\CSO$T<MP%>&38VG7A6H9?4I9C?#PE.5+
M*YXVM3E%T:E.-9>S/&\"\CQL?"+Q+HU*V44*_&?#G$.!X<H8GB'(,+7Q^*K8
M2&74J52CB,SI5<O<\9AJU*,\SC@Z?+&-?F]A4IU9_!?QOOM:B_X(:?\ !*.:
MUN]4N#XJ\.?LP:KXUO9I[K4;G6KKQ!^R?\3?%VKZGK^H7;7-U<W&K>-)+?6;
MV]N[@RW>LRQR22O+*%;W#_@C:EMJ'PS_ &UM)U@I<:%/X9\!)?65Y(?[/-KJ
M&@?%VVU0RQNXAC2ZLX(X;R7Y3)!!$LKE8DV^<?L>?%7]G_\ :T_X)PZ+^QI\
M:_B)I/[*GBWX6R>')OA_X@\56W@_PCHL/@_2=;TSQGX(@\*:-XIU2TTV*Q\.
M>&->N?@+XO\ !^L?\(5XV:ST+Q+KWAC2/"EG>>'=:TR]XE\1? #_ ()[_L:?
M'7X'_!_]I#3/VFOV@/VN-4\;Q/XN^'^H6<7ASX<^%-1T7P_\-)=3T]],U+XO
M>&?AP_PX^'%];Z[X6\+:_K>I7OQA^-U_XL\4Z3H&A^"-0\:CX9?B^;X;-J7A
MKXY>&M+(>(,?Q/XF^)<<XX0A_86;0PF;Y7GN7\(4,!CZN)K82V"A*IP_5J8]
M9BL++ 87&T<1BG&&%S/ZC^ZX2ODV)\6?!KQ4J<1<,Y5PKX=>&.(X?XJC#B')
MZF/R;-LEQW%^)Q^"I87#8MK$_5J6?PI86> EB)5\3EV(HTZ,8ULOJ8OD?CW>
M:K;_ /!$#_@E:^G7FI7$/BC1?V9]3\7WTES=ZI/K<FO?LJ?$_P 6ZGJ>NZG=
MR7=U>3ZOXQ>UUJ[U"[N7EO=8ECEEFDEF ?V?_@C:EMJ'PS_;6TG6"EQH4_AG
MP$E]97DA_L\VNH:!\7;;5#+&[B&-+JS@CAO)?E,D$$2RN5B3;QW[+/Q#_9[_
M &FO^"?O_##GQE^*?A_]FCQ1\%]:TVS^'7C/6U\"^&O"]WX+\-^)K+Q3X%N/
M ^GZYKK: ^CZ1X6UFX^!OB;PM>7OA7Q9/IVC>(O$/A"R\-Z=?>&M?TZOXE\1
M? #_ ()[_L:?'7X'_!_]I#3/VFOV@/VN-4\;Q/XN^'^H6<7ASX<^%-1T7P_\
M-)=3T]],U+XO>&?AP_PX^'%];Z[X6\+:_K>I7OQA^-U_XL\4Z3H&A^"-0\:C
MX9;\097GF5^'OCUX35,AS['\8>('BE/&\+QIY3F%; YO@<TP7"6"PN/EF4*%
M7#4J,J_#E:IC:V*J4J6&PF-H8RK5='#YE+!897FW#N?>*/@GXT8?B'AK*>">
M#/"N>7Y_!9SEM',<EQN"Q?%N8XC PROVU&O?"X7B.E1PU+#TYXB6*RW$85X6
MBZF!EB?P9^%5_P")]4^%_P -]3\;1WD7C+4? 7@^^\6QZCIR:/J$?B>[\/:=
M<:\E]I,=K91Z7>)JLEVMUIR65HEE.'MEM;=8A$G>T45_H5@L//"8+"82>(K8
MN>%PN'P\\5B).>(Q,J-*%.6(KS;DY5JSBZE63;<IRDVVW<_S-S/%PS#,LPQ]
M+"8? 4L;CL7BZ>!PD%3PN"IXFO4K0PF&IQC&,,/AHS5&C",8QC3A%**2L%%%
M%=1PA1110 4444 %%%% !1110 45]I_LQ?LS^'?B-^SW^V3^U#\8I_&&D?#K
MX Z5:^&/A-X?\+WGAKPMKWQ0^+]IX/C\7:A8?\)'XK@\0:%-X3\1:AXZ^$OP
MW\)%K#PU>Q>/&\=1ZKJ3:7:Z3<-\65\IDW&>29]Q%Q1PQET\54S/@_\ LE9U
M*>%J4\'"IG*S"6%HX;&/]SBJ]..6UWBZ5)N6%]IAU5M*LHK[+/\ @7/^&N'>
M$N)\UA@Z>6<:TLSKY%&EC*57'3H94LN^L8C%X)6KX.A5EF=&&#JUHJ&+E2Q3
MH.<*#D_LS]EW]O/]H?\ 9*TN3PI\-]<T/6?ANT_BG5(?A?XYT4:SX/T_Q+XN
MU+1]6U7Q-HUQIEUH7C'0KQK[3M4OFT/1O%EAX*O]9\8^,_%.M>%M5\7ZX?$%
MOTG[2G_!1O\ :3_:A\&ZS\-O&VH>$?#/PU\4Z%<>'?&?@+P)X=DL-"\::5?"
MZBU*Q\3W/B/4O%'B'4-+U:PNWTK6?#R:Y;^&=8TQ1:ZGHET)+AY_@^BN#&^&
M7A]F6;_V]C^#L@QF:O$?6YXG$9=0JJOBK2MB<3AY1>%Q6(C.?MHUL30JU(XF
M%+%1DL31HU8>A@O%GQ+R[)?]7L!QQQ)A,H6'^J0PF'S/$4I4<(Y1;PN'Q4)+
M&8;#RC'V,J&'Q%.E+#3JX247AJU:E,HHKZ>_99_9-^)7[77C'Q#X+^&NJ>#M
M&O\ PSX:;Q1J6H>-]3U?3-+-H-4T_28K.W?0]!\2:A+J$\VH":)6TZ.S6WM+
MHSWL,YM(+KZO-,TR_)<OQ6:YKBZ6!R[!4_;8O%UVXTJ%+F4>>;2;2YI16B>K
M1\AD^3YIQ!F>#R;)<%6S'-,?4='!X+#I2K8BHH2J.%-2<4VH0G)W:5HMW/F&
MKND:EJ.@:]H?BK0;^]T3Q/X8N[V_\->(](NI]-U[P]?ZEH>K>&-1O=#UBSDA
MU#2;N_\ #6OZ[X>O;FPN+>:ZT/6M6TF=Y+#4KRWF_7G_ (<F?M5?]#_^S[_X
M57Q&_P#G45\\_![]D3PA8_M\)^Q3^T]XMGT:ZU32-9T+POKGPJU^SC?Q)\4_
M^%;^'?C?X=TW2+SQ?X.O!<>'#\*K/XER:XE_H&C:TGBCP]IEOIB76D2RW]U^
M<XCQ@\,,7A<=2I<19=G?)EN98O$95@Z4L9B,9@,!@:^-S*$,+5IPI8B-/+Z&
M)KUJ,Y6GAZ59N,HQDC].PW@CXMX3&8"=7AC-,@=;'X/!4,UQU:& PV%QF.KT
M\)@_:8RG6E/#^VQ-:E0A42LJE6*DXJ[7YYZ=IVGZ/I]CI.DV%GI>E:79VNG:
M9IFG6L-EI^G:?90);65C8V5LD5M:6=I;11V]K:V\<<%O!&D42)&BJ+E=;\1/
M!.L_"WXF_$SX1^)Y(7\6?"?QUKO@+Q)Y:V-L;FYTF2*XT?7UTNRUK7Y-%TWQ
MQX4O_#WQ!\,Z7J>I2:S%X1\6>'Y]4AM[NYDA3DJ^]X>SG*^(LAR7/\CJQKY-
MG658#-,KJPA[.,\!CL+2Q.$?LM/8M4:D%*BTI4I)TY)2BTOSGB7)<WX;XBSS
MA_/Z4Z6=Y+FV899FT*DW5E_:&"Q56ABI>V?\>-2M"52GB$W'$0E&M&4HS4F4
M445[!X@4444 %%%% !1110 4444 %%%% !1110 45]I^#?V9_#ME_P $_/'/
M[9'Q7G\867BOQ/\ &6Y^'/[.7P\T>\\->&!J_A[2?&-A\-M9\2>,U\00:[)K
M[_VKX9^+OQ4TF#PYJWANYU+X1Z!X>C@TU_%5[=0'XLKY3AWC/).*L?Q/E^33
MQ5>IPCFZR'.:\\+4I8.GF\</3Q5?+Z&(E[E?%8.A6PU3&T5:IAHXO"NK&*KT
M[_8\4\"Y_P &X+AC'9[#!X>/%N4?V]E&&IXRE6QLLIE6>'HX[$X6/[RAAL57
MIXBC@\0U*ABZF#QL</5J/"UN4K[,_9=_;S_:'_9*TN3PI\-]<T/6?ANT_BG5
M(?A?XYT4:SX/T_Q+XNU+1]6U7Q-HUQIEUH7C'0KQK[3M4OFT/1O%EAX*O]9\
M8^,_%.M>%M5\7ZX?$%O\9T5ZF=Y!DO$F GEF?Y7@LWP$YQJ/"X[#PKTXU8*2
MA6I\Z<J5:"E)0K4G"K%2DHS2E)/RN'^)>(.%,PCFO#><9ADN80A*E]:R_$5,
M/4G2G;GHU5!\E>C)I.5&M&I2E*,9.#E&+7WA^TI_P4;_ &D_VH?!NL_#;QMJ
M'A'PS\-?%.A7'AWQGX"\">'9+#0O&FE7PNHM2L?$]SXCU+Q1XAU#2]6L+M]*
MUGP\FN6_AG6-,46NIZ)="2X>?X/HK8\.^']>\8>(]$\'^$]$U;Q/XM\375U8
M^'/"_A[3KS6?$.OWMCI6HZ]>VFBZ-IT-SJ.J7-GH>CZMK5W!96T\EMI.EZCJ
M4RI9V-U-%P9!PKPIP5@L52X?R;*L@PE64\7F%7"T*6'E7=/VD_;YAC)_OL0L
M-"<X49XJM4CA,,HX>A[+#4X4X]_$/%O&7'N/PE7B/.\YXEQU.,<)EU'%5Z^+
M]A&:IP=#+L%"]'#O$2IPJ5X82A3EB\3S8BNJN(J3J2QZ*^P_VA?V&_CI^RY\
M(_A=\6OC)!X3T!?B?XET+P:G@"P\0_V_XY\$^*M:\">*_'TVB^,9=&LKSP%)
M+H=CX-UG1M6OO!?CKQEI$FN?9%T34=9T><ZS'0_9:_8K^-_[7LNO7'PIL_#5
MOX9\*ZNWASQ/XU\5:_'IGAS0O$G]B67B*'P[=PZ;;:UXEN=7N-'U32+XVVF>
M'K];&TUK1KS59-/LM4LKF;AP?B+P-C\HS;/\)Q3DU;),CS"659KFBQD(X+"9
ME'"X+&K!2KSY85<14PN8X"K0IT'5EB%BZ$:'M)S43T<9X7^(67Y[E7#.+X0S
MREG^=Y='-\LRGZG.IC<5EDL7C,#]?5&DYNEA:>*R_'4:U:O[*&'>%K2KNG"#
MD?+&D:EJ.@:]H?BK0;^]T3Q/X8N[V_\ #7B/2+J?3=>\/7^I:'JWAC4;W0]8
MLY(=0TF[O_#6OZ[X>O;FPN+>:ZT/6M6TF=Y+#4KRWFQM.T[3]'T^QTG2;"ST
MO2M+L[73M,TS3K6&RT_3M/LH$MK*QL;*V2*VM+.TMHH[>UM;>.."W@C2*)$C
M15'Z)_M*_P#!-+]HG]ESX5Z_\9O&U[\._$_@#P=;/JGCC5? >O:[J$O@GP]%
M)!%=>*O$5IXC\*^%IH_#&F>>+K7M9TX:C;>&='M]0\1^)#I/AO2]3U>TY;]F
M']F/P;^TK^S]^UQJWAW6_%-W^T[^SW8:%\0O"7PY\/7&A7NC>+OACKFA7=_H
M.EWFBZQ::-?'QWXV\0_#;XT^#_#MY%XVTOPSI=Y'X)U35A<11ZWI]Q\]C_%K
MPSP.19YQO1SK+\TP'#]/ 8;B#'9/2IXW,<LP>+KS6!ECZ,>3&T\OE7G7E0E.
M/L9U(XKZNJE6E74?I<!X->*^89[DO N)R/,LHQN=K&XO(<#GM:I@,KS#$8*%
M/Z[' 5ZCGE]3'TH8FBJU*G/V]..)P_MN2.)H^T^(:*IZ=J.GZQI]CJVDWUGJ
MFE:I9VNHZ9J>G7,-[I^HZ?>P)<V5]8WML\MM=V=W;2QW%K=6\DD%Q!(DL3O&
MZL;E?J<)QJ1C.$HSA.*G"<&I1G&23C*,DVI1DFFFFTTTT['Y#4IU*52=*K"=
M.K3G*G4IU(RA4IU(-QG"<))2A.$DXRC))Q:::3044451 4444 %%%% !1110
M 4444 %%%% !117VGX-_9G\.V7_!/SQS^V1\5Y_&%EXK\3_&6Y^'/[.7P\T>
M\\->&!J_A[2?&-A\-M9\2>,U\00:[)K[_P!J^&?B[\5-)@\.:MX;N=2^$>@>
M'HX--?Q5>W4!^4XOXSR3@C 8+,,\GBE3S+-\MR'+J&"PM3&8S'9OF^(CA<NR
M_"8>E[]?%8NO)4Z-&%ZE23M",FG;['@O@7/^/<;F.!R&&#YLIRC'Y]F>)Q^,
MI8'!8#*<LHRQ&.QV+Q5;]WA\-A:$)UJ^(JN%"C3@Y5JM-./-\64445]6?'%>
M\M+34+2ZL+^UM[ZQOK>>SO;*\@CN;2\M+F)H;FUNK:97AN+>XA=XIX)4>*6)
MVCD5E8@_I[\(_P#@K7^U[\*O"</A&_U;P7\6[:P.GV^BZW\6=!U75O%.D:+I
M>@:-H5IH;^(?"GB+P;?^)XR^DSZ[?>(_'3^*_'.KZ]K>L76K^++ZU?3K'3?S
M*HKY[B'A/AKBS#T<-Q)DF79S1PTY5,.L=AX59X><^53EAZVE:A[10@JJI5(*
MK&,8U%)127T_#/&G%?!F(KXGA;/\SR.MBH*GB7@,3.E3Q,(N\%B*#YJ%9TVV
MZ<JE.4J;E+V;CS2O]'_M+?M7?&G]K/6-&U'XR^(++5],\*:[?^(O!'A'3-(L
MM+\*^"=5U"PU/1WOM L42:]?5(-"UK6/#]MXAUS4M9\3)H.K:II,FMRV6I7T
M-Q\X5L>'?#^O>,/$>B>#_">B:MXG\6^)KJZL?#GA?P]IUYK/B'7[VQTK4=>O
M;31=&TZ&YU'5+FST/1]6UJ[@LK:>2VTG2]1U*94L[&ZFB^J_VA?V&_CI^RY\
M(_A=\6OC)!X3T!?B?XET+P:G@"P\0_V_XY\$^*M:\">*_'TVB^,9=&LKSP%)
M+H=CX-UG1M6OO!?CKQEI$FN?9%T34=9T><ZS'X<,?X=^&E+)>&:5?(.%(YOC
M\'@,FRB@J.%K9EF>98O"Y7AI>QI1>(Q>,Q^.KX7#5<PQ7/5Q.*J0>)Q,ZLG(
M]ZIE?B=XI2SWBZOA^).+_P"Q<OQ>/SO/,3*MBZ.6Y7EN%QF9XB/MZ\U1PV"R
M_!8?&8BGE^#Y:.$PU*<</AJ=-1B?'E%=7X&^'_Q#^*OB:/P+\)O GB/XG?$"
M[TN^UC3/ _A&/3GUS4+"PO=*TNXOI+G6M1T;P_H.BV^KZ_H&E:CXL\6:WX?\
M&Z!=ZYI<GB7Q%HUE=+=K]"?M8_L=_$_]CC5/AEI'Q1UGP/K%Y\5=+\<ZMH(\
M#:IKNJQZ?#\/[CP/:ZW!KCZYX;\-^1<SR^/M'_LX:<-4@G6UU,W$]IY-I]M]
MG,^,>%\FS;*\BS3/<NP><YS7IX;+,LJUT\9BZU:2A1A"A#FG#VLI*-*554X5
M&I*$I<DK>)E? _%V=9+F7$>5\/9GC<BRBCB*^99M2P[^HX2EA*7ML3.I7FXP
M?L:5YS4'.22>ETTOE%24L?$6EH2FF>+SX,;Q9IR_+8^*#\.-?O?%?P\/B*T&
M+?6SX#\4ZEJ/B7P8=2CN3X7U^_O=9T/[#J-U/<R)7VEH'[.GP]\;_P#!/7XA
M?M7>#?%.N7GQ5_9Z^*FL>&?VA_";ZCX;E\$:%X'M[G3O$$6M:>^J6_A>_P##
MDWA7X/?$7X8?%?QWK6M>(M;L(-)T?XA:?H6BZC<3Z#+;?%M<7#7%7#?$&;\8
M9;E$'1SGAK.*.6<1T*^$AA,75KO!TY8#,/\ GYC,OQ5"G5PN Q\_=JRR_%X:
MG;ZI.*]#BW@_BOAG*.#<RSV?M\FXIR6>:\,XBCCIXW!PPT:L(8O QO[F$QV%
M<\)6QF$IJT*6,P57GFJT;%%%%?8GPH4444 %%%% !1110 4444 %%%% !111
M0 45]I_$']F?P[\(?V%OV8?CUX^G\8#]H']IS57\3Z9X BO/#6@>'_ 'P@UO
M2O$'CKPY?^*/#-_!JOB/4O%GAWPC=_"[P?X^&A>+KFRMOB/XWDN=/TV/PQ8R
M/'\65\IPIQGDG&=//*V1SQ56CP_Q!B^&L=5Q&%J8:G4S+ X3 8S$/!3G[N,P
MD89C1IQQ=%RHSKPQ%*$FZ,F?9<9\"Y_P%B<FP?$,,'2Q.>Y!A.),'1PN,I8N
MI2RW'8O'X/#+'0I^]@L9.67UJSP==1KPPU7#5IPBJ\4%.CDF@N;&^M+F[L-0
MTK4]+UO2-3TV\NM-U71M<T/4+;5]"UW1=4L9K?4-(US0M8LK+5]$UG3;FUU/
M1]6LK/4]-NK:^M;>>-M%?52C&<90G%2A).,HR2E&49*THRB[IIIM--6:T9\A
M"I.E.%6E.=.I3G&=.I"4H3A.#4H3A.+4HSC)*491:<6DTTT?JYX+_P""R7[8
M/A;P[::)KD7PG^).I6]UJL\WB_QIX)O['Q%?Q:CJU[J-I97=M\.O$O@'PFEK
MH5G=P:#I3V/A>SO9M)TRRFUN[UG7)-2UK4/@'XZ?'?XJ?M)>--+^('QG\4/X
MR\3Z!I6IZ#X:NY]-TG3;;PQH6M76F7NLZ1X=T_2+&QL=(L]9NM#T*XUO[) E
MQKL^A:+<ZW/J%SI5C-!Y#75^!OA_\0_BKXFC\"_";P)XC^)WQ N]+OM8TSP/
MX1CTY]<U"PL+W2M+N+Z2YUK4=&\/Z#HMOJ^OZ!I6H^+/%FM^'_!N@7>N:7)X
ME\1:-972W:_ X3P]\-^&,;/B7"\,<-Y-BL$J^)6:/"X;#4\M52,E6Q&'G6MA
MLMM2E4I>UPT</[+#U*M"$H4*M2G+]'Q?B/XJ<986CPIBN+.*,]P^85*.%AE"
MQN)KSS*=U&EA\3&DU6S"+FHS=/%RKPE5A"O-.I3C./*45]7_ +6/['?Q/_8X
MU3X9:1\4=9\#ZQ>?%72_'.K:"/ VJ:[JL>GP_#^X\#VNMP:X^N>&_#?D7,\O
MC[1_[.&G#5()UM=3-Q/:>3:?;> _9V_9U^+7[4OQ*B^&?P?\-C6;VQM8-6\<
M>)[^^M-,\'_#'PY?Q:O'HWB'QSJ<TK7\5MXCUC1[GP_X:T3PUI7B7QAK]_'J
MFHZ5X9NO"_A'QWX@\*^G@>.^#\SR+&\38'B'+:_#^75ZN%QV;*OR8+#8B@Z*
MJTJM6I&"4XNO1C9)\TJL(QYG)(\?&^'G&^79_@>%<;PSFU#B+,L-3QF!R:6'
M<L?B<-5==0JTZ$'*7+)X;$*TN62=*2:5M?#Z7)_LL:'D_P!BCQFWQ&&D?\PL
M?$)O""?#YO'@T_\ X]/^$S;P%''X(;Q1Y7]MGP@B>&C??V,HLA^D/QW_ ."5
M_P"U%\!?AWJGQ-U/_A7_ ,0/#OAWSKSQ7#\-_$&MZAJ_A;PW::;J&HZCXPU3
M3_%7A?P@;OP[I7V&*VU1M!EUG6+ :A!JMQHZ>';#7M:T;R_0/V=/A[XW_P""
M>OQ"_:N\&^*=<O/BK^SU\5-8\,_M#^$WU'PW+X(T+P/;W.G>((M:T]]4M_"]
M_P"')O"OP>^(OPP^*_CO6M:\1:W80:3H_P 0M/T+1=1N)]!EMODLR\7_  P>
M4RS:>>9?G.5X#/\ A_+L?6PM*&,AD6,S3$\V49QF=*NH3R_+*%?#U:ZSJ4/J
M^'G@<7*E5=;+\5&A]IE7@IXMK-YY-2R',\BS;'<-Y[F>#PV+KSP$\_RW+J4:
M6;91EU6A*=/,,?6AB*%"ID[J*I5CC<&L33A1Q^$E7^+:***_63\9"BBB@ HH
MHH **** "BBB@ HHHH **** "BBOM/X@_LS^'?A#^PM^S#\>O'T_C ?M _M.
M:J_B?3/ $5YX:T#P_P" /A!K>E>(/'7AR_\ %'AF_@U7Q'J7BSP[X1N_A=X/
M\?#0O%US96WQ'\;R7.GZ;'X8L9'C^4XGXSR3A&IP_1SB>*5;B;B#+.&LII83
M"U,74JYEFN+H8/#NK"E>5'"49UX5,9BYKV.%H*56K)))/[+A3@7/^,L-Q-C,
MFA@_JW".09AQ)G5;&XRE@J='+<NPF)QE549UK1KXRO'"SHX/!P?M\7B94Z-&
M$G)N/Q95>\M+34+2ZL+^UM[ZQOK>>SO;*\@CN;2\M+F)H;FUNK:97AN+>XA=
MXIX)4>*6)VCD5E8@V**^K/CDW%J46TTTTTVFFM4TUJFGJFMC]-?A'_P5K_:]
M^%7A.'PC?ZMX+^+=M8'3[?1=;^+.@ZKJWBG2-%TO0-&T*TT-_$/A3Q%X-O\
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MK]"K_DJ>-?\ L08#_P!6+/X\_P!K3_DZK]IG_LX+XS?^K&\25\^U]!?M:?\
M)U7[3/\ V<%\9O\ U8WB2OGVOZ?X:_Y)SA__ +$F5?\ J!0/Y(XJ_P"2GXC_
M .Q]G'_JPQ!Y_P#%CQ7J/@3X6?$OQQI$-E<ZMX-^'_C+Q7I=OJ4<\VG3ZCX=
M\.:EJ]E#?Q6MQ9W,ME+<V<274=O=VL[P-(L5Q!(5E7^C;XR_\$\_V$_V>_&'
MPD^(_P :_CQXN\ ?"+4? 7@_PRWPJ:VO?$GBKXJ_$WPAJ4.O^)?'U]KGAGP]
MJ_BC1O#?BOPU./#GQ4TOPIX:TG0+34-7\)W'P_U[X,ZHT5EXV_FC_:-_Y-Z^
M/'_9&?BA_P"H1KE?T5?\%Q?^1B_8B_[)W^T9_P"EW[,M?A'CIFF?X?B[P9R7
M)>(LZX>H\2<4XW*LSK9/C:N%G5PF+CEN!Q#G14GA<57I8''8[^S98ZABZ&79
MC4PV;4L-/%X'#V_I'P&RGANIX>^+'$.<\+</\28S(,AS+,\OAGV74L;3AB<G
MP^ S; PC4:CB\-AY8ZA3680P&)P=;,,OGB\LKXCZIC*\)>5?MW?LD? '2_@)
M\(?VQ/V,;J>7X,^.=0TO3_$OAW5KSQ;&+3P_XBT;5)=!\8:1;_$-5^(.@^)M
M)\6:1'X+\=_#/QE9Q:Y8ZAXB>XND\%:C\/\ 7/#?B;\9?'?B.Y\'>!_&7BZS
MTH:[>>%O"GB+Q':Z(;Y-+&L7.AZ1>:G!I1U.2WNX].&H2VJVGVZ2UN4M/.^T
M-;S+&8V_8GXP_P#*O/\ #_\ [.J^&O\ Z],@K\:/B?=7]C\-/B'>Z5IE]K6J
M6?@;Q;=:;HVEV,^IZEJU_;Z!J$MGIFG:;:E;K4+Z_N$CM;2RMF6>[N)8X(2)
M)%-='@)GN=8JMXO<+9WGN;9]#@7Q,S7(\ISC.\8L=F4<GCEN7>RP]>O5I>TK
M2HXNCCL=[6O5K+FS!X:E"AA,+AZ*Y_I <,\/8;$>"O%>1\.Y+D,/$#@/)\TS
MGAW)\,\LRFIFSS"6(Q&(I^QK0AA:>*P>:8++'##4L+[*GE<<9.K5Q6+K5(_M
MY_P5@\,>'?@3\&_^"9O['F@Z1':^$OAM\-_'?BGPW%8S36]AIVM? 3X?_"7X
M):7=%(9XGOI+CPW\>?&D7EW\=W:S2ZA+J4\0U2VL+J'S;X/?!;QQ^UC_ ,$H
M++]G;X4Q:?\ %;XM_![]K3XM^.?C3\*+C6]#TJ^\=?#+XI7WQ]U?X;Z)=/\
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MTEM,\+>+KSQKXPN?"^L_%;P[8>&/"_@WX>>)O$__  JV?XT_X(\?\I.O"/\
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MT_Q'<Z)'XRTRRT=_$VF> [+Z,_X=N?LJ_P#23[]GW_P&^'/_ -$%53]M^X^
MD'_!;>!?VG+#7[WX)W/[(W[/MOXPDT9]22QT^0ZQ^V[-X>O_ !0/#5[:>/'T
M!?$T.CVL:> $OO$'_"176@-J5DW@M?%EQ;?1O_&A_P#S_P -CUXG"'B3Q[G/
M W!N:/'>+.*Q-?+L[P6,Q?"' '#'%V!Q=?(.->*>&Z6)Q^:9GAJ6(CF]? Y/
MA*F+P\8."A+#XF=2MB<1B:M3U.,_"GPYR#C[C7)_J/@QA<-A\PR+'X'"\:^)
M?%G!>987#<0<$\*\1U,-@\HRG%5L+_9=''YMCH86NYPJ.?M:=/#87 TL%0C^
M8?B;6)/V"?VLK"3]GOXM> /CV- ^#^G>*='^+^E:1H^J>$+7Q+\3I?B[\/=>
M\)6UEH_BGQ;I8\5^ =%\/:)XM\T^)Y)''C70;?7?#9T&5X/$WV_??&7XG_'[
M_@@]X_\ BG\8?&&I>._'VN?M/>+=-U+Q%JJ64$\NF^$_^"H4OA'PSIEO::;:
MV.FZ?IN@^&=#TC0]*T_3[*UL[+3M/MK>"!$C%?!/[2OAGX1?$#]IVX\)?L)^
M"_$7B?X57/@/PG!X?T/0=(^)/B/Q;XC^(]H?&.M?$6^T/1O$[:KXRG\)V'A5
M?!L=LM]8V>HP:[HWC^]:T_X1A- U*[^__AO\"/CC8_\ !"+Q'\(+[X,_%:S^
M+,_[2OQ$UV#X7W7P[\7V_P 1)M#O?^"F^K^/K+68O!,VCIXEDTJ[\"RQ^-+7
M44TPVEQX3D3Q'%,^CNMX?&\:(X7,/##A+B'.(9O6XVQ7%F"P.)QG&60Y5PUQ
MK'A_!<1\4U,)A\5D66<N&R[+*;G'ZK7PE."S;!4<MS#,9UL5RNG]!X(2Q>7^
M(/&?#62/)J/ V!PF7X[!8'@?B#..*N!GGF,X0P4<TQ6!X@S;FQ>98^M.G3GC
MZ.+JU%E&85L;EV A0PB2J?&__!-;]H/X8?LS?M:V'Q#^,]]H7A'X<>(/A!\0
M?ACJGQ3UR_\ L.G?#35/$?BSX6^*]*UCQ7=7'E:9HGPVOHO .HV/C/QG?7*6
M_@N\_P"$9UK7!I_@6/QIXI\,?I;\.O\ @GG\9O@M^W!?_MG^+OCGX3/[-WPY
M\4_'+X_W.O>#M0\>ZC\1/B=X4\;?#WQG;Z=X(\=>!-,T/4-.U:R\/O\ $#7_
M !5X@\1:5XS\6GQAK_PM^'OB7PWX#M=3^(]_X?\ @]\H_P#!'_X/P:C^V[\=
M_#GQN\#76D>*?V?_ (1_"+Q?\/\ P5X[\)WNDZI9>/?'/BKQE=>)_$M_I_B&
MS2XC\0?#KPYH/PEU3PU!%:V=SX?MOB[9^*;Z*]GUGP)J.D>K_LJ?%G_@J)-^
MV)I6O?%/P3^T/<^'?BM\4'\'?%/PMXQ^'_CK3O@/X&\,^$]4\<PZ@/A[-K/A
MW2_ O@3PQX'TN76#X0^(WABYTO4/C]!X=^'<GBKQG\9-:U_PU>^(-O%C&U,[
M\3^*/]0L\RG*<U_XA)G>"XAS7B'&8&KP_FN2U:V7.M@<D@J=6>)QU1O+N:K1
MQV#HQEA<50J8K 5X.6*7@Y@(<.^%7!U+Q#X>S?.LO?BIE&(X9RSAO YA_;.3
M9IC\#BZM/,^(,0J^'IX3!X;!XG.%.G/!X^I3>+PT_J6)E2=7 ?,GP3^.<OC[
M_@M#X1_:/\(^'+6T\,?&WXV^(_!VJSI96.G^(]'^%&H_LNQ?"CP[_;]U+>R7
M>L3^+/B3\)O@WXBU_2M)"P:;<2:#:SVVJV?@$>)KGR3_ (*(>!T^'_[<'[2>
MC6-C8Z?H&J^-](\;Z##96,UF\K?$/P#X.\<^+[V_=F^S7]]?_$CQ!XVO&O;&
M&WA-M-;6MTMQJEKJ-]=_6OCOPG\)/ '_  6W^'_@'X,:0L%WXZ^/WAOQ!X]\
M.^&EA3PUX(^*$_P,U+X_^/KVYTP-:67AB'Q=X1\,)\0-:BT>VNFU_P")/Q%N
MO$6HQ-JWC#7-1A^>_P#@J-XNTCQ/^W?\>=-TJ[M+J;P-/\-_".M"UN5N6M=7
M;X/_  ^\5O:7:JBBUNXK#Q3IY>U+RLL;Q3,ZM,88GX8U\DAXA> .*X7PN+RF
M&.\+>(N'\PR_%8ZEFN*>4Y?6S7$8FIB,PIX+ 1QU#&<2Y-A,?#-88#+Z=>4<
M+1I8'+*4XY91X/%RAQ!/PN\=<'Q;B<'G%;*_%#AK.<JS'"9=5RK!SK8VGE>%
MP6(PF75,?F3R^I@\AS7$Y)'!_7\:Z>'A6G6Q>8XJI7S7%_ 5%%%?W.?Y]A11
M10 4444 %%%% !1110 4444 %%%% !173>#?!?C'XC:CXCTCX>^$_$WCO5O!
M^B:?XF\6Z7X-T'5/%&H^%O#>K3ZO:Z5X@\1V6B6M]<Z)HFIW/A_7K?3]6U.*
MUL+R?1-7BMKB233;Q8>9KGIXO"UJ]?"T<3AZN)PL:4L5AZ=:G.OAHUW55"5>
MC&3J48UG1K*DZD8JHZ550O[.=NJM@L;AZ&'Q5?"8JAAL6ZBPF(K8>K3H8IT8
MTI55AZTX1IUG2CB*$JGLY2Y(UJ3E95(<Q11170<H4444 %%%% !1173:#X*\
M9>*=)\9:_P"&/"7B;Q'H7PZT5/$GQ!UK0=!U75])\"^'9+?6+R/7O&6I:?:7
M%GX8T62T\/:_=)JFMS6-BUOH>L3K.8M,O6@Y\7C,)@,/5QF.Q6'P6$H14J^*
MQ=:GA\/1BY*"E5KUI0I4XN4HQ3G))RDENTCIP>"QF8XFE@\OPF)QV,KMQHX7
M!X>KB<36DHN3C2H483JU&HQE)J$6U%-[)G,T445T',%%%% !1110 4444 %%
M%% !1110 4444 %%%% 'ZL?'&/1OAC_P1!_8'\%VGA.+0;#]K'XJ?#'XH^,=
M!L-4>Z6P\5?$30?BO^WDQOM;M!ID^K2Z3\2/!^@B6YBAAM=4_LV*RN;!M$GG
ML#XU_P $V?V8/!W[9?Q#_;'^&'C>^U;1;CX??LZ?">^^%GB+0;I+6[\)_$+X
MV^(OCQH;>/;RWNK;4;#7KWP1_P *?\/2^%]%U:QO/"LRZ[XK7Q7X>\4M/X>;
MPY[U^V1I6J?%#_@D3_P2+^(=MIU]93?#^Z^ =[XOTR]M+C2[SP],?V*_C-\-
M=<TW5M+NXYKRRU/1O&M[9:%>V5Q/$]G>BYAF:25$C.Y_P07_ .3F_P!NK_L@
M'[&G_JP/VSZ_@?),US++O"#Z3>?83&8W+L]_XC!F5*MF>6XFOE6:T8O*?#V$
MZ&'Q^!>'Q> 5...QBH+"U*+P<L57GAO93J2/])^)LGR;,?&3Z/N1XW+LOS3(
ML-X)9'F%#*,SHTLZR>>,K<<<3X6KC*^!S%8O!X^MBL)A,%1Q=;&4\3+'T<-A
MOK<ZZIT^7VG]GO\ 95_X)8>/;MOV9;3XS^(OC9^T5JND^(=0N/B-H]K\0O!>
ME#4O!6G^&]'\9'X3W,>C3_!F;0Y-374/&/@WPUK_ (B^+?BC5_#]_P"*-6TC
MQ1XX\(>$;K5= _+;PM^S%!;?M3>(?V9OC3\7_!/P@M?"_B[X@^&]0^+>M16H
M\+7.F>%HM<OO!_B%M/U3Q)H^GZ'<_$'1['0M0_X1O5?&;#PO?Z_)X<'B#Q-J
M>FVSZU:_X)*?\GF_L1_]<O&__K*?QCKT;QU<? 2#_@L;^V$O[3EAK][\$[G]
MHW2K?QA)HSZDECI\A_81^!<WAZ_\4#PU>VGCQ] 7Q-#H]K&G@!+[Q!_PD5UH
M#:E9-X+7Q9<6WTO#_$?&60>(>197B>+^,N):?''T?\QXYQ>&MA,UKX#BQ2P.
M(I8KA7(<10>"C*C[#'X;*LDYJ>'Q$LRI4<RQ&-6$H27QG$7"? _$WAUGN:X?
M@S@/A6MX?^/F'X*I8MRQF1X+-.$,-B*^75<'Q5GV&Q*S"*Q,<QP&,S3.U]9Q
MM.64R>68;"RQ]2G'Z-_X=N?LJ_\ 23[]GW_P&^'/_P!$%7PU\8K'4/V0OC_?
M>#/V=?VE;SQYI=Q\(O!OB2Y^-_P6\23^$;"^O?%_C#Q_INO?"V>^\#>,_$=O
M-=>&(?AWX2\5:O:2>*9)I8O&'AV:\T'3DMM,U#5OUG_XT/\ ^?\ AL>OQZ_;
M2U;]GFU^.FJG]D/1;F[^"@\'?#G0?"NDI=>)(?$OCGXVZ_KGB#3]1T#PI_PM
MC7+*^>V\4SZS\,/!7@G3_$5[H-YJ7Q&E\3V:*N@WGAG4;W[GA/B7BK-^*,DR
M[/:GC%5R7$5<R_M.AQ?X4\(9+PO7P]'(LUQ%.&=YQA*+Q>78>&*I8>MA:N':
M>(S*E@<!6?U;%UU+\]XPX3X1R?A;.<?PU2\$*?$--932R>OP1XR<:Y[Q;A\7
MB>(,HPLYY'DV.Q$<#F%>IA:V)P^,ABVX87*Z^/S"E;%8*A-?J;_P2:\;?'GX
ME_$+XY_M#?&_X]?&C4?V?/V<O!]WX7DA\<_%+QYJ/@G7_B;K>A6'CKQCK6KZ
M)KZM;ZG8?!SX4_V#>6FIVNL:KX8OM3^+M\MSI:^+?AQ:76D?EGJ7QW\7>.OV
MXO!O[5O]E75]XFU?]L?X0?$6&ROYHH]4\$?"P_$'P?\ #C5=)TU+_P 2:_IF
ME:OX5_9?&J^$/$T?@W5+2P\:WB^+;G2M-6Z\<WUA=_J[^VY#H'[%7_!.KX2?
ML*0:KHEQ\4?C[I&HR_%<6EZEZ/%&@Z;J7A_Q-^T?J=CIOBK3_$MQK/@;Q1XJ
M\5^'?A#%X?UH1?V5\)O&?]B:5K6GW7AS1H3^'O@V[DM_B'\*+&WT^_U.]\4_
M&3X.> -+M-.BAEF.L_$CXH^$O &BW-QY\]ND6EV.K>)+.^UNZ#O+9Z-;7]W!
M;7D\$=I/X'ACE>3^('&OBCXGXG"X2APOEV&QOA]P?]7P^'P]&CE\,/'&<39Q
M3PT:-6@YUL/+*:6 QT5#$T*M7B7!5J4Z-=1/J?%'.LZ\.^%/!OPFP&*QF*XG
MQN.RKC[C.&*KXNO7QF95<7'"<.9/6Q4JU#%/#O&+.99CE=6K.C4AA^',12G2
MGA*4W^E__!8[P.GA7]M*;Q%I]C8VNF?$KX-_#KQ;J=S#8S0W^I>.-+U?QOX"
MUBZO;\,MG>0Q>#/!OPYLK.!83J%F;6Z:\NYK.[TJVL?RQK]?_P#@M?XNTC4/
MVK_!'@BVN[276O"_P \(^(=6M8KE9+NTL_&'Q!^*EEI)N[4(#;)<-X0U%[:1
MI6-R%EQ%$L*O/^0%?<?1<KUL1X(<*SK5)5)0S;C[#QE)6<:&$\1>+,+AJ222
M]RCAZ-*C3T^"$=7N_P P^EC0I8;QZXRIT:4:4)9=P%B)1CLZV+\.>$L5B*KW
M]ZO7K5*T^\ZDGIL%%%%?T"?SF%%%% !1110 4444 %%%% !1110 5RGCOQ'<
M^#O _C+Q=9Z4-=O/"WA3Q%XCM=$-\FEC6+G0](O-3@THZG);W<>G#4);5;3[
M=):W*6GG?:&MYEC,;=77#?$^ZO['X:?$.]TK3+[6M4L_ WBVZTW1M+L9]3U+
M5K^WT#4);/3-.TVU*W6H7U_<)':VEE;,L]W<2QP0D22*:F;2A)N7LTHR;FK>
MXDG>?O)Q]W?WDUIJFCLR^$:N/P-*5&&(C4QF&A+#U*DJ-.O&=:$71J5H2A.E
M"JGR2J0G"5.,G*,HM)K]O/\ @K!X8\._ GX-_P#!,W]CS0=(CM?"7PV^&_CO
MQ3X;BL9IK>PT[6O@)\/_ (2_!+2[HI#/$]])<>&_CSXTB\N_CN[6:74)=2GB
M&J6UA=0^+_L#?L=> OVQ?V;?VU/$?B[Q\GPC\;?";X[^%? ?@7XL7OV>[\(_
M#;P7X0^#_P %/CAXPU[Q5X:U+4]'TKQ#:^)XOB1XH\/>-9=6U_18[+P;H^A-
MX.UGX=^);?6?&NI_1?\ P7$T"3Q5\1?V'/C3H[?;/#$_P=_:1T!M0B;_ $5I
M/&FN?LN^+/#30Q^46'V_3_#^N3AGN?\ 5VR*D3$22+YO_P $ZO\ E&)_P6H_
M[&KX\?\ KN;]GJO\Z\%Q+G?"_P!%_P 0.*\LQ>+RCB=>).>YIFE?+\17RS&2
MQN%K8'V%*O6PCH5Z<<1E>7Y53KP3BJ^#:HUE4HU)PG_IK/A?A_C'Z4O O#.=
MX/!\0Y!#PBRC!Y?1SC"T<SPE.C7S;'4_;T\!C8UL-3G1K9CCJM&/(XQQ-26-
MI^SKU%*'U/\ "C]C[_@F'^T[X,\:?!;]F[XH>-=9^-WA+PH_BQ?BKXFTSXE6
M>N6\7B/6O$4'AV^O_"_B3PY\-_AKXX\.>&]4BLM"\3>'_ VEZ3XITKP\OA5/
M$_B3P_KOC31?%NO_ ),_LQ_L]>&_C#X_\2_#WXY_&[X?_LOZCX3\-WMYJ^I>
M*KW2==T27QAI6M:5HFJ^#M'UC6?$7P]TG5#:SWFI7$&I+J$%[?VFE_:K/0)+
M:2^FTO[!_P""*W_)[GB'_LU?XK_^K;_9TKY7_8[N/V1T_:G_ &H[;]LFPU^;
MX;7'Q]_;QDT#4+5_%8\,6/C:W_;7\;"Q@UI/AM>Q?$A]:OM#FU\^'386-YX-
M2SM/$G_"5S6>LMX*%S^K8/-^+N#/%3C7@2'%W'G%&%K>&>(XSH5G2P?$V>X3
M.L!G'"N7U/\ 5[)L?0>#A3Q$,^Q;IY72G1P-.E3IJI0Q.(IQQ)^-XW(N"N.?
M";P_\0Y\&>'/"6)7B;2X(Q6&GB<?PEPYBLEQ.1<89A"7$6?Y;B8XUU*=;AW"
MN69UZ>)S&K7J1IT\30H3KT,1]G?\.W/V5?\ I)]^S[_X#?#G_P"B"KXT\/\
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MW[/O_@-\.?\ Z(*OG+]B2X_8+/Q4_;BM/VV+#7UE3]KG]IBX^'&ISO\ $/\
MX1::.7]KG]IR+Q98:7'\'KUO%0U^V:'P[<:\_C33XO#[:==>&U\&7L^HKXU@
MMOT/_P"-#_\ G_AL>OJ<%XC<=YODW"^=4ZOC&O[=X,X)SZLN%/##A'B#(/K>
M=\)Y+FN._L_-\9AZ6(Q2>,Q>(>(4J5*&'Q;KX:A2AAZ-*)\1CO"_P[R7.^*L
MBK4? IOA_C7C;(*3XM\7>->'.(/JF2\69QEN _M#)L%C,3AL')8'"X>-&,,3
MB*M3#JC5Q=:>,GB&_P @O@S^T7\3?V4/B-\:Y_@QK.@)JBZ_\5/@GI'Q!N]
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MFE?PER7 Y/C+8N@IXSVF?5\;AJ6,O3PJQT)1P5=PJU5BZ<8.M2Y:<,1)4?\
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MHHHK^M#^- HHHH **** "O[COV2_^35?V9O^S??@S_ZKGPW7\.-?W'?LE_\
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MBLLRFI2PZP.&J9='!8',LTI8SVN.S1Y@ZN ]E_9U'+84*Y1117Z.?EH4444
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M'G^#M+\&:#^T%:VMGJFKZA=6A\:V45LM^-0U:^A_53]F'6OV5_VC?@%^T?\
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M&=-\(6-S+:Z7HFEV.@Z3JFNZS:P67AKPW8:/X9M+Z74/$FJ2:EK5OH\6MZS
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M^":__P O/RC_ .'/7[-'_0\_'3_PIO '_P [*C_ASU^S1_T//QT_\*;P!_\
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M\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?]$#D/_@FO_\
M+S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=/_"F\ ?_ #LJ_5RB
MC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S\H_^'/7[-'_0\_'3
M_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\ B,_BE_T6V=?^#:/_
M ,I#_B!/A!_T0.0_^":__P O/RC_ .'/7[-'_0\_'3_PIO '_P [*C_ASU^S
M1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X0?\ 1 Y#_P""
M:_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3_P *;P!_\[*O
MU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_*/\ X<]?LT?]
M#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_XC/XI?]%MG7_@
MVC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\ "F\ ?_.RH_X<
M]?LT?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?]$#D
M/_@FO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=/_"F\ ?_
M #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S\H_^'/7[
M-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\ B,_BE_T6
MV=?^#:/_ ,I#_B!/A!_T0.0_^":__P O/RC_ .'/7[-'_0\_'3_PIO '_P [
M*C_ASU^S1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X0?\
M1 Y#_P"":_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3_P *
M;P!_\[*OU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_*/\
MX<]?LT?]#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_XC/XI
M?]%MG7_@VC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\ "F\
M?_.RH_X<]?LT?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@
M3X0?]$#D/_@FO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=
M/_"F\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S
M\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\
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MLT?]#S\=/_"F\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\
M@FO_ /+S\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.R
MK]7**/\ B,_BE_T6V=?^#:/_ ,I#_B!/A!_T0.0_^":__P O/RC_ .'/7[-'
M_0\_'3_PIO '_P [*C_ASU^S1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_
MX-H__*0_X@3X0?\ 1 Y#_P"":_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^
M'/7[-'_0\_'3_P *;P!_\[*OU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1
MY#_X)K__ "\_*/\ X<]?LT?]#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '
M_P [*OU<HH_XC/XI?]%MG7_@VC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU
M^S1_T//QT_\ "F\ ?_.RH_X<]?LT?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]
M%MG7_@VC_P#*0_X@3X0?]$#D/_@FO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\
M.RH_X<]?LT?]#S\=/_"F\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_
M $0.0_\ @FO_ /+S\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\
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M/QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X0?\ 1 Y#_P"":_\
M\O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3_P *;P!_\[*OU<HH
M_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_*/\ X<]?LT?]#S\=
M/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_XC/XI?]%MG7_@VC_\
MI#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\ "F\ ?_.RH_X<]?LT
M?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?]$#D/_@F
MO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=/_"F\ ?_ #LJ
M_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S\H_^'/7[-'_0
M\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\ B,_BE_T6V=?^
M#:/_ ,I#_B!/A!_T0.0_^":__P O/RC_ .'/7[-'_0\_'3_PIO '_P [*C_A
MSU^S1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X0?\ 1 Y#
M_P"":_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3_P *;P!_
M\[*OU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_*/\ X<]?
MLT?]#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_XC/XI?]%M
MG7_@VC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\ "F\ ?_.R
MH_X<]?LT?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?
M]$#D/_@FO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=/_"F
M\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S\H_^
M'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\ B,_B
ME_T6V=?^#:/_ ,I#_B!/A!_T0.0_^":__P O/RC_ .'/7[-'_0\_'3_PIO '
M_P [*C_ASU^S1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X
M0?\ 1 Y#_P"":_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3
M_P *;P!_\[*OU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_
M*/\ X<]?LT?]#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_X
MC/XI?]%MG7_@VC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\
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M0_\ @FO_ /+S\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\
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M  IO '_SLJ/^'/7[-'_0\_'3_P *;P!_\[*OU<HH_P"(S^*7_1;9U_X-H_\
MRD/^($^$'_1 Y#_X)K__ "\_*/\ X<]?LT?]#S\=/_"F\ ?_ #LJ/^'/7[-'
M_0\_'3_PIO '_P [*OU<HH_XC/XI?]%MG7_@VC_\I#_B!/A!_P!$#D/_ ()K
M_P#R\_*/_ASU^S1_T//QT_\ "F\ ?_.RH_X<]?LT?]#S\=/_  IO '_SLJ_5
MRBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?]$#D/_@FO_\ +S\H_P#ASU^S1_T/
M/QT_\*;P!_\ .RH_X<]?LT?]#S\=/_"F\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:
M/_RD/^($^$'_ $0.0_\ @FO_ /+S\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU
M^S1_T//QT_\ "F\ ?_.RK]7**/\ B,_BE_T6V=?^#:/_ ,I#_B!/A!_T0.0_
M^":__P O/RC_ .'/7[-'_0\_'3_PIO '_P [*C_ASU^S1_T//QT_\*;P!_\
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M\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@3X0?]$#D/_@FO_\
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M*C_ASU^S1_T//QT_\*;P!_\ .RK]7**/^(S^*7_1;9U_X-H__*0_X@3X0?\
M1 Y#_P"":_\ \O/RC_X<]?LT?]#S\=/_  IO '_SLJ/^'/7[-'_0\_'3_P *
M;P!_\[*OU<HH_P"(S^*7_1;9U_X-H_\ RD/^($^$'_1 Y#_X)K__ "\_*/\
MX<]?LT?]#S\=/_"F\ ?_ #LJ/^'/7[-'_0\_'3_PIO '_P [*OU<HH_XC/XI
M?]%MG7_@VC_\I#_B!/A!_P!$#D/_ ()K_P#R\_*/_ASU^S1_T//QT_\ "F\
M?_.RH_X<]?LT?]#S\=/_  IO '_SLJ_5RBC_ (C/XI?]%MG7_@VC_P#*0_X@
M3X0?]$#D/_@FO_\ +S\H_P#ASU^S1_T//QT_\*;P!_\ .RH_X<]?LT?]#S\=
M/_"F\ ?_ #LJ_5RBC_B,_BE_T6V=?^#:/_RD/^($^$'_ $0.0_\ @FO_ /+S
M\H_^'/7[-'_0\_'3_P *;P!_\[*C_ASU^S1_T//QT_\ "F\ ?_.RK]7**/\
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M&KVI_P#(2U#_ *_KO_THDJC7RRV7HOR/L HHHI@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5[%IG_ "#=/_Z\;3_TGCKQVO8M,_Y!NG_]>-I_Z3QUG4Z?
M/]"X;_+]4>5ZG_R$M0_Z_KO_ -*)*HU>U/\ Y"6H?]?UW_Z4251JULO1?D0%
M%%?BU\ O^"OW_"\?CW^S7\$/^&>?^$7_ .&AO$OBOP[_ ,)/_P +9_MK_A$/
M^$8^ OQ5^-_VS^Q?^%9Z3_PD'V[_ (5E_P (Q]G_ +6T3[-_;?\ ;7GW']F_
MV3?_ $&7<,9YFV39_P 09?@?K&4<,?V:\\Q?UG!TOJ/]KUJ]#+_]GKXBGBL3
M]8JX6O#_ &.CB/9<G-7]E&4'+YS-^+>'\BS?A[(<US#ZKFO%=?&8;(,+]4QU
M?Z_6R^G1JXN'M\-AJV&POL:>(HRYL;6PT*G/:E*<HR4?VEHHHKP#Z,**** "
MBBB@ HHHH **** "BBB@ HHHH ***_.#_@IQ\=?BU^S]\'/AAXM^#WC&7P9K
MVM?''2O"FM7D>@^%?$"ZIX;NOA=\6=<FTB:U\6:%KUK;1MK7A_0M3%YIT-EJ
MBS:7%;"__LZZU*RO?H.%>&\=Q?Q!E?#>65<+1QV;5Y8?#U<=.K2PD)QHU*SE
M7J4*&)K1AR4I:TZ%27-9<NMU\_Q5Q)@>$.'<XXFS.GBJV R3!5<?BJ6"ITJN
M+J4J5KPP].O6PU&=63:455KTH7^*I%:GZ/T5\7_\$^/BG\0?C5^R9\.OB3\4
MO$LOB[QQK_B+XQVVJZ]+I/A_1'N;/PY\;_B/X7\/V@TWPOI&AZ+!%I'AO1=(
MT>&2#38[J[AL([S5+B_U6XO=0NOM"O(QN$JX#&8O U^1UL%B:^$K.FW*#JX>
MK.C4<)-1<H<\'RMQBVK-I;'?E&9X?.LIRO.<)&K'"9MEV"S/"QKQC"O'#X_#
M4L51C6A"=2$:JIU8JI&%2I&,[J,Y)*3**_(K]H;_ (*M67P/_:!^*/P*T_X"
M:WXJ7X3R^#-(UGQAK'CVR\(6NN>)?%G@3P]\29X?"^D6GA7Q?->^&=(\,>-?
M"5DWB'5+_1]1O?%P\7Z*OAFVTKPYI?B/Q5]:?L5_M<Z?^V-\-_&/CBU^'VN_
M#C4/ ?Q-U?X8:]H^JZI8Z_I>HZA9>%?!OCK3]<\)^(+2#3;G6-"O/#'C_P /
MVU_)JWA[PY?Z9XPL?%6@0V.J:1I&E^*?$/TV<<!\6Y!P_D_%.;Y/4P60Y_\
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M*5/V3O)*WLY3IU%5C&\O<3NU.\5_4G17\=O[1WQ,\=?\%I?^"CWA/]F3X/\
MB35M/_9>^#%_JEY<1V_Q*\ QZ!K7@/P!X[B\&?'+]LGP3-HFB^,]*\2:_P"+
MM$\<:%\,_P!F:&[C^+%E#I&M^&?&4]I\-?"OQD^.UEX:_K@^'/P_\)_";X>^
M!/A9X!TR;1? OPT\&^&/A_X+T>XU76-=GTGPGX-T2Q\.>'-,FUSQ%J&K>(-9
MFL-'TVSM9-5UW5=3UC47B:[U/4+R]FGN9.;%X;ZI.G1E/FQ'LHU,32Y;?59U
M/?IT)2YFY5O8N%2M%PA[&4XTGSS510UH5O;QJ5(QM251TZ-2]_;QAI4JQ5E:
MDJEZ=*:<U5Y)S7+%1Y^RHHHKE-PHHHH **** "BBB@ HHHH **** "BBOXR?
MV^/VD?\ @JQ^T-\"/B5^T/\ $/X3?$_]C;]C_P +6?PH\*>(/@3J^KWWP^UG
M6-?^)?B3P#\$M>T#Q7J.L^$_ ?QJ^-%IXMN/VCM2O=7TK6_!OA?]FVY\'_#^
M+0[O0$^,W@B36/&/H9?@'CZJ@Z]+#P=6A1YZC3G*KB).%&E1H)^TK5)N,G[J
M5.$8N56I3C9OEQ6*^K0;5*I6GR5)QA!6BHTDG.=2JUR4H1YHW<GS.]H0G+0_
MLVHK\ O^#=%57]D'X]E5 +_M@>*V<@ %F'[/W[-Z!F(^\VQ57)R=JJO0 5]9
M?\%I]=USP[_P30_:0O?#^LZKH=Y?3_!3PS>W>CZA>:9<WGASQE^T+\)_"/B_
MP_=3V4T$MQHGBKPIK>M>&/$FE3.]AKGA[5]4T74X+K3=0N[:6*&#=?,XY=[3
ME<LSEERK<MU[N-EA%6Y.9;V]I[/GTOR<[MS.JF(]G@WB^2]L''%^SO;XL.J_
ML^:W2_)S<NOQ<JV/U+HK^-7]B'_@B[_PV3^S)\//VC?^&D_^%<?\)[J'Q%L?
M^$._X4[_ ,)?_97_  @'Q1\:_#7S?^$A_P"%I^%_MW]K?\(?_;6S^P[/[!_:
M/]G;[S[)]ON?VR_X)V?\$IO^&!_B9\0/B5_PTCXQ^)__  FW@6S\#?\ "#:?
MX4_X5QX ?R?$%MK_ /PEGBWP_P#\)EXX_P"$P\8Z!]A_L?X=ZS]JT/\ X0G1
M?%GQ0LOL^M_\)WYFAZ8O#9?1I<^%S+ZY5YX+V/U.OA_=;M*?M*DG'W%KRVO+
M9:F>'KXNI44:V"^KTW&3]I]8IU=5&\8\D$I>\[*^T;W9^O%%%?EM_P %?OVS
M?&O[%/[(DGBSX52R:9\9/C!\1_#7P*^%'BN;PWI'BK1O ?B+Q'HGBKQOXF\<
M:SI6MZI9Z>]SX>^%WP\^(%SX%>]TCQGHC?%1O -MXO\ !'B+P1<^)K9.7#8>
MIB\11PU%)U*]2-.',[13D[<TW9\L(J\IRL^6*;Z'15JPHTJE:H[0I0E4F[7:
MC"+E*RW;LM$M6]$?J317\D'_  3H_P"":$W_  45^"][^TQ^V1\:_P!I7Q")
M]>OOA9\#]7N_BGI/CCQ9KWP[^&.I:MI?B/Q!K'C?XDO\7?%4NDGXJWWCSPCH
M_A#6K'PAJNC:MX,\5>,7/B32/B-H=]9^/?LF?M#?M/?\$S?^"A=M^P1J'CO3
M_CG\-X?CW\(/V>?&'@==7\1Z3X%TG3/V@];\'^,O!WQE^%NBZW_;<OPG\;Z=
MI_QUL/B#\2/ ^E'7/#7C#4KOQMX!UKQ)XOU2P^'_ ,:_#/=4R^A*CBJN#QL<
M7+ TW6Q-/V$Z/[B$XTZM>A.4Y*M2I.2E)M4VZ5ITU.ZB<L,7553#PQ&&=".*
MG"E1G[6-2U6I'GITZT8I>QE->[O.,*B<*DH_$?V@45_+C_P6M^-7Q_\ 'G[9
M_P"SU_P3W\+?%.?X5? SXX^#?@OH_BJ3P[I^J7%UXR\3?M3_ !G^)?[-FL6O
MQ7LK#Q/X?F^(OPH\*>$=/@N(/@^-4\,>&/&%YXF\33>.+O7;VP^'VH_#[XD_
M:"\7ZG_P0V_X* >%/#7PV^+GQB\7?LP>%O"?PX_:K\:_"235M5AAU[P7\1(_
MB/\  3XK:5XG\&>&?&WPX^&7Q<^)NG^&OA+K?BSX4>)_$>D>#M%T/Q#'\)])
M\0:1J</PR;Q'XFEY;;#RG[>/UJ.7_P!JO"<DO]QYJT>?VU^5UI1HRJ0I<MG"
MZE4A./(VL9>KRJE)T/K<<"\1S*RQ,_8*,7#XO9\]>-*52^D[*,9J5U_;317X
M0?\ !<W_ (*%W/[*GP4@^!'PQ\7:WX,^-7QM\.:EK6K_ !*\'^+O#6AZY\!O
M@SX>UG2T\4>*[J*3^T_&>D^(?BU:P^)/AM\+M>T+2?#USIG]G?%'X@>$_B1X
M;\>_"3P_I6O^]?\ !(?]@"3]AS]GV:_\>Z%_8/[0WQFAT/4?B]H]AXQ'B?PS
MX.T+P??>*T^$_P -?#]II-K8>$=/NO!OA;Q3>7'C>\T)?$O]H?$;Q#XNT_3?
MB-XV^'&@_#4Z/S5<-['"T*]2?+5Q4Y.CA^6\GAJ:<98JI+F7LX3K+V-"+BY5
MG"M-<L*5Y;0K>TK5*4(WA1BO:U>;15I-.-",;/GFJ=ZE5W2I)TE*\JL4OUEH
MHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\R^,OQE^%_[/?P
MP\8_&;XS^,](^'_PS\ Z6-6\4>*M::X:WLX9KNVTW3;"QL;&"\U;7O$7B#6;
M[3O#OA3PIX?T_5/$_B_Q1JNC^%_"^D:OXAU?3--NJC&4Y1A",ISG)1C&*<I2
ME)VC&,5=RE)M)))MMV0FTDVVDDFVWHDEJVV]$DMV>FT5_FH_M(?M'?%;]J?]
MH#Q1\:_C#I?BVZO?BS<>-V\.W.M2R:[X*^'7A'P=J^@ZGH7[-?@GQ;;>%/"G
MAG7[7X/>&/BMX<;6;32-%T35K^Y\6Q?%?QSH,?BOXR7^M:[_ '^_L%>(_$/C
M']AC]B_Q=XNU[6?%/BOQ3^R=^SIXC\3^)_$>J7VN>(?$?B'7/@_X.U/6M>U[
M6M3GNM2U?6=7U*ZN=0U35-0N;B^U"^N)[N[GEGEDD;T,TR[^S7@HNO#$/%T\
M6Y.FO<I5L#6HX?$T5-3DJJA7JRI*HN5-TI/ELT<F"Q?USZPU2E25"5#EYG>5
M2GB85*M&IR\J<.>G34U%W?+.#OJTOK&BBBO-.P**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BOP6_;H_X)T_\% OVW/CYXTT#6OV
MKO '@W]AO5]:T2?P3\-E'B75-9\)Z?I/PU^'.LR7?B_X4^'?!W@+PW\9]57]
MI7X?)XO\,K\1?C/?77P^T/69O$G@;7]#U.U?P/?_ )%_\%)O^";^K_\ !-2]
M^'7[0OP/^/\ XM3PAXO^)MW\+O 5S#?:QX"^/WPK\4Z_\&?$M_+-I/Q/^']U
MI%MXB@\5Z!X8^-4&K>)=!L/A+JWA/0M4\+^"8=&\>+K'B3Q99>QA<LP^+=.A
M2S&D\=5I>TA0]A5]AS>S57V,L4[6K1I\WM$J,J<9Q=*-2<[(\^OC:N'4ZL\)
M/ZM3GRSJJK3]IRJ7)[2-'K!R^&]2,G'WY1C'4_M=HKX'_P""8'QX^*?[2W["
M_P "OC'\:M4T77?B;XA@^(>A>)O$&A:+#X=M?$C?#SXL^//AOI'B6_T6S?\
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M:K331]5YA1113$%%%% !1110 4444 %>Q:9_R#=/_P"O&T_])XZ\=KV+3/\
MD&Z?_P!>-I_Z3QUG4Z?/]"X;_+]4>5ZG_P A+4/^OZ[_ /2B2J-7M3_Y"6H?
M]?UW_P"E$E4:M;+T7Y$!7\6O[ W_ "?K_P $UO\ LI7Q6_\ 6"_VJZ_M*K^+
M7]@;_D_7_@FM_P!E*^*W_K!?[5=?O?AU_P F:\>O\/AQ_P"K;/C^<_%O_D[O
MT>?^QYQC_P"J[)1/V9_V]O\ @HE\4- ^"_CGPS\>/BUX\^,GQW\/?"^?5_A_
MX=\*_#+Q):?$SQ6G@.>VLM&\*^ _%OA6?X9_!W2"EUJ'C#Q]X@^'UA\)?#T-
MIH-SX^^+'BW3_"/ACQ!K5KZU\<_CS^WM^QA\2_B/X>M/CI\1M1^*?P@\+:5>
M:3'\2-;^(_Q$^"'Q0T+4=-\&?$Z&*UTKXI16<'C+P;XCN_#\OPH\4_$WP=;:
M%\0_"]]8_%SP;X!^(_A#Q'%K^I'P3_@BS_R5_P#X)G?]BWJ__K''QLK[2_X+
M7?\ )T6M?]F:^ ?_ %8?[3-?MV8PR*?'/$OAW#A'A/#Y#BO#:6<5ZF'R/!T<
MQEF^%RBA5P>-AC(03H?4:<8PP=&A"G2P]9U<;!?6J]6I+\!J3XACP#F7B:^-
M>,I\0<-^+.)RC)Z$\_QD\IP^65<^HPQ6$J8"<Y1Q$<9+'5?K;KSFJ^&IT,#.
M/U.#I3_6W_@H[^VKXD_98\/>!/ GP\T&ZD^)OQLTKXA7/ASQ[>0:5=^%OAQH
MGP]E\#6/B369M-O9;B;7O'-U<?$;P_'X"T.[T>X\(AK;Q!XD\77EW;^&;#P'
M\0/RK^!OAW_@HI^U#\);S]IWX1_&?XJZ_H*_&[66\)Z"/C[JOA^]\?Z[X$^+
MMOI_C37?#/A6Z\4V7PZM/A/X0^)FG>,_"VM?#/QY>^$M#UWPS\.?%?A+0?A?
MXH^%^L>!=-\<^M_\%H/!6H:7\;/V?/B9_:?Q-U'1/&7PV\??#FXTR\NK^\^"
MW@GQ!X$\1^'_ !;HLN@6J:8-*\,_%CXO:1XY\5MXD:ZUI]4^(/@OX#>'6TO2
M5LOA9K=[7T)^Q;_P4 ^%7PQ_84^%,'Q\\6^'[/XF?"]/%/P5M_AU\.]"\1WW
MB76M#^&+^*8O@K/#I&H3WD<=[XV^"'AKP%=^(_B%J>MZ'\(H_BSKNI^$9?$G
MA'5&C\)Z5^<Y-0S#A[PM\/,PX+X(R;BS,N,<QXDH\5U<PX<?$-2=7!YK+!97
MDM5K]]@L%BL!AJE65*%7#Q;HU<91G1J5JU:?ZMQ1B,OXE\8^-<CXYXZSK@[(
M>$>',@S+A2GEO$[X6I.MB<+2QF99_3J\T(8O,,NQ56>'HU9JM[*"Y'3G&DE'
MX'_;#_:H_;A^&_QM^ GP.\5_&SQGX2\3^#OV%?V-OCK\0[+04\"Z!>WW[4>H
M>+_VB?"7Q0\0>++[X::=I^A^,/#VMZCX%TB'7_A6+[5O@)JTFCQ/8^"IK&42
M3>H_L\>$O^"K'Q@\7?LS_'/3?BQ\3KWP/XG^+/@7Q)X^\:^/_&?AKPGX)\0?
M!;P'>^ =,^(^HWWP(TFUTWPR;#]H'X5MX]\.?!^;P#\&TT:^\?Q1?&8W'PZL
M-7\ _&G6/DS_ (*+_$/1_BY^W7X(^*_AVSU;3O#_ ,3O^":?['WQ"T/3]>AL
MK?7+#1_&GQA_:\\2:99ZS!IM_JNG0:M:V6I00:C#I^J:E91WB3):W]Y L=Q)
M_2A^PA_R8]^QK_V:G^SQ_P"JB\(5X_$N9X/A?P=\,J>7<.<.3S#C;(N+\#G.
M=XO*:-7.'@\KSSEH4Z&,2IU:=7VN9K$_6).=6-7 X17=.#IOT<BRO%\7>/'B
M#3QW%?%#R3@JMX<Y]DN3X/.*U#*<3CZ^08#%*OB\*DZ%7"UUAJ\<5A*-.A0Q
MD<PQ,ZJYW&2_#FT_;5_:<_X*(_'_ .$W@+X-:Y\3O@#\./B+K*:_X8T3PQ+J
MEEK?PY^'OASPGXNUC5?BA\>/%7PUDEU W^N:!JMMH4G@BZ\6R?!BS^+NO_!K
MX;VFLW'B@6?QDUO#U3_@H!\=?^"=WQR^/G@[XJ?$#Q;^TO\ #7X!>*Y9?C#X
M=OM5N_$/BW4/#>N?#'X:_$NS\4?#+7/&]S)K.A>-M!^%FM^&-=M?A;=>)8?A
M=JWBJ^\:>%)=0L]4\2V_QKTGX0_9E@\!:O\ $;X(>"_C_IGC7P-\.O%=VWPY
M^)NL0WDO@OQG\"_&R:/=:?I,OCCP[KW@#Q=>Q6^C_$S2(/A-\2] UO1_"$WP
MUO?$MUX_\<^)O#'ACX9>,;*\_5'XK_L5?\$K=:M=+^"NM?M:_%.YU#X^,_PM
M\/O\,?%G@7X@W)U7QOJ_AWX>Z?I]SKGA+X*>-_"_@W4]7UKQUHUCH4OCDZ;9
MWX?5-3M4NM,\->)+K2OU?C[+>">'(\5<)RRW$8SA["\&U7PYE^6^',:GU',<
M-E/UO#<9+CRA6GB<;6BJ.+GFF*KTX86-+ZS#&2G3P^-GB_Q[@_->/>*<3@.+
M*>:8?+N*H<?.CFV9YKXHRP%*&61S:.'K<$R\/<1AXX2C@9*M0A@Z,:T\57KR
MI3HISK4Z4/HS]I/PE_P52^+W[2?Q.^'OP\N;OX9_LK7^O_#C0OA=XY\*^-?A
M[X&BM]'\*_#?0OBKXC^(_C/Q-X<\2W_[25IJ/B'XV-X@^"NH:#X3TNWT#6/#
M'A_P/8ZE\.QX'U[XH_$#Q1^</Q-^,W[>7[%GQKM? _C#]H677OC-I_PD\,_$
MFY\.O\1_B%\<?@U<>$?'/Q#\6:;HNDZYI?Q+T3P1<7\^MZI\#-6TS6]:T+P]
MX4\<Z!X7U76=+\"?$#P[=>(M5U"H_P#@HU\?/BG\0?VAOCM\'/B7XT\<>&O@
M9X-^+O@#0;?X<ZWX2T#Q]I/P]\*6VD_!#Q%/\4=1^&?P.O=3U[XXVEEJND0_
MM2_#'P?XD\0:W\8+.TUK1_#&AVWPJ\;WESX/\-^#_M4>%?A3\//VBO%OPZ_9
M_P#%U_\ $;X/^&/AI\.Y[CQYJ5[8ZRU[\7]>O_'FJ^-_#FA>)M&TCP_X:\5^
M%] \ 2_!V]@UGPOI^JZ19^*_$'C'PI>>*[WQ1X9\1^%_!VOA]PI"IEF0<,<3
MX/AS$9=Q%P##/_['RC@/VM"I@\?@:4\MSG-N.JU1SI<2P>'I8BI"C3;H8RK2
M6'J4U'+:M.O%[BV7U[CCB7A7'<483..#^+<+E"SO,O$98!X+'X7&X;"8W*^'
M/#^C1:S#(JL*U6%:I.I1=6E&MCZSQ-..8T*OUY^VO_P4"_:)^(7AK]G3Q%X*
M\0^(_@K\,?C+^PM^SQ^UAJWPQ^$^N7@^*W_">?%G6]6^(#>&[CXP:+'X8\77
M^D^#;;X;Z!X4\,6/@9/AQI_Q @\2?$W2_BAIOC#PSXBT'PWX4^JO@_\ L[_M
MX:MKOP*^-WP2_;_\#?%WP,^O?#:R^+]TGQJ\9_%OX;:SX8T/XX>%E_:P^%O@
M*UU;PW\1? /BW6=/T3X=^*/AQX+^+4UA\._B9I'B2Y\2^'47X/"\\4M?>6>!
M/A_^P7\5_P!E_P#X)9>"OV@?B9K/P>^.J?L)_LKWND^*?"EG_P (\?%'PNN/
M@'J5WIO@[XI?$3Q%\/?%GPTL/ MMXE\.>+=>\(2>*-8\-^)/#WCJ ^'_  7X
MBTI?BYXC\*_$OX"NO$OQ/_9"_:3DL?V8/'T_QH\4^'/B=\!_#^A?\*Z\:^&O
MA?X$_;!U'6;'P['I7PAUF_U/7_B#\/;7PUXFU_XQ>.?@UHFK^/[OQ=;?"KQA
MK6J?$?P]-H'C+1=+US3/SK*L'2XC\()8/(,%A>'<PX?X)S//^*<!G_!="=#B
MC"P]CC)\291QC7P]2M0QN&HRI++*;Q%&5L2H4X_4<!#%T/T3B;,\1PUXQ4,]
MXDQ^*XDR7-^+.&LGX:J\-<>8C!XW@G'SITZ-7(LUX)H8JG2S# YK5YWFRE2K
M^VP/,ZT_K6.EA*OV]^U/^WK^T3\??CW??LV_L\V_C_X8:-9?':Z_9TTJU\-3
M7EK\0/'WCOPE\7['PEX@^*7B3Q-\/K3Q!XQ^'OP=\&ZUX.U[Q+J(\&WDTT?[
M/^E^./'GQ<L=5T[7+OX9> .>^+/[0G[57_!/7]J'5?AP_P =-=_:,6W^'OPS
M^+=_X2^(NO\ B&YT;QQX \0:C\5O"FF:!/+XHE\;:C\(/$ESXJ\(?$&*/Q%X
M O\ 6([@:/\ #WQ'XQMO&VE:?<?#*R^(_C%JND:+^UM\9S\3?"GC6V\%VG[9
M?Q7T[XJZ3I\>J^&_B#X=^%WBCXV^(YKGXF^'-*G\#>-M:UT:7\//$>C?'/PG
MX;TOP-KFH?&3P%_96D> I5F\?>&/%,'Z7?%#]F;_ ()4?"KPR_B3Q?\ M>^-
MSH\LMY9RW/@3QKX'^*>I:=]GT/6->N-0O]%^&GPB\::MI>EV^G:)??\ $[U;
M2X-#_M1]+T-KM]9US1=-U']"S++>".&\)EG#^*RW$X_A;'<!X:O_ &7E7AU#
M-L1F.98[!SK?ZW1XWHUGC(YM!TVW",(8;"X6$(PIT:2PU6E^<O-./N*,SXUS
MK"9IA\KXOR3Q!QV"R[.,W\49<.83AS*LIQE&"X>EP)B:"P.,RG%X=UJ=?%U\
M1?&XF<W/VDZ&.I8WYU_;0_X*I^./BF]IXB^$/CCXF? +]FW2_P!GWX)_%[7X
M+G3M*\"?$[6=9^)_P[^'7[5MKKFL^-_!7BKQ7XETWP_X'^&GB7X;^$G\->"M
M=\'Q:KXJNOCUX4\>0?%CP%J/@*\M/,/VHOA?^V=\--.^&\W[37BCXPZIX8^)
M.F>$?&]MH_BOXDWOQ6\&>$OB9H7AWQM8CX<ZQJ%SJ_B[0/ OQ<\'^'O'?BHZ
M_;_#S7+;P;\6=.N3J>C>+/C#9?"0WOPX\Z_:L\%>*?V1_P!H7Q+X"^"6DZGJ
M6O\ [+/A[]DO_AGBZ^-MA=C3OB='^S]^SO\  :P^&7B+Q->Z%:> [3Q5X4U[
MQI\,[WP9XU\0^!#X?TB;Q+X<\>Z%H]UX?U?0+^PT;]!/^"GG[8_PI_:!\+_!
MSX9_!;5+;QMHVE>+F^*OC;Q9+:>-/"]UX8NQ\+[.'P#X7LO#_BCP-I=KXD?Q
M5HGQDUZ]\4WUCXDMM0^%WB?X>7WP\\6>'3XOO=;L/!W9P5AL7DF;>"F29!P=
ME.,X=SG@G+.*,_XBCDJKXNAQ'B<KJXC-<5_;R@I8.ME^(GA<'%5JO-5P^/AE
M7*XUL-2B<?XO"\04/'[->*>-\VRKB#AS/:_#G"W#,,^E@<!6R*$HT<%AH9#.
M2CF5#/*<95<0X4&_:T?[1YH3]I5/T@_X)4?\F*?"'_L9_CY_ZT9\6J^VOB3\
M1/!_PB^'7C[XL?$+57T'P#\,/!7BKXA^.-<CTS5];DT;P?X*T*_\2>)=6CT;
MP_8:KKVKOIVBZ9>WBZ9HFEZEJ]^T(M=-L+R]EAMY/B7_ ()4?\F*?"'_ +&?
MX^?^M&?%JO*?^"PGQB_X0K]F_0/A!I&K"S\5?M ^/M%\/W4&C_$0^#?&6G_"
M[P!/!\1/B/XBM/#]C#+K7CWP%K%[HG@GX$_$_0HYM*\.MH/QYM;3Q3J=U9:G
M;^$O%?\ )V%X>K\6>)<N&\.Y0GG/%^+P52M%*3PV&J9G6>,QCB_BC@\)&OBI
MI)MPHR48RE:+_K;*.(,+PIX.Y+Q+C5S8;(_#O)\SJ4^;D=9X3A["U:>&A)IV
MJXFK&&'I:.]2I!).Y_-Q\.O@U\9/VPOB'K7@[PM!H.F?'?Q+X._::_;T\?>
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M\5O$_AGXH^-_%V@_L]Z/?>&?&NH^*YKOPY-\*OC9H?AC2_&%CX8\?:]\*)/
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M* MXL\-:C<?#'P?K6O\ BWPA\*/AS\*/$E_X=;XG?'CX3ZK\#_[6OV\OVV/
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M\>/^SOO%?_J@/V<:^]/^"J'P.^*/[1_["OQD^#?P8\+_ /"9?$CQ7K7P4N]
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M^@O^"9__  6PMOVO?B7X2_9[^-_@;P[X3^*7Q$TGQ%JOPI^(GPJ/B#4_A?\
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M/_@L-^R?\//V+_!/_!,_X'^ -/T-KS3/AY^U]J_Q-\;:1H5SH%W\7/BW>O\
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M39_X*$NC%73]A[]K%E920RLOP%\?%6!'(((!!'0U_-W_ ,&Z/Q=\2:1^U_\
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MLDK)7>NW<]-MR;;W;;>EM7J]%I]P4444Q!1110 4444 %%%% !1110 4444
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M>LZ3OUV'4W7[9]O5AJ=O:WL':_&O]BK]F7]HKQ3/XT^,?PT_X3#Q-<>#=/\
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MQ#\=W\2W,FC^%/$^A:5JE_??\(5X;B@U+5[._P!0TNWLI[72;FQMM5U>*_\
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MDG7<?9TX0MRQBE\7^*/^">G['GC+QEXR\?>(/@Y!<>)_'_B&?Q7XIN;'QO\
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M4XTU-IRY5;F<4U'F>[Y4WRINRYI-6<I7****YS8**** "BBB@ HHHH ****
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M'VVS_P"?JV_[_P 7_P 50!9HJM]ML_\ GZMO^_\ %_\ %4?;;/\ Y^K;_O\
MQ?\ Q5 %FBJWVVS_ .?JV_[_ ,7_ ,51]ML_^?JV_P"_\7_Q5 %FBJWVVS_Y
M^K;_ +_Q?_%4?;;/_GZMO^_\7_Q5 %FBJWVVS_Y^K;_O_%_\51]ML_\ GZMO
M^_\ %_\ %4 6:*K?;;/_ )^K;_O_ !?_ !5'VVS_ .?JV_[_ ,7_ ,50!9HJ
MM]ML_P#GZMO^_P#%_P#%4?;;/_GZMO\ O_%_\50!9HJM]ML_^?JV_P"_\7_Q
M5'VVS_Y^K;_O_%_\50!9HJM]ML_^?JV_[_Q?_%4?;;/_ )^K;_O_ !?_ !5
M%FBJWVVS_P"?JV_[_P 7_P 51]ML_P#GZMO^_P#%_P#%4 6:*K?;;/\ Y^K;
M_O\ Q?\ Q5'VVS_Y^K;_ +_Q?_%4 6:*K?;;/_GZMO\ O_%_\51]ML_^?JV_
M[_Q?_%4 6:*K?;;/_GZMO^_\7_Q5'VVS_P"?JV_[_P 7_P 50!9HJM]ML_\
MGZMO^_\ %_\ %4?;;/\ Y^K;_O\ Q?\ Q5 %FBJWVVS_ .?JV_[_ ,7_ ,51
M]ML_^?JV_P"_\7_Q5 %FBJWVVS_Y^K;_ +_Q?_%4?;;/_GZMO^_\7_Q5 %FB
MJWVVS_Y^K;_O_%_\51]ML_\ GZMO^_\ %_\ %4 6:*K?;;/_ )^K;_O_ !?_
M !5'VVS_ .?JV_[_ ,7_ ,50!9HJM]ML_P#GZMO^_P#%_P#%4?;;/_GZMO\
MO_%_\50!9HJM]ML_^?JV_P"_\7_Q5'VVS_Y^K;_O_%_\50!9HJM]ML_^?JV_
M[_Q?_%4?;;/_ )^K;_O_ !?_ !5 %FBJWVVS_P"?JV_[_P 7_P 51]ML_P#G
MZMO^_P#%_P#%4 6:*K?;;/\ Y^K;_O\ Q?\ Q5'VVS_Y^K;_ +_Q?_%4 6:*
MK?;;/_GZMO\ O_%_\51]ML_^?JV_[_Q?_%4 6:*K?;;/_GZMO^_\7_Q5'VVS
M_P"?JV_[_P 7_P 50!9HJM]ML_\ GZMO^_\ %_\ %4?;;/\ Y^K;_O\ Q?\
MQ5 %FBJWVVS_ .?JV_[_ ,7_ ,51]ML_^?JV_P"_\7_Q5 %FBJWVVS_Y^K;_
M +_Q?_%4?;;/_GZMO^_\7_Q5 %FBJWVVS_Y^K;_O_%_\51]ML_\ GZMO^_\
M%_\ %4 6:*K?;;/_ )^K;_O_ !?_ !5'VVS_ .?JV_[_ ,7_ ,50!9HJM]ML
M_P#GZMO^_P#%_P#%4?;;/_GZMO\ O_%_\50!9HJM]ML_^?JV_P"_\7_Q5'VV
MS_Y^K;_O_%_\50!9HJM]ML_^?JV_[_Q?_%4?;;/_ )^K;_O_ !?_ !5 %FBJ
MWVVS_P"?JV_[_P 7_P 51]ML_P#GZMO^_P#%_P#%4 6:*K?;;/\ Y^K;_O\
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M?_%4?;;/_GZMO^_\7_Q5 %FBJWVVS_Y^K;_O_%_\51]ML_\ GZMO^_\ %_\
M%4 6:*K?;;/_ )^K;_O_ !?_ !5'VVS_ .?JV_[_ ,7_ ,50!9HJM]ML_P#G
MZMO^_P#%_P#%4?;;/_GZMO\ O_%_\50!9HJM]ML_^?JV_P"_\7_Q5'VVS_Y^
MK;_O_%_\50!9HJM]ML_^?JV_[_Q?_%4?;;/_ )^K;_O_ !?_ !5 %FBJWVVS
M_P"?JV_[_P 7_P 51]ML_P#GZMO^_P#%_P#%4 6:*K?;;/\ Y^K;_O\ Q?\
MQ5'VVS_Y^K;_ +_Q?_%4 6:*K?;;/_GZMO\ O_%_\51]ML_^?JV_[_Q?_%4
M6:*K?;;/_GZMO^_\7_Q5'VVS_P"?JV_[_P 7_P 50!9HJM]ML_\ GZMO^_\
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M?;;/_GZMO^_\7_Q5'VVS_P"?JV_[_P 7_P 50!9HJM]ML_\ GZMO^_\ %_\
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M4 6:*K?;;/\ Y^K;_O\ Q?\ Q5'VVS_Y^K;_ +_Q?_%4 6:*K?;;/_GZMO\
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M3+'_ ,#-5_\ D^BBIYY_SR_\"?\ GY+[BO9T_P#GW#_P"/\ EY(/^%%?"?\
MZ$RQ_P# S5?_ )/H_P"%%?"?_H3+'_P,U7_Y/HHI^TG_ #S_ / G_GY+[@]E
M3_Y]P_\  (_Y>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D
M^BBCVD_YY_\ @3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]
M'_"BOA/_ -"98_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>
M2^X/^%%?"?\ Z$RQ_P# S5?_ )/H_P"%%?"?_H3+'_P,U7_Y/HHH]I/^>?\
MX$_\_)?<'LJ?_/N'_@$?\O)?<'_"BOA/_P!"98_^!FJ__)]'_"BOA/\ ]"98
M_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\ Y]P_\ C_ )>2^X/^%%?"?_H3
M+'_P,U7_ .3Z/^%%?"?_ *$RQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_
M #[A_P" 1_R\E]P?\**^$_\ T)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\
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M98_^!FJ__)]'_"BOA/\ ]"98_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\
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MQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_ #[A_P" 1_R\E]P?\**^$_\
MT)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\ \GT44>TG_//_ ,"?^?DON#V5
M/_GW#_P"/^7DON#_ (45\)_^A,L?_ S5?_D^C_A17PG_ .A,L?\ P,U7_P"3
MZ**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\ ]"98_P#@9JO_
M ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_ / G_GY+[@]E3_Y]P_\  (_Y
M>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D^BBCVD_YY_\
M@3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]'_"BOA/_ -"9
M8_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>2^X/^%%?"?\
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ML?\ P,U7_P"3Z**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\
M]"98_P#@9JO_ ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_ / G_GY+[@]E
M3_Y]P_\  (_Y>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D
M^BBCVD_YY_\ @3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]
M'_"BOA/_ -"98_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>
M2^X/^%%?"?\ Z$RQ_P# S5?_ )/H_P"%%?"?_H3+'_P,U7_Y/HHH]I/^>?\
MX$_\_)?<'LJ?_/N'_@$?\O)?<'_"BOA/_P!"98_^!FJ__)]'_"BOA/\ ]"98
M_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\ Y]P_\ C_ )>2^X/^%%?"?_H3
M+'_P,U7_ .3Z/^%%?"?_ *$RQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_
M #[A_P" 1_R\E]P?\**^$_\ T)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\
M\GT44>TG_//_ ,"?^?DON#V5/_GW#_P"/^7DON#_ (45\)_^A,L?_ S5?_D^
MC_A17PG_ .A,L?\ P,U7_P"3Z**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O
M)?<'_"BOA/\ ]"98_P#@9JO_ ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_
M / G_GY+[@]E3_Y]P_\  (_Y>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z
M$RQ_\#-5_P#D^BBCVD_YY_\ @3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)
MEC_X&:K_ /)]'_"BOA/_ -"98_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_
M )]P_P# (_Y>2^X/^%%?"?\ Z$RQ_P# S5?_ )/H_P"%%?"?_H3+'_P,U7_Y
M/HHH]I/^>?\ X$_\_)?<'LJ?_/N'_@$?\O)?<'_"BOA/_P!"98_^!FJ__)]'
M_"BOA/\ ]"98_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\ Y]P_\ C_ )>2
M^X/^%%?"?_H3+'_P,U7_ .3Z/^%%?"?_ *$RQ_\  S5?_D^BBCVD_P">?_@3
M_P _)?<'LJ?_ #[A_P" 1_R\E]P?\**^$_\ T)EC_P"!FJ__ "?1_P **^$_
M_0F6/_@9JO\ \GT44>TG_//_ ,"?^?DON#V5/_GW#_P"/^7DON#_ (45\)_^
MA,L?_ S5?_D^C_A17PG_ .A,L?\ P,U7_P"3Z**/:3_GG_X$_P#/R7W![*G_
M ,^X?^ 1_P O)?<'_"BOA/\ ]"98_P#@9JO_ ,GT?\**^$__ $)EC_X&:K_\
MGT44>TG_ #S_ / G_GY+[@]E3_Y]P_\  (_Y>2^X/^%%?"?_ *$RQ_\  S5?
M_D^C_A17PG_Z$RQ_\#-5_P#D^BBCVD_YY_\ @3_S\E]P>RI_\^X?^ 1_R\E]
MP?\ "BOA/_T)EC_X&:K_ /)]'_"BOA/_ -"98_\ @9JO_P GT44>TG_//_P)
M_P"?DON#V5/_ )]P_P# (_Y>2^X/^%%?"?\ Z$RQ_P# S5?_ )/H_P"%%?"?
M_H3+'_P,U7_Y/HHH]I/^>?\ X$_\_)?<'LJ?_/N'_@$?\O)?<'_"BOA/_P!"
M98_^!FJ__)]'_"BOA/\ ]"98_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\
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MQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_ #[A_P" 1_R\E]P?\**^$_\
MT)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\ \GT44>TG_//_ ,"?^?DON#V5
M/_GW#_P"/^7DON#_ (45\)_^A,L?_ S5?_D^C_A17PG_ .A,L?\ P,U7_P"3
MZ**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\ ]"98_P#@9JO_
M ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_ / G_GY+[@]E3_Y]P_\  (_Y
M>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D^BBCVD_YY_\
M@3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]'_"BOA/_ -"9
M8_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>2^X/^%%?"?\
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ML?\ P,U7_P"3Z**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\
M]"98_P#@9JO_ ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_ / G_GY+[@]E
M3_Y]P_\  (_Y>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D
M^BBCVD_YY_\ @3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]
M'_"BOA/_ -"98_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>
M2^X/^%%?"?\ Z$RQ_P# S5?_ )/H_P"%%?"?_H3+'_P,U7_Y/HHH]I/^>?\
MX$_\_)?<'LJ?_/N'_@$?\O)?<'_"BOA/_P!"98_^!FJ__)]'_"BOA/\ ]"98
M_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\ Y]P_\ C_ )>2^X/^%%?"?_H3
M+'_P,U7_ .3Z/^%%?"?_ *$RQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_
M #[A_P" 1_R\E]P?\**^$_\ T)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\
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M98_^!FJ__)]'_"BOA/\ ]"98_P#@9JO_ ,GT44>TG_//_P "?^?DON#V5/\
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MQ_\  S5?_D^BBCVD_P">?_@3_P _)?<'LJ?_ #[A_P" 1_R\E]P?\**^$_\
MT)EC_P"!FJ__ "?1_P **^$__0F6/_@9JO\ \GT44>TG_//_ ,"?^?DON#V5
M/_GW#_P"/^7DON#_ (45\)_^A,L?_ S5?_D^C_A17PG_ .A,L?\ P,U7_P"3
MZ**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\ ]"98_P#@9JO_
M ,GT?\**^$__ $)EC_X&:K_\GT44>TG_ #S_ / G_GY+[@]E3_Y]P_\  (_Y
M>2^X/^%%?"?_ *$RQ_\  S5?_D^C_A17PG_Z$RQ_\#-5_P#D^BBCVD_YY_\
M@3_S\E]P>RI_\^X?^ 1_R\E]P?\ "BOA/_T)EC_X&:K_ /)]'_"BOA/_ -"9
M8_\ @9JO_P GT44>TG_//_P)_P"?DON#V5/_ )]P_P# (_Y>2^X/^%%?"?\
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ML?\ P,U7_P"3Z**/:3_GG_X$_P#/R7W![*G_ ,^X?^ 1_P O)?<'_"BOA/\
M]"98_P#@9JO_ ,GUZE:6MO8VMM96D0AM;.WAM;:%2Q6*WMXUBAB4L68B.-%4
=%F+$#DD\T45+E)[MOU;8XQC'X8QC??EBE^2/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gqb5bzr5wcdj000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqb5bzr5wcdj000006.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /N!YX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7XI#PSYY'B<^ V^(/_"@C\0%TG/A\^)5^%;>)!_:2>$R/@[_ ((1_M,_"?\
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M4W_$ZV?\(3_PH/RO^%M_\5KY>S=_Q._^$VK7_P""4/\ P]P_X5WXY_X=G_\
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MK$&@:Q\(_%NA^.?"7C;X;_!S2-5\=O/\);OQ_KWA;PYX/U37QXUT*>^U;1-
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M')2LI22<8MK[0^!?_!PS^PK\=OB'\&/ASIWA;]HKP%>_';QAX&\ >"]?\?>
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MTLUTWOK?0_T2**_.WXV?\%7OV _V=/BAXZ^#'QD^/+^#OB5\-9M%M_&GAO\
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MFIKJ/@[QCX-\7:?J7A7Q)XBTK^R_$]EINH7NG^*M.\1^'=$^PZ_C<_X()?\
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M]Z^B<G]DY'F&8K&0P/U7#^WJ4I5HKVLN7DC&M)MRM9.U"IIY+N?WR_##X^?
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M/B/PYKVDW%WI6MZ#K>E7=IJ>D:OIEW=:?J6GW5O>V5Q-;31R-_%1_P $=_\
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M=/ ^IVVK>'KNWDLO&7@!?'.C:0/&6@-H,NH>)O"[>,M%TCP@;ZTT'1O[Q_\
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M7G:,=VZ<&U:3]-_X++?!_P 3?L]?\$<_^":7P"\:7>@7_C'X'>/_ -E_X/\
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MTU9N4-;M7]6E3JO/,=B)TY\E3"KEJN#4)5'+"\RA.W+S64[J+O92TLF?(/\
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MK_@Z'_M'_A9G_!._R/,_LS_A#?VUO[0^_P"3]H_M?]CO^S]V/E\__C\\K?\
M\LOM.WFOFB\_X(>_\%1OV6/BK\.?B;\ ;_P)\5O&OP_\<>(?$7P^^*?P>^(&
MB?#SQ!X;C\-7:Z3X=U[QCX4^,=]X-LM&N/BKX0UK5+#Q9\+_  [XC^,O@MM
MN?'GPQ\<^)/%G@[5H9_&V_K_ /P2._X*W_MN?M'/\0?VN(M(\&ZOKVA>&]-\
M2_&WXC>//A7XDTG0/!GA36="T:#P3X"^&GP2\1:R]MJEGH_B+Q?X_P##'@;2
M]!^'/PS\1^*;7QSJ7BSX@>#_ !IX_N?$'B/MI_4,-G5;/99K@ZF%E"M5ITJ=
M24\;.57"2PCIRP_*JD5%.4H7C[1PC3HNE&_M5S2^M5<LI92L!B(XB,E3E4G!
M1PJC'%/%>T5;F<'+7ET?)S+GC4D_</+/@7+:2?\ !NW_ ,%(%M@!+#_P4)^
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M?\EV_P"%@^,_^%T_\@+_ (IG_DIG_"3_ /(H_P#%'?\ 0J?\2#^SZ_K_ /\
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M+EC*LI3E;V<;.2@HKW&Z<&TE?X2_X.-?^4E_A3_LQ?X$?^K^_:]K])OV0/\
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MJ^'OPG\7^.=?UOXH_!/P_I.B_%[PQX?N_@UK/@SPIH'BOQ7X,\4V>@6OPO\
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M#+7?&GBCX;_#[Q-\1_ 8^%GQ#\1>"/"FN^/?ABOBG2_'"_#GQGJ^@V&H>*/
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M ((^?M<?LR_&OXY?\* \8? K]O[6/"-OI_AKP;X%M=5L(/$?QHU74++QU?\
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MFC^$[^\3PGJ/AGQ3XC\?ZWHFD^+K3Q)\*/&WAY?#O^"-7_*5O]A7_L</CO\
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MOC6?BC\;_"GB;QE<>+_VC]5\)7>CVOQ-^(;V7A746T?1]"CGN_"^@:+X;O\
MQ5IO@SPA>^'?#NI^![/P5\'(]2\._"NX\(7&@>#;?3OZPOV,?VCOV1?VM/\
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MAZEI6OV>GZM9_P!2/_!KS_R9W^UI_P!G^>-O_66OV1J_DI_X)B_\EQ_X)O\
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MC;D<;*WIRIPQ&8Y+&O%58RRNA4DIZJ<J>$G5BYIZ3O.*<U*ZGJIJ2E)/L/\
M@LG^S+\'/V.OV]9/@K\"-%UCPY\.O%/[-GPE^.%MX9U77[[Q-:^%=>\3^.OC
M)\,-<T3P[JNMM=^)Y?#U[%\(-*\6F+Q5KWBC5X/$_BCQ6EGK-IX6_P"$:\,>
M'>F_;"^(WQT\=?\ !*#_ ((XZ1XKO=3\0?"+2M<_;'T35-0@\ ^';/PGH_BW
M]G?XDWGP*_9#\,W7BG2?"MHFA>)/"W[-TWQB\,>%]%CUBPU/XC:-X>\8^,/$
MUMXSU[PA=^(](]4_X.-/^4IOA7_LP#X#_P#K17[7U>(?M/ZOXT'_  2*_P""
M1?ADC5_^%17_ ,7OV_O%&MY\,VUQX5/QL\-?'WX@Z/\ "1;[QK)I$MSHWB__
M (5OXS_:*E\*^#8/$.GQ^,=#A\=>(IM"UY_AS;ZGX6]/#2E7K<(5ZKC4K3PV
M:\]2J_>ER49P4N9IN591HPE"[O4KJ+<E*3F<>(C&BN(Z--.%*,LO:A3CHN>-
M*I)6^S2<JU3VGV:=*4K+EBHGJOPB^#?_  3#U?\ X)(?&GXK_$;XFV>G_MXZ
M1;_%.;POH,GQ#UC3_'NE_$K1_$,%O\!_AWX)^$D5@UAXR^%/Q&TM/A]_PL;Q
MV?!?CB+PQ;_$3XMW4_Q9^'1^'TES\)D_X(._LW^$_P!H+]N^;5OB5X#\0>,O
M 7P*^$C?&70=6M)?%>D>&/!'[0?A'XX_ [6_@=K&M>)/"USI,9UV>RT;XFWW
MAOP/XFU>Y\/>-M-\.^+KB\\+>(+;PM>RZ7\K?L^1_P#!,"/X2^'E_:HN/V^K
MCXZ-J/C&3Q;)\!(OV=(OA2FF2^-O$4G@.#PRGQ '_"6FYMOAVWA2#Q/)JVY9
M?%\>O2Z:3I#V%?TY?\$;OVBO^"4VE#4_V?\ ]D+2_'GPL^-GCHVDNOQ_M$VE
MF/C1^T<?A-X \.K)XS@\::!KOBKX<W:0VFI^+O$EE\%_!6J^ X="U>U^.OQ(
M\$_ OPQX.O/%?BG5//SFKB</E%?#+^U:L<5BO:5L7BTXJA0J3I7PDI1E).G6
MY?JTJ<E'#SC7G"G&$IPC+JRVG1JYA2K-X"#PU!PIT,.^:5>K",TL0HRC&TJ:
M?MU.[Q$73A)\RC.=/^2'XK?M5>)?VV_VB+3]I7]I+4?'1\+?$WQ[X7U36O"_
MA_Q!H6O>*_A#^S9?^-%U>/X0_"+4=0\->'O!ESK'PT^&6LZMIG@V_P!1\(>'
M]#\;?$?[;\0?']@VO^-O&FKZA](_MX>/_P#@FCX_\+_#*?\ 8#^!_P >/@CX
M[T7QM?0_$JR^)^LQZGX$\6_#/5?#.JNUW:MJ?Q9^,?B>'XB>&?&FE^$8O#$6
MEW?A3PK<^$_$?Q&/BJ/7=:M_ TFA_(>K?#RZ_8X_:6NOA)XT\.S?%*Y_8X_:
M.\/^'_$?A'QYH-W\*[+XZ>%_@9\1M$UW1H/$WAW5]/\ 'K^%OAU^TO\ #G1-
M#U^T^TZ;\0M$O?A?\3=.U:RB\>^'=1M7UK^M0_MZ?\&_/_"O/^$U_P"%$? 4
M^)/^$,_X2C_A40_8=T/_ (6&=<_L/^UO^%<?VF?AF/A/_P )G]O_ .*8^W'X
MGCX>?VY_I'_">?\ "-_\5#7MX[$/"X_#RPF"S3$X98>E]4^I5)/+Y4/?C3A.
MC&+IIJE*#C.I:])TI4IKV=X>;AJ/M\-7CB,3@:%=UZJK_68+ZVJG+!RG"I)J
M:_>JHN2-VIQFIIJ:B_(O^#9'XS^/-<\)?M>_LZ:O>0WOPU^#VN?!GXK?#J*Y
MN_$%YJGAS5?V@7^,=A\1/"^FQW^MW?AW1/ TFM?!G3O'NEZ!X9T#0V;XA_$#
MXK>+==N];U+Q?YEA^@7_  < _P#*)W]I#_L=?V3/_6S/V?*]@_X)C?&?]B;]
MI#X?_%SXR_L8_LTZ-^SQIMI\3+/X-?$9H_@[\(_A-XE\;:UX%\$>&?B'H,^H
M'X3ZMKT'B+PYH&E_&J>W\.OX@U..]TK5]2\7QV6DV=K?&_U;Q_\ X. ?^43O
M[2'_ &.O[)G_ *V9^SY7Q& E&7$6%E&G[%//:?[G2]%_VBN:BTM(NC*]-Q5H
MQ<>5)))'U&(3CE-1.?M+9795-?WD?J?NU%?6TXVDF]6GKK<_G\_X-RO^4E7B
MS_LQOXZ?^K[_ &1:_(7]N[7X/"G[3?[?GBBYLO[1B\.?MA_ML:[]AW)&;E]*
M_:3^+%]%$LLB2+"[2P)LG\N0P-B549D"G]>O^#<K_E)5XL_[,;^.G_J^_P!D
M6OQ>_P""DG_):_\ @I)_V=+^W;_ZT-\7J^EIU9T<;QG6I2Y*M&C1JTYV3<*E
M/+.>$DI)IN,HJ2NFKK5'B3A&KA.&:4U>%2K5IS5VKQGF,XR5TTU=-JZ::Z,_
M<'_@KU_P3(^!W_!/+]CS]COQ;X(UKQ9XP^,NM_'NW^!7QA^(6H7/]EZ#\59?
M&_PC^,'Q6NO%8^'\UQKMMX$7P9XA^$]EX:^&NA^&/$"_V?X \0ZO8?$S5_BY
MXW@TOX@6?V-_P;#^,?%L]K^W#\-9]7C?X>:!JW[._P 2]!\.)I>D0-8_$'XC
M:9\8?!WC[Q)-K$&GQZ]J,GB+PK\&_A1HXT_4]5O=)TJ+P?'/HFGZ9>:OK]SJ
MWK/_  =$_P#)G7[)/_9__@;_ -9;_:XKP7_@V#_Y&G]O7_L ?LC_ /IQ_:HK
MR\75J8GA;"5L14G6JT\VJ4XU*LG.IRQH3:4IR;E)KVTTG)M\O+&_+&*7=1A"
MAGU6G1A&E3J99"<H4XJ$')XB2;48I1C?V-/2*4;QYK<SDW_6G7^:9^UC\</'
M7_!1W]M[QUXQ\'^/M U:7]I;]H'PW\ OV3=<\1R_$CP]\.="^&?BGQ_IWP4_
M9@O#H/BJV\2>-_A_X=\3:?JOA_XN?$W1--\+VMQ%\1/'WQ.\5V/P_P!(U77K
MGPW#_<#_ ,%@/VD9OV8O^">W[0GBS0?$+>'?B1\0O#(^!/PDN]*^)!^%_CJU
M\>_&:0^!_P#A+_AAK]K%/KU[X^^#?@_4O%WQ[T[1/"T</B"\TGX4ZU<V^K^%
MK*RO_%N@_P 8?_!-+]@75/\ @H#\;/%/P6TSQ5KOPI\*?#[X/WOQ U;XG67P
MRO\ XA^%-%U2#Q;X/\*>#?AWK+1>)?!NE:'KOCG3=5\9^(/"D=YXA%_JNF_"
M_P 8'2]%U&VTO5[[1JR2E1P^59IC\1B/J:Q2_LNAB52G6E3=2,9UI0I4_P!Y
M*2G/#2A*'P^SJRG*-.,[SFE2I6QN P=*C]9]G+Z]7P_/&DJD*;:IQE4G[L8S
MC#$1?-HY<BC&4W%'Z??\'!G[&WAKX!O^Q-\3?A)X?\0:/\'?#/P6TG]AZ'3+
MWQCI^L>&/ &F?!&RU/QG^SCX5T2R\1W=Y\4]>\2^*?!.K?'7_A*?&&KZUXOT
M^;2_A3X5CUN[T'Q%J"7?C?\ 0G_@VV^/5CXP_9 ^(?[--S/X?M_$'[,?Q8U[
M4M$T31-!\4V5ZOPC_:'UCQ%\5O#OB3Q7KVIR7?A;6_$>L_&B3]HC0[>S\*75
MA/HGA#PAX3'B'PW97.HV/B+Q;^='[7/_  ;]:[^S/^S%\=_VBO#_ .U5H7Q!
MN/@3\,?%?Q>U?P?XB^$6H?#RPUGP;\.M,F\6>/TMO%>F?$/XD7-GK]GX&TGQ
M%J'A33I?"<^G^(_%%IH_AO5]:\):5J][XNT/Y _X(D_M7Z9^S'^WE\/M-\5:
MOKMO\-_VGK"V_9NU:WL]=\4)X8LOB)X[\3>';GX$^,=8\%>'=#\0V_C/7?\
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MY<ZJ/&C?#H?LI>'8/ 1U,:^?AW%XU;XO?%F3XMCP4;M?^$63QI/H2_!3_A:
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M1?P+XKF_::_X*&^!=3T'5_#/B?7/VHOVP;C3]*\4:7?:!>RZ=X^^,OQ#\7^
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M?\,>;_\ AF7[?X'_ .%3;O\ AC''V/\ X55X"_X3/9_PL_\ XN#M_P"%F_\
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MJTZ<Z=ZJER\UW-0:ORV/X^M!72_AO\7_ !#-^U?\%?C-X]UFSN9O%OC[X/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+I_LD?'K]L?]F?X&_#[]GCX9-\4O&/@[]JGPU\2-8TL>*? /A(:#X5L/@?\
M'[P==>)FO_B%XJ\)Z9=+;:YXV\/Z1]@TJ[U#76;6EO(-+DT^SU.]L/./^"%G
M[$G[77[&V@_M,Q?M+Z1_P@GASXBZ]\+)OAS\,_\ A8VC^,_L.O>%-+\:Q_$+
MXB?V/X,UCQ)X$T'_ (3;3?$/PY\+?VI;:W_PFGB'_A6/V/Q1H^GZ!X:\"7^L
MY3PE&.7T<8L92G7J8B5&6"7+[:G!1J-5I6J.?*W"*]ZE&%IQM4<O<=QQ%1XR
MIAGAJD:4**J+%._LYS;BO9KW>6Z3>U1SO%WIJ/OG[YT445PG4%%%% !1110
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M6^IZ7X9U/Q-!I%GXLO\ P[XMM?#$NK3>#_%*:1]HU_G4_P#!6WXY^*/VE_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN[^+6US[ )ZQCA<2XIZI2E1Q7,UV<N2GS6WY8WV5OL7_ (.A?^2E_P#!//\
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MD^%W@_QO\68?BS\6-=L_'<'BOP=XTTWQ9X[^)^J?$_P'HW@;^9/]OC_DO_\
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M%*S\>>"_B[\1;2[\*ZI^S#\5M%\>7_C*#X?^!_#^L_!'6?V==?\ %=W%\3_
M6D_#KPE =)\3_"33/ >E>(O#&J?!VSADM-5\.^$K7P;J.DZE<A++5KC^Q/\
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M^@O_ (((_P#**C]F_P#[&O\ :D_]:]^/5>CGO_(MX<_[ JO_ *;P)QY7_O\
MF_\ U_C_ .EUS]A:_D$_:I_X-I=4\.Z3\0=6_8R\>>&_$?@1;F_G\!_LM?$C
M3KW3]1T+P!%X.O[FX^'&A?&;Q!XH\2:=\1-9N_%MM!X8\"6WQ-T/P!IL/@_7
M+&#XD_%;5-9\+:MXR\:_U]U_,=^VE_P<6>"O!.L>(/A[^P]X+\,?&;5=$UF;
M29?V@O'FHMJ7P'U1M*U'P/>7%]\+/#O@3Q%8^)?C'X7UW2[KXC^#HO&UUXS^
M$VC:/XGT#P]XZ\%6_P ;/AMKEC>ZER9'+-O;5899352,U!8J%6,'A90]]05=
MSLEHZG*H2C5FO:1@I+FB^K,U@'2A+&S<'!R="4)2592]UMTE&[;TC=N+A%\K
ME;1GY^? #_@JS_P4,_X)V?&;3/@3^VK9_$7XD?#[3M>,WC;P3\=M.U#5OCIH
MO@BX\9?%73-;\>?!+XP:SJEAJGQ%TC6O',NH7/AS6?B!X@^*_P *_%WA3X5:
M9\-O@OXF^%GA>ZE\8Z7_ %H_LB_MB_ S]MWX63?%OX"ZYK6JZ!I6N0>#_%VE
M^(_#6K^&=?\ !7CW_A#O"/C?5? ^M0ZA;_V3JFK^']&\<>'X]3UCP7K'BOP5
M<7\]Q;:%XKUE;.XE3^-&#P7_ ,%8_P#@M=XAB\3NFKZ_\(HM:U;5?"_B+QOJ
M%Y\'_P!CGP%J6F7OQNT_1X_"4&FZ1K5Q\0=;\*Z_8>./@9J_C/X>^#/CI\:?
M!9U3P[X>^->O6F@W$>MQ_P!9W_!-G]@O3?\ @GA\ M=^#5M\3]3^+NL^+_BI
MXI^*_BKQ?=>%[7P3I+:MK>C^%_!^DZ3X8\(Q:WXJO-#TK2_!7@7PG;ZD-5\8
M>)[O6O%__"4>)K6YT+1M;TKP;X9TSVGED/8/!NA''.I;&T<'.53 PA[.HY2I
MRE"*C4594H*G2:C"'M%4I*=IF>5SQTG5^L>U>%Y+X:IB8QABI2YX64U&4G*'
MLW.3G-.4I<CA-QO$^9_^"V_[=]O^R%^RSJ'PT\&:[XDT+]HG]J;0?&?@'X0:
MMX=L?%=I-X,\,:6?"^F?&?XIQ>/?#6O^$;CP!XH\"^$/'-C;?"S6=,\07?BJ
MU^,'B;P!K]AX/\1^#O#7Q O?#W\H_P ,OV"[A?\ @E]^U3^WSX^T#PT?"-L_
MP%^%7[)=I%=^%]<GM[^S_;0^%7@?XZ?%!M$/AW4=0\!ZOH4WA=_@?\.M6TGQ
M?X<\33:#J?[1&C^)_!]QX+\5^!=>UGZZ_P""Q?[/'[;W[0'_  4B_:/\2:%^
MSK^T7\1OAWX0T?X-?"SX+>./!'[/GB_6/#T?PWL?@QX,^(>J:1X<\8^&? <V
MG>-+71_C=\4/C+>W&JZIJ/B6]TOQ%J>M>$Y;Z'3O#MCH&D4/VI_VLO\ @HSK
M'["%U^RG\7/V&IOV?_V4O"?AKX$^ [?Q9<? K]J+PW/X)\-_"3QW\-YOA1HD
MWQ,^,OQ"\7V<TVH>(/"'@SP?)J/C*76]>\3/J367]I3>)M6M]2'OY=@YT:60
M4L-5P[ISQ^7YMF<O;P56K*-6A6P^%A2NY3CAX>\Z;7,\5!2IR2G."\O&8B-2
MKFE2O"LI4\+BL#@(^RDZ<%4I5*>(KRG\,959)14[N/L7>:4J<)'W!_P;#?\
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M%JOAC_A<_B:R\8_,G_!M/_PN#_AK7]H[_A'=G_"@O^&=-!_X7#C_ (0[S/\
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M_*U9]U&5.I%J[4\--+E:;/C'_@Z%_P"2E_\ !//_ +$K]M;_ -/7['%?9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^2_^$D/+_J:>?Y=S]CZ*_'#^ROC!_P! WXD_^ ?B?_XW1_97Q@_Z!OQ)_P#
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M+^'/F^%=.UE=6.L1^+]$&I^ 5N_%<5?_ (*A-_P[L_X+;?L]_M^:EMLOA/\
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MQ!_\/=?_ .@T/^)?Z/\ T7^2_P#A)#R_ZFGG^7<_8^BOQP_LKXP?] WXD_\
M@'XG_P#C=']E?&#_ *!OQ)_\ _$__P ;H_XJ>9C_ -(P^(/_ (>Z_P#]!H?\
M2_T?^B_R7_PDAY?]33S_ "[G['T5^.']E?&#_H&_$G_P#\3_ /QNOK3]E"T\
M:VVL^,#XJM?%%O"^F:6+0^((-6BB:475SYHMCJ*JAD"%=_E98*5W<8K]/\&/
MIZ8WQ<\3>%?#JKX"\9<(T^)L1CZ$N(LSS6KB,#EGU+*,PS15,11EPQ@%.-9X
M%86">+HVJ5X2O*W)+Y_BGP<I<-9!F.>1XQRO,W@*=&:P.'PT85L1[7$T,/RP
MFL?6:Y/;>T?[N5XPM97NOMNBBBO]$#\1"BBB@ HKY0_:NMO%5SX?\)KX5M_$
M%Q<+K-\;M?#\6HRS+";)0AN!IRLXCW\*9/EW=.:^'_[*^,'_ $#?B3_X!^)_
M_C=?P'X\_3CQG@EXEYQX=T? [B_C:GE.$RC%+B+*<TJX; XO^U<LPN8NE3HQ
MX;S%1EA7B7AJC^MU.:=.4K0OR+]FX.\(Z7%F0X7.Y<79;E+Q-7$TW@<3AXU*
MM/ZOB)T.9R>.H-JIR<\?W<;*25WN?L?17XX?V5\8/^@;\2?_  #\3_\ QNC^
MROC!_P! WXD_^ ?B?_XW7XY_Q4\S'_I&'Q!_\/=?_P"@T^H_XE_H_P#1?Y+_
M .$D/+_J:>?Y=S]CZ*_'#^ROC!_T#?B3_P" ?B?_ .-T?V5\8/\ H&_$G_P#
M\3__ !NC_BIYF/\ TC#X@_\ A[K_ /T&A_Q+_1_Z+_)?_"2'E_U-//\ +N?L
M?17XX?V5\8/^@;\2?_ /Q/\ _&Z/[*^,'_0-^)/_ (!^)_\ XW1_Q4\S'_I&
M'Q!_\/=?_P"@T/\ B7^C_P!%_DO_ (20\O\ J:>?Y=S]<?%/BKPQX&\,>(_&
MWC;Q'H/@[P9X.T'5_%/B[Q=XIU?3_#WACPMX8\/:?<:MK_B/Q'K^K7%II6AZ
M#H>E6EWJ>KZOJ=W:Z?INGVMQ>WMQ#;0R2+_-!^SK^W+_ ,%-O^"L'[0'B.?]
ME+5+;]B/]C?X=7/B:/4/BOXA^$O@;XG^)[L:MHWAZ7P'X)\7P>.9/$6@^-_C
MI/<V$GC'6/!/PCU+P5X*^"_@'Q[J5G\2?'WQ%UN#X(ZK\6?T^_:P-_8?\$A?
MVU'\5QZE#=6O[$G[94VK)JZW46HI;)\+_BM+FX%X8[I<V/EM"9"G[@Q,C"/8
M:_.W_@V/\0:#-^RO^U'X3B\1:)=>*K+]KBZ\<7OA:#6+&X\1Z5X+\8?L]_ 3
MPYX2\4:CH27#:GIWAWQ3XA^'7Q!TCPYK%S:Q:9KFJ>"_%MEIES=7?A[6(K/_
M %'\/.*/];O#/@WQ _L:>4XKC/).&<Z>49E&&,KY!#/N':6?5,MQ"KX:E2K8
MS#U,1' U:]7!T6I86M*%*C.?+'^=<]R]Y?Q)F60O%NO0RJMF='ZUAI2H0S">
M!S*G@(5:<J=3VD*3CS8CDIUIJ2JTU.4H1]_S;]I/_@H?_P %#O\ @DC^U!X+
M\*_M=^-_#'[:7[-'Q>T@>*?"/BC1/A[\-?A7\4]2\*?#>TM]/^-6G?#GPMX-
MO?#-IX;^*?@WQ!\1_ NM7F@_$^Y\=?#KXE^$X/ &C^"OB/\ #+Q'XI^*]]\,
M/U1_:@TS_@I/\?O%OP=UW_@G]^TG^R5\,_V3/%'A_P"%'CG4OC&;2Y^)OQ=\
M8V/B34?&G_"8:EX*BO\ P#\3_@AXY^$5[\+?$/PW^(/PSBT74/ OBGQEX]T"
M73;OXL>&/AYK4UQ?_F__ ,'//Q&\%Z1^S9^R]\,]3UYK#QKKG[1.N?&'2]%;
M2]:EM[_X=?"7X)_$KP7\0=<N-<M["3P]IR^'O$?QS^%]N-,U75+35]7_ +>:
M[T+3M3M-#\076D?I#X+^.7@;_@E[_P $LOV4]6_:\:X\"^(/@O\ LM_LY?!K
M5OAGH=UX<\4>//%WQO\ "_P7\/:%/\%_AI9Z3KS^&O&GC6ZU?PQK\45WIOB5
M/ VD^']"\0_$3Q1XP\/?"[POXH\;Z+]C54G+*L1AL-1EBL=AZT9T(X>G5I3K
M4L54PU.O#"SC.E&6(7N\D8>P53#U)4Z<+N*\NDTUF%"M6FJ&%JX=QJRK3IU(
MTJE#VU6G+$*4*G+2<$Y5'/VJAB+3J64&?F5XO_;[_P""@'[!?_!27X*_L8_'
MWXN?#7]LCP!^T#XH_9?M;/Q-?_#31?@KXQ\*^"?C[\3/%OP*BUW0H_AWI5OH
MFA>*="^)EIJ/B#7?#GB5?BWI/C#P+X#\.Z;H/B'X6:_X^U[4/"O6_MR?M_\
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M**_2CP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#RCX\_![PW^T-\#?C/\ /&6I>(=&\(?'+X4?$7X/>*M7\)
M7=AI_BK2O#?Q,\(:QX+US4O#-_JNEZWI=CXAL=,UNZNM%O-2T75["VU**VFO
M-+O[=)+27_.U_84^)%[^QG_P4&_9F\=_'/P]H/AS7/@1^T-J?PD^-MCXH^(O
MA;PWX9^$NJ^+[#QM^RI\:?%/B;XC6O\ PDO@MM$^!/\ PL#QAXTUW4+74_\
MA&-?LO UW:0^+]&TC4AXGLO]*&OYT/VT/^#>;X<?M3?M!?%[XV^"OCVGP1T7
MXX31>(?'/PQM_@?X>\4Z!'\0-2TI=(\>^*O#]YX?\:_#);2#XD36MOXW\7VN
MN:7XC\2:Q\4]=^(?CC4_&6HIXQM=#\-^YEN-P\,OS?+L74]G#%T(U<--QJ34
M<;0;]E%QIQDXQJ2E"=23M%K#P@_B37F8[#UI8K+\90A[26%K2C5IJ48.>&K*
M/MK2G**;48<BC=.U64HM-6E[I_P6-_X)??%G_@HA=_LU>*?@[\0OAWX3\1_
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MY-O6. P<<-+!JA'V$[.<;RO.2Y6IRG?GYE*"E%J24)?PU!61_')X5_X("?\
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MOCAXK:/XOW/@GQ!IWA73? /C'XQ^*X_$]]=:J/$/BK5?]$_X%_"/P_\ L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#/QYJ.C7=S\=;7QYX.@^%?Q+?0/C%\/&-S?Z=X(^''BR7-_X-K]''@?X@?\
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M+)\'/".E1?$#Q%I>E?$GQW\%]*\9Z'XC\+>'8O&^@^ /"/B'PC\2)/$">%/
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M:/0--U;Q#H&EW^LO:#3K/4=<T>RN+F.YU.RBG_C$_P""KO[*'P(^&'_!9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\+=_M__ (2SX3_M-_"__A</_" _V7]@_P"&C->^*NN?VY_PK[_A-=1^U?\
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MYITU34'I)<ME2AI&R?+JG=W_ !K_ &D/^"2/_#07_!/S]BG]A3_AH'_A$?\
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M#4E*$:M6G&<9)QE&:ISA[2+3:<9\T?(_++]G/]@'X[?#;P'>?L]?M!?MG/\
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MUTN#XA7T^E^&? WPC^)=SH/@GQ;XFU+3/B'\%O\ 0$KB_B%\-_AW\7/"6I>
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M;](;7]0\.76F_!KX]ZC\7?&6N;]5^"_BOX7>,-$M_BQ\3/A;_6K^R1KGQ/\
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M3\1W'A$6D7@#P[KVG6'Q#\4^$H_@KX=:X\4^)-<^"'ACP/X8\+?$+Q_XDO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45YYXZ^+OPH^%SZ9'\3/B?\//A
MT^MK=OHR>.O&GAOPB^K)IYMEOVTQ?$&I:>;];(WEF+MK42BV-W;"8H9XMW ?
M\-:?LJ_]',_L^_\ AYOAS_\ -)6D:-::4HTJDHO9QA)IV=G9I-;Z>I#J03LY
MP371R2?3HWYK[T?05%?/C?M;_LIHK._[37[/BJH+,S?&?X<*JJ!DEB?$@  '
M))X JK_PV)^R/_T=-^SE_P"'O^&?_P T]5["O_SXK?\ @N?_ ,CYK[Q>VI?\
M_*?_ (''_,^C:*^<O^&Q/V1_^CIOV<O_  ]_PS_^:>C_ (;$_9'_ .CIOV<O
M_#W_  S_ /FGH]A7_P"?%;_P7/\ ^1\U]X>VI?\ /VG_ .!Q_P SZ-HKYR_X
M;$_9'_Z.F_9R_P##W_#/_P":>C_AL3]D?_HZ;]G+_P /?\,__FGH]A7_ .?%
M;_P7/_Y'S7WA[:E_S]I_^!Q_S/HVBOG+_AL3]D?_ *.F_9R_\/?\,_\ YIZ/
M^&Q/V1_^CIOV<O\ P]_PS_\ FGH]A7_Y\5O_  7/_P"1\U]X>VI?\_:?_@<?
M\SZ-HKYR_P"&Q/V1_P#HZ;]G+_P]_P ,_P#YIZ/^&Q/V1_\ HZ;]G+_P]_PS
M_P#FGH]A7_Y\5O\ P7/_ .1\U]X>VI?\_:?_ (''_,^C:*^>8_VNOV4)EWP_
MM._L\RIDKNC^-/PW=<C!(W+XE(R 1D9SR*D_X:T_95_Z.9_9]_\ #S?#G_YI
M*/85_P#GQ6_\%S_^1\U]X>UI?\_*?_@<?\SZ"HKY]_X:T_95_P"CF?V??_#S
M?#G_ .:2C_AK3]E7_HYG]GW_ ,/-\.?_ )I*/85_^?%;_P %S_\ D?-?>/VM
M/_GY#_P./^?FOO/H*BOGW_AK3]E7_HYG]GW_ ,/-\.?_ )I*S7_;-_8^C=XY
M/VKOV:XY(V9'1_CI\+U='4E61U;Q2&5E8$,I ((((S36&Q,ML/7?I2J/\HDN
MO1C\56DK[7J17YOS/I2BOFG_ (;0_8[_ .CL/V:?_#[?"[_YJ:/^&T/V._\
MH[#]FG_P^WPN_P#FII_5,7_T"XC_ ,$U/_D1?6</_P _Z/\ X-A_\EYK[SZ6
MHKYI_P"&T/V._P#H[#]FG_P^WPN_^:FC_AM#]CO_ *.P_9I_\/M\+O\ YJ:/
MJF+_ .@7$?\ @FI_\B'UG#_\_P"C_P"#8?\ R7FOO/I:BOFG_AM#]CO_ *.P
M_9I_\/M\+O\ YJ:/^&T/V._^CL/V:?\ P^WPN_\ FIH^J8O_ *!<1_X)J?\
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MBSZ.HKYI_P"&T/V._P#H[#]FG_P^WPN_^:FC_AM#]CO_ *.P_9I_\/M\+O\
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M&M/V5?\ HYG]GW_P\WPY_P#FDI>PK_\ /BM_X+G_ /(^:^\OVM/_ )^0_P#
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M_HZS]FW_ ,/G\,/_ )J*/J>+_P"@7$_^"*O_ ,CYK[P^MX7_ *":'_@ZG_\
M)>:^\^DJ*^;?^&R_V0/^CK/V;?\ P^?PP_\ FHH_X;+_ &0/^CK/V;?_  ^?
MPP_^:BCZGB_^@7$_^"*O_P CYK[P^MX7_H)H?^#J?_R7FOO/I*BOFW_ALO\
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M<\9NW]H-%?C-_P %NOV[/'G[$_[,7A"/X'^,=(\)?M!?&CXH:)X7\#:@NI>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>UMK^TV-OJ6#O;ZIAK6O;ZO2M>ZU^#?^NI^8G_#D3_@E_P#]&Q_^9H_:$_\
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M9AW.$(.$W1Q'M*;G!MN,G&\;Z-'XSX\UZV3^'V)QN45:N5XR.:993CB\NG/
MXF-.I5FJD%7PSI55":24XJ?+):-,_ 3^P-)_Y]/_ "/<_P#QZC^P-)_Y]/\
MR/<__'JV**_L7_5KAS_HG\D_\-6 _P#E!_#G^N?&/_15\2_^'W-/_FHQ_P"P
M-)_Y]/\ R/<__'J/[ TG_GT_\CW/_P >K8HH_P!6N'/^B?R3_P -6 _^4!_K
MGQC_ -%7Q+_X?<T_^:C'_L#2?^?3_P CW/\ \>H_L#2?^?3_ ,CW/_QZMBBC
M_5KAS_HG\D_\-6 _^4!_KGQC_P!%7Q+_ .'W-/\ YJ,?^P-)_P"?3_R/<_\
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M5JBOY9_M3,O^AACO_"O$?_+#^O\ ZC@O^@/"_P#A/2_^0/RE_P"'(G_!+_\
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M-,%/+\TG/"9CF6,QN%G.GA)2ISEA\36JTI2A+WH2<&XRUBTSZR_X<B?\$O\
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M_P#QZC^P-)_Y]/\ R/<__'JV**/]6N'/^B?R3_PU8#_Y0'^N?&/_ $5?$O\
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MG[0G_!'K1/CW^T;_ ,%%=$\4)\<M;O[+0OV.O&?P._9T^'?Q)^+8_9]_;/\
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MCC(RDZN(C"<E_M,91BE&*:E:,6W*?Y*?L!?&C_@G%8?\$;?@9:?&=_A)X?\
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MK_0^_P""=_\ R8M^R;_V0?X<_P#J.V=?SK](W_DG>'_^QU4_]0:Y_3WT7?\
MDI^)/^Q#2_\ 5AAS[*HHHK^03^V@KP;]JC_DV']H[_L@WQ?_ /5?>(:]YKP;
M]JC_ )-A_:._[(-\7_\ U7WB&O0RG_D:Y9_V,,%_ZDTSSLX_Y%.:?]B[&_\
MJ-5/\W"BBBO].#_)@**** "BBB@ HHHH *_K\_X-V?\ DV+XW_\ 9>)/_5?>
M#:_D#K^OS_@W9_Y-B^-__9>)/_5?>#:_'O'7_DW>8?\ 8?E7_J9 _</H\?\
M)S<N_P"Q;F__ *AS/Z#****_A@_T("BBB@#_ #U?^"D__)^?[5G_ &63Q5_Z
M/CKXAK[>_P""D_\ R?G^U9_V63Q5_P"CXZ^(:_TKX7_Y)GAW_L191_ZK\.?Y
M3\6?\E5Q-_V4&<_^K'$A1117NGSX4444 %%%% !7[3?\$%/^3\X?^R-_$7_T
M?X;K\6:_:;_@@I_R?G#_ -D;^(O_ */\-U\3XD?\D%Q;_P!B/'?^FF??>%G_
M "<;@S_LH,O_ /3R/[8J***_SM/].CD/#3NVL_$%7DF=8_%]DD2RZI;Z@D*'
MP%X(D,=O:0JLFAPF1Y)6TJ[+W$UQ+/K:L+76+9%Z^N0\-(ZZS\06>.9%D\7V
M3Q-+I5OIZ3(/ 7@B,R6]W"S2:Y")(Y(FU6["7$-Q%/HBJ;71[9VZ^F]_E'_T
ME"6WSE_Z4S^:;_@N#_R6KX,_]DNO_P#U+-3K\2*_;?\ X+@_\EJ^#/\ V2Z_
M_P#4LU.OQ(K_ %.\"_\ DTW!?_8NQ'_JRQQ_C_\ 2&_Y/-QY_P!C/"_^JG+P
MHHHK]9/Q@**** "BBB@ HHHH _L]_P""=?\ R93^SY_V)UU_ZD>N5]IU\6?\
M$Z_^3*?V?/\ L3KK_P!2/7*^TZ_R"X\_Y+CC/_LJ^(O_ %;XP_VV\.O^3?<"
M?]D;PQ_ZI,"%%%%?*'V1S_BS_D5?$W_8OZS_ .FZYK^ ^O[\/%G_ "*OB;_L
M7]9_]-US7\!]?VW]$'_=N/O^O_#7_IO/3^!/IM_[SX;_ /7CBS_TYPZ%%%%?
MV:?PD%%%% !1110 4444 ?T4_P#!#'_D5/VC/^QA^&__ *;?&%?O/7X,?\$,
M?^14_:,_[&'X;_\ IM\85^\]?Y=_2!_Y._QC_P!?LG_]9[*3_7;Z-G_)D^!O
M^P?.O_6DSD****_&S]R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OXB?^",FF?M4
M_P#!273OVM/"OC__ (*&?MP_#_Q3\%OA%^S?JOPJ\5>&_P!H+XC:SI:>-/C7
MIGQ_M;S6/B7X;UKQ*=1\;Z!H>J?"[PKJ">'O#GB[X=:KJEI<>(]/E\6VEQJ>
MG:IH?]NU?P2?\$#/V0?#7[;%I^VG\-/&GQ>^/OPF\':/\%_V3]%\6:/\ _']
MAX#L?C)X:^*^F_M+Z)KOA+XU:?JWAGQ7I?Q#\*Z5I?ABZL?#F@ZE81:?8VOC
M3QW;7D6HV_B.2*W]S+IQI9?C*CKK"M9CE</:_5XXEN,L-G$I4U"2M:3IQFTV
MHR=.,9;H\O&1<\9AH>R==?4\?+V?M712:KY;%3<D]7%3E%=4IMKJ?KM_P;:_
MML?M!?M2_##X]> OCAX]U_XC6'PLTSX'?$;P+K?Q$UO7/&7Q9T>/]H.?XRZK
MXI\(>*/B#X@U2[UKQ=X7T75OA_!>^!AXAMIM=\-)K/B#PQ::[-X#TOP%X/\
M GO'_!NS\8OBY\;?V)_B3XK^,_Q3^(WQ<\46'[2FN:%8^)/B?XW\3>/M?L]#
MA^!?P U>+1K76/%6IZMJ-OI46K:SK&J1Z=#<):)J.JZE>K"+F^NI9?A?_@@9
M\8/B]\,_VR/VK?\ @G3>>)O"GB7X*_!*7]J&2*ZC^&6@^#/%.K_%CX!_M0^'
M?@CJOQ*M-:TFXN/$NHZ;\3]%\1S/J^A?$OQ/\5K[P=H/@_X2^!OA]XL\->&/
M!NJV/BKZB_X-B_\ DPCXJ?\ 9U/B#_UGK]FZGF-&%&EG$8TJ=+ES_+73A2?-
M"GA\5E^>XNC"E-QB_92HSP\E#E@HVA%P@Z:C%8.I*I4RYRJ3F_[+QT*KGI)U
ML/B\LP]1U%>2=2-2%5<_--RNY<\G-M_,/[/?[6'[7_\ P7._:;\:Z9\(?C;\
M6_V(_P!B[X0Z3\-_B:;/X87F@:3\7;W2-=\5:KH?@[PY\0?%?AGQUX=\:V?Q
M)^/GP\'QDUZ-=$N_B5^S]\%]7^&GA+3]?\$?$;Q7H6B>.OB9RW_!2?3/^"A'
M_!(_Q[\*OV@O@/\ MS?M _&SX2?$_P 5ZG\--,\._M-^)O\ A:_ACPEXBTC0
M?!'Q-TOX8_$S1?$WCF>/XA#XWI\-OC!>1_$WX4?#/X-^-_A1\.O#>L> -(^)
M&A^)_&UKXH\5\;_P:ZZU9^!OC=^V/\(/&]GK_@OXM^*/@K^SK?P?#7Q-X3\4
MZ-XCT-?V<O&?QK\%_&?2O%:7^E+9^$/$W@'Q?\<OAUX:U;P=XHO]+\6MJ>I:
MG%9:1>KX8\4R:-];?\'0GC;PE9_LY_LD?#N_UDV7C"\_:@U;XT6.F2Z7K3V=
MQ\//A3\ _B[X$\>ZW/X@AT^3PWI;Z'XC^._PRM(]+U?5['6-8AUVZO="T_4[
M'P_XDN=([DHRSW$Y34A2AEM.MC,+[+V5.*I83#TJKIXM57'VJJQI4X8Z6)E-
MSJ2<ISE*C-P?.[QRJGF$)U/KKHT\2JG/4DZF*J.-\*X<S@Z4JK>!]@H*G&.B
M@I\TG:_X+1?\%+/CWX0_8P_8S^)?[).F_%WX8>#/VTOA]XB^)^L_$^UMM'T?
MQ9X9\)ZY\$-#\0>"_P!GK6-7L/#_ (WL?AY\6?B9I_Q5U#QUX>\8_#;XG^'?
MB%X2U/\ 9W\3S?#S6/$FE?\ "0ZUH7S3_P %'_\ A>O_  3=^"?[(O[17P!_
MX*O?M&?&'QO\39=2TS4_^$^^+VB?%3X>?$#PWJ?P4U/Q!J7[27PI^''B[6?&
MO@V\^$7AC4'TJR.D>+M+^.>DZ;J'QJ^#VM0?$?3-<\-Z1?\ CV'_ (*7?M7_
M !2^#/\ P2S_ .">_P"P;;?"Y?"/CK]HK]BKX$1?&C4?C?X:7X<0?#&Q\!>!
MO@_I3?#O3_%?QV\/>'?@O\/OB>/'TDJ_$3X@^*?'.F^,/V0=%\+V7C;6]*^&
MOBGQ[\)OC)X'\@_:R_X)L^*O^",WACX.?MG?#'XU_"+XU>,;?XR_#CP9XF\-
M?%KX!?!ZPTO4_%$'B_QI\4_#7C?P5H_Q,^)7BWQ-?:UI>C?#'X0> KC1_@U%
M=_M&>%]/T_XL_'3P7\6/AW\/XM<TKX8YY?%3P664I*BL9BL%C)4LNJ48J.9U
M:]2M1PU6KB'%RPM5XBG/#T:=24G'ZG3G"MA95_:NL;=8C'5%[14,/6H*IBH5
M).6!C3C2K58TJ*ERUX1H5%B*E1)<RK.$H8E05./U#_P5B_X*6?MP_#S]FS_@
MGUX0\)7\W[-7QJ_:F_9@_P"%H?M3VUQX.UGX!2>&O&_C+X>?#GPP/A-X6^./
MQ\O+/P9^S_9>&?'7Q ^(NH?$[4)OB#IWQO\ V=9_"7P@\5^-_B1\,/#>L'4?
MB+R/_!1OP5^W=_P2;F_9*_:8^''_  4%^-_QY\.ZAXMT?X4>-O!'Q^\?_$KQ
M)X<\2?'Y_AS\1_&=]J<WPUE\7:CX6\0?L_?$?P7X.\;Z7<^!->UU?B;\&=>T
MOPSK_@_XI^-?%.NZ9XU^#WZ<_M'?L>?"C_@N=^Q7^R]\9]7E\3? #XB:AX)M
MO&7@S4->\)^+_%FD^$](^**>$8_CC\,?$/P]\:P_!Y?BOX&\4)X.LH/ 7Q3M
M=/\ "L'B%?#_ ('^+7P[UG7OA%XLUKPM\2OP[_X+E?!7X]_LU_"3]CCPE^T+
M_P %"/$_[4MKI'B7QFO@+X:>-?@IJ7@\Z7X$^&_PLCT7QI\;_%/Q2TWQ[XIL
M_'WQ)\(7NN_#3P-;^)/C/<^*/BOK&E_&#XB:MX8\02P:I\6KS45E4L'B89=A
MW6HK#_4\7',</4PT_K%>;>*KRQJK1PWLU['"?5IPG*M1J81X2I*G3YG^]>8+
M$4GCJZI5?:^UI2P-6G5BZ=)1A2C##.DZJFW/%^TBXQI5?K,,1&G4FHQ7+_8A
M^S+\8I_VA_V;OV??C_<^%_\ A![GXY_!#X4?&*X\%?VT?$G_  B$_P 3? >@
M>-9?"_\ PD1TC0#KW_"/R:VVD_VT="T0ZI]D^W'2--\_['#Y3^W%\0?VR/AS
M\&K+5/V&?@-X2^/_ ,;-4\<:%I%QH7CGQ;X=\,^&O"/@:/3]<U[Q+XOO+'Q%
MX^^%T?B^\O)-#TSX>Z)H&G_$#PW=:7KGCW3?'=\^L^'_  9K?AO6O@WX ^ ?
M^"T/PI^ _P  /A=X,T'_ ()U>%O"'PV_9M_9@\ Z;X8^,.I?'_6?BUX<\1^#
MOV<OA7X>^*N@^/\ 5_A7J&K?#'5;_2/C)IWQ#T_P_J7@+5=3T"^\$V_A>Z_M
M"]U&6_N9/TB_9=_X;#_X0[Q;_P -I_\ #-7_  L#_A/[[_A!/^&7?^%H_P#"
M'?\ "K?^$6\(_P!F_P#"6_\ "U_^)W_PG_\ PFW_  GGV[^Q_P#BG?\ A%O^
M$1\C_B;?VS7@4HRH0PM>H\+7G.G"<Z/-*:A4E2C)QK4XN%G"<M8.4H.<'":G
M#FC+UJC56=>E%5J,82DE4224HJIR_NJCY^;F6TDK\C<HM2LU_-?_ ,$4/V@?
MVMO'/_!4/]J7X-_M'_M"_%'XKW'PR\$_MC>&O%6@:U\4/&/BGX72?%+X5_M=
M_";X<:WXN\"^#=471?"_AC1VO1XJC\#Z9H'@GPG8>$/"&O-X6\/:!X=T,#18
M?LC_ (+T?\%#_C)^S1X4^'?[+'[+7G:A\=/VCO"WC.[UU_AEKU_J7[1OA+PD
MNI^'?!O@/PW\)_ 7A:WG\7:1XV_:(\6:UXH\&_#CXH64T.MZ1??#GQMI7PNT
MZZ^)$NG>-OA?\!?\$8_^4YG_  4@_P"QH_X*?_\ KQSX?4[_ (+VJW[-?_!4
M3]AW]N/QNK:[\+-)\!_!?5'\'^"0=4^*U_%^P[^U)J7QQ^*\>F^'M9_X1[PS
M<R:_X6^/G@O2_ 0?QG"=3\26FO6?B!?#.GV^EZIK'NUH0_M[-IJG3<\/E\\9
MAZ/LZ?LI8JAPYA\53_=<OLN6%5/$.FX>SFZ;IN#C-Q?EP<EEM&"G-*692PLI
M\\_:*A/B"IA9KVO-[3F^KMP]IS^T7Q<_,KGKO_!2[X,?MI?\$TO@5\"_VD?@
M1_P4#_;F^*OC'3_&]I\+/C-J'C_7M1^*_P +O#^I^//ACXJL--^,\W@+Q>?&
M'@3P7X!M?'.E_P#"%Z/X5^,&F_%RT/CKXJ_"F/3?'-CXQ\+:7=>,MO\ X*<_
M\%D?B)JO[('[)NA?L;+HL_QI_;K^!][XY\8:+\#?B</BA\>O@ZUU)X9\#GX)
M_"VP\":58^)O^%I>.OC'J7Q)^!>@?%*#3?#OBSPWXT^"GQ-\,^!?!^F?%Z"/
MQ!\(_MO_ (.&/BCH7@3_ ()P^(? VJZ;X@OM4^/OQJ^"'PO\)W>CVFGW&F:)
MKGA/QG#^T7J&I^+IKW5=.N-/\/S>#?@/XKT6UN])M=<U!_%FK^&+&32HM*O=
M3UG2/Y5/&'PJU_\ 8,M?^",/[87Q7O\ P]XS^&NL_!;P=^T3I?AOX/SZCKWQ
M O\ P3\-?V_OBC^WYK%A8Z%XLTOP/H4NO7WP>_;/^%/AK2;1?%/V"7XE:5XU
MT:YU*U\-:?X>\7>)W04:M#"8RK"G+&4\'Q)4I0E3I_[6\MP.&Q."K58.+A5=
M"O6Q/O3C*-:.&CAZBFH)(J?NIXK#TYSC0=;(X2Y9S_<_7L=5P^*A":ES4O:8
M>%.7+&2E!MU8<KFV_P!M?^"EWP8_;2_X)I? KX%_M(_ C_@H'^W-\5?&.G^-
M[3X6?&;4/'^O:C\5_A=X?U/QY\,?%5AIOQGF\!>+SXP\">"_ -KXYTO_ (0O
M1_"OQ@TWXN6A\=?%7X4QZ;XYL?&/A;2[KQE_1Q^RA^T%X?\ VJ_V:_@C^T5X
M;7P_:V?Q<^''AGQ?JFA>&?&%AX^TSP5XOO+".#QY\-YO%NFV.EV^KZY\,?&]
MOXA^'OB@S:/H>HV7B;PSJ^G:OH.A:M9WND67Y>_\'#'Q1T+P)_P3A\0^!M5T
MWQ!?:I\??C5\$/A?X3N]'M-/N-,T37/"?C.']HO4-3\737NJZ=<:?X?F\&_
M?Q7HMK=Z3:ZYJ#^+-7\,6,FE1:5>ZGK.D>W?\$0OA9KOPA_X)8_LB>'_ !!J
M/AS5;CQ?X2\;?'32+SPK<:C<Z3_PAW[2_P 6OB!^T7X!M)'U/2](N8];T[P-
M\4_#NG^*+2.UFT^Q\36NKV6DZIKFE6]EK6H>;C7[7 Y9B*BBL14JYE1G)1C&
M5?#X;^SYT*U1)+GE"IB<5057>4:<:<F_8KEZ\-%4\3C*--MT84\#446Y2C2J
MUGC8U(Q;;Y5.%"C/V>R=ZD4O:2<OU7HHHKS#M"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\#?!O_*PM\6?^S/=-_P#23X:5
M^^5?@;X-_P"5A;XL_P#9GNF_^DGPTK]\J]3--\O_ .Q7@O\ TB1PX';%_P#8
M=B?_ $M'CW[0G_)"?C%_V33QI_ZC]_7\V%?TR?&?1-5\2_"+XF^'=#LWU#6=
M<\">*=*TJQC>*.2\U"_T:\MK2V22>2*%&FGD2-6EECC4MEW5<D?AC_PQY^TG
M_P!$LU;_ ,&OAK_Y=T\OG"-.IS2C&\U;FDE?1=V<N9TZDYTG"G.:4&FXQE*V
MO6R9\TT5]+?\,>?M)_\ 1+-6_P#!KX:_^7='_#'G[2?_ $2S5O\ P:^&O_EW
M7?[:E_S]I_\ @<?\SS/85_\ GS5_\%S_ ,CYIHKZ6_X8\_:3_P"B6:M_X-?#
M7_R[H_X8\_:3_P"B6:M_X-?#7_R[H]M2_P"?M/\ \#C_ )A["O\ \^:O_@N?
M^1\TT5]+?\,>?M)_]$LU;_P:^&O_ )=T?\,>?M)_]$LU;_P:^&O_ )=T>VI?
M\_:?_@<?\P]A7_Y\U?\ P7/_ "/FFBOI;_ACS]I/_HEFK?\ @U\-?_+NC_AC
MS]I/_HEFK?\ @U\-?_+NCVU+_G[3_P# X_YA["O_ ,^:O_@N?^1^D?\ P3H_
MY(3K?_92]?\ _4?\)U][U\??L2_#GQK\,/A%JOA[QYH-QX=UFX\=ZQJL-C<W
M%E<R/I]SHWARV@N1)875W"%DGLKF,*91(#$2R!2I;[!KPL2U*O5:::<M&G=/
M1=4?285..'HJ2::IQ33336G5/8S]6S_9>I;=P/\ 9]Y@HR(X/V>3&UY/W:-G
M[K/\BG!;Y0:H>$RQ\+>&BYD+G0-&+&62*:4M_9UMN,LT&()9"<EY80(I&R\?
MR$5?U<9TK4QC.=/O1CRO.SFVEX\GCS<_\\LCS/N]ZSO"0V^%/#*[=NWP]HHV
M_9OL>W&FVPV_9,G[+CI]FR?(_P!5D[:R^Q_V]^AK]K_MW]5T_K\#H:_SA/VQ
M/^3N/VIO^SC?C?\ ^K,\3U_H]U_G"?MB?\G<?M3?]G&_&_\ ]69XGK^D/HW_
M /(XXF_[%N!_]2JI_+/TI?\ D2\)_P#8TS#_ -1*)\Y4445_6Q_%X4444 %%
M%% !1110!^^__!N]_P G<?%[_LW+7?\ U9GPPK^Q&OX[O^#=[_D[CXO?]FY:
M[_ZLSX85_8C7\->.W_)P\;_V+LK_ /49'^@OT=O^3:8+_L:YM_ZDH****_'#
M]S"OXVO^#AO_ )/2^&/_ &:]X+_]6O\ &NO[):_C:_X.&_\ D]+X8_\ 9KW@
MO_U:_P :Z_9_ 7_DX&'_ .Q5F?\ Z;IGX5](O_DVN*_[&^4_^GIGX.4445_<
M)_GX%%%% !1110 4444 %?Z'W_!._P#Y,6_9-_[(/\.?_4=LZ_SP:_T/O^"=
M_P#R8M^R;_V0?X<_^H[9U_.OTC?^2=X?_P"QU4_]0:Y_3WT7?^2GXD_[$-+_
M -6&'/LJBBBOY!/[:"O!OVJ/^38?VCO^R#?%_P#]5]XAKWFO!OVJ/^38?VCO
M^R#?%_\ ]5]XAKT,I_Y&N6?]C#!?^I-,\[./^13FG_8NQO\ ZC53_-PHHHK_
M $X/\F HHHH **** "BBB@ K^OS_ (-V?^38OC?_ -EXD_\ 5?>#:_D#K^OS
M_@W9_P"38OC?_P!EXD_]5]X-K\>\=?\ DW>8?]A^5?\ J9 _</H\?\G-R[_L
M6YO_ .H<S^@RBBBOX8/]" HHHH _SU?^"D__ "?G^U9_V63Q5_Z/CKXAK[>_
MX*3_ /)^?[5G_99/%7_H^.OB&O\ 2OA?_DF>'?\ L191_P"J_#G^4_%G_)5<
M3?\ 909S_P"K'$A1117NGSX4444 %%%% !7[3?\ !!3_ )/SA_[(W\1?_1_A
MNOQ9K]IO^""G_)^</_9&_B+_ .C_  W7Q/B1_P D%Q;_ -B/'?\ IIGWWA9_
MR<;@S_LH,O\ _3R/[8J***_SM/\ 3HXKPMY/]N_$GROL?F?\)K8?:?LO]H>?
MY_\ PKKP#M_M'[;_ *-]L^S?9]G]D_\ $O\ [/\ L/F?\37^TZ[6N0\-.[:S
M\05>29UC\7V21++JEOJ"0H? 7@B0QV]I"JR:'"9'DE;2KLO<37$L^MJPM=8M
MD7KZ<M_E'_TE?UY;"CM\Y=/[S_KSW/YIO^"X/_):O@S_ -DNO_\ U+-3K\2*
M_;?_ (+@_P#):O@S_P!DNO\ _P!2S4Z_$BO]3O O_DTW!?\ V+L1_P"K+''^
M/_TAO^3S<>?]C/"_^JG+PHHHK]9/Q@**** "BBB@ HHHH _L]_X)U_\ )E/[
M/G_8G77_ *D>N5]IU\6?\$Z_^3*?V?/^Q.NO_4CUROM.O\@N//\ DN.,_P#L
MJ^(O_5OC#_;;PZ_Y-]P)_P!D;PQ_ZI,"%%%%?*'V1S_BS_D5?$W_ &+^L_\
MINN:_@/K^_#Q9_R*OB;_ +%_6?\ TW7-?P'U_;?T0?\ =N/O^O\ PU_Z;ST_
M@3Z;?^\^&_\ UXXL_P#3G#H4445_9I_"04444 %%%% !1110!_13_P $,?\
MD5/VC/\ L8?AO_Z;?&%?O/7X,?\ !#'_ )%3]HS_ +&'X;_^FWQA7[SU_EW]
M('_D[_&/_7[)_P#UGLI/]=OHV?\ )D^!O^P?.O\ UI,Y"BBBOQL_<@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;^(O_H_PW7Q/B1_R07%O_8CQW_IIGWWA9_R<;@S_ +*#+_\ T\C^V*BBBO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?\ #J^^.UA\+_@+\0?"GBK]E/Q;\,6\7?%6YMOB5J6I?"?X/^-/#VA6%O\
M%GQ/\/M.^)VCZC?-J4^OZ)KVG>,8C87OB[6H[GHC&AEV)IU)1Q5*-3#9C24Y
M0PN(J4ZM;!5</0K4J2JPA)T*U>%62J5(7Y4X/F1C)U<90G",J$Y0KX.IRJ5>
MC"=.GB85JM.<W3E./M:=*5-.$)+WFI*S-'PM_P $QO\ A%_&'@?Q?_P\*_X*
M@>(O^$(\>>!_'?\ PB_BG]K'^U_!_B__ (0CQ7H_BO\ X0WQQHG_  @-O_;_
M (#\7_V1_P (WXX\/?:;3^W_  IJFL:/]LM/MOVB+]/Z_A,_X*W_  J\(_\
M!'3]KOX6_'+]AKXIW?@G6=6^&=_\5]3^ K>./%#/X"TCX1^-/AIK-AX4\?Z]
MH/Q$T7XJ^,?V8/VK/$_@J7_A(/AKX[U-K;Q+XA^$WQ9L=,\?:OH(T+P?\(_[
MLZY,PIRA5H576>(CB\+#$TJDJ2H3]G[:OA^2I13DH3A4P]1>[*<)PY)PJ24M
M.G"2C[.K25/V4J&(E3JTU-U8>TE1P]53A4DHRE&=*I2^*$'&2DN7[4BBBBN
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MOAG_ ()Q_L;Z/^PK^R/\,?@3'#H-QX_6TN/'/QR\4Z"+&[MO&GQP\:^3JOQ
MU:#Q%!X.\":OXL\->'KK[)\.?A=K'C#P]!XRLO@UX'^''ACQ!<7-SX>62ON:
MN+%5_K6*Q&*]FJ7UBM*K&E%)*E3TC1I:>ZW2HQITY327M)0=1I.3.FA2^KT*
M-#F]HZ--0E/?GGK*K-.[=IU93E%-OEBXP3Y8I(HHHK U"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P-\&_\
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MO_)N\P_[#\J_]3('[A]'C_DYN7?]BW-__4.9_091117\,'^A 4444 ?YZO\
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MJ^(O_5OC#_;;PZ_Y-]P)_P!D;PQ_ZI,"%%%%?*'V1S_BS_D5?$W_ &+^L_\
MINN:_@/K^_#Q9_R*OB;_ +%_6?\ TW7-?P'U_;?T0?\ =N/O^O\ PU_Z;ST_
M@3Z;?^\^&_\ UXXL_P#3G#H4445_9I_"04444 %%%% !1110!_13_P $,?\
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M,8I=VVDO,4I**<I-1C%.4I2=E%)7;;>B26K;T2/4**_F*_8N^/\ _P %3O\
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MQI\6M?CU*_\ #GAWPGH\UO9^(_'6K66CK:Z#9R6^B6^G6U[+J%_#<ZE=YO\
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M>NLI6O*3O*3U;9]6T5\I?\-X?L._]'E_LI?^)$?"'_YL*/\ AO#]AW_H\O\
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M"CZKB?\ H'K_ /@FI_\ (A[>C_S^I?\ @R'^9]6T5\I?\-X?L._]'E_LI?\
MB1'PA_\ FPH_X;P_8=_Z/+_92_\ $B/A#_\ -A1]5Q/_ $#U_P#P34_^1#V]
M'_G]2_\ !D/\SZMHKY2_X;P_8=_Z/+_92_\ $B/A#_\ -A1_PWA^P[_T>7^R
ME_XD1\(?_FPH^JXG_H'K_P#@FI_\B'MZ/_/ZE_X,A_F?5M%?*7_#>'[#O_1Y
M?[*7_B1'PA_^;"C_ (;P_8=_Z/+_ &4O_$B/A#_\V%'U7$_] ]?_ ,$U/_D0
M]O1_Y_4O_!D/\SZMHKY2_P"&\/V'?^CR_P!E+_Q(CX0__-A1_P -X?L._P#1
MY?[*7_B1'PA_^;"CZKB?^@>O_P"":G_R(>WH_P#/ZE_X,A_F?5M%?*7_  WA
M^P[_ -'E_LI?^)$?"'_YL*/^&\/V'?\ H\O]E+_Q(CX0_P#S84?5<3_T#U__
M  34_P#D0]O1_P"?U+_P9#_,^K:_-'_@H-_P2N_9\_X*2ZK\']7^.7C'XR^%
M+GX*>'_C!X;\*I\*/$/@G0X-0L?C6?AL?%4OB!?%_P //'4EU=Z?_P *N\/_
M /"/OITNE0VOVS6/[1@U7[19?V?] _\ #>'[#O\ T>7^RE_XD1\(?_FPH_X;
MP_8=_P"CR_V4O_$B/A#_ /-A5TZ6-I2YZ='$0DX5(<RI5+\E6G*E4C\.TZ<Y
M0?E)DSJ8:I'EG4HRCS1E9U(6YH24XOXMXRBI+S1R_P"W3^PC\(O^"@GPR\$?
M"GXR^(_B/X9\/> OBC8?%O1[SX8ZOX9T;6KGQ'IW@3X@?#V"RU*X\5>$/&EC
M-HC:+\2-<NI;:UTZSOVU2UTJ9-22T@O+*^]\^ GP<\,?LZ_ OX+?L^^";[7M
M4\&? KX3?#GX.>$=3\4W.GWOB?4?#'PQ\'Z-X)T&^\1WNDZ7HFE7>O7>E:):
M7&KW6F:+I&GW&H27$MEI>GVSQVD7E?\ PWA^P[_T>7^RE_XD1\(?_FPH_P"&
M\/V'?^CR_P!E+_Q(CX0__-A1*EC9PIPE1Q$H45.-*+HSM!5)<\TO=^U/WGYA
M&IAH2J2C4HJ55TW4:J0O-THRC3OK]F,I)>K/JVORY_:F_P""57P[_:]\5_$W
M6/BM^U/^V]%X$^*>J^"-8U?X >'?C?H<?[/.AW7@#1_!%EH"^%OA5XD^'?B;
M1],A3Q'X"TCXE3BZEU"1?B==ZIXRLI;*_GMDL_IG_AO#]AW_ */+_92_\2(^
M$/\ \V%'_#>'[#O_ $>7^RE_XD1\(?\ YL*TPZS#"S]KAZ>(I5+6YXT9-I*4
M9JS<'RM2A%J2LTUH]R*KPE>/)5G1G"]^5U8I7LXZVDKJTFK/1WV/FS]E_P#X
M)9> OV2?%WPSUSX8_M6?MQ7O@CX6ZCXQU+1_@+XH^.>C7/[/NM2^-]"\9Z9K
M$/B?X6^'_A[X;TC4K:/7/'&I?$.SCM9M/9?B18Z1XMNI+N\MKB.[C^)7_!)3
M]F_XQ?MMZ-^W;\3_ !Q^T!XS^)'ACQA\*O&OA/X>:I\2K*/X/^$;[X)Z7I;?
M#71?"^B:?X6LO&NA^#M ^(6EM\:[GP98>/H?#7B'XKZWXMU;Q+INL>'/&7BG
MPMJ_TO\ \-X?L._]'E_LI?\ B1'PA_\ FPH_X;P_8=_Z/+_92_\ $B/A#_\
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M7,:S6]U:W$+/#/;W$+I+#-$[QRQNKHS*P)L5@:A1110 4444 %%%% !1110
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MX\ U*.*<6FGC<2TT[IIR5FFM&@HHHKRCO"BBB@ HHHH \=\(_L\? #P!X_\
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M_P!D;^(O_H_PW7XLU^TW_!!3_D_.'_LC?Q%_]'^&Z^)\2/\ D@N+?^Q'CO\
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MR?C 4444 %%%% !1110!_9[_ ,$Z_P#DRG]GS_L3KK_U(]<K[3KXL_X)U_\
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ML#ZC@O\ H#PO_A/2_P#D#XE_X=T?L;?]$=_\R%\4_P#YMZ/^'='[&W_1'?\
MS(7Q3_\ FWK[:HH_M3,O^AACO_"O$?\ RP/J."_Z \+_ .$]+_Y ^)?^'='[
M&W_1'?\ S(7Q3_\ FWH_X=T?L;?]$=_\R%\4_P#YMZ^VJ*/[4S+_ *&&._\
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MOK?_  M?XWZM_9FKV4*-:W?]FZY\2M3TB]\IB3]GU"PN[5^DD+BOZ *^(?\
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M#2?^?3_R/<__ !ZOT0_X)9?LV?!7]H[]L_X>?"?XS^"_^$R^'^NZ#\0+W5=
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M*_@C^U,R_P"AACO_  KQ'_RP_P!&_J."_P"@/"_^$]+_ .0/RE_X<B?\$O\
M_HV/_P S1^T)_P#/8H_X<B?\$O\ _HV/_P S1^T)_P#/8K]6J*/[4S+_ *&&
M._\ "O$?_+ ^HX+_ * \+_X3TO\ Y S](TJPT+2M,T32H/LNEZ-I]EI6FVOF
MS3_9K#3[:.TLX/.N9)KB;R;>&./S9Y99I-N^61W+,="BBN&YU!1110 4444
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MOBE^R9XP^'WQ0N?&7]L'BGX$^(_@I^QWXD_9^_X)^Z!\-_@QXOT+X>:SX+^
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MHHHKR3O"BBB@ HHHH **** "BBB@ HHHH S]6!.EZD%5F)T^\ 5($NG8FWD
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M4D&GZG8PQ=?52W^4?/[*_KRV%';YRZ?WG_7GN?S3?\%P?^2U?!G_ +)=?_\
MJ6:G7XD5^V__  7!_P"2U?!G_LEU_P#^I9J=?B17^IO@7_R:;@O_ +%V(_\
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M^D#_ ,G?XQ_Z_9/_ .L]E)_KM]&S_DR? W_8/G7_ *TF<A1117XV?N04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\^
M_P#P5$_Y29_\$AO^RK:G_P"I[\,:_H(K^??_ (*B?\I,_P#@D-_V5;4__4]^
M&-?T$5ZV/_W')O\ L%Q'_J97.'"_[SF/_812_P#46@%%%%>2=P5^0_[57_)<
MO%__ %[^&_\ U&-(K]>*_(?]JK_DN7B__KW\-_\ J,:10!\[T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'H'PF_Y*I\-/\ LH'@W_U(]-K]P*_#
M_P"$W_)5/AI_V4#P;_ZD>FU^X% !1110 4444 %%%% !7Q#_ ,%)_P#DPS]J
MS_LC?BK_ -$1U]O5\0_\%)_^3#/VK/\ LC?BK_T1'7N<,?\ )2\/?]CS*?\
MU/PY\_Q9_P DKQ-_V3^<_P#JNQ)_GJT445_I8?Y3A1110 4444 %%%% !111
M0 4444 %%%% !1110 5^M7_!$/\ Y2*?";_L5_BM_P"JX\1U^2M?K5_P1#_Y
M2*?";_L5_BM_ZKCQ'7R/'_\ R0_%_P#V3><_^J^N?:^&_P#R<'@G_LJ<B_\
M5EAS^YZBBBO\Y3_4,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /)^?[5G_99/%7_H^.OB&O\ 2OA?_DF>'?\ L191_P"J_#G^4_%G_)5<3?\
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MG+?Y1Z?W5_7GN*.WSE_Z4_Z\MC^:;_@N#_R6KX,_]DNO_P#U+-3K\2*_;?\
MX+@_\EJ^#/\ V2Z__P#4LU.OQ(K_ %.\"_\ DTW!?_8NQ'_JRQQ_C_\ 2&_Y
M/-QY_P!C/"_^JG+PHHHK]9/Q@**** "BBB@ HHHH _L]_P""=?\ R93^SY_V
M)UU_ZD>N5]IU\6?\$Z_^3*?V?/\ L3KK_P!2/7*^TZ_R"X\_Y+CC/_LJ^(O_
M %;XP_VV\.O^3?<"?]D;PQ_ZI,"%%%%?*'V1S_BS_D5?$W_8OZS_ .FZYK^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X&^#?^
M5A;XL_\ 9GNF_P#I)\-*_?*OP-\&_P#*PM\6?^S/=-_])/AI7[Y5ZF:;Y?\
M]BO!?^D2.' [8O\ [#L3_P"EH****\L[@HHHH **** "BBB@ HHHH **** ,
M[6,'2=4#!2/[.O<AT=T(^S2YW)'\[KC[RI\[#(7DBL[PAM'A/PN$$80>'=$"
M"&.6&(+_ &;;;1%%/F>*,#&R.8^:BX63YP:TM7.W2M3;(7&GWIW,[QJ,6TIR
MTD?[R,#J73YU'S+\P%9WA)]_A3PRX9'#^'M%;?'+-.C[M-MCN2>X_P!(F1LY
M66?]]("'E^<M5?8_[>_0G[7_ &[^IT-?YPG[8G_)W'[4W_9QOQO_ /5F>)Z_
MT>Z_SA/VQ/\ D[C]J;_LXWXW_P#JS/$]?TA]&_\ Y''$W_8MP/\ ZE53^6?I
M2_\ (EX3_P"QIF'_ *B43YRHHHK^MC^+PHHHH **** "BBB@#]]_^#=[_D[C
MXO?]FY:[_P"K,^&%?V(U_'=_P;O?\G<?%[_LW+7?_5F?#"O[$:_AKQV_Y.'C
M?^Q=E?\ ZC(_T%^CM_R;3!?]C7-O_4E!1117XX?N85_&U_P<-_\ )Z7PQ_[-
M>\%_^K7^-=?V2U_&U_P<-_\ )Z7PQ_[->\%_^K7^-=?L_@+_ ,G P_\ V*LS
M_P#3=,_"OI%_\FUQ7_8WRG_T],_!RBBBO[A/\_ HHHH **** "BBB@ K_0^_
MX)W_ /)BW[)O_9!_AS_ZCMG7^>#7^A]_P3O_ .3%OV3?^R#_  Y_]1VSK^=?
MI&_\D[P__P!CJI_Z@US^GOHN_P#)3\2?]B&E_P"K##GV51117\@G]M!7@W[5
M'_)L/[1W_9!OB_\ ^J^\0U[S7@W[5'_)L/[1W_9!OB__ .J^\0UZ&4_\C7+/
M^QA@O_4FF>=G'_(IS3_L78W_ -1JI_FX4445_IP?Y,!1110 4444 %%%% !7
M]?G_  ;L_P#)L7QO_P"R\2?^J^\&U_('7]?G_!NS_P FQ?&__LO$G_JOO!M?
MCWCK_P F[S#_ +#\J_\ 4R!^X?1X_P"3FY=_V+<W_P#4.9_091117\,'^A 4
M444 ?YZO_!2?_D_/]JS_ ++)XJ_]'QU\0U]O?\%)_P#D_/\ :L_[+)XJ_P#1
M\=?$-?Z5\+_\DSP[_P!B+*/_ %7X<_RGXL_Y*KB;_LH,Y_\ 5CB0HHHKW3Y\
M**** "BBB@ K]IO^""G_ "?G#_V1OXB_^C_#=?BS7[3?\$%/^3\X?^R-_$7_
M -'^&Z^)\2/^2"XM_P"Q'CO_ $TS[[PL_P"3C<&?]E!E_P#Z>1_;%1117^=I
M_IT<AX:=VUGX@J\DSK'XOLDB675+?4$A0^ O!$ACM[2%5DT.$R/)*VE79>XF
MN)9];5A:ZQ;(O7UQWAF)H]:^(CM'<(+CQC93(TVFQ6,<JK\/_ T!>TN8Y'?6
M+</"\3:E.L4L5W'=:0(S!I4,LG8TY;_*/_I*$MOG+_TIG\TW_!<'_DM7P9_[
M)=?_ /J6:G7XD5^V_P#P7!_Y+5\&?^R77_\ ZEFIU^)%?ZG>!?\ R:;@O_L7
M8C_U98X_Q_\ I#?\GFX\_P"QGA?_ %4Y>%%%%?K)^,!1110 4444 %%%% ']
MGO\ P3K_ .3*?V?/^Q.NO_4CUROM.OBS_@G7_P F4_L^?]B==?\ J1ZY7VG7
M^07'G_)<<9_]E7Q%_P"K?&'^VWAU_P F^X$_[(WAC_U28$****^4/LCG_%G_
M "*OB;_L7]9_]-US7\!]?WX>+/\ D5?$W_8OZS_Z;KFOX#Z_MOZ(/^[<??\
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MX8U_017K8_\ W')O^P7$?^IE<X<+_O.8_P#812_]1: 4445Y)W!7Y#_M5?\
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M .GD?VQ4445_G:?Z='%>%O)_MWXD^5]C\S_A-;#[3]E_M#S_ #_^%=> =O\
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M +SF/_812_\ 46@%%%%>2=P5^0_[57_)<O%__7OX;_\ 48TBOUXK\A_VJO\
MDN7B_P#Z]_#?_J,:10!\[T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'H'PF_P"2J?#3_LH'@W_U(]-K]P*_#_X3?\E4^&G_ &4#P;_ZD>FU^X%
M!1110 4444 %%%% !7Q#_P %)_\ DPS]JS_LC?BK_P!$1U]O5\0_\%)_^3#/
MVK/^R-^*O_1$=>YPQ_R4O#W_ &/,I_\ 4_#GS_%G_)*\3?\ 9/YS_P"J[$G^
M>K1117^EA_E.%%%% !1110 4444 %%%% !1110 4444 %%%% !7ZU?\ !$/_
M )2*?";_ +%?XK?^JX\1U^2M?K5_P1#_ .4BGPF_[%?XK?\ JN/$=?(\?_\
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MO_)N\P_[#\J_]3('[A]'C_DYN7?]BW-__4.9_091117\,'^A 4444 ?YZO\
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M5?$W_8OZS_Z;KFOX#Z_OP\6?\BKXF_[%_6?_ $W7-?P'U_;?T0?]VX^_Z_\
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M@5^'_P )O^2J?#3_ +*!X-_]2/3:_<"@ HHHH **** "BBB@ KXA_P""D_\
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M "BBB@ HHHH **** "BBB@#/U8$Z7J0568G3[P!4@2Z=B;>0 +;2$1W#$\+
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M_P F+?LF_P#9!_AS_P"H[9U_.OTC?^2=X?\ ^QU4_P#4&N?T]]%W_DI^)/\
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M9_R2O$W_ &3^<_\ JNQ)_GJT445_I8?Y3A1110 4444 %%%% !1110 4444
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MM:TEAI_QK\,6\NJ>#="\9^'M:^+6N>+-<73OB9\4;Z]\,6C:G\.8=%\7:?\
M$3T*F5./U=PQ-)TZN"KX^I4JPJTOJV%I5?8TZE6FH5*TOK-13CAXTJ=2<THR
MY>2I"3Y88Z[JQE0J*=/$T<)"$)0FZV(K14_9TYN4*:=*,H.K*<XPAS/FDG&2
M7]3%%?S>_LA_\%$_VM_AS_P5*\5_\$P?VQ?'WA'X^27OB/Q]X?\  7Q<\&?#
M+2/"GB./Q+'\#O"W[2OPW7Q(VA7G@#PKX<\!77P$T7QE>^+-#M?A_P#$/QAI
M/QR\7:5X4TSXC^(_AWHP\1UXI^V/^U!^UK_P4A_X*(6__!/S_@GM^T)XH_9\
M\!_ F#QH?C9\4-+_ .$@^&'B&S\;_#?QG+\-_CA\09Y]/\8^'/B)\6?AM\(;
MWQ1X3^&?PW^&&@6?@;1OB/\ &W7];\3^*M4U?X1VWPS^.GP\P>7U(5<3"K.$
M*6%H4\14Q"O.E*G7HTZV#]EI&4YXQ5J,:%-J,[U&ZL::I5G3U^MPE3HRIQE*
MIB*TZ%.B_=FJE*I4IXA5'[T8QPZHUJE6:<H<E-N$IN4%+^JVBL/PQX>L/"/A
MKP]X4TJXUR[TOPQH>D^'M-NO$_B?Q+XV\2W-AHMA;Z;9W'B'QGXSU;7_ !AX
MNUR:WMHY-6\3^*]=UKQ+K]^UQJNNZMJ.J7=U>3;E<!U!1110 5_&U_P<-_\
M)Z7PQ_[->\%_^K7^-=?V2U_&U_P<-_\ )Z7PQ_[->\%_^K7^-=?L_@+_ ,G
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M'_\ EW7]==%'_$UGB3_T+N$?_#9FG_S\_J_I8_XDX\*_^AGQM_X=LH_^A_\
MJ_I;YG_8Y^&WBWX0?LR_"'X:^.["'3/%WA+PY<:=KEA;7UGJ4%M=/K6J7BI'
M?6$UQ9W*FWN87WP3.H+%20RL!],445_.V:YEB,XS3,LWQ4:4<5FN88S,L3&A
M&4*,:^.Q%3$UHT8SG4G&DJE62IQE4G*,+*4Y-.3_ *=R;*\/D>3Y5DF#E6GA
M,GRW Y7A9XB49UY8;+\+2PE"5:<(4H3K2I48NI*%.G&4W)QA!-111117GGI'
M/^+/^15\3?\ 8OZS_P"FZYK^ ^O[\/%G_(J^)O\ L7]9_P#3=<U_ ?7]M_1!
M_P!VX^_Z_P##7_IO/3^!/IM_[SX;_P#7CBS_ -.<.A1117]FG\)!1110 444
M4 %%%% ']%/_  0Q_P"14_:,_P"QA^&__IM\85^\]?@Q_P $,?\ D5/VC/\
ML8?AO_Z;?&%?O/7^7?T@?^3O\8_]?LG_ /6>RD_UV^C9_P F3X&_[!\Z_P#6
MDSD****_&S]R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=U\+/'UYJ'[15C\:O%-G>0:./AQX'%_X]^(O@&SU#6[O4-$U!_@MXM\0P^)
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MN74_A[7-)UR&VFL+!(KB72;^WOXX)70[UCF>W$;LGS*K$KR!7V)110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU"1B27O856*[8F>,!) *K['_ &]^A/VE_A?3S77]#?KY,_:>_;E_9:_8TN/
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MXRA.+M*$XN,HNU[.+2:=FGJMF*,HSBI1:E%ZJ46G%ZVT:NGJFM.H45\B1?\
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MNFFK]&F5&2DE*+4HO9Q::=G9V:T>J:]58****D84444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOA31?"OB/Q+X&73/@_+XS\6:-JOC;1-7UV^^)7BS4O$/B?\ M^+P._P]\#>
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M'_=N/O\ K_PU_P"F\]/X$^FW_O/AO_UXXL_].<.A1117]FG\)!1110 4444
M%%%% ']%/_!#'_D5/VC/^QA^&_\ Z;?&%?O/7X,?\$,?^14_:,_[&'X;_P#I
MM\85^\]?Y=_2!_Y._P 8_P#7[)__ %GLI/\ 7;Z-G_)D^!O^P?.O_6DSD***
M*_&S]R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6G+?Y1Z?W5_7GN*.WSE_Z4_Z\M@HHHI#/C[]J3XS_M9_"C6/AM9?LS_L6_\
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MF<A1117XV?N04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?#?_ ).#P3_V5.1?^K+#G]SU%%%?YRG^H84444 %%%% !1110 4444 %%%%
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MG14445)04444 %%%% !1110 4444 %%%% !1110 5_&U_P '#?\ R>E\,?\
MLU[P7_ZM?XUU_9+7\;7_  <-_P#)Z7PQ_P"S7O!?_JU_C77[/X"_\G P_P#V
M*LS_ /3=,_"OI%_\FUQ7_8WRG_T],_!RBBBO[A/\_ HHHH **** "BBB@ K_
M $/O^"=__)BW[)O_ &0?X<_^H[9U_G@U_H??\$[_ /DQ;]DW_L@_PY_]1VSK
M^=?I&_\ ).\/_P#8ZJ?^H-<_I[Z+O_)3\2?]B&E_ZL,.?95%%%?R"?VT%>#?
MM4?\FP_M'?\ 9!OB_P#^J^\0U[S7@W[5'_)L/[1W_9!OB_\ ^J^\0UZ&4_\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;3_Z-"_:A_\ # ?%?_YDJ/[=R3_H<97_ .'#"?\ R[S7WA_J_G__ $(\X_\
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M$-?Z5\+_ /),\._]B+*/_5?AS_*?BS_DJN)O^R@SG_U8XD****]T^?"BBB@
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M_OP\6?\ (J^)O^Q?UG_TW7-?P'U_;?T0?]VX^_Z_\-?^F\]/X$^FW_O/AO\
M]>.+/_3G#H4445_9I_"04444 %%%% !1110!_13_ ,$,?^14_:,_[&'X;_\
MIM\85^\]?@Q_P0Q_Y%3]HS_L8?AO_P"FWQA7[SU_EW]('_D[_&/_ %^R?_UG
MLI/]=OHV?\F3X&_[!\Z_]:3.0HHHK\;/W(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#^??_@J)_P I,_\ @D-_V5;4
M_P#U/?AC7]!%?S[_ /!43_E)G_P2&_[*MJ?_ *GOPQK^@BO6Q_\ N.3?]@N(
M_P#4RN<.%_WG,?\ L(I?^HM ****\D[@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(?^"D_P#R89^U9_V1
MOQ5_Z(CK[>KXA_X*3_\ )AG[5G_9&_%7_HB.O<X8_P"2EX>_['F4_P#J?ASY
M_BS_ ))7B;_LG\Y_]5V)/\]6BBBO]+#_ "G"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K]:O^"(?_*13X3?]BO\5O\ U7'B.OR5K]:O^"(?_*13X3?]
MBO\ %;_U7'B.OD>/_P#DA^+_ /LF\Y_]5]<^U\-_^3@\$_\ 94Y%_P"K+#G]
MSU%%%?YRG^H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?@;X-_Y6%OBS_V9[IO_ *2?#2OWRK\#?!O_ "L+?%G_ +,]TW_T
MD^&E?OE7J9IOE_\ V*\%_P"D2.' [8O_ +#L3_Z6@HHHKRSN"BBB@ HHHH *
M*** "BBB@ HHHH SM8*C2=4+E50:=>EF<RJBJ+:7<6:%6F50,EC$K2@9,:EL
M"L[P@4/A/PN8FC>(^'=$,;PM<O$\9TVV*-$]XD=VT;+@HUU''<LI!G192RC2
MU8D:7J14LI&GWA#).EJZD6\A!6YD!CMV!Y6=P4A.)&!535#PHS/X6\-L[R2.
MV@:.SR37L6IRNQTZV+/+J4 6#4)&))>]A58KMB9XP$D JOL?]O?H3]I?X7T?
M==?T-^BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /\]7_ (*3_P#)^?[5G_99/%7_ */CKXAK[>_X*3_\GY_M6?\ 99/%7_H^
M.OB&O]*^%_\ DF>'?^Q%E'_JOPY_E/Q9_P E5Q-_V4&<_P#JQQ(4445[I\^%
M%%% !1110 5^TW_!!3_D_.'_ +(W\1?_ $?X;K\6:_:;_@@I_P GYP_]D;^(
MO_H_PW7Q/B1_R07%O_8CQW_IIGWWA9_R<;@S_LH,O_\ 3R/[8J***_SM/].C
MD/#08:S\028V0-XOLBK&TL[83+_P@7@A?,2:V437ZAE:$W>HEKQ&B:Q1O[/L
MK%5Z^N,\+A!K?Q&*+"&/C.Q,AB@N(79_^%>^ P#<23$QW4WEB-5GM,6ZVZP6
MS#[5;W)/9U4M_P#MV/3^ZOZ\]Q1V^<O_ $I_UY;!1114C"BBB@ HHHH ****
M "BBB@ HHHH **** .?\6?\ (J^)O^Q?UG_TW7-?P'U_?AXL_P"15\3?]B_K
M/_INN:_@/K^V_H@_[MQ]_P!?^&O_ $WGI_ GTV_]Y\-_^O'%G_ISAT****_L
MT_A(**** "BBB@ HHHH _HI_X(8_\BI^T9_V,/PW_P#3;XPK]YZ_!C_@AC_R
M*G[1G_8P_#?_ --OC"OWGK_+OZ0/_)W^,?\ K]D__K/92?Z[?1L_Y,GP-_V#
MYU_ZTF<A1117XV?N04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'Y>^(_P#@M#_P3%\,^(=6\-W'[6/A+7KG1SI?FZWX \'_ !2^)W@;5(M9
MT+2O$=C=>%OB1\./ OBKX>^,[$Z;K-G%>:AX1\3ZW8Z9K,>I^&]3N+3Q%HFL
MZ58?<7P0_: ^"G[2?@>V^(_P'^)W@_XI>#II+*TNM5\)ZO!?SZ!K%_X>T+Q6
MGA?QAH[&+7/!'C6S\/>)O#^J:SX'\8:;H?B_0(-8L%US1-/FN$B/SC\4/ O[
M"G[ W[-/[1?Q7_X9O^ /PO\ @]:?"BXM_B]X-^&GPD^"_@./XR^&-!TW7M'\
M'?!JXT2Y@\$>#_'VL>,=1\9ZG\-_A?X \7:O!I.N^*_B*/"5@UM)XMN4N?Y$
M?^">6M_'7]CC_@EQ_P %6/VM)O _C32]-^*_PR_9(_9L^$GQBT?Q;<_#+6-<
M^)7B+XD?%3]GGQS\3?AOXJTFWN/&0D^ ?B+]I#PMXOL/%&D6&FZ7K7C?0=;\
M >&?&NC>+_"_C.\\%^Q# X?%TL//">WHSK9GALMIK$U*=6.(EB*=63J4_9TJ
M+IN@X4W6I/VRC'$4DJK:O+SWB:M"K.&(=.I"."KXQ^PA*$Z2HSI1Y9J=6:FJ
MJJ35*7[GFE2G[ME)1_JY^)G_  5W_P""=?P@^(_CCX3>/OVD-.T[QW\.-?F\
M*^,M,TCX=?&#QAIND>)+2UM;C4]$3Q1X,^'WB#PIJFI:%/='1O$MKH^MZA+X
M9\4V&M^#_$"Z;XJ\/:[H^G?8'P,_:$^"7[2_@:W^)/P$^)_@_P"*?@V66PL[
MS4_">K0WMSX=UG4/#F@>+H_"OC31'\G7O GCBS\-^*?#FK:SX$\9Z7H/C+P_
M;ZUIZZ[H>G37,<1_%7_@WS_9C\":+_P3J\5>+_%&E>#/'MA^UU\0_BF?%/A[
M6_AWH(@M?A1X!N]0_9SL?@EXINKR?6%^)'@0WO@+XB^/+/3=;L]/T/3V^-/B
MWP[#X;8/JVM>(_A+_@WR\7^+/V=?VX_VT/\ @G1K7B/Q!\4-(\,:'\2]:B^(
MUYJ][X;\/R>,/V//CKIO[.'BWQ;8?!YKGQ-I6B^)/CUI_P 3_"6N>)=;L_%9
MU#2=.^%/A3PKJ=SXTMH=(U'PSE7P^#EAL17P;Q$5A<52H3^L3IS]O2KJNJ>(
M@J=*E["7/0BI4).O95XI5FZ4G4JC6Q'ML/2Q'L6\5AZE:$:,9Q=*K2C3JU:,
MG.<U64:<ZG[R*I7=)M0M))?U]445\%_MS_"+]MKXLZ5\.;?]C#]H;PO\ -3T
M34/$DWC^\\3::NHIXGL;ZVT=/#]M9AO!GC'RGTNXMM6EF(CL-XOH\O<;0L7#
M0IQK584Y5:=",KWJU>94X6BW[W)&<M6N56B]6NFIUU)NG"4U3G5:M:%/EYY7
M:6G/*,=+W=Y+1/KH?G7_ ,%1/^4F?_!(;_LJVI_^I[\,:_H(K^03XN_"+]MK
MX3?\%'?^"9=O^V?^T-X7^/\ J>M_&?3IO -YX9TU=.3PS86/C3P2GB"VO O@
MSP=YKZI<7.DRPDQW^P64@WV^[;+_ %]UZV:TXTL+E-.-6G7C'"U[5:7-[.=\
M75?N\\82T;Y7>*U3Z:G#@9NI5Q\W3G2;Q%/W*G+SQMAJ*][EE*.MKJTGHU?7
M0****\0]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OB'_@I/\ \F&?M6?]D;\5?^B(Z^WJ^(?^"D__ "89
M^U9_V1OQ5_Z(CKW.&/\ DI>'O^QYE/\ ZGX<^?XL_P"25XF_[)_.?_5=B3_/
M5HHHK_2P_P IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_6K_@B'_R
MD4^$W_8K_%;_ -5QXCK\E:_6K_@B'_RD4^$W_8K_ !6_]5QXCKY'C_\ Y(?B
M_P#[)O.?_5?7/M?#?_DX/!/_ &5.1?\ JRPY_<]1117^<I_J&%%%% !1110
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M5K+%0C1@L3A*M*G4IRK2]B_;P56G.-947)J5)3=O8)J<>25E+F7ZF45_-/\
M\%/O^">/_!+7]CG]B7XW_%:P^";>#OBAK'A;4OAE^S_>V/QB^)NJ>(I/CW\0
M],U#0OAOJ?A[PIX_^,<.@^-%^'^H27/Q;\:^'SI_B2XA^%WP\\>>(CX3\366
M@7NCW7YX_P#!/E_V@_V)/^"3?[?/_!0KX:Z]H.A^(_C#XF^ OPG^!TFN>&_#
MOBF#3]!^'7QMN_@GXZ^,UK)9^*K^VN_$$7C#XX?$WPIX4\%>/O!VF:=X;\:_
M!&S\6:_X>^(OP_\ &]OHMSO#*Z>(I8.>$Q-2=3'9C3RW#T\3AH8?GJ2C!RJ\
MU/$XG]U2E5HPG+E^*K%*[31E+'3I5*\<11A&.&P4\;5G1K2J\M.,G&,.6="@
MO:5.6K*$5)W5*;=DKG]LU%?PAWWQG_;+^$'_  31_8H_X*,?#7]O?]K>'XB_
M%OXZ?M"?L\>)/ OQ.^)NJ?''P-;7OAC6_P!IKP9X&\=Z3HGQ5NO$?AJ]?2/"
M?P!UF?7M!^)OA?XJ?VWXU\8Z%XNT/6?!MWX$AAU_]6O^"F'_  5L\3O^P;^R
MKH/P TGQ]X'_ &I?^"CG[/OP?^+FAZ1\&?&.C^+?B9\!_ GQ5T[X?:R_AOPY
M%I.A2?$KQ1\1_C+J7B?6/@-\"-<\$^ O!VN:]J^G_$GQY\//&'@_XG?#/PMX
M;UW!9<ZE3"JC7IU,/BZ5;$1Q4E*E"CA\-*:Q5;$1FKTXX>$'5E9SYJ;CR<U2
M7LUJL8E#$>TI3A5PU2C2G13C.4ZN)C?#TZ3B^6<JTDZ<=E&<7S\L+2?],5?B
M[_P5_P#^"BGQO_8,^'UY%\-?A?\ #+6S\3OA5XOM/AY\4=3_ &C_  1X2^)W
MP_\ BA%KF@^!6\0Z5^S-XN^&7BK7OC-X;\ WGQ*^'7C:34/ TOC+0[:.'Q+:
M?&O3OA'X*LM$\:>,?8_^"4__  3ET?\ X)S_   U#P=JVM:!XT^-7Q/UG3_&
M/QB\::!H6FV&C65UIVBVNC^%_A-X#U=M#TCQ?J_PG^%]JNJOX6E\9RO?:MXQ
M\7?$KX@V'A_X?6OQ"?X>^&?H[]IG]AW]EC]KCP[XXTOXW?!'X8>*O%'C;X9:
MC\*%^+6H?#;X=:Y\7_!OANXC\1RZ'<> _'GB[PEXEU'P[JO@77?%>N>,? <H
MCN[#PQXQOKCQ#9Z<UY<W9N<\%4P='&PJ5X/$82-5V52FXRG3YOW=2I251J,E
M&U2=&3KPNG2E&M%MN\1#$5,-*%.2HXB4(7<)\RA/W75A&IRQ<E\=-5%&G)JT
MX2I2M*/YT_\ !$S]N;]J3]L;X/W]G^T1IOPS\5:O\/T\87GB+XW:3\8_ALWQ
M)\7W?BGXS?$:W^&&@ZW^RY\.?AQX;O/A%H_A[X?>&[_PZ_BOQW>>%Y/'8\*>
M'O%G@/2_B5I?B_Q-XJ\)_N/7PW^Q1_P3M_9<_8*\!Z+X1^"/@+2;KQ/I*?$>
MTO/C=XO\+?#R?X[^*-'^)_Q,U#XIZ]X<\6_$GPEX(\':AK?AVRUVYTC3-&TB
M6VCM;?0/!O@NSO%U"\\/6NHM]R5R57"524J4/9TWR<E.\I<EJ<%)<TI3E+]X
MIOF<WS7YDJ:DJ5/>"DHI3ESR3E>5DN;WY.+LE%+W.7W;>[\+E-IU)E%%%04%
M%%?-G[7?A?\ :9\9_L^>.?#G['OQ&\*?";]HF^O? DW@/Q[XWM-/OO"VCV>F
M?$7PEJOCNTU6VU7X??%*R=?$/PZLO%OAJT9O VKSPW^L6LUG<Z%>QV_B'2KI
MQ52I3@YPI*<XP=6IS>SIJ4DG.IR1G/D@GS2Y(3ERI\L9.R<SDX0E)1E-QC*2
MA!)SG9-\L5)Q3E*UHWE%7:NTM3Z3HK^9K]KW]A']NKX0_L*_$/\ :9NO^"E_
M[3-Q^T]\+O!WC/\ :&_:)\.Z9\=?B7X>_9RU;POH6E>*_'_Q;\"? K2O"5GX
M5\0^!;WPEHS$_##6KG2+7P?XKN/!T7AC_A67P/T#Q_8W_P '>Y_X(_\ [<?Q
M\_X*6_!C]LW]FS]HGQCX@TCQE\/_  9X9TS2OVGO@]J6C?"WXN_\(Q^T_8?&
M[0K"XT.T\,>&;?PKX,^*/P4OOAUJ5[X"^)/AW2;:UO;'4?!*ZOX/E\5^"O$7
MC+XB=M; QAAZ6,IXF%;#3Q/U2<U3G"=&K[/VOO4II.4)4TY1E!M-IQ?*SGIX
MF4ZTL/4HRI5HT/K$4YPG"<.=4FHS@VN>,Y+F327*U)2>R_HLHK\I!_P2KP /
M^'D'_!5LX &3^V#DG'<G_A7?7UK^??X<^+?VN?%G_!9/3?V4?V:OVROVNOC'
M\"_A#^U-X+3Q1J?Q9^,GQ]U*V@^&O[.K>#-=_:OTOXORZ5I5IHUQI<_Q+\*_
M%#X$^#+_ %3P1H'PQ\=^)/$7PN\)7?B+4-%\>6GB_5[C@:-3#XS$4L9&:P>'
M]M-2H5*:G*4X4J-",Y/E]K7JU(PIQ?3GF[0ISDH>*JPJX:E4PSB\365*/+5A
M-Q7+*=2HXJSY*5.,ISELK);RBG_;'17\K^E?MW_\%#_VW?\ @I9^UQ^R%^S5
M\=_"?[*MK\!OA[^T;-\+O"NH?#3X?_$_PKXYU_\ 9D^-WAGX)1:G\1O'OBSP
M-K?C+PG??&/Q/\0K'6]5U;PKH/B/1/AAX*T32/#^E?#?QSXJTS7O&?C[Z;_X
M)$?\%?M2_:K_ &</VF_''[5-Y9Z=JO['O@+P+\7?'7Q-\*_#G5;'2=<^ GB/
MX9^*-7M_%NL^'_#&M>+-:\2_%^/7/@I\9/$WCK0_AW\.O"'AD:/J_@#2/A]X
M/NM3FU33K.,1EM?#QOS4ZTXUZ.%K4J#J3J8?$XBC.M1H5%*G!3G.-.K%/#RK
MTU4I3IN:ERJ54<93K224:D(SI5J]&I44%"M2H5H4*M2'+.4HJ,YQ=JT:4I0:
MG%..I_0+7@G[1WQTOOV=_AW'\1K;X%_'O]H"UC\2:)H&J^$?V<?!_A_X@?$3
M1K+76N+2V\62>"M7\8>$M8U_PW9:S_96CZW_ ,(7%XH\0:&NNV_BC5= M? >
MA^,_%OA?^>?_ ()X^.OVUO\ @J/^W'X[_;-USX[^/_AQ^PE\#_BUJ_AKPS\!
M?#7CWQ7\.8?%5QX<T8^*?@W\(O%GP[^%'Q8EL9/%'A;1O'/P_P#C5^TKX]\?
M:_XW\,_$SQ!J>F?!/PQHWC7X'ZU?>&_@M_0M^TA^S%\%?VM_AU'\)?C_ .&-
M7\:_#@>)=#\6WGA+3_'_ ,1? 6EZWK/AF2>Z\/CQ0/ASXL\)7'BS1]&U:6V\
M2:=X:\33ZMX;M?%^B^%_&46DKXJ\(^%]8TC.5&EAL8J&(G[6G2G3CBG07-RS
MLGB*--\\(U)T).5%S514Y5H3Y7*FHRG<:LZ^&=6C'DE5A.6&=3W5*#3]A6E[
MDW"-96JQBZ<I*E*$G'FDX1_$;_@FM_P6U^+G[<'[1?Q>^']]^RQX[\2?!_4/
M%/@,_ #QO\%O V@3M\.OAWXQ\6?&AY/$_P"V!XTUS]H77O GA8Q_#3PCX)UW
M0[OP)Y]MXV\0:1\3= ^'%GXZ\12^#_"MQ_1M7X7?L9?\$(OV??V2?VC_ (D?
MM S>.O%OQ!#>-M!\5_LQ^%K'Q#\9_A[>?LT:;I'BWXIZQJ'AJ3Q?IOQXUR^^
M-=GXJ\(^./"7PY\7R_$73&A\7>%? VHZ9XML-?T7X@>)=#7]T:G&O#2Q55X-
M26'<I\BDK;U:LKQ3UY.1TU!N-)\BC&5&$XRG4>&5=48+$<OM;0ORN]DJ5--2
MW]_G4W/WJB<FY1J.,HP@4445RFY_GJ_\%)_^3\_VK/\ LLGBK_T?'7Q#7V]_
MP4G_ .3\_P!JS_LLGBK_ -'QU\0U_I7PO_R3/#O_ &(LH_\ 5?AS_*?BS_DJ
MN)O^R@SG_P!6.)"BBBO=/GPHHHH **** "OVF_X(*?\ )^</_9&_B+_Z/\-U
M^+-?M-_P04_Y/SA_[(W\1?\ T?X;KXGQ(_Y(+BW_ +$>._\ 33/OO"S_ ).-
MP9_V4&7_ /IY']L5%%%?YVG^G1QWAELZU\1!OW;/&-DN/MOVOR\_#_P,VSR,
M#^S,[O,^Q9;S-_\ :6?^)AM7L:Y#PT'&L_$$N)@I\7V1B,L-O$C)_P (%X(!
M-N\)\RYA\P2*TUWBX6X$]NH^RP6Q/7U4M_\ MV/_ *2OZ\MA+;YR_P#2F%%%
M%2,**** "BBB@ HHHH **** "BBB@ HHHH Y_P 6?\BKXF_[%_6?_3=<U_ ?
M7]^'BS_D5?$W_8OZS_Z;KFOX#Z_MOZ(/^[<??]?^&O\ TWGI_ GTV_\ >?#?
M_KQQ9_Z<X="BBBO[-/X2"BBB@ HHHH **** /Z*?^"&/_(J?M&?]C#\-_P#T
MV^,*_>>OP8_X(8_\BI^T9_V,/PW_ /3;XPK]YZ_R[^D#_P G?XQ_Z_9/_P"L
M]E)_KM]&S_DR? W_ &#YU_ZTF<A1117XV?N04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >+_ +0G[/7P?_:I^$OB3X%_'KPA_P )W\*_%U_X/U3Q
M#X6_M_Q1X7_M"^\!>-O#GQ%\)S_VWX,UOP[XCM/[)\9>$_#^L>58ZO;0WW]G
M_P!GZE'>:5=7MC<_$OAG_@C%_P $U?!WC'P'X_\ #G[-W]G>+?AGX_\  _Q1
M\$:M_P +A^/=W_8GCKX;^*=)\:^"]<^P7_Q2NM,U+^QO$VAZ7J?]F:O9W^CZ
MC]E^QZMI]]I\UQ:2_J%16T<3B(498>%>M'#SDY3H1JU(T9R:BG*5)24)2:A!
M-N+;4(K[*MFZ-*52-:5*G*K"W)5<(NI"S;7+-KFC9MM6:LVVMS_/\_:*_;TT
MW_@KM^U)\/V_:-^,FL?L<_L"^$;R_P#%OP[T"/0-=\=^,='\/+:Q:8OC'4?#
MG@7PS\1-&\0?M=?%70->OM*\/:YXDT_6/@M^S-X!O?%NB>&KOXB:TOC6W_:I
M_H2A\0?\$R?V[/V,?BO_ ,$H_P!A3Q'X+NKVS_9O\6>,/@Y\,[WPO^T3\,_"
M7ACQ-\,?&G@WQ+\/?BCXR^(&K>"+/7M<N-%_:6\1_"_X@?$;5M3U+QKXY^)F
MMZGXA\1^--&^(S:MXT34?WQHKT<3F-&=3#UL)AZ^%G@Y47@H2Q5.MA\.J52%
M235*.#H3G5K2BZE6M*MSSJR4I\T(0I1Y*.$JQC5AB*U*O'$JI]9E&A.E6J\T
M)PIKVCQ-2,*=%3Y:=.-/EC#GM:K5JUI?R+_\$E/^"G7PY_83_9@^+_[-O[<-
MQ\8?AK\1/@_XZUOQ_P#![X->)O@=K'AKQS;_  ^^*/@;0OBBGPAATQM%T35]
M'^(E]\3=3\<^/)+GX]R^"M,72?C1X#AT[QW/X3T^\MO _M'_  ;U_LB?&>#6
M?C)_P4<_:<T.QO\ XB_M+^$;.#X5_$JYN;CP]XI\>Z/\4O&^J_&#]HOXG/\
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M=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA1HO@GPIJUAX?\*>,?%$FN:]\-?A987/PY^!GA+PK_PL;Q3J<MC\*_W>\?\
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MI7B/1?&&H?"NQN/V7=,\16\5C/X'^$_PZ^!OC6V^%_C^?X>Z%;Q^-=G]H?\
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M\6M6\?Z%\8_ 7PI^)GP;^/5OX1L=1AUNUA_9=TWXGV'[-W@7P'X>\)?$R_\
M!7PO\9>(?&.F^(/AQ\,-$\8:/IW7?M4?M;_';]E__@J7\6_^"E>F?"+]HKX'
M^'O'5@R?#+X<_M*>#KWX-Z9\0HD_9'\%_ S5M(^+'A6X^)7ACQ#XX^"/PO\
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M_P (Z1X&O/#/@3]GCX;Z5X!^-_\ 9E^SE_P4G_8K_:U^)5W\(/V?/C/_ ,+
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MJ,*DZU.<J]+E4I1YJ/)2J-)N5-8F-.J^>)]04445YIVA1110!_GJ_P#!2?\
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M82P\9V(D$4]Q,ZO_ ,*]\!D"XCF CM9O+,;+!:9MVMV@N6/VJXN0.SJI;_\
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M3]HS_L8?AO\ ^FWQA7[SU_EW]('_ )._QC_U^R?_ -9[*3_7;Z-G_)D^!O\
ML'SK_P!:3.0HHHK\;/W(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#^??\ X*B?\I,_^"0W_95M3_\ 4]^&-?T$5_/O
M_P %1/\ E)G_ ,$AO^RK:G_ZGOPQK^@BO6Q_^XY-_P!@N(_]3*YPX7_><Q_[
M"*7_ *BT HHHKR3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KXA_X*3_\ )AG[5G_9&_%7_HB.OMZOB'_@
MI/\ \F&?M6?]D;\5?^B(Z]SAC_DI>'O^QYE/_J?ASY_BS_DE>)O^R?SG_P!5
MV)/\]6BBBO\ 2P_RG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]:O^
M"(?_ "D4^$W_ &*_Q6_]5QXCK\E:_6K_ ((A_P#*13X3?]BO\5O_ %7'B.OD
M>/\ _DA^+_\ LF\Y_P#5?7/M?#?_ ).#P3_V5.1?^K+#G]SU%%%?YRG^H844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@;X-
M_P"5A;XL_P#9GNF_^DGPTK]\J_ WP;_RL+?%G_LSW3?_ $D^&E?OE7J9IOE_
M_8KP7_I$CAP.V+_[#L3_ .EH****\L[@HHHH **** "BBB@ HHHH **** ,_
M5QNTK4UP6W:?>C:J)(S9MI1A8Y/W;D] DGR,>'^4FL[PDI3PIX90HZ%/#VBJ
M4DAAMW3;IML-KP6_^CP.N,-#!^YC(*1?(JUH:Q@Z3J@8*1_9U[D.CNA'V:7.
MY(_G=<?>5/G89"\D5G>$-H\)^%P@C"#P[H@00QRPQ!?[-MMHBBGS/%&!C9',
M?-1<+)\X-5]C_M[]"?M?]N_J=%1114E!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '^>K_ ,%)_P#D_/\ :L_[+)XJ_P#1\=?$-?;W
M_!2?_D_/]JS_ ++)XJ_]'QU\0U_I7PO_ ,DSP[_V(LH_]5^'/\I^+/\ DJN)
MO^R@SG_U8XD****]T^?"BBB@ HHHH *_:;_@@I_R?G#_ -D;^(O_ */\-U^+
M-?M-_P $%/\ D_.'_LC?Q%_]'^&Z^)\2/^2"XM_[$>._]-,^^\+/^3C<&?\
M909?_P"GD?VQ4445_G:?Z='&>%WC;6_B,J-:LT?C.Q246[:B94D/P]\!R!;X
M7I^S+=&)XG1='QIWV)[-I1_:S:H3V=<AX:=VUGX@J\DSK'XOLDB675+?4$A0
M^ O!$ACM[2%5DT.$R/)*VE79>XFN)9];5A:ZQ;(O7TY;_*/_ *2OZ\MA1V^<
MNG]Y_P!>>X4444AA1110 4444 %%%% !1110 4444 %%%% '/^+/^15\3?\
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MOT445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
MGJ_\%)_^3\_VK/\ LLGBK_T?'7Q#7V]_P4G_ .3\_P!JS_LLGBK_ -'QU\0U
M_I7PO_R3/#O_ &(LH_\ 5?AS_*?BS_DJN)O^R@SG_P!6.)"BBBO=/GPHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^K+#G]SU%%%?YRG^H84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_ZKCQ'7Y*U^M7_!$/\ Y2*?";_L5_BM_P"JX\1U\CQ__P D/Q?_ -DWG/\
MZKZY]KX;_P#)P>"?^RIR+_U98<_N>HHHK_.4_P!0PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ WP;_ ,K"WQ9_[,]TW_TD
M^&E?OE7X&^#?^5A;XL_]F>Z;_P"DGPTK]\J]3--\O_[%>"_](D<.!VQ?_8=B
M?_2T%%%%>6=P4444 %%%% !1110 4444 %%%% &?JV?[+U+;N!_L^\P49$<'
M[/)C:\G[M&S]UG^13@M\H-4/"98^%O#1<R%SH&C%C+)%-*6_LZVW&6:#$$LA
M.2\L($4C9>/Y"*OZLI;2]24*6+:?>*%$1G+$V\@"B <S$]/*',GW.]4/"B-'
MX6\-1NC1-'H&C(T;6IL6C9-.ME*-9')LV0@J;4DFW(\K^"J^Q_V]^@OM?)_F
MC?HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M^>K_ ,%)_P#D_/\ :L_[+)XJ_P#1\=?$-?;W_!2?_D_/]JS_ ++)XJ_]'QU\
M0U_I7PO_ ,DSP[_V(LH_]5^'/\I^+/\ DJN)O^R@SG_U8XD****]T^?"BBB@
M HHHH *_:;_@@I_R?G#_ -D;^(O_ */\-U^+-?M-_P $%/\ D_.'_LC?Q%_]
M'^&Z^)\2/^2"XM_[$>._]-,^^\+/^3C<&?\ 909?_P"GD?VQ4445_G:?Z='%
M>%O)_MWXD^5]C\S_ (36P^T_9?[0\_S_ /A77@';_:/VW_1OMGV;[/L_LG_B
M7_V?]A\S_B:_VG7:UQWAF9I-:^(B,]PXM_&-E$BS:C%?1Q*WP_\  TYCM+6.
M-'T>W+S/*VFSM+++=R76KB00:K#%'V-5+?Y1_P#24*.WSET_O/\ KSW"BBBI
M&%%%% !1110 4444 %%%% !1110 4444 <_XL_Y%7Q-_V+^L_P#INN:_@/K^
M_#Q9_P BKXF_[%_6?_3=<U_ ?7]M_1!_W;C[_K_PU_Z;ST_@3Z;?^\^&_P#U
MXXL_].<.A1117]FG\)!1110 4444 %%%% ']%/\ P0Q_Y%3]HS_L8?AO_P"F
MWQA7[SU^#'_!#'_D5/VC/^QA^&__ *;?&%?O/7^7?T@?^3O\8_\ 7[)__6>R
MD_UV^C9_R9/@;_L'SK_UI,Y"BBBOQL_<@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **\7_:$_:&^#_[*WPE\2?'3X]>+_\ A!/A7X1O_!^E^(?%
M/]@>*/%']GWWCWQMX<^'7A.#^Q/!FB>(O$=W_:WC+Q9X?T?S;'2+F&Q_M#^T
M-2DL]*M;V^MOB7PS_P %G?\ @FKXQ\8^ _ 'AS]I'^T?%OQ,\?\ @?X7>"-)
M_P"%/?'NT_MOQU\2/%.D^"O!>A_;[_X6VNF:;_;/B;7-+TS^T]7O+#1].^U?
M;-6U"QT^&XNXMHX;$3HRQ$,/6EAX2<9UXTJDJ,))1;C*JHN$9)3@VG)-*<7]
MI7S=:E&I&C*K3C5G;DI.<54G=M+E@WS2NTTK)W::6Q\^Z;_P51_;.\?+\3_$
MWPF_X(Y?M93_  X^'/A3P[XV%U\=M;NOV>OBWK6B:QX2N]=U#3M+^#NO?"[Q
M/<>,O'&D:WH/BK07^'_P6\7_ !B\4M#;>#[G4K#1M>^(7A[PF?;/^">7_!63
MX)_MU_!SXO\ Q(US3K']G[7_ -GBR3Q3\<M&\7>,8-7^'7@KX8:Y'XUUCP1\
M5[;XU:EH'@CPKJ'@O6/"G@+Q5?>*9=6T_P ,ZI\/]:\*>*K;7=.E\%KX)^(7
MCW _;\_:'_X*=^#?#7[0OA+]D7]BJ;4-/T'PG#<?#K]JNQ^*OPR^(.O)8GPE
MH'B+QQXC\&_LHW5D/&GBGX@^&7N/&/A#X=>%;Q/%\6N>.M$\/>))?AY\2_#]
M\/AMXE_E@_9P^(/[/OP,_P""0W_!26^_9W_:'\4W'[1_Q9\'?L4?#GQ_\./&
M7@_X?:)I%E^S/KGQB^&GP1\=7_P<BE\0_$X_%;P?K$7[47QC^&GC'XRRZGX6
M\5Z%#K/PLOYOA-\&-;U/P#XV^)WN+ 4<52P7+0H86IBLTP.$IRPF)GBXQPV+
MI5')XUNOB*="O&;H<E.^'JRG]8C+#TU2<5YJQ52C6KIU:M>%'!8JO*&(I1PS
M=;#U*=HX5^QI2JTY0]LY32KPC3A"?M973E_1KX._X+&_&O\ :!NOC_XM_8Q_
MX)W?$3]ICX _ O5I=/3XO1_%NW^&NL^.;>R\+)XCO3X9^%.O_"O5/%.L>*;F
M*&ZU+1OA=X0N_&7Q6_X1/6_AMJ?B_P %>"_%GQ(T;P';?;/_  3L_P""B_PD
M_P""B_PN\1>-_A_HNI>!O%WP_P!2\,Z#\2/AQX@\0^$-<U72-0\1^#M&\2V?
MBGPS-X=UFYU?6_A+KFKW'BOPCX"^('BKPO\ #_4/&VL?#GQR8?!VE#0[B%?E
MO_@WZ^'7@_P7_P $T_AYXM\.:(VE>(?C1\4OCO\ $;XE7S:CK-[_ ,)+XPT'
MXJ>)/@EHVMBTU34+RST80?"[X0?#GPX-.\/V^E:/.- _MJ73Y-=U?6M4U+\C
MO^"')/P&_P""P/[<W[(7PJ/_  B?[/6A^"?VK++2_AP8VUU[6R_98_;&\$?"
M;X!D^,O%!UKQW<KX)^'OQ7\?Z"@N/%$W_"2#7SJ_BW^WM7T[1-0T[BKQPM?"
M8JO0PRPLL)BZ%.'+4K5'6PV(^L17M_;5)KZQ"5*E)SH*C3ES5OW,4H*&U&5>
MG7PM*K7=?ZUA:LY<U.G"-*O0A2K3=)TXQ:HN+JPA&JZDW^Z]_F;O_8[117P7
M^W/\!/VM?CKI7PYM/V4_VF_^&;-0\.:AXDN/&E[]BO;W_A+;/4K;1X]$M<6<
M$YC_ +(GL]2FS(%#?VA\I)!QY]&G&K5A3G5A0C)N]6HIN$+)OWE",I:M<JM%
MZM7LKL[:DY0A*4:<JLE:U.'*I2NTM'.48Z)W=Y+1/KH?G7_P5$_Y29_\$AO^
MRK:G_P"I[\,:_H(K^03XN_ 7]K7X%_\ !1W_ ()EVG[5G[3?_#2>H>(_C/I]
MQX+OOL-[9?\ ")6>F^-/!,6M6F+R" R?VO/>:;-F,,%^P?,06&?Z^Z];-:<:
M6%RF$*L*\8X6O:K34U"=\75;Y54C">C;B^:*U3MI9G!@)RJ5<?.5.5*3Q%.]
M.?*Y1MAJ*U<'*.J5U9O1J]G=!1117B'I!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\0_\ !2?_ ),,_:L_
M[(WXJ_\ 1$=?;U?$/_!2?_DPS]JS_LC?BK_T1'7N<,?\E+P]_P!CS*?_ %/P
MY\_Q9_R2O$W_ &3^<_\ JNQ)_GJT445_I8?Y3A1110 4444 %%%% !1110 4
M444 %%%% !1110 5^M7_  1#_P"4BGPF_P"Q7^*W_JN/$=?DK7ZU?\$0_P#E
M(I\)O^Q7^*W_ *KCQ'7R/'__ "0_%_\ V3><_P#JOKGVOAO_ ,G!X)_[*G(O
M_5EAS^YZBBBO\Y3_ %#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#\#?!O\ RL+?%G_LSW3?_23X:5^^5?@;X-_Y6%OBS_V9
M[IO_ *2?#2OWRKU,TWR__L5X+_TB1PX';%_]AV)_]+04445Y9W!1110 4444
M %%%% !1110 4444 9NL[?[(U7?Y>S^S;[?YWG>3M^RR[O-^S_O_ "\9W^1^
M^VY\OY]M9W@[R_\ A$?"WD_9_)_X1S1/*^R?:_LOE_V9:[/LWV[_ $[[/MQY
M/VS_ $KR]OVC]]OK3U8D:7J14LI&GWA#).EJZD6\A!6YD!CMV!Y6=P4A.)&!
M535#PHS/X6\-L[R2.V@:.SR37L6IRNQTZV+/+J4 6#4)&))>]A58KMB9XP$D
M JOL?]O?H3]I?X7T\UU_0WZ***DH**** "BBB@ HHHH **** "BBB@ HHHH
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MGJT445_I8?Y3A1110 4444 %%%% !1110 4444 %%%% !1110 5^M7_!$/\
MY2*?";_L5_BM_P"JX\1U^2M?K5_P1#_Y2*?";_L5_BM_ZKCQ'7R/'_\ R0_%
M_P#V3><_^J^N?:^&_P#R<'@G_LJ<B_\ 5EAS^YZBBBO\Y3_4,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P-\&_\K"WQ9_[
M,]TW_P!)/AI7[Y5^!O@W_E86^+/_ &9[IO\ Z2?#2OWRKU,TWR__ +%>"_\
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MY-_V"XC_ -3*YPX7_><Q_P"PBE_ZBT HHHKR3N"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^!O@W_E86^+/_9GNF_\ I)\-*_?*OP-\&_\ *PM\6?\
MLSW3?_23X:5^^5>IFF^7_P#8KP7_ *1(X<#MB_\ L.Q/_I:"BBBO+.X****
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M_P ,>6?_ #+Y+[CX-_X=@?L _P#1K'PO_P# '4__ )9T?\.P/V ?^C6/A?\
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M"?X#^!O WC?28-0M=-\2:':WT6HV=OJME/INHQ0O-?3QA;NQN9[:7,9)CE8
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M+_9MMM$44^9XHP,;(YCYJ+A9/G!JOL?]O?H3]K_MW]5T_K\#HJ***DH****
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MCX26]U\---@7P]X5\.^(/'GAKQ#X[U;QOK?B3\4(_P#@AY_P5#\*?LS?&_\
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MUHJ6K$'@M;*MN3S"HCV@5]C_ +>_0G[7_;O;S77^OQ-^BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\[/^"H_[<S_
M /!/[]DW7_C+H&B:)XJ^*WBCQ5X<^$_P.\*>*(/%+^%=:^)OBY=1U$WWBFY\
M*Z=<SP>'? 7@+PYXZ^*.JZ9J&L^";?QO:^!7^'&E>//"GBOQGX<U./\ FP_X
M)<_\%@OV\?VGO^"@/[''P;^(O[1+^._@Y\4_&7QV\/>.-#?X4_ _0/\ A*8/
MA[^S?\>O%^E.FN>$_AOHFO:=%;>// 6AZY#<:#JNEF_BL$L[D2Z1>WNGW'?'
M+L1++ZN9-TXX>E4C3492DJU:]6A1G.E!1:E3I5,11C4G*4%>3C#GE&48\LL7
M2CBZ>#M.56I&4KQ2=.G:G5JQC4DY)J52%"JX1C&3]QN7*G%O^V*BN'^)WQ'\
M&_!SX;?$+XN_$;5I- ^'OPK\#^+/B/X[UV'2=:UZ;1?!O@?0;_Q/XGU:+0_#
MFG:OXAUF33M$TN^O$TK0=)U/6=1:$6>EZ=>WTT%M+_G\_'G_ (.(?^"DWB=O
MCAXP^'7Q8T+X#RV'ARY\8^'OA'X:^&_P?^(&D_"73-0TJ_/A7PO/XQ^(?PVU
MSQ!XV\1V5IHRW_BWQ#JZ6.F^(/$EYJ6KZ!X4\&>%=1T7P3X>,+EU?%8?%XJ#
MIPHX.G*I.564HNK*%*I6=&@E"7/6]E1J5+/EA&,??G%R@I%?%TJ%7#T9*<IX
MBI&G%02:@IU*=%5:K<ERT_:U:4+KFDY37+&5I-?Z'U%?C!_P68_X*GZS_P $
MSOAE\.)_ O@31_%7Q+^*[>.->T?7_'-I?ZC\,/!G@;X.W'@2]^)%WXAT?PYX
ME\->,/$?BS7K'QUHN@^ ]"T?4-(TRWGN]<\8:[K\O_"'Z;X ^(GBF@_\%6/V
MI/V=_P!OKX??L-_\%!_A=^SSHG_"YM6^$^E_#WXP? +7/B,GAVWB^+Y\:>#_
M (>:G#X5UF/XD>+?%T'Q!^/FF:!\"8+;Q-8?!!_A_JNG>,/B#KL_B/X<'0?$
M%S*P&(>&^M6I\CHRQ"A[2/MGAHUWA98A4[\WLEB(SI-_%>$Y<OLXN97UJE[=
M4/?YW5C0YE"7)]8G3C5A0Y[6]K*G.$HQV?/"*?/)1/Z"J*_ '_@K%_P4H^/'
MPV^*WPL_88_X)V_V)X^_:_\ '^LV\_Q$A\,V&E>-O'7PHM'L]"\3> _ =KX=
M\5Z'>_"C1_$OQ3T*ZU3QCXU\3_$C719_!7X#^'[SX@>+O#'AWP_\3O ?QB\&
M_LI^SEX9^,G@_P"!?PL\/?M#_$*+XI_':R\':3-\7_'%E;>'+70M5^(NI1'5
M/%MGX0B\+?#[X6::? /A[6KV[\-?#V>\\!Z'XFNO!&D:!=>-#JOC&;7=:U'&
MMAYT(8>51Q4L13=:-*[]K"BY<M*K5BTE".(M.5#WG*=.FZKC&G4HSJW3K1JS
MK1@I-491IRG9>SE4:<ITX.]Y2I+E]KHHQE4C!2<XU(P_FC_X+)?\%@_VV/V>
M?%7BG]FOX":!\+?@-\2_#/CKQ9=Z;\;?!?QM^%G[2NJZYX#TWX:VOB#PAI'C
MGX!ZS\#-=\1_!/Q'XHM_BI\-/&EQHGQ#TO2?$%Y?^$O$.F?".7XT?#5KSXAW
MOZ'_ !<_X*I?'CX0_L=>"OVQ-7_97_9MU?PSXM\5_%/PX_A+0O\ @I!\+-7O
MHH? /AOQ!K.AR^#_ !=HWP?U7P+\9_%?B;4/AM\7--OOA/\ !'7OB'\6=(CT
M/P4=!\%^-O$&N?$[PO\ !3VK]M/_ ((W?L)_MO>#-0\+^,OA3H?P<U_6_&_B
MCQ_XC^+7[/'@7X._#WXQ^*=<\<:3XQL?&R>)O'FJ_"_Q9>ZW9>,=7\9WGC7Q
M4M_;RW?B'QQI&@>(]6O;NYL)4NOI^\_8-_8;U#1K3PY?_L9?LHWWA[3[OQ+J
M%AH-Y^SM\(;G1K*_\::9X1T3QC>VFES>#WL;:[\6:-\/_ >D>);F&!)M=TSP
M3X1L-4>ZM?#>C167=4Q&6OZGRX/2E1Y<3%2J0=:?+BD_>]JW&3JRH5N9^U:N
MHW]A06$J\T*.,3K\V(?OU9RI>[3?LX.5!PWIZJ-.-2GR6@KW;YZE7ZS#\@_^
M"+'_  4(_:P_:C2S\ ?'#2O@U\2=8U6+QE\2O'7QKB^./PG\%?%&QT+0-.\)
M^#=-T:#]E+P%\*M$\5Z[(GB6X\,VB_$.Z;1/AT/"NK3_ &CX@/XTT31/AKKW
MQ#^VE_P6Y_;F\+?M6?!?X+_#OP3\%O@G/\+_ (O:?I'Q\\,>#_VG_@C\?OAW
M\<M/L?VA?#WP_P#$?P_U?XU:W\"[:R_9NBM]+^'/Q-T'6-2\9/\ #_XH?#;1
MOB1IWC'XV> OA!)H&BSM^[7["_\ P39_98_8SLM0T'P#X4TSXA^*/A?X^OS\
M/?B[\5/"7PX\0?&_P!IOB3X8>&K?5/"NB_$?1/AOX,U+2]'N(O%7C"Y2ST8O
M";#Q]XBL+B^>/5M2TRWXCX[?\$3O^">GQT\:_ 'QG_PHWP7\'4^ 'BS0?$]E
MX-^!/PS^"'P^\"?%6Q\->./A[X[TCP-\:O#W_"J=7'CGX?VE[\/8]$A\,Q76
MC0P>&O&/CS3;6X@E\0K>66RQ.5K'8VK/!J>'J\SPL.6<8TD\-5C;V<:L5:K5
ME"48Q]E*DW&I1JX7V2A+&%#'?5,'36(<*].5#V\[QJ<W)B*4IN4IP;J<E.,U
M-2<XUDI4ZL:ZJ-GZ"?L_?$+Q;\6O@K\-/BAXW\*>#O _B#XA^%-.\9MX7\ _
M%/3?C9X4TO1?$:-JWA8:;\5-"\/^&O#GC.6\\+76C:AJFI^%+'4/"$>L7=_8
M^$?%7CCPU::5XTU_V&N.\ _#SP!\*?"FF^!/A=X&\'?#;P/HTNJ3Z1X-\ ^&
M=%\'>%-*GUS6+_Q#K<VF^'?#UEIVD6,NL:_JNJ:YJDEK9Q/J&L:E?ZG=F:]O
M+B>3L:\17LKZOJ^_F>H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7&2GAG#ZOA\7%86A2O7YU*HG.K-SC3A[?$24W&G3C,_I+_X+X_\ !-'XW_\
M!0?X5_"74_@0VG^)/$WPGM?BGX.U?X4RWFA>&M<\8^'/CK/\,--O_%7A7QMX
MLU_1?".G:M\-I/ ,&JWWACQ&]C;>)_#>K:[?:3KZ>)O#&A^"?'_Y(?\ !3_0
M/VR(OVE/!'_!3/\ :R^!GA3]F+1OA!KWP&^'W[-/PMTWXA:;\9?$_P 0OC%\
M)X/C;^T3\"-(\2:G\.)]8\.:UX'T7]HC1KGQI^TIJWBO6?V9#+^RY+>_#_X+
M:KXM^/\ ::+<^*_ZO_@1X9^,7[.GPI^)NM?MC?M@Z%\?8]'U_P 0_$B3XP>*
M/A7\./V;?#7PH^$6B^!/#"ZIX?\ $4/AC5YO#$NA>&=4\-^-OB#JWQ"\1W]C
M/:V'BJXTS4&@T;PO8W+_ ,S_ ,#-/\:?\%\_^"B&G?M'?$SX:>/?AQ^PW^R]
MI>DVWA;PAXEL-&\6^&/%$VC^,]$\:Z3\$?B-H_B_7O$7PX7XH?'^SO[+QA^U
M+8?#/P7XOTG0_@=X,^''P(\9:[+JNK?"#XZ^(?/PF)MA:CQ-*C/!X.B\%[6/
MM85\73K8JKC*65PDYJ"IXBO[>M6K?5_K%'"?6+STA2?3B*/[^G["I4CB<35I
MXJ-.7)*EAJM.C2HU,=42CS.6$I^RA&$:KHU<5&C"*DI^U//_ /@E3^T1^Q_\
M(_BOXY_;>_X*/?M+:3XU_;(^+^EZ3XU^&">+?A%\<?&?Q(^$W@[Q=:^*M OO
MB;XAU7PMX#O?AGX'\4?M ^ O^$=O?@WX%\*^'-+N?A_^QC>?"[7?ACK.G_ S
M]INT\&6G]:_[.?[3GP(_:U^'7_"U_P!GCXBZ7\2? T?B'7/"5]J5E8ZYH>IZ
M+XG\.S11ZGH/B3PMXJTO0O%GAC5?LEUINNZ?9^(=$TR;6O">N^&O&.BKJ'A3
MQ/X?UG4OXXOV=OB?\"/AC_P6H_X*#>*/^"C"6MSX"5O^"B?A*WM?VBOAMXI^
M*MPUOK/C[2M0^&ND:?X<USPEXSUF/P_XV_81LO&_@'X/Z?;Z?%I7Q'^#7CCP
MO\$?AG;>([+XL^!O!'BGZ:_X-0_#?BC3]!_;%UWQ#H6NJ[^#_P!CCP/JGB^[
MTV_?1-5\<^$-*_:!UWQ7X3M_%+0G2-8\4>%-.\>>%==\2Z-9WUSJ>B:7X\\)
M:IJD%M9^*M%GO3-<(HK$8J<JSQ$,3E].K6J<BPV.^NY=/%<^ A"G#V6'PBI0
MP]&G[3$16%5)7HVC33P-=MT:$%35%TL8X4H\SQ&&^J8R.&?UN<IR52MB)3E6
MK34*5JU2W[WF<S^ONBBBO!/4.0\-.[:S\05>29UC\7V21++JEOJ"0H? 7@B0
MQV]I"JR:'"9'DE;2KLO<37$L^MJPM=8MD7KZY#PTCKK/Q!9XYD63Q?9/$TNE
M6^GI,@\!>"(S);W<+-)KD(DCDB;5;L)<0W$4^B*IM='MG;KZ;W^4?_24);?.
M7_I3"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HKQ?]H3XS?\,_?"7Q)\6?\ A5'QH^-W_".7_@^P_P"%:?L]^!?^%D_%K7O^
M$O\ &WASP5]M\-^#?[4T7^U+#PO_ ,)%_P );XPN/[2@_L3P3H7B/7MES_9G
MV2?\Z?%O_!8GP1\.M"N_&GQ-_8._X*A_#KX;^'WMK_X@_$SQ-^QSJ\G@[X7>
M"(KF(^+/B?X[?P_XOUW7K/P!\.]!^W^,?'&HZ)H.O:OIWA;1M5O=-T/5[V"'
M3[C>&&KU*3K0IN5-3Y&TXWY_<]U0OSM^_&UHN][+9VS=6G&I&DY6J3MRQM+6
M[:6MN5:I[M&?_P %EO\ @J#J'_!-+X-?#K6/ 6B>"?$?Q@^*OBG5SH=G\2+'
MQO=>"O#?PM^&UGINL_%SQ[J,7A*/28->U*PDU[P+X"\/^#[CX@>"-9N=7^)5
MOX\TM?%VB?#CQ9X5U%G_  31_P""E_B?]IW]C']H_P#:W_:GM/A_\//#_P"S
MS\1OB19^)=0^%_A/Q])I>F_"OX:_ SX7_&#7_$=YX;FU[XD^+]>UZPA\6>)I
M'LO#,=S=ZE8V&EZ=I'AZYU?>VH_S#_$&]^&/_!2'7_\ @JS^WS^TK\4O"GA6
M+P[^S/\ M#>&/V+_ -F?XE^)?A8OBCX@:W)^SK\6/"WP!\&:1\+/&GQ/^)?B
MW1]6^#%KJ7A7XLRZ7\*=&'A3QQ^W!\4]0^(OP:\?:=JG@3QQX%U/K?@9\8-,
M\,_\$'/V\_@WX2^*-IX?^/WQ _:Q\&ZQH/PK\+^-H]*^,OC;X)V-G^QG>_'_
M %31? ^C:G;^.?$GPOL_@3X)^.5W\8+[3]+O?"MO\)?"/Q7N/&<J>#] \7O:
M?0SRJE[# 81TI4ZRSW!Y?C<7:2<GB*&)^LQC*2<%0PU9T<-%VE"IB*$ZT92A
M7IQ7DQQLW5J8B-13I3R['8FA04HN*CAJF!>'J.VOM<1"IB*S6\:$Z<6HSIU$
MOVQ_9^_X*-_\%.?V];#]I7XP_L2_ W]E"P^ _P )/&EWX.^'OA?X]W_C-?C9
MXVU[3/ &B^,IO 4UYX.^*=GX"M_B-J&G:WX5\0W@\1GX?_#'PS_PM'PKX,L/
MB9X]3PAXU^(2?8'_  20_P""G^G?\%*_A1XWU?5_"WA[P5\4_A1/\/8?%VD^
M$M1\3ZQX7\5^%_'W@R*_\,_%C0IM<\-Z?9^%=+\;>-?#?Q7T;2_ABGC'XD>)
M?!ND>"M.U#Q/XKO%\4Z+<7?GO_!OS_PKC_AVG\/?^$*_X07_ (2__A:GQX_X
M77_PB7_"/?\ "1?\+'_X6KXD_P"$?_X6G_8G_$Q_X3K_ (4?_P *=_LS_A+?
M^*B_X5=_PK?R/^*6_P"$:K\C_P#@AOG_ (>__MR?\*$W_P##'_\ PA?[5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^*?"WACQSX
M8\1^"?&WAS0?&/@SQCH.K^%O%WA'Q3H^G^(?#'BGPQXAT^XTG7_#GB/0-6M[
MO2M<T'7-*N[O3-7TC4[2ZT_4M/NKBRO;>:VFDC;>HIIM---IIW36C36S3Z-
M?FU^U+_P34_9J^*'[,7[1GPQ^"7[,G[*/PY^,OQ$^ _Q=\"?"+X@#X,> ?"
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M=YN-*FG)I:E%%%<9TA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#<7BOQCHUUXP\0Q66MZCX>\)6^MZUI'ACQ7JMA9>&]5^#O\ @W\_Y11_L_\
M_93/VS?_ %N+]I"OSS_X.//CGIFJ:S^S-^RK92>']0NO#T^L_M1^.+*]\/\
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M6_!WC'Q]KOB>;Q+K6GR^(/B_\.=9^$FE7&@ZW/X?T\_$OP_=^,-*\&Z)\*?
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M8^UY*7M?9>UY/:>RI\_+S<D+\J****Y#U0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /C?]N7]ACX)?\%!?@O9_!#XYR>,-/T'1_'&@_$3P
MUXB\!ZOIFD^*/#?BC1;#6_#UQ<V2>(M#\5^$=5L_$/@GQ7XS\"ZYIGBOPGXB
ML/[!\6ZGJ.CV^C^,-/\ #/BC0/C'Q)_P1"_9L^*'BSP7XE_:*^/G[;7[4UAX
M%M_%MEHGA'X_?M$W'B?18;'QKI5OI^O6=AKGAWPIX2^(OA6*[OM+\+^(KE_
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M/VB_#/P[^)_PGU2SL]?_ +.U/PWX+^%GP[^"7COPW>ZKJ>@Z7H-YXW\(^,O
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MO!NC:OX/^%?P_P#ACH7P?\.^)_&4W]FW_CKPA\.?%7Q(\8M\4[WPU<VEK>^
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MX#>$M4\1:YX5^"7_  3/^-?PB\,ZUXON]/U#Q9K'A_X;?LM>)?!NC:IXHO\
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M3-%M?B(L6BZ9KUD?ZQ?C]_P5 _9G^$GP%7XP?#[Q7H?QX\4^)+'1$^&WP?\
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M2M8-7T/4]-UG3)I[:.._TG4+'4;1I;.[@FD_6#P+\2_AS\4=,O\ 6OAGX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\5OCE;7M[I,'BSQKXUMEUF[M_B;'<Z_?V>M_$#Q)!9:SKDNH:S9>&O^$?\
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M8R4.://*-*G[*A!RA">)JT8U*E*FYU(?%>(?&F&X X1S7B?$86IF%3!1P]#
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M_!0[X4?L8V^F^&+O2;[XG_&[Q5X<UOQ!X1^$WA[5],TG^S]/M](\2#PQXO\
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M<,5A\;PC3XCGBJSGS0K0KSSS*OJT84_W;I*G5YG>?M%I%?CS_P /L_V5?^A
M_:"_\)7X<_\ SUZ_2KX#?&CPI^T3\'OA_P#&WP/IOC'2/"?Q'T"'Q#HFG>/O
M".M>"/%-M:R33VS"^T/6[>%Y[22>VFFT3Q-HEQK/@GQOH4FF^-?A[XG\6^!/
M$'ASQ1J_\I?_  40^(5_^VG_ ,%$K;X9?#75_'5I'8>-/"7["?PVOK+1_&GQ
M#T_PYXPA^(FLV_[0WQWT;X*ZCIG@Z;28_AYK][XD7XMW5E>C0?'GPH_9+\/?
M$RY^)*_#J/0=2\-_UM_#7X>>$?A#\.? 'PG^'VF3Z+X"^&'@KPK\._!&C7.K
MZWX@N=)\(>"M"L/#7AK3+C7_ !+J.L>(];GL-&TRRM9=7U_5M4UO4I(FO=5U
M&]OII[F7ZSQ2R+A3(<-P7#),GQV1YUG&0OB'/<JQ><2SI9?A<TJ0_L'#2Q,\
M'@90QL\'0KXS&X>IA</5PWUK#TIPG'DJS^&\*.(.-,]SOC_#Y]GV7<1Y!PUG
M.'X;RG.,%D$,A^OYQ@J#J\1*.'AC\Q3P^78BMA\#"HL35CB*L:M2/LDN0R_C
M+\4O#_P.^#_Q6^-?BRSUC4/"OP?^&WCGXI>)=/\ #MO97?B"^\/_  _\+ZIX
MLUFST*UU+4-(TZYUBYT[2+F'3+?4-5TRRFO7@CNM0LH&DN8_F']D3_@H%\&_
MVT?%WQ;\&?"WPS\3=!U3X,^'OA;XE\43^/M&\*Z787]C\7-1^*.F>&XM!E\.
M^,_%5Q=7=E/\)/$;ZW'J%KI<-M#>Z(UA/J3W-_'IO2?\%#O^3 /VY?\ LSS]
MIG_U2OC:OQ:_X(%_\EZ_;S_[)/\ L1_^I;^VS7B8/AS+*_ACG?%52-;^UL!Q
M=E&38>:JM4%@L9EN,Q->,J%K2J.K0IN-2]XQNK:GT6<\49M@O%+@GA.A.@LH
MSWA_BK,<?"5%2KRQ.4O+E@W2KM\U*$?K-7VD$FJEU=Z']-%?F?\ L<?\%4_V
M>_VWO'GASX>?"CP=\9?#^M>)_@GK/QXL+KXA>'O!&DZ7#X0T/6?A?H=WIUY-
MX;^(?BR[C\227?Q:\.26]G#97&F/;V6MO+K$,MM8PZE^F%?QJ_\ !O9_R=!\
M(?\ M&_\1/\ U8G[%-&0\.9;F'AUXF<2XF%9YIPM5X"AE,X57"C"/$/$W]EY
MC[>BE:LY83W:/,U[*?OJ[#B[BG-LFXZ\+<@P4Z$<NXLS+B?"YO&I152K.EE7
M#U7,L)]7JMIT)1Q,(N;BGSPO!Z']E5?R;?M'_M%?M!_M7?\ !2OQ9\"?@9\>
M/C3X3^&^O_&CP1^QUX?T_P" _P 4_'?P,U?2_"?PEN-7NOVO_BC9VGCG7['P
ME)\:OA5JTG[3DUCXUT?PI]C\=^#?@7\+-/\ "N@?$:6RT"[\8?TJ_M.?&ZP_
M9N_9[^,7QTOK/0]7F^&?@#Q%XD\/^&/$/B^R\!:?X[\;0V,EMX ^&L/BZ_T_
M5X=&UGXF^.+GP]\/_#<T6BZ[?W'B+Q)I5EI6@ZYJ=S9Z3>?SJ_\ !#_]FS7/
M&GQ_\8?M/^--03QQH/P#\(:U\*M!\4^/+31_'OC;Q;^TQ\6H/"_BSXE_%.3Q
MKKGB74/'?AGXF^%/A7,EEXJ\5ZAX>FO?BGI/[67BR"+QU)+I/CO1M6]?@G#X
M?)N"O$#C;'4*%6I+ T.!N&HXFE3J0GGG$G-5S'&87VD9Q6,R7(<)BL53YHZ/
M%PE!3<9.GXOB5BL3G7%'AUX>X#$XBA_:^=RXKXDJ86K4IRAPOPA[/&2PF)E1
ME"K3H9UG-7+<!"HI)2=.M#NU^MWQ0_X*J?L]_";]I6Y_99\1^#OC+>_$&U^-
MOP%^ LFL:)X>\$7/@T^,/VB/^%1_\(5J2:A??$/3=;/AO2_^%S^%_P#A*;QO
M#RZI9?8-?_LG1];^RZ=_:GZ85_&I^VK_ ,ICM7_[21_\$NOY_L$U_977D>(?
M#F6\-XC@VGED:T(YWX;\(<38_P!M5=9RS7.:.,GC9TFTO9T92HT_9T5>--)I
M-W/:\..*,VXFK^(=/-)T)QX;\2.(.&,L]C1C1<,JR["956PT*SBW[:NIXRMS
MUG:4TXIKW0K\^?\ @H]^UA\1?V/_ (/_  ^^(/PTT7P7KFL^*_C'I7P\U&V\
M<Z=KFIZ9#HM]\._B7XMFNK*'0/$?AFZCU1=2\&:7!'-/>W-H+&>_C:R>>6WN
M;7]!J_%S_@N5_P FR_!?_LY_P[_ZI/X\UOX193EV>>)'"F4YO@Z6/R[&X^K3
MQ6$KINC7IQP.*J*,U%Q;2G"$M&M8HT\7<VS'(_#/C3-\HQ=7 9EE^1XK$X+&
M4&E6P]>#ARU:;DI)2C=VNFO(^K/^"9/[4OQ!_;0_8P^''[17Q1T?P=H/C;Q?
MXX_:'\-:EI?@'3];TOPM!8?"7]I+XN?!WPY+8V7B+Q#XIU:*[O?#/@'1[[6Y
M+C7+F&YUVYU*YL(--T^:UTRS^]Z_E#_X)7?\%!O&/P%_9-^%/[*'@?\ 9-^*
M'QC^+/A#Q9^U[X[\6:-INL6]C>MX,\7_ +5GC/XB^$/%_@_0_!>@?%+Q'K?A
M>71?C%H6F>+]3\4:3X#N/"'B670])&GZW#XGL;^W_6;]B7_@JG\-?VLO'6I?
M"GQAX7TKX(?$S5KRYN_@WH%S\08?&NE?&CPOI_AA?$.N#PQK\_A/P0(/B3X;
MAT[Q/KFM?#*+3M5N+GX;Z3'\1?"GB'Q3I^D_%#3?A;R9UX:\:Y+EF*S_ ##A
M_$83*,-5H+%5'B,#4Q661Q\VL!_:V64<54S3*%BTX?5GF>#PBK>TI<CE[6GS
M<O#'BSP)G>+RCAW#<3X?&9_C,%%4HO#9A#"9EB\'AJ4LQHY=G%7!T\FS3%8>
M<I_6,/E^/Q-:G.-6,J:=*HH_JM17Y/\ [8G_  5W_9]_95U_XC?#G2]/O_B5
M\6?A'J&D6GQ1T*^O+KX8_#_X:QW_ (<^&/Q*F?QG\4/$V@WUF\EU\'?B3#X[
M\/3>!/#WCS0Y-0TB7PGXZU[X=7-W_:=IX5\0/^"QGQ.^$VI^#['XH_L(>/?A
MZGBG5(YDMO&?Q$UGPEX@U/P9HFL^';7XC:[X#T?Q9\%M!M/&>O>$-(\16%U9
MZ!/K7AK0M1U[4_#>@^(_&W@FQ\01^(K/;+/"GQ SC+L-FF7\.UJV&QN&GC,!
M2J8[*\+F6882$)5/K67Y-BL=0S?'X>I3A*I0K8/ UH8F$7/#RJQ5S?.O%_PY
MX>S/$Y1FW$E/#XS UZ6&S"5'+<XQV!RS$5W3C"CFF:Y?EV*RO+*B=6G[2&/Q
MF&=%33K*FM3]U:*^2OB!^VW^S[X%_9/UC]L^P\3:A\2?@G8:397>CW?PPTB?
MQ-XD\5^(=7\8V?PUT7P!I.AW+Z5_8OCB[^*&H6?PVUS3/'MWX-T[X;^+O[4M
M_BWJW@#3?#'BS4]!_-VT_P""RWCG5O"?Q(^)F@?L2^,M9^$/PTU7QU)XC^)U
MK\1]7E\*>%O!OA&&;Q+'XA^).N6/P9O_  O\/=5M_AK<:%XX\=:'?>)-3TKP
M-#JLT2^+/$>@6MGXLU;SN'?#_B[BK"XC'9)E*K8+"XI8&MC<9F.59/A%CG3C
M5^I4\3G&.P%"OC%2E&K/"T*E2O"E*-2=.,)*3]+B7Q'X+X1J9?1SS.E2Q&:4
M)8O 83+\OS3/<;B,'&U\='!9%@<RQ4,"VU"&-J4886=1^SA6E4]T_=>BOAC]
M@#]MG3_VZ?A)XU^(<7P^G^&>O?#GXM^(OA'XM\-)XKM?'.AOJ5CX8\%_$7P[
MK'AGQ;%HOA:^U;3M8^'7Q*\$7NKPZOX0\-7>@^,9/%'AFQB\2:!HNB^.O%?W
M/7RN,PF)P&,QF7XRC/#XS 8O$X#&8>I;VF'QF"KU,-BL/4LVE4H5Z52E-)M*
M<&DV?5Y;F."SC+L!FV6XB&+R[,\'ALPP&*IJ:AB<'C*,,1AJ\%.,)J-6C4A-
M*<(S2E:48R32_ +_ ()R_P#!57]H7]KW]L'1OV?OB5X-^#.B>#=1_9'^)WQ[
MGU/P/X>\;Z;XG7QAX+^*'[._@K2]-BO=>^(GB;2E\-7&E?%OQ)<:A9OHKZI+
MJ%EHDMOK%K;6U_::E^_M?P9?L&?M,V'[&/[5FD_M&>)_ OB#Q?X2MOV#OC=\
M,K>ZT[5?#GA_P]I?CWQ#X[_9V^(GA*/QSXBU_4H;GP[X-U&S^$_B"RUOQ-X>
M\/\ CC5O#8FM-1D\):C9^<4_>[Q=_P %JO$7PI\6V7AWXR?L1?%'P2T.B7'B
MOQ!X:@\;P1_%S_A%;G3/%T/A?5?!?P[^(W@3X6:/XF/B;QMX8/A2TE\0>/\
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M9;G.:8?*IUG:G'-\=E678W Y5)_%*.8XG#.G!2J5%&$927[I45\8Z?\ MW_
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M[^S_ .T/!/CSQC_;/]H?\(SXI^U^5_PA']G?V=]AMO,_M/[7]N3[%]EN_FN
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M]?)L%C:F(K4:#PN+S"C6IUJU*E5A"=2$9?N11117PI^A!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?PF?\%I_A;X_\/\ [5G_  4TDU#15T^7XY>
M?!GQ*^%,MOJVFWU]XG\&/^Q[\.?@A#KGV+2=1OK_ $0'XI_!CXE^%[33]:LM
M)UJYE\-3ZK;V%QH>I:'J>H?W9U^.'_!6?]AWQY^T=HWPS^+?P ^'^F>-/C7X
M)UBT\!>,=#CUWP/X*UCQK\%/$UY/*95UWQ5ING6_B?6/A#XRN8?%7A?PWXC^
M(_@_P[H_@3QC\?+[P]:>*/B+KWA?PMKOZOX.9WE64<68O!YWC:65Y9Q3PYGO
M">(S:O94,KGG.%4<-C*\I.,:=&.+HT*-:M4G"E0I5IUZTX4:<Y+\A\<.'LYX
MBX!Q4>'\)+,<XR3-<DXEP.60^/,Y9'F-'&5L%32NYU:N%C7="E&,JE>O"G1I
MQE4J11^Q]%?S)?L4?\%/]9_9.\#^'_V4OVD/A-XJ_P"$>^!7A6P\$^$+C0]!
MM?!?Q;^''A33O#'PZO/@W\'?'GP<\4V?@ZVV:%\.M9O;C3_'=_KOA'Q2O@:U
M^%=AKO@+QQXAUGQ5\6M4Z_5OV[/^"BO[>/BK6? ?["?AE?@'X%M/&]AX)U+X
MWZ3X*\%?&/7_ (96I\90Z/KOC_Q_J_QAN_#'P2N=6T/X/?%CX2?''4/V5]"L
M)OBXESX8UZV\%?$OXJ>$-;66'#,_!_CC)*.98W.\'@,IRG+:&(Q']N8W-L!'
M*,RC3HRK82GD^(IUJE7,\1FJ5.&6X;#4)8BI4K4X8FEA7"O[%97XY< 9U_9V
M%RG%YIF&?YAB,+A?]5,+DN8SXCR_$5Z]/#XE9K@IT*=++,/E<ISJ9EF&,Q-+
M+J-&E*I2Q==5<*L1\6?\''?B;7?!OQ2\=^*_#.H2Z3XA\/?L,:!J^BZI!'#)
M-I^I67CS]HJ>TNX4N8IH#+!,BR1^;$ZAU!VD@5_4GXL_9H^$VN?LY?$S]EKP
MAX>LO@G\*?B;\/OBO\/+K3_@=HOA;X>3>$;7XS6?BB/QMXF\#6%EX>NO"NB>
M,+S6?&&O^,%U:Z\-:G;7?C&_N->UK3]7N+N^2Z_E/_X.8O\ D<?BK_V8/I?_
M *F_[1E?V75['BAC<70RSP>5'%8BDL)X;Y-C,+&%6I&.&Q<LTS+FQ5"*ERTL
M1+ZMAU*M!*<E0HJ4FJ4.7RO"W"86IQEXXUIX;#SJU^.J&$K594:<JE;"QX>R
MV4<-5J.+G4P\95JTHT9-TU*K4:C><F_Y*O\ @A9\8_$NG?MK^,?@S%IOAV3P
M]\9OV,KSXQ>+=:FL;S_A*8/$OP!^+/PT\*^"]-TB_AU*'3H/#M[8_M1?$2[U
M^QO](U*\GU&Q\,3:/J6B06NN6WB#[8L/^"A'[*OP,^,)^%O_  3U_8?\ ?$#
M_A);7_A"-<\6_ 71/!?PHM?B78_"S0%UWX<Z?\)-+^%?PS\::O\ &7X>^%=+
MU_XQ?8]7U2+P?H_A2ST'4_$GPTT_QS\/_'3>,K;\=O\ @EM\/O$_Q;_;!\?_
M  I\$_$C7?@WXS^)O_!(']L+X>^$?B]X734'\3?"KQ/XT^*'['OAS0/B1X=3
M2=>\+:J^N^!M5U*T\3Z0NF>)_#FH-J&EVXLM>TBY,>H6_J_[#GQR\:_\$[_V
ME9KS]H3]G>;PU-XH^%C^!_B+X7\0^%[33OCW\)+'2O$'B<66M?!/Q!=7R>%/
M&?PI\>_$?P1/X/\ &EKHNLP?#KXNVG@?P)\6?A[\6-5LO@]IWA7XG?KO$O".
M59WXD>->(CDE;B[-\IS[)I95P+A\XJ9)0S&EC*56..SC$/#5:&-QJRE6Y*.
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ME.(Q%#"UL\PF&P^+R_'8;+*F(J4J-;'8-8BGBI8252%;$47_ +)"O.%2-/\
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MP5\!WO@K]G[4]<\4O!X@O=*^$VBV\^C>%+&RL/"&@?SP>-73_@K-_P %(?\
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M??$_POX0\;/X4F\1Z7I'BU= /AGQ!++H.JZE;3?SYPKC<#EO$_#F8YG%RRW
M9]D^-S"*@ZCE@<+F&'KXN*IQ4G-O#TZBY$FY?"DV[']99_AL9C<DSK!Y=4]C
MC\7E698; U>;D]EC*^$K4L-4YTUR<E:4)<UURVO=6/QX_P""#_PB\%W5C^TS
M^T;=V=Y>_$BV^(>E_LV:)=ZK9>'I['PG\._#?P[^&GQCUA? E\-"C\4Z--\2
MO%7Q1TZ/XI0?\)+=:#XK'P@^$9.AV-_X'2^U#]T;_P"#_P )=5^).D_&74_A
M=\.M1^+^@:1;Z!H7Q5O_  3X:O/B3HN@V</BVWM-$TGQS<:9)XGTW2+6#Q]X
M[@M]-L]4ALX(?&OBV.*%4\1ZPMY_)I^PE^U7\4/^">'QY\<^#_CO\-_B5X7\
M)?$CPYI5Y\7?@5XJ?5['Q[\./%O@_4?B!X1\*_&#X1^']3\1VWPP\5^'_'6O
M>'/$_P +?&/CGPXTOA#XX^&_ G@+QS\.?C-JWA_X+V7ACXE?I_\ "C_@J9\<
M?VF/VT_"?PF_9N^#/A;Q!^S[]O\  ^F?$V[\;:5XYMOB1\.='USPS\3_ !/K
M7Q)\>>.OAW>?$/P'\+].UV+P/J?A_P""O@OQ?X+N=,^*/C;P)<^$I_B]X5N_
MBBEW\'?U?Q+X XT?$O&_&3C2K\,8[,<XSO!<2QS; /+,QR7,,9.OEF#P&)CB
MW]?K/"5L-@Z. PT:M6:P\Y1I_5Z-2K#\#\(_$/@C+N$."/#W%^WP'&.6T\MX
M?S#@^IDV8/-<#GN'Q$?K6.QF&C@Y4L+A'B[YU4S6M4AA:4*T:LJZQ<E2?Y+?
M\$;]*T;]K_\ ;)^&?QG^*>A:'I^L^(O!/Q<_X*#ZUX/\):18)\.M2^.OC[QS
MX'UN2&ZT#QG!XVU4^&/"'CK]HK6?B?X#>#Q%!XS\-_$;X?\ PR\2IXQNF\/W
M]KK/];GQ]^"?@O\ :/\ @Q\2/@;\08[@>%?B5X6U#PY=ZGIUIX?N]?\ "VHR
MJMSX=\=^#CXJT+Q-X?T[Q]\/O$EMI/CCX?Z_J/A_5X_#7C;P_H'B&&QGN=,A
M6OYBOC)^S[\>?^"6O[5VF_M&?#+POH]W\#=%^(_C7Q7X*'@'0_$OPX^!]I\'
M/BGXPE\,_P##*GQ.T;P1?C0_AXOA:+X@>$O!_P '(M9&M?#O6O'_ (2^#GQ>
M\(^ /$6M^"M<^"G@SZ?_ &N/^"QFG?$CX=7OP9_9I\$>/?#'B/XW:3J?PD7X
ME>)_$TO@7XB>#?%?Q%U?POX(\&Z?\$= ^&&N:QKWB7XI>+[?Q%XITKP!KUA\
M0?!6O> ?B?!\.M5T'PO\4WU"^\.V/T_&_!G%7'/&>6\;<%RHUN$\9EW"\LFX
M@HYGA*&7<(T,IRK+Z.*P>/K5,13J935R3'T<7CJV&E3A5A4KM4:<\7*=)>+P
M'QWPAX<Y'Q5PAQ[.KE_%4.*^+<9C\JQ.4XO$X[C*EG69XFOE^/RJG##5:6>0
MS?!5</@:*52<G[&-/$JE0=.<OQO_ &;/BSK%O\#/^"H/P^M='\,1:9\??^"(
MO[8/Q;\9ZH]EJ+>*H-:_9Y\'66A> -)T;4HKZ'38_#)M?VM/B=/K]GJFG:CJ
M-SJ%OX5GT6^T:WM/$$&N_H]_P1%^!/@OXE?'WQ9\:/%-UXFE\1_LQ^"/ -Y\
M,=%T[79])\*?\)'\==$^+W@?Q-XK\5:98107OBG5-"\%>%M5\-^$=)U35)/!
MNGQ^._%&OZKX7UOQAI?P\\2>!;/P._X)]?&7P9_P3B_X*8?&3Q?\+6_X6S^T
ME_P3X^-/PF_9N^"MK\+M1N_VBO"/@R[^#?Q5OI-#O[<V+>-?#OBW]HKQ7K7P
M[-S^SKINAP>(=#3X6?"W_A8,*_%6[U/X:?"CUS_@@*ROKG[5[HRNC^!OV565
ME(965KS]H\JRL,@JP((()!!R*[.,.(<#G/#WT@LVX<Q+CE6:<=\$4H5,*W2I
M8W#)9S1K5;0:]IAL?BL)4Q<;WA64U.SCHO#X-X:Q^2YI]%K)N)L!*GF6 RGQ
M7QTL#CX>UK9=4KT<'F>54*D*T7*CB\LPF)PM%0FE6P>(P_*O9U:*4/U3_P""
MI7_*,C_@HQ_V8C^UW_ZS]\0J_$?_ ((B_ GP7\2OC[XL^-'BFZ\32^(_V8_!
M'@&\^&.BZ=KL^D^%/^$C^.NB?%[P/XF\5^*M,L(H+WQ3JFA>"O"VJ^&_".DZ
MIJDG@W3X_'?BC7]5\+ZWXPTOX>>)/ O[K?\ !2'PMXG\<_\ !._]O7P3X)\.
M:]XQ\9^,?V+_ -J3PMX1\(^%M'U#Q!XG\4^)_$'P.\<Z3H'ASPYH&DV]WJNM
MZ]K>JW=IIFD:1IEI=:AJ6H75O965O-<S1QM^1W_! 5E?7/VKW1E='\#?LJLK
M*0RLK7G[1Y5E89!5@0002"#D5^>\+XFO0\%_%&-"M4I>WXBX"H8A4IRA[7#U
M)9[)T:O*US4JDJ2;A+W9NGJGRL_5>/,-A\5XT>!:Q-"E7C1H>)N)I*M3C4C3
MQ-#)<DG0KQ4TXQK4:B52C42YZ52,:E-QG",E^BW_  6!\?ZM\//^"<G[25WI
M.G^&-4'CW3_AO\!-?L?%UMJ%WH\O@?\ :8^,GP[_ &=OB&\4.F:IH]S_ &_;
M^ _BCXCN?",LMY)I]MXLAT6XU;3=:TJ*]T>__$__ ()M_%37?@'+\3_BE\.?
MV&O&?[37Q*UK5S\.I_C5X,/C":[^'W@*WT/P3XGG^"%I_9'P\^(6E>'WU'Q$
M]I\3/&$FE3^&]8\;VVK?#2+QG8ZUIWPY^'%[I_\ 29^US^S=X8_:Y_9R^*7[
M/GBN[72K7Q[HVGS>'O$3P:Q>IX,^(O@WQ!I'CWX4>/Y-(T/Q)X0O?$:?#[XG
M^%_"'C9_"DWB/2](\6KH!\,^()9=!U74K:;^<;]CG]H;]I#_ ()A_$6Z\ ?M
M0_!OQ5X+^$/QBLY_&GBOX9W&E>$]4\9>'/BUIG@KP3!?>./A-\4/#^OR?#[X
MLZ=#H=Q\/OAM\7/"MGXQUSPYHMU#X1\1>&?%?@CQ/X=\<>"?B_\ 4^&/U+.?
M#3B#A?!\,X+C+B&GQA@L]K\,XC.\?D>+Q^20R>IA*>,P+R['Y?B<UEE>-C5E
MB,$JE6CAX8R&+JTO;+!L^4\8UC\H\1^!^+,5Q/F'!?#F'X?S[)?];,)D. X@
MPV29SCL5@ZJI8^EF67YEA\LI9UA(+"T\Q]A&7-A70E6I8>>(9@?\%#/#?QX_
M;B\3V/Q F_8"_:'^'.MQ_"/7OA+X[#^%_C-\1X/'7@Z+4=3USP5I]OX>'@#P
MUHV@3>$[SQ=\3S=3Z%H4WB#QLOC>RLM;U2:U\&^%[.V[/_@JQ_PN_P#X9I_X
M)H?\--<_M(_\,I_$3_AH,_\ %(\_&_\ X0']E[_A:Y_XM_\ \4'_ ,CY_;__
M ")/_%(_]"W_ ,2;[%7VA\5/^"YOAK3_ .S-,_9S_93^+/Q]\;ZMH/Q N]%^
M&EUK=IX3^(GC7Q3X0\*7/C;2?!WPR\(^ /#OQQUSQ[J6K>&?#_CG6=<6PL;+
M5/#.F>&4U*TT3Q-87.KW'ASR7_@X"=8Y?V8))&5$3P3^U([NY"HB*WP 9F9F
M("JH!+,2  "2<5];P_B\YCXF^'N29OP=A>"J>0\&^(M++,MAFM?-<:LOQG"?
M%N)MCJV-QV.S&A"EB5B)8+#XZI"=/"UHO#P6!>%M^?\ %6$R*MX3^,G$N3\>
MXOQ!Q7$>9>'RS?-:F2X;)\%#&95GV386@L%'+\NR_+<56JX.M0I8ZK@X57&>
M$H0Q,HXGVO/Z/\+_ !_^P[\-?^"2O_!+?7_VP_@]\-/CGJ>J_L$_LQ^#/AS\
M.O$WPP^&?Q4\?:WX<\3_  -^!47Q77PKH?Q(-OI]GX#L+6R\&ZU\5;VZU;2?
M#UTND^#-%NFUGQIJOP]\,ZY)=?\ !1/XM_M5_ +Q-X4\2?\ !,GXH?$?X5?&
MOP!XU^&?C^#X;?$SXI^(O"&OZ#XDT_6OA_\ $CPSX?\ B5X/^ 7AG6)4@>3Q
M#X9FU[0Y/#?B'2]0M;EH1H>M612T_,3]J#]D[]IC0?V._P#@FG\1=9TGXTVW
M@/PE_P $K?V?O@=\5? MQX4UZSA_8_\ B=\(/@]!XP\<^/?'&@7^KRZK\/\
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M-&OF4\!C\EQ^,I82G*4(5<7[!5*\<+1O5FHU'3@XTYN/Y_DN(CDW@S]'C/\
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M?PY>>%/$5]^T/^T'-JM]8W\_BC2?'?P1T7X5?";PE'H5\FJPZ59Z/?\ A?\
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MP#<ZU!J/B'2OA7X$\!^%M6UW7)O#RZG<_C%_P7A^!/P\LOC)X!\90:>8[O\
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M;G4/B)X6;PO^VGJW@#6_AOJ?A_\ M;_A)?#7P:\222_$G4O"6I6Q^('ZZ_\
M!1C]F3PYX[_8 \?_  W^%_P_T32;KX >#= ^)/P%\%?#_P"#EEXTU3PX_P
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M;XDVNJ^%_'&I?MX7WPY\<>(;+7[W4O$'@#2O@Y^W1XP^ O[+VA:3X3@M-,\
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MB_Y/A[C*?%7 '%>4/A[!\=<78OCJEQ5F>08K.\?D6,S;+L1EM>%7,\&\NS#
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MK_BIJ'Q!U/Q!8ZUXAUO7Y/#=_#K>G[=;CUS[$_X+W?\ (Z?L>_\ 8D_M5_\
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MSG&\/Y[DF;95P4^",ERG'Y=F>349TI97CUE'#V%QV683#X?ZUEF/E7KT\O\
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MU>QNM$L= ^%/V/\ _E,OX2_[21?\%//_ $U?\% *^F_^#??_ ).?_P""CO\
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MFG^,X]-3Q)'X)U#QU</XNOO#C:F^EWGB&.UU6YMI;RRLY8/$/@]X8\2^$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME**4I1L[I-M6=]BX5J-24H4ZM.I."3G&$XRE!.UG*,6W%.ZM=*]UW/=:*_D
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M=:UXR\*^&?'%CJO@JQ\37_U5^VU_P6(^+&L^"/\ @G1\'/V0[CPI\(?VG/\
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M?'_ACQ7IEB)_$_@+PIJ1U/3;*SUF,:6;*'48["^U&UN^2_X(+_\ !2SXI?\
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MO?XM^%O'_P 49OB+\ _A;^VG^U5X2U+X26WPE^#TFKZI^SY\&_VCO%_P^O\
MP;X0U/2]'^'/B;4/B!X<^%<27?PXU/7/B5I\>I^.O#NA77Q$U/Q%H%SXDT_5
MNN>38J%.K4E.A^ZP%/,)14JG/[.<JL702=)+ZU2E0JPJTFTHU(.DIRK+V9A'
M,*,O96C4M5QTL!&34>7VD:;JNLWSZ8=P5XU$FW%J?)[-J9_=/17Y?_\ !8']
MLOQ)^P_^Q#XW^*'PY\3Z'X3^,OB_Q1X.^%7P<U3Q%X4U'Q=IT'B?Q-J,FM>,
M]4@LH;:X\/66O^$/@IX7^*OC[PA?^/\ =X!?Q?X2T+2_$.E>+5U.V\#^)_Y1
M/ O_  7F_P""D6J?L]?%7QV/CAH^MZMXC^,'["7@/P1K^N?"#X00ZK\-O#'Q
MC^'/[?WQ5\?W_ABR\/\ @G1/#VI>(/%TG[-/PV\+WTWQ T;QSIFC>&9_$W_"
M*Z7H/B?4[3Q/IL87*<3BZ>%J4Y48K%X^G@*:J2G&2J5(3E&M-*G*V';IU8*I
M%RE*I2JPA3DZ<[56QU&A+$1E&I+ZKA)XRHX*+7LZ;LZ<6Y*]:SC+D=HJ,H2E
M**G&_P#?W17\D/Q__;7_ ."J'['_ .R;^PM^WE>_M9_#OX]>!_VK?#G@J;5?
M@Y\0OV=/ 7A72_!7C3XQ?LXZ[\:O ^DZQJ'PPM/"_B?QQX-\/V&@^,WUGQ/H
M_C_X0ZO;^*?#7@*V7PWXD\.>,O%-EX8\(_X*3?\ !;/]L[X?^/\ ]EOQY\"_
MB4_P$^%?[17_  3<_8M_:IO/AA'X3^$'Q-'@[QW^TOXX^,\&L/\ \)WX\^%-
MUKFN#1=&TKP=H1F^S:+H=Y'X<?6+;POI%YJVI),8;*ZN,G0CAL1AJM/$X:IB
MJ%?FK4Z52G3ER2C:K0IUJ<^>T4JM*G'WE)R5.\TJN.A0IUYU:->$L/6P]&K1
MM3E4C+%5%3HM<E6=.<92YKN%232A)-<W+&7]JM%?G_\ LB_MS^&_C;_P3O\
M!'[=7Q=MI?ASHVE?"+Q[XV^.LMOX7U8Z9X>U?X#W?B[PQ\<O$/@_PGH&L_$G
MQ3?> G\2?#KQCXB^&^F1:CXD\<:MX%G\.+J.GCQ7=W>C0?S0?\$O_P#@LI^W
MY^UE_P %'OV</@Q\6_C+HMQ\.O'OQ1^-&A?%'X9>%OA=\+=%\)03:9^RA\9_
MC7I/A#PKKY\)ZA\3+'PUX&\6Z3X4M=#NM0^(.J^++ZP\.16/B_Q-XH>\UJZU
M;FI82K5P>)QJ<8TL*Z"G&?-&K/VU2%+]U'E:E[&52E]8<I1]E[:BG>56$9;3
MQ$(8BCAG>4ZZJRC*-G"*I0<[SE=->T2:I63<^63TC"37]K]%?B1_P5-_:\_:
M'_9Q_:P_X)5?#3X,?$+_ (0WP3^TC^TA8> OC3HO_")^!_$/_"9^$YOCU^R7
MX+ETG^TO%?AK7-6\.[O#/Q-\;Z;]N\)W^A:DO]M_;%O!J&FZ1=6'Z:?M;?%/
MQ1\#/V5/VFOC9X(@\/77C/X._L^?&?XI^$;;Q;9ZAJ/A2X\3_#[X<>)/%N@0
M>)M/TC5] U6^\/3:KI%I'K5GIFO:)J%SIK7,%EJ^FW+QWD*^JU?:8*E'EE/'
MT:=>@D[>[5QN+P$(3<E%1FZV"JMV;@J<J<N?F<HP?MX<F(F[QAA:LZ55M7UA
MAL/BI2BH\S<52Q,%LI.<9I1LHN7T'17\P/[(GQ._X+._MQ? :+]JKX#_ +;O
M[*,>LS?M$^,=%O\ ]FGQM\/O"]OX&\$>#/"DL^M+X,^(OBGP;\*O&/Q:\,:G
MK&IR^'=,T;X8S:K)XYO_ -FKQGX.^,G_  T3!X\\16.E-^HG_!8[]H7XP_LK
M_P#!.[XV_'/X">,3X!^*GA+Q;^SAI?AWQ6OA_P *^*&TVQ\??M1?!?X=>+(1
MH?C70_$GAJ[.J^#?%OB#1Q)?Z-=RV/V_^T-->SU2ULKVVTC@G4QF'P5'$8>O
M/$5J5"%6'MXTHU:M9T%&I[6A3JQY96E)JE*/)*+@YN\5'UFV'GB9T:M*,*3K
M<D_9.<J?LE54H^SJSA[T791E.,E)6DHJS?Z=45_,E_P0A_X*R?'K]M3XK?&_
M]G[]H_Q!+\1O$>A^%-5^*'P[\>6'@7P1X570]/\ A_XUT3X9?%#P/XQNO!LG
MA?39OMFH^,OAIXI^&-O9_#RYU.2.Z^*S^*_&[V=KX#T&V\(_X+3?\%COVE/V
M:?VU]"_9F_9;^,&D>!-%\)>!?#NF?$&*S^%OAS7O$TWQI\9Z'KWQ0OM+UO6/
MBQX3\2Z'J/AOPQ\&XOA-KWA:X^'.GVMBFM?$KQ;I7C#7_$>KZ99:%X"TI99B
M*V*Q&%C*DIX:G[:I4E*7LG2E[+V%2$E!R<,4L1AWAI.$5..(I3ER0DY**N.H
MTL-'%251PES^Y&,753I>T>(BXN2CS8:-&NZT>9M>PJ1ASSY8R_KDHK\JOA-_
MP4?^#'P=_8#_ ."?7QX_;?\ CEIOAWXA?M.?LS? 7Q?>ZLWA#5M5U_Q_\0?$
M7P-\'^/OB/XHM? /PD\(:E+HWAZWU;6!-KNM:=X6T7P!X7U?Q/X3\+M<:1?^
M*_"&C:G].?LW?MY_L@?M<WVIZ-^SW\>/!GC[Q/H\&JW]]X'D&L>#_B(NAZ&W
MA:'5_%EM\.?'>E^&/'-_X'T^^\;>%M'N?'6G^'[KP<GB#5X/#O\ ;AUV*ZT^
M#C="NJ,,2Z%:.'J.U.O*E-4IR]Y<L:CCR2DG"::4F[QDOLNW5*I3C7GAO:TW
M7IWYZ49Q=1)?:<+\ZCLTW%*S3ZGUS17Y2ZE_P6\_X)=Z9=:]:O\ M26>H_\
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MP\VKVE[?1ZO\3?!OQ3^#GA/2[33]%O=?NY_%'C;XM>!/!/@_P:B:?I]PD?\
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MAYX0^$7_  7!_P""8'PH^'VE2:'X"^&/P[_X)"_#SP1HDVJ:QKDNC^$/!?\
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MQ;XIUO63<^&-:\0Z[\8[C]H31[:P\,S:=<Z'X0\(^$T\2^&+"[U"S\0>+/\
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M2:>:<M?&8B@IQK5L[PV:X=U.5QBJ$LQFHUI<Z]_FQ=*Z7NR4:EYQM'F(8/\
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MY02JJK%V7\H7_!-#5/VN?VUO^"F>K?&3XL_'#X5_LL_MD_&+X.ZQ\?\ PO\
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MLJ5>=1QCRJKC:E*?UG$5&EB\15K>S^K3M0H\D:SIN=-OG]G&?(IU)2C^,?\
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MT73;NQ\__A*M-GL_&T4/B2/#/_!(7_@G<?@Q+^SV?V>O^+03?'(_M)2>$?\
MA;/QQ^;XTGX4K\$#XS_M_P#X67_PDX_XM>J^&/\ A'5UH>%./[:_L+_A(2=6
MIK-J,9T)QC7C*E]5?,E!24J&1T,L;BU4NG]8I.I!W3]ERR=IWIIU,%4G"M"]
M/]YALQH)-RMS8O-,+C:?-[C]U4:$XU-&U4<8Q4HMS7\>/_!8*RL=+_X)J_\
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MQ?J&@6>O_#G1?CAXGT#P[;^-/##:UX<USPUJ=M\4-!U+4_A67\:+_3/\>?\
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MO_#/W_"'Q?VY_P -@?\ "._\*Z_X:BV?$C_AH[^SO^&G?]"_MK_A:7_#0O\
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MO^"MG_!,;]J']LG_ (*??LR_%GP;\&;SQ[^RWIWA?]BSX?\ QV\2V/Q6\$^
M+B'P-X._:W^+_C#X_:*+.;XB^#_B:\5I\&/',5W<W/@ZR?4M5M]7ETOPI=7W
MB*WGL;;]R/V:/^"?'['?['WBCQ/XV_9W^"NE^ ?%_C#0++PKK?B6Y\3^//&^
MM?\ "-V6HOJ[:%H^H?$+Q3XKN?#.EZIJGV*_\267AJ32(/%=WH/A2?Q.FKR>
M#_"S:/WXC&8>G2BX3G7KSRK X-TFH3PL.2IA\14<JBJN=X^SE'ZK[%<M=^UE
M66M-<]*A6E6DY0IPI4\SGBE-\RK3Y<-1IJ*@X*+IS?NNM[3WJ:J453^V?A+_
M ,&V<7P!3]@+]KN#X@I\%?\ A&5^)=U%\3X_%P\$-IY_99'[-GPT70E^*O\
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M>*O$*:YXBUNUM/B7!^WSK_C?P+\*K5M.\'^(Y/$?@WX:77A7PU<ZY=Z%XO\
M%G[7_#/_ ()#_P#!.KX0?$;P/\5_ 7[-VFZ?XZ^''B"W\5>#=3UGXB?%_P 9
M:=I'B6QMKF#2M<?POXT^(/B'PKJFJ:#<7*ZWX:O-8T34)O#/BK3]$\8: VF^
M*O#VA:SIWT+^TW^QE^S+^V/I/A'1OVD?A3I?Q(MO 6KZAK7@^\?6?%7A37M
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M4(1<ZD9U9VITJ;E6FG.53FFH1@H4H_Q[6'_*VMKW_9:=-_\ 7,(K4^+=G<_
M?_@Z1\"?$?XLPOX3\&_%7XJ_##Q+\.]5LQ_PDUQXHT3XP?L$ZI^Q+\/]1N]%
M\'GQ#KVBVNL_M-:#K?PX>7Q/I>AIHL6DOXVUQM.^'T:>*W_<_P#X<B?\$O\
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M1_%5Y\4;_7_$?_"5VGQ"@\;ZS]ON_C/\2I?[(\0>)-5T*U_X23R[+2[>+1]
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M]K>A:7\0[J?P)I&I^,_%%YJD-OIFNZ^]S_4Q\4_AGX(^-7PQ^(WP;^)NB?\
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MK24I./\ &_\ \$H/V0H/VG/V#_VQ=+M_VQ/@I^S1\"[C5M(LOVB?!OC7X!?
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MN:46FUF53&P@J]?#J5.KE=' 2C*M07M*<U556O:*G":M&=_:U%'^$;_@I_\
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ML1>(;'PUI_A#6-1\>:WH/ACPEX>L+[Q_KXBBBL/VS_X-.O"?BKP-%^VGX/\
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MV)]C_LCP[_9&A7%UID_EWA7_ ()E?L,_LW?$(_M0_ S]E*Y@^-'PT'Q%\<^
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MEG\<_B/\8_\ @GY\#/VXO^"3WQ1E7Q?X?N?VA_@]XS\2>(=1\)>$(-&C\&_
MJQF^*4OQEMM5\*^/=6UWPK\1OVE="\'_ +"'BGP_\//$FJ?$_P /^"_A[IOQ
M-\,:I;>#?B5]IU'5?[V1_P $]?V/Q^UH?VY_^%1?\93'7QXG/Q1_X3[XH?\
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M*S?OW<N517-_GB_MG?L@R_LR_L(?L,^/M?TC0K/Q;^T]\&?V_/BQHTUOX?\
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M5%AL;1Y:5+ZS3<*-"G4G4H8=^QJ4Y<LY4Z;4:LIP<H0HPITU23A!RJ5&_P"
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M'^%M/T?PGH6A1V_AC1-%T_PW:VVE0^Q>(O\ @F%^PUXK_9R^&W[)6O\ P/\
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ME%3FHMJZ4Y):2=^BRYN:RYN64.:WO<DI0G*%]^64J=.4H[.5.#:O&+7\;?\
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M?'6M:=XO^'WP,\;?$'7/AWXQTKP]_H'5\<?%'_@GM^Q%\8_#7C_PKXY_9?\
M@ZUC\4_&^A_$OXB:KX0\(V/PS\:>+_B'X=\0>)O$^F>-];^(?PT'A'Q]=>*O
M[6\<^/\ ^T==/B5=2UO3/B+\1]!UJXU#0?B%XSTW7(69TJTJDL53J1E7PE?
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MU9_ 'BF6&^TB2ZATB32%;5;G3GO=,-Y^MGP _P""7O["/[+WQ)TGXO\ P2^
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M^I:C8W7U-^T_^PO^RO\ MF7?@&^_:3^%O_"R+KX86_B^T\#2_P#";?$;P?\
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MN>!CAI15'E<*:]LIU%^^G:G*,/B@Y3_!#XX?#VR_9.UK]MW_ (*)?LV_$O\
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M_P %''\(&W'A$0'X!OXP_9D;]ELP#P0!HPA/[,Y^$AC%X!XM";?^$_ \>?\
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M'<=V/B%#J\?QZC^,\'P9_P""A<?P/72ELT7PBGAV/P*WQ[7XIC4P/$(\2/\
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M445YYUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>16
<FILENAME>etnb-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6442908+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:etnb="http://www.89bio.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="etnb-20201231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_etnbSegment">
    <xbrli:measure>etnb:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001785173_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20210301">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementClassOfStockAxis_etnbConvertiblePreferredSharesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">etnb:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementClassOfStockAxis_etnbConvertiblePreferredSharesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">etnb:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">etnb:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">etnb:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">etnb:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">etnb:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAgencySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMunicipalBondsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_etnbAgencyDiscountSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">etnb:AgencyDiscountSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputSharePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputSharePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExercisePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">etnb:ConvertiblePreferredStockLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_etnbFurnitureAndOfficeEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">etnb:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_etnbFurnitureAndOfficeEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">etnb:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20180501_20180531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20180531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapBalanceSheetLocationAxis_etnbRestrictedCashAndOtherAssetsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">etnb:RestrictedCashAndOtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapBalanceSheetLocationAxis_etnbRestrictedCashAndOtherAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">etnb:RestrictedCashAndOtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_etnbTevasGlycoPEGylatedFGF21ProgramMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">etnb:TevasGlycoPEGylatedFGF21ProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_etnbTevasDevelopmentProgramMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">etnb:TevasDevelopmentProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:TevaAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">etnb:TermALoanFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermBLoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">etnb:TermBLoanFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">etnb:TermALoanFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">etnb:TermALoanFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermBLoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">etnb:TermBLoanFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendPaymentMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendPaymentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">etnb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFinancialInstrumentAxis_etnbSeriesASharePurchaseAgreementMember_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">etnb:SeriesASharePurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">etnb:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapFinancialInstrumentAxis_etnbSeriesASharePurchaseAgreementMember_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">etnb:SeriesASharePurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">etnb:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20191113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">etnb:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_20191113_20191113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-13</xbrli:startDate>
      <xbrli:endDate>2019-11-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20190118_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-18</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndTwentyEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndTwentyEquityIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">etnb:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioLtdMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:EightyNineBioLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioLtdMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:EightyNineBioLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioManagementIncorporationMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:EightyNineBioManagementIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioManagementIncorporationMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:EightyNineBioManagementIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbUABEightyNineBioLithuaniaMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:UABEightyNineBioLithuaniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtConsolidatedEntitiesAxis_etnbUABEightyNineBioLithuaniaMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">etnb:UABEightyNineBioLithuaniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryUS_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryUS_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryIL_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryIL_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryUS_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryIL_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryUS_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryLT_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:LT</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryLT_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:LT</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_srtStatementGeographicalAxis_countryIL_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_etnbSharesAvailableForFutureOptionGrantsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">etnb:SharesAvailableForFutureOptionGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_etnbSharesAvailableForFutureOptionGrantsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">etnb:SharesAvailableForFutureOptionGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001785173_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001785173_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001785173_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001785173_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001785173_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityRegistrantName id="F_000005" contextRef="C_0001785173_20200101_20201231">89bio, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000006" contextRef="C_0001785173_20200101_20201231">0001785173</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus id="F_000007" contextRef="C_0001785173_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000008" contextRef="C_0001785173_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityInteractiveDataCurrent id="F_000009" contextRef="C_0001785173_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:CurrentFiscalYearEndDate id="F_000010" contextRef="C_0001785173_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0001785173_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer id="F_000012" contextRef="C_0001785173_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityPublicFloat id="F_000013" contextRef="C_0001785173_20200630" decimals="-6" unitRef="U_iso4217USD">72707052000000</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="F_000014" contextRef="C_0001785173_20210301" decimals="INF" unitRef="U_xbrlishares">19946426</dei:EntityCommonStockSharesOutstanding>
  <dei:IcfrAuditorAttestationFlag id="F_000015" contextRef="C_0001785173_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityShellCompany id="F_000016" contextRef="C_0001785173_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness id="F_000017" contextRef="C_0001785173_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000018" contextRef="C_0001785173_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000019" contextRef="C_0001785173_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber id="F_000020" contextRef="C_0001785173_20200101_20201231">001-39122</dei:EntityFileNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000021" contextRef="C_0001785173_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000022" contextRef="C_0001785173_20200101_20201231">36-4946844</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000023" contextRef="C_0001785173_20200101_20201231">142 Sansome Street</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000024" contextRef="C_0001785173_20200101_20201231">Second Floor</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000025" contextRef="C_0001785173_20200101_20201231">San Francisco</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000026" contextRef="C_0001785173_20200101_20201231">CA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000027" contextRef="C_0001785173_20200101_20201231">94104</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000028" contextRef="C_0001785173_20200101_20201231">415</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000029" contextRef="C_0001785173_20200101_20201231">500-4614</dei:LocalPhoneNumber>
  <dei:DocumentAnnualReport id="F_000030" contextRef="C_0001785173_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000031" contextRef="C_0001785173_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000032" contextRef="C_0001785173_20200101_20201231">&lt;p&gt;Portions of the registrant&amp;#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders, to be held on or about June 2, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <dei:Security12bTitle id="F_000033" contextRef="C_0001785173_20200101_20201231">Common stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000034" contextRef="C_0001785173_20200101_20201231">ETNB</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000035" contextRef="C_0001785173_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">98183000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000037" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">93335000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashCurrent id="F_000038" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashCurrent id="F_000039" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:RestrictedCashCurrent>
  <us-gaap:ShortTermInvestments id="F_000040" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">106446000</us-gaap:ShortTermInvestments>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000041" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">5548000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000042" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">1966000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">210202000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000044" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">95326000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">166000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000046" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">155000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000047" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">706000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000048" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">72000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000049" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">211074000</us-gaap:Assets>
  <us-gaap:Assets id="F_000050" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">95553000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000051" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">2065000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000052" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">989000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000053" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">6048000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000054" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">4620000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000055" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">8113000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000056" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">5609000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingencies id="F_000057" xsi:nil="true" contextRef="C_0001785173_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000058" xsi:nil="true" contextRef="C_0001785173_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000059" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000060" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000061" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">326046000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000062" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">163526000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000063" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000064" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">-123095000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000065" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">-73596000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000066" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">202961000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000067" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">89944000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000068" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">211074000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000069" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">95553000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000070" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000071" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000072" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000073" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000074" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000075" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000076" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000077" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000078" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000079" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000080" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000081" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000082" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">19931660</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000083" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">13788982</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000084" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_xbrlishares">19931660</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000085" contextRef="C_0001785173_20191231" decimals="INF" unitRef="U_xbrlishares">13788982</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000086" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">36199000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000087" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21346000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000088" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13156000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000089" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5294000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000090" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">49355000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000091" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26640000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000092" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49355000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000093" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-26640000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000094" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-203000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000095" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-30562000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000096" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49558000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000097" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-57202000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000098" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-59000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000099" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">218000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000100" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49499000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000101" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-57420000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000102" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="F_000103" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-18000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000104" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000105" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49509000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000106" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-57420000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000107" contextRef="C_0001785173_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000108" contextRef="C_0001785173_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-24.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000109" contextRef="C_0001785173_20200101_20201231" decimals="0" unitRef="U_xbrlishares">16087785</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000110" contextRef="C_0001785173_20190101_20191231" decimals="0" unitRef="U_xbrlishares">2344191</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000111" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">24000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000112" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">23073000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000113" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">611226</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000114" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000115" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">118000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000116" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000117" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-16176000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000118" contextRef="C_0001785173_20181231" decimals="-3" unitRef="U_iso4217USD">-16057000</us-gaap:StockholdersEquity>
  <etnb:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000119" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">20000000</etnb:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000120" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26673000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000121" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <etnb:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares id="F_000122" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-44000000</etnb:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares>
  <etnb:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue id="F_000123" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-49746000</etnb:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000124" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">7077366</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000125" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000126" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49739000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000127" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000128" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49746000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000129" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6100390</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000130" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000131" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">87685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000132" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000133" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">87691000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability id="F_000134" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">25595000</etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability>
  <etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability id="F_000135" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability>
  <etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability id="F_000136" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">25595000</etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000137" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">389000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000138" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000139" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">389000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000140" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000141" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-57420000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000142" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">13788982</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000143" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000144" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">163526000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000145" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000146" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-73596000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000147" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">6072040</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000148" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000149" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">157674000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000150" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000151" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">157680000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000152" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">63366</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000153" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000154" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000155" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000156" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">7272</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000157" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000158" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000159" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing id="F_000160" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">634000</etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing>
  <etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing id="F_000161" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing>
  <etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing id="F_000162" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">634000</etnb:IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000163" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000164" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000165" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000166" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000167" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49499000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000168" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:SharesOutstanding id="F_000169" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">19931660</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000170" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000171" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">326046000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000172" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">-10000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000173" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-123095000</us-gaap:StockholdersEquity>
  <etnb:TemporaryEquityIssuanceCosts id="F_000174" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_etnbConvertiblePreferredSharesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1208000</etnb:TemporaryEquityIssuanceCosts>
  <etnb:TemporaryEquityIssuanceCosts id="F_000175" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_etnbConvertiblePreferredSharesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</etnb:TemporaryEquityIssuanceCosts>
  <etnb:TemporaryEquitySettlementOfConvertiblePreferredStockLiability id="F_000176" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_etnbConvertiblePreferredSharesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6673000</etnb:TemporaryEquitySettlementOfConvertiblePreferredStockLiability>
  <etnb:StockIssuedDuringPeriodIssuanceCosts id="F_000177" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3083000</etnb:StockIssuedDuringPeriodIssuanceCosts>
  <us-gaap:ProfitLoss id="F_000178" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-49499000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000179" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-57420000</us-gaap:ProfitLoss>
  <us-gaap:Depreciation id="F_000180" contextRef="C_0001785173_20200101_20201231" decimals="0" unitRef="U_iso4217USD">60000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000181" contextRef="C_0001785173_20190101_20191231" decimals="0" unitRef="U_iso4217USD">17000</us-gaap:Depreciation>
  <us-gaap:ShareBasedCompensation id="F_000182" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3807000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000183" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">389000</us-gaap:ShareBasedCompensation>
  <etnb:DeferredTaxAssets id="F_000184" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">69000</etnb:DeferredTaxAssets>
  <etnb:DeferredTaxAssets id="F_000185" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20000</etnb:DeferredTaxAssets>
  <etnb:RevaluationOfConvertiblePreferredStockLiability id="F_000186" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30597000</etnb:RevaluationOfConvertiblePreferredStockLiability>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000187" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-268000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AmortizationOfFinancingCosts id="F_000188" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">230000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000189" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000190" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1918000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000191" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">72000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000192" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1131000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000193" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-520000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000194" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1428000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000195" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3447000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000196" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-46244000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000197" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-25460000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="F_000198" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">118895000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities id="F_000199" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12189000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000200" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">126000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000201" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000202" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-106832000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000203" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-139000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <etnb:ProceedsFromIssuancePublicOffering id="F_000204" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">157680000</etnb:ProceedsFromIssuancePublicOffering>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000205" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">87691000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000206" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="F_000207" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000208" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000209" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">11000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="F_000210" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">161000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000211" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">157924000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000212" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">107702000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000213" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4848000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000214" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">82103000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000215" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">93360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000216" contextRef="C_0001785173_20181231" decimals="-3" unitRef="U_iso4217USD">11257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000217" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">98208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000218" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000219" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:RestrictedCashAndCashEquivalents>
  <etnb:IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility id="F_000220" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">634000</etnb:IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility>
  <etnb:PropertyAndEquipmentPurchasesIncludedInAccountsPayable id="F_000221" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">55000</etnb:PropertyAndEquipmentPurchasesIncludedInAccountsPayable>
  <us-gaap:IncomeTaxesPaidNet id="F_000222" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet id="F_000223" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:IncomeTaxesPaidNet>
  <etnb:ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering id="F_000224" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49746000</etnb:ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000225" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Organization and Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio, Inc. (&amp;#8220;89bio&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company&amp;#8217;s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21, is currently being developed for the treatment of nonalcoholic steatohepatitis and for the treatment of severe hypertriglyceridemia. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio, Inc. was formed as a Delaware corporation in June 2019, for the purpose of completing an initial public offering (&amp;#8220;IPO&amp;#8221;) and related transactions in order to carry on the business of 89Bio Ltd., which was incorporated in Israel in January 2018. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company completed an internal reorganization transaction in September 2019, pursuant to which 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (the &amp;#8220;Reorganization&amp;#8221;). As part of the Reorganization, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. The Reorganization was considered a transaction between entities under common control.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Public Offerings&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, 89bio, Inc. completed its IPO, pursuant to which it issued and sold an aggregate of 6,100,390 shares of common stock (inclusive of 795,703 shares pursuant to the underwriters&amp;#8217; option to purchase additional shares), at the IPO price of $16.00 per share, &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;resulting in net proceeds of $87.7 million after deducting underwriting discounts and commissions of $6.8 million and other offering expenses of $3.1 million. Upon the closing of the IPO, the Company&amp;#8217;s outstanding convertible preferred stock automatically converted into 7,077,366 shares of common stock of 89bio, Inc. based on a proportional adjustment to the conversion ratio of the convertible preferred stock on a 1-for-6.217 basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company completed an underwritten public offering of 3,047,040 shares of its common stock (inclusive of 397,440 shares pursuant to the underwriters&amp;#8217; option to purchase additional shares), at the public offering price of $27.50 per share. The Company raised a total of $83.8 million in gross proceeds from the offering, or approximately $78.2 million in net proceeds after deducting underwriting discounts and commissions of $5.0 million and offering costs of approximately $0.6 million. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company completed an underwritten public offering of 3,025,000 shares of its common stock, at a public offering price of $28.00 per share. The Company raised a total of $84.7 million in gross proceeds from the offering, or approximately $79.5 million in net proceeds after deducting underwriting discounts and commissions of $4.6 million and offering costs of approximately $0.6 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate substantial operating losses for the foreseeable future until it completes development of its products and seeks regulatory approvals to market such products. The Company had cash, cash equivalents and short-term investments of $204.6 million as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects that its cash, cash equivalents and short-term investments as of December 31, 2020, together with proceeds available from the Company&amp;#8217;s term loan (see Note 6), will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the date these audited consolidated financial statements are filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000226" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain prior year footnote amounts have been updated for consistency with the current year presentation. Such reclassification has no effect on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currencies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain transactions during the years ended December 31, 2020 and 2019 were denominated in currencies other than the U.S. dollar. Gains and losses from foreign currency transactions were not material for all periods presented and are reflected in the consolidated statements of operations and comprehensive loss as a component of other expenses, net. The Company&amp;#8217;s subsidiary in Lithuania uses the Euro as its functional currency for financial reporting. The re-measurement from Euros to U.S. dollars results in translation gain and loss adjustments, which are reflected as a component of comprehensive loss as foreign currency translation adjustments.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of Company&amp;#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;font style="font-weight:normal;"&gt;&amp;#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;font style="font-weight:normal;"&gt;&amp;#8212;Inputs (other than quoted prices included in Level&amp;#160;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;font style="font-weight:normal;"&gt;&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;instruments&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company to a concentration&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of cash and cash equivalents.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Bank&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are held by accredited&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and these deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;may at times&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;be in excess&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of insured&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;limits. The Company limits&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;associated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with cash and cash equivalents&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;by placing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;them&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;it believes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are of high quality.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company has not experienced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;any losses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of cash or cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Other Risks and Uncertainties &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company&amp;#8217;s early stages of clinical drug development; the Company&amp;#8217;s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company&amp;#8217;s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company&amp;#8217;s ability to enroll patients in its ongoing and future clinical trials; the Company&amp;#8217;s ability to successfully manufacture and supply its product candidates for clinical trials; the Company&amp;#8217;s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company&amp;#8217;s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company&amp;#8217;s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ongoing COVID-19 pandemic has disrupted and may continue to disrupt the Company&amp;#8217;s business and delay its preclinical and clinical programs and timelines. &lt;font style="color:#000000;"&gt;The Company does not yet know the full extent of potential delays to clinical trials, which could prevent or delay the Company from obtaining approval for&amp;#160;BIO89-100.&amp;#160;&lt;/font&gt;The extent to which the COVID-19 pandemic may impact the Company&amp;#8217;s future operating results and financial condition is uncertain.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has one operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;segment.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company&amp;#8217;s chief&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;decision&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;maker,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Chief Executive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Officer,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;manages&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s operations&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on a consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the purposes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of allocating resources&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and evaluating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;performance.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper that are stated at fair value.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of a money market account that serves as collateral for the Company&amp;#8217;s operating lease agreement for its facility in Israel.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Generally, investments with original maturities beyond three months at the date of purchase are classified as short-term because it is management&amp;#8217;s intent to use the investments to fund current operations or to make them available for current operations.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss.&amp;#160;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&amp;#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other expenses, net. The cost of investments sold is based on the specific-identification method. There are no material realized gains or losses on investments for the periods presented. Interest on available-for-sale securities is included in other expenses, net and is not material for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Equipment, Net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and equipment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are stated&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;at cost, less&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;accumulated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;depreciation.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Depreciation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;is calculated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;useful&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lives&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;ranging&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to seven years.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Leasehold&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;improvements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are amortized&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the shorter&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets&amp;#8217;&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimated useful&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;life&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or the remaining&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the lease.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#000000;"&gt;Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gains or losses are recorded in the consolidated statements of operations and comprehensive loss. &lt;/font&gt;Maintenance&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and repair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;evaluates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and equipment,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;whenever events&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or changes in business&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;circumstances&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;indicate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets or group of assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;may not be fully&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;recoverable.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;If indicators&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;exist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and the undiscounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;future cash flows that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to generate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are less&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;than the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;value of the assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company reduces&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;through an impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;charge,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to their&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;values&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on a discounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;cash flow approach&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or, when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;available&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and appropriate,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to comparable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;values.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;There were no such indicators&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for the periods&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;study and research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on the services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;performed,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;pursuant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to contracts&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;conduct and manage&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;studies&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;behalf. The Company records&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;activities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;based upon the estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;but not yet invoiced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and includes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;in the consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;balance sheets.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;These costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are a component&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on factors&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;such as estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of the work completed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and in accordance&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with agreements established&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;third-party&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;under the service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;The Company makes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;judgments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in determining&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;the accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;balance.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;become&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;known,&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;the Company adjusts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses. The Company has not experienced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;any material&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;between accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;incurred.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;However, the status&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and timing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;performed&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;may vary from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s estimates,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;resulting&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in adjustments&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to expense in future&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;periods.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Changes in these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimates that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in material&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;changes to the Company&amp;#8217;s accrued expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;could materially&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;affect&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s results&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of operations.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Contingent&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;milestone&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payments,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;if any, are expensed when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;the milestone&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;results&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are probable and estimable, which is generally&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;upon achievement&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of the milestone.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;facilities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;under non-cancelable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and recognizes related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;rent&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expense on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the lease.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The freestanding instruments related to the commitment by the Series A convertible preferred stockholders to purchase and by the Company to sell its Series A convertible preferred stock in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per stock, were considered a liability (or an asset), measured at fair value as the shares underlying the &lt;font style="color:#231F20;"&gt;rights&lt;/font&gt; contained liquidation preferences upon certain &amp;#8220;deemed liquidation events&amp;#8221; that were not solely within the Company&amp;#8217;s control and which were considered in-substance contingent redemption features. The instruments were subject to revaluation at each balance sheet date until settlement or extinguishment, with revaluations recognized as either a component of other expenses, net in the consolidated statements of operations and comprehensive loss, or additional paid-in capital in the consolidated balance sheets. Upon the completion of the Company&amp;#8217;s IPO, the remaining shares of convertible preferred stock that were previously issuable under subsequent closings were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Expenses&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;incurred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s lead product&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;candidate,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;BIO89-100. Research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of external&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to acquiring&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and licensing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;patents&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and intellectual&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;properties,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;supplies, and personnel&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Personnel&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of salaries,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;benefits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;compensation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for individuals&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;involved&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;efforts. Payments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;associated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with licensing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to acquire&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;licenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to develop, use, manufacture&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and commercialize&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;products&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;have not reached&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;technological&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;feasibility&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and do not have alternate&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;commercial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;use are expensed as incurred.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards made to employees,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;directors,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and&lt;font style="color:#000000;"&gt; &lt;/font&gt;non-employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on estimated fair values and recognizes compensation over the requisite service period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;the fair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;value of share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards on the date of grant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using a&lt;font style="color:#000000;"&gt; &lt;/font&gt;Black-Scholes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option pricing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;model.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company recognizes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;compensation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for the value of share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards, which have graded vesting,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using the straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the requisite&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of each award. The Company accounts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for forfeitures&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;as they occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option pricing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;model&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;a number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of assumptions,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of which the most significant&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;volatility,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the grant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;date until&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the options&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are exercised&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or expire),&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk-free&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;rate,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;divided&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;rate. These assumptions include:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&amp;#8212;Since the Company has limited trading history for its common stock due to its short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&amp;#8212;The expected term of options granted to employees and directors is determined using the &amp;#8220;simplified&amp;#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&amp;#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&amp;#8212;The Company has never paid dividends and has no foreseeable plans to pay dividends on its shares of common stock. Therefore, an expected dividend of zero is used.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are accounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for under the asset&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liability&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;method.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Under this&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;method,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;are recognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the future&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax consequences&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;attributable&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;between the consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of existing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and their&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;respective&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax bases and operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;loss and tax credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;carryforwards.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;are measured&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using enacted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax rates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;applied&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to taxable&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in the years&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in which those temporary&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to be realized.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;The effect&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;of a change in tax rates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is recognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;as income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or loss in the period that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;includes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the enactment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;date. A&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;allowance&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is established&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;necessary&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to reduce&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to the amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to be realized.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Interest&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and penalties&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to unrecognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax benefits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are included&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;within the provision&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Diluted Net Loss per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is computed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;by dividing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the net loss by the weighted average&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;during the period.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Diluted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is computed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;by dividing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the net loss by the weighted average&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;together&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with the number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of additional&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;would have been outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;if all&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;dilutive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;had been issued.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Since the Company is in a loss position&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the periods&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;presented,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;basic&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;net loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is the same&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;as diluted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;net loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the effects of potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;dilutive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;securities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s comprehensive loss is comprised of changes in unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2018-13, &lt;font style="font-style:italic;"&gt;Disclosure Framework &amp;#8211; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard effective from January 1, 2020, with the removed and modified disclosures adopted on a retrospective basis and the new disclosures adopted on a prospective basis. The standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02&amp;#8212;&lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;(&amp;#8220;ASU 2016-02&amp;#8221;), requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for nonpublic entities for fiscal years beginning after December 15, 2021. As an emerging growth company, ASU 2016-02 is effective for the Company for the year ending December 31, 2022 and interim periods within the year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000227" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the Company&amp;#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Municipal bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,593&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency discount securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&amp;#8217;s cash equivalents and available-for-sale securities by contractual maturity as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,304&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After one year through two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not hold any financial assets as of December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock liability represented a Level 3 financial liability measured at fair value on a recurring basis prior to its extinguishment in the fourth quarter of 2019. Accordingly, there was no Level 3 financial liability outstanding during the year ended and as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2019, changes in the fair value of the Company&amp;#8217;s Level&amp;#160;3 financial liability measured on a recurring basis were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revaluation of convertible preferred stock liability&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; recorded in other expenses (income), net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Partial settlement of convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liability upon third closing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital contribution related to extinguishment of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stock liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock liability resulted from the initial sale of Series A convertible preferred stock where the investors&amp;#8217; committed to purchase additional shares of Series A convertible preferred stock in subsequent closings, contingent upon the achievement by the Company of certain development milestones and approval by the board of directors. The investors&amp;#8217; commitment to purchase and the Company&amp;#8217;s commitment to sell shares of Series A convertible preferred stock represented a freestanding instrument accounted for at fair value and re-measured at each reporting date. The Company estimated the fair value of this commitment using the Black Scholes option pricing model using the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.99-$2.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00-2.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0-2.4%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000228" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Consolidated Balance Sheet Components &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment, Net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for property and equipment was $60,000 and $17,000 for the years ended December 31, 2020 and 2019, respectively.&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000229" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2018, the Company entered&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;into an operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;facility&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in Israel.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months. Under the lease agreement,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;monthly&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are approximately&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;$4,000. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company entered into an operating lease for its headquarters in San Francisco. The lease term is for 24 months, expiring in January 2022, and monthly lease payments during 2020 were approximately $17,500. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;under the Company&amp;#8217;s non-cancellable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;obligations&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;as of December&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;31, 2020, are as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.86%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum annual payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense was $273,000 and $159,000 for years ended December 31, 2020 and 2019, respectively. The Company has security deposit balances of $95,000, which are included in restricted cash and other assets in the consolidated balance sheets as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Asset Transfer and License Agreement with Teva Pharmaceutical Industries Ltd &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company concurrently entered into two Asset Transfer and License Agreements (the &amp;#8220;Teva Agreements&amp;#8221;) with Teva Pharmaceutical Industries Ltd (&amp;#8220;Teva&amp;#8221;) under which it acquired certain patents and intellectual property relating to two programs: (1)&amp;#160;Teva&amp;#8217;s glycoPEGylated FGF21 program, including the compound TEV-47948 (BIO89-100), a glycoPEGylated long-acting FGF21 and (2)&amp;#160;Teva&amp;#8217;s development program of small molecule inhibitors of Fatty Acid Synthase. Pursuant to the Teva Agreements, the Company paid Teva an initial nonrefundable upfront payment of $6.0&amp;#160;million and the Company could be obligated to pay Teva up to $67.5&amp;#160;million under each program, for a total of $135.0&amp;#160;million, upon the achievement of certain clinical development and commercial milestones. In addition, the Company is obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales on all products containing the Teva compounds. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Teva Agreements can be terminated (i)&amp;#160;by the Company without cause, after the first anniversary of the effective date, upon 120 days&amp;#8217; written notice to Teva, (ii)&amp;#160;by either party, if the other party materially breaches any of its obligations under the Agreements and fails to cure such breach within 60 days after receiving notice thereof, or (iii)&amp;#160;by either party, if a bankruptcy petition is filed against the other party and is not dismissed within 60 days. In addition, Teva can also terminate the agreement related to the Company&amp;#8217;s glycoPEGylated FGF21 program in the event the Company, or any of its affiliates or sublicensees, challenges any of the Teva patents licensed to the Company, and the challenge is not withdrawn within 30 days of written notice from Teva. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020 and 2019, there were no license payment expenses related to the Teva Agreements. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:LongTermDebtTextBlock id="F_000230" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Term Loan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Loan and Security Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2020, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (the &amp;#8220;Loan Agreement&amp;#8221;) with the lenders referred to therein (the &amp;#8220;Lenders&amp;#8221;), and Silicon Valley Bank, as collateral agent. The Loan Agreement provides for (i) a secured term A loan facility (the &amp;#8220;Term A Loan Facility&amp;#8221;) of up to $10.0 million and (ii) a secured term B loan facility (the &amp;#8220;Term B Loan Facility&amp;#8221;) of up to $5.0 million that is available upon the Company satisfying certain milestones. The Term A Loan Facility matures on November 1, 2022, provided, that if the Term B Loan Facility is funded, the facilities instead mature on September 1, 2023. The loans will bear interest at the greater of (i) 4.50% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 1.25%. As of December 31, 2020, the Company had not drawn any amount under the Loan Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the execution of the Loan Agreement, the Company agreed to issue the Lenders warrants to purchase shares of the Company&amp;#8217;s common stock. In April 2020, the Company issued Silicon Valley Bank a warrant to purchase 25,000 shares of the Company&amp;#8217;s common stock with a warrant exercise price of $22.06 per share that is immediately exercisable. The initial expiration date of April 7, 2030 was changed to June 30, 2025 in connection with the July 2020 offering. The Company determined the fair value of the warrant at the issuance date by&amp;#160;using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of 0.75%, no dividends, expected volatility of 92.3% and expected term of 10.0 years. Upon issuance, the fair value allocated to the warrant of $0.6 million was recorded as a debt issuance cost and classified within other assets and met the requirements for equity classification within additional paid-in capital on the consolidated balance sheets. An additional warrant to purchase 8,333 shares of the Company&amp;#8217;s common stock will be issued in connection with the Term B Loan Facility, if funded, with the exercise price determined on the Company&amp;#8217;s stock price at the time of issuance.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, the Company incurred $0.2 million in closing costs that were recorded as debt issuance costs and classified within other assets on the consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The deferred assets related to the debt issuance cost and warrant are recognized as interest expense over the duration of the Loan Agreement and are recorded within other expenses, net on the consolidated statements of operations and comprehensive loss. As of December 31, 2020, the remaining unamortized debt issuance costs classified within other assets on the consolidated balance sheet is $0.6 million.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
  <etnb:ConvertiblePreferredStockDisclosureTextBlock id="F_000231" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company entered into the Series A Share Purchase Agreement (the &amp;#8220;Series A SPA&amp;#8221;), pursuant to which the investors committed to invest an aggregate amount of up to $60.0 million for the issuance of shares of Series A convertible preferred stock at a price of $1.00 per share in subsequent closings. Upon the completion of the Company&amp;#8217;s IPO on November 13, 2019, there were 16,000,000 remaining shares of convertible preferred stock that were previously issuable that were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders during 2019. Additionally, immediately prior to the completion of the Company&amp;#8217;s IPO, all outstanding shares of convertible preferred stock automatically converted into 7,077,366 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital.&lt;/p&gt;</etnb:ConvertiblePreferredStockDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000232" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Share-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the Company&amp;#8217;s board of directors adopted the 89Bio Ltd. 2018 Equity Incentive Plan (the &amp;#8220;2018 Plan&amp;#8221;). In connection with the Reorganization in September 2019, the Company&amp;#8217;s board of directors approved the 2019 Equity Incentive Plan (the &amp;#8220;2019 Plan&amp;#8221;), which became effective in September 2019. From and after the effective date of the 2019 Plan, the Company will no longer be making any future awards under the 2018 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company initially reserved 2,844,193 shares of common stock for issuance under the 2019 Plan. In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2020, in an amount equal to 4% of the total number of shares of the Company&amp;#8217;s capital stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&amp;#8217;s board of directors. As of December 31, 2020, there were 1,433,991 shares of common stock available for issuance as future option grants under the 2019 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following 36-month period. The options will expire within ten years from the date of grant. The exercise price of awards granted will not be less than the estimated fair value of the shares on the date of grant.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;), which became effective following the date of the IPO. The Company initially reserved 225,188 shares of common stock for purchase under the ESPP. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on the first day of January for a period of up to ten years, in an amount equal to 1% &lt;font style="color:#000000;"&gt;of the total number of shares of the Company&amp;#8217;s common stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&amp;#8217;s board of directors. Purchases will be accomplished through the participation of discrete offering periods and each offering is expected to be 6 months long. For each offering period, ESPP participants will purchase shares of common stock at a price per share equal to&lt;/font&gt; 85% &lt;font style="color:#000000;"&gt;of the lesser of the fair market value of the Company&amp;#8217;s common stock on (1) the first trading day of the applicable offering period or (2) the last trading day of the applicable offering period&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The first six-month offering period under the ESPP commenced on January 1, 2020 and ended on June 30, 2020 and the second six-month offering period commenced on July 1, 2020 and ended on December 31, 2020. A total of 7,272 shares of common stock were purchased pursuant to the ESPP for the year ended December 31, 2020.&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;As of December 31, 2020, there were 355,806 shares of common stock available for issuance under the ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded share-based compensation for the periods indicated as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,807&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of option awards granted for the periods indicated was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.4-97.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61.8-87.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2-1.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.6-2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity for the year ended December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;682,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,898,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535,084&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,684&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the estimated total grant date fair value of options vested was $0.8 million. The weighted-average&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;date fair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;value of options&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the years ended December 31, 2020 and 2019 was $21.88 and $2.90 per share, respectively.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;of December&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;31, 2020, there&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;was $13.5 million of unrecognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;share-based compensation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;cost related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to stock options&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;under the 2019 Plan, which is expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to be recognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over a weighted-average&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of 2.5 years. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000233" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;9. Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Tax Rates Applicable to the Income of the Company and its Subsidiaries&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89Bio Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio Management, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UAB 89bio Lithuania&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax benefit (expense)&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is comprised&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;reflect&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;the net tax effects&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of temporary&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;between the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amounts of assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;for financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and the amounts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;used for income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax purposes. Significant&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;components&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,342&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Israel net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,392&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. research and development expenses and accrued expenses disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification had no impact on the consolidated financial statements for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;of December&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;31, 2020 and 2019, the Company recorded&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;a valuation&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;allowance&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of $21.9 million and $10.0 million, respectively,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in respect&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;resulting&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax loss carryforwards&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and other&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;temporary&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the time and amount of which are uncertain. The Company regularly assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through an adjustment to income tax expense. The valuation allowance increased by $11.9 million in 2020, which primarily relates to significant taxable losses. The change in valuation allowance during 2020 also includes a partial release of the valuation allowance against deferred tax assets in Israel due to achievement of recent profitability and the expectation of future profitability in the jurisdiction, which decreased the valuation allowance by $69,000 in 2020. The valuation allowance increased by $6.5 million in 2019, which primarily relates to significant taxable losses. It also includes a recapture of the valuation allowance against the Company&amp;#8217;s deferred tax assets in the United States due to the Reorganization that occurred in 2019, which increased the valuation allowance by $20,000. &amp;#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Available&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Carryforward&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Tax &lt;font style="letter-spacing:-0.05pt;"&gt;Losses and Credits&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company has an accumulated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax loss carryforward&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of approximately $54.1 million and $17.3 million for U.S. and Israeli tax purposes, respectively. As of December 31, 2019, the Company has an accumulated tax loss carryforward of approximately $9.1 million and $23.8 million for U.S. and Israeli tax purposes. Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized. Carryforward tax losses in Israel have no expiration date. &lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company has federal research and development credit carryforwards of approximately $0.6 million, which expire beginning in 2040. As of December 31, 2020 and 2019, the Company has state research and development credit carryforwards of approximately $0.7 million and $0.2 million, respectively, which will carry forward indefinitely.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Loss from Continuing Operations, Before Income Tax&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,502&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lithuania&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Israel&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss before income tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reconciliation of Income Tax Benefit (Expense) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;of income tax benefit (expense) based on the statutory&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax rate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to the effective&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax rate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit computed at statutory rates&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits, net of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;uncertain tax position&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,914&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in Israel effective tax rate due to the 2019&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; reorganization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revaluation of convertible preferred stock liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,039&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits, net of uncertain tax position disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification has no impact on the consolidated financial statements for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the U.S. federal and state net operating losses and credit carryforwards may be subject to an annual limitation provided for in Section 382 of the Internal Revenue Code and similar state codes. Any annual limitation could result in a deferral of the utilization of the net operating loss and credit carryforwards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Unrecognized Tax Benefits &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020 and 2019, the amount of gross unrecognized tax benefits increased by $0.3 million and $39,000, respectively. If the total amount of unrecognized tax benefits was recognized, it would not have an impact to the effective tax rate as it would be offset by the reversal of related deferred tax assets which are subject to a full valuation allowance.&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2020 and 2019, such interest and penalties are not material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to taxation in the United States, California, and several foreign jurisdictions. To date, the Company has not been subject to any federal or state income tax audits. The Company is currently under examination by the Israeli taxing authorities for 2019 and 2018. As of December 31, 2020, all tax years remain open to examination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020 and December 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security (&amp;#8220;CARES&amp;#8221;) Act and the Consolidated Appropriation Act (&amp;#8220;CAA&amp;#8221;), respectively, as a result of the COVID-19 pandemic, which contain among other things, numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company has evaluated the current legislation and at this time, does not anticipate the CARES Act or the CAA to have a material impact on its consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000234" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares, including all outstanding stock options, have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,898,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future option grants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,523,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,332,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,844,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000235" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000236" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000237" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription id="F_000238" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reclassification&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain prior year footnote amounts have been updated for consistency with the current year presentation. Such reclassification has no effect on the consolidated financial statements.&lt;/p&gt;
</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="F_000239" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign Currencies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain transactions during the years ended December 31, 2020 and 2019 were denominated in currencies other than the U.S. dollar. Gains and losses from foreign currency transactions were not material for all periods presented and are reflected in the consolidated statements of operations and comprehensive loss as a component of other expenses, net. The Company&amp;#8217;s subsidiary in Lithuania uses the Euro as its functional currency for financial reporting. The re-measurement from Euros to U.S. dollars results in translation gain and loss adjustments, which are reflected as a component of comprehensive loss as foreign currency translation adjustments.&amp;nbsp;&amp;nbsp; &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000240" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000241" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of Company&amp;#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;font style="font-weight:normal;"&gt;&amp;#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;font style="font-weight:normal;"&gt;&amp;#8212;Inputs (other than quoted prices included in Level&amp;#160;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;font style="font-weight:normal;"&gt;&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000242" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;instruments&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company to a concentration&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of cash and cash equivalents.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Bank&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are held by accredited&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and these deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;may at times&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;be in excess&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of insured&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;limits. The Company limits&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;associated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with cash and cash equivalents&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;by placing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;them&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;it believes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are of high quality.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company has not experienced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;any losses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of cash or cash equivalents. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <etnb:OtherRisksAndUncertaintiesPolicyTextBlock id="F_000243" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Other Risks and Uncertainties &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company&amp;#8217;s early stages of clinical drug development; the Company&amp;#8217;s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company&amp;#8217;s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company&amp;#8217;s ability to enroll patients in its ongoing and future clinical trials; the Company&amp;#8217;s ability to successfully manufacture and supply its product candidates for clinical trials; the Company&amp;#8217;s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company&amp;#8217;s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company&amp;#8217;s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ongoing COVID-19 pandemic has disrupted and may continue to disrupt the Company&amp;#8217;s business and delay its preclinical and clinical programs and timelines. &lt;font style="color:#000000;"&gt;The Company does not yet know the full extent of potential delays to clinical trials, which could prevent or delay the Company from obtaining approval for&amp;#160;BIO89-100.&amp;#160;&lt;/font&gt;The extent to which the COVID-19 pandemic may impact the Company&amp;#8217;s future operating results and financial condition is uncertain.&lt;/p&gt;</etnb:OtherRisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000244" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has one operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;segment.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company&amp;#8217;s chief&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;decision&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;maker,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Chief Executive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Officer,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;manages&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s operations&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on a consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the purposes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of allocating resources&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and evaluating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;performance.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000245" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper that are stated at fair value.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of a money market account that serves as collateral for the Company&amp;#8217;s operating lease agreement for its facility in Israel.&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:InvestmentPolicyTextBlock id="F_000246" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Generally, investments with original maturities beyond three months at the date of purchase are classified as short-term because it is management&amp;#8217;s intent to use the investments to fund current operations or to make them available for current operations.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss.&amp;#160;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&amp;#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other expenses, net. The cost of investments sold is based on the specific-identification method. There are no material realized gains or losses on investments for the periods presented. Interest on available-for-sale securities is included in other expenses, net and is not material for all periods presented.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000247" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Equipment, Net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and equipment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are stated&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;at cost, less&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;accumulated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;depreciation.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Depreciation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;is calculated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;useful&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lives&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;ranging&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to seven years.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Leasehold&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;improvements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are amortized&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the shorter&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets&amp;#8217;&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimated useful&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;life&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or the remaining&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the lease.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;font style="color:#000000;"&gt;Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gains or losses are recorded in the consolidated statements of operations and comprehensive loss. &lt;/font&gt;Maintenance&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and repair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are expensed as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000248" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;evaluates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and equipment,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;whenever events&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or changes in business&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;circumstances&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;indicate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets or group of assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;may not be fully&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;recoverable.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;If indicators&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;exist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and the undiscounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;future cash flows that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to generate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are less&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;than the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;value of the assets,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company reduces&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;through an impairment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;charge,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to their&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;values&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on a discounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;cash flow approach&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or, when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;available&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and appropriate,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to comparable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;values.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;There were no such indicators&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for the periods&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;presented.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <etnb:AccruedResearchAndDevelopmentExpensesPolicyTextBlock id="F_000249" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;study and research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on the services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;performed,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;pursuant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to contracts&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;institutions&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;conduct and manage&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;studies&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;behalf. The Company records&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;activities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;based upon the estimated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;but not yet invoiced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and includes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;in the consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;balance sheets.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;These costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are a component&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on factors&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;such as estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of the work completed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and in accordance&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with agreements established&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;third-party&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;under the service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;The Company makes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;judgments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in determining&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;the accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;balance.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;become&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;known,&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;the Company adjusts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses. The Company has not experienced&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;any material&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;between accrued&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;incurred.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;However, the status&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and timing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of actual&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;performed&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;may vary from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s estimates,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;resulting&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;in adjustments&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to expense in future&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;periods.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Changes in these&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;estimates that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in material&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;changes to the Company&amp;#8217;s accrued expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;could materially&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;affect&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s results&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of operations.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Contingent&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;milestone&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payments,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;if any, are expensed when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;the milestone&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;results&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are probable and estimable, which is generally&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;upon achievement&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of the milestone.&lt;/p&gt;</etnb:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000250" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;facilities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;under non-cancelable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and recognizes related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;rent&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expense on a straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the lease.&lt;/p&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
  <etnb:ConvertiblePreferredStockLiabilityPolicyTextBlock id="F_000251" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The freestanding instruments related to the commitment by the Series A convertible preferred stockholders to purchase and by the Company to sell its Series A convertible preferred stock in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per stock, were considered a liability (or an asset), measured at fair value as the shares underlying the &lt;font style="color:#231F20;"&gt;rights&lt;/font&gt; contained liquidation preferences upon certain &amp;#8220;deemed liquidation events&amp;#8221; that were not solely within the Company&amp;#8217;s control and which were considered in-substance contingent redemption features. The instruments were subject to revaluation at each balance sheet date until settlement or extinguishment, with revaluations recognized as either a component of other expenses, net in the consolidated statements of operations and comprehensive loss, or additional paid-in capital in the consolidated balance sheets. Upon the completion of the Company&amp;#8217;s IPO, the remaining shares of convertible preferred stock that were previously issuable under subsequent closings were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders.&amp;nbsp;&amp;nbsp;&lt;/p&gt;</etnb:ConvertiblePreferredStockLiabilityPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000252" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Expenses&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;incurred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s lead product&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;candidate,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;BIO89-100. Research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of external&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to acquiring&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and licensing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;patents&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and intellectual&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;properties,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;preclinical&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and clinical development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;supplies, and personnel&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Personnel&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of salaries,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;benefits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;compensation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for individuals&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;involved&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in research&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and development&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;efforts. Payments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;associated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;with licensing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;to acquire&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;licenses&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to develop, use, manufacture&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and commercialize&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;products&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;have not reached&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;technological&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;feasibility&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and do not have alternate&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;commercial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;use are expensed as incurred.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000253" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards made to employees,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;directors,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and&lt;font style="color:#000000;"&gt; &lt;/font&gt;non-employee&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;based on estimated fair values and recognizes compensation over the requisite service period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;the fair&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;value of share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards on the date of grant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using a&lt;font style="color:#000000;"&gt; &lt;/font&gt;Black-Scholes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option pricing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;model.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The Company recognizes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;compensation&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;for the value of share-based&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;awards, which have graded vesting,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using the straight-line&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over the requisite&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of each award. The Company accounts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for forfeitures&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;as they occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option pricing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;model&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;a number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of assumptions,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;of which the most significant&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;volatility,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;option term&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the grant&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;date until&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the options&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are exercised&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or expire),&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;risk-free&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;rate,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;divided&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;rate. These assumptions include:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&amp;#8212;Since the Company has limited trading history for its common stock due to its short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&amp;#8212;The expected term of options granted to employees and directors is determined using the &amp;#8220;simplified&amp;#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&amp;#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&amp;#8212;The Company has never paid dividends and has no foreseeable plans to pay dividends on its shares of common stock. Therefore, an expected dividend of zero is used.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000254" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are accounted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for under the asset&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liability&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;method.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Under this&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;method,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;are recognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the future&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax consequences&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;attributable&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;between the consolidated&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;carrying&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of existing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and their&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;respective&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax bases and operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;loss and tax credit&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;carryforwards.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;are measured&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using enacted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax rates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;applied&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to taxable&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in the years&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;in which those temporary&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to be realized.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;The effect&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;on deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;of a change in tax rates&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is recognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;as income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;or loss in the period that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;includes&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the enactment&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;date. A&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;allowance&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is established&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;necessary&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to reduce&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to the amount&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to be realized.&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Interest&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;and penalties&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to unrecognized&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax benefits&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are included&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;within the provision&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000255" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and&lt;font style="letter-spacing:-0.05pt;"&gt; &lt;/font&gt;Diluted Net Loss per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is computed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;by dividing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the net loss by the weighted average&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;during the period.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Diluted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is computed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;by dividing&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the net loss by the weighted average&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;together&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;with the number&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of additional&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;would have been outstanding&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;if all&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;dilutive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;common stock&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;had been issued.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Since the Company is in a loss position&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;for the periods&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;presented,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;basic&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;net loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is the same&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;as diluted&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;net loss per share&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the effects of potentially&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;dilutive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;securities&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;are antidilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000256" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s comprehensive loss is comprised of changes in unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <etnb:RecentlyAdoptedAccountingStandardsPolicyTextBlock id="F_000257" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2018-13, &lt;font style="font-style:italic;"&gt;Disclosure Framework &amp;#8211; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard effective from January 1, 2020, with the removed and modified disclosures adopted on a retrospective basis and the new disclosures adopted on a prospective basis. The standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/p&gt;</etnb:RecentlyAdoptedAccountingStandardsPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000258" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02&amp;#8212;&lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;(&amp;#8220;ASU 2016-02&amp;#8221;), requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for nonpublic entities for fiscal years beginning after December 15, 2021. As an emerging growth company, ASU 2016-02 is effective for the Company for the year ending December 31, 2022 and interim periods within the year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000259" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the Company&amp;#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Municipal bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,593&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agency discount securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock id="F_000260" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&amp;#8217;s cash equivalents and available-for-sale securities by contractual maturity as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,304&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After one year through two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000261" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2019, changes in the fair value of the Company&amp;#8217;s Level&amp;#160;3 financial liability measured on a recurring basis were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revaluation of convertible preferred stock liability&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; recorded in other expenses (income), net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Partial settlement of convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liability upon third closing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital contribution related to extinguishment of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stock liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="F_000262" contextRef="C_0001785173_20200101_20201231">The Company estimated the fair value of this commitment using the Black Scholes option pricing model using the following assumptions:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.99-$2.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00-2.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0-2.4%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000263" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000264" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000265" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;under the Company&amp;#8217;s non-cancellable&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;obligations&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;as of December&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;31, 2020, are as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.86%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum annual payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000266" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded share-based compensation for the periods indicated as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,807&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000267" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of option awards granted for the periods indicated was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86.4-97.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61.8-87.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2-1.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.6-2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000268" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity for the year ended December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;682,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,898,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535,084&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,684&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <etnb:ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock id="F_000269" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89Bio Ltd&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89bio Management, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UAB 89bio Lithuania&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</etnb:ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000270" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax benefit (expense)&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is comprised&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000271" contextRef="C_0001785173_20200101_20201231">Significant&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;components&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of the Company&amp;#8217;s deferred&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;tax assets&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;are as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,342&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Israel net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,392&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock id="F_000272" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,502&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lithuania&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Israel&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss before income tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,558&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000273" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;of income tax benefit (expense) based on the statutory&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax rate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to the effective&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;tax rate&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;is as follows&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;(in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit computed at statutory rates&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits, net of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;uncertain tax position&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,914&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in Israel effective tax rate due to the 2019&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; reorganization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revaluation of convertible preferred stock liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,039&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit (expense)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000274" contextRef="C_0001785173_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares, including all outstanding stock options, have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,898,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future option grants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,523,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,332,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,844,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000275" contextRef="C_0001785173_20200101_20201231">2019-06-30</dei:EntityIncorporationDateOfIncorporation>
  <etnb:ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange id="F_000276" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</etnb:ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange>
  <etnb:ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged id="F_000277" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</etnb:ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000278" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="INF" unitRef="U_xbrlishares">6100390</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000279" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20191101_20191130" decimals="INF" unitRef="U_xbrlishares">795703</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000280" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130" decimals="INF" unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000281" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="-5" unitRef="U_iso4217USD">87700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000282" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="-5" unitRef="U_iso4217USD">6800000</us-gaap:PaymentsOfStockIssuanceCosts>
  <etnb:PaymentsOfStockIssuanceCostsOther id="F_000283" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="-5" unitRef="U_iso4217USD">3100000</etnb:PaymentsOfStockIssuanceCostsOther>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000284" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191130" decimals="INF" unitRef="U_xbrlishares">7077366</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000285" contextRef="C_0001785173_20191101_20191130" decimals="6" unitRef="U_xbrlipure">0.160849</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000286" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731" decimals="INF" unitRef="U_xbrlishares">3047040</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000287" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731" decimals="INF" unitRef="U_xbrlishares">397440</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000288" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200731" decimals="INF" unitRef="U_iso4217USD_xbrlishares">27.50</us-gaap:SharesIssuedPricePerShare>
  <etnb:ProceedsFromIssuanceOfCommonStockGross id="F_000289" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">83800000</etnb:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000290" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:PaymentsOfStockIssuanceCosts>
  <etnb:PaymentsOfStockIssuanceCostsOther id="F_000291" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">600000</etnb:PaymentsOfStockIssuanceCostsOther>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000292" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">78200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000293" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930" decimals="INF" unitRef="U_xbrlishares">3025000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000294" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200930" decimals="2" unitRef="U_iso4217USD_xbrlishares">28.00</us-gaap:SharesIssuedPricePerShare>
  <etnb:ProceedsFromIssuanceOfCommonStockGross id="F_000295" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">84700000</etnb:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000296" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">4600000</us-gaap:PaymentsOfStockIssuanceCosts>
  <etnb:PaymentsOfStockIssuanceCostsOther id="F_000297" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">600000</etnb:PaymentsOfStockIssuanceCostsOther>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000298" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_etnbUnderwrittenPublicOfferingMember_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">79500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments id="F_000299" contextRef="C_0001785173_20201231" decimals="-5" unitRef="U_iso4217USD">204600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:NumberOfOperatingSegments id="F_000300" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_etnbSegment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000301" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000302" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000303" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_20200101_20201231">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000304" contextRef="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Leasehold improvements are amortized on a straight-line basis over the shorter of the assets&#8217; estimated useful life or the remaining term of the lease.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <etnb:CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability id="F_000305" contextRef="C_0001785173_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">25600000</etnb:CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000306" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">46134000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000307" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" unitRef="U_iso4217USD">76605000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000308" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAgencySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">29654000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000309" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">11890000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000310" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7093000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000311" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMunicipalBondsMember_20201231" decimals="-3" unitRef="U_iso4217USD">5592000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000312" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">4680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000313" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_etnbAgencyDiscountSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000314" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">181848000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000315" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAgencySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000316" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMunicipalBondsMember_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000317" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000318" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000319" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000320" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMunicipalBondsMember_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000321" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000322" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">46134000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000323" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" unitRef="U_iso4217USD">76603000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000324" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAgencySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">29669000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000325" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">11884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000326" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000327" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMunicipalBondsMember_20201231" decimals="-3" unitRef="U_iso4217USD">5593000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000328" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">4680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000329" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_etnbAgencyDiscountSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000330" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">181856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000331" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">75410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000332" contextRef="C_0001785173_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">106446000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue id="F_000333" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">160304000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <etnb:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue id="F_000334" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">21552000</etnb:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000335" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">181856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000336" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue id="F_000337" contextRef="C_0001785173_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000338" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">1671000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000339" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30597000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <etnb:FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing id="F_000340" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-6673000</etnb:FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing>
  <etnb:FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability id="F_000341" contextRef="C_0001785173_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-25595000</etnb:FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000342" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputSharePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.99</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000343" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputSharePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.57</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000344" contextRef="C_0001785173_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExercisePriceMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentTerm id="F_000345" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20190101_20191231">P0Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentTerm id="F_000346" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20190101_20191231">P2Y2M30D</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000347" contextRef="C_0001785173_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="1" unitRef="U_xbrlipure">72.0</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000348" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="1" unitRef="U_xbrlipure">0.0</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000349" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFairValueByLiabilityClassAxis_etnbConvertiblePreferredStockLiabilityMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20191231" decimals="1" unitRef="U_xbrlipure">2.4</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000350" contextRef="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000351" contextRef="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">67000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000352" contextRef="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_etnbFurnitureAndOfficeEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">144000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000353" contextRef="C_0001785173_us-gaapPropertyPlantAndEquipmentByTypeAxis_etnbFurnitureAndOfficeEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">111000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000354" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">249000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000355" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">178000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000356" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">83000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000357" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">23000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <etnb:AccruedResearchAndDevelopmentExpenseCurrent id="F_000358" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">2884000</etnb:AccruedResearchAndDevelopmentExpenseCurrent>
  <etnb:AccruedResearchAndDevelopmentExpenseCurrent id="F_000359" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">2326000</etnb:AccruedResearchAndDevelopmentExpenseCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000360" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">2552000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000361" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">1396000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000362" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">453000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000363" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">573000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000364" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">159000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000365" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases id="F_000366" contextRef="C_0001785173_20180501_20180531">The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months.</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
  <etnb:OperatingLeaseMonthlyRentalPayments id="F_000367" contextRef="C_0001785173_20180501_20180531" decimals="0" unitRef="U_iso4217USD">4000</etnb:OperatingLeaseMonthlyRentalPayments>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000368" contextRef="C_0001785173_20180531">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases id="F_000369" contextRef="C_0001785173_20191201_20191231">The lease term is for 24 months, expiring in January 2022</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
  <etnb:OperatingLeaseMonthlyRentalPayments id="F_000370" contextRef="C_0001785173_20200101_20201231" decimals="0" unitRef="U_iso4217USD">17500</etnb:OperatingLeaseMonthlyRentalPayments>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000371" contextRef="C_0001785173_20191231">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000372" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">232000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000373" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000374" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">240000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LeaseAndRentalExpense id="F_000375" contextRef="C_0001785173_20200101_20201231" decimals="0" unitRef="U_iso4217USD">273000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000376" contextRef="C_0001785173_20190101_20191231" decimals="0" unitRef="U_iso4217USD">159000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:SecurityDeposit id="F_000377" contextRef="C_0001785173_us-gaapBalanceSheetLocationAxis_etnbRestrictedCashAndOtherAssetsMember_20201231" decimals="0" unitRef="U_iso4217USD">95000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit id="F_000378" contextRef="C_0001785173_us-gaapBalanceSheetLocationAxis_etnbRestrictedCashAndOtherAssetsMember_20191231" decimals="0" unitRef="U_iso4217USD">95000</us-gaap:SecurityDeposit>
  <etnb:AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment id="F_000379" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430" decimals="-5" unitRef="U_iso4217USD">6000000</etnb:AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment>
  <etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones id="F_000380" contextRef="C_0001785173_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_etnbTevasGlycoPEGylatedFGF21ProgramMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430" decimals="INF" unitRef="U_iso4217USD">67500000</etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones>
  <etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones id="F_000381" contextRef="C_0001785173_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_etnbTevasDevelopmentProgramMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430" decimals="INF" unitRef="U_iso4217USD">67500000</etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones>
  <etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones id="F_000382" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20180401_20180430" decimals="INF" unitRef="U_iso4217USD">135000000</etnb:ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones>
  <etnb:AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice id="F_000383" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231">P120D</etnb:AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice>
  <etnb:AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure id="F_000384" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231">P60D</etnb:AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure>
  <etnb:AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled id="F_000385" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231">P60D</etnb:AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled>
  <etnb:UpFrontLicensePayment id="F_000386" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20200101_20201231" decimals="-6" unitRef="U_iso4217USD">0</etnb:UpFrontLicensePayment>
  <etnb:UpFrontLicensePayment id="F_000387" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_etnbTevaAgreementMember_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</etnb:UpFrontLicensePayment>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000388" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="-5" unitRef="U_iso4217USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000389" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermBLoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000390" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430" decimals="4" unitRef="U_xbrlipure">0.0450</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000391" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20200401_20200430" decimals="4" unitRef="U_xbrlipure">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000392" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">2022-11-01</us-gaap:LineOfCreditFacilityExpirationDate1>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000393" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">2023-09-01</us-gaap:LineOfCreditFacilityExpirationDate1>
  <us-gaap:LineOfCreditFacilityDescription id="F_000394" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430">In April 2020, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the lenders referred to therein (the &#8220;Lenders&#8221;), and Silicon Valley Bank, as collateral agent. The Loan Agreement provides for (i) a secured term A loan facility (the &#8220;Term A Loan Facility&#8221;) of up to $10.0 million and (ii) a secured term B loan facility (the &#8220;Term B Loan Facility&#8221;) of up to $5.0 million that is available upon the Company satisfying certain milestones. The Term A Loan Facility matures on November 1, 2022, provided, that if the Term B Loan Facility is funded, the facilities instead mature on September 1, 2023. The loans will bear interest at the greater of (i) 4.50% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 1.25%.</us-gaap:LineOfCreditFacilityDescription>
  <us-gaap:LineOfCredit id="F_000395" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit id="F_000396" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermBLoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LineOfCredit>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000397" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="INF" unitRef="U_xbrlishares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000398" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermALoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="2" unitRef="U_iso4217USD_xbrlishares">22.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000399" contextRef="C_0001785173_us-gaapDebtInstrumentAxis_etnbTermBLoanFacilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="INF" unitRef="U_xbrlishares">8333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:WarrantsAndRightsOutstandingMaturityDate id="F_000400" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430">2030-04-07</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
  <us-gaap:WarrantsAndRightsOutstandingMaturityDate id="F_000401" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200731">2025-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000402" contextRef="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200430" decimals="4" unitRef="U_xbrlipure">0.0075</us-gaap:DebtInstrumentMeasurementInput>
  <etnb:FairValueOfWarrantsAssumptionsDividends id="F_000403" contextRef="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendPaymentMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200401_20200430" decimals="INF" unitRef="U_iso4217USD">0</etnb:FairValueOfWarrantsAssumptionsDividends>
  <us-gaap:DebtInstrumentMeasurementInput id="F_000404" contextRef="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200430" decimals="3" unitRef="U_xbrlipure">0.923</us-gaap:DebtInstrumentMeasurementInput>
  <us-gaap:DebtInstrumentTerm id="F_000405" contextRef="C_0001785173_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200401_20200430">P10Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredFinanceCostsGross id="F_000406" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20200430" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DeferredFinanceCostsNet id="F_000407" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredFinanceCostsGross id="F_000408" contextRef="C_0001785173_us-gaapTypeOfArrangementAxis_etnbLoanAndSecurityAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DeferredFinanceCostsGross>
  <etnb:AmountOfPreferredSharesIssuableByEntity id="F_000409" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapFinancialInstrumentAxis_etnbSeriesASharePurchaseAgreementMember_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20180430" decimals="INF" unitRef="U_iso4217USD">60000000</etnb:AmountOfPreferredSharesIssuableByEntity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000410" contextRef="C_0001785173_us-gaapFinancialInstrumentAxis_etnbSeriesASharePurchaseAgreementMember_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20180430" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <etnb:NumberOfSharesCommittedToPurchaseNoLongerIssuable id="F_000411" contextRef="C_0001785173_us-gaapStatementClassOfStockAxis_etnbSeriesAConvertiblePreferredStockMember_20191113" decimals="INF" unitRef="U_xbrlishares">16000000</etnb:NumberOfSharesCommittedToPurchaseNoLongerIssuable>
  <etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability id="F_000412" contextRef="C_0001785173_20191113_20191113" decimals="-5" unitRef="U_iso4217USD">25600000</etnb:CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000413" contextRef="C_0001785173_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191113" decimals="INF" unitRef="U_xbrlishares">7077366</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <etnb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement id="F_000414" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2844193</etnb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement>
  <etnb:PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance id="F_000415" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P10Y</etnb:PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance>
  <etnb:PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding id="F_000416" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.04</etnb:PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000417" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1433991</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000418" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000419" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward id="F_000420" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following 36-month period. The options will expire within ten years from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
  <etnb:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod id="F_000421" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P36M</etnb:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000422" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <etnb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement id="F_000423" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">225188</etnb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement>
  <etnb:PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance id="F_000424" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">P10Y</etnb:PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance>
  <etnb:PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding id="F_000425" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" decimals="2" unitRef="U_xbrlipure">0.01</etnb:PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000426" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" decimals="2" unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <etnb:ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod id="F_000427" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">P6M</etnb:ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod>
  <etnb:ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate id="F_000428" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">2020-01-01</etnb:ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate>
  <etnb:ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod id="F_000429" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">P6M</etnb:ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod>
  <etnb:ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate id="F_000430" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">2020-07-01</etnb:ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate>
  <us-gaap:CommonStockSharesIssued id="F_000431" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">7272</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000432" contextRef="C_0001785173_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">355806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000433" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1250000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000434" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000435" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2557000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000436" contextRef="C_0001785173_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">359000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000437" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3807000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000438" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">389000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000439" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_20200101_20201231">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000440" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod id="F_000441" contextRef="C_0001785173_20200101_20201231">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000442" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000443" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000444" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000445" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000446" contextRef="C_0001785173_srtRangeAxis_srtMinimumMember_20190101_20191231">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000447" contextRef="C_0001785173_srtRangeAxis_srtMaximumMember_20190101_20191231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod id="F_000448" contextRef="C_0001785173_20190101_20191231">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000449" contextRef="C_0001785173_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000450" contextRef="C_0001785173_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000451" contextRef="C_0001785173_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000452" contextRef="C_0001785173_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000453" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1320243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000454" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">682000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000455" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">63366</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000456" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">40482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000457" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1898395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000458" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">535084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000459" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000460" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">29.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000461" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000462" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000463" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000464" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000465" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20190118_20191231">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000466" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000467" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P8Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000468" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">30353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000469" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">25918000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000470" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">11684000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="F_000471" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndTwentyEquityIncentivePlanMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD_xbrlishares">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000472" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndTwentyEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">21.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000473" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndTwentyEquityIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000474" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="-5" unitRef="U_iso4217USD">13500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000475" contextRef="C_0001785173_us-gaapPlanNameAxis_etnbTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000476" contextRef="C_0001785173_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000477" contextRef="C_0001785173_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000478" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioLtdMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000479" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioLtdMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000480" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioManagementIncorporationMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000481" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbEightyNineBioManagementIncorporationMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000482" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbUABEightyNineBioLithuaniaMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.15</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000483" contextRef="C_0001785173_srtConsolidatedEntitiesAxis_etnbUABEightyNineBioLithuaniaMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.15</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000484" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-11000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000485" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-167000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000486" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000487" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit id="F_000488" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-30000</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000489" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-10000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000490" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-198000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_000491" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">69000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_000492" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000493" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">69000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000494" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000495" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" unitRef="U_iso4217USD">11342000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000496" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20191231" decimals="-3" unitRef="U_iso4217USD">1916000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000497" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20201231" decimals="-3" unitRef="U_iso4217USD">3978000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000498" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20191231" decimals="-3" unitRef="U_iso4217USD">4328000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000499" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">5392000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000500" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">3419000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000501" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">635000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000502" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">349000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsOther id="F_000503" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">658000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000504" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000505" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">22005000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000506" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">10022000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000507" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">21936000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000508" contextRef="C_0001785173_20191231" decimals="-3" unitRef="U_iso4217USD">10022000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000509" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">69000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000510" contextRef="C_0001785173_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">11900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000511" contextRef="C_0001785173_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">6500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000512" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">20000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000513" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-69000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <etnb:AccumulatedTaxLossCarryForward id="F_000514" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20201231" decimals="-5" unitRef="U_iso4217USD">54100000</etnb:AccumulatedTaxLossCarryForward>
  <etnb:AccumulatedTaxLossCarryForward id="F_000515" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20191231" decimals="-5" unitRef="U_iso4217USD">9100000</etnb:AccumulatedTaxLossCarryForward>
  <etnb:AccumulatedTaxLossCarryForward id="F_000516" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20201231" decimals="-5" unitRef="U_iso4217USD">17300000</etnb:AccumulatedTaxLossCarryForward>
  <etnb:AccumulatedTaxLossCarryForward id="F_000517" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20191231" decimals="-5" unitRef="U_iso4217USD">23800000</etnb:AccumulatedTaxLossCarryForward>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="F_000518" contextRef="C_0001785173_20200101_20201231">Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <etnb:TaxableIncomeUtilizationPercentage id="F_000519" contextRef="C_0001785173_20201231" decimals="2" unitRef="U_xbrlipure">0.80</etnb:TaxableIncomeUtilizationPercentage>
  <etnb:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal id="F_000520" contextRef="C_0001785173_20201231" decimals="-5" unitRef="U_iso4217USD">600000</etnb:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000521" contextRef="C_0001785173_20201231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000522" contextRef="C_0001785173_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000523" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-58760000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000524" contextRef="C_0001785173_srtStatementGeographicalAxis_countryUS_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19502000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000525" contextRef="C_0001785173_srtStatementGeographicalAxis_countryLT_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-73000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000526" contextRef="C_0001785173_srtStatementGeographicalAxis_countryLT_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000527" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9275000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000528" contextRef="C_0001785173_srtStatementGeographicalAxis_countryIL_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-37900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000529" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8285000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000530" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13095000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000531" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">815000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000532" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">93000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000533" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-11914000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000534" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-6520000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <etnb:IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization id="F_000535" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">647000</etnb:IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization>
  <etnb:IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization id="F_000536" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-734000</etnb:IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential id="F_000537" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1671000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <etnb:IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability id="F_000538" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-6039000</etnb:IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000539" contextRef="C_0001785173_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">555000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000540" contextRef="C_0001785173_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-113000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="F_000541" contextRef="C_0001785173_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="F_000542" contextRef="C_0001785173_20190101_20191231" decimals="0" unitRef="U_iso4217USD">39000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:UnrecognizedTaxBenefits id="F_000543" contextRef="C_0001785173_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000544" contextRef="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1898395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000545" contextRef="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1320243</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000546" contextRef="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_etnbSharesAvailableForFutureOptionGrantsMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1433991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000547" contextRef="C_0001785173_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_etnbSharesAvailableForFutureOptionGrantsMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1523950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000548" contextRef="C_0001785173_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3332386</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000549" contextRef="C_0001785173_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2844193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>etnb-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6442908+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:etnb="http://www.89bio.com/20201231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.89bio.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.89bio.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponents" id="Role_DisclosureConsolidatedBalanceSheetComponents">
        <link:definition>100100 - Disclosure - Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>100120 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100130 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100140 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100160 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100170 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100190 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsTables" id="Role_DisclosureConsolidatedBalanceSheetComponentsTables">
        <link:definition>100200 - Disclosure - Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100210 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100220 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100230 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100240 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100270 - Disclosure - Fair Value Measurements - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails">
        <link:definition>100290 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails">
        <link:definition>100300 - Disclosure - Fair Value Measurements - Summary of Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100310 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Consolidated Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" id="Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
        <link:definition>100330 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails">
        <link:definition>100350 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" id="Role_DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails" id="Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails">
        <link:definition>100390 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100400 - Disclosure - Share-Based Compensation - Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100410 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails" id="Role_DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails">
        <link:definition>100420 - Disclosure - Income Taxes - Summary of Statutory Tax Rates Applicable to Income of Company and Subsidiaries (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" id="Role_DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
        <link:definition>100430 - Disclosure - Income Taxes - Income Taxes - Summary of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100440 - Disclosure - Income Taxes - Summary of Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails" id="Role_DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Summary of Loss from Continuing Operations Before Taxes on Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails" id="Role_DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails">
        <link:definition>100480 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" name="TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" name="TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" name="CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" name="IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" name="TemporaryEquitySettlementOfConvertiblePreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_StockIssuedDuringPeriodIssuanceCosts" name="StockIssuedDuringPeriodIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_ConvertiblePreferredSharesMember" name="ConvertiblePreferredSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_DeferredTaxAssets" name="DeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_RevaluationOfConvertiblePreferredStockLiability" name="RevaluationOfConvertiblePreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_ProceedsFromIssuancePublicOffering" name="ProceedsFromIssuancePublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" name="IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" name="PropertyAndEquipmentPurchasesIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" name="ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_ConvertiblePreferredStockDisclosureTextBlock" name="ConvertiblePreferredStockDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" name="ConvertiblePreferredStockLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" name="RecentlyAdoptedAccountingStandardsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" name="ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" name="ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" name="ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_PaymentsOfStockIssuanceCostsOther" name="PaymentsOfStockIssuanceCostsOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" name="CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_AgencyDiscountSecuritiesMember" name="AgencyDiscountSecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" name="FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" name="FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_ConvertiblePreferredStockLiabilityMember" name="ConvertiblePreferredStockLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_OperatingLeaseMonthlyRentalPayments" name="OperatingLeaseMonthlyRentalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_RestrictedCashAndOtherAssetsMember" name="RestrictedCashAndOtherAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TevaAgreementMember" name="TevaAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TevasGlycoPEGylatedFGF21ProgramMember" name="TevasGlycoPEGylatedFGF21ProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TevasDevelopmentProgramMember" name="TevasDevelopmentProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" name="AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" name="ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" name="AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" name="AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" name="AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_UpFrontLicensePayment" name="UpFrontLicensePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TermALoanFacilityMember" name="TermALoanFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TermBLoanFacilityMember" name="TermBLoanFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_FairValueOfWarrantsAssumptionsDividends" name="FairValueOfWarrantsAssumptionsDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_AmountOfPreferredSharesIssuableByEntity" name="AmountOfPreferredSharesIssuableByEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" name="NumberOfSharesCommittedToPurchaseNoLongerIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="etnb_SeriesASharePurchaseAgreementMember" name="SeriesASharePurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" name="NumberOfSharesIssuableUnderShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" name="PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" name="PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" name="TwoThousandAndNineteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" name="ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" name="ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_EightyNineBioLtdMember" name="EightyNineBioLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_EightyNineBioManagementIncorporationMember" name="EightyNineBioManagementIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_UABEightyNineBioLithuaniaMember" name="UABEightyNineBioLithuaniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="etnb_AccumulatedTaxLossCarryForward" name="AccumulatedTaxLossCarryForward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_TaxableIncomeUtilizationPercentage" name="TaxableIncomeUtilizationPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" name="IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" name="IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="etnb_SharesAvailableForFutureOptionGrantsMember" name="SharesAvailableForFutureOptionGrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>etnb-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6442908+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="etnb-20201231.xsd#TemplateLink" roleURI="http://www.89bio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RevaluationOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssets" xlink:type="locator" xlink:label="etnb_DeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuancePublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="etnb_ProceedsFromIssuancePublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="etnb_DeferredTaxAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="etnb_RevaluationOfConvertiblePreferredStockLiability" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="etnb_AccruedResearchAndDevelopmentExpenseCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>etnb-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6442908+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="etnb-20201231.xsd#TemplateLink" roleURI="http://www.89bio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="12160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_StockIssuedDuringPeriodIssuanceCosts" xlink:type="locator" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="etnb_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredSharesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="etnb_ConvertiblePreferredSharesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityIssuanceCosts" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_StockIssuedDuringPeriodIssuanceCosts" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" xlink:type="locator" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" xlink:type="locator" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuancePublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RevaluationOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssets" xlink:type="locator" xlink:label="etnb_DeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10250.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="etnb_DeferredTaxAssets" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="etnb_RevaluationOfConvertiblePreferredStockLiability" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="etnb_ProceedsFromIssuancePublicOffering" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="12280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PaymentsOfStockIssuanceCostsOther" xlink:type="locator" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="etnb_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="etnb_UnderwrittenPublicOfferingMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_PaymentsOfStockIssuanceCostsOther" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ProceedsFromIssuanceOfCommonStockGross" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="etnb_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:type="locator" xlink:label="us-gaap_MunicipalBondsMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AgencyDiscountSecuritiesMember" xlink:type="locator" xlink:label="etnb_AgencyDiscountSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AgencySecuritiesMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="etnb_AgencyDiscountSecuritiesMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="12040.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockLiabilityMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="etnb_ConvertiblePreferredStockLiabilityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11040.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="etnb_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="etnb_FurnitureAndOfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UpFrontLicensePayment" xlink:type="locator" xlink:label="etnb_UpFrontLicensePayment" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:type="locator" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_OperatingLeaseMonthlyRentalPayments" xlink:type="locator" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasDevelopmentProgramMember" xlink:type="locator" xlink:label="etnb_TevasDevelopmentProgramMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasGlycoPEGylatedFGF21ProgramMember" xlink:type="locator" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevaAgreementMember" xlink:type="locator" xlink:label="etnb_TevaAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RestrictedCashAndOtherAssetsMember" xlink:type="locator" xlink:label="etnb_RestrictedCashAndOtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="etnb_RestrictedCashAndOtherAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="etnb_TevaAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="etnb_TevasGlycoPEGylatedFGF21ProgramMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="etnb_TevasDevelopmentProgramMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_OperatingLeaseMonthlyRentalPayments" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_UpFrontLicensePayment" order="11030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueOfWarrantsAssumptionsDividends" xlink:type="locator" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermBLoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermBLoanFacilityMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermALoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermALoanFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="etnb_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="etnb_LoanAndSecurityAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="etnb_TermALoanFacilityMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="etnb_TermBLoanFacilityMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityDescription" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="etnb_FairValueOfWarrantsAssumptionsDividends" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="11820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" xlink:type="locator" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AmountOfPreferredSharesIssuableByEntity" xlink:type="locator" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="etnb_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesASharePurchaseAgreementMember" xlink:type="locator" xlink:label="etnb_SeriesASharePurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="etnb_SeriesASharePurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="etnb_SeriesAConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_AmountOfPreferredSharesIssuableByEntity" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" xlink:type="locator" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" xlink:type="locator" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:type="locator" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UABEightyNineBioLithuaniaMember" xlink:type="locator" xlink:label="etnb_UABEightyNineBioLithuaniaMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioManagementIncorporationMember" xlink:type="locator" xlink:label="etnb_EightyNineBioManagementIncorporationMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioLtdMember" xlink:type="locator" xlink:label="etnb_EightyNineBioLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_EightyNineBioLtdMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_EightyNineBioManagementIncorporationMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_UABEightyNineBioLithuaniaMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_IncomeTaxDisclosureTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TaxableIncomeUtilizationPercentage" xlink:type="locator" xlink:label="etnb_TaxableIncomeUtilizationPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccumulatedTaxLossCarryForward" xlink:type="locator" xlink:label="etnb_AccumulatedTaxLossCarryForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_AccumulatedTaxLossCarryForward" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_TaxableIncomeUtilizationPercentage" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_LT" xlink:type="locator" xlink:label="country_LT" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_LT" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SharesAvailableForFutureOptionGrantsMember" xlink:type="locator" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="etnb_SharesAvailableForFutureOptionGrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>etnb-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6452834+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively, no shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 19,931,660 and 13,788,982 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" />
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of convertible preferred stock into common stock, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of convertible preferred stock into common stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital contribution related to extinguishment of preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" />
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock warrant in connection with debt financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" xlink:to="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon completion of initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Conversion of convertible preferred stock into common stock upon completion of initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Conversion of convertible preferred stock into common stock upon completion of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon completion of initial public offering, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital contribution related to extinguishment of convertible preferred stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Contribution Related To Extinguishment Of Preferred Stock Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon ESPP purchase, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Of Common Stock Warrants In Connection With Debt Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Warrants In Connection With Debt Financing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="etnb_TemporaryEquityIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TemporaryEquityIssuanceCosts" xlink:to="etnb_TemporaryEquityIssuanceCosts_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity settlement of convertible preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" xlink:to="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_StockIssuedDuringPeriodIssuanceCosts" xlink:type="locator" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_StockIssuedDuringPeriodIssuanceCosts" xlink:to="etnb_StockIssuedDuringPeriodIssuanceCosts_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredSharesMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ConvertiblePreferredSharesMember" xlink:to="etnb_ConvertiblePreferredSharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, settlement of convertible preferred stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Settlement Of Convertible Preferred Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Issuance Costs</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssets" xlink:type="locator" xlink:label="etnb_DeferredTaxAssets" />
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_DeferredTaxAssets" xlink:to="etnb_DeferredTaxAssets_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RevaluationOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revaluation of convertible preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_RevaluationOfConvertiblePreferredStockLiability" xlink:to="etnb_RevaluationOfConvertiblePreferredStockLiability_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuancePublicOffering" />
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ProceedsFromIssuancePublicOffering" xlink:to="etnb_ProceedsFromIssuancePublicOffering_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" />
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock warrant in connection with term loan facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" xlink:to="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" xlink:type="locator" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment purchases included in accounts payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" xlink:to="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" xlink:type="locator" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock into common stock at initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" xlink:to="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP Purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revaluation of convertible preferred stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revaluation Of Convertible Preferred Stock Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaids and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon public offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock and convertible preferred stock liability, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of cash and cash equivalents, and restricted cash:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrant in connection with term loan facility</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Warrant In Connection With Term Loan Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Purchases Included In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock at close of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock Into Common Stock At Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt [Text Block]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockDisclosureTextBlock" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ConvertiblePreferredStockDisclosureTextBlock" xlink:to="etnb_ConvertiblePreferredStockDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Reclassification Adjustment Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="etnb_OtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="etnb_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" xlink:to="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Liability Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:type="locator" xlink:label="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently adopted accounting standards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:to="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Standards</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Standards Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Fair Value of Level 3 Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" xlink:type="locator" xlink:label="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of effective income tax rate of company and subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" xlink:to="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate of Company and Subsidiaries [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Of Company And Subsidiaries Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax Benefit (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loss from Continuing Operations Before Taxes on Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="etnb_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_UnderwrittenPublicOfferingMember" xlink:to="etnb_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" />
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reorganization exchange of equity percentage of ordinary shares exchanged.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" />
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reorganization exchange of equity percentage of common stock issued upon exchange.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reorganization exchange of equity percentage of ordinary shares exchanged</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reorganization Exchange Of Equity Percentage Of Common Stock Issued Upon Exchange</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reorganization exchange of equity percentage of common stock issued upon exchange</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reorganization Exchange Of Equity Percentage Of Ordinary Shares Exchanged</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PaymentsOfStockIssuanceCostsOther" xlink:type="locator" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther" />
    <link:label xml:lang="en-US" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock issuance costs, other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_PaymentsOfStockIssuanceCostsOther" xlink:to="etnb_PaymentsOfStockIssuanceCostsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of underwriting discounts, commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock automatically converted into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ProceedsFromIssuanceOfCommonStockGross" xlink:to="etnb_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issue of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriters discount and commissions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="etnb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to various accounting policies of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="etnb_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements amortization, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital contributions related to extinguishment of preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" xlink:to="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital contribution by the preferred stockholders</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Contributions Related To Extinguishment Of Preferred Stock Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agency bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AgencySecuritiesMember" xlink:to="us-gaap_AgencySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agency Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Shortterm Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasury bills</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AgencyDiscountSecuritiesMember" xlink:type="locator" xlink:label="etnb_AgencyDiscountSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_AgencyDiscountSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agency discount securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AgencyDiscountSecuritiesMember" xlink:to="etnb_AgencyDiscountSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AgencyDiscountSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agency discount securities</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AgencyDiscountSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agency Discount Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:type="locator" xlink:label="us-gaap_MunicipalBondsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term investments, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments, Gross Unrealized Holding Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Short-term investments, Gross Unrealized Holding Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments, Aggregated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After one year through two years</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement, financial liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement, financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" />
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation partial settlement of convertible preferred stock liability upon third closing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation capital contribution related to the extinguishment of preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revaluation of convertible preferred stock liability recorded in other expenses (income), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partial settlement of convertible preferred stock liability upon third closing</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Partial Settlement Of Convertible Preferred Stock Liability Upon Third Closing</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital contribution related to extinguishment of preferred stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Capital Contribution Related To Extinguishment Of Preferred Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockLiabilityMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ConvertiblePreferredStockLiabilityMember" xlink:to="etnb_ConvertiblePreferredStockLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Liability [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black Scholes Option Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique Option Pricing Model [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Share Price [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Exercise Price [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="etnb_FurnitureAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_FurnitureAndOfficeEquipmentMember" xlink:to="etnb_FurnitureAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense for property and equipment</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="etnb_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and legal fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_OperatingLeaseMonthlyRentalPayments" xlink:type="locator" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments" />
    <link:label xml:lang="en-US" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease monthly rental payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_OperatingLeaseMonthlyRentalPayments" xlink:to="etnb_OperatingLeaseMonthlyRentalPayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RestrictedCashAndOtherAssetsMember" xlink:type="locator" xlink:label="etnb_RestrictedCashAndOtherAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_RestrictedCashAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and other assets member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_RestrictedCashAndOtherAssetsMember" xlink:to="etnb_RestrictedCashAndOtherAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_RestrictedCashAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash And Other Assets Member</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_RestrictedCashAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevaAgreementMember" xlink:type="locator" xlink:label="etnb_TevaAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevaAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Teva agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TevaAgreementMember" xlink:to="etnb_TevaAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevaAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Teva Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TevaAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Teva Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasGlycoPEGylatedFGF21ProgramMember" xlink:type="locator" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tevas glycoPEGylated FGF21 program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TevasGlycoPEGylatedFGF21ProgramMember" xlink:to="etnb_TevasGlycoPEGylatedFGF21ProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Teva?s GlycoPEGylated FGF21 Program</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tevas Glyco P E Gylated F G F21 Program [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasDevelopmentProgramMember" xlink:type="locator" xlink:label="etnb_TevasDevelopmentProgramMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevasDevelopmentProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tevas development program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TevasDevelopmentProgramMember" xlink:to="etnb_TevasDevelopmentProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TevasDevelopmentProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Teva?s Development Program</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TevasDevelopmentProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tevas Development Program [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Lessee Leasing Arrangements Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Monthly Rental Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum annual payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset transfer and license agreements initial nonrefundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" xlink:to="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:type="locator" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to payment upon maximum achievement of certain clinical and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:to="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Transfer And License Agreement Initial Nonrefundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment upon achievement of certain clinical and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Payment Upon Maximum Achievement Of Certain Clinical And Commercial Milestones</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset transfer and license agreement termination period after written notice.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset transfer and license agreement termination period notice of failure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset transfer and license agreement termination notice period if bankruptcy petition filed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset transfer and license agreement, termination period after written notice</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Transfer And License Agreement Termination Period After Written Notice</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset transfer and license agreement, termination period notice of breach</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Transfer And License Agreement Termination Period Notice Of Failure</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset transfer and license agreement termination notice period if bankruptcy petition filed</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Transfer And License Agreement Termination Notice Period If Bankruptcy Petition Filed</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UpFrontLicensePayment" xlink:type="locator" xlink:label="etnb_UpFrontLicensePayment" />
    <link:label xml:lang="en-US" xlink:label="etnb_UpFrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_UpFrontLicensePayment" xlink:to="etnb_UpFrontLicensePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_UpFrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front license payment</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_UpFrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Up Front License Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="etnb_LoanAndSecurityAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_LoanAndSecurityAgreementMember" xlink:to="etnb_LoanAndSecurityAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermALoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermALoanFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TermALoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term A loan facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TermALoanFacilityMember" xlink:to="etnb_TermALoanFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TermALoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Loan Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TermALoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term A Loan Facility [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermBLoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermBLoanFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TermBLoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term b loan facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TermBLoanFacilityMember" xlink:to="etnb_TermBLoanFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TermBLoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Loan Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TermBLoanFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term B Loan Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Payment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, maximum borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, basis spread on variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDescription" xlink:to="us-gaap_LineOfCreditFacilityDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount drawn</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueOfWarrantsAssumptionsDividends" xlink:type="locator" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends" />
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrant assumptions, dividends.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_FairValueOfWarrantsAssumptionsDividends" xlink:to="etnb_FairValueOfWarrantsAssumptionsDividends_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrant assumptions, dividends</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Assumptions Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Net</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AmountOfPreferredSharesIssuableByEntity" xlink:type="locator" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity" />
    <link:label xml:lang="en-US" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total amount of preferred shares issuable by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AmountOfPreferredSharesIssuableByEntity" xlink:to="etnb_AmountOfPreferredSharesIssuableByEntity_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" xlink:type="locator" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" />
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares committed to purchase, no longer issuable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" xlink:to="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesASharePurchaseAgreementMember" xlink:type="locator" xlink:label="etnb_SeriesASharePurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesASharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A share purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_SeriesASharePurchaseAgreementMember" xlink:to="etnb_SeriesASharePurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesASharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Share Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesASharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="etnb_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_SeriesAConvertiblePreferredStockMember" xlink:to="etnb_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total amount of preferred shares issuable by the entity</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Preferred Shares Issuable By Entity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Per share price of issuance of shares</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares committed to purchase, no longer issuable</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Committed To Purchase No Longer Issuable</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:type="locator" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" />
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issuable under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:to="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" xlink:type="locator" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for increase in number of shares of common stock reserved for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" xlink:to="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" xlink:type="locator" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" />
    <link:label xml:lang="en-US" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in number of shares of capital stock reserved for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" xlink:to="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="etnb_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="etnb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares issuable under the plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issuable Under Share Based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for increase in number of shares of common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period For Increase In Number Of Shares Of Common Stock Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in number of shares of capital stock issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Number Of Shares Of Capital Stock Issued And Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved and available for issuance as future option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award remaining options vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of option vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining option vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Remaining Options Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment second offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment second offering period commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment first offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment first offering period commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment First Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commencement date of first six month offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment First Offering Period Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Second Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commencement date of second six month offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Second Offering Period Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock available for issuance under ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Simplified Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (In years)</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Remaining Contractual Term (In years), Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (In years), Exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated total grant date fair value of options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock option granted under plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="etnb_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioLtdMember" xlink:type="locator" xlink:label="etnb_EightyNineBioLtdMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">89Bio Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_EightyNineBioLtdMember" xlink:to="etnb_EightyNineBioLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">89Bio Ltd</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Eighty Nine Bio Ltd [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioManagementIncorporationMember" xlink:type="locator" xlink:label="etnb_EightyNineBioManagementIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioManagementIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Eighty Nine Bio Management, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_EightyNineBioManagementIncorporationMember" xlink:to="etnb_EightyNineBioManagementIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioManagementIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">89bio Management, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_EightyNineBioManagementIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Eighty Nine Bio Management Incorporation [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UABEightyNineBioLithuaniaMember" xlink:type="locator" xlink:label="etnb_UABEightyNineBioLithuaniaMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_UABEightyNineBioLithuaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UAB Eighty Nine Bio Lithuania.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_UABEightyNineBioLithuaniaMember" xlink:to="etnb_UABEightyNineBioLithuaniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_UABEightyNineBioLithuaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UAB 89bio Lithuania</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_UABEightyNineBioLithuaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U A B Eighty Nine Bio Lithuania [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:label xml:lang="en-US" xlink:label="country_IL_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Israel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_IL_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">ISRAEL</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccumulatedTaxLossCarryForward" xlink:type="locator" xlink:label="etnb_AccumulatedTaxLossCarryForward" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccumulatedTaxLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated tax loss carry forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_AccumulatedTaxLossCarryForward" xlink:to="etnb_AccumulatedTaxLossCarryForward_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TaxableIncomeUtilizationPercentage" xlink:type="locator" xlink:label="etnb_TaxableIncomeUtilizationPercentage" />
    <link:label xml:lang="en-US" xlink:label="etnb_TaxableIncomeUtilizationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable income utilization percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_TaxableIncomeUtilizationPercentage" xlink:to="etnb_TaxableIncomeUtilizationPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_AccumulatedTaxLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated tax loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_AccumulatedTaxLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Tax Loss Carry Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TaxableIncomeUtilizationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable income utilization percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_TaxableIncomeUtilizationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Income Utilization Percentage</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research, federal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:to="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Federal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_LT" xlink:type="locator" xlink:label="country_LT" />
    <link:label xml:lang="en-US" xlink:label="country_LT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lithuania</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_LT" xlink:to="country_LT_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_LT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">LITHUANIA</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss before income tax</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" xlink:type="locator" xlink:label="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" />
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in effective tax rate due to reorganization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" xlink:to="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization_lbl" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" xlink:type="locator" xlink:label="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" />
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation revaluation of convertible preferred share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" xlink:to="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit computed at statutory rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits, net of uncertain tax position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Israel effective tax rate due to the 2019 reorganization</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Effective Tax Rate Due To Reorganization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revaluation of convertible preferred stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Revaluation Of Convertible Preferred Share Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Period Increase Decrease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SharesAvailableForFutureOptionGrantsMember" xlink:type="locator" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future option grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="etnb_SharesAvailableForFutureOptionGrantsMember" xlink:to="etnb_SharesAvailableForFutureOptionGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Available for Future Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Option Grants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>etnb-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-24T20:03:05.6452834+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 51b5ca7752a14298bf99f22a970b8ade -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.89bio.com/20201231/role/TemplateLink" xlink:href="etnb-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="etnb-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:type="locator" xlink:label="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_StockIssuedDuringPeriodIssuanceCosts" xlink:type="locator" xlink:label="etnb_StockIssuedDuringPeriodIssuanceCosts" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="etnb_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredSharesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="etnb_ConvertiblePreferredSharesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquityIssuanceCosts" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="etnb_StockIssuedDuringPeriodIssuanceCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="etnb-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" xlink:type="locator" xlink:label="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" xlink:type="locator" xlink:label="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuancePublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RevaluationOfConvertiblePreferredStockLiability" xlink:type="locator" xlink:label="etnb_RevaluationOfConvertiblePreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssets" xlink:type="locator" xlink:label="etnb_DeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="etnb_DeferredTaxAssets" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="etnb_RevaluationOfConvertiblePreferredStockLiability" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="etnb_ProceedsFromIssuancePublicOffering" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" xlink:href="etnb-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="etnb-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponents" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoan" xlink:href="etnb-20201231.xsd#Role_DisclosureTermLoan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="etnb-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockDisclosureTextBlock" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="etnb_ConvertiblePreferredStockDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="etnb-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="etnb-20201231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="etnb-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:type="locator" xlink:label="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="etnb_OtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="etnb_OtherRisksAndUncertaintiesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsTables" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" xlink:type="locator" xlink:label="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="etnb-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_li0l2" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="etnb_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PaymentsOfStockIssuanceCostsOther" xlink:type="locator" xlink:label="etnb_PaymentsOfStockIssuanceCostsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" xlink:type="locator" xlink:label="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="etnb_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="etnb_UnderwrittenPublicOfferingMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_PaymentsOfStockIssuanceCostsOther" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="etnb_ProceedsFromIssuanceOfCommonStockGross" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_li0l2" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="etnb_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="etnb_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="etnb_SummaryOfSignificantAccountingPoliciesLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:type="locator" xlink:label="us-gaap_MunicipalBondsMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AgencyDiscountSecuritiesMember" xlink:type="locator" xlink:label="etnb_AgencyDiscountSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AgencySecuritiesMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="etnb_AgencyDiscountSecuritiesMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" xlink:type="locator" xlink:label="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ConvertiblePreferredStockLiabilityMember" xlink:type="locator" xlink:label="etnb_ConvertiblePreferredStockLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="etnb_ConvertiblePreferredStockLiabilityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="etnb_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="etnb_FurnitureAndOfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="etnb_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="etnb_AccruedResearchAndDevelopmentExpenseCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UpFrontLicensePayment" xlink:type="locator" xlink:label="etnb_UpFrontLicensePayment" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" xlink:type="locator" xlink:label="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" xlink:type="locator" xlink:label="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_OperatingLeaseMonthlyRentalPayments" xlink:type="locator" xlink:label="etnb_OperatingLeaseMonthlyRentalPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:type="locator" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasDevelopmentProgramMember" xlink:type="locator" xlink:label="etnb_TevasDevelopmentProgramMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevasGlycoPEGylatedFGF21ProgramMember" xlink:type="locator" xlink:label="etnb_TevasGlycoPEGylatedFGF21ProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TevaAgreementMember" xlink:type="locator" xlink:label="etnb_TevaAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_RestrictedCashAndOtherAssetsMember" xlink:type="locator" xlink:label="etnb_RestrictedCashAndOtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="etnb_RestrictedCashAndOtherAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="etnb_TevaAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="etnb_TevasGlycoPEGylatedFGF21ProgramMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="etnb_TevasDevelopmentProgramMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_OperatingLeaseMonthlyRentalPayments" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="etnb_UpFrontLicensePayment" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_FairValueOfWarrantsAssumptionsDividends" xlink:type="locator" xlink:label="etnb_FairValueOfWarrantsAssumptionsDividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendPaymentMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendPaymentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermBLoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermBLoanFacilityMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TermALoanFacilityMember" xlink:type="locator" xlink:label="etnb_TermALoanFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="etnb_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="etnb_LoanAndSecurityAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="etnb_TermALoanFacilityMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="etnb_TermBLoanFacilityMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendPaymentMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityDescription" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="etnb_FairValueOfWarrantsAssumptionsDividends" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" xlink:type="locator" xlink:label="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" xlink:type="locator" xlink:label="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AmountOfPreferredSharesIssuableByEntity" xlink:type="locator" xlink:label="etnb_AmountOfPreferredSharesIssuableByEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="etnb_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SeriesASharePurchaseAgreementMember" xlink:type="locator" xlink:label="etnb_SeriesASharePurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="etnb_SeriesASharePurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="etnb_SeriesAConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_AmountOfPreferredSharesIssuableByEntity" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" xlink:type="locator" xlink:label="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" xlink:type="locator" xlink:label="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:type="locator" xlink:label="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndTwentyEquityIncentivePlanMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="etnb_TwoThousandAndNineteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_UABEightyNineBioLithuaniaMember" xlink:type="locator" xlink:label="etnb_UABEightyNineBioLithuaniaMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioManagementIncorporationMember" xlink:type="locator" xlink:label="etnb_EightyNineBioManagementIncorporationMember" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_EightyNineBioLtdMember" xlink:type="locator" xlink:label="etnb_EightyNineBioLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_EightyNineBioLtdMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_EightyNineBioManagementIncorporationMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="etnb_UABEightyNineBioLithuaniaMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="etnb_IncomeTaxDisclosureLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxDisclosureTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="etnb_IncomeTaxDisclosureLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_TaxableIncomeUtilizationPercentage" xlink:type="locator" xlink:label="etnb_TaxableIncomeUtilizationPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_AccumulatedTaxLossCarryForward" xlink:type="locator" xlink:label="etnb_AccumulatedTaxLossCarryForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="etnb_IncomeTaxDisclosureLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_AccumulatedTaxLossCarryForward" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_TaxableIncomeUtilizationPercentage" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:type="locator" xlink:label="country_IL" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_LT" xlink:type="locator" xlink:label="country_LT" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="etnb_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_LT" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureTable" xlink:to="etnb_IncomeTaxDisclosureLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="etnb_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" xlink:type="locator" xlink:label="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" xlink:type="locator" xlink:label="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails" xlink:href="etnb-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="etnb-20201231.xsd#etnb_SharesAvailableForFutureOptionGrantsMember" xlink:type="locator" xlink:label="etnb_SharesAvailableForFutureOptionGrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="etnb_SharesAvailableForFutureOptionGrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222344156840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">89bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001785173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,707,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,946,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ETNB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4946844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">142 Sansome Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line Two</a></td>
<td class="text">Second Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-4614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p>Portions of the registrant&#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders, to be held on or about June 2, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222342812424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 98,183<span></span>
</td>
<td class="nump">$ 93,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">106,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">5,548<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">210,202<span></span>
</td>
<td class="nump">95,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">211,074<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,048<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 19,931,660 and 13,788,982 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">326,046<span></span>
</td>
<td class="nump">163,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(123,095)<span></span>
</td>
<td class="num">(73,596)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">202,961<span></span>
</td>
<td class="nump">89,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 211,074<span></span>
</td>
<td class="nump">$ 95,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343304632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">19,931,660<span></span>
</td>
<td class="nump">13,788,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">19,931,660<span></span>
</td>
<td class="nump">13,788,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343266504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 36,199<span></span>
</td>
<td class="nump">$ 21,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,156<span></span>
</td>
<td class="nump">5,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,355<span></span>
</td>
<td class="nump">26,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(49,355)<span></span>
</td>
<td class="num">(26,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(30,562)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(49,558)<span></span>
</td>
<td class="num">(57,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">59<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,499)<span></span>
</td>
<td class="num">(57,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (49,509)<span></span>
</td>
<td class="num">$ (57,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (24.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">16,087,785<span></span>
</td>
<td class="nump">2,344,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345498984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public Offerings</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Public Offerings</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Offerings</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Public Offerings</div>
</th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (16,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,073<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon completion of initial public offering</a></td>
<td class="nump">49,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares', window );">Temporary Equity, Conversion of convertible preferred stock into common stock upon completion of initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue', window );">Temporary Equity, Conversion of convertible preferred stock into common stock upon completion of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon completion of initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,077,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability', window );">Capital contribution related to extinguishment of convertible preferred stock liability</a></td>
<td class="nump">25,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 89,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,788,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,072,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock Issued During Period Value Employee Stock Purchase Plan</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing', window );">Issuance Of Common Stock Warrants In Connection With Debt Financing</a></td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 202,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (123,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,931,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital contribution related to extinguishment of preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock warrant in connection with debt financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IssuanceOfCommonStockWarrantsInConnectionWithDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of convertible preferred stock into common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of convertible preferred stock into common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222439553608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_StockIssuedDuringPeriodIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=etnb_ConvertiblePreferredSharesMember', window );">Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TemporaryEquityIssuanceCosts', window );">Temporary equity, issuance costs</a></td>
<td class="nump">$ 1,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability', window );">Temporary equity, settlement of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_StockIssuedDuringPeriodIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_StockIssuedDuringPeriodIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity settlement of convertible preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TemporaryEquitySettlementOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=etnb_ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=etnb_ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343061704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (49,499,000)<span></span>
</td>
<td class="num">$ (57,420,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,807,000<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="num">(69,000)<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_RevaluationOfConvertiblePreferredStockLiability', window );">Revaluation of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,597,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on available-for-sale securities</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="num">(1,918,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,131,000<span></span>
</td>
<td class="num">(520,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,428,000<span></span>
</td>
<td class="nump">3,447,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,244,000)<span></span>
</td>
<td class="num">(25,460,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(118,895,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of available-for-sale securities</a></td>
<td class="nump">12,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(126,000)<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(106,832,000)<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance of common stock upon public offerings, net of issuance costs</a></td>
<td class="nump">157,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,691,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock and convertible preferred stock liability, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon stock option exercises</a></td>
<td class="nump">271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(161,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">157,924,000<span></span>
</td>
<td class="nump">107,702,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents, and restricted cash</a></td>
<td class="nump">4,848,000<span></span>
</td>
<td class="nump">82,103,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">93,360,000<span></span>
</td>
<td class="nump">11,257,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">98,208,000<span></span>
</td>
<td class="nump">93,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Components of cash and cash equivalents, and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">98,183,000<span></span>
</td>
<td class="nump">93,335,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">98,208,000<span></span>
</td>
<td class="nump">93,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of noncash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility', window );">Issuance of common stock warrant in connection with term loan facility</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable', window );">Property and equipment purchases included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering', window );">Conversion of convertible preferred stock into common stock at close of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability', window );">Capital contribution related to extinguishment of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,595,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital contribution related to extinguishment of preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock into common stock at initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ConversionOfConvertiblePreferredStockIntoCommonStockAtInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock warrant in connection with term loan facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment purchases included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_PropertyAndEquipmentPurchasesIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_RevaluationOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of convertible preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_RevaluationOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222347823736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc. (&#8220;89bio&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company&#8217;s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21, is currently being developed for the treatment of nonalcoholic steatohepatitis and for the treatment of severe hypertriglyceridemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc. was formed as a Delaware corporation in June 2019, for the purpose of completing an initial public offering (&#8220;IPO&#8221;) and related transactions in order to carry on the business of 89Bio Ltd., which was incorporated in Israel in January 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company completed an internal reorganization transaction in September 2019, pursuant to which 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (the &#8220;Reorganization&#8221;). As part of the Reorganization, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. The Reorganization was considered a transaction between entities under common control.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, 89bio, Inc. completed its IPO, pursuant to which it issued and sold an aggregate of 6,100,390 shares of common stock (inclusive of 795,703 shares pursuant to the underwriters&#8217; option to purchase additional shares), at the IPO price of $16.00 per share, <font style="Background-color:#FFFFFF;color:#000000;">resulting in net proceeds of $87.7 million after deducting underwriting discounts and commissions of $6.8 million and other offering expenses of $3.1 million. Upon the closing of the IPO, the Company&#8217;s outstanding convertible preferred stock automatically converted into 7,077,366 shares of common stock of 89bio, Inc. based on a proportional adjustment to the conversion ratio of the convertible preferred stock on a 1-for-6.217 basis.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company completed an underwritten public offering of 3,047,040 shares of its common stock (inclusive of 397,440 shares pursuant to the underwriters&#8217; option to purchase additional shares), at the public offering price of $27.50 per share. The Company raised a total of $83.8 million in gross proceeds from the offering, or approximately $78.2 million in net proceeds after deducting underwriting discounts and commissions of $5.0 million and offering costs of approximately $0.6 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company completed an underwritten public offering of 3,025,000 shares of its common stock, at a public offering price of $28.00 per share. The Company raised a total of $84.7 million in gross proceeds from the offering, or approximately $79.5 million in net proceeds after deducting underwriting discounts and commissions of $4.6 million and offering costs of approximately $0.6 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate substantial operating losses for the foreseeable future until it completes development of its products and seeks regulatory approvals to market such products. The Company had cash, cash equivalents and short-term investments of $204.6 million as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its cash, cash equivalents and short-term investments as of December 31, 2020, together with proceeds available from the Company&#8217;s term loan (see Note 6), will be sufficient to fund operating expenses and capital expenditure requirements for a period of at least one year from the date these audited consolidated financial statements are filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222350713992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassification</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year footnote amounts have been updated for consistency with the current year presentation. Such reclassification has no effect on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain transactions during the years ended December 31, 2020 and 2019 were denominated in currencies other than the U.S. dollar. Gains and losses from foreign currency transactions were not material for all periods presented and are reflected in the consolidated statements of operations and comprehensive loss as a component of other expenses, net. The Company&#8217;s subsidiary in Lithuania uses the Euro as its functional currency for financial reporting. The re-measurement from Euros to U.S. dollars results in translation gain and loss adjustments, which are reflected as a component of comprehensive loss as foreign currency translation adjustments.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1<font style="font-weight:normal;">&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2<font style="font-weight:normal;">&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3<font style="font-weight:normal;">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.05pt;"> </font>instruments<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>the Company to a concentration<font style="letter-spacing:0.1pt;"> </font>of credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>consist primarily<font style="letter-spacing:0.1pt;"> </font>of cash and cash equivalents.<font style="letter-spacing:0.1pt;"> </font>Bank<font style="letter-spacing:-0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>are held by accredited<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>and these deposits<font style="letter-spacing:0.05pt;"> </font>may at times<font style="letter-spacing:0.05pt;"> </font>be in excess<font style="letter-spacing:0.05pt;"> </font>of insured<font style="letter-spacing:0.05pt;"> </font>limits. The Company limits<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with cash and cash equivalents<font style="letter-spacing:0.1pt;"> </font>by placing<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>with financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>it believes<font style="letter-spacing:0.05pt;"> </font>are of high quality.<font style="letter-spacing:0.05pt;"> </font>The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any losses<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>of cash or cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Risks and Uncertainties </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company&#8217;s early stages of clinical drug development; the Company&#8217;s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company&#8217;s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company&#8217;s ability to enroll patients in its ongoing and future clinical trials; the Company&#8217;s ability to successfully manufacture and supply its product candidates for clinical trials; the Company&#8217;s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company&#8217;s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company&#8217;s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has disrupted and may continue to disrupt the Company&#8217;s business and delay its preclinical and clinical programs and timelines. <font style="color:#000000;">The Company does not yet know the full extent of potential delays to clinical trials, which could prevent or delay the Company from obtaining approval for&#160;BIO89-100.&#160;</font>The extent to which the COVID-19 pandemic may impact the Company&#8217;s future operating results and financial condition is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one operating<font style="letter-spacing:0.05pt;"> </font>segment.<font style="letter-spacing:0.05pt;"> </font>The Company&#8217;s chief<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>decision<font style="letter-spacing:0.05pt;"> </font>maker,<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>Chief Executive<font style="letter-spacing:0.05pt;"> </font>Officer,<font style="letter-spacing:0.05pt;"> </font>manages<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s operations<font style="letter-spacing:0.05pt;"> </font>on a consolidated<font style="letter-spacing:0.1pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>for the purposes<font style="letter-spacing:0.05pt;"> </font>of allocating resources<font style="letter-spacing:0.05pt;"> </font>and evaluating<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>performance.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper that are stated at fair value.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of a money market account that serves as collateral for the Company&#8217;s operating lease agreement for its facility in Israel.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Generally, investments with original maturities beyond three months at the date of purchase are classified as short-term because it is management&#8217;s intent to use the investments to fund current operations or to make them available for current operations.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss.&#160;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other expenses, net. The cost of investments sold is based on the specific-identification method. There are no material realized gains or losses on investments for the periods presented. Interest on available-for-sale securities is included in other expenses, net and is not material for all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and equipment<font style="letter-spacing:0.05pt;"> </font>are stated<font style="letter-spacing:0.05pt;"> </font>at cost, less<font style="letter-spacing:0.05pt;"> </font>accumulated<font style="letter-spacing:0.1pt;"> </font>depreciation.<font style="letter-spacing:0.1pt;"> </font>Depreciation<font style="letter-spacing:0.1pt;"> </font>is calculated<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the estimated<font style="letter-spacing:0.1pt;"> </font>useful<font style="letter-spacing:0.05pt;"> </font>lives<font style="letter-spacing:0.05pt;"> </font>of the related<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.05pt;"> </font>ranging<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>to seven years.<font style="letter-spacing:0.05pt;"> </font>Leasehold<font style="letter-spacing:0.05pt;"> </font>improvements<font style="letter-spacing:0.1pt;"> </font>are amortized<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the shorter<font style="letter-spacing:0.05pt;"> </font>of the assets&#8217;<font style="letter-spacing:0.05pt;"> </font>estimated useful<font style="letter-spacing:0.05pt;"> </font>life<font style="letter-spacing:0.05pt;"> </font>or the remaining<font style="letter-spacing:0.1pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of the lease.<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gains or losses are recorded in the consolidated statements of operations and comprehensive loss. </font>Maintenance<font style="letter-spacing:0.1pt;"> </font>and repair<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment<font style="letter-spacing:0.1pt;"> </font>of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically<font style="letter-spacing:0.1pt;"> </font>evaluates<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>long-lived<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>and equipment,<font style="letter-spacing:0.05pt;"> </font>for impairment<font style="letter-spacing:0.1pt;"> </font>whenever events<font style="letter-spacing:0.05pt;"> </font>or changes in business<font style="letter-spacing:0.05pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>indicate<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets or group of assets<font style="letter-spacing:0.05pt;"> </font>may not be fully<font style="letter-spacing:0.05pt;"> </font>recoverable.<font style="letter-spacing:0.1pt;"> </font>If indicators<font style="letter-spacing:0.1pt;"> </font>of impairment<font style="letter-spacing:0.1pt;"> </font>exist<font style="letter-spacing:0.05pt;"> </font>and the undiscounted<font style="letter-spacing:0.05pt;"> </font>future cash flows that<font style="letter-spacing:0.05pt;"> </font>the assets<font style="letter-spacing:0.05pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to generate<font style="letter-spacing:0.05pt;"> </font>are less<font style="letter-spacing:0.05pt;"> </font>than the carrying<font style="letter-spacing:0.05pt;"> </font>value of the assets,<font style="letter-spacing:0.05pt;"> </font>the Company reduces<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets<font style="letter-spacing:0.05pt;"> </font>through an impairment<font style="letter-spacing:0.1pt;"> </font>charge,<font style="letter-spacing:0.05pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>estimated<font style="letter-spacing:0.1pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>values<font style="letter-spacing:0.05pt;"> </font>based on a discounted<font style="letter-spacing:0.05pt;"> </font>cash flow approach<font style="letter-spacing:0.05pt;"> </font>or, when<font style="letter-spacing:-0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>and appropriate,<font style="letter-spacing:0.1pt;"> </font>to comparable<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>values.<font style="letter-spacing:0.05pt;"> </font>There were no such indicators<font style="letter-spacing:0.1pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>study and research<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>based on the services<font style="letter-spacing:0.05pt;"> </font>performed,<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to contracts<font style="letter-spacing:0.1pt;"> </font>with research<font style="letter-spacing:0.05pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>conduct and manage<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and research<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>behalf. The Company records<font style="letter-spacing:0.05pt;"> </font>the costs<font style="letter-spacing:0.05pt;"> </font>of research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>based upon the estimated<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of services<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>but not yet invoiced<font style="letter-spacing:0.05pt;"> </font>and includes<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>in accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>in the consolidated<font style="letter-spacing:0.1pt;"> </font>balance sheets.<font style="letter-spacing:0.05pt;"> </font>These costs<font style="letter-spacing:0.05pt;"> </font>are a component<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>based on factors<font style="letter-spacing:0.05pt;"> </font>such as estimates<font style="letter-spacing:0.1pt;"> </font>of the work completed<font style="letter-spacing:0.05pt;"> </font>and in accordance<font style="letter-spacing:0.05pt;"> </font>with agreements established<font style="letter-spacing:0.1pt;"> </font>with its<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>under the service<font style="letter-spacing:0.05pt;"> </font>agreements.<font style="letter-spacing:0.1pt;"> </font>The Company makes<font style="letter-spacing:0.05pt;"> </font>judgments<font style="letter-spacing:0.05pt;"> </font>and estimates<font style="letter-spacing:0.1pt;"> </font>in determining<font style="letter-spacing:0.1pt;"> </font>the accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>balance.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>known,<font style="letter-spacing:-0.05pt;"> </font>the Company adjusts<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>accrued<font style="letter-spacing:0.05pt;"> </font>expenses. The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any material<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>between accrued<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>incurred.<font style="letter-spacing:0.05pt;"> </font>However, the status<font style="letter-spacing:0.05pt;"> </font>and timing<font style="letter-spacing:0.05pt;"> </font>of actual<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>performed<font style="letter-spacing:0.1pt;"> </font>may vary from<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s estimates,<font style="letter-spacing:0.1pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>in adjustments<font style="letter-spacing:0.1pt;"> </font>to expense in future<font style="letter-spacing:0.05pt;"> </font>periods.<font style="letter-spacing:0.05pt;"> </font>Changes in these<font style="letter-spacing:0.05pt;"> </font>estimates that<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.05pt;"> </font>in material<font style="letter-spacing:0.1pt;"> </font>changes to the Company&#8217;s accrued expenses<font style="letter-spacing:0.05pt;"> </font>could materially<font style="letter-spacing:0.15pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s results<font style="letter-spacing:0.05pt;"> </font>of operations.<font style="letter-spacing:0.05pt;"> </font>Contingent<font style="letter-spacing:0.05pt;"> </font>milestone<font style="letter-spacing:0.1pt;"> </font>payments,<font style="letter-spacing:0.05pt;"> </font>if any, are expensed when<font style="letter-spacing:-0.05pt;"> </font>the milestone<font style="letter-spacing:0.1pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>are probable and estimable, which is generally<font style="letter-spacing:0.05pt;"> </font>upon achievement<font style="letter-spacing:0.1pt;"> </font>of the milestone.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>facilities<font style="letter-spacing:0.1pt;"> </font>under non-cancelable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and recognizes related<font style="letter-spacing:0.05pt;"> </font>rent<font style="letter-spacing:0.05pt;"> </font>expense on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the term<font style="letter-spacing:0.05pt;"> </font>of the lease.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The freestanding instruments related to the commitment by the Series A convertible preferred stockholders to purchase and by the Company to sell its Series A convertible preferred stock in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per stock, were considered a liability (or an asset), measured at fair value as the shares underlying the <font style="color:#231F20;">rights</font> contained liquidation preferences upon certain &#8220;deemed liquidation events&#8221; that were not solely within the Company&#8217;s control and which were considered in-substance contingent redemption features. The instruments were subject to revaluation at each balance sheet date until settlement or extinguishment, with revaluations recognized as either a component of other expenses, net in the consolidated statements of operations and comprehensive loss, or additional paid-in capital in the consolidated balance sheets. Upon the completion of the Company&#8217;s IPO, the remaining shares of convertible preferred stock that were previously issuable under subsequent closings were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders.&nbsp;&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and<font style="letter-spacing:-0.05pt;"> </font>Development<font style="letter-spacing:0.05pt;"> </font>Expenses<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of costs<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>for the development<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s lead product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of external<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to acquiring<font style="letter-spacing:0.05pt;"> </font>and licensing<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>and intellectual<font style="letter-spacing:0.15pt;"> </font>properties,<font style="letter-spacing:0.1pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical development<font style="letter-spacing:0.05pt;"> </font>and related<font style="letter-spacing:0.05pt;"> </font>supplies, and personnel<font style="letter-spacing:0.05pt;"> </font>costs.<font style="letter-spacing:0.05pt;"> </font>Personnel<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>of salaries,<font style="letter-spacing:0.1pt;"> </font>employee<font style="letter-spacing:0.05pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for individuals<font style="letter-spacing:0.1pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>efforts. Payments<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with licensing<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>licenses<font style="letter-spacing:0.05pt;"> </font>to develop, use, manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have not reached<font style="letter-spacing:0.05pt;"> </font>technological<font style="letter-spacing:0.1pt;"> </font>feasibility<font style="letter-spacing:0.15pt;"> </font>and do not have alternate<font style="letter-spacing:0.1pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>use are expensed as incurred.<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards made to employees,<font style="letter-spacing:0.05pt;"> </font>directors,<font style="letter-spacing:0.1pt;"> </font>and<font style="color:#000000;"> </font>non-employee<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>based on estimated fair values and recognizes compensation over the requisite service period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates<font style="letter-spacing:0.1pt;"> </font>the fair<font style="letter-spacing:0.05pt;"> </font>value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards on the date of grant<font style="letter-spacing:0.05pt;"> </font>using a<font style="color:#000000;"> </font>Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model.<font style="letter-spacing:0.05pt;"> </font>The Company recognizes<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for the value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards, which have graded vesting,<font style="letter-spacing:0.05pt;"> </font>using the straight-line<font style="letter-spacing:0.15pt;"> </font>method<font style="letter-spacing:0.05pt;"> </font>over the requisite<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of each award. The Company accounts<font style="letter-spacing:0.05pt;"> </font>for forfeitures<font style="letter-spacing:0.15pt;"> </font>as they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model<font style="letter-spacing:0.05pt;"> </font>requires<font style="letter-spacing:0.05pt;"> </font>a number<font style="letter-spacing:0.05pt;"> </font>of assumptions,<font style="letter-spacing:0.1pt;"> </font>of which the most significant<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>volatility,<font style="letter-spacing:0.1pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>option term<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the grant<font style="letter-spacing:0.05pt;"> </font>date until<font style="letter-spacing:0.05pt;"> </font>the options<font style="letter-spacing:0.05pt;"> </font>are exercised<font style="letter-spacing:0.05pt;"> </font>or expire),<font style="letter-spacing:0.05pt;"> </font>risk-free<font style="letter-spacing:0.1pt;"> </font>rate,<font style="letter-spacing:0.05pt;"> </font>and expected<font style="letter-spacing:0.05pt;"> </font>divided<font style="letter-spacing:0.05pt;"> </font>rate. These assumptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility&#8212;Since the Company has limited trading history for its common stock due to its short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term&#8212;The expected term of options granted to employees and directors is determined using the &#8220;simplified&#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend&#8212;The Company has never paid dividends and has no foreseeable plans to pay dividends on its shares of common stock. Therefore, an expected dividend of zero is used.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>are accounted<font style="letter-spacing:0.05pt;"> </font>for under the asset<font style="letter-spacing:0.05pt;"> </font>and liability<font style="letter-spacing:0.1pt;"> </font>method.<font style="letter-spacing:0.05pt;"> </font>Under this<font style="letter-spacing:0.05pt;"> </font>method,<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are recognized<font style="letter-spacing:0.05pt;"> </font>for the future<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to differences<font style="letter-spacing:0.1pt;"> </font>between the consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>carrying<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of existing<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>tax bases and operating<font style="letter-spacing:0.05pt;"> </font>loss and tax credit<font style="letter-spacing:0.05pt;"> </font>carryforwards.<font style="letter-spacing:0.1pt;"> </font>Deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are measured<font style="letter-spacing:0.05pt;"> </font>using enacted<font style="letter-spacing:0.05pt;"> </font>tax rates<font style="letter-spacing:0.05pt;"> </font>applied<font style="letter-spacing:0.05pt;"> </font>to taxable<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>in the years<font style="letter-spacing:0.05pt;"> </font>in which those temporary<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>The effect<font style="letter-spacing:0.05pt;"> </font>on deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>of a change in tax rates<font style="letter-spacing:0.05pt;"> </font>is recognized<font style="letter-spacing:0.05pt;"> </font>as income<font style="letter-spacing:0.05pt;"> </font>or loss in the period that<font style="letter-spacing:0.05pt;"> </font>includes<font style="letter-spacing:0.05pt;"> </font>the enactment<font style="letter-spacing:0.1pt;"> </font>date. A<font style="letter-spacing:-0.05pt;"> </font>valuation<font style="letter-spacing:0.05pt;"> </font>allowance<font style="letter-spacing:0.05pt;"> </font>is established<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to reduce<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>to the amount<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>Interest<font style="letter-spacing:0.1pt;"> </font>and penalties<font style="letter-spacing:0.1pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to unrecognized<font style="letter-spacing:0.05pt;"> </font>tax benefits<font style="letter-spacing:0.05pt;"> </font>are included<font style="letter-spacing:0.05pt;"> </font>within the provision<font style="letter-spacing:0.05pt;"> </font>of income<font style="letter-spacing:0.05pt;"> </font>tax. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and<font style="letter-spacing:-0.05pt;"> </font>Diluted Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>during the period.<font style="letter-spacing:0.05pt;"> </font>Diluted<font style="letter-spacing:0.05pt;"> </font>loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the number<font style="letter-spacing:0.05pt;"> </font>of additional<font style="letter-spacing:0.1pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would have been outstanding<font style="letter-spacing:0.05pt;"> </font>if all<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>had been issued.<font style="letter-spacing:0.05pt;"> </font>Since the Company is in a loss position<font style="letter-spacing:0.05pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented,<font style="letter-spacing:0.05pt;"> </font>basic<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>is the same<font style="letter-spacing:0.05pt;"> </font>as diluted<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>the effects of potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>are antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive<font style="letter-spacing:0.05pt;"> </font>Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s comprehensive loss is comprised of changes in unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <font style="font-style:italic;">Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</font>, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard effective from January 1, 2020, with the removed and modified disclosures adopted on a retrospective basis and the new disclosures adopted on a prospective basis. The standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02&#8212;<font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;), requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for nonpublic entities for fiscal years beginning after December 15, 2021. As an emerging growth company, ASU 2016-02 is effective for the Company for the year ending December 31, 2022 and interim periods within the year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222351668696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,654</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,669</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,890</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,884</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,592</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,593</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency discount securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,848</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,446</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and available-for-sale securities by contractual maturity as of December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,304</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through two years</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not hold any financial assets as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock liability represented a Level 3 financial liability measured at fair value on a recurring basis prior to its extinguishment in the fourth quarter of 2019. Accordingly, there was no Level 3 financial liability outstanding during the year ended and as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, changes in the fair value of the Company&#8217;s Level&#160;3 financial liability measured on a recurring basis were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; recorded in other expenses (income), net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partial settlement of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liability upon third closing</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,673</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital contribution related to extinguishment of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,595</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock liability resulted from the initial sale of Series A convertible preferred stock where the investors&#8217; committed to purchase additional shares of Series A convertible preferred stock in subsequent closings, contingent upon the achievement by the Company of certain development milestones and approval by the board of directors. The investors&#8217; commitment to purchase and the Company&#8217;s commitment to sell shares of Series A convertible preferred stock represented a freestanding instrument accounted for at fair value and re-measured at each reporting date. The Company estimated the fair value of this commitment using the Black Scholes option pricing model using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.99-$2.57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00-2.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0-2.4%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222351651672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Consolidated Balance Sheet Components</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Consolidated Balance Sheet Components </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for property and equipment was $60,000 and $17,000 for the years ended December 31, 2020 and 2019, respectively.<font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,326</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee and related expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and legal fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,620</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222350723416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, the Company entered<font style="letter-spacing:0.05pt;"> </font>into an operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>for its<font style="letter-spacing:0.05pt;"> </font>facility<font style="letter-spacing:0.1pt;"> </font>in Israel.<font style="letter-spacing:0.05pt;"> </font>The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months. Under the lease agreement,<font style="letter-spacing:0.1pt;"> </font>monthly<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>are approximately<font style="letter-spacing:0.1pt;"> </font>$4,000. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into an operating lease for its headquarters in San Francisco. The lease term is for 24 months, expiring in January 2022, and monthly lease payments during 2020 were approximately $17,500. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum<font style="letter-spacing:0.1pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>under the Company&#8217;s non-cancellable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>as of December<font style="letter-spacing:0.05pt;"> </font>31, 2020, are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.86%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum annual payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $273,000 and $159,000 for years ended December 31, 2020 and 2019, respectively. The Company has security deposit balances of $95,000, which are included in restricted cash and other assets in the consolidated balance sheets as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Asset Transfer and License Agreement with Teva Pharmaceutical Industries Ltd </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company concurrently entered into two Asset Transfer and License Agreements (the &#8220;Teva Agreements&#8221;) with Teva Pharmaceutical Industries Ltd (&#8220;Teva&#8221;) under which it acquired certain patents and intellectual property relating to two programs: (1)&#160;Teva&#8217;s glycoPEGylated FGF21 program, including the compound TEV-47948 (BIO89-100), a glycoPEGylated long-acting FGF21 and (2)&#160;Teva&#8217;s development program of small molecule inhibitors of Fatty Acid Synthase. Pursuant to the Teva Agreements, the Company paid Teva an initial nonrefundable upfront payment of $6.0&#160;million and the Company could be obligated to pay Teva up to $67.5&#160;million under each program, for a total of $135.0&#160;million, upon the achievement of certain clinical development and commercial milestones. In addition, the Company is obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales on all products containing the Teva compounds. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Teva Agreements can be terminated (i)&#160;by the Company without cause, after the first anniversary of the effective date, upon 120 days&#8217; written notice to Teva, (ii)&#160;by either party, if the other party materially breaches any of its obligations under the Agreements and fails to cure such breach within 60 days after receiving notice thereof, or (iii)&#160;by either party, if a bankruptcy petition is filed against the other party and is not dismissed within 60 days. In addition, Teva can also terminate the agreement related to the Company&#8217;s glycoPEGylated FGF21 program in the event the Company, or any of its affiliates or sublicensees, challenges any of the Teva patents licensed to the Company, and the challenge is not withdrawn within 30 days of written notice from Teva. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, there were no license payment expenses related to the Teva Agreements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222382617080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Term Loan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Term Loan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loan and Security Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the lenders referred to therein (the &#8220;Lenders&#8221;), and Silicon Valley Bank, as collateral agent. The Loan Agreement provides for (i) a secured term A loan facility (the &#8220;Term A Loan Facility&#8221;) of up to $10.0 million and (ii) a secured term B loan facility (the &#8220;Term B Loan Facility&#8221;) of up to $5.0 million that is available upon the Company satisfying certain milestones. The Term A Loan Facility matures on November 1, 2022, provided, that if the Term B Loan Facility is funded, the facilities instead mature on September 1, 2023. The loans will bear interest at the greater of (i) 4.50% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 1.25%. As of December 31, 2020, the Company had not drawn any amount under the Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Loan Agreement, the Company agreed to issue the Lenders warrants to purchase shares of the Company&#8217;s common stock. In April 2020, the Company issued Silicon Valley Bank a warrant to purchase 25,000 shares of the Company&#8217;s common stock with a warrant exercise price of $22.06 per share that is immediately exercisable. The initial expiration date of April 7, 2030 was changed to June 30, 2025 in connection with the July 2020 offering. The Company determined the fair value of the warrant at the issuance date by&#160;using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of 0.75%, no dividends, expected volatility of 92.3% and expected term of 10.0 years. Upon issuance, the fair value allocated to the warrant of $0.6 million was recorded as a debt issuance cost and classified within other assets and met the requirements for equity classification within additional paid-in capital on the consolidated balance sheets. An additional warrant to purchase 8,333 shares of the Company&#8217;s common stock will be issued in connection with the Term B Loan Facility, if funded, with the exercise price determined on the Company&#8217;s stock price at the time of issuance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company incurred $0.2 million in closing costs that were recorded as debt issuance costs and classified within other assets on the consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deferred assets related to the debt issuance cost and warrant are recognized as interest expense over the duration of the Loan Agreement and are recorded within other expenses, net on the consolidated statements of operations and comprehensive loss. As of December 31, 2020, the remaining unamortized debt issuance costs classified within other assets on the consolidated balance sheet is $0.6 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222350708472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ConvertiblePreferredStockDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into the Series A Share Purchase Agreement (the &#8220;Series A SPA&#8221;), pursuant to which the investors committed to invest an aggregate amount of up to $60.0 million for the issuance of shares of Series A convertible preferred stock at a price of $1.00 per share in subsequent closings. Upon the completion of the Company&#8217;s IPO on November 13, 2019, there were 16,000,000 remaining shares of convertible preferred stock that were previously issuable that were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders during 2019. Additionally, immediately prior to the completion of the Company&#8217;s IPO, all outstanding shares of convertible preferred stock automatically converted into 7,077,366 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222351657000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Share-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company&#8217;s board of directors adopted the 89Bio Ltd. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). In connection with the Reorganization in September 2019, the Company&#8217;s board of directors approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;), which became effective in September 2019. From and after the effective date of the 2019 Plan, the Company will no longer be making any future awards under the 2018 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company initially reserved 2,844,193 shares of common stock for issuance under the 2019 Plan. In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2020, in an amount equal to 4% of the total number of shares of the Company&#8217;s capital stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&#8217;s board of directors. As of December 31, 2020, there were 1,433,991 shares of common stock available for issuance as future option grants under the 2019 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following 36-month period. The options will expire within ten years from the date of grant. The exercise price of awards granted will not be less than the estimated fair value of the shares on the date of grant.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective following the date of the IPO. The Company initially reserved 225,188 shares of common stock for purchase under the ESPP. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on the first day of January for a period of up to ten years, in an amount equal to 1% <font style="color:#000000;">of the total number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31, or a lesser number of shares determined by the Company&#8217;s board of directors. Purchases will be accomplished through the participation of discrete offering periods and each offering is expected to be 6 months long. For each offering period, ESPP participants will purchase shares of common stock at a price per share equal to</font> 85% <font style="color:#000000;">of the lesser of the fair market value of the Company&#8217;s common stock on (1) the first trading day of the applicable offering period or (2) the last trading day of the applicable offering period</font>.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first six-month offering period under the ESPP commenced on January 1, 2020 and ended on June 30, 2020 and the second six-month offering period commenced on July 1, 2020 and ended on December 31, 2020. A total of 7,272 shares of common stock were purchased pursuant to the ESPP for the year ended December 31, 2020.<font style="font-size:12pt;">&#160;</font>As of December 31, 2020, there were 355,806 shares of common stock available for issuance under the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded share-based compensation for the periods indicated as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of option awards granted for the periods indicated was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.4-97.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.8-87.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2-1.5%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6-2.6%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,482</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.87</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,918</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,084</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,684</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the estimated total grant date fair value of options vested was $0.8 million. The weighted-average<font style="letter-spacing:0.1pt;"> </font>grant<font style="letter-spacing:0.05pt;"> </font>date fair<font style="letter-spacing:0.05pt;"> </font>value of options<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>for the years ended December 31, 2020 and 2019 was $21.88 and $2.90 per share, respectively.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>of December<font style="letter-spacing:0.05pt;"> </font>31, 2020, there<font style="letter-spacing:0.05pt;"> </font>was $13.5 million of unrecognized<font style="letter-spacing:0.05pt;"> </font>share-based compensation<font style="letter-spacing:0.1pt;"> </font>cost related<font style="letter-spacing:0.05pt;"> </font>to stock options<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>under the 2019 Plan, which is expected<font style="letter-spacing:0.05pt;"> </font>to be recognized<font style="letter-spacing:0.05pt;"> </font>over a weighted-average<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of 2.5 years. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222348032232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">9. Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Tax Rates Applicable to the Income of the Company and its Subsidiaries</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89Bio Ltd</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio Management, Inc.</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UAB 89bio Lithuania</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income<font style="letter-spacing:0.05pt;"> </font>tax benefit (expense)<font style="letter-spacing:0.05pt;"> </font>is comprised<font style="letter-spacing:0.05pt;"> </font>of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.05pt;"> </font>Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>reflect<font style="letter-spacing:0.1pt;"> </font>the net tax effects<font style="letter-spacing:0.1pt;"> </font>of temporary<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>between the carrying<font style="letter-spacing:0.05pt;"> </font>amounts of assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>for financial<font style="letter-spacing:0.1pt;"> </font>reporting<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>and the amounts<font style="letter-spacing:0.05pt;"> </font>used for income<font style="letter-spacing:0.05pt;"> </font>tax purposes. Significant<font style="letter-spacing:0.1pt;"> </font>components<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,342</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,978</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,392</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,005</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,936</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. research and development expenses and accrued expenses disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification had no impact on the consolidated financial statements for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:-0.05pt;"> </font>of December<font style="letter-spacing:0.05pt;"> </font>31, 2020 and 2019, the Company recorded<font style="letter-spacing:0.05pt;"> </font>a valuation<font style="letter-spacing:0.05pt;"> </font>allowance<font style="letter-spacing:0.05pt;"> </font>of $21.9 million and $10.0 million, respectively,<font style="letter-spacing:0.1pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>tax loss carryforwards<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>temporary<font style="letter-spacing:0.1pt;"> </font>differences.<font style="letter-spacing:0.1pt;"> </font>Realization of deferred tax assets is dependent upon future earnings, if any, the time and amount of which are uncertain. The Company regularly assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through an adjustment to income tax expense. The valuation allowance increased by $11.9 million in 2020, which primarily relates to significant taxable losses. The change in valuation allowance during 2020 also includes a partial release of the valuation allowance against deferred tax assets in Israel due to achievement of recent profitability and the expectation of future profitability in the jurisdiction, which decreased the valuation allowance by $69,000 in 2020. The valuation allowance increased by $6.5 million in 2019, which primarily relates to significant taxable losses. It also includes a recapture of the valuation allowance against the Company&#8217;s deferred tax assets in the United States due to the Reorganization that occurred in 2019, which increased the valuation allowance by $20,000. &#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Available<font style="letter-spacing:0.05pt;"> </font>Carryforward<font style="letter-spacing:0.05pt;"> </font>Tax <font style="letter-spacing:-0.05pt;">Losses and Credits</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company has an accumulated<font style="letter-spacing:0.1pt;"> </font>tax loss carryforward<font style="letter-spacing:0.1pt;"> </font>of approximately $54.1 million and $17.3 million for U.S. and Israeli tax purposes, respectively. As of December 31, 2019, the Company has an accumulated tax loss carryforward of approximately $9.1 million and $23.8 million for U.S. and Israeli tax purposes. Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized. Carryforward tax losses in Israel have no expiration date. <font style="letter-spacing:0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company has federal research and development credit carryforwards of approximately $0.6 million, which expire beginning in 2040. As of December 31, 2020 and 2019, the Company has state research and development credit carryforwards of approximately $0.7 million and $0.2 million, respectively, which will carry forward indefinitely.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss from Continuing Operations, Before Income Tax</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,760</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,502</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,275</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reconciliation of Income Tax Benefit (Expense) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation<font style="letter-spacing:0.15pt;"> </font>of income tax benefit (expense) based on the statutory<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>to the effective<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>is as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at statutory rates</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,095</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;uncertain tax position</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,914</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Israel effective tax rate due to the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; reorganization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,039</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits, net of uncertain tax position disclosed for the year ended December 31, 2019 were previously reported in the 2019 notes to the consolidated financial statements as a component of other. The reclassification has no impact on the consolidated financial statements for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the U.S. federal and state net operating losses and credit carryforwards may be subject to an annual limitation provided for in Section 382 of the Internal Revenue Code and similar state codes. Any annual limitation could result in a deferral of the utilization of the net operating loss and credit carryforwards.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the amount of gross unrecognized tax benefits increased by $0.3 million and $39,000, respectively. If the total amount of unrecognized tax benefits was recognized, it would not have an impact to the effective tax rate as it would be offset by the reversal of related deferred tax assets which are subject to a full valuation allowance.&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2020 and 2019, such interest and penalties are not material.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States, California, and several foreign jurisdictions. To date, the Company has not been subject to any federal or state income tax audits. The Company is currently under examination by the Israeli taxing authorities for 2019 and 2018. As of December 31, 2020, all tax years remain open to examination.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020 and December 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act and the Consolidated Appropriation Act (&#8220;CAA&#8221;), respectively, as a result of the COVID-19 pandemic, which contain among other things, numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company has evaluated the current legislation and at this time, does not anticipate the CARES Act or the CAA to have a material impact on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222350713992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares, including all outstanding stock options, have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future option grants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523,950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,332,386</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844,193</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222347855880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343229352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassification</p>

<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year footnote amounts have been updated for consistency with the current year presentation. Such reclassification has no effect on the consolidated financial statements.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain transactions during the years ended December 31, 2020 and 2019 were denominated in currencies other than the U.S. dollar. Gains and losses from foreign currency transactions were not material for all periods presented and are reflected in the consolidated statements of operations and comprehensive loss as a component of other expenses, net. The Company&#8217;s subsidiary in Lithuania uses the Euro as its functional currency for financial reporting. The re-measurement from Euros to U.S. dollars results in translation gain and loss adjustments, which are reflected as a component of comprehensive loss as foreign currency translation adjustments.&nbsp;&nbsp; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1<font style="font-weight:normal;">&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2<font style="font-weight:normal;">&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3<font style="font-weight:normal;">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.05pt;"> </font>instruments<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>the Company to a concentration<font style="letter-spacing:0.1pt;"> </font>of credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>consist primarily<font style="letter-spacing:0.1pt;"> </font>of cash and cash equivalents.<font style="letter-spacing:0.1pt;"> </font>Bank<font style="letter-spacing:-0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>are held by accredited<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>and these deposits<font style="letter-spacing:0.05pt;"> </font>may at times<font style="letter-spacing:0.05pt;"> </font>be in excess<font style="letter-spacing:0.05pt;"> </font>of insured<font style="letter-spacing:0.05pt;"> </font>limits. The Company limits<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>credit<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with cash and cash equivalents<font style="letter-spacing:0.1pt;"> </font>by placing<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>with financial<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>it believes<font style="letter-spacing:0.05pt;"> </font>are of high quality.<font style="letter-spacing:0.05pt;"> </font>The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any losses<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>deposits<font style="letter-spacing:0.05pt;"> </font>of cash or cash equivalents. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Risks and Uncertainties </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company&#8217;s early stages of clinical drug development; the Company&#8217;s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company&#8217;s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company&#8217;s ability to enroll patients in its ongoing and future clinical trials; the Company&#8217;s ability to successfully manufacture and supply its product candidates for clinical trials; the Company&#8217;s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company&#8217;s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company&#8217;s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has disrupted and may continue to disrupt the Company&#8217;s business and delay its preclinical and clinical programs and timelines. <font style="color:#000000;">The Company does not yet know the full extent of potential delays to clinical trials, which could prevent or delay the Company from obtaining approval for&#160;BIO89-100.&#160;</font>The extent to which the COVID-19 pandemic may impact the Company&#8217;s future operating results and financial condition is uncertain.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one operating<font style="letter-spacing:0.05pt;"> </font>segment.<font style="letter-spacing:0.05pt;"> </font>The Company&#8217;s chief<font style="letter-spacing:0.05pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>decision<font style="letter-spacing:0.05pt;"> </font>maker,<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>Chief Executive<font style="letter-spacing:0.05pt;"> </font>Officer,<font style="letter-spacing:0.05pt;"> </font>manages<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s operations<font style="letter-spacing:0.05pt;"> </font>on a consolidated<font style="letter-spacing:0.1pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>for the purposes<font style="letter-spacing:0.05pt;"> </font>of allocating resources<font style="letter-spacing:0.05pt;"> </font>and evaluating<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>performance.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>

<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper that are stated at fair value.</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>

<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of a money market account that serves as collateral for the Company&#8217;s operating lease agreement for its facility in Israel.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Generally, investments with original maturities beyond three months at the date of purchase are classified as short-term because it is management&#8217;s intent to use the investments to fund current operations or to make them available for current operations.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss.&#160;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in other expenses, net. The cost of investments sold is based on the specific-identification method. There are no material realized gains or losses on investments for the periods presented. Interest on available-for-sale securities is included in other expenses, net and is not material for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property<font style="letter-spacing:0.05pt;"> </font>and equipment<font style="letter-spacing:0.05pt;"> </font>are stated<font style="letter-spacing:0.05pt;"> </font>at cost, less<font style="letter-spacing:0.05pt;"> </font>accumulated<font style="letter-spacing:0.1pt;"> </font>depreciation.<font style="letter-spacing:0.1pt;"> </font>Depreciation<font style="letter-spacing:0.1pt;"> </font>is calculated<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the estimated<font style="letter-spacing:0.1pt;"> </font>useful<font style="letter-spacing:0.05pt;"> </font>lives<font style="letter-spacing:0.05pt;"> </font>of the related<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.05pt;"> </font>ranging<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>three<font style="letter-spacing:0.05pt;"> </font>to seven years.<font style="letter-spacing:0.05pt;"> </font>Leasehold<font style="letter-spacing:0.05pt;"> </font>improvements<font style="letter-spacing:0.1pt;"> </font>are amortized<font style="letter-spacing:0.1pt;"> </font>on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the shorter<font style="letter-spacing:0.05pt;"> </font>of the assets&#8217;<font style="letter-spacing:0.05pt;"> </font>estimated useful<font style="letter-spacing:0.05pt;"> </font>life<font style="letter-spacing:0.05pt;"> </font>or the remaining<font style="letter-spacing:0.1pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>of the lease.<font style="letter-spacing:0.05pt;"> </font><font style="color:#000000;">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and the resulting gains or losses are recorded in the consolidated statements of operations and comprehensive loss. </font>Maintenance<font style="letter-spacing:0.1pt;"> </font>and repair<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment<font style="letter-spacing:0.1pt;"> </font>of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically<font style="letter-spacing:0.1pt;"> </font>evaluates<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>long-lived<font style="letter-spacing:0.05pt;"> </font>assets,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>and equipment,<font style="letter-spacing:0.05pt;"> </font>for impairment<font style="letter-spacing:0.1pt;"> </font>whenever events<font style="letter-spacing:0.05pt;"> </font>or changes in business<font style="letter-spacing:0.05pt;"> </font>circumstances<font style="letter-spacing:0.15pt;"> </font>indicate<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets or group of assets<font style="letter-spacing:0.05pt;"> </font>may not be fully<font style="letter-spacing:0.05pt;"> </font>recoverable.<font style="letter-spacing:0.1pt;"> </font>If indicators<font style="letter-spacing:0.1pt;"> </font>of impairment<font style="letter-spacing:0.1pt;"> </font>exist<font style="letter-spacing:0.05pt;"> </font>and the undiscounted<font style="letter-spacing:0.05pt;"> </font>future cash flows that<font style="letter-spacing:0.05pt;"> </font>the assets<font style="letter-spacing:0.05pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to generate<font style="letter-spacing:0.05pt;"> </font>are less<font style="letter-spacing:0.05pt;"> </font>than the carrying<font style="letter-spacing:0.05pt;"> </font>value of the assets,<font style="letter-spacing:0.05pt;"> </font>the Company reduces<font style="letter-spacing:0.05pt;"> </font>the carrying<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the assets<font style="letter-spacing:0.05pt;"> </font>through an impairment<font style="letter-spacing:0.1pt;"> </font>charge,<font style="letter-spacing:0.05pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>estimated<font style="letter-spacing:0.1pt;"> </font>fair<font style="letter-spacing:0.05pt;"> </font>values<font style="letter-spacing:0.05pt;"> </font>based on a discounted<font style="letter-spacing:0.05pt;"> </font>cash flow approach<font style="letter-spacing:0.05pt;"> </font>or, when<font style="letter-spacing:-0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>and appropriate,<font style="letter-spacing:0.1pt;"> </font>to comparable<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>values.<font style="letter-spacing:0.05pt;"> </font>There were no such indicators<font style="letter-spacing:0.1pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>study and research<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>based on the services<font style="letter-spacing:0.05pt;"> </font>performed,<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to contracts<font style="letter-spacing:0.1pt;"> </font>with research<font style="letter-spacing:0.05pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>conduct and manage<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and research<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>on its<font style="letter-spacing:0.05pt;"> </font>behalf. The Company records<font style="letter-spacing:0.05pt;"> </font>the costs<font style="letter-spacing:0.05pt;"> </font>of research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>based upon the estimated<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of services<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>but not yet invoiced<font style="letter-spacing:0.05pt;"> </font>and includes<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>in accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>in the consolidated<font style="letter-spacing:0.1pt;"> </font>balance sheets.<font style="letter-spacing:0.05pt;"> </font>These costs<font style="letter-spacing:0.05pt;"> </font>are a component<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>based on factors<font style="letter-spacing:0.05pt;"> </font>such as estimates<font style="letter-spacing:0.1pt;"> </font>of the work completed<font style="letter-spacing:0.05pt;"> </font>and in accordance<font style="letter-spacing:0.05pt;"> </font>with agreements established<font style="letter-spacing:0.1pt;"> </font>with its<font style="letter-spacing:0.05pt;"> </font>third-party<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>under the service<font style="letter-spacing:0.05pt;"> </font>agreements.<font style="letter-spacing:0.1pt;"> </font>The Company makes<font style="letter-spacing:0.05pt;"> </font>judgments<font style="letter-spacing:0.05pt;"> </font>and estimates<font style="letter-spacing:0.1pt;"> </font>in determining<font style="letter-spacing:0.1pt;"> </font>the accrued<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.15pt;"> </font>balance.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>known,<font style="letter-spacing:-0.05pt;"> </font>the Company adjusts<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>accrued<font style="letter-spacing:0.05pt;"> </font>expenses. The Company has not experienced<font style="letter-spacing:0.05pt;"> </font>any material<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>between accrued<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and actual<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>incurred.<font style="letter-spacing:0.05pt;"> </font>However, the status<font style="letter-spacing:0.05pt;"> </font>and timing<font style="letter-spacing:0.05pt;"> </font>of actual<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>performed<font style="letter-spacing:0.1pt;"> </font>may vary from<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s estimates,<font style="letter-spacing:0.1pt;"> </font>resulting<font style="letter-spacing:0.1pt;"> </font>in adjustments<font style="letter-spacing:0.1pt;"> </font>to expense in future<font style="letter-spacing:0.05pt;"> </font>periods.<font style="letter-spacing:0.05pt;"> </font>Changes in these<font style="letter-spacing:0.05pt;"> </font>estimates that<font style="letter-spacing:0.05pt;"> </font>result<font style="letter-spacing:0.05pt;"> </font>in material<font style="letter-spacing:0.1pt;"> </font>changes to the Company&#8217;s accrued expenses<font style="letter-spacing:0.05pt;"> </font>could materially<font style="letter-spacing:0.15pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the Company&#8217;s results<font style="letter-spacing:0.05pt;"> </font>of operations.<font style="letter-spacing:0.05pt;"> </font>Contingent<font style="letter-spacing:0.05pt;"> </font>milestone<font style="letter-spacing:0.1pt;"> </font>payments,<font style="letter-spacing:0.05pt;"> </font>if any, are expensed when<font style="letter-spacing:-0.05pt;"> </font>the milestone<font style="letter-spacing:0.1pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>are probable and estimable, which is generally<font style="letter-spacing:0.05pt;"> </font>upon achievement<font style="letter-spacing:0.1pt;"> </font>of the milestone.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>

<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>facilities<font style="letter-spacing:0.1pt;"> </font>under non-cancelable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and recognizes related<font style="letter-spacing:0.05pt;"> </font>rent<font style="letter-spacing:0.05pt;"> </font>expense on a straight-line<font style="letter-spacing:0.15pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>over the term<font style="letter-spacing:0.05pt;"> </font>of the lease.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock', window );">Convertible Preferred Stock Liability</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The freestanding instruments related to the commitment by the Series A convertible preferred stockholders to purchase and by the Company to sell its Series A convertible preferred stock in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per stock, were considered a liability (or an asset), measured at fair value as the shares underlying the <font style="color:#231F20;">rights</font> contained liquidation preferences upon certain &#8220;deemed liquidation events&#8221; that were not solely within the Company&#8217;s control and which were considered in-substance contingent redemption features. The instruments were subject to revaluation at each balance sheet date until settlement or extinguishment, with revaluations recognized as either a component of other expenses, net in the consolidated statements of operations and comprehensive loss, or additional paid-in capital in the consolidated balance sheets. Upon the completion of the Company&#8217;s IPO, the remaining shares of convertible preferred stock that were previously issuable under subsequent closings were no longer issuable. Accordingly, the preferred stock liability was extinguished and because the transaction occurred between related parties, the resulting $25.6 million was accounted for as a capital contribution by the preferred stockholders.&nbsp;&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and<font style="letter-spacing:-0.05pt;"> </font>Development<font style="letter-spacing:0.05pt;"> </font>Expenses<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of costs<font style="letter-spacing:0.05pt;"> </font>incurred<font style="letter-spacing:0.05pt;"> </font>for the development<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s lead product<font style="letter-spacing:0.05pt;"> </font>candidate,<font style="letter-spacing:0.05pt;"> </font>BIO89-100. Research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>expenses<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>primarily<font style="letter-spacing:0.1pt;"> </font>of external<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to acquiring<font style="letter-spacing:0.05pt;"> </font>and licensing<font style="letter-spacing:0.05pt;"> </font>patents<font style="letter-spacing:0.05pt;"> </font>and intellectual<font style="letter-spacing:0.15pt;"> </font>properties,<font style="letter-spacing:0.1pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical development<font style="letter-spacing:0.05pt;"> </font>and related<font style="letter-spacing:0.05pt;"> </font>supplies, and personnel<font style="letter-spacing:0.05pt;"> </font>costs.<font style="letter-spacing:0.05pt;"> </font>Personnel<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>consist<font style="letter-spacing:0.05pt;"> </font>of salaries,<font style="letter-spacing:0.1pt;"> </font>employee<font style="letter-spacing:0.05pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for individuals<font style="letter-spacing:0.1pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>efforts. Payments<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with licensing<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>to acquire<font style="letter-spacing:0.05pt;"> </font>licenses<font style="letter-spacing:0.05pt;"> </font>to develop, use, manufacture<font style="letter-spacing:0.1pt;"> </font>and commercialize<font style="letter-spacing:0.15pt;"> </font>products<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>have not reached<font style="letter-spacing:0.05pt;"> </font>technological<font style="letter-spacing:0.1pt;"> </font>feasibility<font style="letter-spacing:0.15pt;"> </font>and do not have alternate<font style="letter-spacing:0.1pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>use are expensed as incurred.<font style="letter-spacing:0.05pt;"> </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards made to employees,<font style="letter-spacing:0.05pt;"> </font>directors,<font style="letter-spacing:0.1pt;"> </font>and<font style="color:#000000;"> </font>non-employee<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>providers<font style="letter-spacing:0.05pt;"> </font>based on estimated fair values and recognizes compensation over the requisite service period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates<font style="letter-spacing:0.1pt;"> </font>the fair<font style="letter-spacing:0.05pt;"> </font>value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards on the date of grant<font style="letter-spacing:0.05pt;"> </font>using a<font style="color:#000000;"> </font>Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model.<font style="letter-spacing:0.05pt;"> </font>The Company recognizes<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>for the value of share-based<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>awards, which have graded vesting,<font style="letter-spacing:0.05pt;"> </font>using the straight-line<font style="letter-spacing:0.15pt;"> </font>method<font style="letter-spacing:0.05pt;"> </font>over the requisite<font style="letter-spacing:0.1pt;"> </font>service<font style="letter-spacing:0.05pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>of each award. The Company accounts<font style="letter-spacing:0.05pt;"> </font>for forfeitures<font style="letter-spacing:0.15pt;"> </font>as they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes<font style="letter-spacing:0.05pt;"> </font>option pricing<font style="letter-spacing:0.05pt;"> </font>model<font style="letter-spacing:0.05pt;"> </font>requires<font style="letter-spacing:0.05pt;"> </font>a number<font style="letter-spacing:0.05pt;"> </font>of assumptions,<font style="letter-spacing:0.1pt;"> </font>of which the most significant<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>volatility,<font style="letter-spacing:0.1pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>option term<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the grant<font style="letter-spacing:0.05pt;"> </font>date until<font style="letter-spacing:0.05pt;"> </font>the options<font style="letter-spacing:0.05pt;"> </font>are exercised<font style="letter-spacing:0.05pt;"> </font>or expire),<font style="letter-spacing:0.05pt;"> </font>risk-free<font style="letter-spacing:0.1pt;"> </font>rate,<font style="letter-spacing:0.05pt;"> </font>and expected<font style="letter-spacing:0.05pt;"> </font>divided<font style="letter-spacing:0.05pt;"> </font>rate. These assumptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility&#8212;Since the Company has limited trading history for its common stock due to its short trading history, the expected volatility is estimated based on the volatility of comparable publicly traded biotechnology companies during the equivalent period of the calculated expected term of the options granted. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term&#8212;The expected term of options granted to employees and directors is determined using the &#8220;simplified&#8221; method. Under this approach, the expected term is presumed to be the midpoint between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is estimated on a grant-by-grant basis.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds in effect on the grant date for periods with an equivalent expected term as the option.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend&#8212;The Company has never paid dividends and has no foreseeable plans to pay dividends on its shares of common stock. Therefore, an expected dividend of zero is used.</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income<font style="letter-spacing:0.05pt;"> </font>taxes<font style="letter-spacing:0.05pt;"> </font>are accounted<font style="letter-spacing:0.05pt;"> </font>for under the asset<font style="letter-spacing:0.05pt;"> </font>and liability<font style="letter-spacing:0.1pt;"> </font>method.<font style="letter-spacing:0.05pt;"> </font>Under this<font style="letter-spacing:0.05pt;"> </font>method,<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are recognized<font style="letter-spacing:0.05pt;"> </font>for the future<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>attributable<font style="letter-spacing:0.15pt;"> </font>to differences<font style="letter-spacing:0.1pt;"> </font>between the consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>carrying<font style="letter-spacing:0.05pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>of existing<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>tax bases and operating<font style="letter-spacing:0.05pt;"> </font>loss and tax credit<font style="letter-spacing:0.05pt;"> </font>carryforwards.<font style="letter-spacing:0.1pt;"> </font>Deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>are measured<font style="letter-spacing:0.05pt;"> </font>using enacted<font style="letter-spacing:0.05pt;"> </font>tax rates<font style="letter-spacing:0.05pt;"> </font>applied<font style="letter-spacing:0.05pt;"> </font>to taxable<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>in the years<font style="letter-spacing:0.05pt;"> </font>in which those temporary<font style="letter-spacing:0.1pt;"> </font>differences<font style="letter-spacing:0.1pt;"> </font>are expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>The effect<font style="letter-spacing:0.05pt;"> </font>on deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>and liabilities<font style="letter-spacing:0.15pt;"> </font>of a change in tax rates<font style="letter-spacing:0.05pt;"> </font>is recognized<font style="letter-spacing:0.05pt;"> </font>as income<font style="letter-spacing:0.05pt;"> </font>or loss in the period that<font style="letter-spacing:0.05pt;"> </font>includes<font style="letter-spacing:0.05pt;"> </font>the enactment<font style="letter-spacing:0.1pt;"> </font>date. A<font style="letter-spacing:-0.05pt;"> </font>valuation<font style="letter-spacing:0.05pt;"> </font>allowance<font style="letter-spacing:0.05pt;"> </font>is established<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to reduce<font style="letter-spacing:0.05pt;"> </font>deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>to the amount<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>to be realized.<font style="letter-spacing:0.1pt;"> </font>Interest<font style="letter-spacing:0.1pt;"> </font>and penalties<font style="letter-spacing:0.1pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to unrecognized<font style="letter-spacing:0.05pt;"> </font>tax benefits<font style="letter-spacing:0.05pt;"> </font>are included<font style="letter-spacing:0.05pt;"> </font>within the provision<font style="letter-spacing:0.05pt;"> </font>of income<font style="letter-spacing:0.05pt;"> </font>tax. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and<font style="letter-spacing:-0.05pt;"> </font>Diluted Net Loss per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>during the period.<font style="letter-spacing:0.05pt;"> </font>Diluted<font style="letter-spacing:0.05pt;"> </font>loss per share<font style="letter-spacing:0.05pt;"> </font>is computed<font style="letter-spacing:0.05pt;"> </font>by dividing<font style="letter-spacing:0.05pt;"> </font>the net loss by the weighted average<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of common stock<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the number<font style="letter-spacing:0.05pt;"> </font>of additional<font style="letter-spacing:0.1pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would have been outstanding<font style="letter-spacing:0.05pt;"> </font>if all<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>common stock<font style="letter-spacing:0.05pt;"> </font>had been issued.<font style="letter-spacing:0.05pt;"> </font>Since the Company is in a loss position<font style="letter-spacing:0.05pt;"> </font>for the periods<font style="letter-spacing:0.05pt;"> </font>presented,<font style="letter-spacing:0.05pt;"> </font>basic<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>is the same<font style="letter-spacing:0.05pt;"> </font>as diluted<font style="letter-spacing:0.05pt;"> </font>net loss per share<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>the effects of potentially<font style="letter-spacing:0.1pt;"> </font>dilutive<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>are antidilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#231F20;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive<font style="letter-spacing:0.05pt;"> </font>Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s comprehensive loss is comprised of changes in unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <font style="font-style:italic;">Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</font>, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard effective from January 1, 2020, with the removed and modified disclosures adopted on a retrospective basis and the new disclosures adopted on a prospective basis. The standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02&#8212;<font style="font-style:italic;">Leases </font>(&#8220;ASU 2016-02&#8221;), requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for nonpublic entities for fiscal years beginning after December 15, 2021. As an emerging growth company, ASU 2016-02 is effective for the Company for the year ending December 31, 2022 and interim periods within the year ending December 31, 2023. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ConvertiblePreferredStockLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_RecentlyAdoptedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222349376936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,134</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency bonds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,654</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,669</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,890</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,884</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,093</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,592</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,593</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,680</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agency discount securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,848</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,446</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and available-for-sale securities by contractual maturity as of December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,304</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After one year through two years</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Liability</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, changes in the fair value of the Company&#8217;s Level&#160;3 financial liability measured on a recurring basis were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; recorded in other expenses (income), net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partial settlement of convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liability upon third closing</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,673</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital contribution related to extinguishment of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,595</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Fair Value Assumptions</a></td>
<td class="text">The Company estimated the fair value of this commitment using the Black Scholes option pricing model using the following assumptions:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.99-$2.57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00-2.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0-2.4%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222348123912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,326</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee and related expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and legal fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,620</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222348019784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum<font style="letter-spacing:0.1pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>under the Company&#8217;s non-cancellable<font style="letter-spacing:0.1pt;"> </font>operating<font style="letter-spacing:0.05pt;"> </font>lease<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>as of December<font style="letter-spacing:0.05pt;"> </font>31, 2020, are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.86%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum annual payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222349348792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded share-based compensation for the periods indicated as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of option awards granted for the periods indicated was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.4-97.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.8-87.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2-1.5%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6-2.6%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the year ended December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,482</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.87</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,918</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,084</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,684</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343183720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock', window );">Schedule of Effective Income Tax Rate of Company and Subsidiaries [Table Text Block]</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the Reorganization described in Note 1, the Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio, Inc.</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89Bio Ltd</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89bio Management, Inc.</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UAB 89bio Lithuania</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax Benefit (Expense)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income<font style="letter-spacing:0.05pt;"> </font>tax benefit (expense)<font style="letter-spacing:0.05pt;"> </font>is comprised<font style="letter-spacing:0.05pt;"> </font>of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Components of Deferred Tax Assets</a></td>
<td class="text">Significant<font style="letter-spacing:0.1pt;"> </font>components<font style="letter-spacing:0.05pt;"> </font>of the Company&#8217;s deferred<font style="letter-spacing:0.05pt;"> </font>tax assets<font style="letter-spacing:0.05pt;"> </font>are as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,342</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,978</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,392</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,005</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,936</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss from Continuing Operations Before Taxes on Income</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded a loss from continuing operations, before income tax for the periods indicated as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,760</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,502</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lithuania</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,275</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,558</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation<font style="letter-spacing:0.15pt;"> </font>of income tax benefit (expense) based on the statutory<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>to the effective<font style="letter-spacing:0.1pt;"> </font>tax rate<font style="letter-spacing:0.05pt;"> </font>is as follows<font style="letter-spacing:0.05pt;"> </font>(in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at statutory rates</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,285</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,095</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;uncertain tax position</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,914</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Israel effective tax rate due to the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; reorganization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revaluation of convertible preferred stock liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,039</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of effective income tax rate of company and subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ScheduleOfEffectiveIncomeTaxRateOfCompanyAndSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343006744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares, including all outstanding stock options, have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,898,395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future option grants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,523,950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,332,386</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844,193</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345934408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange', window );">Reorganization exchange of equity percentage of ordinary shares exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged', window );">Reorganization exchange of equity percentage of common stock issued upon exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.160849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of underwriters discount and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock automatically converted into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,077,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,077,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offerings | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,390<span></span>
</td>
<td class="nump">6,072,040<span></span>
</td>
<td class="nump">6,100,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">IPO price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of underwriting discounts, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PaymentsOfStockIssuanceCostsOther', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of underwriters discount and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,440<span></span>
</td>
<td class="nump">795,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=etnb_UnderwrittenPublicOfferingMember', window );">Underwritten public offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold | shares</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="nump">3,047,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">IPO price per share | $ / shares</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 79,500<span></span>
</td>
<td class="nump">$ 78,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of underwriting discounts, commissions</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PaymentsOfStockIssuanceCostsOther', window );">Other offering expenses</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issue of common stock</a></td>
<td class="nump">84,700<span></span>
</td>
<td class="nump">83,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of underwriters discount and commissions</a></td>
<td class="nump">$ 79,500<span></span>
</td>
<td class="nump">$ 78,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_PaymentsOfStockIssuanceCostsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs, other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_PaymentsOfStockIssuanceCostsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reorganization exchange of equity percentage of common stock issued upon exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reorganization exchange of equity percentage of ordinary shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=etnb_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=etnb_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345477320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gains or losses on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability', window );">Capital contribution by the preferred stockholders</a></td>
<td class="nump">$ 25,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements amortization, description</a></td>
<td class="text">Leasehold improvements are amortized on a straight-line basis over the shorter of the assets&#8217; estimated useful life or the remaining term of the lease.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital contributions related to extinguishment of preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222346116968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">$ 181,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Holding Gains</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Holding Losses</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">181,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">75,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">106,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">181,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">160,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">After one year through two years</a></td>
<td class="nump">21,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">46,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">46,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">76,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Holding Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">76,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">29,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Holding Gains</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">29,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">11,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Holding Losses</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">11,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Agency discount securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Municipal Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Holding Gains</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Aggregated Fair Value</a></td>
<td class="nump">$ 5,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=etnb_AgencyDiscountSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=etnb_AgencyDiscountSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345084264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value measurement, financial liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222351758152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liability (Details) - Recurring - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of convertible preferred stock liability recorded in other expenses (income), net</a></td>
<td class="nump">30,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing', window );">Partial settlement of convertible preferred stock liability upon third closing</a></td>
<td class="num">(6,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability', window );">Capital contribution related to extinguishment of preferred stock liability</a></td>
<td class="num">$ (25,595)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation capital contribution related to the extinguishment of preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_FairValueMeasurementWithUnobservableInputsReconciliationCapitalContributionRelatedToExtinguishmentOfPreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation partial settlement of convertible preferred stock liability upon third closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_FairValueMeasurementWithUnobservableInputsReconciliationPartialSettlementOfConvertiblePreferredStockLiabilityUponThirdClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222342765144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value Assumptions (Details) - Convertible Preferred Stock Liability - Black Scholes Option Pricing Model<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Stock Price | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">0.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Stock Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">2.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Expected Term (Years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Fair Measurement Input</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Expected Term (Years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Fair Measurement Input</a></td>
<td class="text">2 years 2 months 30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Risk-free Interest Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember', window );">Risk-free Interest Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=etnb_ConvertiblePreferredStockLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345290856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=etnb_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=etnb_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=etnb_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222348115128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense for property and equipment</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222346746408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 2,884<span></span>
</td>
<td class="nump">$ 2,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee and related expenses</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and legal fees</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 6,048<span></span>
</td>
<td class="nump">$ 4,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343106808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases', window );">Lessee, operating lease, description</a></td>
<td class="text">The lease term is for 24 months, expiring in January 2022<span></span>
</td>
<td class="text">The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_OperatingLeaseMonthlyRentalPayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease term of contract</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember', window );">Teva Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment', window );">Nonrefundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones', window );">Payment upon achievement of certain clinical and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice', window );">Asset transfer and license agreement, termination period after written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure', window );">Asset transfer and license agreement, termination period notice of breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled', window );">Asset transfer and license agreement termination notice period if bankruptcy petition filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember', window );">Teva Agreements | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_UpFrontLicensePayment', window );">Up-front license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember', window );">Teva Agreements | Teva?s GlycoPEGylated FGF21 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones', window );">Payment upon achievement of certain clinical and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember', window );">Teva Agreements | Teva?s Development Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones', window );">Payment upon achievement of certain clinical and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=etnb_RestrictedCashAndOtherAssetsMember', window );">Restricted Cash And Other Assets Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset transfer and license agreements initial nonrefundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AssetTransferAndLicenseAgreementInitialNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset transfer and license agreement termination notice period if bankruptcy petition filed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AssetTransferAndLicenseAgreementTerminationNoticePeriodIfBankruptcyPetitionFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset transfer and license agreement termination period after written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AssetTransferAndLicenseAgreementTerminationPeriodAfterWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset transfer and license agreement termination period notice of failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AssetTransferAndLicenseAgreementTerminationPeriodNoticeOfFailure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligation to payment upon maximum achievement of certain clinical and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_OperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease monthly rental payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_OperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_UpFrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_UpFrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4)  restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=etnb_TevaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=etnb_TevasGlycoPEGylatedFGF21ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=etnb_TevasGlycoPEGylatedFGF21ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=etnb_TevasDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=etnb_TevasDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=etnb_RestrictedCashAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=etnb_RestrictedCashAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222349413400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum annual payments</a></td>
<td class="nump">$ 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222272699320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details) - Loan Agreement<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Credit facility maturity date</a></td>
<td class="text">Sep.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit facility, description</a></td>
<td class="text">In April 2020, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the lenders referred to therein (the &#8220;Lenders&#8221;), and Silicon Valley Bank, as collateral agent. The Loan Agreement provides for (i) a secured term A loan facility (the &#8220;Term A Loan Facility&#8221;) of up to $10.0 million and (ii) a secured term B loan facility (the &#8220;Term B Loan Facility&#8221;) of up to $5.0 million that is available upon the Company satisfying certain milestones. The Term A Loan Facility matures on November 1, 2022, provided, that if the Term B Loan Facility is funded, the facilities instead mature on September 1, 2023. The loans will bear interest at the greater of (i) 4.50% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 1.25%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">Apr.  07,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs, gross</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_FairValueOfWarrantsAssumptionsDividends', window );">Fair value of warrant assumptions, dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Black Scholes Option Pricing Model | Risk-free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">0.0075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Black Scholes Option Pricing Model | Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Fair Measurement Input</a></td>
<td class="nump">0.923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Black Scholes Option Pricing Model | Expected Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Fair Measurement Input</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Term A Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Credit facility maturity date</a></td>
<td class="text">Nov.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 22.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember', window );">Term B Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_FairValueOfWarrantsAssumptionsDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant assumptions, dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_FairValueOfWarrantsAssumptionsDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=etnb_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=etnb_TermALoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=etnb_TermALoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=etnb_TermBLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=etnb_TermBLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343267688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Per share price of issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability', window );">Capital contribution related to extinguishment of convertible preferred stock liability</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="nump">$ 25,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock automatically converted into common stock</a></td>
<td class="nump">7,077,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,077,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=etnb_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable', window );">Number of shares committed to purchase, no longer issuable</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=etnb_SeriesASharePurchaseAgreementMember', window );">Series A Share Purchase Agreement | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Per share price of issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=etnb_SeriesASharePurchaseAgreementMember', window );">Series A Share Purchase Agreement | Series A Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AmountOfPreferredSharesIssuableByEntity', window );">Total amount of preferred shares issuable by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AmountOfPreferredSharesIssuableByEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of preferred shares issuable by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AmountOfPreferredSharesIssuableByEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital contribution related to extinguishment of preferred stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares committed to purchase, no longer issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_NumberOfSharesCommittedToPurchaseNoLongerIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=etnb_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=etnb_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=etnb_SeriesASharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=etnb_SeriesASharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222342839864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,931,660<span></span>
</td>
<td class="nump">13,788,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement', window );">Number of common shares issuable under the plan (in shares)</a></td>
<td class="nump">225,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding', window );">Percentage of increase in number of shares of capital stock issued and outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of purchase shares of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod', window );">First offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate', window );">Commencement date of first six month offering period</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod', window );">Second offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate', window );">Commencement date of second six month offering period</a></td>
<td class="text">Jul.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=etnb_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement', window );">Number of common shares issuable under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,844,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding', window );">Percentage of increase in number of shares of capital stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved and available for issuance as future option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following 36-month period. The options will expire within ten years from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod', window );">Remaining option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option granted under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=etnb_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Estimated total grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.88<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance', window );">Period for increase in number of shares of common stock reserved for issuance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance', window );">Period for increase in number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in number of shares of capital stock reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_PercentageOfIncreaseInNumberOfSharesOfCapitalStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for increase in number of shares of common stock reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_PeriodForIncreaseInNumberOfSharesOfCommonStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award remaining options vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingOptionsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment first offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment first offering period commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentFirstOfferingPeriodCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment second offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment second offering period commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentSecondOfferingPeriodCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=etnb_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=etnb_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=etnb_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=etnb_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222344113016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 3,807<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 2,557<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343259160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod', window );">Contractual term (years)</a></td>
<td class="text">P10Y<span></span>
</td>
<td class="text">P10Y<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">86.40%<span></span>
</td>
<td class="nump">61.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">97.60%<span></span>
</td>
<td class="nump">87.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses use of the simplified method to calculate the expected term that stock option awards under the specified plan will exist before being exercised or terminated, the reason and justification for its use, and the periods for which the method was used if it was not used in all periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345309064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Details) - 2019 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,320,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance</a></td>
<td class="nump">1,320,243<span></span>
</td>
<td class="nump">1,898,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending Balance</a></td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="nump">12.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable as of December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (In years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (In years), Outstanding</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (In years), Exercisable as of December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding</a></td>
<td class="nump">$ 30,353<span></span>
</td>
<td class="nump">25,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable as of December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=etnb_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=etnb_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345435352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Statutory Tax Rates Applicable to Income of Company and Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioLtdMember', window );">89Bio Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioManagementIncorporationMember', window );">89bio Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=etnb_UABEightyNineBioLithuaniaMember', window );">UAB 89bio Lithuania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioManagementIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=etnb_EightyNineBioManagementIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=etnb_UABEightyNineBioLithuaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=etnb_UABEightyNineBioLithuaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343231864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Taxes - Summary of Income Tax Benefit (Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">$ (59)<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222344373608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">$ 5,392<span></span>
</td>
<td class="nump">$ 3,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">22,005<span></span>
</td>
<td class="nump">10,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(21,936)<span></span>
</td>
<td class="num">(10,022)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,342<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222345786344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 21,936,000<span></span>
</td>
<td class="nump">$ 10,022,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, change in valuation allowance</a></td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_TaxableIncomeUtilizationPercentage', window );">Taxable income utilization percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal', window );">Federal research and development credit carryforwards</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">State research and development credit carryforwards</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase in unrecognized tax benefits</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AccumulatedTaxLossCarryForward', window );">Accumulated tax loss carryforward</a></td>
<td class="nump">54,100,000<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, change in valuation allowance</a></td>
<td class="num">(69,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_AccumulatedTaxLossCarryForward', window );">Accumulated tax loss carryforward</a></td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="nump">$ 23,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_AccumulatedTaxLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_AccumulatedTaxLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research, federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_TaxableIncomeUtilizationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Taxable income utilization percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_TaxableIncomeUtilizationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222349472328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss from Continuing Operations Before Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">$ (49,558)<span></span>
</td>
<td class="num">$ (57,202)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(58,760)<span></span>
</td>
<td class="num">(19,502)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_LT', window );">Lithuania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="nump">$ 9,275<span></span>
</td>
<td class="num">$ (37,900)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_LT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_LT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222382897000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit computed at statutory rates</a></td>
<td class="nump">$ 8,285<span></span>
</td>
<td class="nump">$ 13,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits, net of uncertain tax position</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(11,914)<span></span>
</td>
<td class="num">(6,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization', window );">Change in Israel effective tax rate due to the 2019 reorganization</a></td>
<td class="nump">647<span></span>
</td>
<td class="num">(734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability', window );">Revaluation of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">555<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in effective tax rate due to reorganization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation revaluation of convertible preferred share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">etnb_IncomeTaxReconciliationRevaluationOfConvertiblePreferredShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>etnb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140222343237880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,332,386<span></span>
</td>
<td class="nump">2,844,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,898,395<span></span>
</td>
<td class="nump">1,320,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=etnb_SharesAvailableForFutureOptionGrantsMember', window );">Shares Available for Future Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,433,991<span></span>
</td>
<td class="nump">1,523,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=etnb_SharesAvailableForFutureOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=etnb_SharesAvailableForFutureOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M6HO$_HP8A2XT+\#SE1!Z=V$:*$_FSO\%4$L#!!0    ( ,:B>%+/1V%EQ@0
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MLO.P36DAE6CYAM"+906HP2FGDGM=[<8_$#>R$W=[7)WN'%<;\]%LY*$L&_>
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M ?R^D]*\?K$##/\C</-?4$L#!!0    ( ,:B>%(4C/-!! @  &\4   8
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MIND83KI*9+(@=]2>";U!^(2%+QNUS\S=A[_M%7ARJ.?*;,B<0JZM62ON/-L
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M>Q.N 3R9AEF>/;"W )P"*A\#^?+T>+Q,YRUQ7R5%++BVLQ((<TTG8B;V9U"
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M5NW#.C0(QK ]=6GRJ)GG31;JY^-T 8<7?<!2";P"VOGI<KPX,/SYH'UNY@'
MLV5RW /PL"U;+EUL%\9S%1$\[T$/$,>0Q3#H0%Y8LPT:6U5C6F5X!8(G"7P(
MQ/?-<I7,^C(&9?('JN(X28=5T;J;&><#R3-#TN3D4!HWPY'R1S$P.QZGZ6L8
M",GAKZ5F->@M_SLUBUYS^;VI.4V._Q^I61PB_3M2\YW$H,MIU%$(>-9LMDU/
M:NX9M,)U5PIWN%*4'$6VI@&'1H"!'78M7)F)NY_@';2%:2=U+>(ZMC&-"JQO
MNMUQB$0 "U#@@@!L?OW5&<)%$P45[.Y.E.1KJ>*,E;$-:[H(DUJ4?,AZNU\A
MVX;%A;AO) H=/-AMA19QP[+8-6%PDU\"6;B71RUD1!EWLCIV0&P\:.=A0<36
M2ST3'F(6A#7](_;H30A;&"&9=P/EM NV\<%S:\.K0KM]%?]Q,1*<.G)1^]I2
M7_-2T0[0UI8;7$Z:FFFN"-$92'AP\'E3(_X&>UN S2-7CBS:<OL P+H::6K9
MAF53<KJGN'(<_H8%"LRBA:TK,6N.@')$$@,DSIJ(X%DZP'!XB1MT;!?M+7JH
M[!!#5'HH_]^L^04] (79B##T=]*7O1)]Y%+%&+?E_GRB!QW*H(N]132QPB&#
M)Q@5 ?]KRF:!"Y=LAFQ14[5V2>TVBWCAJR0UG_ 2Y4DYM>28;4J/<L^I@TF3
MA]+P=.O#U<S@.K,7W!ZL)*C3 \VQ&K)$_@6E33>E0BH<ARB0G'L!I!_ _Z%9
MKBD*34/J+D+W'ZZ[9?YS7QLFO8] N"%OPJ<NZN' ;?P>U+WMOJ9=QH](!_+X
M*>XCM[BZTIVW &N:+(]'S,;/6_&'-U7XI+0V'GM4>"QQ/Q:6"'!>&*2I^4$*
MNF^,%[\"4$L#!!0    ( ,:B>%)L(I@08Q$  ,@P   8    >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULM5M;<]M&EGZ?7X'25FTE511UL2?CQ)<J2;%G7)5L
M7%:4>=C:AR;0)#L&T4@W()GSZ^?[SND& 8JT/+.[+S$$HD^?ZW<NW7GUX,.G
MN+:V*SYOZB:^/EEW7?O#V5DLUW9CXMRWML$O2Q\VIL.?8746VV!-)8LV]=GE
M^?EW9QOCFI,WK^3=A_#FE>^[VC7V0RABO]F8L+VVM7]X?7)QDE]\=*MUQQ=G
M;UZU9F5O;7?7?@CXZVR@4KF-;:+S31'L\O7)U<4/U\_YO7SPF[,/<?1<4)*%
M]Y_XQ_OJ]<DY&;*U+3M2,/CGWM[8NB8AL/%'HGDR;,F%X^=,_9W(#ED6)MH;
M7__=5=WZ]<F+DZ*R2]/7W4?_\#>;Y/DSZ96^CO+?XD&_??[LI"C[V/E-6@P.
M-J[1?\WGI(?1@A?G1Q9<I@67PK=N)%S^:#KSYE7P#T7@UZ#&!Q%55H,YU] H
MMUW KP[KNC>W:HS"+XM;MVK<TI6FZ8JKLO1]T[EF57SPM2N=C:_..NS'56=E
MHGVMM"^/T+ZX+'[V3;>.Q=NFLM64P!D8';B]S-Q>7WZ1XH^VG!?/+F;%Y?GE
M^1?H/1ND?R;TGAVA=T#,XK^O%K$+\);_^<(&SX<-GLL&S_]?U/M%V@S7'V)K
M2OOZ!/$8;;BW)V\NY\77[UE<F^@B/_Q  DUG)%)^7=NB]$W$5Y7I;%4L76.:
MTIFZB/C$(B:[6*S-O2T6UC8%=F]-P'>NX3HBA>NV<.1NC:@;=FV# Y&VQKXK
MV]A@ZGK+WVW;Z=H.^]XUCG_=<I]8?/.?__'B\O+\Y=W\=E[\]>KJ@_Q]\?+;
M.3@>J('_FX'=+  WWK2FV7+KIZ4!L;JOK/"0>!;"_/M&"16F 9MX_;#V9-T_
M-* 6^T5TE3,!^IP75W4-4IT-:7,@1HW-P"07PZV:: 2.QOJSM4-DFV[0X$Z4
M>?'1EK6)4:PHPMW8T %LJ4X?BJTUH5AZWS6^ ^<;97Q'NV^3T/B6E%WL;%,F
MXU"XL@\!&E!"[<@-Z$CE&L"[M__:Q*+QA5TN :R%5[,]J>!Y 1 %1()_V5#<
M+XLRT4O5!YJ,5,E3+"S!HT#HV\W"AB'\1:.7YQ??%P\V6"!QX\=:W.WB02J
MGDD>1E^J8$$3X%/87FU3^QCQ\3+X#94EK"8BVRF#LAW4#1B&H2DFE0MO+EK\
MZ:N8U0A.2!FAP?3%/+3S\XG"1GX(ET/"#4:WXG)Z4K!KYD$8E6P6L("1][ZA
MZ;A&9+2?D:LAQ:QH;#>7,$B^R[BY^,O+N'/7+3GY"5[0F\:9HJ?P9.QM'SPW
MH*,O^T9DAHB#*BCKSL"(?!\8W;I;L*<;:V(?1!I5)@F"M!\K/N++B+P9BVS]
M6IUK17?(YBA,]3LRH"AFAJAS<,>I,A\KXK"V#ALT[3G:95[<14LR;V/G-@)!
M%$L!3K^6/9Y&DT= .$ 8V/^C=Y ?_M.@[A%-03T;\\D6=MA7/">B5FK5%>"_
M76$TZ#I1-35/'6P&L,+WMDON[,S"U:YSB53E8@EMP#)) AJ-.Q];,Z ?Q<S/
M3TLN,'>$O>R>XQ ?'"@%SWR2LXZK8V, UBF6_DVH7_2=N!-#F0C,!; #*2Z-
M"\6]J7N1'$58^0EA.8K)!%S8.?18EB6;Q%QA24&X9S =EX4^",=J5IX"+"0G
M]Y'/:\"U#]!%+5L@QR"7R'H-^"4PR8=$4=R8CN+CEQSI <$A"Y,H+I3]!NJ1
M+%6YDHI"(BN[7N);PQ0)L:83P?^"AO7>-L!WZNPWT=G/.PR(Q;O!!L=<34*Z
M]($P#R<?*Q^:X6\(VYUJDM539BVD]DV:+TT(X@6R/%4&4P!</L'.+/F'^)*)
M:U42'QBVH*MH!,5T, Q]AC_.%"-<-3).SJRZSVQ75K1F:Q:UG:EI]ERH,&T;
M_&?1:G)'%\8ZJ?K\'J(C=DZ1A#;,10BJ;ILB-3(XP&&?D^]N/32(KL4U"I^=
MP)LKK0+,@]AY(0:Q0%")"/10-3U4!"F _R(H>2"*TB/,H,%M\0V^M)]=IV2_
M+9QZ-ZP;ZDDFQ3;= VL45*N?0!@0VZ$LA;5HE6X/'BIUR\,N=,1]Z%FH6NP*
M,?0/_,KVK4))E(J6VM[;F@K[O:]6FV0J#]^@58<"R35MWS$@51DIOSVRR[SX
MFT/>#N5:PE5HJV]7 /NR@^S!UF8$,HJ, C#]XG=VJ?=#MAAMG+Y6+$D92"V<
M'!@&V4/N)9*L?X@_%#^)A!>%>/_ERU\6[!+H>YEX9(F'%7VC\&&K6?%'[\FE
MF$^B33OG9"9)IH5#N=6)H$>84/.-BP$:\&7BZ#)S]%[9^&94H^UO+V M=5.2
MYEO1JG6R9% NF6IV?SV2E%Q'H#RJC\,\"X)(W&AZF/(Q%?HI6@>T1I?]WY+,
MM+062*E+]\F:?98U>]<\UL&P+O9M2L^++3;I.GR#[1J?8]%D;]1\GI>-4O/!
M3"EN?5BYZ-!*R)HK6R(S6D; Q$<7/XV2Q"]B5KY4G=TU*=F*$@Z5M,N^ZR6%
M:*J:5M"NN?<US&"*II?V82B6P[!%/]Z"6*E)5<36Q#>JNX[LGK8$4&4^-&_T
MC--I+H7F[EE_Y_8![BH9E1F@[ :^Q0MG1ZJ4V4%>T"Z!&'+Y2G-?6;M&G*L*
M/1"4#N);!N/+@\LS@H-!4]U+<D4JJGI(#I-74E.1,VY/Z0 >\..X["D"2[#:
M=N!XV+6C=#&WB"@4+$<8K(9(EX@7OX(1I%WLBQTJN_',:4R,L5\N.<* (T:S
MM,E1+5^:4I(@2Z['W#^YGVV"9R<',^1*GI1R<<9=DL7WQ'R2\D1;*/U[UF D
MI*IL6[P^S+0V[__B=GZA%6J%&$LMG&E=1P(^%4%611N"Y>4T$O;S5;)9#E\I
M0)!6^9S45;2^[>ODP321E;(MU8O,A!$)(36:N4I&/=*9L+(,GJ^4:E9PW*Q/
MU!XXZQB?3@P&9V%[R)###Y .2P.'LQ!P% -)/FE$_,%]Z=)@:ZBPE7R%-!FV
MDS)1OY,1UR/;I88H0/ETOS3Y*E"P<%Y1RN\)=/%*C87O=F7D49PZA(4'&'AP
M=9U[3BTN[QF5@U&D,7WGO9:N/Q(IKJH-G"TFL!ZF$&B!F4QR,QWLBL;V@#(
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M83S_0!8>5)_'_ \RJ(I?+"*ED!L<9.UKG5<?5\BVX/DEZ$KA _"BO3AP F]
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MDF8;J36*_TQ-68S3.)@;7?C$4*5J0D)  ,-NI2%HFSXK<.63OV$G_-;&MH:
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M.Y1<%=)X90TY.3OO34:GEP=L'PV^*;GT:]?$D4RM_<XWM_EY+V%"4LLL,(+
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M;(#W,VM#>\,.NN_;BW\!4$L#!!0    ( ,:B>%*/C\#]$ 8  $,/   9
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MUO3G 1T;T/[:VG!X88+A[\CB'U!+ P04    " #&HGA2S1<^?"H(  #&%0
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M[!PQ-*=-X!K6V)*ST@R6GL+2>Q8ZD8;T8Y&UPTM1"$UP60M !PG@8&&M^PB
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MB6(N-.570/F%G\$TF$SG4H7DQUX0#X*_^)_)]%HJ]L%F09S06N+6L)/]Q$O
M%8#)'A ]SJZ9W_1!VF4%O_)@,,('^G'V>DM>H=5-I35$G <_>K<&;X+N8!"\
M=?_C,SP\D(^# 5[Q H@" )7!7W^8Q(/X7=!-(JQ^5A:4W0$]=P?3"?YNQ4*
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MOR)##88&9QOD*$:X<CA_D3IS(<K]LMXT8*&VM=CR!Z\(E ^43_VA$H!:H1H
M4"^\ (HY(^IL:!W3J7YXA?E%2^<;0@L'O+4K)R>='5(:.$5\[6E!]X-4UB5I
MWQ)+%QTX45-G::+4L-N-S7NN12DCW2E5G'5:E?Q9Z@H3NT2%W$-[L? N?P_
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M&;4+('^MZ'4<%R[!..57OP%02P,$%     @ QJ)X4B(1<<#5 0  # 0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULG91-;]LP#(;_BJ#S$-E.VFV%
M8R!I.VR' D&#;8=A!]FF;:'Z<"6Z[O[])-GQLD.#81=)E/@^(DW*^6CLD^L
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MD^<G6:'7JBV;3_;^'SH0] /@Y;;T_#>[EW=_^/XDRUO?V%U83!CL3"7_U9?
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MTZB_4#9$5,RR2C=S]A+!M.'E%C^^])TU[X')!U+05E5&92V(!V+O6F>Q ?S
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M*Y:(&+S:[3P)K0[>@'X6# <9P=N7Z\-F<$MR"741X;;W/P^I/^[2N$7PK%T
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MP <C2". YRLA]'YA+NB?H+/_ %!+ P04    " #&HGA2BG$XT:\%   8#@
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M) 8\F'BI[[?9=.[]X )*'('$.&FDQQ,O1.E',IMTF4U.S>P<HBPS48JF]-Y
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MX+!Q&%3BT*<$^O5A@+ZCL=]!5\N X0[HX1$&!#H 0W38D!3VG\T-/R"D86Y
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MM#Z ]^?&T&;B"S2_Q-$O4$L#!!0    ( ,:B>%+:?O/3M ,  *T0   9
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M*(,5+;F9R^V?4!?4=WJIY-I_HFV]-HE06FHCBSK89E P47W3I[H1.P&D?R"
MU '$YUUMY+.\IH9.QTIND7*KK9I[\*7Z:)L<$X[*PBC[EMDX,_U F4+WE)>
M;H'J4H%MN='H+5I4G)!<H9U%E]KRV[B&:O3F&@QE7/]N5U])\0C*L"4'=&<;
M"TI!AA9&I@_H(Z-+QIEYMNMFG-J919I+#AI]]DHV@*5,K-&MS("/8V/K<MG%
M:5W#K*J!'*@!$QLI3*[1>Y%!]KU ;!O2=(6\=&5&@HK7D'90%_^!2()'OZ$8
MZ9PJT 'E;M/OKE?N'5"N.N(*!O0?NF6"%641T.TUNCVOVSW.T2("2_!29$WG
MF>UUC3=#GP6:0UHJY5KN5GV20C43,ZJ9]DK4L_D":2[8M](J_//1;HIN#!3Z
MWT#*_2;E?K 5/N6='QVZ$9O2[,-?Z>#$"SF?>9PFG=%H'#_NV7[0;#]X#0GZ
M=(3$L-$=G@N)BR;EBQ.1N/B9!.GTA_M)C)KM1\'MWS^!2IF&"D:@'IRTKI:<
M"P2\8\7X1!AJH<$.!KR? 2;M[N0(A8W]2VD;\@54@=[\#5199_\5C\*M^>'N
MV6!IG17W3H4E+)2@9]?44%*M=^*P>1ZD==3'<&N0>' VM%KWQ<-3T0H+D8H6
M(JBH#A?=!&7T.8BO-5P<=MP&W[WDMB?N<!32;9T4C\X%&6G-FB0G0E8+[?K>
MD.PW/M+:+@G;[ISIA[<K!;8F8< >\PR:4_-KQS/2VBLA9T.F]6L2/JV^@DSW
M)S+) 3"M\9*P7P; ''4YTCHIZ9\-F-::2?CP^@HPE1#&WQW9>C^PB7=ND 6H
MM;\G:Y3*4ICJ,MG,-G?QR^H&VBZO+O*W5*V9O1UR6-G0I#.T[5?5W;@:&+GQ
M]]&E-/9VZQ]SH!DHM\"^7TEI7@9N@^8_%-/_ 5!+ P04    " #&HGA2*WG+
MF-0"  #I"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU5EU/VS 4
M_2M6Q -(C'RW!;65H!T:$MLJ"MO#M >3W#06CAULA\*_G^VF(;1IA29X2>SD
MGG///;FV,UQR\2!S (6>"\KDR,F5*L]<5R8Y%%B>\!*8?I-Q46"EIV+ARE(
M3BVHH&[@>3VWP(0YXZ%]-A/C(:\4)0QF LFJ*+!XN0#*ER/'=]8/;L@B5^:!
M.QZ6> %S4'?E3.B9V["DI  F"6=(0#9RSOVSB6\!-N(7@:5LC9$IY9[S!S.Y
M2D>.9Q0!A409"JQO3S !2@V3UO%8DSI-3@-LC]?LE[9X7<P]EC#A]#=)53YR
M!@Y*(<,553=\^0WJ@F+#EW J[14MZUC/04DE%2]JL%90$+:ZX^?:B!; CW8
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M=V]R:W-H965T<R]S:&5E=#,U+GAM;+5876_B.!3]*Q;:AQFI4Q)#H*U:5K3
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M@3E;9N9>KCY!%5!D]<4RT^X_655[@PZ)E]K(O!)&#W(NRD_VO4K$ED!T=D"
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M]RT[3/6O!0ACH/?7G*O#Q!Q0_:R,_@)02P,$%     @ QJ)X4@\*N!Q< P
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M,H>4K/K<:J#%VK6*CT*;QM/=%N;; *4-,,^70NC]P+Z@^=J8_ ]02P,$%
M  @ QJ)X4DA?93Y*!   !Q$  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULI5A-<^(X$/TK7=0<DJH$6S(V]A10%4AV-X?9H<)DYBQL :[8%BN)D/S[
ME61CD\$62>:"O]3OO>Z6NB5&>\:?Q(92"2]Y5HAQ;R/E]JOCB'A#<R+Z;$L+
M]67%>$ZD>N1K1VPY)8DQRC,'NV[@Y"0M>I.1>3?GDQ';R2PMZ)R#V.4YX:]3
MFK']N(=ZAQ</Z7HC]0MG,MJ2-5U0^;B=<_7DU"A)FM-"I*P 3E?CW@WZ.L.>
M-C C?J9T+X[N0;NR9.Q)/]PGXYZK%=&,QE)#$'5YIC.:91I)Z?BO NW5G-KP
M^/Z _I=Q7CFS)(+.6/8K3>1FW M[D- 5V67R@>W_H95#OL:+62;,+^RKL6X/
MXIV0+*^,E8(\+<HK>:D"<62 _0X#7!G@WPT&'09>96 BYY3*C%NW1)+)B+,]
M<#U:H>D;$QMCK;Q)"YW&A>3J:ZKLY&2Q(9Q>3U4@$IBQ7,T.04Q\KV%19A;8
M"A:2Q4_P?6N^W.C(I_(5+FZI)&DF+M5@[*((YAG1AH^+6[CX<@E?P &A\06D
M!3P6J117ZJ6Z_[%A.T&*1(P<J9S04IRX$CPM!>,.P0C!-U;(C8"[(J%)"\#L
M# "V #@J?'4,\2&&4VQ%O*5Q'SQT98+0)NC=YMBUR/'JE'H&S^O ^W>7+RG7
M:2L3)BR8@QIS8# ''9C?=U)(E;"T6%_!E*[3HE"W,"4JXS%M\[G$"PR>KB7/
M$^0I!P?>R'EN$>+70GRKD+\Y*61[VOT3QB!4U<QM)PQJPL!*>/=">9R*=LK@
MA/(Z\+P@:*<<UI1#*^5,QS3+VBF'IY0#=Q#B=LJPI@S?G]\[<[4D=QJ>36XI
MMF5<&(5>Y+>KC6JUT7MR0I89!2+T3%=KB)I9W[Z.2C71B1K?\]UPT"X&N4T)
M=:T+[I?I%:J WCQ3KGH?'.8,S'GZ>P#?<AR5:61U^0P'?'R!5H3A43B\OM<5
M#-P(Q7\B] HL*[B"UN&N->&H/PP[1#45$7E_)LJZRBOP-[(&?1QUJ&IJ*K(7
MU;.JK(6@ G\;K'XX[%#5%%ADK[ ?FFGG2T7%UCG-*F?\4V<0[@^[8MQ4;V0O
MW^_-?'<M:6_I%6WX)OA^UT1M*C\:?JR4/%"]%]<QGJE-"U>[WAW)X ?E.5S<
M%_!*"1>7M@K3= !D;P&?H[XZG@^M^;>S1B4.8,C+31GV("&O;1O#V1FHL((:
M'J""%J2WP6D:#K)WG,\&Y[.SRZ[FX"DJ/87HG*.XZ678WLMNUFM.UT12N%=N
MI>JX%L-/DNUL70PW70S;NU@G^IE9-*MP_>,JXGI^QV82-]T*V[O59P5-*]QN
M095N?++GP'Z$.NH$;AH:MC>T3MV?GG(5X;%#" 4GFR/GZ*B94[XV)W !,=L5
MLCQUUF_K4_Z-.=LZS?#R+X)OA*MMBH",KI2IVQ\J;EZ>NLL'R;;FX+ID4AV#
MS>V&DH1R/4!]7S$F#P^:H/[O8_(_4$L#!!0    ( ,:B>%*@&@#0T@(   8*
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+56;6_:,!#^*U:D29O4
MD3>@4 $2+YU6J96JLFX?IGTPR8583>S,O@SZ[V<[(4!5TG5JOQ"_W//</7?8
MOM%&R >5 B#9YAE78R=%+"Y<5T4IY%1U1 %<[R1"YA3U5*Y=54B@L07EF1MX
M7M_-*>/.9&37;N5D)$K,&(=;2529YU0^SB 3F['C.[N%.[9.T2RXDU%!U[ $
MO"]NI9ZY#4O,<N"*"4XD)&-GZE_,_=  K,5W!AMU,"9&RDJ(!S.YBL>.9R*"
M#"(T%%1__L <LLPPZ3A^UZ1.X], #\<[]B]6O!:SH@KF(OO!8DS'SL A,22T
MS/!.;+Y"+:AG^"*1*?M+-K6MYY"H5"CR&JPCR!FOOG1;)^( X/=/ ((:$#P%
M=$\ PAI@,^=6D5E9"XIT,I)B0Z2QUFQF8'-CT5H-XZ:,2Y1ZEVD<3JYX)'(@
MW^@6%/E,EE4UB4C($BF6*/1$;Y([BMI@6A09B^@J X*"U%AM.Q=Y0?DCH3S6
M%"O%8D8ETX"/"T#*,O5IY**.UOATHSJR6159<"(R/R W@F.JR"6/(3XF<+7,
M1FNPTSH+6AD7$'5(Z)^1P N\9P*:_S/<'[:$$S:I#RU?^&+JR8*I*!.JE$!^
M7FLS<H60JU\M3KJ-DZYUTCWAY#))P)X4PBIWJ-U)7<SG"M).%?@=S_OP7-Y>
MCSO2TFNT]%J)!L,9$^0:V_X+_8:K_W[)/V^<G+]=\MNI@O!4\E^/.](R:+0,
M7DC^2B?_AG)]N>MK',_,\>^T$ \;XN'[5<+W]O><]W:U>('K]$GX#^"QGH-[
MVV^ENI_.2%63:X9I23FC;;S!GC=XQW+L[SX_?,-RM'/YO9/E>#VPTN,>O*@Y
MR+5M-!2)1,FQ>G":U::9F=HG_,GZS#0Y]J7>TU0=T@V5:\85R2#1E%[G7%]^
MLFHZJ@F*PK[;*X&Z"[##5#=J((V!WD^$P-W$.&A:O\E?4$L#!!0    ( ,:B
M>%(Y.I*3S0(  , (   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;)U6
MVVZC,!#]%0OUH94VX9:0I")(3=)J^U"I:MK=9P>&@ IVUC9-]N_7-H32<-&J
M+^#+G#-GQF8&_TC9.T\ !#KE&>%+(Q'B<&N:/$P@QWQ,#T#D3DQ9CH6<LKW)
M#PQPI$%Y9CJ6Y9DY3HD1^'KMF04^+426$GAFB!=YCMG?%63TN#1LX[SPDNX3
MH1;,P#_@/6Q!O!V>F9R9-4N4YD!X2@EB$"^-._MV;6N MOB5PI$WQDB%LJ/T
M74T>HZ5A*46002@4!9:O#UA#EBDFJ>-/16K4/A6P.3ZS/^C@93 [S&%-L]]I
M))*E,3=0!#$N,O%"CS^A"FBJ^$*:<?U$Q\K6,E!8<$'S"BP5Y"DIW_A4):(!
ML+T>@%,!G$O I ?@5@!7!UHJTV%ML,"!S^@1,64MV=1 YT:C930I4<>X%4SN
MIA(G@D<2TAS0*SX!1R-T,=V6AXMHW-A!*R 0IP)=WY_D;>)P@ZXW('":\1N)
M>=MNT/75#;I"*4&O"2TX)A'W32'5*I]F6"E;E<J<'F6V@YXH$0E']R2"Z"N!
M*<.L8W7.L:Z<0<8-A&/DVC^08SE6AZ#U?\/MQ8 <MTZ]J_G<'KYUP1@0<3M
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M&N#SA93F96$'C7*P'/\#4$L#!!0    ( ,:B>%*I6%87)P0  +T.   9
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M0]W:FJ,SA]WN::FT"&&B7J@6>C2]Z)\VK1NH1U(K5GK6?KK#4ZCG,G<Q'9Q
M#8]F;@%ZXY\B!J-62EN-F6:W>>X\^"%_LC]USR _RP]FJC?41Z8W7!HB8(TF
MH_L^0M+5LZ1:6+7UDWVE++X3_&>.3SG03@#/UTK9MX5ST#P.)S\ 4$L#!!0
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MKH(O(*]N/ZP*XW"FZ"KH7I$-H3J9))-<)4PU:0*R#HT&@J5@1_'9',XZ+WP
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M.'8C@+D=A"&&P-V((Y@#\( A85B]!W?>1_[Z/>5O?JT=_0502P,$%     @
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M]!-02P$"% ,4    " #&HGA2!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,:B>%)E\5;<[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,:B>%*97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ QJ)X4HU^_MCT!@  I1L  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,:B>%+/1V%EQ@0   $1   8              " @38/  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #&HGA2D70S";X"  !'"0
M&               @($R%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ QJ)X4BQ[.C(Z!   # X  !@              ("!)A<  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,:B>%)<R]+(L08
M "L@   8              " @98;  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #&HGA2&N.OF9("  !<!@  &               @(%]
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ QJ)X4C9M
MZHTZ!P  +R   !@              ("!124  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( ,:B>%(4C/-!! @  &\4   8
M  " @;4L  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #&
MHGA2;"*8$&,1  #(,   &               @('O-   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ QJ)X4H" +DIQ!@  IA   !D
M         ("!B$8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #&HGA2R3XTH$X#  "E!P  &0              @($P30  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,:B>%+98@Q&@ 8  .L.
M   9              " @;50  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ QJ)X4H^/P/T0!@  0P\  !D              ("!;%<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #&HGA2K6\3
MN>4#  ":"   &0              @(&S70  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( ,:B>%+-%SY\*@@  ,85   9
M  " @<]A  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MQJ)X4N,*'9?R"   H1<  !D              ("!,&H  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #&HGA20L)YU,X"  #Q!0  &0
M            @(%9<P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( ,:B>%(B$7' U0$   P$   9              " @5YV  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ QJ)X4MU_Z'HB$P
MXST  !D              ("!:G@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #&HGA295\=8<D%  #8#@  &0              @('#
MBP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,:B>%*)
M;BNI+P,  &0'   9              " @<.1  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ QJ)X4L*$]S); @  &04  !D
M     ("!*94  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,:B>%(&:<4/@ ,  . *   9              "
M@96K  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ QJ)X
M4HBVEZE;!0  7"   !D              ("!3*\  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #&HGA2?PE>Q3X"  "M!0  &0
M        @('>M   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( ,:B>%(T2HCL!@,  !X'   9              " @5.W  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ QJ)X4MI^\].T P  K1
M !D              ("!D+H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #&HGA2*WG+F-0"  #I"   &0              @(%[O@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,:B>%).%ZL2
M70(  %$%   9              " @8;!  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ QJ)X4E_NPBNW @  2 <  !D
M ("!&L0  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #&
MHGA2V0YT\C4%  ">%   &0              @($(QP  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,:B>%)$[E#J5@(  "T%   9
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M970T,"YX;6Q02P$"% ,4    " #&HGA2#PJX'%P#  !Y#   &0
M    @(%@XP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M ,:B>%)(7V4^2@0   <1   9              " @?/F  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ QJ)X4J : -#2 @  !@H  !D
M             ("!=.L  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #&HGA2.3J2D\T"  # "   &0              @(%][@  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,:B>%((@=>#- ,
M &0*   9              " @8'Q  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ QJ)X4JE85A<G!   O0X  !D              ("!
M[/0  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #&HGA2
M>1@GQ.X"  !O"0  &0              @(%*^0  >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,:B>%*P2]9IG@,  "@*   9
M      " @6_\  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ QJ)X4C='*D4D P  S@D  !D              ("!1  ! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #&HGA2&@'8TE$#  "Z%0
M#0              @ &? P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,:B
M>%*7BKL<P    !,"   +              "  1L' 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ,:B>%*TYV];"@0  ! A   /              "  00( 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #&HGA2CF$X^KT!  !Z'0  &@
M            @ $[# $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #&HGA2G"O3#[T!  !W'0  $P              @ $P#@$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y (8/   >$ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>370</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponents</Role>
      <ShortName>Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3LiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements - Summary of Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Consolidated Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConsolidatedBalanceSheetComponentsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableOperatingLeaseObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Share-Based Compensation - Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfEstimatedFairValueOfOptionAwardsGrantedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Estimated Fair Value of Option Awards Granted Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Income Taxes - Summary of Statutory Tax Rates Applicable to Income of Company and Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfStatutoryTaxRatesApplicableToIncomeOfCompanyAndSubsidiariesDetails</Role>
      <ShortName>Income Taxes - Summary of Statutory Tax Rates Applicable to Income of Company and Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Income Taxes - Income Taxes - Summary of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes - Income Taxes - Summary of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Income Taxes - Summary of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Summary of Loss from Continuing Operations Before Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossFromContinuingOperationsBeforeTaxesOnIncomeDetails</Role>
      <ShortName>Income Taxes - Summary of Loss from Continuing Operations Before Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfIncomeTaxBenefitExpenseStatutoryTaxRateToEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Income Tax Benefit (Expense) Statutory Tax Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="etnb-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>etnb-20201231.xml</File>
    <File>etnb-20201231.xsd</File>
    <File>etnb-20201231_cal.xml</File>
    <File>etnb-20201231_def.xml</File>
    <File>etnb-20201231_lab.xml</File>
    <File>etnb-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001564590-21-015214-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-015214-xbrl.zip
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MKGN@L/+G8)_8(S4G2?91,)]I/5DFX=^E1OD#F58/7"_^L2H@Z!MOBD84IOM
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M,+W:W*DKKJY8JU8"9_75W<]!#N$-Q[?.$SQ-A8ZPN+-MNK?"X@;]\=G9.+7
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MW%76UF($[N+R\NRLTM($E0VJK7BA;4;>UEV/;2NIO^X68W+K[DJU93^0!1X
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MFNIW1]G/.J61!2(#*?0#L?5G'8!@N!YF;;,,34?[1^@0#;57)P;=,H0G?(*
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MXSZS<#BH,+!@ I[F%D<;V<*HT9/15DD5(I+)DE;_T:-HMA61#BG[,O%.E:Y
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MFB6LXBIJQQT7*SW/61\<DT:B6#PT8;RXH5L.[PJT/B4VBRW!>U/7_284 -#
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M]^^%VHF?N#&1/\37)<W(?2V\?W7_-?7Z'VZ/+JD[&'6TK#A8IX=7S%?S\9J
M$*3EC0<*D5XI'G/.X)UVG;[#3WC^"VL@P*Y:0#OC!ALC_4G;G?S.CE.C\'XL
M:Z+6(S 3)A%>W5]K%\-^9\.KF$9HX5-?M85K8L4&T]QFL@@ONPCA(I!%,A)U
MO.!/]PF@VF&CK>B?_/8'@'5\O4D\>N827)V3-ZUJ\3EFN.9$J8+%ZMH_="?$
MFSL''< %;BWV2NCTO."#;\<4)XO'IZ48'@D\-\I#8)48<9&+ ^2]\<5E]C5>
M]!*MU[1,H2E@?&.B9L$FDR3P#3>.)'=@Q%DSFG#AAM J. 7&(Q)S(G?>>:X#
M?QM)\D^;.G2? NZ&3#U*QB!/QES$@;2*)11P)/[2[0^%+..2(H?=J)>V03)B
M+3LXBK<.Y_4H2L5/!:++5NA56OP$2,L<"D=$G;JW)<T6;[77^D^:@3V5$S%#
M@,CC"70VQ3OM]?2G2.S@M238^#>N<4,QR58"0_D^;4)"!XB*:N%W9A0$N<_Y
M[^C:7QNP%KQ9!2\"@"TQ^1N?@_"[^G*WQ>Y*86,+M[?0X@W@8 ^3FUQ6;D8O
M.NJZLVX808Y*4#XX?X5^ZD:E= LP;/#L&"9^)O83]EMQ@GE6Q."A9B(5L8:$
MUD!KZ%90?%!!#?(!($?3/,"7!H:@-^'H,YA+^P"\AC$<;7#>H3HM,JNPA*WI
M:,-!3[OR:5[Z@B G/FJ/GOL,VV7UT:N.2.#KNQ&]]>@S3AR5\<73C9@2&&I1
MBWG/6J3J:814ETTOC](Z"(U61C]@;T57*'&.B"3X+*.A>*I^&^+[YS>AWWW4
M]>7;^Z3'3B(1[V!\ U#R /+FO>T:WW[]S__0M)^C=U#+4R6?6!')HYIE_O+J
MYJ]^'P V>44+.>&G+V3VRZMK_'8PN3@?3$9_H5;M#_H#^L< ?*Y7O^Y&J907
MOPUD+: WW_;QZYW*R:A/Z&5Y+J9*4$IE524LGN1O-#82 N4R?<-M;]Q80J;
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M6QL)8$R>7!#=#W$(/=!FNN6A7 J)YCKPGH>VHH=925/=MWR8SW(]+7 U"U
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M4(;?.L(@?P"\",8*_-H+F,$#MA6LZLYO.=JM[^G$7KM5IO02'@"O%(H:/+_
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M%DD]DEC*V^XS2)KN E#@ ZG8I&M:CYB"#>M_=CW;!#N,: XPKJ_;A'Z-Q
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MLTB0'G5F&+D&5]13$CP3XL0Z!,\"+.)'$M4/;7IB^L/P/&.+ZK R0#Z\0L\
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MM[=%-/<<:YV)#R/9R[[0*R1@B620P7&@K;/)L%'/--UENQSA)@]70BVJ#4:
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M740X<$D1E6]7KX4^9GZPP]O(<&V#K&^&;0 J2'14A34 &;8!<GTQ)V1AZJ@
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MS*4K%W8HGLN?*^D&LN[1DCO,F@X#U@"7]>&<5\"STV8-]:&53XALVZV9"=4
M_%;MVDF))*-PF0])P\-\R'S(?%CI=#\LVXF,&9'@\?[WT(!%2S]EV7<E5J:P
M$+_E7VZT"K<SP %WF6Z[BUH@.X1-9Q96<>XYUB$(E*NIQA? 3R7OX,@PA V)
M6PTV+6S8P219 *'>&S^<.]%_-7[*X"@+,NF/SG^K><M57A5;K4KIKX?):I;Z
MMB\7CC3#1[\_W'+S6RE<&2HGC5PLX$J//\J62WD+$<KERO,-_[[L-2P;G@&T
MG[G'BFRYQ%R&/Z1T!;Z9:?C^/7RZ].H:2R]RPT# NQE!(/=8G*U7<BWAV,;<
M=NS0WN?MMEP'=K18V*[AFK;.FBFS1KX$F,(J"[.*_)475-BWN!X(4;S"I:\3
M!=(2N"C5I5 D+]477\ 8L!>V"<JB[!K#TZQ \51Y-Y0H6*)KN)+AWJ<3P"Y>
M!<*JJK3P?:MN:1_@"V#Q'<?[4?XRSVT45B\*8$L$+W+]/HY Y_N1RFZJSQL7
MRNR(#;@_G@V>"5,Z3OR*Z;]CXT_].S8K37@HZ:=&9&P!@N'E&*M ODQ^>"6T
ME7@QR!=[;XYEG-I2K9ZJF#M4Z/<_QJF"/0+T\S(4!+,$@5U@U8(./#$L"< S
M?5;G*7]\WI_LEWW_I+*5/XE4PK8"D%?*XGHC3;F<2U^,AST:XO:$)>MDL#A.
MO7I'V:IYRI&IBS(Z*76-:J6NX>1XZ6>=([?1@$X9&=-9W1@4U& I03J]GFP:
M>*PEFP_U:# DD\/"6K*<T<_-D4_DAOK6_])781MO)7T#'?G"\8) QSO@ C\,
MWPI*2@_WLJ1RX")1)-3)+(2RF4%DZGXXZP??=CCLC<]'9+'D!IA4D6&&HH($
M,Q0S5)L9JG<YG)*%D@GJ>(??DWN;.G/X?1_XAG1.=?P]O5>0C0LJ2+!^HXH,
MCW+(X!KW+B_J+EYA&6J>##'/4$&"980J,LPS&5SGO?&(>888*!R()0W/9QE(
MPS=O!98S6?)..MYJ"4\JXCY''(1M@/RPEXV18>O@L8Y"O?$EAU*)@=( &6*>
MH8($RPA59)AG\M[.\]*)ORQ#33J%<D3T6/!<F:8?2:OJH9-=TE0HA]UIW46&
MC8$,KNEX0A8GEB"JR##+4$&"980J,LPRN2/G>=V5IBQ!30I[UC+*E3YF'\-;
MZ=?LN2'=6X:T--7N6.-I=,U%CP?)'WBNG91-M.)A<YT4/>8UTO PK[43/>:U
M \M9>89J$V#B<"YI>+YZH>&D'?Y%L5,_22\5>]RI(,'],AH+'3?..*0]Y*@W
M&'!PF!@J#9 RIBHJ2#!5-18ZIJJ##L6]P:ALZ0Q359/.P!QA/BEF'V00O,2U
MCXS0]EQAX. YPS4E#:\3>^>;YM]E[WR3T6/O_&&0/A\->Y?CNMM-LHN^XAQT
MIC16BDQI[42/*>U 2JMTN&9*(T)IM06;=QVT+2_"8=^C?O=X[N\R)!A_WF&3
M=!BK!KB+#Y^!5\"STT9+V4$/9(( QT.V[<;,M.XRM&UVS%;MVDF))*-PF0])
MP\-\R'S(?%A5DG^9C8:CND6Y4<2H,4D@V85>O1'UWT,#%J_$JA06X;=#-NGN
MY[3LNP.?9K3V-)/^Z/R@!SH!#&HVL/]87VKU!V.M;YBP[,!TO !^!7<2X:T4
M]W 9(>'M+/%&FG(YE[X8#WL"QW.+']*78N7+.]N+ N<>[KKR_! ^:KOJR^I#
MKA?"E4-/_<;T7*44#?S4PG8-U[0-!]8:?H'/!\\%_\''EBMX2WA>;R$\K"OO
MBZ_P=5^:CA$$]L(V=0; K6'!#82]!$F##[M[WF2?M^MGN^. '3&DN"6NE.<&
M_YZ\@R/#$-08*BA0=2_/!OW!))$/H5X</XW_ @"2I7GD(MNOH9=T-%";#M>V
MIU;_&E V7-PV)FI5J_3UC2PGI/PU\KDDI:X *_7K:-B_%("RH])3X&U_'<(7
MDM_T4"Y7T@QM$,C[WJ-W&FZ^$4A7?)TJSYKX]TI?H^@7+'4)>(W(P?EM99=B
MX7O+2B^P>6Y<F4=!M+VD!4:YYY&@]7S#OR_["):] $PE;.*@7_8:GR584_^G
MM6MNE^2\P,(&HI KJ?2;B$!1BT441D %H$U=N'C0$_8"=O^]%O,0])VFFZ47
M:94.YA%R$WPE@H?U0\-VM8+/5,)-Y!@^< K>$_]3EW+L[]*Q;ST/GN?6"(4=
M!AN?\ ?(FY@KOO#N)/X1-TKRF/!!M#R I8!GU*/U$GX"M8HO98?P;<<&W@S$
MW$ ^5*^)G]":&5_"N#-L1UT("-#"54\>"E=HZ?GQ\][CKUWD0?UWT#0"^,<0
M2)8[EEF]!'Y+O0BB(N%!C4WY;WA#&: ]90>W>)5;WXMND/V%8?T["D+%_?".
M\2OC76+2U^N^\9JN";?%EY_?@Q[+:S;00*C/>S&0*]\&"K25!> 8,=T'8),K
MHL8[QRN.T@9[4]W2A$6YP;MLO+D5^;"38M9P O7D3F2AX2+ Q@Z1T.%F^'RX
M?N&6=S!N8&L%&X,9>.=XE*0527QBP[Q%R)>QW0&;!W]:^=["AJ6U'3N\5_M8
M;Q34OZF8Q#NK^-G8"OHWO$I@V6:H&$"OF"63M=WVY+CFT\L>6/7):N^+U+0_
M*0*%?%L2J/?A@]6'93%6ZFWW6/<<S:>GN8M7FX4V7JYOKHUVVY=0/5\,#?[A
ML_3\&\--E).2)<\T(W6=M1?-5F37^L(.AO7M"_UHP^D@UH4'&WVS+:<2;;/!
MCG!LLV#8S3W'.L0H/-#>2S13:2JZSC%BZ8M\!6P/,3P_J$VG1.P:,+7C@&-R
MN5+03$F:XR)G58O$.BX:Q;=X$'+QB!8M(Y35QW'8PN@;S9RR%T/>6X&:^PF*
M)$1N^W5RWA^NF;P7_7'Z&SQJJ2,I_DGK6UM)_2KR5W#4#(I&<5]L7)WU(\/#
MU1$;7U,\?-[+]<<=C?NS_1^W+]Y)2_K&I@'$L(]NI(N_@><Q%K"@^.@7\$0N
MDC@^F*W/UNK9<$O"\=16SS6/P)8*[=3V2DP8QUXJ?0A*<#;X3>G<HOD2JTUX
M$#LQBS8^&5I;<XF_T+>15E_DQ3Q=0)FGQEOC3N()&_C.]O63X;FZ_YA@;]U
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MNQUQ4M!35M;T?#ZY7]+#MOVB!V]57;"*MJN:?E:CV!02_DI=X7^\'Y@8HQ-
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M4WI<*:'2 +6XAT.BE0+3 &B8L9BQ6BZ 61]5BG@R;9%%AFF++#1,6TQ;+1=
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MX?WVUJ.S[K4>3;M\ZNZ=L.CPU/!$ ;P6KD[2C31>N[0/*984"5GH:R?&PY[
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MR6#$C?TZI1"[U-JO>>APIROR^I) <S]F*]9RS<6&=1QY)+F;'W4YXM*3VEQ
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M#.67&UK5J*]80CWPRL5!<%.H)#5&$_?;QBXY%*&PS:Z[3@I;@/](\(%N9#U
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M3.>9XUE_?_S/_Y"DWUZ/=.J&]M1V(ACL'EF1;X<V"BY_6$XT1=,KWYN?DV;
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M>EV'9!Y)BBK-,3'/P0GM,%;@D%(/V4\^P_#.\@Y_!RY/Q@7L:7GL4. ;\J
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MEF@K']*DL6QQ)IM>]GI[C>W[L6UK2K&3..5\3B2F3KZ"=T1ILH1L%:C:MC\
MQN,F3VRK\UYZZ-YNVDY_:]M."VA-]I,M5-5(DWL;>NWT.;* *XIGU*'JODO0
M;H]EU.66W1/UK@30CI[M94;U&N.8K"Q;:RM*UU/VER FA+(1ELG.8&P128&G
MZXVO)>.K[:_J8S$93K:*5VPXO2_ZDWS1V1)#2BXN6>P7YE?DB3A'X83=-'=
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MP=F!Z%S![HBZ&5,F3\64\.;O8"0.S*B27GR7.R&F5K!U\ #.]-F=+EU/ (E
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M;@O;>Y*@7WA-7O/P/\?H!Z'ZVS);YS?K]'C+]<5__Z6PEI"C_/)_4$L#!!0
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MFC"KB#6)$X8J/ JO.(_$N2[*0_Q6,:;;ZZ)X,89I;6XN(:PY3'(LX=]@RL?
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MZG,9:FY<6Q9\M YTV/6VM2ULLMZVELM[5I_I4(V&]=58J\]YJ$9$WE*ZU<=
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MM'QE6.W&*?!0V,>L#K*5-489A!394JM#;B6-VMO^DC]R6GTHB#8?1?Z1U8>
MZ+>27%^X\D$?#4SZEM.6=*59')JPL0&S\GQ/JYB=FNJI(3#HBR[+EJL'.B[H
MI@23GO2R;/BPL;-.+!JR9RR"U')-!/F\VFLSZBNS$8;$#D3J8LZS5U,K,5$H
MNQ'$:<"-<GZ.&)N/*7M!S*M6[=O$-H+S^V*+]\#WZ8M85ZF$+TM<([B4$SSS
M)#2BO6)"9_;SS3LZ6W%ES TVN;=ZLJ@-/JL/5<_%W"DJUGOG-C*V&4RKIXH5
M."D<,:V>'54@1MNILOJ<Q"J]*_:Z*Q]FF#M[3'X0_XP0Q[_\#5!+ P04
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MW8;&@7TW*LE+S5>M/=?]9%9_%J3/BWA%_W/Q^RYZ"1#->1;969 D^RA^^B5
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MPR5[+DA^F7:QH>N=198ET>,NHTN>!WP;Z"98!L3-T=-FYN0*U!J2_$#L#)^
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M!@W:Z)M[#[,,B>Y=K5>:]1M^#N1BJ;^Z%M=QVN*FA4S*UR \M%Q#JVGKN6Z
MDY'MM^P$F85--6*&EJQ"W(G!\LV'B&]4K?A&%9_+/(RG6GAB;=6:M55N,F V
MV:O7UE(D9-H0N8>PFV['S9&.L?7!E)1APUI:]!HBA29+EMZFC3,>U#\4A;)E
M_F2XS6_HFM/;.8P'U8<BWJ\5>^!G3D8R11K8#9U!$G@46FDS@%*6O@>,"M=?
M_4NQ#F^%V/;=\<;2?YZIZLUJZ=2YP/\A>%VDQ&_4\_.&;QK.Q@>4G&1(.1>0
M!:\@8'Q\2(S: <#=ZC'*GN_@2X!V3"-6]R.TZ1J:BB8?)X8DR3"K/093[/$0
MW1M9Z6V"0PA7Z241/@]WO,YP7F98V3!52!G:8C]I)^:7LP44VG*FJ[T4]\'@
M-&#$FCHU,JNN*RGU&RD/,-E<XR"^#$*]2#B,B:$I#F'JQ$A;K^-]XT*!B%8\
M*&[=?*.W;D@:MP&(2 ;60C0?C-B*T6!K.)G&TRT)UOM%O*(K@BT%*K\ EU[%
M(=JMX.HJ7H0A/6Y,;X,]/6K4B;%&Y,WCK@$[5[&8B0*">,56GTR8XJ9I2LR<
MBT/M/1 "@2V7R ?K'F@9V (D W:!]2H%+8B+L:HJAJF$59Z#-BZMR.!P&]JL
M#$Z0M96]\<%37%@<=H5JMT]9[A1!9 [2YTN$OZ6+QS1+@C!3\2DU.A:Z&#30
M==3/@&ZN$5: \0*_YMQ\:R?1!5A38XE6!8YA9I4'!/KM<QJ_/J!W]R$Y!TW3
MZ6N58OKTPWBZ8, *^O%0Y<)]:P]#)NJ[<P,SZF0DD7J)2*YTNO^:THQI2=*J
M@-:L6)!UP0LKZF428TVHFR.FS\U%R102A]<L#K-]$IPS!T'!_6<_7&L ]'BX
MTN<'L_!;>KV;H9P+ $[W@(I ;[H70H!2"J4)V8ES$PG744:OBNLXK?PM<Y1*
M*E/=L!_+CQJTC-OUX(]&A3USLCW-O-V_.*-//>(P0K#R.N,!.YR=W/"W].K'
MDCP.NL)+SWW(4CK)Y62=+ZA7TM_2GT,:)'<IWX3R>!YT:H9MC\ZLPGN,)H<.
MK>T!@T)$0.< T;J>2DG_.)-9^1QNB=-$?.=*(UQ5OV>.N4S'?GB0J?OAWXWZ
MQEWZ\$FW2$>M[KH'GM8?FFIMM;50&-C)[H#B]_9TN@>9>BO!%GWYB0*2  "G
M!V^&A]^MLWW[ZQ.7.X9/M.IG$0T/+G_Y)WD]T@B1"7FPL"3R)/>G9$<VN3PU
MTV&CPQ$/OWWK9@$8A@EK/;'88"+:WX6BSJ.4G]<NXA41=1/M-ND5D5[D@5I+
M/$,. S)J(XXN8H\L +7Y+6<+R+^"ER!"]"C\S1HG;]* V$2JV#IKM%79,-O
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M^04'KM'#S[F#=/+WPDU")J'H$QXQ&<%N*WUS7NZB9F#Z3J, Y#$84[7YAZ6
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M^>$;_B\8)&5I"O5[(M88FEY;L"2 F[LG!?8D](*48E]><P KBOVFD! $5$2
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M6(ZMO8,[V)'Q@8P.$(1\A#Y<>?##?; /TJA<KK <A!I:KNMV7'<>@JS(.'(
MLB"SC^$GY,.B :<8%_D,OQV;81)=(("5X='PU!J2YAQ_;'K.T.ACS=J.<N&[
MA4F$R7!)B!9KD5/X%,4QS08? S*T<)ZKUD)7].T+O8E^%8=HMX*KJ_@B2.CP
MS XKW LU]1I%04@7C6]IW.5Q5#EGH_$W(8(!>BV/1->$A-<MC%.8@A^C.,0;
M^(<3$$-/'M2.;]?6E]/*IO'=V+";!7BY;<A>[K&'-/D(R \@'\/PZW4>I/0V
MP\BMU17@/]1KS<)S8,H1@>4:2&,"Q:  &Y7D W1<@ T,G$T-C#=+EVI-MNZ%
MA\:BXQ^:M63P.2;R>( 8$'C H#HDZ@RM#C (D]DL02[B_)$R^<F#U<> @D*_
MY*GL PR?X^CW'4S-[T@[D6/:@DMM<HU1[6M0$:9"<%!*[NE5:I?F:[D86+<Y
M'+.I'DXUTUFIVVAZNB]FCC,4I*EN#]T>0A:,I(FP@SO815;+F'@6-#I1:O+Z
M=J5YC<BAWYWN00V::1KQ6KS[65??.=X$43S1#>TV8;RX)=LLG--LY/' WCP+
M!<[MS\TE["XHC][67%[/;@J07/;!S6/Z=[8TV\BH$S0\^%9EX.24^DQE-].'
MPV-M7+&1>F>!8;6MG,*NY_"-N'$'B#3&-M6+M\/%G.XRI(V"^=323-&^T96+
MPL5VF^ @?&8ES0NN?J0?/0AA-;WYB0:J U'PF&:I<3A6_15".PV;&+C*Q^?J
M$^V9=+?N?,6DRS-T<TQ7OK'<LG/9) I)UOP%KR#2+R*@0]4F5FU<['O4*0K(
M1'\?/I,_I(#S!8(Q8)Q]]:E>?#N]K%O#\\&RPQ.;P)RLV6!YALD6JP]DP+JI
M7#N- =WO6F@Z:#PH'4GS]3KEY8=S]:*#537F*Q*H"X1ILKFF >OG<UU4[(+A
M*J>;FV.TYW)]6O,7CQ[WF":EJP_Z_CE(()W-H$&SVEY:]L"ITW90]YOMSC 6
M?OI)*U0=WM*L-M]A:?4<QHYCY$O2=?$*DS!*;?E0(SE[>#60M^]).1.?G:D+
MM@Y_:M7?#"!J]:HJ7OXXUA:&]-XK3#8V_.J0FDW,ZM1=>!7GP9N\_L@*Y_[!
M5^=JA:[3MYJ5Z#],'9XE8^:)8S$O_P6C(-,\5=8D: ^W1@8./:QDY:=_=2/8
MX6(=BIP%6JV.QF>NDJDOOG87I;]=)A!>Q<308)K=!9F%)+&+JCT<V[DX>/A*
M>+U9$V8@YP8H.S_=3P'4#A_L4^M\ &SU1LH87!Z@.7F)7[LWX*^G:E#?+8MW
M+P6NQVQC[^#)P+6W58%=V[/[%R[7UJL%>VV[R#>S=1)O:>>7JSC-$G9?LSXK
MZ43+/DKF]M)-V5&D.I@I_8@GBGAA/>WYC8WP1-:DJ.2E@] (KD-W#<S=A7_;
M%@R4VO?L%A4L6EVAU))_>F\Q><I@9"N_#Y_A:H<@+6& MS#)]K=$+1F9WBY^
MWT5;-FS=E^+J-,V14>7AX'!2<.85$CAOP)BSI*!@[]<S;&V<L:FNYX(IL@VG
M$_\\PQL2A6%2R*&_9=5*PARI%I(N7J9P1B4.?KA3'RQ845>>0H#:M*^_;]16
M 7>7Q%%&4@WB9,OU.@JA@86K4C*M)MM'V4W-UYPKN_J/&5\ <\8^/*-3QP[K
M:=)OG"K)<@4DSE0U1GDT)%0?S:)A-%/M%;<F 4:[O2K4S*-Q/W4'I04[LQ7O
MMDHUX,3ZBO4?.F0-M7&][7."4SN>)B@Y@(I1MN]A#Y@6S-OFB-%0#_W*0Q51
M4W$H28=^(Z3B2(S=R!ZT"$D>MV/U%,_A-H$A+U1!?D:0_D D7&QPDD5_YQ55
MVU2EXVOV>)IC;DN&@=;QB5M'#)^H),*#KV&:_@R"4D*PDD3TPX>MVPUVA<WL
M;:0:022A@"P5*,1B4446K'.+R$I9U-:AWT!;9V%T5E.8X10JU2MOHY?*M3.&
M%Y@\XF*>KH G*NZ#-4ZTIVZUO0MB-\D.KNY@"HF;/Q.0SFG?;,R(7W#V9[LD
M48SE^C0-U\D:/)SL; C^(!$",%16I0@%="$7PH>]#A.LL:F^NWM)6<KS@SW=
MQZ;7,IA\ 4H7CVF6!*%6XM%)9D#^V$[6;O(H^/  +SB!7W->OBR9%;#"&LJ;
M2]R0UV"J0<-"ZXG1QXFJ0\P9,Z.46 /!&PCF(Z]K+C9;A/<0BEKQTMTHC4E.
M@YAY].@E[LX\H6#-S#/O=*!FFF-%$W4<L;9*O<=,N%K.K6A\(-_TF\:]A 61
MO']-%JLD40K0)33RK3Y*@Y9O'93=>=568L@\"Y'5/0)KZ(M/*8*']53I-U"U
M64OF!2BSB?QH2?NM":&&S5%]E,SAZ:;LSH]8+SH_/$81)JRG-+\A$1[#6($<
M$ZV91S\$.#.O@]VC($^!>K,=M>V5Y18F >U%= V#%'[!<?:,]G=T&P&1%0Y-
MB)6.H]1I&2Z+%&@[V48I^)+9D# &&\X9)(PUV K>/NR>Z$")==4ZQFX);71(
M&V81<6 <1@9MD]HHF$>L9HH..H/0)H\51GY=:>W!!JMIS$\<D#D$3OS@E+<^
MNW^&,+NF]D[/;#3K&[;3,,>@C::#0J*<$V"L0,[+#T_H10>K:LQ7)% 7"-/4
M-VP:L'Y]PRXJ=L%P5=]P;H[17M^P3VO^XM'C'I;:HMS!-$LB6I;E+$CI]CA?
M.[%GLYJ7ME5(&:;E_:2=9.4E6Q 2OOSR-EOP!?Q=\8;Q]B$KU\ 1:RK5<\PJ
M=4Y*P"A3?O69K] Y8)SQ\&.EL0:'%,<UT75N6FIUN5XD"=$6>V"JFS^V$#"/
MRHT$7;QA0H0QIHO:%P@D=BQ&R/_F,&7/00PJ7_)C,NT&$"OIU4NPA..P6L#+
M=06123)+28"4%\<(RM\\D)_2(&2=L/7? FJ3'G 4H<?J'W[7>L9D: YX(!8S
M@SX_EI)XYU5:).Y 9F_M->,#? D63PF$!N\7&[]KF$<UT'*2[%(^(,@9^9#3
M=B& ^[3CF[8K;U"HJ@LN%FXY.9,:-0D\5;;9?(E+"@YT5Y7>C'O MS!9XV1S
MB1,V#Z2G>YH)Z&:GEAB:!UTK CA99I7W]N1+;9)D)R"7#608".G8!6XNWXE'
M+3/L&A9V@M]1&!&JV4_]4J2<P!7F\U":SV5A/K15,$ON)\GF!ZB4"JV_I6R)
MX21&5 KPCTCD,!(U&):=2%3'[RB,R&(DXF'(TGX\S;32SV@?XMN+SWMVG_7R
M\^7'#[<)?DH"C4X-.M0&Y,J]U)VM55+P5&$-&&]ZO90R]V7]HHXEUM>J_[C5
M5SW_GH+/3:@)UG960B.-35H;B5&!6W !BH&!ST :FM5]B50*50,B0SN5(9;5
M1M5A))#?#OD6 'JAPNK*\Q>6!D>7IU.[_NUV*!6_;AC$5-L?5W&(-_">6#Y+
M2TRO;'62,<_M.LC:MS#.#!3</+NBHH(4UE"=QZB@'D"F69^W#%M_W=U#R#HP
MKM;)\W28]N6L@OJ\QJ;?;:;I7]OY3EK_:%J)G.W]A KY$;><+KQZ&:R#9.\^
M48-*9X!:WQY/_@1_HGSNX*W!M4D-S"XJ%M]!7+NK>=GT(.+:MTJ7"F!U/4ZY
MME79TC4P:" FCMIVI&$2;>G$N%S3\F\0TH=DM,^0=#.D^LA,RXD,&0QI0F'
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M1/$_;WQ/!\6>W+11G3- K"<3+7F"<T_<3.I_,]3%*J3L@B61'G%5Z%VS)U4
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M>J5R\B:.D0?DEQOPXYXL$_M*QGK_QD3=Q&R\,5$$[7C-2=Z9'O#&A$H+F+A
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M\"ZW55+VW,#M<&!:G)4+  K8Z4T?28:I_9B^?A&_$UMD5-+D!:9$T$48)KL
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M@/U&?IG_BOS/(UEF_]O_#U!+ P04    " #&HGA2&F+I@Z9%  #O8@4 %0
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M@5;KV?8:VD;N/C5J1L/U<'#)&#V=IG+G!Y\AZSV*:>'%2];H/KCU>;'%>7P
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M2^^X)I J&%]V19:2Z, NO-AFMX5T&K\(M0ZD:I;@+T"L<R^7N,!(;K:&4@5
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MNP7:O'=1Y(=X&^.?_.40^N3'?]S>B?"9_>V6&?K^),,0_>VV8E>?P()N@:\
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M,2YX;6Q02P$"% ,4    " #&HGA2PU=) J<3  #HS@  $0
M@ '##P$ 971N8BTR,#(P,3(S,2YX<V102P$"% ,4    " #&HGA2?@[S"LT,
M  !/K0  %0              @ &9(P$ 971N8BTR,#(P,3(S,5]C86PN>&UL
M4$L! A0#%     @ QJ)X4E!DEI*8+P  YV,# !4              ( !F3 !
M &5T;F(M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,:B>%(B3HQAHG0
M "\B!P 5              "  61@ 0!E=&YB+3(P,C Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " #&HGA2&F+I@Z9%  #O8@4 %0              @ $YU0$
K971N8BTR,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  !(; @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
